Clustering O 0 9.809902257984504e-05
of O 0 1.962168198588188e-06
missense O 0 0.001646496239118278
mutations O 0 8.900891407392919e-05
in O 0 2.4273801955132512e-06
the O 0 6.805000884924084e-05
ataxia B-Disease 1 0.9990125894546509
- I-Disease 1 0.9698848724365234
telangiectasia I-Disease 1 0.9976166486740112
gene O 0 1.8883989469031803e-05
in O 0 2.7723496032194817e-07
a O 0 3.966486929130042e-06
sporadic B-Disease 0 0.006597242318093777
T I-Disease 1 0.9961084723472595
- I-Disease 1 0.8635047078132629
cell I-Disease 0 0.39277276396751404
leukaemia I-Disease 1 0.9953768253326416
. O 0 8.692839764989913e-05

Ataxia B-Disease 1 0.9881411790847778
- I-Disease 1 0.9596700072288513
telangiectasia I-Disease 1 0.9907088279724121
( O 0 0.00014448963338509202
A B-Disease 0 0.000892014941200614
- I-Disease 1 0.5923060178756714
T I-Disease 1 0.9894759654998779
) O 0 7.040335958663491e-07
is O 0 8.55113810871444e-08
a O 0 1.7310661633018753e-06
recessive B-Disease 0 0.4147379696369171
multi I-Disease 1 0.9262645840644836
- I-Disease 1 0.9986133575439453
system I-Disease 1 0.8727478384971619
disorder I-Disease 1 0.9996856451034546
caused O 0 0.00331854703836143
by O 0 1.785612795401903e-07
mutations O 0 1.7260450704270625e-06
in O 0 1.3344873650567024e-08
the O 0 1.4003512127658269e-08
ATM O 0 5.99569011683343e-06
gene O 0 5.327823942025134e-07
at O 0 2.0606010764367966e-07
11q22 O 0 0.0004734538379125297
- O 0 0.0010927332332357764
q23 O 0 0.00696502486243844
( O 0 7.5274369919497985e-06
ref O 0 0.0028315221425145864
. O 0 4.825182031709119e-08
3 O 0 4.731538467694918e-07
) O 0 5.377696652431041e-07
. O 0 1.401954136781569e-06

The O 0 3.2321968319593e-05
risk O 0 0.007196853403002024
of O 0 3.614824163378216e-05
cancer B-Disease 1 0.9980369210243225
, O 0 1.9231623809901066e-05
especially O 0 0.00017614837270230055
lymphoid B-Disease 1 0.8187660574913025
neoplasias I-Disease 0 0.27614453434944153
, O 0 1.2814776937375427e-06
is O 0 3.2412020800620667e-07
substantially O 0 8.650730887893587e-05
elevated O 0 0.00032157785608433187
in O 0 8.28651195661223e-07
A B-Disease 0 0.03772014006972313
- I-Disease 1 0.9987749457359314
T I-Disease 1 0.9995660185813904
patients O 1 0.5770500898361206
and O 0 1.5169727021202561e-06
has O 0 1.1318218184896978e-06
long O 0 2.8638020012294874e-05
been O 0 4.3973352603643434e-07
associated O 0 2.35899533436168e-05
with O 0 5.0501286750659347e-05
chromosomal O 1 0.9855905771255493
instability O 1 0.946511447429657
. O 0 0.00017514551291242242

By O 0 3.1518018658971414e-05
analysing O 0 0.0033285156823694706
tumour B-Disease 1 0.9920404553413391
DNA O 0 0.00011396795889595523
from O 0 1.248790886165807e-05
patients O 0 0.0026398543268442154
with O 0 1.644505005060637e-06
sporadic B-Disease 0 0.0014239514712244272
T I-Disease 1 0.9698665738105774
- I-Disease 0 0.05004578456282616
cell I-Disease 0 0.014860570430755615
prolymphocytic I-Disease 1 0.9644156694412231
leukaemia I-Disease 1 0.9984090924263
( O 0 0.00023638767015654594
T B-Disease 1 0.8414096236228943
- I-Disease 0 0.007481653708964586
PLL I-Disease 0 0.1735866814851761
) O 0 1.936161595494923e-07
, O 0 3.457926212036e-08
a O 0 1.5402696362798451e-07
rare O 0 0.0001135464190156199
clonal B-Disease 0 0.22179734706878662
malignancy I-Disease 1 0.8121951222419739
with O 0 8.878964763425756e-08
similarities O 0 5.705169314751402e-07
to O 0 3.116483071607945e-08
a O 0 1.3965616290079197e-06
mature B-Disease 0 0.006561706308275461
T I-Disease 1 0.986491322517395
- I-Disease 0 0.18736273050308228
cell I-Disease 0 0.029886022210121155
leukaemia I-Disease 1 0.9849569201469421
seen O 0 2.233760596936918e-06
in O 0 1.6629049071070767e-07
A B-Disease 0 0.00012152924318797886
- I-Disease 0 0.3295220732688904
T I-Disease 1 0.835274875164032
, O 0 3.1957842594465546e-08
we O 0 1.5933649955002238e-09
demonstrate O 0 8.184878552697228e-09
a O 0 2.4857611524709e-09
high O 0 2.0170404013697407e-08
frequency O 0 5.174094930282536e-09
of O 0 1.0790262905402415e-08
ATM O 0 0.00012323184637352824
mutations O 0 1.5753119441797026e-05
in O 0 2.0831269011978293e-06
T B-Disease 1 0.8552874326705933
- I-Disease 0 0.06572344154119492
PLL I-Disease 1 0.8075334429740906
. O 0 2.2286187231657095e-05

In O 0 1.372342467220733e-06
marked O 0 2.7746773412218317e-06
contrast O 0 8.534890412192908e-07
to O 0 1.313560105131728e-08
the O 0 2.5605290332464392e-08
ATM O 0 3.5218217817600816e-05
mutation O 0 3.216385039195302e-06
pattern O 0 1.2625586123249377e-06
in O 0 1.6082834974895377e-07
A B-Disease 0 0.00013149592268746346
- I-Disease 1 0.5288139581680298
T I-Disease 1 0.9422535300254822
, O 0 3.5189586355954816e-08
the O 0 3.9204497426226226e-09
most O 0 4.060140668116219e-09
frequent O 0 3.218215454126039e-07
nucleotide O 0 1.2937360338582948e-07
changes O 0 1.4208558241080027e-07
in O 0 1.1719819781319529e-07
this O 0 8.759967045079975e-07
leukaemia B-Disease 1 0.9938940405845642
were O 0 2.158355755454977e-06
missense O 0 0.0057843998074531555
mutations O 0 0.0006679057842120528
. O 0 1.5377891031675972e-05

These O 0 9.158478064819064e-07
clustered O 0 1.0222564014839008e-05
in O 0 7.897174469917445e-08
the O 0 3.506061929670068e-08
region O 0 1.6784906620159745e-07
corresponding O 0 2.456441627884942e-08
to O 0 2.9182913863223803e-09
the O 0 1.011874228851184e-08
kinase O 0 5.758329280070029e-06
domain O 0 5.912184875001003e-08
, O 0 5.435203842552028e-09
which O 0 1.1703447100330777e-09
is O 0 9.220967878142972e-10
highly O 0 7.53789120011561e-09
conserved O 0 2.2646121422553733e-08
in O 0 1.5359621130528467e-08
ATM O 0 2.9484068363672122e-05
- O 0 1.2898794921056833e-05
related O 0 3.9566532450407976e-07
proteins O 0 2.560983247690274e-08
in O 0 3.415111748950039e-08
mouse O 0 2.8179309083498083e-05
, O 0 9.117199795127817e-08
yeast O 0 1.4331448255688883e-05
and O 0 3.6831414718108135e-07
Drosophila O 0 2.6918320145341568e-05
. O 0 5.59123873244971e-06

The O 0 1.7907506162373465e-06
resulting O 0 5.563213562709279e-06
amino O 0 1.1455291542006307e-06
- O 0 4.878925028606318e-05
acid O 0 3.62393166142283e-06
substitutions O 0 2.223339237161781e-07
are O 0 6.242364847253157e-09
predicted O 0 1.1331219411658822e-06
to O 0 1.2739135968331539e-08
interfere O 0 6.029550831954111e-07
with O 0 1.114746908115194e-07
ATP O 0 0.00019965277169831097
binding O 0 9.977698027796578e-07
or O 0 3.961531547247432e-07
substrate O 0 1.091464491764782e-05
recognition O 0 5.639102255372563e-06
. O 0 6.9668126343458425e-06

Two O 0 2.878364853131643e-07
of O 0 2.9896591513534077e-07
seventeen O 0 2.5698289391584694e-05
mutated O 0 0.005900036543607712
T B-Disease 1 0.6570078730583191
- I-Disease 0 0.009014544077217579
PLL I-Disease 0 0.06961438804864883
samples O 0 2.3490648004553805e-07
had O 0 2.370854446098747e-08
a O 0 7.203980345593664e-08
previously O 0 1.0496249842617544e-06
reported O 0 1.6001740732463077e-05
A B-Disease 0 0.0004436914750840515
- I-Disease 1 0.7218365669250488
T I-Disease 1 0.9942761063575745
allele O 0 0.00044022503425367177
. O 0 1.5878140402492136e-05

In O 0 1.1660797099466436e-05
contrast O 0 7.564642874058336e-05
, O 0 7.416423386530369e-07
no O 0 3.21041085271645e-07
mutations O 0 3.2588081921858247e-06
were O 0 9.325520800018694e-09
detected O 0 6.241176606636145e-07
in O 0 5.164098038079601e-09
the O 0 1.5867453129203568e-08
p53 O 0 7.000980076554697e-06
gene O 0 1.748543809299008e-06
, O 0 1.057569321005758e-07
suggesting O 0 1.446433429919125e-06
that O 0 5.479130749108663e-08
this O 0 2.2998547137831338e-06
tumour B-Disease 1 0.9990457892417908
suppressor O 0 0.0790560394525528
is O 0 1.622451577532047e-07
not O 0 2.77046741103959e-08
frequently O 0 9.966238394554239e-07
altered O 0 1.0687484973459505e-05
in O 0 5.839873438162613e-07
this O 0 4.953513780492358e-06
leukaemia B-Disease 1 0.9959477782249451
. O 0 9.227696864400059e-05

Occasional O 0 0.0003052755491808057
missense O 0 0.0009495839476585388
mutations O 0 2.403684629825875e-05
in O 0 2.5082903221118613e-07
ATM O 0 2.0226736523909494e-05
were O 0 1.3955196997983421e-08
also O 0 2.466375725873604e-08
found O 0 1.1270205391156196e-07
in O 0 2.4682215098437155e-06
tumour B-Disease 1 0.9904946088790894
DNA O 0 1.201980012410786e-05
from O 0 1.57660213062627e-06
patients O 0 0.0006768197054043412
with O 0 7.476950827367546e-07
B B-Disease 0 0.002233030740171671
- I-Disease 0 0.005032963119447231
cell I-Disease 0 0.0021174277644604445
non I-Disease 0 0.0015077723655849695
- I-Disease 1 0.9700534343719482
Hodgkins I-Disease 1 0.9995831847190857
lymphomas I-Disease 1 0.9910184144973755
( O 0 3.7535044157266384e-06
B B-Disease 0 4.48265673185233e-05
- I-Disease 0 1.1154567800986115e-05
NHL I-Disease 0 1.1423512660257984e-06
) O 0 1.3725484748761119e-08
and O 0 3.6916423251653896e-09
a O 0 7.25032478499088e-08
B B-Disease 0 0.00010271527571603656
- I-Disease 0 0.000118449424917344
NHL I-Disease 0 2.4240111088147387e-05
cell O 0 4.13377201766707e-05
line O 0 5.926821813773131e-06
. O 0 3.650407506938791e-06

The O 0 8.255740908680309e-07
evidence O 0 3.817521587734518e-07
of O 0 2.5758906119222047e-08
a O 0 8.7311946117552e-08
significant O 0 1.6575754102632345e-07
proportion O 0 3.2666324045749207e-07
of O 0 5.735141073159866e-08
loss O 0 0.000535912811756134
- O 0 0.00020193315867800266
of O 0 1.1420544865359261e-07
- O 0 0.0004486757970880717
function O 0 3.7303937006072374e-07
mutations O 0 5.380682068789611e-07
and O 0 3.143735272104209e-09
a O 0 1.29275621318925e-08
complete O 0 2.108430692260299e-07
absence O 0 2.0024972968712973e-07
of O 0 2.8708564414614557e-09
the O 0 3.986047936166415e-09
normal O 0 3.834597350760305e-08
copy O 0 6.44211866074329e-08
of O 0 3.826317929167544e-09
ATM O 0 3.010372438438935e-06
in O 0 4.9311332794843565e-09
the O 0 6.1409108909060706e-09
majority O 0 1.351408798200282e-07
of O 0 3.7518364592870057e-07
mutated O 0 0.061477817595005035
tumours B-Disease 1 0.9913694262504578
establishes O 0 0.000666269741486758
somatic O 0 0.0007908447296358645
inactivation O 0 0.0005738172912970185
of O 0 9.700651837363239e-09
this O 0 7.984318983744743e-09
gene O 0 2.0884925788777764e-07
in O 0 1.1068417293813582e-08
the O 0 4.3663948900984906e-08
pathogenesis O 0 0.0008231064421124756
of O 0 1.805608320637475e-07
sporadic B-Disease 0 0.0010779055301100016
T I-Disease 1 0.9680869579315186
- I-Disease 0 0.05811479687690735
PLL I-Disease 0 0.4017089009284973
and O 0 2.074877869517877e-07
suggests O 0 2.2899973828316433e-06
that O 0 1.5679750831054662e-08
ATM O 0 2.1946916604065336e-05
acts O 0 3.752749080376816e-07
as O 0 2.74906028607802e-07
a O 0 4.789528975379653e-05
tumour B-Disease 1 0.9946876764297485
suppressor O 0 0.15220290422439575
. O 0 4.489650746108964e-05

As O 0 3.0578078167309286e-06
constitutional O 0 3.1284532724384917e-06
DNA O 0 5.753498953708913e-06
was O 0 1.8330335649352492e-07
not O 0 8.659014838485746e-09
available O 0 1.5334711278569557e-08
, O 0 1.733138788040378e-08
a O 0 1.7751605696503248e-07
putative O 0 0.0007454376318491995
hereditary O 0 0.1903260052204132
predisposition O 1 0.5330121517181396
to O 0 1.6249543477897532e-05
T B-Disease 1 0.9812809824943542
- I-Disease 0 0.02554602362215519
PLL I-Disease 0 0.17856502532958984
will O 0 8.461498879341889e-08
require O 0 3.5931105912823114e-07
further O 0 3.306475093722838e-07
investigation O 0 3.5069094792561373e-06
. O 0 1.094234676202177e-06
. O 0 4.9293676056549884e-06

Myotonic B-Disease 1 0.994126558303833
dystrophy I-Disease 1 0.9960326552391052
protein O 0 0.00026760168839246035
kinase O 0 0.00025241138064302504
is O 0 8.233092074760862e-08
involved O 0 2.6829711785580912e-08
in O 0 5.490929044782433e-09
the O 0 4.031480926869335e-09
modulation O 0 1.9419015018229402e-07
of O 0 6.813762887247776e-09
the O 0 1.8428686132665462e-07
Ca2 O 0 0.0077770478092134
+ O 0 0.018322793766856194
homeostasis O 0 0.06727490574121475
in O 0 1.5310055459849536e-05
skeletal O 1 0.9806804060935974
muscle O 1 0.9481814503669739
cells O 0 0.0022942875511944294
. O 0 2.9494163754861802e-05

Myotonic B-Disease 1 0.9898209571838379
dystrophy I-Disease 1 0.9960286617279053
( O 0 0.07370453327894211
DM B-Disease 1 0.9971234202384949
) O 0 1.6526031686225906e-05
, O 0 6.803116434639378e-07
the O 0 9.385191788169323e-07
most O 0 4.2914976802421734e-05
prevalent O 1 0.9866709113121033
muscular B-Disease 1 0.9996927976608276
disorder I-Disease 1 0.9997486472129822
in O 0 0.0002239687746623531
adults O 0 0.015130670741200447
, O 0 1.692324417490454e-06
is O 0 3.685580054479942e-07
caused O 0 2.154467256332282e-05
by O 0 7.672709756434415e-08
( O 0 1.8801870282914024e-06
CTG O 0 0.003163472982123494
) O 0 1.4375221724094445e-07
n O 0 1.7926574855664512e-06
- O 0 1.376323780277744e-05
repeat O 0 1.776464046088222e-06
expansion O 0 8.571027620973837e-08
in O 0 1.1843841463132776e-09
a O 0 1.7643638772213421e-09
gene O 0 1.7994828738210344e-08
encoding O 0 9.07247521553245e-09
a O 0 1.2564523643732173e-08
protein O 0 1.856003279954166e-07
kinase O 0 6.2992062339617405e-06
( O 0 1.1706385976140155e-06
DM B-Disease 1 0.9470649361610413
protein O 0 1.002832391350239e-06
kinase O 0 1.5224935850710608e-05
; O 0 9.850597280092188e-07
DMPK O 0 0.0015868231421336532
) O 0 4.9084928122056226e-08
and O 0 6.786214701293147e-09
involves O 0 2.4615991378595936e-07
changes O 0 1.387973469491044e-07
in O 0 1.4686200699998153e-07
cytoarchitecture O 0 0.0005732820718549192
and O 0 1.0172673228225904e-06
ion O 0 0.0005591960507445037
homeostasis O 0 0.10102381557226181
. O 0 2.1073457901366055e-05

To O 0 1.8572670796856983e-06
obtain O 0 7.688925620641385e-07
clues O 0 1.012577172332385e-06
to O 0 2.4020613054176465e-08
the O 0 1.8405090784767708e-08
normal O 0 2.386676101195917e-07
biological O 0 3.1020428536976397e-07
role O 0 2.9520622391032703e-08
of O 0 2.2013017186850448e-08
DMPK O 0 0.0018372490303590894
in O 0 5.8744497266616236e-08
cellular O 0 2.7832011255668476e-05
ion O 0 0.00015554316632915288
homeostasis O 0 0.0029328118544071913
, O 0 4.16007459591583e-08
we O 0 2.185899461437657e-09
have O 0 1.4272728554587388e-09
compared O 0 5.3593989690625676e-08
the O 0 1.3945538945847602e-08
resting O 0 4.342483953223564e-05
[ O 0 2.188296457461547e-05
Ca2 O 0 0.001899919705465436
+ O 0 0.00021779740927740932
] O 0 2.793376552290283e-06
i O 0 2.668879517386813e-08
, O 0 1.6095201837984519e-09
the O 0 6.426036369688859e-10
amplitude O 0 1.3320512692871489e-08
and O 0 2.2940471744448132e-09
shape O 0 1.6268519686946092e-07
of O 0 2.4319943392470122e-08
depolarization O 0 0.0010558736976236105
- O 0 0.005839542951434851
induced O 0 0.016386762261390686
Ca2 O 0 0.005812548100948334
+ O 0 0.00038289392250590026
transients O 0 3.975473009631969e-05
, O 0 9.192524075274378e-09
and O 0 9.130696199122212e-10
the O 0 5.010160619711712e-10
content O 0 1.175804009712067e-09
of O 0 1.2135029647808437e-09
ATP O 0 8.264380994660314e-06
- O 0 3.1183315059024608e-06
driven O 0 1.8006524271640956e-07
ion O 0 1.6772581830082345e-06
pumps O 0 8.47084174893098e-06
in O 0 2.2624453777098097e-07
cultured O 0 0.00025729602202773094
skeletal O 0 0.2581219971179962
muscle O 0 0.0045926556922495365
cells O 0 1.1206558383491938e-06
of O 0 1.348933409417441e-08
wild O 0 4.252764028933598e-06
- O 0 0.00016762316226959229
type O 0 7.891700079198927e-06
and O 0 2.6792159246724623e-07
DMPK O 0 0.05683539807796478
[ O 0 8.651234384160489e-05
- O 0 0.0059155430644750595
/ O 0 0.020476844161748886
- O 0 0.0023524146527051926
] O 0 0.00023075718490872532
knockout O 0 0.004613490309566259
mice O 0 0.0011654944391921163
. O 0 8.424534826190211e-06

In O 0 7.571332389488816e-06
vitro O 0 0.00013644984574057162
- O 0 0.0007227998576126993
differentiated O 0 0.0005126466858200729
DMPK O 0 0.14505262672901154
[ O 0 0.00021536750136874616
- O 0 0.003943099174648523
/ O 0 0.006354787386953831
- O 0 0.0006919577717781067
] O 0 2.8766338800778612e-05
myotubes O 0 0.00011402502423152328
exhibit O 0 3.494379541280068e-07
a O 0 1.761593892979363e-08
higher O 0 2.6452508450347523e-07
resting O 0 2.8872698749182746e-05
[ O 0 1.561962199048139e-05
Ca2 O 0 0.0008922462002374232
+ O 0 0.00015125640493351966
] O 0 2.000562972170883e-06
i O 0 1.7042264488509318e-08
than O 0 4.013443355432855e-09
do O 0 2.0215464857642473e-08
wild O 0 1.7466090866946615e-06
- O 0 0.0008597312262281775
type O 0 6.266834679991007e-05
myotubes O 0 0.00025313731748610735
because O 0 8.434103193621922e-09
of O 0 1.1097393004533274e-09
an O 0 3.986656338383909e-09
altered O 0 1.46029634606748e-07
open O 0 2.387422171068465e-08
probability O 0 3.940120230083721e-09
of O 0 3.972689732734125e-09
voltage O 0 1.3664905509358505e-06
- O 0 7.714875391684473e-05
dependent O 0 5.242740826361114e-06
l O 0 0.0014528074534609914
- O 0 3.923759868484922e-05
type O 0 5.736962521041278e-06
Ca2 O 0 9.447648335481063e-05
+ O 0 1.3746932381764054e-05
and O 0 1.664072613039025e-07
Na O 0 0.0013121789088472724
+ O 0 3.9921054849401116e-05
channels O 0 1.4046092928765574e-06
. O 0 1.4400786767509999e-06

The O 0 6.451416993513703e-06
mutant O 0 0.00022294353402685374
myotubes O 0 0.0014829399297013879
exhibit O 0 7.726023795839865e-06
smaller O 0 7.522460805375886e-07
and O 0 2.0908242959194467e-07
slower O 0 3.93813279515598e-05
Ca2 O 0 0.0017133336514234543
+ O 0 0.00011935296060983092
responses O 0 6.89729233727121e-07
upon O 0 6.895096760217712e-08
triggering O 0 1.4699622624902986e-05
by O 0 8.09057496553578e-08
acetylcholine O 0 0.0001617367670405656
or O 0 1.5615975712535146e-07
high O 0 4.294125574233476e-06
external O 0 2.6247877030982636e-05
K O 0 0.000689863576553762
+ O 0 0.0004553824837785214
. O 0 3.093433178946725e-06

In O 0 4.7583362174918875e-06
addition O 0 2.1978548829793e-06
, O 0 2.1496612134797033e-07
we O 0 1.974401087068145e-08
observed O 0 4.565150035773513e-08
that O 0 7.94706522810884e-09
these O 0 4.7579369777395186e-08
Ca2 O 0 0.0011788966367021203
+ O 0 0.0021038895938545465
transients O 0 0.0018265793332830071
partially O 0 4.0138920667232014e-06
result O 0 4.047747736990459e-08
from O 0 7.238066146442179e-09
an O 0 3.151900740405722e-09
influx O 0 3.462863560343976e-07
of O 0 3.645412638419998e-09
extracellular O 0 1.9497024368320126e-06
Ca2 O 0 2.6454037652001716e-05
+ O 0 1.9160861484124325e-06
through O 0 9.279618851110172e-09
the O 0 7.595305362428917e-08
l O 0 0.0027266156394034624
- O 0 0.0003160054620821029
type O 0 6.471823144238442e-05
Ca2 O 0 0.000490036909468472
+ O 0 9.990402031689882e-05
channel O 0 4.122282462049043e-06
. O 0 2.8384940833348082e-06

Neither O 0 1.2756353498843964e-05
the O 0 3.187548429650633e-07
content O 0 2.0393929389683763e-07
nor O 0 1.6875429764695582e-07
the O 0 4.538217357463736e-09
activity O 0 1.617695488675963e-08
of O 0 3.731193842781977e-08
Na O 0 0.002025056630373001
+ O 0 9.934968693414703e-05
/ O 0 6.000322900945321e-05
K O 0 9.348974344902672e-06
+ O 0 1.0127884706889745e-05
ATPase O 0 3.6892964999424294e-05
and O 0 1.9316836130656156e-07
sarcoplasmic O 0 0.006709190551191568
reticulum O 0 0.0012747772270813584
Ca2 O 0 0.000560036685783416
+ O 0 0.0004641223349608481
- O 0 0.0005303399520926178
ATPase O 0 0.00048186464118771255
are O 0 4.985790269529389e-08
affected O 0 3.400738251002622e-06
by O 0 6.862100008220295e-07
DMPK O 0 0.2282467484474182
absence O 0 0.00023607030743733048
. O 0 2.0332483472884633e-05

In O 0 3.521695816743886e-06
conclusion O 0 3.6698918393085478e-06
, O 0 3.064903353333648e-07
our O 0 7.520905143110213e-08
data O 0 1.4917162616256974e-07
suggest O 0 8.347491302629351e-07
that O 0 6.7858032082313e-08
DMPK O 0 0.0033743635285645723
is O 0 1.8245813748762885e-08
involved O 0 3.176077711941616e-08
in O 0 1.8506154830788546e-08
modulating O 0 6.616157406824641e-06
the O 0 3.2797966564857006e-09
initial O 0 3.163218664781198e-08
events O 0 1.1196133797852781e-08
of O 0 1.3340929250205136e-08
excitation O 0 1.7186179320560768e-05
- O 0 0.005852917209267616
contraction O 0 0.002297159982845187
coupling O 0 7.218849350465462e-05
in O 0 8.531019375368487e-06
skeletal O 1 0.9350667595863342
muscle O 0 0.47026997804641724
. O 0 9.895916264213156e-06
. O 0 2.031403528235387e-05

Constitutional O 0 0.001440402353182435
RB1 O 1 0.9645105004310608
- O 0 0.0711965411901474
gene O 0 0.0011701787589117885
mutations O 0 0.0014786721440032125
in O 0 1.8906368495663628e-05
patients O 0 0.237663134932518
with O 0 4.96845823363401e-05
isolated O 0 0.026141570881009102
unilateral B-Disease 0 0.18828636407852173
retinoblastoma I-Disease 1 0.9908301830291748
. O 0 0.00021697103511542082

In O 0 3.3614865969866514e-05
most O 0 2.186139863624703e-05
patients O 0 0.04532564431428909
with O 0 6.987465440033702e-06
isolated O 0 0.0038374802097678185
unilateral B-Disease 0 0.0729183629155159
retinoblastoma I-Disease 1 0.9963582158088684
, O 0 0.0001373449485981837
tumor B-Disease 1 0.84218829870224
development O 0 2.3205602701636963e-06
is O 0 6.398499152737713e-08
initiated O 0 1.1459706001915038e-06
by O 0 5.615894949073663e-08
somatic O 0 3.246072810725309e-05
inactivation O 0 0.00011808663111878559
of O 0 4.483609039596104e-09
both O 0 1.3827542666433601e-08
alleles O 0 5.538913114833122e-07
of O 0 7.100482690702847e-08
the O 0 6.45602722215699e-06
RB1 O 1 0.9799320101737976
gene O 0 0.00021125294733792543
. O 0 1.3648633284901734e-05

However O 0 5.440098448161734e-06
, O 0 2.861783343632851e-07
some O 0 2.472281934728926e-08
of O 0 7.560212367252461e-08
these O 0 2.256948846479645e-06
patients O 0 0.24719074368476868
can O 0 9.711126040201634e-06
transmit O 0 0.007408818230032921
retinoblastoma B-Disease 1 0.9946444034576416
predisposition O 0 0.1136002242565155
to O 0 4.441632199814194e-07
their O 0 6.651038688687549e-07
offspring O 0 0.00046652957098558545
. O 0 2.8041091354680248e-05

To O 0 1.5964769772836007e-06
determine O 0 4.603026582117309e-07
the O 0 2.7766143162466506e-08
frequency O 0 8.298582088173134e-08
and O 0 1.9647165672154188e-08
nature O 0 6.82107312854896e-08
of O 0 2.3948469873857903e-08
constitutional O 0 2.3276277715922333e-05
RB1 O 1 0.9925851225852966
- O 0 0.03467467054724693
gene O 0 6.848097109468654e-05
mutations O 0 9.259437501896173e-05
in O 0 3.36002904077759e-06
patients O 0 0.02353302203118801
with O 0 3.641242528829025e-06
isolated O 0 0.004190710373222828
unilateral B-Disease 0 0.009914039634168148
retinoblastoma I-Disease 1 0.8151891827583313
, O 0 1.864998893097436e-07
we O 0 1.962731310811705e-08
analyzed O 0 4.3938979388258304e-07
DNA O 0 1.4710298046338721e-06
from O 0 1.6473539972139406e-06
peripheral O 0 0.1004055067896843
blood O 0 0.0014192321104928851
and O 0 3.891756477969466e-06
from O 0 0.00028508761897683144
tumor B-Disease 1 0.9947454929351807
tissue O 0 0.43923601508140564
. O 0 7.824275962775573e-05

The O 0 1.1746230939024827e-06
analysis O 0 1.7496732880317722e-06
of O 0 1.3542745591621497e-06
tumors B-Disease 1 0.7719683647155762
from O 0 4.548783749669383e-07
54 O 0 9.934014087775722e-06
( O 0 6.458561756517156e-07
71 O 0 8.560274409319391e-07
% O 0 2.9121988376346053e-08
) O 0 1.6150163872907797e-08
of O 0 1.2480306565976207e-08
76 O 0 0.00013186984870117158
informative O 0 0.00013508264964912087
patients O 0 0.01972358673810959
showed O 0 6.789364306314383e-06
loss O 0 1.7136851965915412e-05
of O 0 1.0464849964364475e-07
constitutional O 0 8.518891263520345e-05
heterozygosity O 1 0.905612587928772
( O 0 0.00465795211493969
LOH O 1 0.9981295466423035
) O 0 5.1813058234984055e-06
at O 0 5.981184585834853e-06
intragenic O 0 0.012998362071812153
loci O 0 0.00014436776109505445
. O 0 1.29498721435084e-05

Three O 0 1.8523619473853614e-06
of O 0 1.643203859202913e-06
13 O 0 0.0003373999788891524
uninformative O 1 0.9338511824607849
patients O 0 0.13252463936805725
had O 0 4.128065484110266e-06
constitutional O 0 3.1262195989256725e-05
deletions O 0 0.0012482455931603909
. O 0 5.294551738188602e-05

For O 0 1.2932564459333662e-06
39 O 0 4.646709840017138e-06
randomly O 0 1.143598183261929e-06
selected O 0 7.585309504065663e-06
tumors B-Disease 1 0.9772132039070129
, O 0 4.03838157581049e-06
SSCP O 0 0.036435145884752274
, O 0 1.57661111188645e-06
hetero O 0 0.010555831715464592
- O 0 6.98519143043086e-05
duplex O 0 7.999237277545035e-05
analysis O 0 5.976730932388818e-08
, O 0 1.831383578121404e-08
sequencing O 0 1.0366334635136809e-07
, O 0 1.0558678376071384e-08
and O 0 7.107661126326548e-09
Southern O 0 2.1661699634023535e-07
blot O 0 5.423125548986718e-05
analysis O 0 2.58156163113199e-08
were O 0 2.3791340009182704e-09
used O 0 1.6887787168684554e-08
to O 0 6.133842589406413e-08
identify O 0 7.43908049116726e-06
mutations O 0 9.40186801017262e-05
. O 0 1.725036599964369e-05

Mutations O 0 5.642417090712115e-05
were O 0 3.8327846141328337e-07
detected O 0 2.0683298771473346e-06
in O 0 5.273934533533975e-08
21 O 0 4.458841829091398e-07
( O 0 3.3125095910691016e-07
91 O 0 2.4352029868168756e-06
% O 0 6.850644496125824e-08
) O 0 6.145283037994886e-08
of O 0 1.5977808232037205e-07
23 O 0 0.0005717629683203995
tumors B-Disease 1 0.9976691603660583
with O 0 0.0007449228432960808
LOH O 1 0.9972934126853943
. O 0 0.00015019229613244534

In O 0 2.514767402317375e-06
6 O 0 4.168878149357624e-06
( O 0 7.132712767088378e-07
38 O 0 4.312929036132118e-07
% O 0 7.9182910894815e-08
) O 0 5.150133119968814e-08
of O 0 4.794065233681977e-08
16 O 0 0.00010743056191131473
tumors B-Disease 1 0.9974918365478516
without O 0 4.491256913752295e-05
LOH O 1 0.9990419745445251
, O 0 1.5894630678303656e-07
one O 0 2.9441112658901147e-08
mutation O 0 1.6284675439237617e-06
was O 0 6.450098055665876e-08
detected O 0 3.205375378456665e-07
, O 0 3.2022564599998304e-09
and O 0 1.7697531218274776e-09
in O 0 3.694149874888808e-09
9 O 0 8.23774115588094e-08
( O 0 4.067894110448833e-08
56 O 0 8.004374052461571e-08
% O 0 7.299511661784663e-09
) O 0 1.005130201292559e-08
of O 0 1.5417766618952555e-08
the O 0 4.3515519791981205e-06
tumors B-Disease 1 0.998643696308136
without O 0 0.00011621596058830619
LOH O 1 0.9992644190788269
, O 0 3.366722012287937e-07
both O 0 8.190566802568355e-08
mutations O 0 2.9836201065336354e-06
were O 0 2.0763023300673922e-08
found O 0 8.548412324671517e-07
. O 0 6.963683972571744e-06

Thus O 0 4.230217655276647e-06
, O 0 1.566022405086187e-07
a O 0 4.0729872807787615e-08
total O 0 1.13646621002772e-08
of O 0 8.695840492123352e-09
45 O 0 5.272617613627517e-07
mutations O 0 2.1669275156455114e-06
were O 0 1.636420954298501e-08
identified O 0 1.301533984587877e-06
in O 0 4.585117494571023e-06
tumors B-Disease 1 0.9823606014251709
of O 0 2.881388127207174e-06
36 O 0 0.0014336856547743082
patients O 0 0.4968998432159424
. O 0 8.178577991202474e-05

Thirty O 0 1.9325572793604806e-05
- O 0 1.144453290180536e-05
nine O 0 8.968936526798643e-08
of O 0 1.4031130923797264e-08
the O 0 5.0416367969319253e-08
mutations O 0 2.9366744911385467e-06
- O 0 5.233379397395765e-06
including O 0 4.283452526010478e-08
34 O 0 2.7066309371548414e-07
small O 0 9.702136338773926e-08
mutations O 0 5.150664037500974e-07
, O 0 1.3795666831128983e-08
2 O 0 1.8597027917621745e-07
large O 0 5.627715609080042e-07
structural O 0 0.0002790105645544827
alterations O 0 3.2741212635301054e-05
, O 0 1.0803879746390521e-07
and O 0 1.814839265534829e-07
hypermethylation O 0 0.06515365093946457
in O 0 1.9197038909624098e-06
3 O 0 0.0004677046381402761
tumors O 1 0.9983537197113037
- O 0 0.00011432476458139718
were O 0 7.456241846170997e-09
not O 0 6.078982650592479e-09
detected O 0 1.667055613552293e-07
in O 0 5.39082956052539e-09
the O 0 6.343428538002627e-08
corresponding O 0 6.4069772633956745e-06
peripheral O 0 0.01900889351963997
blood O 0 0.0014598023844882846
DNA O 0 8.12221405794844e-05
. O 0 1.4000746887177229e-05

In O 0 2.3403445084113628e-06
6 O 0 5.121268713992322e-06
( O 0 9.313638997809903e-07
17 O 0 1.3515943919628626e-07
% O 0 1.9643682236392124e-08
) O 0 6.469229596461901e-09
of O 0 2.314872515896127e-09
the O 0 5.643716605163718e-08
36 O 0 2.310126365046017e-05
patients O 0 0.0009744652779772878
, O 0 6.33166692409759e-08
a O 0 1.9445479892965523e-07
mutation O 0 9.375071385875344e-06
was O 0 7.707207316798304e-08
detected O 0 3.649067252808891e-07
in O 0 4.59753168868815e-09
constitutional O 0 7.735498286365328e-08
DNA O 0 4.0806705214890826e-07
, O 0 1.6589758899954177e-08
and O 0 4.7177395323672044e-09
1 O 0 2.042043156791351e-08
of O 0 2.2144437394899796e-09
these O 0 1.669403104642697e-08
mutations O 0 2.925437684098142e-06
is O 0 1.330877896776883e-08
known O 0 5.4065868226871316e-08
to O 0 1.1024592794228738e-08
be O 0 1.2435232399354845e-08
associated O 0 6.252030857467616e-07
with O 0 6.359030635394447e-07
reduced O 0 0.0002511209459044039
expressivity O 1 0.5092026591300964
. O 0 4.549533696263097e-05

The O 0 1.0531865655138972e-06
presence O 0 7.081107469275594e-07
of O 0 3.795826231112187e-08
a O 0 1.6250376688731194e-07
constitutional O 0 3.0463163511740277e-06
mutation O 0 3.2632418879074976e-05
was O 0 1.237679043697426e-07
not O 0 1.0881137768592453e-08
associated O 0 2.1977193398470263e-07
with O 0 2.5772568079673874e-08
an O 0 6.481966607907452e-08
early O 0 3.7276558941812254e-06
age O 0 0.00013734180538449436
at O 0 5.079649781691842e-05
treatment O 0 0.06950177997350693
. O 0 7.246459426824003e-05

In O 0 1.2830679224862251e-05
1 O 0 4.5050437620375305e-05
patient O 0 0.004287605173885822
, O 0 4.705413175543072e-06
somatic O 0 0.00589733524248004
mosaicism O 0 0.31429335474967957
was O 0 5.74276953102526e-07
demonstrated O 0 3.5259060382486496e-07
by O 0 1.526248993855006e-08
molecular O 0 1.860089469118975e-07
analysis O 0 1.0665488048289262e-08
of O 0 3.265490100545776e-09
DNA O 0 2.2055596105019504e-07
and O 0 4.7776893552509136e-08
RNA O 0 5.1214883569628e-06
from O 0 3.0147739380481653e-06
peripheral O 0 0.11651823669672012
blood O 0 0.005290500354021788
. O 0 1.9811286620097235e-05

In O 0 4.624697248800658e-05
2 O 0 0.0004498393682297319
patients O 0 0.01031698752194643
without O 0 9.207827815771452e-07
a O 0 2.91196283797035e-06
detectable O 0 0.0008400920196436346
mutation O 0 5.824625623063184e-05
in O 0 1.577561420162965e-06
peripheral O 0 0.2746332585811615
blood O 0 0.012588182464241982
, O 0 7.304357950488338e-06
mosaicism O 0 0.33368924260139465
was O 0 2.9485630648196093e-07
suggested O 0 4.2558457380437176e-07
because O 0 4.2420275292442966e-08
1 O 0 7.177715843909027e-08
of O 0 3.50424329553789e-08
the O 0 7.501566415157868e-06
patients O 1 0.9569476842880249
showed O 0 0.29232701659202576
multifocal O 1 0.9996334314346313
tumors B-Disease 1 0.9995670914649963
and O 0 6.945398354218923e-07
the O 0 6.465679547318359e-08
other O 0 5.2030053154794587e-08
later O 0 1.1514765674291993e-06
developed O 0 0.00014609252684749663
bilateral B-Disease 0 0.004316638223826885
retinoblastoma I-Disease 1 0.9653419256210327
. O 0 9.559870522934943e-05

In O 0 2.2984033876127796e-06
conclusion O 0 2.129015229002107e-06
, O 0 2.1082438195207942e-07
our O 0 4.3615255407303266e-08
results O 0 1.3243857210909482e-07
emphasize O 0 1.2570226317620836e-06
that O 0 9.700023007042091e-09
the O 0 3.4190090758556835e-08
manifestation O 0 4.197157613816671e-05
and O 0 3.005731343819207e-07
transmissibility O 0 0.013765126466751099
of O 0 3.875294964927889e-07
retinoblastoma B-Disease 0 0.3648027181625366
depend O 0 4.07945663027931e-07
on O 0 7.351292019563971e-09
the O 0 4.912658280176174e-09
nature O 0 3.7745209624517884e-08
of O 0 1.9184454025378272e-09
the O 0 5.202377195701047e-09
first O 0 1.486089828972581e-08
mutation O 0 5.112374878990522e-07
, O 0 3.766593703602439e-09
its O 0 1.6544217107394843e-09
time O 0 3.5991030156168335e-09
in O 0 9.777648912745462e-09
development O 0 8.626873437833638e-08
, O 0 1.124231285842825e-08
and O 0 3.604963216830015e-09
the O 0 2.9540658808002718e-09
number O 0 4.403426512311626e-09
and O 0 3.202313081374086e-08
types O 0 6.313987341854954e-07
of O 0 6.522657969298962e-08
cells O 0 2.3299195163417608e-05
that O 0 3.6728287966525386e-08
are O 0 4.7873125907926806e-08
affected O 0 9.1265565060894e-06
. O 0 7.038892704258615e-07
. O 0 3.9750602809363045e-06

Hereditary B-Disease 1 0.9904668927192688
deficiency I-Disease 1 0.995756208896637
of I-Disease 0 2.6507839834266633e-07
the I-Disease 0 1.1377854036709323e-07
fifth I-Disease 0 1.0029118584498065e-06
component I-Disease 0 4.965850735061395e-07
of I-Disease 0 3.73634989614402e-08
complement I-Disease 0 3.1655536076868884e-06
in O 0 7.937613304420665e-07
man O 0 4.996619827579707e-05
. O 0 1.72808940988034e-05

I O 0 0.001589385443367064
. O 0 0.00020733079873025417

Clinical O 0 0.05830616503953934
, O 0 6.720379315083846e-05
immunochemical O 0 0.18494448065757751
, O 0 4.773326054419158e-06
and O 0 1.4882094774293364e-06
family O 0 1.946768861671444e-05
studies O 0 2.305891757714562e-05
. O 0 3.389945050003007e-05

The O 0 2.3117117962101474e-06
first O 0 9.734478680911707e-07
recognized O 0 1.108432661567349e-05
human O 0 5.707889795303345e-05
kindred O 0 0.2364075928926468
with O 0 0.0006617942126467824
hereditary B-Disease 1 0.9989173412322998
deficiency I-Disease 1 0.9992969036102295
of I-Disease 0 7.006096325312683e-08
the I-Disease 0 9.491913033343735e-08
fifth I-Disease 0 8.251844860751589e-07
component I-Disease 0 2.641804712766316e-07
of I-Disease 0 3.203718179634052e-08
complement I-Disease 0 9.260823389922734e-06
( O 0 8.52799439599039e-06
C5 O 0 0.02581816539168358
) O 0 6.094566060710349e-07
is O 0 1.7614132730159326e-07
described O 0 6.297068921412574e-06
. O 0 4.590454864228377e-06

The O 0 2.6156226340390276e-06
proband O 0 0.0002656076103448868
, O 0 1.9822617502995854e-07
a O 0 9.356221397638365e-08
20 O 0 3.615452897065552e-07
- O 0 6.635201134486124e-05
year O 0 3.5385487535677385e-06
- O 0 0.0007879749173298478
old O 0 0.0003564258513506502
black O 0 0.005437728017568588
female O 0 0.008751653134822845
with O 1 0.7310100197792053
systemic B-Disease 1 0.9998100399971008
lupus I-Disease 1 0.9998393058776855
erythematosus I-Disease 1 0.9997003078460693
since O 0 0.001584819401614368
age O 0 0.0006063688779249787
11 O 0 2.9206876206444576e-05
, O 0 1.2339172826614231e-05
lacked O 0 0.019418863579630852
serum O 1 0.978960394859314
hemolytic O 1 0.9988583326339722
complement O 0 2.8108317565056495e-05
activity O 0 1.800202426238684e-06
, O 0 3.588685899558186e-07
even O 0 1.4419669014387182e-06
during O 0 5.463010893436149e-05
remission O 0 0.3758152723312378
. O 0 4.745184924104251e-05

C5 O 0 0.05000622943043709
was O 0 1.3780848348687869e-05
undetectable O 0 0.003708824049681425
in O 0 6.082012760089128e-07
her O 0 5.834668627358042e-06
serum O 0 0.0005719259497709572
by O 0 2.898871684919868e-07
both O 0 9.170425414595229e-07
immunodiffusion O 0 0.28254035115242004
and O 0 0.00013529870193451643
hemolytic O 1 0.9980093836784363
assays O 0 0.0024559595622122288
. O 0 7.999396621016786e-05

Other O 0 5.362660999708169e-07
complement O 0 1.7179307860715198e-06
components O 0 4.258248793576058e-07
were O 0 2.350014227658903e-08
normal O 0 9.399271903021145e-07
during O 0 9.622862307878677e-06
remission O 0 0.21475499868392944
of O 0 3.871330773108639e-05
lupus O 1 0.999646782875061
, O 0 2.1741120690421667e-06
but O 0 7.072239895933308e-07
C1 O 0 0.12011144310235977
, O 0 8.019140409487591e-07
C4 O 0 0.0016708321636542678
, O 0 8.111787792586256e-07
C2 O 0 0.029869670048356056
, O 0 2.377353212068556e-07
and O 0 6.360796191984264e-07
C3 O 0 0.18686307966709137
levels O 0 3.418623600737192e-05
fell O 0 0.00019593980687204748
during O 0 4.1782357584452257e-05
exacerbations O 1 0.9268394708633423
. O 0 5.2257553761592135e-05

A O 0 1.853857065725606e-05
younger O 0 5.6694600061746314e-05
half O 0 1.0203561032540165e-05
- O 0 0.0014069376047700644
sister O 0 9.904368198476732e-05
, O 0 1.7480338101449888e-06
who O 0 1.8835107766790316e-06
had O 0 4.421389803610509e-06
no O 0 0.00011299848119961098
underlying O 1 0.9368248581886292
disease O 1 0.9993353486061096
, O 0 2.9266850560816238e-06
was O 0 4.051467783483531e-07
also O 0 5.522494106457998e-08
found O 0 7.171639992975543e-08
to O 0 2.0509550324732118e-07
lack O 0 6.78749056532979e-05
immunochemically O 1 0.7282386422157288
detectable O 0 0.05101277306675911
C5 O 0 0.2044145166873932
. O 0 1.8484077372704633e-05

By O 0 0.001041105599142611
hemolytic O 1 0.9950376152992249
assay O 0 0.000327557441778481
, O 0 1.9663700641103787e-06
she O 0 1.1422520174164674e-06
exhibited O 0 1.7574897128724842e-06
1 O 0 4.329177443196386e-07
- O 0 5.906159458390903e-06
2 O 0 5.2361873059680875e-08
% O 0 2.7262341273370794e-09
of O 0 7.645296618008501e-10
the O 0 1.0565728736366964e-08
normal O 0 1.0445720590723795e-06
serum O 0 0.0010226024314761162
C5 O 0 0.0010937810875475407
level O 0 1.3302920365276805e-07
and O 0 9.81189351989542e-09
normal O 0 7.132937440701426e-08
concentrations O 0 1.8209556174042518e-07
of O 0 2.1660360172148785e-09
other O 0 1.1524226906090007e-08
complement O 0 1.028762994792487e-06
components O 0 4.160061507718638e-06
. O 0 4.880951564700808e-06

C5 O 0 0.0996001586318016
levels O 0 1.5458510461030528e-05
of O 0 8.502819071054546e-08
other O 0 7.72407204863157e-08
family O 0 7.254494676089962e-07
members O 0 1.1108602038234494e-08
were O 0 1.632186941158409e-09
either O 0 9.100412867724117e-09
normal O 0 2.9582341909417664e-08
or O 0 7.3720731741389045e-09
approximately O 0 2.3691368866707307e-08
half O 0 1.8896535891599342e-07
- O 0 8.400148362852633e-05
normal O 0 3.0904737968739937e-07
, O 0 4.0677001322819706e-08
consistent O 0 2.759535675522784e-07
with O 0 1.2406090945660253e-06
autosomal O 0 0.18858087062835693
codominant O 0 0.06215212494134903
inheritance O 0 1.938380410138052e-05
of O 0 7.998345807891383e-08
the O 0 1.4973047655075788e-06
gene O 0 0.0006679405341856182
determining O 0 0.002775813452899456
C5 B-Disease 1 0.997700035572052
deficiency I-Disease 1 0.9986308217048645
. O 0 0.000185590804903768

Normal O 0 0.031778063625097275
hemolytic O 1 0.994073212146759
titers O 0 0.12912362813949585
were O 0 4.702971807546419e-07
restored O 0 2.6601235276757507e-06
to O 0 9.750480955972307e-08
both O 0 4.653396672438248e-07
homozygous O 0 0.0005093943909741938
C5 B-Disease 1 0.9886584877967834
- I-Disease 1 0.9270069003105164
deficient I-Disease 1 0.9872196912765503
( O 0 6.163943908177316e-05
C5D B-Disease 1 0.8273331522941589
) O 0 2.0086802123842062e-06
sera O 0 9.403050353284925e-05
by O 0 1.6122740476021136e-08
addition O 0 3.7677022390880666e-08
of O 0 3.302018569684151e-08
highly O 0 5.480392246681731e-06
purified O 0 0.00013965924154035747
human O 0 4.797034853254445e-05
C5 O 0 0.12621678411960602
. O 0 3.937689325539395e-05

In O 0 6.329406005534111e-06
specific O 0 1.2502637218858581e-05
C5 O 1 0.6138840913772583
titrations O 0 0.2203415036201477
, O 0 1.3998659369462985e-06
however O 0 2.587887593108462e-07
, O 0 5.613164333340137e-08
it O 0 1.146350125935669e-08
was O 0 3.368327128328019e-08
noted O 0 3.904727563508459e-08
that O 0 1.5290134713907833e-09
when O 0 6.703904542604278e-09
limited O 0 1.6842623296042802e-08
amounts O 0 2.4584196012256143e-08
of O 0 1.4433185313578178e-08
C5 O 0 0.00013940551434643567
were O 0 2.8245479288813158e-09
assayed O 0 3.2136057370735216e-07
in O 0 2.071838922645952e-09
the O 0 2.036895541124295e-09
presence O 0 1.0841196385058538e-08
of O 0 3.6150644699972645e-09
low O 0 1.5351441788880038e-06
dilutions O 0 6.281074456637725e-05
of O 0 2.931084175372689e-08
either O 0 3.291503844593535e-06
C5D B-Disease 1 0.9557896256446838
serum O 0 0.0009486654889769852
, O 0 5.555699544856907e-08
curving O 0 4.353681561042322e-06
rather O 0 2.856896053060609e-08
than O 0 1.7902772597722105e-08
linear O 0 4.81288907394628e-06
dose O 0 0.00041839524055831134
- O 0 9.749230230227113e-05
response O 0 8.463062499686203e-07
plots O 0 1.6259399160389876e-07
were O 0 5.498024258088208e-09
consistently O 0 1.64341557251646e-07
obtained O 0 2.323331216302904e-08
, O 0 3.8729663032199824e-08
suggesting O 0 5.30571185208828e-07
some O 0 3.99009678631046e-08
inhibitory O 0 1.6050937119871378e-05
effect O 0 8.361406798940152e-06
. O 0 6.0652196225419175e-06

Further O 0 1.1706013538059779e-05
studies O 0 4.15384511143202e-06
suggested O 0 1.6638392708046013e-06
that O 0 4.372278539221952e-08
low O 0 5.054962457506917e-06
dilutions O 0 0.0005323434597812593
of O 0 7.164694011407846e-07
C5D B-Disease 1 0.9878236055374146
serum O 0 0.005321536213159561
contain O 0 1.5868230320847942e-06
a O 0 2.3641584334654908e-07
factor O 0 2.6450163659319514e-06
( O 0 4.706318748048943e-07
or O 0 5.005361103371797e-08
factors O 0 1.4589684838028916e-07
) O 0 3.679384619204029e-08
interfering O 0 1.4743484655355132e-07
at O 0 1.5287749732806333e-08
some O 0 3.025389050392846e-09
step O 0 1.7822850395532441e-07
in O 0 6.326825996438856e-08
the O 0 9.269801921618637e-07
hemolytic O 1 0.9986749291419983
assay O 0 8.170941327989567e-06
of O 0 1.0173182829475991e-07
C5 O 0 0.01066198293119669
, O 0 3.522295699553979e-08
rather O 0 1.338596788968971e-08
than O 0 1.0387211091256177e-08
a O 0 1.33349800535143e-07
true O 0 5.612201675830875e-06
C5 O 0 0.1414221078157425
inhibitor O 0 0.0021197444293648005
or O 0 6.6166999204142485e-06
inactivator O 0 0.028675410896539688
. O 0 1.6279758710879833e-05

Of O 0 5.208627953834366e-06
clinical O 0 0.0005476841470226645
interest O 0 6.274082693380478e-07
are O 0 2.5925011470917525e-08
( O 0 1.4372753298630414e-07
a O 0 2.1935395722039175e-08
) O 0 2.7868066965197613e-08
the O 0 9.285567870165323e-09
documentation O 0 1.974357473955024e-06
of O 0 4.780159542860929e-06
membranous O 1 0.9985172152519226
glomerulonephritis B-Disease 1 0.9996182918548584
, O 0 0.06350116431713104
vasculitis B-Disease 1 0.9996904134750366
, O 0 0.001604099990800023
and O 0 0.023768939077854156
arthritis B-Disease 1 0.9998822212219238
in O 0 1.0962212400045246e-06
an O 0 2.8690303111034154e-07
individual O 0 8.619715572422137e-07
lacking O 0 0.00010873089195229113
C5 O 0 0.02903064712882042
( O 0 2.487482504420768e-07
and O 0 5.2267448147347295e-09
its O 0 1.68742637640662e-08
biologic O 0 0.00012242392404004931
functions O 0 2.1412269290976838e-08
) O 0 4.313895374252752e-08
, O 0 9.906216291710734e-09
and O 0 8.929367467658267e-09
( O 0 1.927557775616151e-07
b O 0 7.75149146647891e-07
) O 0 1.0044039377987701e-08
a O 0 3.108065627088763e-08
remarkable O 0 5.520131253433647e-06
propensity O 0 0.002358078258112073
to O 0 1.636203160160221e-05
bacterial B-Disease 1 0.9983186721801758
infections I-Disease 1 0.9934346675872803
in O 0 2.2223768780804676e-07
the O 0 3.6989536056353245e-07
proband O 0 0.004603356588631868
, O 0 4.471058190347321e-08
even O 0 1.616125722136985e-08
during O 0 7.053790795907844e-08
periods O 0 2.2346374350945553e-07
of O 0 2.5016198890170926e-08
low O 0 1.3925086022936739e-05
- O 0 0.00046301513793878257
dose O 0 4.3996740714646876e-05
or O 0 1.7069322666429798e-07
alternate O 0 2.29419447350665e-06
- O 0 0.0015206721145659685
day O 0 6.174674490466714e-05
corticosteroid O 1 0.8369821310043335
therapy O 0 0.061810340732336044
. O 0 3.4340362617513165e-05

Other O 0 7.845271738915471e-07
observations O 0 1.364339368592482e-06
indicate O 0 7.823710461707378e-07
that O 0 2.0925112309555516e-08
the O 0 1.7234842175639642e-07
C5D B-Disease 0 0.17260479927062988
state O 0 8.54103276992646e-08
is O 0 4.100166606235689e-08
compatible O 0 5.642801284011512e-07
with O 0 7.340814534018136e-08
normal O 0 3.6507940421870444e-06
coagulation O 0 0.001442858250811696
function O 0 5.173703598870816e-08
and O 0 6.36577546231365e-09
the O 0 9.264887523841026e-09
capacity O 0 1.5571629319310887e-07
to O 0 4.2532001032213884e-08
mount O 0 6.148808461148292e-05
a O 0 5.196941128815524e-05
neutrophilic O 1 0.9935135245323181
leukocytosis O 1 0.9938442707061768
during O 0 0.02046644315123558
pyogenic B-Disease 1 0.9965633749961853
infection I-Disease 1 0.9914469718933105
. O 0 1.8041477233055048e-05
. O 0 3.3346634154440835e-05

Susceptibility O 1 0.9282724857330322
to O 0 0.05274391174316406
ankylosing B-Disease 1 0.998511016368866
spondylitis I-Disease 1 0.9992424249649048
in O 0 0.00010045406816061586
twins O 0 0.006010542623698711
: O 0 3.752151542357751e-06
the O 0 2.7824620829619562e-08
role O 0 4.8945253183774184e-08
of O 0 2.4673543208564297e-08
genes O 0 2.74751096185355e-06
, O 0 2.7116841465613106e-06
HLA O 1 0.6673582792282104
, O 0 4.0980484072861145e-07
and O 0 1.2150522366027872e-07
the O 0 5.719289219996426e-07
environment O 0 4.733135938295163e-05
. O 0 1.5491155863855965e-05

OBJECTIVE O 0 1.3109292922308668e-05
To O 0 4.977391085958516e-07
determine O 0 2.387031088346703e-07
the O 0 8.946503271545225e-08
relative O 0 5.123584742250387e-06
effects O 0 5.390303340391256e-05
of O 0 2.400728931206686e-07
genetic O 0 0.00023985056031960994
and O 0 1.800913423721795e-06
environmental O 0 0.00042725674575194716
factors O 0 9.637942639528774e-06
in O 0 1.18699244922027e-05
susceptibility O 1 0.9377917051315308
to O 0 0.025892730802297592
ankylosing B-Disease 1 0.999642014503479
spondylitis I-Disease 1 0.9997327923774719
( O 0 0.0009747856529429555
AS B-Disease 0 8.30973731353879e-05
) O 0 1.6233836504397914e-05
. O 0 9.316951036453247e-06

METHODS O 0 4.7350324166473e-05
Twins O 0 0.0003129915858153254
with O 0 1.0799383289850084e-06
AS B-Disease 0 7.544956019955862e-07
were O 0 1.182919628917034e-08
identified O 0 6.918902784036618e-08
from O 0 4.479261050960304e-08
the O 0 3.613477872477233e-07
Royal O 0 0.0006736288196407259
National O 0 0.013037064112722874
Hospital O 1 0.9859476089477539
for O 0 0.05114521458745003
Rheumatic B-Disease 1 0.9996621608734131
Diseases I-Disease 1 0.9991459846496582
database O 0 0.04487869516015053
. O 0 0.00047354097478091717

Clinical O 0 0.0050373561680316925
and O 0 7.425726835208479e-06
radiographic O 0 0.02152443304657936
examinations O 0 1.0696376193664037e-05
were O 0 5.7286030141767696e-08
performed O 0 3.185281514106464e-07
to O 0 3.2704164709684846e-07
establish O 0 0.00014776657917536795
diagnoses O 1 0.9951985478401184
, O 0 0.0004802047333214432
and O 0 0.02860330045223236
disease O 1 0.9997594952583313
severity O 1 0.887442409992218
was O 0 1.1588200550249894e-06
assessed O 0 1.3739256701228442e-06
using O 0 1.3282278388260238e-08
a O 0 3.2636609859082455e-08
combination O 0 4.585466228945734e-07
of O 0 1.1894013773883216e-08
validated O 0 4.5833076001144946e-06
scoring O 0 1.072349959940766e-06
systems O 0 0.00012243082164786756
. O 0 6.06952471571276e-06

HLA O 0 0.058344606310129166
typing O 0 0.00013630940520670265
for O 0 6.378202215273632e-06
HLA O 0 0.346792072057724
- O 0 0.0027629511896520853
B27 O 0 0.0023697782307863235
, O 0 4.567442374536768e-06
HLA O 0 0.22468174993991852
- O 0 0.00044186977902427316
B60 O 0 0.0002807642740663141
, O 0 3.190480128978379e-07
and O 0 9.519187074147339e-07
HLA O 1 0.9209593534469604
- O 0 0.06869455426931381
DR1 O 0 0.2939024865627289
was O 0 5.232513089481472e-08
performed O 0 3.316264240993405e-08
by O 0 1.7471551316816658e-08
polymerase O 0 9.203155059367418e-06
chain O 0 1.6178547639356111e-06
reaction O 0 8.597945111432637e-08
with O 0 3.896653666402017e-09
sequence O 0 3.9130629403416606e-08
- O 0 5.697574579244247e-06
specific O 0 3.8076311881241054e-08
primers O 0 7.048719453450758e-06
, O 0 4.491863236921745e-08
and O 0 1.8163629533773928e-07
zygosity O 0 0.00161504908464849
was O 0 2.768978220046847e-07
assessed O 0 3.880204985762248e-06
using O 0 6.636503826484841e-07
microsatellite O 0 0.018076639622449875
markers O 0 0.000608379952609539
. O 0 3.66989552276209e-05

Genetic O 0 0.0005556687247008085
and O 0 1.771777419889986e-06
environmental O 0 1.5567928130622022e-05
variance O 0 4.269236058007664e-07
components O 0 3.932172205622919e-07
were O 0 6.2885407992041564e-09
assessed O 0 1.8149118830024236e-07
with O 0 1.1206688022014077e-08
the O 0 4.9968619464380026e-08
program O 0 3.0379842428374104e-06
Mx O 0 0.0010023008799180388
, O 0 4.122788777038977e-09
using O 0 1.5907686279348354e-09
data O 0 5.426088911519855e-09
from O 0 1.7705196198036788e-09
this O 0 9.54730183799768e-10
and O 0 4.458307500954106e-09
previous O 0 7.038832450234622e-08
studies O 0 8.979806409570301e-08
of O 0 3.835138784324954e-08
twins O 0 0.0001923154923133552
with O 0 1.8206253571406705e-06
AS B-Disease 0 4.45109217253048e-05
. O 0 2.078445686493069e-05

RESULTS O 0 4.658081707020756e-06
Six O 0 4.0568227177573135e-07
of O 0 1.7452109091209422e-07
8 O 0 5.288921329338336e-06
monozygotic O 0 0.011295761913061142
( O 0 3.586810635169968e-05
MZ O 1 0.9720028042793274
) O 0 3.255366664234316e-06
twin O 0 0.0004506900440901518
pairs O 0 1.832128327805549e-05
were O 0 2.930720938820741e-06
disease O 1 0.9926548004150391
concordant O 0 0.010291636921465397
, O 0 2.3171405416633206e-07
compared O 0 3.838615327822481e-07
with O 0 1.720228759438669e-08
4 O 0 4.0486437313802526e-08
of O 0 5.615827358695924e-09
15 O 0 3.0995232691566343e-07
B27 O 0 7.869824912631884e-05
- O 0 2.6773977879201993e-05
positive O 0 4.174094954123575e-07
dizygotic O 0 0.0012751688482239842
( O 0 1.6687113202351611e-06
DZ O 0 0.004030551295727491
) O 0 7.258502421336743e-08
twin O 0 3.4844667879951885e-06
pairs O 0 1.520551791145408e-07
( O 0 5.308368855594381e-08
27 O 0 4.6097564876390607e-08
% O 0 6.934674168235233e-09
) O 0 3.8226120047113454e-09
and O 0 6.400018848218281e-10
4 O 0 3.533079828699215e-09
of O 0 1.324359288901178e-09
32 O 0 3.6043331874680007e-07
DZ O 0 0.0019206847064197063
twin O 0 9.830525414145086e-06
pairs O 0 2.1160271046483103e-07
overall O 0 9.21204332371417e-07
( O 0 1.788238677136178e-07
12 O 0 4.5166572704147256e-08
. O 0 1.2869280752170198e-08
5 O 0 1.6608603914392006e-07
% O 0 2.1643529635184677e-07
) O 0 7.639661703251477e-07
. O 0 2.1428586478577927e-06

Nonsignificant O 0 0.1284676343202591
increases O 0 0.0001090638033929281
in O 0 4.959726425113331e-07
similarity O 0 1.2945595244673314e-06
with O 0 2.5170680828523473e-07
regard O 0 1.9842298115690937e-06
to O 0 9.823878599490854e-07
age O 0 0.005135414656251669
at O 0 0.05841519311070442
disease O 1 0.999735414981842
onset O 1 0.9956721067428589
and O 0 1.8379033406290546e-07
all O 0 2.3742801502635302e-08
of O 0 1.032847649184987e-06
the O 0 0.0006283089751377702
disease O 1 0.9996308088302612
severity O 1 0.8383011221885681
scores O 0 3.9204940549097955e-05
assessed O 0 2.5399340302101336e-05
were O 0 8.51788257705266e-08
noted O 0 2.3320622858591378e-05
in O 0 2.9869408535887487e-05
disease O 1 0.9979925155639648
- O 0 0.40839800238609314
concordant O 1 0.9417352080345154
MZ O 1 0.997962236404419
twins O 0 0.005495033226907253
compared O 0 0.00012116072321077809
with O 0 2.5707335225888528e-05
concordant O 1 0.9409864544868469
DZ O 1 0.9874934554100037
twins O 0 0.0711427703499794
. O 0 8.785349200479686e-05

HLA O 1 0.6802890300750732
- O 0 0.004053926095366478
B27 O 0 0.002759605646133423
and O 0 1.8488162822904997e-06
B60 O 0 0.0003015903348568827
were O 0 4.5492175360095644e-08
associated O 0 2.6781149244925473e-06
with O 0 8.989511570689501e-07
the O 0 1.8686909243115224e-05
disease O 1 0.9929375052452087
in O 0 1.8571909095044248e-06
probands O 0 0.09324456751346588
, O 0 6.997068879854851e-08
and O 0 1.0538859562814196e-08
the O 0 4.943406040069931e-08
rate O 0 1.9487524696160108e-06
of O 0 1.7320469396508997e-06
disease O 1 0.9927099943161011
concordance O 0 0.00031749517074786127
was O 0 8.390197763219476e-07
significantly O 0 1.332203100901097e-05
increased O 0 6.771916218895058e-07
among O 0 3.693807286708761e-07
DZ O 0 0.02477549947798252
twin O 0 3.286289575044066e-05
pairs O 0 2.2194052462509717e-07
in O 0 7.038077676213561e-09
which O 0 7.0220944614618475e-09
the O 0 5.150869952785797e-08
co O 0 0.00012394705845508724
- O 0 0.0012179194018244743
twin O 0 8.79442595760338e-05
was O 0 7.813481062157734e-08
positive O 0 6.137177877008071e-08
for O 0 2.2793850362745616e-08
both O 0 2.0603160066912096e-07
B27 O 0 0.001690506935119629
and O 0 7.000812729529571e-06
DR1 O 0 0.4090760350227356
. O 0 1.9674389477586374e-05

Additive O 0 0.0009780024411156774
genetic O 0 0.0010519420029595494
effects O 0 0.00014683662448078394
were O 0 5.1543491252914464e-08
estimated O 0 4.852565780311124e-07
to O 0 1.7319226941481247e-08
contribute O 0 8.216993592213839e-07
97 O 0 1.6563253666390665e-06
% O 0 1.8281170355294307e-08
of O 0 3.4551288496942334e-09
the O 0 2.339517735094887e-08
population O 0 3.283560943145858e-07
variance O 0 2.095556055792258e-06
. O 0 4.720689958048752e-06

CONCLUSION O 0 0.00040374105446971953
Susceptibility O 0 0.006469117011874914
to O 0 1.2596012766152853e-06
AS B-Disease 0 3.6467090467340313e-06
is O 0 2.1528165916606667e-07
largely O 0 6.080342132008809e-07
genetically O 0 1.0556225788604934e-05
determined O 0 7.662924303986074e-07
, O 0 8.02530237820065e-08
and O 0 4.1164106789892685e-08
the O 0 2.6397293595437077e-07
environmental O 0 0.00021647490211762488
trigger O 0 0.0028712772764265537
for O 0 2.5057324819499627e-06
the O 0 0.00020505383145064116
disease O 1 0.9989103078842163
is O 0 4.820343292522011e-06
probably O 0 2.576656152086798e-05
ubiquitous O 0 0.0011734896106645465
. O 0 2.3581071218359284e-05

HLA O 1 0.8052734732627869
- O 0 0.0030750862788408995
B27 O 0 0.0008290708065032959
accounts O 0 4.5162522610553424e-07
for O 0 5.5609369553621946e-08
a O 0 6.756859960432848e-08
minority O 0 4.19630282522121e-07
of O 0 2.4648661778314818e-08
the O 0 4.440556153895159e-07
overall O 0 0.00024119738372974098
genetic O 0 0.0023330149706453085
susceptibility O 0 0.021293044090270996
to O 0 1.521629542367009e-06
AS B-Disease 0 3.0470248020719737e-05
. O 0 2.2759393687010743e-05

Cell O 0 0.0003280180389992893
cycle O 0 0.00019565359980333596
- O 0 0.00021550903329625726
dependent O 0 1.1539794286363758e-05
colocalization O 0 0.00040999907650984824
of O 0 3.6932505054210196e-07
BARD1 O 0 0.04885140806436539
and O 0 8.68563120093313e-07
BRCA1 O 0 0.0003098161250818521
proteins O 0 9.450328519733375e-08
in O 0 4.881836090930847e-08
discrete O 0 1.7661849369687843e-06
nuclear O 0 7.588933658553287e-05
domains O 0 4.289222852094099e-05
. O 0 9.193102414428722e-06

Germ O 0 0.48880982398986816
- O 0 0.0005803311942145228
line O 0 4.7744415496708825e-06
mutations O 0 1.2332070582488086e-06
of O 0 2.951876609813553e-08
the O 0 3.2117492310135276e-07
BRCA1 O 0 0.006277254316955805
gene O 0 4.103650644537993e-05
predispose O 0 0.0012624746887013316
women O 0 2.660458221726003e-06
to O 0 6.096717015680042e-07
early O 0 0.0006757822702638805
- O 1 0.9976569414138794
onset O 1 0.999601423740387
breast B-Disease 1 0.9995214939117432
and I-Disease 1 0.8384242057800293
ovarian I-Disease 1 0.999881386756897
cancer I-Disease 1 0.9996765851974487
by O 0 7.230318260553759e-06
compromising O 0 0.0017747451784089208
the O 0 1.944158157130005e-06
genes O 0 2.964143277495168e-05
presumptive O 0 0.1373509019613266
function O 0 2.026188440140686e-06
as O 0 1.448066200282483e-06
a O 0 9.569218673277646e-05
tumor B-Disease 1 0.9858798384666443
suppressor O 0 0.24486693739891052
. O 0 5.125701500219293e-05

Although O 0 2.2656374767393572e-06
the O 0 5.802550617772795e-07
biochemical O 0 1.4807790648774244e-05
properties O 0 1.2952696124557406e-06
of O 0 5.941666927355982e-07
BRCA1 O 0 0.04006151109933853
polypeptides O 0 8.000998786883429e-05
are O 0 1.6988551010399533e-08
not O 0 1.3908721285815773e-08
understood O 0 2.177374938128196e-07
, O 0 6.652216555380619e-09
their O 0 2.827280631834128e-09
expression O 0 5.305797756705033e-08
pattern O 0 6.401868404282141e-07
and O 0 1.790243153720894e-08
subcellular O 0 2.6442849048180506e-06
localization O 0 1.948358658410143e-06
suggest O 0 8.71101732968782e-08
a O 0 2.7164205107510497e-08
role O 0 1.1335657745803474e-07
in O 0 1.4311531515431852e-07
cell O 0 0.0001610398176126182
- O 0 0.0016992706805467606
cycle O 0 0.00013185299758333713
regulation O 0 6.448499334510416e-05
. O 0 7.641332558705471e-06

When O 0 0.00010665043373592198
resting O 0 0.007305250037461519
cells O 0 0.00013909282279200852
are O 0 3.016523066889931e-07
induced O 0 0.0012387116439640522
to O 0 3.1092577046365477e-07
proliferate O 0 0.00025594441103748977
, O 0 2.3254681735807026e-08
the O 0 8.485560698545669e-09
steady O 0 1.4695491472593858e-06
- O 0 5.209179562370991e-06
state O 0 1.2927020343056483e-08
levels O 0 4.4607681104480434e-08
of O 0 6.097272020610944e-09
BRCA1 O 0 2.2915790395927615e-05
increase O 0 5.232373467833895e-08
in O 0 9.785895649372378e-09
late O 0 8.953977612691233e-07
G1 O 0 0.0025036607403308153
and O 0 6.930469531596373e-09
reach O 0 2.394595988164383e-08
a O 0 1.916859027062401e-08
maximum O 0 1.292813465170184e-07
during O 0 1.2551646477731992e-06
S O 0 0.0007285202736966312
phase O 0 5.207944559515454e-05
. O 0 7.910599379101768e-06

Moreover O 0 0.00010529092833166942
, O 0 2.2562410322279902e-06
in O 0 9.066905590771057e-07
S O 0 0.0017401808872818947
phase O 0 4.6466684580082074e-05
cells O 0 3.6873763747280464e-05
, O 0 6.088895929678984e-07
BRCA1 O 0 0.00043910724343732
polypeptides O 0 3.524410431055003e-06
are O 0 8.446321864141737e-09
hyperphosphorylated O 0 5.957032408332452e-05
and O 0 2.6270161157526672e-08
accumulate O 0 3.8459365896414965e-06
into O 0 2.501305118585151e-08
discrete O 0 1.770509015841526e-06
subnuclear O 0 0.014646371826529503
foci O 0 0.0020059184171259403
termed O 0 0.0003948634839616716
" O 0 7.5655875662050676e-06
BRCA1 O 0 0.00652373256161809
nuclear O 0 0.00018340468523092568
dots O 0 0.0004586146678775549
. O 0 8.083638931566384e-06

" O 0 0.0002061919221887365
BRCA1 O 0 0.2401418834924698
associates O 0 0.0031825059559196234
in O 0 1.5247395594997215e-06
vivo O 0 8.300937770400196e-05
with O 0 4.919956495541555e-07
a O 0 5.008244443160947e-06
structurally O 0 0.0029222045559436083
related O 0 0.00010564926196821034
protein O 0 6.027793642715551e-05
termed O 0 0.0026169377379119396
BARD1 O 1 0.6119880080223083
. O 0 3.546691368683241e-05

Here O 0 2.286656126671005e-06
we O 0 7.381066779998946e-08
show O 0 3.784728974665086e-08
that O 0 3.0172979670339828e-09
the O 0 1.2681704575356889e-08
steady O 0 3.0428554964601062e-06
- O 0 8.479029929731041e-06
state O 0 2.244286001484852e-08
levels O 0 9.517655996660324e-08
of O 0 1.8081012242987526e-08
BARD1 O 0 0.0067254602909088135
, O 0 4.697521305274677e-08
unlike O 0 1.8435083859458246e-07
those O 0 7.2519261706816e-09
of O 0 1.0121834748133551e-07
BRCA1 O 0 0.054911352694034576
, O 0 3.2001398153624905e-07
remain O 0 3.2654236292728456e-07
relatively O 0 4.7357232801914506e-07
constant O 0 1.7339277746941661e-06
during O 0 4.62734533357434e-06
cell O 0 0.0004504872777033597
cycle O 0 0.0009579489124007523
progression O 0 0.0516459085047245
. O 0 3.090656900894828e-05

However O 0 2.9995489967404865e-05
, O 0 7.492650638596388e-06
immunostaining O 0 0.006257510744035244
revealed O 0 2.664067505975254e-05
that O 0 5.212978635427135e-07
BARD1 O 0 0.03547782823443413
resides O 0 1.3142214811523445e-05
within O 0 2.7555014980862325e-07
BRCA1 O 0 0.0023381884675472975
nuclear O 0 2.365183536312543e-05
dots O 0 2.2134086975711398e-05
during O 0 4.041160650558595e-07
S O 0 5.629131192108616e-05
phase O 0 4.5737874643236864e-07
of O 0 5.913850742444993e-09
the O 0 4.4529219422884125e-08
cell O 0 1.286749102291651e-05
cycle O 0 2.749568693616311e-06
, O 0 2.4659712494212727e-08
but O 0 3.9995278200422035e-09
not O 0 1.429714124867587e-09
during O 0 6.127960716639791e-08
the O 0 1.7331593937797152e-07
G1 O 0 0.02870102785527706
phase O 0 7.402144547086209e-05
. O 0 6.7629139266500715e-06

Nevertheless O 0 0.00018734134209807962
, O 0 1.0914749509538524e-05
BARD1 O 0 0.01918974332511425
polypeptides O 0 3.437650957494043e-05
are O 0 1.7779585803623377e-08
found O 0 1.2266235138724824e-08
exclusively O 0 9.631956565669952e-09
in O 0 3.163283412987994e-09
the O 0 2.708007595941808e-09
nuclear O 0 8.493854863900197e-08
fractions O 0 8.867740319828954e-09
of O 0 2.501446827452014e-09
both O 0 3.6250781931812526e-08
G1 O 0 0.020207513123750687
- O 0 8.479227835778147e-05
and O 0 3.3648089470261766e-07
S O 0 0.004216074477881193
- O 0 0.0006736583891324699
phase O 0 9.206638787873089e-05
cells O 0 0.0001619877148186788
. O 0 4.8072329263959546e-06

Therefore O 0 1.0123539141204674e-05
, O 0 1.962722308235243e-06
progression O 0 0.00021576377912424505
to O 0 2.9714507832068193e-07
S O 0 0.0012469704961404204
phase O 0 4.457082923181588e-06
is O 0 1.2078991140640483e-08
accompanied O 0 1.366462782925737e-07
by O 0 4.891657745531575e-09
the O 0 5.718840512258794e-09
aggregation O 0 2.763470092759235e-07
of O 0 2.0829025615398677e-08
nuclear O 0 1.3092077097098809e-05
BARD1 O 0 0.003132578916847706
polypeptides O 0 1.243063888978213e-05
into O 0 1.6591457097092643e-06
BRCA1 O 0 0.00896504893898964
nuclear O 0 0.00020976686209905893
dots O 0 0.00046164990635588765
. O 0 8.38096639199648e-06

This O 0 4.135986273468006e-06
cell O 0 5.177727871341631e-05
cycle O 0 7.459441258106381e-05
- O 0 0.00018738942162599415
dependent O 0 7.0146402322279755e-06
colocalization O 0 0.00039164620102383196
of O 0 2.752061050159682e-07
BARD1 O 0 0.1578514575958252
and O 0 1.4596434994018637e-06
BRCA1 O 0 0.0021372418850660324
indicates O 0 1.013569203678344e-06
a O 0 3.116280922199621e-08
role O 0 1.4619001831306377e-07
for O 0 2.3233363322106015e-07
BARD1 O 0 0.08677910268306732
in O 0 7.886426828918047e-06
BRCA1 O 1 0.8364995121955872
- O 0 0.44694259762763977
mediated O 0 0.24944670498371124
tumor B-Disease 1 0.989902138710022
suppression O 0 0.03782220929861069
. O 0 5.331400825525634e-05

Ethnic O 0 6.390488579199882e-06
differences O 0 5.244161002337933e-06
in O 0 2.887580876631546e-07
the O 0 3.5050263136326976e-07
HFE O 0 0.021640611812472343
codon O 0 1.5691284716012888e-05
282 O 0 0.00032554316567257047
( O 0 5.4385796829592437e-05
Cys O 1 0.9328266978263855
/ O 0 0.09082967042922974
Tyr O 0 0.2840171456336975
) O 0 3.92870424548164e-06
polymorphism O 0 7.718099368503317e-05
. O 0 5.281532594381133e-06

Recent O 0 7.160627137636766e-05
studies O 0 6.762572411389556e-06
have O 0 4.85818702600227e-07
shown O 0 4.388254183140816e-06
that O 0 2.7158741431776434e-05
hereditary B-Disease 1 0.9982238411903381
hemochromatosis I-Disease 1 0.9996718168258667
( O 0 0.1292356550693512
HH B-Disease 1 0.9992246627807617
) O 0 4.3958148125966545e-06
is O 0 9.854547045051731e-08
likely O 0 3.572554874153866e-07
to O 0 2.0309611770130687e-08
be O 0 8.814335039630805e-09
caused O 0 6.887544714118121e-06
by O 0 4.311361934128399e-08
homozygosity O 0 0.0003332076012156904
for O 0 3.229011724670272e-08
a O 0 2.3108380275971285e-07
Cys282Tyr O 0 0.005183025728911161
mutation O 0 1.938237801368814e-06
in O 0 5.403947156423783e-08
the O 0 4.89744877540943e-07
HFE O 0 0.35372769832611084
gene O 0 7.556112905149348e-06
located O 0 1.0115820714418078e-06
4 O 0 8.715854164620396e-06
. O 0 5.830385362060042e-06

5 O 0 7.760038715787232e-05
Mb O 0 0.006983062718063593
telomeric O 0 0.018793566152453423
to O 0 1.986535789910704e-05
HLA O 1 0.8755434155464172
- O 0 0.0031910960096865892
A O 0 3.4109707485185936e-05
. O 0 2.8280697733862326e-05

Population O 0 8.690572030900512e-06
studies O 0 7.599550144732348e-07
of O 0 2.6717010825905163e-08
this O 0 2.8072820512647922e-08
polymorphism O 0 1.8833886770153185e-06
are O 0 3.1486679930026185e-09
facilitated O 0 2.4355836103495676e-07
by O 0 7.293778025996289e-09
the O 0 5.397300828491325e-09
fact O 0 1.4632650646717593e-08
that O 0 3.196946929406863e-09
the O 0 3.434152162640203e-08
Cys282Tyr O 0 0.005766713991761208
mutation O 0 9.671642146713566e-06
creates O 0 8.661017091071699e-06
a O 0 1.8671502175493515e-06
Rsal O 0 0.009397724643349648
restriction O 0 3.0826882721157745e-05
site O 0 6.162559657241218e-06
. O 0 7.357336471613962e-06

We O 0 9.570809424985782e-07
have O 0 6.492099657862127e-08
studied O 0 5.429673421986081e-08
the O 0 2.6630011973338696e-08
codon O 0 2.228717448815587e-06
282 O 0 6.240072252694517e-05
( O 0 2.2731021090294234e-05
Cys O 1 0.8314893245697021
/ O 0 0.03141263499855995
Tyr O 0 0.05149431154131889
) O 0 1.6805311986445304e-07
polymorphism O 0 4.575209686663584e-07
in O 0 9.224367936155886e-09
different O 0 5.264082947320503e-09
ethnic O 0 2.5004186454680166e-07
groups O 0 9.903091040541767e-07
. O 0 8.840418558975216e-06

In O 0 1.7503791696071858e-06
agreement O 0 8.874145009940548e-07
with O 0 9.020043023610924e-08
previous O 0 2.3596129494762863e-07
observations O 0 3.2185161558118125e-07
the O 0 5.455401606013766e-07
Tyr O 0 0.21293121576309204
allele O 0 1.3872769159206655e-05
appeared O 0 7.176599865488242e-07
to O 0 2.0747664919440467e-08
be O 0 7.63957164195972e-09
rare O 0 4.31885382567998e-06
or O 0 4.102788295767823e-07
absent O 0 7.525764885940589e-06
in O 0 4.2719767634480377e-07
Asiatic O 0 0.00948162842541933
( O 0 2.242781192762777e-06
Indian O 0 1.1497669447635417e-06
, O 0 1.2752974498653202e-07
Chinese O 0 8.611564794591686e-07
) O 0 2.248306600449723e-06
populations O 0 1.270986922463635e-05
. O 0 4.367371730040759e-06

The O 0 6.054592631699052e-07
highest O 0 1.0910855507972883e-06
allele O 0 1.5379282558569685e-06
frequency O 0 1.0069132372336753e-07
( O 0 8.493093872630197e-08
7 O 0 5.737317820830867e-08
. O 0 6.150511211444609e-09
5 O 0 3.598219322498153e-08
% O 0 1.8003925461584913e-08
) O 0 1.707851460253096e-08
was O 0 6.933404517184272e-09
found O 0 2.2165830060316694e-08
in O 0 1.205420829819559e-07
Swedes O 0 7.550921873189509e-05
. O 0 9.326427971245721e-06

Saamis O 0 0.005351008847355843
( O 0 5.8882528719550464e-06
2 O 0 1.177334979729494e-06
% O 0 2.4834125156303344e-07
) O 0 1.2810534144591657e-07
and O 0 5.1516266807993816e-08
Mordvinians O 0 0.0002814363979268819
( O 0 9.783081367231716e-08
1 O 0 1.5642829254147728e-08
. O 0 1.6472866404271258e-09
8 O 0 2.929603049039997e-08
% O 0 1.8103166965488526e-08
) O 0 1.7309847777369214e-08
had O 0 6.034564403734066e-09
significantly O 0 1.0474016676198517e-07
lower O 0 2.7526375845354778e-08
frequencies O 0 3.4600156073594235e-09
of O 0 4.615860582646292e-09
the O 0 2.3666578385928005e-07
Tyr O 0 0.265699565410614
allele O 0 8.276349399238825e-05
. O 0 8.995319149107672e-06

Comparisons O 0 9.125372343987692e-06
with O 0 5.064962351752911e-07
allele O 0 2.649924454090069e-06
frequencies O 0 1.6059338747709262e-07
based O 0 1.3977006574350526e-07
on O 0 2.355794919139953e-07
prevalence O 0 0.008655508048832417
estimates O 0 7.182007266237633e-06
of O 0 9.727425549499458e-07
HH B-Disease 1 0.9954912066459656
showed O 0 1.5137009086174658e-06
some O 0 1.8095846598953358e-08
disagreements O 0 1.1054261221943307e-06
with O 0 3.1243452269791305e-08
the O 0 1.0952749107673299e-07
RFLP O 0 0.000415110494941473
data O 0 7.029453996665325e-08
, O 0 5.475860831438695e-08
particularly O 0 4.03611522870051e-07
in O 0 3.9650691974202346e-07
Finns O 0 0.00026306419749744236
. O 0 1.4880256458127405e-05

The O 0 5.3802182264917064e-06
newly O 0 4.895315578323789e-05
described O 0 0.00015480189176741987
HFE O 1 0.5740823745727539
marker O 0 2.9647255360032432e-05
provides O 0 4.2231650354551675e-07
a O 0 4.582729218327586e-08
new O 0 7.336419116654724e-08
approach O 0 6.607731251051518e-08
to O 0 7.008486679893622e-09
the O 0 1.8940065515948845e-08
screening O 0 4.275594164937502e-06
of O 0 3.2691346518731734e-07
HH B-Disease 1 0.9876784682273865
as O 0 4.0835193004795656e-08
well O 0 9.99822358238589e-09
as O 0 5.893604715367928e-09
studies O 0 1.5763893301823373e-08
of O 0 2.084980410543835e-09
the O 0 1.1794478282922682e-08
relationship O 0 7.606597591802711e-07
between O 0 3.6443651652007247e-07
the O 0 7.768818250042386e-06
HFE O 1 0.9948140382766724
Tyr O 1 0.9794689416885376
allele O 0 0.00023075587523635477
and O 0 5.480162144522183e-06
different O 0 2.7063699235441163e-05
disorders O 1 0.9976871013641357
including O 0 0.020906800404191017
cancer B-Disease 1 0.9961613416671753

Autosomal B-Disease 1 0.9870170950889587
dominant I-Disease 1 0.9845888018608093
neurohypophyseal I-Disease 1 0.9965804219245911
diabetes I-Disease 1 0.9993335604667664
insipidus I-Disease 1 0.9977118968963623
associated O 0 6.867257616249844e-05
with O 0 4.147604784066061e-07
a O 0 1.1434051430114778e-06
missense O 0 9.940094605553895e-05
mutation O 0 4.092185008630622e-06
encoding O 0 1.9684712242451496e-06
Gly23 O 0 0.011198149994015694
- O 0 0.005708066280931234
- O 0 0.01589091867208481
> O 0 0.00960878562182188
Val O 0 0.002764603355899453
in O 0 2.834658289430081e-06
neurophysin O 0 0.1681763082742691
II O 0 0.10077904164791107
. O 0 2.9540831746999174e-05

Autosomal B-Disease 1 0.9765106439590454
dominant I-Disease 1 0.9768202304840088
neurohypophyseal I-Disease 1 0.9942911863327026
diabetes I-Disease 1 0.9992008805274963
insipidus I-Disease 1 0.9976028800010681
( O 0 0.00911027006804943
ADNDI B-Disease 1 0.9807190895080566
) O 0 6.466665945481509e-05
is O 0 2.0706191207864322e-05
an O 0 0.014418360777199268
inherited B-Disease 1 0.9997509121894836
disease I-Disease 1 0.9998341798782349
caused O 1 0.606456995010376
by O 0 6.520638999063522e-05
progressive O 1 0.5911695957183838
degeneration O 1 0.9967401623725891
of O 0 3.0861502864354406e-07
the O 0 1.9299836822028738e-06
magnocellular O 0 0.13786636292934418
neurons O 0 5.347153091861401e-06
of O 0 9.844961290639276e-09
the O 0 1.4748209764547937e-07
hypothalamus O 0 6.828103505540639e-05
leading O 0 1.9567191884561908e-06
to O 0 1.785210912430557e-07
decreased O 0 1.4493853086605668e-05
ability O 0 8.645915272609273e-08
to O 0 5.844038586388933e-09
produce O 0 5.8421687043619386e-08
the O 0 1.4312814755612635e-07
hormone O 0 0.00013812191900797188
arginine O 0 2.8802844099118374e-05
vasopressin O 0 0.0006764614954590797
( O 0 1.3431228580884635e-05
AVP O 0 0.014712533913552761
) O 0 3.7629624785040505e-06
. O 0 3.566995928849792e-06

Affected O 0 0.0006024304893799126
individuals O 0 3.6077897220820887e-06
are O 0 1.3754893757322861e-07
not O 0 4.5600768316944595e-07
symptomatic O 0 0.41030293703079224
at O 0 8.488455932820216e-06
birth O 0 0.0003041019954252988
, O 0 1.8378785853201407e-06
but O 0 2.0809745819860836e-06
usually O 0 9.843787120189518e-05
develop O 1 0.8583769202232361
diabetes B-Disease 1 0.9996954202651978
insipidus I-Disease 1 0.9983571171760559
at O 0 6.5819099290820304e-06
1 O 0 9.344847967440728e-06
- O 0 0.0006131483241915703
6 O 0 2.2937458197702654e-05
yr O 0 0.017016274854540825
of O 0 2.5884355636662804e-07
age O 0 5.073771899333224e-05
. O 0 1.3234504876891151e-05

The O 0 4.845980129175587e-06
genetic O 0 5.116642205393873e-05
locus O 0 2.5516823370708153e-05
of O 0 6.22620746071334e-07
the O 0 1.8971080862684175e-05
disease O 1 0.8909764885902405
is O 0 2.1108027681293606e-07
the O 0 7.629591891600285e-07
AVP O 0 0.32163864374160767
- O 0 0.020117511972784996
neurophysin O 0 0.37451937794685364
II O 0 0.07968033850193024
( O 0 1.0945103895210195e-05
NPII O 0 0.028267957270145416
) O 0 3.224070326268702e-07
gene O 0 7.503266488129157e-07
, O 0 2.176809665854762e-08
and O 0 4.1465202826884706e-08
mutations O 0 7.872315109125338e-06
that O 0 2.4143625410033565e-07
cause O 0 0.0014114670921117067
ADNDI B-Disease 0 0.33798155188560486
have O 0 2.2662931087324978e-08
been O 0 5.295886396083915e-09
found O 0 6.197851565303836e-09
in O 0 1.3720714564513514e-09
both O 0 1.1713316983019695e-09
the O 0 1.936913740507862e-09
signal O 0 2.706924462358984e-08
peptide O 0 5.203789754659738e-08
of O 0 2.4941482212881283e-09
the O 0 3.830883343880487e-08
prepro O 0 0.0038414429873228073
- O 0 0.0037310379557311535
AVP O 0 0.22473843395709991
- O 0 0.0014851141022518277
NPII O 0 0.013574160635471344
precursor O 0 1.055906614055857e-05
and O 0 1.6934501445575734e-07
within O 0 5.167697736396804e-07
NPII O 0 0.04687377065420151
itself O 0 4.830260149901733e-05
. O 0 1.0921892680926248e-05

An O 0 2.0790088456124067e-05
affected O 0 0.00021974123956169933
girl O 0 7.709403871558607e-05
who O 0 5.391247555053269e-07
presented O 0 3.901482443779969e-07
at O 0 2.0836903047438682e-07
9 O 0 9.775151283974992e-07
months O 0 3.311479872536438e-07
of O 0 2.1939664307524254e-08
age O 0 6.012014182488201e-06
and O 0 1.4594108677101758e-07
her O 0 5.651888386637438e-06
similarly O 0 7.914898014860228e-05
affected O 0 0.0001221523416461423
younger O 0 0.00012704485561698675
brother O 0 4.143453770666383e-05
and O 0 1.9644473070457025e-07
father O 0 5.329185910341039e-07
were O 0 1.4287599992002242e-09
all O 0 9.187296479140628e-10
found O 0 4.215786830741308e-09
to O 0 1.0219187718263356e-09
have O 0 1.100129209952172e-09
a O 0 1.647180525310432e-08
novel O 0 1.161671548288723e-06
missense O 0 3.900487718055956e-05
mutation O 0 2.287478537255083e-06
( O 0 8.916774731915211e-07
G1758 O 0 0.0005355824832804501
- O 0 0.0008824376855045557
- O 0 0.0019180612871423364
> O 0 0.0009224468376487494
T O 0 0.0001743866305332631
) O 0 2.8085282988143945e-09
encoding O 0 1.9121693117796212e-09
the O 0 4.702715994397977e-10
amino O 0 3.991555974636185e-09
acid O 0 1.6121794033097103e-07
substitution O 0 3.432391508795263e-07
Gly23 O 0 0.0008140567224472761
- O 0 0.0007183720590546727
- O 0 0.0018926489865407348
> O 0 0.0017696162685751915
Val O 0 0.0014360087225213647
within O 0 1.351371679447766e-06
NPII O 0 0.0219113826751709
. O 0 1.387218708259752e-05

The O 0 1.0993244359269738e-05
mutation O 0 9.51397159951739e-05
was O 0 1.1380690239093383e-06
confirmed O 0 1.0048860303868423e-06
by O 0 2.238141689758777e-07
restriction O 0 2.5525489036226645e-05
endonuclease O 0 0.005651565734297037
analysis O 0 1.2103296285204124e-05
. O 0 1.094940489565488e-05

A O 0 4.4258991692913696e-05
T1 O 0 0.02489938586950302
- O 0 3.603218647185713e-05
weighted O 0 6.224568664947583e-07
magnetic O 0 9.88304236670956e-07
resonance O 0 3.5781167753157206e-06
imaging O 0 1.1477904081402812e-05
of O 0 5.087919063839763e-08
the O 0 7.632554002157121e-07
fathers O 0 0.0004338812141213566
pituitary O 1 0.9503145217895508
gland O 0 0.3562261164188385
demonstrates O 0 0.00022329197963699698
an O 0 1.0643891073414125e-05
attenuated O 0 0.3188576102256775
posterior O 0 0.21654430031776428
pituitary O 1 0.8011195063591003
bright O 0 0.002772497246041894
spot O 0 0.00015316800272557884
. O 0 2.8422535251593217e-05

This O 0 9.957307156582829e-06
mutation O 0 0.00019338088168296963
may O 0 9.94381366581365e-07
be O 0 6.813880126799177e-09
valuable O 0 4.3465771426554056e-08
for O 0 2.1661033855480127e-08
developing O 0 5.442308975034393e-06
models O 0 2.9015427571721375e-06
of O 0 2.6710060865298146e-06
dominantly B-Disease 1 0.9905891418457031
inherited I-Disease 1 0.9986542463302612
neurodegeneration I-Disease 1 0.9996417760848999
, O 0 1.1307299701002194e-06
as O 0 2.6601076896781706e-08
the O 0 1.641594593593254e-08
early O 0 3.135652946184564e-07
age O 0 5.359631359169725e-06
of O 0 2.6536065433901967e-06
onset O 1 0.9990561604499817
of O 0 0.00023861609224695712
symptoms O 1 0.9993283748626709
suggests O 0 0.0004042138170916587
that O 0 1.3798843667700567e-07
this O 0 2.4349608906959475e-07
mutation O 0 4.82216892123688e-05
may O 0 5.045417879045999e-07
be O 0 8.36444691287852e-09
particularly O 0 4.0614060026200605e-07
deleterious O 0 1.9859693566104397e-05
to O 0 5.764267996255512e-08
the O 0 1.4671659300802276e-06
magnocellular O 1 0.5286292433738708
neuron O 0 0.04563414305448532
. O 0 2.6483201054361416e-06
. O 0 7.99328881839756e-06

Frequent O 0 0.0008136732503771782
inactivation O 0 0.005093565210700035
of O 0 2.3661492377868854e-05
PTEN O 1 0.9834386706352234
/ O 1 0.7199036478996277
MMAC1 O 1 0.9454978108406067
in O 0 0.0016288512852042913
primary O 1 0.9456170797348022
prostate B-Disease 1 0.99908447265625
cancer I-Disease 1 0.9982302784919739
. O 0 0.0021853165235370398

Sporadic B-Disease 1 0.9828384518623352
prostate I-Disease 1 0.9987478256225586
carcinoma I-Disease 1 0.999170184135437
is O 0 4.080633971170755e-06
the O 0 8.694067332726263e-07
most O 0 1.2533763538158382e-06
common O 0 0.0001001008422463201
male B-Disease 0 0.006502251140773296
cancer I-Disease 1 0.9877816438674927
in O 0 2.5454926344536943e-07
the O 0 1.5510980233557348e-07
Western O 0 3.832970833173022e-06
world O 0 4.584675480145961e-06
, O 0 9.832973546508583e-08
yet O 0 1.8521021161177487e-08
many O 0 1.3145845523254707e-09
of O 0 1.520808368127291e-09
the O 0 2.1845709241574696e-08
major O 0 1.5480227375519462e-06
genetic O 0 8.531637831765693e-06
events O 0 1.487455989490627e-07
involved O 0 1.0230624525320309e-07
in O 0 5.454907991975233e-08
the O 0 1.0325408794642499e-07
progression O 0 0.0009968166705220938
of O 0 1.0586712306803747e-07
this O 0 3.2436494166177e-06
often O 0 0.0012695270124822855
fatal O 1 0.999163031578064
cancer B-Disease 1 0.9992331266403198
remain O 0 8.691168659424875e-06
to O 0 4.646691422749427e-07
be O 0 8.034558049985208e-07
elucidated O 0 0.005129025783389807
. O 0 2.4260691134259105e-05

Numerous O 0 6.72041715006344e-05
cytogenetic O 0 0.011388413608074188
and O 0 1.187713769468246e-05
allelotype O 0 0.017186354845762253
studies O 0 6.2777135099167936e-06
have O 0 1.824153770257908e-07
reported O 0 1.0592165381240193e-05
frequent O 0 3.456684135016985e-05
loss O 0 9.778419916983694e-05
of O 0 2.832180996392708e-07
heterozygosity O 0 0.06658174842596054
on O 0 2.473796939739259e-06
chromosomal O 0 0.0868428647518158
arm O 0 0.17743892967700958
10q O 0 0.49544069170951843
in O 0 0.0004287349584046751
sporadic B-Disease 1 0.9852985143661499
prostate I-Disease 1 0.9994526505470276
cancer I-Disease 1 0.9988998174667358
. O 0 0.002365570282563567

Deletion O 0 0.0010592882754281163
mapping O 0 6.333837518468499e-05
studies O 0 7.2459115472156554e-06
have O 0 2.3278208516330778e-07
unambiguously O 0 2.14672527363291e-05
identified O 0 5.186978455640201e-07
a O 0 8.73394299105712e-08
region O 0 4.5910582002761657e-07
of O 0 4.427709043852701e-08
chromosome O 0 9.91189808701165e-05
10q23 O 0 0.00021442989236675203
to O 0 2.665994536243943e-08
be O 0 4.600408498589559e-09
the O 0 2.9729180894833007e-08
minimal O 0 4.949448339175433e-06
area O 0 2.429435710382677e-07
of O 0 2.3318557396123651e-07
loss O 0 0.005165583919733763
. O 0 2.8315020244917832e-05

A O 0 3.485057095531374e-05
new O 0 8.760092896409333e-05
tumor B-Disease 1 0.7871606945991516
suppressor O 0 0.016929738223552704
gene O 0 9.334688365925103e-05
, O 0 1.9859446183545515e-05
PTEN O 1 0.9156261682510376
/ O 0 0.058814071118831635
MMAC1 O 0 0.07942388206720352
, O 0 5.715451152354944e-07
was O 0 3.2439541541862127e-07
isolated O 0 8.15031035017455e-06
recently O 0 1.0896047797359643e-06
at O 0 6.52809646339847e-08
this O 0 6.765601412439537e-09
region O 0 1.0594347799042225e-07
of O 0 1.9341014123597233e-08
chromosome O 0 4.8664576752344146e-05
10q23 O 0 0.0003906863566953689
and O 0 3.0242709669892065e-08
found O 0 1.9475203671959207e-08
to O 0 5.514607437362429e-09
be O 0 6.891425652355565e-09
inactivated O 0 4.460923264559824e-06
by O 0 4.7579550965792805e-08
mutation O 0 6.683289939246606e-06
in O 0 2.8459915029088734e-06
three O 0 0.0009984333300963044
prostate B-Disease 1 0.9997032284736633
cancer I-Disease 1 0.9995200634002686
cell O 0 0.04448896273970604
lines O 0 0.0005972457001917064
. O 0 4.469001942197792e-05

We O 0 1.9542614609235898e-05
screened O 0 0.0020178593695163727
80 O 0 0.17156703770160675
prostate B-Disease 1 0.999103307723999
tumors I-Disease 1 0.9983059167861938
by O 0 3.2816244583955267e-06
microsatellite O 0 0.02717532031238079
analysis O 0 9.596492418495473e-07
and O 0 1.7368127203098993e-07
found O 0 4.033979337236815e-07
chromosome O 0 3.003313031513244e-05
10q23 O 0 0.0001579050294822082
to O 0 2.5893235999774333e-08
be O 0 9.254149446746851e-09
deleted O 0 1.5694043895564391e-06
in O 0 1.1512258879520232e-07
23 O 0 1.0154539268114604e-05
cases O 0 3.448051575105637e-05
. O 0 9.913911526382435e-06

We O 0 4.17277391306925e-07
then O 0 7.746364616423307e-08
proceeded O 0 9.353474439421916e-08
with O 0 6.028513244160649e-09
sequence O 0 8.333235435031838e-09
analysis O 0 6.8772965100549754e-09
of O 0 2.4461310754730903e-09
the O 0 2.6086018678483924e-08
entire O 0 1.5480271031265147e-05
PTEN O 1 0.6955304145812988
/ O 0 0.04650980979204178
MMAC1 O 0 0.21410778164863586
coding O 0 0.0002021373511524871
region O 0 9.019059916681726e-07
and O 0 2.943044563608055e-08
tested O 0 5.34769753812725e-07
for O 0 1.4898303923871481e-08
homozygous O 0 2.3238624180521583e-06
deletion O 0 1.5266910850186832e-05
with O 0 9.63060031722307e-08
new O 0 1.849699856393272e-06
intragenic O 0 0.04017135128378868
markers O 0 1.2708123904303648e-05
in O 0 2.685648858857803e-08
these O 0 1.4832608030701522e-08
23 O 0 1.0304195257049287e-06
cases O 0 7.903199730208144e-07
with O 0 1.0039902917924337e-06
10q23 O 0 0.03889597952365875
loss O 0 0.0005809781141579151
of O 0 4.29154215453309e-06
heterozygosity O 0 0.4744583070278168
. O 0 8.61744410940446e-05

The O 0 4.7507643330391147e-07
identification O 0 1.9902667247606587e-07
of O 0 1.887868172900653e-08
the O 0 2.6813136599912468e-08
second O 0 1.816641770346905e-07
mutational O 0 0.00016065238742157817
event O 0 2.972811330437253e-07
in O 0 1.7787794348578245e-08
10 O 0 7.137197144402307e-08
( O 0 1.443957842184318e-07
43 O 0 9.631828561396105e-07
% O 0 9.644944611864048e-07
) O 0 1.270257416763343e-05
tumors B-Disease 1 0.98954176902771
establishes O 0 0.0077644954435527325
PTEN O 1 0.9434658885002136
/ O 0 0.008825442753732204
MMAC1 O 0 0.0011562422150745988
as O 0 6.461953638847717e-09
a O 0 1.5269945308205024e-08
main O 0 1.092172894345822e-07
inactivation O 0 5.8644091041060165e-05
target O 0 1.1375510666766786e-07
of O 0 1.3508302743048262e-07
10q O 0 0.027124891057610512
loss O 0 0.015887152403593063
in O 0 0.0002305840898770839
sporadic B-Disease 1 0.9918829202651978
prostate I-Disease 1 0.9997938275337219
cancer I-Disease 1 0.9994971752166748
. O 0 0.00010399870370747522
. O 0 8.907659503165632e-05

Risk O 0 0.015074786730110645
reversals O 0 0.0012148114619776607
in O 0 5.2826003411610145e-06
predictive O 0 0.0008668048540130258
testing O 0 0.008701968006789684
for O 0 0.010018989443778992
Huntington B-Disease 1 0.9986599683761597
disease I-Disease 1 0.9984439015388489
. O 0 0.0016826839419081807

The O 0 7.658540539523528e-07
first O 0 6.480532306341047e-07
predictive O 0 5.018754745833576e-05
testing O 0 0.00038867921102792025
for O 0 0.001993985613808036
Huntington B-Disease 1 0.9995704293251038
disease I-Disease 1 0.9995493292808533
( O 0 0.00010981612285831943
HD B-Disease 0 0.0018295611953362823
) O 0 1.6575248196204484e-07
was O 0 3.6842773276646312e-09
based O 0 1.7752265213388796e-09
on O 0 1.3036578483394123e-09
analysis O 0 7.84651366103617e-09
of O 0 4.607047188187607e-09
linked O 0 3.800408421739121e-06
polymorphic O 0 5.3388841479318216e-05
DNA O 0 1.9967774278484285e-06
markers O 0 1.7946947536984226e-06
to O 0 1.0063521571623824e-08
estimate O 0 1.7657609419075015e-07
the O 0 9.893395436222363e-09
likelihood O 0 6.967968602111796e-07
of O 0 1.2082677969260658e-08
inheriting O 0 0.00010857971938094124
the O 0 1.1814747580274343e-07
mutation O 0 7.931249456305522e-06
for O 0 3.459968525021395e-07
HD B-Disease 0 0.002467838581651449
. O 0 4.767002792505082e-06

Limits O 0 1.8874036413762951e-06
to O 0 7.86574148037289e-08
accuracy O 0 1.2303168261951214e-07
included O 0 3.82675011678657e-08
recombination O 0 7.080560635586153e-07
between O 0 2.814246080617977e-08
the O 0 1.9548744845110377e-08
DNA O 0 1.1473899803604581e-06
markers O 0 3.3779053865146125e-06
and O 0 1.9789819560855904e-08
the O 0 8.439835852414035e-08
mutation O 0 1.802252882043831e-05
, O 0 3.769237366668676e-07
pedigree O 0 0.0006390787311829627
structure O 0 1.7199816966240178e-06
, O 0 3.22947961706177e-08
and O 0 6.154853071649313e-09
whether O 0 1.5763202299012846e-08
DNA O 0 1.7752265080162033e-07
samples O 0 1.960497897357527e-08
were O 0 1.5700659661277427e-09
available O 0 1.9226810366035352e-08
from O 0 9.935758527035432e-08
family O 0 1.4144058013698668e-06
members O 0 4.3765089685621206e-07
. O 0 8.905079994292464e-06

With O 0 7.80819107149e-07
direct O 0 5.408070933299314e-07
tests O 0 8.989923117042053e-07
for O 0 4.349330495756476e-08
the O 0 1.0878277834081018e-07
HD B-Disease 0 0.0013644571881741285
mutation O 0 6.152394689706853e-06
, O 0 2.6108667228186277e-08
we O 0 2.4464295034221095e-09
have O 0 7.713817917753829e-10
assessed O 0 2.0170826786625184e-08
the O 0 5.242917211489839e-10
accuracy O 0 3.8514689215674025e-09
of O 0 7.641214883058467e-10
results O 0 1.555574158373929e-08
obtained O 0 6.327764534574953e-09
by O 0 4.46913706042551e-09
linkage O 0 2.213361085523502e-06
approaches O 0 3.2321054277417716e-07
when O 0 3.317149577242162e-08
requested O 0 9.40357836043404e-08
to O 0 7.892081654858885e-09
do O 0 1.0890792268014593e-08
so O 0 2.9554523273134237e-09
by O 0 6.1781411098138506e-09
the O 0 2.997018100359128e-08
test O 0 2.539455635997001e-06
individuals O 0 1.631623376852076e-06
. O 0 1.1432643077569082e-05

For O 0 2.210956154158339e-06
six O 0 8.344243838109833e-07
such O 0 2.088715689296805e-07
individuals O 0 5.791421813228226e-07
, O 0 2.2415657952024048e-07
there O 0 4.2417202195110804e-08
was O 0 1.6982113493213546e-07
significant O 0 1.2940978422193439e-06
disparity O 0 0.0005721194320358336
between O 0 8.558878334952169e-07
the O 0 1.2490926337704877e-06
tests O 0 2.31741250900086e-05
. O 0 1.1511984666867647e-05

Three O 0 1.346218709841196e-06
went O 0 2.5843162347882753e-06
from O 0 6.782283321626892e-07
a O 0 5.50288632439333e-06
decreased O 0 0.001239462522789836
risk O 0 0.00010940492938971147
to O 0 3.037938256511552e-08
an O 0 1.383469765414702e-07
increased O 0 1.5943734979373403e-05
risk O 0 0.00014997132529970258
, O 0 4.045200796554127e-08
while O 0 9.94914373109168e-09
in O 0 9.51088363621011e-09
another O 0 2.734537041249041e-08
three O 0 2.0175944470679497e-08
the O 0 8.102796300590853e-07
risk O 0 0.0023239385336637497
was O 0 4.772688953380566e-06
decreased O 0 0.0006983813364058733
. O 0 1.553351103211753e-05

Knowledge O 0 1.981138211704092e-06
of O 0 2.1260397886635474e-07
the O 0 2.38670338603697e-07
potential O 0 3.931185347028077e-06
reasons O 0 2.0083574270302051e-07
for O 0 8.889482927543213e-09
these O 0 5.196842955967895e-09
changes O 0 1.2715157993170578e-07
in O 0 4.772424588850299e-08
results O 0 1.8071500562655274e-07
and O 0 3.5579066803848036e-08
impact O 0 3.482788031305972e-07
of O 0 9.298559255910277e-09
these O 0 1.2714259867152577e-07
risk O 0 0.0004454157897271216
reversals O 0 0.0004085586406290531
on O 0 3.637545944457088e-07
both O 0 1.2287566732993582e-06
patients O 0 0.009606802836060524
and O 0 8.464807876862324e-08
the O 0 1.0765003111146143e-07
counseling O 0 4.5846285502193496e-05
team O 0 1.2020413464597368e-07
can O 0 6.5889267375496274e-09
assist O 0 3.6861983687686006e-08
in O 0 3.526367642336936e-09
the O 0 4.4435362056560734e-09
development O 0 6.478592240455328e-08
of O 0 9.935963163343331e-09
strategies O 0 2.790322696455405e-06
for O 0 4.8042164024764134e-08
the O 0 6.024975505170005e-07
prevention O 0 0.004627809394150972
and O 0 1.0908883041338413e-07
, O 0 4.3623078482823985e-08
where O 0 1.7191725376619615e-08
necessary O 0 6.499260507553117e-08
, O 0 9.228084252299595e-08
management O 0 9.64329842645384e-07
of O 0 1.0099749481184972e-08
a O 0 1.767908884175995e-06
risk O 0 0.0007193440105766058
reversal O 0 2.5880410248646513e-05
in O 0 2.349185024286271e-08
any O 0 2.4648143082117713e-08
predictive O 0 1.166028596344404e-05
testing O 0 1.1975475899816956e-05
program O 0 5.304812475515064e-06
. O 0 6.867742854410608e-07
. O 0 4.905778041575104e-06

A O 0 1.3903880244470201e-05
novel O 0 1.4598033885704353e-05
common O 0 7.001754511293257e-06
missense O 0 0.00030724587850272655
mutation O 0 2.8880685931653716e-05
G301C O 0 0.00013274162483867258
in O 0 4.647941409530176e-08
the O 0 5.264406865990168e-08
N O 0 2.5605258997529745e-05
- O 0 0.00015627653920091689
acetylgalactosamine O 0 0.001871555927209556
- O 0 0.00020058659720234573
6 O 0 1.685123424977064e-05
- O 0 0.0017913251649588346
sulfate O 0 0.025316022336483
sulfatase O 0 0.0823618471622467
gene O 0 1.1739037290681154e-05
in O 0 2.4622477212687954e-06
mucopolysaccharidosis B-Disease 0 0.1759808212518692
IVA I-Disease 1 0.9645590782165527
. O 0 6.406275497283787e-05

Mucopolysaccharidosis B-Disease 1 0.613509476184845
IVA I-Disease 1 0.9589899182319641
( O 0 0.0005824409890919924
MPS B-Disease 0 0.13862591981887817
IVA I-Disease 1 0.994724452495575
) O 0 2.0253602997399867e-05
is O 0 1.5508747992498684e-06
an O 0 5.063196658738889e-05
autosomal B-Disease 1 0.996992826461792
recessive I-Disease 1 0.9991382360458374
lysosomal I-Disease 1 0.9995390176773071
storage I-Disease 1 0.9990280866622925
disorder I-Disease 1 0.999735414981842
caused O 0 0.15572723746299744
by O 0 3.2851628475327743e-06
a O 0 2.9965212888782844e-05
genetic B-Disease 0 0.46156659722328186
defect I-Disease 1 0.9129835367202759
in O 0 2.145539610864944e-06
N O 0 0.0004292391240596771
- O 0 0.0018661353969946504
acetylgalactosamine O 0 0.008752919733524323
- O 0 0.000517981534358114
6 O 0 3.901503441738896e-05
- O 0 0.022826729342341423
sulfate O 0 0.21612031757831573
sulfatase O 1 0.8861165046691895
( O 0 3.828069384326227e-05
GALNS O 0 0.04702572897076607
) O 0 4.580374934448628e-06
. O 0 5.198459803068545e-06

In O 0 3.5199163903598674e-06
previous O 0 7.2947441367432475e-06
studies O 0 4.869114945904585e-06
, O 0 2.2065189853037737e-07
we O 0 1.1602545590960744e-08
have O 0 3.2917295555989767e-09
found O 0 7.189688400188743e-09
two O 0 4.7949040293815415e-09
common O 0 9.371561304760689e-07
mutations O 0 3.0689971026731655e-06
in O 0 2.4504663542757044e-07
Caucasians O 0 0.00048233155393972993
and O 0 4.388863885651517e-07
Japanese O 0 3.066211138502695e-05
, O 0 1.5230319831971428e-06
respectively O 0 9.87001749308547e-06
. O 0 1.1753350918297656e-05

To O 0 2.550396629885654e-06
characterize O 0 4.918932609143667e-05
the O 0 5.97926316459052e-07
mutational O 0 0.00240339245647192
spectrum O 0 4.3879445001948625e-06
in O 0 2.3573001328713872e-08
various O 0 6.758945847451514e-09
ethnic O 0 8.009367746808493e-08
groups O 0 8.379493010579608e-08
, O 0 1.1626863027913714e-07
mutations O 0 9.13946564651269e-07
in O 0 1.2222726830657393e-08
the O 0 5.63729436464655e-08
GALNS O 0 0.0013491649879142642
gene O 0 9.050000358001853e-07
in O 0 1.284917345856229e-07
Colombian O 0 4.392262053443119e-05
MPS B-Disease 0 0.47030144929885864
IVA I-Disease 1 0.9994553923606873
patients O 0 0.4475972056388855
were O 0 1.6820384018956247e-07
investigated O 0 2.373806455580052e-05
, O 0 2.377353212068556e-07
and O 0 2.092052824309576e-07
genetic O 0 1.2844489901908673e-05
backgrounds O 0 1.1577452596611693e-06
were O 0 1.9192917477539595e-08
extensively O 0 1.7876366200653138e-06
analyzed O 0 4.428672468748118e-07
to O 0 1.6230730537358795e-08
identify O 0 2.3339582355674793e-07
racial O 0 8.579873451708409e-07
origin O 0 1.461524501422673e-08
, O 0 1.0621071133698479e-08
based O 0 6.777522099099542e-09
on O 0 1.051221865111529e-08
mitochondrial O 0 4.539389919955283e-06
DNA O 0 2.542809625083464e-06
( O 0 1.0079198773382814e-06
mtDNA O 0 4.16966577176936e-06
) O 0 4.904711659037275e-07
lineages O 0 1.0154549272556324e-05
. O 0 3.7444517602125416e-06

Three O 0 5.266699645289918e-06
novel O 0 0.00015700886433478445
missense O 0 0.0068552372977137566
mutations O 0 0.00028127734549343586
never O 0 5.133449576533167e-06
identified O 0 1.676693614172109e-06
previously O 0 4.70294480692246e-07
in O 0 7.568377924371816e-08
other O 0 4.1759584235023794e-08
populations O 0 1.1420929695304949e-06
and O 0 1.4829271144378708e-08
found O 0 1.0633882219224233e-08
in O 0 5.089993759810341e-09
16 O 0 1.1600045368709289e-08
out O 0 2.419007216758473e-09
of O 0 5.965829608101103e-09
19 O 0 7.586862693642615e-07
Colombian O 0 5.620938281936105e-06
MPS B-Disease 0 0.0011241419706493616
IVA I-Disease 1 0.9876660108566284
unrelated O 0 8.236494613811374e-05
alleles O 0 6.344641860778211e-06
account O 0 5.597681820290745e-07
for O 0 8.382352234548307e-07
84 O 0 0.00026780253392644227
. O 0 1.2730515663861297e-05

2 O 0 3.286992978246417e-06
% O 0 2.134637639983339e-07
of O 0 1.8438155890976304e-08
the O 0 5.556854887345253e-08
alleles O 0 2.804416453727754e-06
in O 0 1.7180801137328672e-07
this O 0 2.5823331384344783e-07
study O 0 1.3524468158720993e-05
. O 0 1.4930021279724315e-05

The O 0 9.643385965318885e-06
G301C O 0 0.0010964620159938931
and O 0 4.019047992187552e-06
S162F O 0 0.0015830554766580462
mutations O 0 1.6164132830454037e-05
account O 0 9.062886192623409e-07
for O 0 7.89638932019443e-07
68 O 0 0.00013624949497170746
. O 0 2.3221731680678204e-05

4 O 0 4.1180024709319696e-05
% O 0 6.519481758004986e-06
and O 0 1.481691015214892e-06
10 O 0 7.621129043400288e-06
. O 0 1.7811167708714493e-05

5 O 0 3.988837306678761e-06
% O 0 4.1470431710877165e-07
of O 0 9.354598518029889e-08
mutations O 0 1.2592621715157293e-05
, O 0 1.5963415478381648e-07
respectively O 0 4.1924866422959894e-07
, O 0 3.11546664022444e-08
whereas O 0 6.452324896599748e-08
the O 0 5.895920640597296e-09
remaining O 0 1.7241482908048056e-07
F69V O 0 0.004613183438777924
is O 0 1.5636771877325373e-08
limited O 0 2.818135058646476e-08
to O 0 6.368229055198071e-09
a O 0 6.539848129705206e-08
single O 0 6.114767643339292e-07
allele O 0 3.0600880563724786e-05
. O 0 5.155655344424304e-06

The O 0 6.566611318703508e-06
skewed O 0 0.00018482613086234778
prevalence O 0 0.001339651644229889
of O 0 1.193760965634283e-07
G301C O 0 0.000213773557334207
in O 0 9.151469271273527e-08
only O 0 5.897858201819872e-08
Colombian O 0 3.112909689662047e-05
patients O 0 0.002104704501107335
and O 0 2.0997961769353424e-07
haplotype O 0 0.00030094297835603356
analysis O 0 3.412819538084477e-08
by O 0 8.749077906600178e-09
restriction O 0 2.764265900623286e-07
fragment O 0 2.192340843976126e-06
length O 0 3.3485693506918324e-07
polymorphisms O 0 1.2474355344238575e-06
in O 0 1.0095242863883414e-08
the O 0 5.2885201995422904e-08
GALNS O 0 0.028033917769789696
gene O 0 4.247511242283508e-06
suggest O 0 5.409556820268335e-07
that O 0 2.4677072829604185e-08
G301C O 0 0.00011228065704926848
originated O 0 4.072614956385223e-07
from O 0 5.209658837657116e-08
a O 0 5.240573841547302e-07
common O 0 1.2544056517072022e-05
ancestor O 0 0.00012054890248691663
. O 0 2.5200992240570486e-05

Investigation O 0 1.1177930900885258e-05
of O 0 3.5372627849028504e-07
the O 0 3.651866222753597e-07
genetic O 0 1.0429504072817508e-05
background O 0 6.382062451848469e-07
by O 0 1.9671913875640712e-08
means O 0 3.067908949105913e-08
of O 0 1.3931155784518978e-08
mtDNA O 0 2.896331579904654e-06
lineages O 0 1.8555444967205403e-06
indicate O 0 3.156788181968295e-07
that O 0 6.608611435865441e-09
all O 0 2.3149622663254377e-08
our O 0 1.6793821941973874e-06
patients O 0 0.0015302489046007395
are O 0 7.063899243320293e-09
probably O 0 1.7838495125488407e-07
of O 0 4.6538225717540627e-08
native O 0 3.7649620026058983e-06
American O 0 3.412226578802802e-05
descent O 0 0.0008939880062825978

Low O 0 1.58773527800804e-05
frequency O 0 2.260464270875673e-06
of O 0 1.0333225191061501e-06
BRCA1 O 0 0.005627369042485952
germline O 0 0.006810820661485195
mutations O 0 5.0361726607661694e-05
in O 0 5.471535587275866e-06
45 O 0 0.0013941533397883177
German O 1 0.9350747466087341
breast B-Disease 1 0.9993026256561279
/ I-Disease 1 0.9990094900131226
ovarian I-Disease 1 0.9996531009674072
cancer I-Disease 1 0.9991330504417419
families O 0 0.0050196475349366665
. O 0 0.0003575411392375827

In O 0 1.39625524298026e-06
this O 0 1.3533743015159416e-07
study O 0 7.96812571479677e-07
we O 0 1.2433505958142632e-07
investigated O 0 3.0236707971198484e-05
45 O 0 0.00030605512438341975
German O 1 0.9441630244255066
breast B-Disease 1 0.9994686245918274
/ I-Disease 1 0.9994775652885437
ovarian I-Disease 1 0.9998596906661987
cancer I-Disease 1 0.999626874923706
families O 0 6.138333264971152e-05
for O 0 6.1210616877360735e-06
germline O 0 0.38784584403038025
mutations O 0 5.8622950746212155e-05
in O 0 2.9913218213550863e-07
the O 0 2.2220663140615216e-06
BRCA1 O 0 0.0583629347383976
gene O 0 0.00010702269355533645
. O 0 1.4990025192673784e-05

We O 0 1.3995108929520939e-06
identified O 0 1.0583698895061389e-06
four O 0 7.65125435009395e-07
germline O 0 0.006731875706464052
mutations O 0 4.431232810020447e-05
in O 0 4.045752120873658e-06
three O 0 0.00033050859929062426
breast B-Disease 1 0.9994571805000305
cancer I-Disease 1 0.9987590312957764
families O 0 1.471437826694455e-05
and O 0 1.7375396055285819e-06
in O 0 1.184007942356402e-05
one O 0 0.0037378468550741673
breast B-Disease 1 0.999674916267395
- I-Disease 1 0.9997640252113342
ovarian I-Disease 1 0.9999432563781738
cancer I-Disease 1 0.9998601675033569
family O 0 0.000879900821018964
. O 0 2.5325289243482985e-07
among O 0 4.8381672002051346e-08
these O 0 2.9652771349475415e-09
were O 0 3.043539198444023e-09
one O 0 3.283948757371036e-08
frameshift O 0 0.003736923448741436
mutation O 0 2.899564833569457e-06
, O 0 1.5481267823247435e-08
one O 0 2.0626648833399486e-08
nonsense O 0 3.274564369348809e-05
mutation O 0 1.3731187209486961e-06
, O 0 8.4399767175114e-09
one O 0 5.012160464445969e-09
novel O 0 7.715957508480642e-07
splice O 0 5.259010140434839e-05
site O 0 7.660863161618181e-07
mutation O 0 1.4067821894059307e-06
, O 0 3.069840559533077e-08
and O 0 4.5865419906476745e-08
one O 0 1.9463513467599114e-07
missense O 0 0.0007178029045462608
mutation O 0 0.00020491797477006912
. O 0 1.2593438441399485e-05

The O 0 1.2228867490193807e-05
missense O 0 0.002004987094551325
mutation O 0 9.91119013633579e-05
was O 0 6.942603931747726e-07
also O 0 1.805413774036424e-07
found O 0 1.8470755946964346e-07
in O 0 2.939934518053633e-07
2 O 0 1.0128869689651765e-05
. O 0 9.637354196456727e-06

8 O 0 3.6792978335142834e-06
% O 0 1.3547612809361453e-07
of O 0 1.665745408274688e-08
the O 0 5.752889009613682e-08
general O 0 1.3036458312853938e-06
population O 0 7.931982963782502e-07
, O 0 2.7743809027924726e-07
suggesting O 0 4.234298103256151e-06
that O 0 2.3075868327282478e-08
it O 0 6.675414709889083e-08
is O 0 1.2103826065867906e-06
not O 0 1.7538985048304312e-05
disease O 1 0.9978740215301514
associated O 0 0.000374212977476418
. O 0 5.8598132454790175e-05

The O 0 5.246156433713622e-06
average O 0 7.043209916446358e-05
age O 0 0.0005240585887804627
of O 0 0.0005442656693048775
disease O 1 0.9994856119155884
onset O 1 0.99828040599823
in O 0 5.337574748409679e-06
those O 0 3.1947229217621498e-06
families O 0 0.00022478256141766906
harbouring O 1 0.9821192026138306
causative O 0 0.14199545979499817
mutations O 0 0.00010644998837960884
was O 0 3.159691459586611e-07
between O 0 1.5819606460354407e-06
32 O 0 4.020239066448994e-05
. O 0 1.2369358955766074e-05

3 O 0 4.5858832891099155e-05
and O 0 8.840181180858053e-06
37 O 0 8.435355266556144e-05
. O 0 3.2586023735348135e-05

4 O 0 4.104527397430502e-05
years O 0 7.538277714047581e-06
, O 0 4.68882916493385e-07
whereas O 0 9.371668170388148e-07
the O 0 9.650661780824521e-08
family O 0 6.779594059480587e-06
harbouring O 0 0.004575327970087528
the O 0 2.6785849627231073e-07
missense O 0 0.00029739030287601054
mutation O 0 4.245413038006518e-06
had O 0 3.3110563180116515e-08
an O 0 1.5808877762424345e-08
average O 0 6.473959501818172e-07
age O 0 8.998715088637255e-07
of O 0 1.2022384510146367e-07
onset O 1 0.6022804379463196
of O 0 1.2170753507234622e-06
51 O 0 0.00023503854754380882
. O 0 1.8631179045769386e-05

2 O 0 0.00030011008493602276
years O 0 0.0001782170875230804
. O 0 0.0001605266734259203

These O 0 1.6612293620710261e-06
findings O 0 6.663750809821067e-06
show O 0 1.1091462965850951e-06
that O 0 2.6157869115195354e-07
BRCA1 O 0 0.0032189907506108284
is O 0 1.3595318648640387e-07
implicated O 0 4.679440280597191e-06
in O 0 1.539355487523153e-08
a O 0 2.7058920437639244e-08
small O 0 3.1051862947606423e-07
fraction O 0 2.0644398318836465e-05
of O 0 0.0005917511880397797
breast B-Disease 1 0.9996365308761597
/ I-Disease 1 0.9996366500854492
ovarian I-Disease 1 0.9999336004257202
cancer I-Disease 1 0.9997913241386414
families O 0 0.00017072343325708061
suggesting O 0 2.027022128459066e-05
the O 0 6.665452900733726e-08
involvement O 0 1.6103274447232252e-06
of O 0 8.340696666664371e-08
another O 0 9.192463039653376e-06
susceptibility O 0 0.12070085108280182
gene O 0 0.0004056832694914192
( O 0 6.737498915754259e-05
s O 0 0.0052225529216229916
) O 0 5.125848110765219e-05

Paternal O 0 0.14711959660053253
transmission O 0 0.19506807625293732
of O 0 0.051069024950265884
congenital B-Disease 1 0.9964029788970947
myotonic I-Disease 1 0.9966071844100952
dystrophy I-Disease 1 0.9964475631713867
. O 0 0.06251958757638931

We O 0 4.199748218525201e-06
report O 0 2.980568524435512e-06
a O 0 1.5530133623542497e-06
rare O 0 3.681392263388261e-05
case O 0 2.260934707010165e-05
of O 0 3.5402539651840925e-05
paternally O 1 0.9928612112998962
transmitted O 1 0.9952530860900879
congenital B-Disease 1 0.999323844909668
myotonic I-Disease 1 0.9993807077407837
dystrophy I-Disease 1 0.9995425939559937
( O 1 0.9298555254936218
DM B-Disease 1 0.9979289770126343
) O 0 0.00039868292515166104
. O 0 6.939023296581581e-05

The O 0 3.830149580608122e-06
proband O 0 0.0010089310817420483
is O 0 2.506793350676162e-07
a O 0 2.9092407771713624e-07
23 O 0 2.6555812837614212e-06
year O 0 5.0258236115041655e-06
old O 0 0.0007435657898895442
, O 0 0.0004474448214750737
mentally B-Disease 1 0.9982197880744934
retarded I-Disease 1 0.9970352649688721
male O 1 0.5935279130935669
who O 1 0.7633320093154907
suffers O 1 0.9992732405662537
severe O 1 0.9991583824157715
muscular B-Disease 1 0.9990420937538147
weakness I-Disease 1 0.9964339733123779
. O 0 0.004385979380458593

He O 0 7.491563883377239e-05
presented O 0 0.000662897655274719
with O 0 0.008656511083245277
respiratory O 1 0.9987756609916687
and O 0 0.00023180793505162
feeding O 0 0.036434974521398544
difficulties O 0 0.05893997475504875
at O 0 6.599762127734721e-05
birth O 0 0.008200698532164097
. O 0 0.00014090097101870924

His O 0 7.035289308987558e-05
two O 0 7.63939751777798e-05
sibs O 1 0.9863899350166321
suffer O 1 0.9837331175804138
from O 0 0.001104007475078106
childhood O 1 0.9934601783752441
onset O 1 0.9977772831916809
DM B-Disease 1 0.9979203343391418
. O 0 0.003346992190927267

Their O 0 1.5361663372459589e-06
late O 0 8.18799435364781e-06
father O 0 4.2044207475555595e-06
had O 0 1.0616700052423766e-07
the O 0 5.0287582098462735e-08
adult O 0 4.153377631155308e-06
type O 0 1.8320219169254415e-05
of O 0 1.4704800150866504e-06
DM B-Disease 1 0.9993639588356018
, O 0 2.613059450595756e-06
with O 0 2.710045237108716e-06
onset O 1 0.6226695775985718
around O 0 1.1440869229772943e-06
30 O 0 2.4383055006182985e-06
years O 0 8.769798114371952e-06
. O 0 8.265429642051458e-06

Only O 0 7.11470249825652e-07
six O 0 2.7773486976911954e-07
other O 0 4.122806629425213e-08
cases O 0 5.331818897502671e-07
of O 0 2.4688989697096986e-07
paternal O 0 0.003520016558468342
transmission O 0 0.009827298112213612
of O 0 0.0007681228453293443
congenital B-Disease 1 0.9996076226234436
DM I-Disease 1 0.9994705319404602
have O 0 5.73967736272607e-06
been O 0 2.0702818801510148e-06
reported O 0 0.00011091514170402661
recently O 0 0.00013159363879822195
. O 0 2.266954288643319e-05

We O 0 1.8394409835309489e-06
review O 0 2.2388512661564164e-06
the O 0 4.070816999046656e-07
sex O 0 1.9900473489542492e-05
related O 0 7.614886271767318e-05
effects O 0 0.0003516080032568425
on O 0 2.3083982796379132e-06
transmission O 0 0.003200334496796131
of O 0 0.0005143823800608516
congenital B-Disease 1 0.9989309906959534
DM I-Disease 1 0.9982953667640686
. O 0 0.002112411893904209

Decreased O 0 0.0036075005773454905
fertility O 0 0.0030204816721379757
of O 0 3.96349264519813e-07
males O 0 1.862013050413225e-05
with O 0 1.2538793271232862e-05
adult O 0 0.12138693034648895
onset O 1 0.9994407296180725
DM B-Disease 1 0.9994134902954102
and O 0 3.4186552966275485e-06
contraction O 0 0.00026451866142451763
of O 0 3.0613797719070135e-08
the O 0 1.0894183333221008e-07
repeat O 0 7.532969175372273e-05
upon O 0 2.3105339153062232e-07
male O 0 3.2955463211692404e-06
transmission O 0 8.449936103716027e-06
contribute O 0 3.8733696783310734e-07
to O 0 4.370558581712203e-09
the O 0 8.772906845422312e-09
almost O 0 6.020724185873405e-08
absent O 0 4.1293333197245374e-06
occurrence O 0 2.188565758842742e-06
of O 0 1.8046289085305034e-07
paternal O 0 0.001805153558962047
transmission O 0 0.002548714866861701
of O 0 0.00021290725271683186
congenital B-Disease 1 0.9987671375274658
DM I-Disease 1 0.9979408383369446
. O 0 0.0009438044507987797

Also O 0 3.02095008919423e-06
the O 0 3.183589853961166e-07
fathers O 0 1.3033348977842252e-06
of O 0 6.30472101192936e-08
the O 0 6.698621177747555e-07
reported O 0 0.00022207328584045172
congenitally O 0 0.4942462742328644
affected O 0 0.00035876259789802134
children O 0 7.819361599104013e-06
showed O 0 1.399560233039665e-06
, O 0 1.8247622080025394e-08
on O 0 1.1145274925183912e-08
average O 0 2.674587449291721e-07
, O 0 9.172159565196125e-08
shorter O 0 2.4201995984185487e-05
CTG O 0 0.028658468276262283
repeat O 0 0.0001816493459045887
lengths O 0 9.162880451185629e-05
and O 0 1.3936863751951023e-06
hence O 0 0.00022954172163736075
less O 0 0.004275968763977289
severe O 1 0.9994350075721741
clinical O 1 0.9982202649116516
symptoms O 1 0.993440568447113
than O 0 1.4614347492170054e-06
the O 0 3.6940714380762074e-06
mothers O 0 0.0012518097646534443
of O 0 2.9194011403888e-06
children O 0 0.017129937186837196
with O 0 0.15958623588085175
congenital B-Disease 1 0.9993659853935242
DM I-Disease 1 0.998503565788269
. O 0 0.003842470934614539

We O 0 2.0086763470317237e-06
conclude O 0 8.78112950886134e-06
that O 0 2.524681690374564e-07
paternal O 0 0.0001579611998749897
transmission O 0 0.0013110925210639834
of O 0 0.0005398703506216407
congenital B-Disease 1 0.9997417330741882
DM I-Disease 1 0.9996646642684937
is O 0 1.202580733661307e-05
rare O 0 8.259712922153994e-05
and O 0 4.733429648240417e-07
preferentially O 0 1.8552100300439633e-05
occurs O 0 2.4296266474266304e-06
with O 0 8.144298249135318e-07
onset O 1 0.5819583535194397
of O 0 1.7237091469723964e-06
DM B-Disease 1 0.9979269504547119
past O 0 7.512101660722692e-07
30 O 0 4.1195059452547866e-07
years O 0 2.5701248773657426e-07
in O 0 4.370285822119513e-08
the O 0 1.0125523175474882e-07
father O 0 9.213061275659129e-06
. O 0 2.2867805000714725e-06
. O 0 1.0056126484414563e-05

The O 0 9.995794243877754e-05
RB1 O 1 0.6429510712623596
gene O 0 0.00013479223707690835
mutation O 0 5.226552457315847e-05
in O 0 9.16818692076049e-07
a O 0 4.922415428154636e-06
child O 0 0.00209584622643888
with O 0 0.001586578437127173
ectopic B-Disease 1 0.9944393634796143
intracranial I-Disease 1 0.9968124032020569
retinoblastoma I-Disease 1 0.991595447063446
. O 0 0.0012030004290863872

The O 0 5.966486787656322e-05
RB1 O 1 0.7868932485580444
gene O 0 9.434710955247283e-05
mutation O 0 6.051292075426318e-05
was O 0 9.700523833089392e-07
investigated O 0 5.839845925947884e-06
in O 0 1.5935808050926425e-07
a O 0 1.3899619943913422e-06
child O 0 0.0003071805404033512
with O 0 7.335823465837166e-05
ectopic B-Disease 1 0.9977866411209106
intracranial I-Disease 1 0.999093770980835
retinoblastoma I-Disease 1 0.544384241104126
using O 0 1.6188766949198907e-07
DNA O 0 8.942832891989383e-07
obtained O 0 2.4343890459022077e-08
from O 0 1.5323278645951177e-08
both O 0 1.7018779274735607e-08
the O 0 9.383410315422225e-07
pineal B-Disease 0 0.1932663470506668
and I-Disease 0 5.750878335675225e-05
retinal I-Disease 1 0.9986690282821655
tumours I-Disease 1 0.9968432188034058
of O 0 1.4111210475675762e-06
the O 0 1.9444272766122594e-05
patient O 0 0.32558509707450867
. O 0 0.00011518441169755533

A O 0 1.5747413272038102e-05
nonsense O 0 6.698777724523097e-05
mutation O 0 6.2354338297154754e-06
in O 0 1.0628147606439597e-07
exon O 0 2.014108031289652e-05
17 O 0 4.173295451437298e-07
( O 0 1.523605845932252e-07
codon O 0 2.4455474090245843e-07
556 O 0 1.9467613583401544e-06
) O 0 6.562249854624724e-09
of O 0 2.640019314270603e-09
the O 0 1.6501340383001661e-07
RB1 O 1 0.7014991641044617
gene O 0 1.8576974980533123e-06
was O 0 2.8082727254741258e-08
found O 0 5.9296407783904215e-09
to O 0 1.5534857844556882e-09
be O 0 1.2254957049151471e-09
present O 0 6.397632290600086e-08
homozygously O 0 0.00012827150931116194
in O 0 1.8052995542916506e-08
both O 0 3.8018761472358165e-08
the O 0 6.147687372504151e-07
retinal B-Disease 1 0.5059700608253479
and I-Disease 0 2.687048436200712e-06
the I-Disease 0 7.668256876058877e-05
pineal I-Disease 1 0.9847905039787292
tumours I-Disease 1 0.9958828687667847
. O 0 0.00010855797881959006

The O 0 9.94801553133584e-07
same O 0 5.096028985462908e-07
mutation O 0 5.634537956211716e-06
was O 0 7.840009175197338e-08
present O 0 2.7932037482969463e-07
heterozygously O 0 0.00017983088036999106
in O 0 1.2343920552382315e-08
the O 0 5.492919452620981e-09
DNA O 0 5.685800985588685e-08
from O 0 6.415679099092131e-09
the O 0 9.183499294351805e-09
constitutional O 0 2.8906447369081434e-07
cells O 0 9.475449473939079e-07
of O 0 2.8378499550285596e-08
the O 0 1.038189225255337e-06
patient O 0 0.006460483185946941
, O 0 4.788061573890445e-07
proving O 0 5.51978928342578e-06
it O 0 4.788022422985705e-09
to O 0 3.297397466184293e-09
be O 0 2.255476472257101e-09
of O 0 5.133010461122467e-08
germline O 0 0.0016044207150116563
origin O 0 2.073514451694791e-06
. O 0 7.221945452329237e-06

The O 0 2.062241946987342e-06
initial O 0 2.7697027690010145e-05
mutation O 0 3.6163412005407736e-05
was O 0 2.4843126311679953e-07
shown O 0 1.0942225259213956e-07
to O 0 8.391852546196787e-09
have O 0 5.2369837355570326e-09
occurred O 0 5.633897259826881e-08
in O 0 1.5583061951929267e-08
the O 0 2.0553373758502858e-07
paternally O 0 0.0035870042629539967
derived O 0 2.818387838487979e-05
RB1 O 1 0.9171469807624817
allele O 0 0.0002662224287632853
. O 0 1.567465551488567e-05

The O 0 4.223860287311254e-06
mutation O 0 3.132513302261941e-05
is O 0 1.1147044176595955e-07
in O 0 1.762161971896603e-08
an O 0 1.2382900926866114e-08
area O 0 1.864457921385565e-08
of O 0 1.103169777749713e-09
the O 0 5.200135433369724e-09
gene O 0 6.515035977372463e-08
that O 0 8.032445819594614e-10
encodes O 0 1.1956519330169613e-08
the O 0 4.5476622467788275e-09
protein O 0 1.3430113199319749e-07
- O 0 2.3396538381348364e-05
binding O 0 2.833486121289752e-07
region O 0 2.742775393471675e-07
known O 0 2.346735428204738e-08
as O 0 5.08697528545099e-09
the O 0 5.76326790735493e-08
pocket O 0 0.00470865610986948
region O 0 2.151262151528499e-06
and O 0 5.024941884812506e-08
has O 0 5.577338058060377e-08
been O 0 2.408291166489107e-08
detected O 0 7.194587965386745e-07
in O 0 1.148639405812446e-08
other O 0 1.5962129396029923e-08
cases O 0 3.248587063353625e-06
of O 0 1.3722259382120683e-06
retinoblastoma B-Disease 1 0.9680850505828857
. O 0 1.247360160050448e-05
. O 0 3.286565333837643e-05

Low O 0 4.602944682119414e-05
levels O 0 2.312487822564435e-06
of O 0 1.6124776891501824e-07
beta O 0 5.207546928431839e-05
hexosaminidase O 0 0.0017871911404654384
A O 0 2.0768982267327374e-06
in O 0 1.4890825923430384e-06
healthy O 0 0.0006610292475670576
individuals O 0 4.657375484384829e-06
with O 0 0.0001200315891765058
apparent O 1 0.9216541051864624
deficiency O 1 0.9992510676383972
of O 0 6.340355298561917e-07
this O 0 1.9553724541765405e-06
enzyme O 0 0.00036184489727020264
. O 0 1.2351960322121158e-05

Appreciable O 0 0.0004814218555111438
beta O 0 0.00024374127679038793
hexosaminidase O 0 0.0017335015581920743
A O 0 2.8412457595550222e-06
( O 0 2.173061147914268e-06
hex O 0 8.204627192753833e-06
A O 0 2.2226311102713225e-07
) O 0 9.022865299357363e-08
activity O 0 3.428177208775196e-08
has O 0 1.2097044255199307e-08
been O 0 7.450612571346937e-09
detected O 0 1.3879723610443762e-06
in O 0 5.894843866371957e-07
cultured O 0 0.019730616360902786
skin O 1 0.9955512285232544
fibroblasts O 1 0.5094929933547974
and O 0 0.0029924374539405107
melanoma B-Disease 1 0.9997547268867493
tissue O 0 0.3067839741706848
from O 0 4.949075446347706e-06
healthy O 0 0.0006074488628655672
individuals O 0 2.0033351120218867e-06
previously O 0 4.581664143188391e-06
reported O 0 2.9206625185906887e-05
as O 0 1.8420636251903488e-06
having O 0 0.00010960175859509036
deficiency B-Disease 1 0.9949901700019836
of I-Disease 0 3.0199938549912986e-08
hex I-Disease 0 1.0984368600475136e-05
A I-Disease 0 1.072088693376827e-07
activity O 0 8.268798978861014e-08
indistinguishable O 0 6.358473569889611e-07
from O 0 1.0281893558783395e-08
that O 0 1.4095210332243369e-08
of O 0 9.28218696572003e-07
patients O 1 0.8168600797653198
with O 0 0.07771439105272293
Tay B-Disease 1 0.9995483756065369
- I-Disease 1 0.9992498755455017
Sachs I-Disease 1 0.9995135068893433
disease I-Disease 1 0.9993094205856323
( O 0 0.004998389165848494
TSD B-Disease 1 0.9949883818626404
) O 0 5.2440209401538596e-05
. O 0 1.4168401321512647e-05

Identification O 0 7.333736448345007e-06
and O 0 8.213467594941903e-07
quantitation O 0 0.00020920198585372418
of O 0 1.4334726472498005e-07
hex O 0 2.668555134732742e-05
A O 0 3.6815018233937735e-07
, O 0 1.174191410768799e-07
amounting O 0 3.2196073789236834e-06
to O 0 1.2795612747140694e-07
3 O 0 5.556336873269174e-06
. O 0 3.5224818475398934e-06

5 O 0 5.3177416702965274e-05
% O 0 1.7967748135561123e-05
- O 0 0.0011980731505900621
6 O 0 7.376213761745021e-05
. O 0 2.140828837582376e-05

9 O 0 5.06009882883518e-06
% O 0 2.455856815686275e-07
of O 0 2.4755093974704323e-08
total O 0 1.957837838517662e-07
beta O 0 2.7681526262313128e-05
hexosaminidase O 0 0.0010593316983431578
activity O 0 4.737950405342417e-07
, O 0 4.8517975415052206e-08
has O 0 5.675440117869357e-09
been O 0 9.32966259803436e-10
obtained O 0 5.06502706443257e-09
by O 0 2.341874960620771e-08
cellulose O 0 8.256862201960757e-05
acetate O 0 9.972773113986477e-05
gel O 0 0.00025215570349246264
electrophoresis O 0 1.6368696378776804e-05
, O 0 1.4406951720502548e-07
DEAE O 0 0.000311411073198542
- O 0 1.2874658750661183e-05
cellulose O 0 2.6332316338084638e-05
ion O 0 3.819498488155659e-06
- O 0 1.049814818543382e-05
exchange O 0 6.670056222901621e-07
chromatography O 0 0.0001887427206384018
, O 0 6.65866707549867e-07
radial O 0 0.0006157258758321404
immunodiffusion O 0 0.0019261075649410486
, O 0 5.512832217391406e-07
and O 0 1.9361850718269125e-06
radioimmunoassay O 0 0.011939720250666142
. O 0 1.768746915331576e-05

Previous O 0 6.308519368758425e-05
family O 0 0.0001027803446049802
studies O 0 1.243642509507481e-05
suggested O 0 8.603014975960832e-06
that O 0 7.862396955715667e-08
these O 0 5.0528139894367996e-08
individuals O 0 6.433646149162087e-07
may O 0 5.000895271223271e-07
be O 0 1.9285943508862147e-08
compound O 0 1.4275574358180165e-05
heterozygotes O 0 0.0006436269613914192
for O 0 5.037417238895614e-08
the O 0 9.012012469611363e-08
common O 0 3.838754309981596e-06
mutant O 0 0.0009726908756420016
TSD B-Disease 1 0.9154945611953735
gene O 0 5.031506134400843e-06
and O 0 9.140183721001449e-08
a O 0 8.144934895426559e-07
rare O 0 0.00010667525930330157
( O 0 1.0082649168907665e-05
allelic O 0 0.0014988768380135298
) O 0 2.7971327654086053e-06
mutant O 0 0.00014740870392415673
gene O 0 5.571815199800767e-05
. O 0 1.3286417924973648e-05

Thus O 0 6.174254394863965e-06
, O 0 3.993120003542572e-07
the O 0 1.0732733102258862e-07
postulated O 0 1.3772953025181778e-05
rate O 0 2.823208433255786e-06
mutant O 0 4.3058742448920384e-05
gene O 0 3.8136238345032325e-06
appears O 0 3.9157441733550513e-07
to O 0 3.132566206431875e-09
code O 0 6.032584654036555e-09
for O 0 1.5072131320792437e-09
the O 0 1.5723616852980626e-09
expression O 0 8.128048456512715e-09
of O 0 2.1900392610518793e-09
low O 0 2.968799321934057e-07
amounts O 0 5.2756952584331884e-08
of O 0 2.559830925008555e-08
hex O 0 2.4235856471932493e-05
A O 0 3.515189973768429e-06
. O 0 8.665760105941445e-06

Heterozygotes O 0 0.0040371110662817955
for O 0 2.4146813757397467e-06
the O 0 2.503468294889899e-06
rare O 0 0.000294129567919299
mutant O 0 0.0009079850860871375
may O 0 2.386535697951331e-06
be O 0 3.0053296740106816e-08
indistinguishable O 0 8.936609447118826e-06
from O 0 5.440874133455509e-07
heterozygotes O 0 0.0003475846315268427
for O 0 1.0476693290684125e-07
the O 0 8.784444958109816e-07
common O 0 7.79065303504467e-05
TSD B-Disease 1 0.9893211126327515
mutant O 0 0.003586571430787444
. O 0 3.476360143395141e-05

However O 0 2.820797362801386e-06
, O 0 4.243630371547624e-07
direct O 0 2.7186291617908864e-07
visualization O 0 1.3589265108748805e-05
and O 0 1.1803586374981023e-07
quantitation O 0 3.4499265893828124e-05
of O 0 3.4304534324292035e-08
hex O 0 8.488576895615552e-06
A O 0 1.203346471356781e-07
by O 0 1.5825078136799675e-08
the O 0 1.985427999784406e-08
methods O 0 1.9287971042558638e-07
described O 0 7.2778939284035005e-06
may O 0 1.2777167057720362e-06
prevent O 0 1.0057487997983117e-05
false O 0 5.1480101319612e-06
- O 0 0.002095935633406043
positive O 0 2.922557177953422e-05
prenatal O 1 0.7535316944122314
diagnosis O 1 0.5850394368171692
of O 0 2.0310831132519525e-06
TSD B-Disease 1 0.9930422306060791
in O 0 1.8219282083009603e-06
fetuses O 0 0.00022286106832325459
having O 0 1.2060692711202137e-07
the O 0 2.9985621097239346e-08
incomplete O 0 4.698453722085105e-06
hex B-Disease 0 0.0009098956361413002
A I-Disease 0 0.0001748036447679624
deficiency I-Disease 1 0.9967400431632996
of O 0 4.0019713765104825e-08
the O 0 2.0833284963828191e-07
type O 0 4.725672260974534e-05
described O 0 1.735459704832465e-06
in O 0 4.591302982248635e-08
the O 0 1.0991905696755566e-07
four O 0 1.1414168739065644e-06
healthy O 0 0.001717707491479814
individuals O 0 0.00012114153651054949

The O 0 0.00010223782737739384
tumor B-Disease 1 0.8971299529075623
suppressor O 0 0.051766108721494675
gene O 0 0.0005547765176743269
Smad4 O 1 0.7981905937194824
/ O 0 0.13264702260494232
Dpc4 O 0 0.004342142958194017
is O 0 6.721242584717402e-08
required O 0 3.6500203748346394e-08
for O 0 3.769190115576748e-08
gastrulation O 0 0.0034732562489807606
and O 0 5.62943966997409e-08
later O 0 8.965412945372009e-08
for O 0 8.424283493013718e-08
anterior O 0 0.0003969759854953736
development O 0 2.5680225235191756e-07
of O 0 3.798368197749369e-08
the O 0 8.423220947406662e-07
mouse O 0 0.00113022536970675
embryo O 0 0.0010359620209783316
. O 0 1.7185360775329173e-05

Mutations O 0 5.956895984127186e-05
in O 0 1.4075432090976392e-06
the O 0 5.578259333560709e-06
SMAD4 O 1 0.9639369249343872
/ O 1 0.9070468544960022
DPC4 O 1 0.9926310777664185
tumor B-Disease 1 0.9843761920928955
suppressor O 0 0.01997719146311283
gene O 0 4.379508482088568e-06
, O 0 2.423571388021628e-08
a O 0 1.2861084641713205e-08
key O 0 6.027250520901362e-08
signal O 0 1.6507165412349423e-07
transducer O 0 6.052161097613862e-06
in O 0 2.445497671033081e-08
most O 0 1.3409163557298598e-07
TGFbeta O 0 0.14674606919288635
- O 0 0.004229918122291565
related O 0 1.6236965166172013e-05
pathways O 0 7.60545344746788e-06
, O 0 2.367930740376778e-08
are O 0 1.0381462356434668e-09
involved O 0 2.1866178201435105e-08
in O 0 2.529800369188706e-08
50 O 0 3.845804599222902e-07
% O 0 9.920171351041063e-07
of O 0 2.203331678174436e-05
pancreatic B-Disease 1 0.998706579208374
cancers I-Disease 1 0.9973714351654053
. O 0 0.000265402311924845

Homozygous O 0 0.007762710098177195
Smad4 O 1 0.738075852394104
mutant O 0 0.3251459002494812
mice O 1 0.5365435481071472
die O 0 0.04680875316262245
before O 0 2.059733787973528e-06
day O 0 3.741510454347008e-06
7 O 0 1.6994026736938395e-05
. O 0 1.1137391084048431e-05

5 O 0 2.5236196961486712e-05
of O 0 9.470215445617214e-06
embryogenesis O 0 0.012093080207705498
. O 0 0.0001802768965717405

Mutant O 0 0.0008569532656110823
embryos O 0 5.058187525719404e-05
have O 0 3.0009252327545255e-07
reduced O 0 5.185773716220865e-06
size O 0 4.639191502064932e-06
, O 0 2.91294981025203e-07
fail O 0 1.0688035217754077e-05
to O 0 4.1902961100959146e-08
gastrulate O 0 0.0007733303937129676
or O 0 1.1653516196474811e-07
express O 0 3.322361692426057e-07
a O 0 1.6891435450361314e-07
mesodermal O 0 0.0029827167745679617
marker O 0 3.0118544600554742e-05
, O 0 1.135682268227356e-07
and O 0 1.209404842938966e-07
show O 0 2.702864549064543e-06
abnormal O 0 0.002197818597778678
visceral O 0 0.017484556883573532
endoderm O 0 0.3239854574203491
development O 0 7.50313192838803e-05
. O 0 1.9031202100450173e-05

Growth B-Disease 1 0.7647309303283691
retardation I-Disease 1 0.9810397624969482
of O 0 1.1757999800465768e-06
the O 0 1.1653949513856787e-05
Smad4 O 1 0.9146161675453186
- O 0 0.38686278462409973
deficient O 0 0.10845797508955002
embryos O 0 1.348410478385631e-05
results O 0 9.879724984784843e-07
from O 0 5.88040222737618e-07
reduced O 0 6.271940947044641e-05
cell O 0 0.00032086827559396625
proliferation O 0 0.0027475866954773664
rather O 0 2.3188957243291952e-07
than O 0 2.6993564006261295e-07
increased O 0 1.1515553524077404e-05
apoptosis O 0 0.0004985577543266118
. O 0 9.875119758362416e-06

Aggregation O 0 6.448265048675239e-05
of O 0 2.7055364171246765e-06
mutant O 0 0.0011010896414518356
Smad4 O 0 0.13685652613639832
ES O 0 0.006980879697948694
cells O 0 1.8673976228456013e-05
with O 0 4.6323202695930377e-07
wild O 0 2.3191501895780675e-05
- O 0 0.0009560334146954119
type O 0 9.495943231740966e-05
tetraploid O 0 0.0012792105553671718
morulae O 0 0.039741359651088715
rescues O 0 0.005728198681026697
the O 0 1.661981877987273e-05
gastrulation B-Disease 1 0.9379873871803284
defect I-Disease 1 0.7959097623825073
. O 0 8.95560224307701e-05

These O 0 1.4239556094253203e-06
results O 0 3.6614947021007538e-06
indicate O 0 2.878068016798352e-06
that O 0 2.0630707808777515e-07
Smad4 O 0 0.006053491961210966
is O 0 5.476529452153045e-08
initially O 0 6.719780998309943e-08
required O 0 7.348039954280239e-09
for O 0 1.5883371284886039e-09
the O 0 3.5269731579745667e-09
differentiation O 0 2.454468130963505e-07
of O 0 6.3557057394803e-09
the O 0 4.2128387889306396e-08
visceral O 0 0.00039203205960802734
endoderm O 0 0.005770570132881403
and O 0 2.8779744809526164e-08
that O 0 1.2120207948385087e-08
the O 0 4.500249985994742e-07
gastrulation B-Disease 1 0.8185927867889404
defect I-Disease 0 0.012936495244503021
in O 0 1.1259120213935603e-07
the O 0 3.0445167453763133e-07
epiblast O 0 0.2817108631134033
is O 0 5.923923751538496e-08
secondary O 0 4.2791492660398944e-07
and O 0 1.069515249696451e-07
non O 0 9.739059350977186e-06
- O 0 0.0008606927003711462
cell O 0 6.859574205009267e-05
autonomous O 0 4.3265667954983655e-06
. O 0 4.668011570174713e-06

Rescued O 0 0.01195957139134407
embryos O 0 0.0023006354458630085
show O 0 0.0025773909874260426
severe O 1 0.9944087862968445
anterior O 1 0.7264070510864258
truncations O 0 0.12451353669166565
, O 0 6.005979685141938e-06
indicating O 0 3.8537750697287265e-06
a O 0 6.538539309985936e-08
second O 0 4.1808835504753006e-08
important O 0 1.8006913293788784e-08
role O 0 2.2534271693075425e-07
for O 0 2.8244588179404673e-07
Smad4 O 0 0.032571252435445786
in O 0 5.558276825468056e-06
anterior O 0 0.34135499596595764
patterning O 0 0.06761928647756577
during O 0 0.00016294103988911957
embryogenesis O 0 0.08287207782268524
. O 0 0.00011391254520276561

Prevalence O 0 0.0027828800957649946
of O 0 1.9640142454591114e-06
p16 O 0 0.0009088099468499422
and O 0 5.119838078826433e-06
CDK4 O 0 0.29012176394462585
germline O 0 0.04767410084605217
mutations O 0 0.0002354175812797621
in O 0 1.0593074875941966e-05
48 O 0 0.0409940704703331
melanoma B-Disease 1 0.9994327425956726
- O 1 0.9693859219551086
prone O 1 0.5982645153999329
families O 0 1.2055800652888138e-05
in O 0 2.675551968422951e-06
France O 0 0.00020033678447362036
. O 0 1.2475980838644318e-05

The O 0 0.00014253590779844671
French O 0 0.15306295454502106
Familial B-Disease 1 0.994714081287384
Melanoma I-Disease 1 0.9984058737754822
Study O 0 0.003208198118954897
Group O 0 0.00041551710455678403
. O 0 9.566289372742176e-05

Germline O 0 0.010385246016085148
mutations O 0 3.46459164575208e-05
in O 0 3.3533788723616453e-07
the O 0 2.73002967787761e-07
p16 O 0 0.000539477274287492
and O 0 1.0737592219811631e-06
CDK4 O 0 0.15357358753681183
genes O 0 1.2454075886125793e-06
have O 0 1.0738053113357182e-08
been O 0 1.0958178364717241e-08
reported O 0 1.0648236070665007e-07
in O 0 6.945529040791598e-09
a O 0 6.522047613088944e-08
subset O 0 7.995369742275216e-06
of O 0 7.372775144176558e-06
melanoma B-Disease 1 0.9996888637542725
pedigrees O 0 0.017617514356970787
, O 0 1.3232435094323591e-06
but O 0 2.3239390145590733e-07
their O 0 4.5502503098759917e-07
prevalence O 0 0.1956826001405716
is O 0 1.2169530805294926e-07
not O 0 3.257249403532114e-08
well O 0 1.8093264486651606e-07
known O 0 3.1981890060706064e-06
. O 0 4.263310074748006e-06

We O 0 1.427237521056668e-06
searched O 0 1.3833472394253477e-06
for O 0 8.094942671732497e-08
such O 0 1.933137667720075e-07
germline O 0 0.0006617847830057144
mutations O 0 5.033805337006925e-06
in O 0 4.191703055766993e-07
48 O 0 0.0002461295807734132
French O 0 0.3828597068786621
melanoma B-Disease 1 0.9996182918548584
- O 1 0.9262621402740479
prone O 0 0.23912778496742249
families O 0 9.221976142725907e-07
selected O 0 2.8493154502484686e-08
according O 0 1.7632746818208034e-08
to O 0 2.844844804172908e-09
two O 0 4.773442086047908e-09
major O 0 1.0087505870615132e-06
criteria O 0 8.330710556947452e-07
families O 0 9.450346283301769e-08
with O 0 1.455437814712468e-08
at O 0 4.275608489479055e-08
least O 0 1.4223220823339489e-08
three O 0 9.554666391409228e-09
affected O 0 4.1797676431087893e-07
members O 0 1.704421492831898e-08
( O 0 3.239486829897942e-07
n O 0 2.7805895115307067e-06
= O 0 4.518787136476021e-06
20 O 0 3.107004431512905e-08
) O 0 3.4740494925245e-08
or O 0 1.205296218387275e-08
families O 0 1.784488290468289e-08
with O 0 8.575634424801137e-09
two O 0 1.0724154897445715e-08
affected O 0 8.185832598428533e-07
members O 0 8.532333062305497e-09
, O 0 5.0895083703039745e-09
one O 0 8.469160373003604e-10
of O 0 2.100211338174063e-09
them O 0 8.434906995091751e-09
affected O 0 3.592966493215499e-07
before O 0 6.767911564509177e-09
the O 0 2.3631694379133705e-09
age O 0 3.439252083126121e-08
of O 0 2.4727191405560234e-09
50 O 0 5.3283830681039035e-08
( O 0 8.78672707926853e-08
n O 0 7.189416351138789e-07
= O 0 2.9424661533994367e-06
28 O 0 6.908194905008713e-08
) O 0 1.5143918119520094e-08
, O 0 3.578813467797204e-09
and O 0 2.482539063208833e-09
one O 0 9.565388481291848e-09
additional O 0 6.718717031617416e-07
minor O 0 0.00020686222705990076
criterion O 0 0.0007348847575485706
. O 0 1.3419014976534527e-05

Sixteen O 0 1.688878364802804e-05
different O 0 1.5806004967089393e-06
p16 O 0 0.011251761578023434
germline O 0 0.02709355764091015
mutations O 0 1.419170257577207e-05
were O 0 2.6520222462522725e-08
found O 0 6.901044002916024e-08
in O 0 5.555932958145604e-08
21 O 0 8.209020165850234e-07
families O 0 2.5575741346983705e-07
, O 0 2.496719808675607e-08
while O 0 1.8358916165084338e-08
one O 0 6.81167335869759e-08
germline O 0 0.001010153559036553
mutation O 0 8.48386662255507e-06
, O 0 4.534291804247914e-07
Arg24His O 0 0.001461670733988285
, O 0 8.30312600896832e-08
was O 0 7.124697987137552e-08
detected O 0 1.0746678071882343e-06
in O 0 2.667327159144861e-08
the O 0 2.5909298528858926e-07
CDK4 O 0 0.039889369159936905
gene O 0 8.52062221383676e-05
. O 0 6.341036623780383e-06

The O 0 4.4085510353397694e-07
frequency O 0 3.789890854477562e-07
of O 0 1.7248720496354508e-07
p16 O 0 0.00029649370117112994
gene O 0 3.846967047138605e-06
mutation O 0 7.902310699137161e-07
in O 0 5.61545299149202e-09
our O 0 5.720400597652997e-09
sample O 0 1.5226842009496977e-08
( O 0 5.2008228834665715e-08
44 O 0 1.6451436124498287e-07
% O 0 5.849237894040016e-08
) O 0 2.5395369362968268e-08
is O 0 2.2045063552411648e-09
among O 0 4.708480272341831e-09
the O 0 4.7301376149277985e-09
highest O 0 4.020985500119423e-07
rates O 0 1.4623493598264758e-06
yet O 0 7.633385479266508e-08
reported O 0 1.4038550943951122e-07
and O 0 5.697978533447667e-09
the O 0 5.696764660001463e-08
CDK4 O 0 0.06134067848324776
mutation O 0 1.2713815067399992e-06
is O 0 2.574135793409482e-09
the O 0 3.997788766696431e-09
second O 0 8.056574074544187e-08
mutation O 0 3.490080644041882e-06
detected O 0 1.1251278237978113e-06
in O 0 2.4676415577573607e-08
this O 0 4.9584681249825735e-08
gene O 0 1.163598062703386e-05
worldwide O 0 3.219644713681191e-05
. O 0 5.7874467529472895e-06

In O 0 5.336709818948293e-06
summary O 0 8.818406968202908e-06
, O 0 3.0385848504010937e-07
our O 0 8.881200841415193e-08
results O 0 1.5641791151210782e-07
show O 0 7.350537600814278e-08
frequent O 0 3.341375816034997e-07
involvement O 0 3.0800637773609196e-07
of O 0 9.26744991858186e-09
the O 0 1.5828857158339815e-07
p16 O 0 0.0018909411737695336
gene O 0 5.028263694839552e-05
in O 0 3.404432209208608e-05
familial B-Disease 1 0.9987755417823792
melanoma I-Disease 1 0.9996792078018188
and O 0 1.4752023389519309e-06
confirm O 0 1.286498218178167e-06
the O 0 1.1396072530089896e-08
role O 0 4.118586005574798e-08
of O 0 8.905962189942329e-09
the O 0 1.5075049475399283e-07
CDK4 O 0 0.04900065436959267
gene O 0 6.407899945770623e-06
as O 0 5.435786647467467e-07
a O 0 0.00011881345562869683
melanoma B-Disease 1 0.9994151592254639
- O 1 0.8581978678703308
predisposing O 0 0.20638608932495117
gene O 0 9.233532182406634e-05
. O 0 1.6014619177440181e-06
. O 0 9.73551141214557e-06

Progression O 0 0.00042698849574662745
of O 0 1.4190521824275493e-06
somatic O 0 0.0009663882665336132
CTG O 0 0.17039519548416138
repeat O 0 0.00039857422234490514
length O 0 1.1747883036150597e-05
heterogeneity O 0 0.00011984036973444745
in O 0 5.028269356444071e-07
the O 0 2.5981203179981094e-06
blood O 0 0.0106330756098032
cells O 0 0.005633071530610323
of O 0 0.004583848640322685
myotonic B-Disease 1 0.999320387840271
dystrophy I-Disease 1 0.9995380640029907
patients O 1 0.9947879314422607
. O 0 0.001031361985951662

The O 0 4.727146006189287e-06
genetic O 0 3.962785558542237e-05
basis O 0 3.208799398635165e-06
of O 0 0.00042643604683689773
myotonic B-Disease 1 0.9990794658660889
dystrophy I-Disease 1 0.9994372725486755
( O 0 0.28185155987739563
DM B-Disease 1 0.9991525411605835
) O 0 2.390677082075854e-06
is O 0 1.664481352747771e-08
the O 0 5.051423723756443e-09
expansion O 0 1.0402383310292862e-07
of O 0 5.028208960311531e-09
an O 0 2.031705719218735e-07
unstable O 0 0.013534191064536572
CTG O 0 0.04330854490399361
repeat O 0 8.480016731482465e-06
in O 0 5.935457014771828e-09
the O 0 3.4636671308874156e-09
34 O 0 7.384446831792957e-08
UTR O 0 9.221711479767691e-06
of O 0 5.067616548615206e-09
the O 0 1.559829314601302e-07
DM B-Disease 1 0.9941321015357971
protein O 0 2.069109314106754e-06
kinase O 0 1.6054105799412355e-05
gene O 0 5.965718514744367e-07
on O 0 7.702063697934136e-08
chromosome O 0 2.646443317644298e-05
19 O 0 5.595575657935115e-06
. O 0 4.473447461350588e-06

One O 0 3.5857368629876873e-07
of O 0 4.8902421667662566e-08
the O 0 5.112589107625354e-08
principal O 0 1.4351195432027453e-07
features O 0 7.444932492717271e-08
of O 0 3.808531801041681e-08
the O 0 6.7959581429022364e-06
DM B-Disease 1 0.9992905855178833
mutation O 0 8.876767969923094e-05
is O 0 3.737789810998038e-08
an O 0 2.919044561622286e-08
extraordinarily O 0 9.899362339638174e-06
high O 0 3.260942662564048e-07
level O 0 1.0177219422757844e-07
of O 0 4.740852332929535e-08
somatic O 0 0.0008460399694740772
mosaicism O 0 0.38130760192871094
, O 0 3.5318595337230363e-07
due O 0 3.1748001561027195e-07
to O 0 1.4650886726030876e-08
an O 0 4.017750043772139e-08
extremely O 0 2.652817101989058e-06
high O 0 1.0042277835964342e-06
degree O 0 3.655908358268789e-07
of O 0 8.521213601397903e-08
somatic O 0 0.000768266967497766
instability O 0 0.00028202630346640944
both O 0 2.212312821825435e-08
within O 0 3.961999084367562e-08
and O 0 3.8811378999525914e-08
between O 0 2.6643024853001407e-07
different O 0 4.734328058475512e-07
tissues O 0 0.0011848419671878219
. O 0 1.6932843209360726e-05

This O 0 2.423044861643575e-05
instability O 0 0.00694931810721755
appears O 0 7.658666618226562e-06
to O 0 3.5646447571480167e-08
be O 0 4.918827567479411e-09
biased O 0 8.180246879874176e-08
towards O 0 1.621578604726892e-08
further O 0 2.5383117829846924e-08
expansion O 0 2.51564983955177e-07
and O 0 5.675028003082616e-09
continuous O 0 4.219006655148405e-08
throughout O 0 1.2316381692301093e-08
the O 0 3.895003874987424e-09
life O 0 4.786920015931173e-08
of O 0 5.008596204447713e-09
an O 0 2.231523410500813e-08
individual O 0 5.604990249707953e-08
, O 0 9.242634035899755e-08
features O 0 6.355563186843938e-07
that O 0 1.581439690312436e-08
could O 0 3.595481956608637e-08
be O 0 3.676198234714434e-09
associated O 0 1.0306420961114782e-07
with O 0 2.0700191782907496e-08
the O 0 2.0175795611976355e-07
progressive O 0 0.0004470762796700001
nature O 0 7.1540134740644135e-06
of O 0 2.4327796381840017e-06
the O 0 0.00036771412123925984
disease O 1 0.998104453086853
. O 0 0.00028839163132943213

Although O 0 8.531198545824736e-06
increasing O 0 7.97702250565635e-06
measured O 0 6.630280950048473e-06
allele O 0 3.1982115615392104e-05
size O 0 1.5703799363109283e-05
between O 0 5.857259111508029e-06
patients O 0 0.010985786095261574
clearly O 0 1.3650055734615307e-06
correlates O 0 1.37629613163881e-05
with O 0 2.798077503030072e-07
an O 0 1.668081267780508e-06
increased O 0 0.0007235969533212483
severity O 1 0.5615478754043579
of O 0 5.343676548363874e-06
symptoms O 1 0.9509727954864502
and O 0 2.016263920268102e-07
an O 0 8.911811733014474e-08
earlier O 0 5.193118340685032e-06
age O 0 2.1632853531627916e-05
of O 0 1.8163088952860562e-06
onset O 1 0.99735426902771
, O 0 4.628690533081681e-07
this O 0 1.2457142872790428e-08
correlation O 0 3.1175744652500725e-07
is O 0 3.913949608858047e-09
not O 0 4.940432507538617e-10
precise O 0 6.44334496868737e-09
and O 0 6.512263173164001e-09
measured O 0 2.4393676767431316e-07
allele O 0 1.6306184988934547e-06
length O 0 3.687661660478625e-07
cannot O 0 2.821114364337518e-08
be O 0 4.472989756365564e-10
used O 0 1.2625511747188511e-09
as O 0 1.2427875395459864e-09
an O 0 2.066152582358427e-09
accurate O 0 7.851306804695923e-08
predictor O 0 2.4810791728668846e-05
of O 0 3.945303461705407e-08
age O 0 1.9724269805010408e-05
of O 0 3.9568599277117755e-06
onset O 1 0.9958477020263672
. O 0 0.00010438767640152946

In O 0 7.472160632460145e-07
order O 0 2.7895433163394046e-07
to O 0 4.8870347768570355e-08
further O 0 1.0822544993516203e-07
characterize O 0 7.892197572800796e-06
the O 0 5.620148968432659e-08
dynamics O 0 1.9165216144756414e-05
of O 0 2.2156375507620396e-06
DM B-Disease 1 0.9985752105712891
CTG O 1 0.9595325589179993
repeat O 0 0.028481753543019295
somatic O 0 0.005074526183307171
instability O 0 0.0051042623817920685
, O 0 1.407039746936789e-07
we O 0 8.801214868014995e-09
have O 0 3.598361608680989e-09
studied O 0 4.419499433083729e-08
repeat O 0 2.891018993977923e-06
length O 0 8.773245951942954e-08
changes O 0 1.9776839721430406e-08
over O 0 2.721611735978513e-08
time O 0 7.184427630591017e-08
in O 0 6.435084287659265e-06
111 O 1 0.8212841749191284
myotonic B-Disease 1 0.999750554561615
dystrophy I-Disease 1 0.9997977614402771
patients O 1 0.7958782911300659
with O 0 1.2005192729702685e-05
varying O 0 0.0006855684332549572
clinical O 1 0.5021172761917114
severity O 1 0.6354665160179138
and O 0 3.095286501775263e-06
CTG O 0 0.1681242436170578
repeat O 0 6.624529487453401e-05
size O 0 2.8406992669260944e-07
over O 0 1.9938756423698578e-08
time O 0 3.8530414414594816e-09
intervals O 0 1.9480070889699164e-08
of O 0 4.734361791491892e-09
1 O 0 6.088953909966222e-07
- O 0 6.123868661234155e-05
7 O 0 2.1390731035353383e-06
years O 0 3.7085649182699854e-06
. O 0 4.3016138988605235e-06

We O 0 9.497850328443747e-07
have O 0 9.436656966954615e-08
found O 0 3.0203164413933337e-08
a O 0 2.444849656058068e-08
direct O 0 7.568464610585579e-08
progression O 0 4.786852514371276e-05
of O 0 9.173240833604268e-09
the O 0 2.2057104587247522e-08
size O 0 1.2375248843454756e-06
heterogeneity O 0 1.1030735549866222e-05
over O 0 5.7232842465282374e-08
time O 0 1.8018766922978102e-08
related O 0 2.153457216991228e-07
to O 0 1.8817349456412558e-08
initial O 0 3.1137435598793672e-06
CTG O 0 0.05775930732488632
repeat O 0 4.4741151214111596e-05
size O 0 2.3461853970729862e-07
and O 0 2.3380177793796975e-09
the O 0 1.4138339388125587e-09
time O 0 3.3245148856053675e-09
interval O 0 7.29837310586845e-08
and O 0 5.84049431040512e-09
always O 0 1.663767079662648e-08
biased O 0 1.2160562334884162e-07
towards O 0 5.6213174559616164e-08
further O 0 4.230134607041691e-07
expansion O 0 3.880859730998054e-05
. O 0 8.237525435106363e-06

Attempts O 0 5.882987807126483e-06
to O 0 2.9212679919510265e-07
mathematically O 0 2.592308874227456e-06
model O 0 1.3936730738350889e-06
the O 0 2.5172815298901696e-07
dynamics O 0 5.294187940307893e-05
have O 0 3.4348335731237967e-08
proved O 0 8.220191602958948e-07
only O 0 1.5575544409784925e-08
partially O 0 4.556478870654246e-06
successful O 0 5.585694111687189e-07
suggesting O 0 9.318711704509042e-07
that O 0 1.2057860487857397e-08
individual O 0 8.149039132376856e-08
specific O 0 5.021330480303732e-07
genetic O 0 0.00012750992027577013
and O 0 6.038324499968439e-06
/ O 0 0.15720252692699432
or O 0 2.3375516775558935e-06
environmental O 0 2.0353476429590955e-05
factors O 0 2.627066919558274e-07
also O 0 5.74672309738844e-09
play O 0 6.6738214954398245e-09
a O 0 3.274023185895203e-08
role O 0 5.295889309309132e-07
in O 0 1.0876841542994953e-06
somatic O 0 0.0071355486288666725
mosaicism O 1 0.7845925688743591
. O 0 4.718210220744368e-06
. O 0 9.23940388020128e-06

Aspartylglucosaminuria B-Disease 1 0.5718607902526855
among O 0 5.847621650900692e-05
Palestinian O 0 0.00030843450804241
Arabs O 0 0.0006728859152644873
. O 0 0.0001372021361021325

Aspartylglucosaminuria B-Disease 1 0.970033586025238
( O 0 0.00958265084773302
AGU B-Disease 1 0.9906876683235168
) O 0 1.1519826330186334e-05
is O 0 1.310710331381415e-06
a O 0 1.1555189303180669e-05
rare O 0 0.060024648904800415
disorder B-Disease 1 0.998143196105957
of I-Disease 0 1.4787865438847803e-05
glycoprotein I-Disease 1 0.9799976348876953
metabolism I-Disease 0 0.04361536353826523
caused O 0 0.0013164881384000182
by O 0 1.0506295211598626e-06
the O 0 7.932793778309133e-06
deficiency B-Disease 1 0.9902504682540894
of I-Disease 0 9.08714810066158e-08
the I-Disease 0 3.179601208103122e-06
lysosomal I-Disease 1 0.9259200692176819
enzyme I-Disease 0 0.0010454999282956123
aspartylglucosaminidase I-Disease 0 0.27691400051116943
( O 0 3.643431409727782e-05
AGA O 0 0.0686694011092186
) O 0 5.124126801092643e-06
. O 0 4.280212579033105e-06

AGU B-Disease 1 0.9861438274383545
is O 0 0.00026716882712207735
inherited O 1 0.6320004463195801
as O 0 2.2932754291105084e-05
an O 0 0.00023656192934140563
autosomal O 1 0.9980150461196899
recessive O 1 0.9959142804145813
trait O 0 0.02011823281645775
and O 0 1.7385475530318217e-06
occurs O 0 3.454753141340916e-06
with O 0 5.831804017475406e-08
a O 0 1.1597416715858344e-07
high O 0 1.088823637473979e-06
frequency O 0 6.351552173100572e-08
in O 0 1.5952299037280682e-08
Finland O 0 2.983222486818704e-07
because O 0 1.666314197734664e-08
of O 0 1.149371353648121e-08
a O 0 1.2021607744827634e-06
founder O 0 0.00025184120750054717
effect O 0 6.791944178985432e-05
. O 0 2.0039382434333675e-05

While O 0 1.379481273033889e-05
very O 0 8.020358109206427e-06
few O 0 4.7736786655150354e-05
patients O 0 0.15505842864513397
with O 0 7.641933189006522e-05
AGU B-Disease 1 0.9983236193656921
have O 0 1.5619058046922873e-07
been O 0 3.9853581768056756e-08
reported O 0 2.6358102900303493e-07
from O 0 3.1184985260779285e-08
non O 0 1.1236029422434513e-06
- O 0 7.709124474786222e-05
Finnish O 0 5.554043673328124e-05
origin O 0 6.539312380482443e-07
, O 0 2.150012960555614e-06
we O 0 9.920569937094115e-06
diagnosed O 1 0.9988775849342346
the O 0 6.475916597992182e-05
disorder O 1 0.9988784193992615
in O 0 7.540448677900713e-06
8 O 0 0.00028692270279861987
patients O 0 0.018390702083706856
originating O 0 1.1388137863832526e-06
from O 0 2.46021215843939e-07
3 O 0 3.7502875329664676e-06
unrelated O 0 4.8518286348553374e-05
families O 0 7.882356953814451e-07
, O 0 2.5265743275326713e-08
all O 0 8.15270428944359e-09
Palestinian O 0 7.623169722137391e-07
Arabs O 0 9.170879593511927e-07
from O 0 3.100303302971952e-08
the O 0 2.4362517336840028e-08
region O 0 6.479425564975827e-07
of O 0 1.730983854031365e-07
Jerusalem O 0 0.0001512904418632388
. O 0 2.7911857614526525e-05

The O 0 0.00025448499945923686
clinical O 1 0.7980747818946838
diagnosis O 1 0.9807806611061096
of O 0 0.0001976678759092465
AGU B-Disease 1 0.9983921647071838
is O 0 3.1499423585046316e-06
often O 0 8.516774983036157e-07
difficult O 0 1.5641298887203448e-06
, O 0 4.212348869714333e-08
in O 0 1.3959403410979121e-08
particular O 0 1.2283280170777289e-08
early O 0 3.3200361571061876e-08
in O 0 9.17752807083616e-09
the O 0 1.9247945459710536e-08
course O 0 1.4428308077185648e-06
of O 0 1.5969627042977663e-07
the O 0 4.881200584350154e-05
disease O 1 0.9966664910316467
, O 0 2.343640659319135e-07
and O 0 3.3188964465580284e-08
most O 0 2.845312963017932e-08
of O 0 1.5193704427929333e-07
the O 0 4.1994237108156085e-05
patients O 1 0.9621543288230896
are O 0 7.196096703410149e-06
diagnosed O 1 0.9972130656242371
after O 0 1.019359160636668e-06
the O 0 1.0478632361810014e-07
age O 0 3.102917844444164e-06
of O 0 8.631678838355583e-08
5 O 0 9.143073839368299e-06
years O 0 3.2339234167011455e-05
. O 0 1.612093547009863e-05

However O 0 1.60399195010541e-05
, O 0 3.3341991638735635e-06
since O 0 3.8956704884185456e-06
these O 0 1.0307998081771075e-06
patients O 0 0.014660988003015518
excrete O 0 0.00022027132217772305
early O 0 1.4786319013637694e-07
large O 0 1.2760979473114276e-07
amounts O 0 1.489285494926662e-07
of O 0 5.13737887786192e-08
aspartylglucosamine O 0 0.001044158125296235
in O 0 1.9458538247363322e-07
urine O 0 1.4353935512190219e-05
, O 0 2.2508714891955606e-07
biochemical O 0 1.0653142453520559e-05
screening O 0 2.2363992684404366e-06
is O 0 2.052821379550096e-08
easy O 0 2.440319519791956e-07
by O 0 1.6183687989723694e-07
urine O 0 3.318127346574329e-05
chromatography O 0 0.0009400576236657798
. O 0 9.660290061219712e-07
. O 0 5.416342901298776e-06

Detection O 0 5.501529813045636e-05
of O 0 7.505728376600018e-07
heterozygous O 0 2.027016489591915e-05
carriers O 0 2.758499795163516e-05
of O 0 4.2224846197314037e-07
the O 0 3.886052218149416e-05
ataxia B-Disease 1 0.9984728693962097
- I-Disease 1 0.9830600619316101
telangiectasia I-Disease 1 0.9981532692909241
( O 0 1.9183100448572077e-05
ATM O 0 7.579958037240431e-05
) O 0 1.5657282403935824e-07
gene O 0 3.811617261817446e-07
by O 0 1.3836518064636039e-07
G2 O 0 0.143670454621315
phase O 0 9.006447362480685e-05
chromosomal O 0 0.009180220775306225
radiosensitivity O 0 0.05792009085416794
of O 0 1.603513373993337e-05
peripheral O 1 0.9359543919563293
blood O 1 0.6038364171981812
lymphocytes O 1 0.8713566660881042
. O 0 4.923438609694131e-05

In O 0 0.0010700694983825088
ataxia B-Disease 1 0.9934154748916626
- I-Disease 1 0.9726726412773132
telangiectasia I-Disease 1 0.995665967464447
( O 0 0.00024464671150781214
A B-Disease 0 0.005613772664219141
- I-Disease 1 0.9903680086135864
T I-Disease 1 0.9992237091064453
) O 0 0.00019162395619787276
patients O 0 0.005809407215565443
, O 0 1.992334830447362e-07
mutations O 0 5.800177405035356e-07
in O 0 2.775342178296114e-09
a O 0 1.1268675770281789e-08
single O 0 2.663986897744053e-08
gene O 0 5.400680151979032e-07
, O 0 5.2500777059094617e-08
ATM O 0 3.095242936979048e-05
, O 0 1.2871372234712908e-07
result O 0 2.0433308236533776e-06
in O 0 3.955282863898901e-06
an O 0 0.003343157935887575
autosomal B-Disease 1 0.9996774196624756
recessive I-Disease 1 0.9997705817222595
syndrome I-Disease 1 0.999908447265625
that O 0 3.1929166652844287e-06
embraces O 0 0.0016549652209505439
a O 0 1.643789914851368e-06
variety O 0 2.3476206933992216e-06
of O 0 6.493821160802327e-07
clinical O 0 0.008394691161811352
features O 0 1.915432767418679e-05
and O 0 3.3130763767985627e-06
manifests O 0 0.012797198258340359
extreme O 0 0.0012362495763227344
radiosensitivity O 0 0.020314369350671768
and O 0 1.3084370209526242e-07
a O 0 2.633157123455021e-07
strong O 0 5.688529199687764e-06
pre O 0 0.0029413914307951927
- O 0 0.02855093404650688
disposition O 0 0.001578406197950244
to O 0 1.927214179886505e-05
malignancy B-Disease 1 0.988584041595459
. O 0 5.148490527062677e-05

Heterozygotes O 0 0.0007228742470033467
for O 0 5.574231636273907e-07
the O 0 2.485710979271971e-07
ATM O 0 0.00020315946312621236
gene O 0 2.999402568093501e-06
have O 0 1.6355533816181378e-08
no O 0 1.1488414486393594e-07
clinical O 0 1.0201672921539284e-05
expression O 0 1.3283576549838472e-07
of O 0 1.0072992751020138e-07
A B-Disease 0 0.002441899385303259
- I-Disease 1 0.9886533617973328
T I-Disease 1 0.999047577381134
but O 0 3.3494966373837087e-06
may O 0 1.2927181160193868e-05
be O 0 3.126443061773898e-06
cancer B-Disease 1 0.9976435303688049
prone O 0 0.014355059713125229
with O 0 2.2577812330837332e-07
a O 0 1.5481439277209574e-06
moderate O 0 0.00024148593365680426
increase O 0 5.858432359673316e-06
in O 0 3.4233687529194867e-07
in O 0 9.775915259524481e-07
vitro O 0 0.0004685243184212595
radiosensitivity O 0 0.04184844717383385
. O 0 1.919241367431823e-05

We O 0 1.1126636536573642e-06
performed O 0 8.361960226466181e-07
a O 0 5.663050046678109e-07
blind O 0 5.9756202972494066e-05
chromosomal O 0 9.424379823030904e-05
analysis O 0 3.22986210221643e-07
on O 0 2.7837634775096376e-07
G2 O 0 0.3071507513523102
- O 0 0.00014868627476971596
phase O 0 2.165419573429972e-05
lymphocytes O 0 0.00033067906042560935
from O 0 5.592026752765378e-08
7 O 0 6.90677097736625e-07
unrelated O 0 3.462098175077699e-05
A B-Disease 0 0.0006702598184347153
- I-Disease 1 0.9669531583786011
T I-Disease 1 0.9989972710609436
patients O 0 0.006073963362723589
, O 0 1.7433976040592825e-07
13 O 0 8.39125391394191e-07
obligate O 0 2.6046252969536e-05
A B-Disease 0 0.00012260850053280592
- I-Disease 1 0.6701086759567261
T I-Disease 1 0.9985590577125549
heterozygotes O 0 0.027141764760017395
( O 0 8.719484299035685e-07
parents O 0 8.950411967134642e-08
of O 0 1.3195943004973287e-08
the O 0 6.071835514376289e-07
patients O 0 0.004418324213474989
) O 0 8.14148890526667e-08
, O 0 7.524101341971345e-09
and O 0 3.994693908992986e-09
14 O 0 2.3629091572274774e-08
normal O 0 3.538753645671022e-08
controls O 0 1.1552819501048361e-07
following O 0 8.802746265246242e-08
X O 0 4.6554770960938185e-05
- O 0 9.71447843767237e-06
irradiation O 0 1.0631406439642888e-06
with O 0 1.648522740538283e-08
1 O 0 4.436615199665539e-07
Gy O 0 0.0028437506407499313
in O 0 3.547334426201587e-09
order O 0 5.538958625095347e-09
to O 0 4.930775787670427e-09
evaluate O 0 2.81758474329763e-07
this O 0 7.277200175792586e-09
cytogenetic O 0 5.2780618716496974e-05
method O 0 1.171238483976822e-08
as O 0 4.242098228246505e-09
a O 0 1.745709354850078e-08
tool O 0 3.413324805023876e-07
for O 0 2.49481555414377e-08
detection O 0 4.45856676378753e-06
of O 0 2.177366695832461e-07
ATM O 0 0.0012537927832454443
carriers O 0 0.0005178462597541511
. O 0 8.08147251518676e-06

Both O 0 1.1911212823179085e-05
A B-Disease 0 0.000967209052760154
- I-Disease 1 0.7085752487182617
T I-Disease 1 0.9941562414169312
homozygotes O 0 0.18861429393291473
and O 0 3.6595681649487233e-06
heterozygotes O 0 0.003576833987608552
showed O 0 1.345806504104985e-05
significantly O 0 1.5806812371010892e-05
increased O 0 8.82534664015111e-07
levels O 0 9.455860663365456e-07
of O 0 3.6632795286095643e-07
radiation O 0 0.2856517732143402
- O 0 0.27566802501678467
induced O 1 0.7347386479377747
chromatid O 1 0.9370136260986328
damage O 0 0.008022695779800415
relative O 0 1.2797581803170033e-06
to O 0 1.8976876958731737e-08
that O 0 5.520564005934148e-09
of O 0 3.9608579527339316e-08
normal O 0 6.129660050646635e-06
controls O 0 6.291775207500905e-05
. O 0 1.5711681044194847e-05

These O 0 5.428150302577706e-07
results O 0 5.193537049308361e-07
show O 0 1.4511572032915865e-07
that O 0 1.1559383672476997e-08
the O 0 1.0662218130619294e-07
G2 O 0 0.23007282614707947
- O 0 0.0002142108278349042
phase O 0 6.100053360569291e-05
chromosomal O 0 0.0023474814370274544
radiosensitivity O 0 0.011297141201794147
assay O 0 4.737914423458278e-06
can O 0 1.3776024765377315e-08
be O 0 4.974623490916485e-10
used O 0 1.456761822282715e-09
for O 0 1.8615075036976236e-09
the O 0 5.901523714157975e-09
detection O 0 1.1117239182567573e-06
of O 0 8.20285492864059e-08
A B-Disease 0 0.0002987323678098619
- I-Disease 1 0.7283614277839661
T I-Disease 1 0.9949997663497925
heterozygotes O 0 0.07164332270622253
. O 0 3.203583764843643e-05

In O 0 3.0749499728699448e-06
combination O 0 2.1280091459630057e-05
with O 0 5.260372404336522e-07
molecular O 0 3.6030880437465385e-05
genetic O 0 5.47846284462139e-05
analyses O 0 1.2952156794199254e-05
, O 0 1.9977477450083825e-07
this O 0 4.299553069131434e-08
test O 0 7.434999247379892e-07
may O 0 4.815886711639905e-08
be O 0 2.1779246461850477e-10
of O 0 3.4546132621215975e-10
value O 0 3.909845780469823e-09
in O 0 8.477778479232256e-09
studies O 0 5.411951775613488e-08
of O 0 3.12660439760748e-08
familial B-Disease 0 0.03368222340941429
and I-Disease 0 2.113611799359205e-06
sporadic I-Disease 0 0.008281300775706768
cancers I-Disease 1 0.9318126440048218
aimed O 0 5.227493147685891e-06
at O 0 2.3577099739213736e-07
determination O 0 4.342169290794118e-07
of O 0 7.4083410517289394e-09
the O 0 2.1274347616895284e-08
potential O 0 4.725428652818664e-07
involvement O 0 1.4000581813888857e-06
of O 0 3.371258685547218e-07
ATM O 0 0.03519859164953232
mutations O 0 0.0026741998735815287
in O 0 0.00013097758346702904
tumor B-Disease 1 0.998426079750061
risk O 0 0.01862557791173458
or O 0 2.0923412193951663e-06
development O 0 9.767502888280433e-06
. O 0 2.95491804536141e-06
. O 0 1.606130535947159e-05

Ataxia B-Disease 1 0.9931364059448242
- I-Disease 1 0.9853728413581848
telangiectasia I-Disease 1 0.9938395619392395
: O 0 1.501454971730709e-05
identification O 0 7.308764793378941e-07
and O 0 6.437844035644957e-08
detection O 0 1.5886157598288264e-06
of O 0 5.7866081704105454e-08
founder O 0 0.00010125055996468291
- O 0 0.0005252903210930526
effect O 0 1.92867355508497e-06
mutations O 0 8.408084681832406e-07
in O 0 1.0276266060316175e-08
the O 0 2.5232898437366202e-08
ATM O 0 3.299151285318658e-05
gene O 0 9.782415872905403e-07
in O 0 8.24069559257623e-08
ethnic O 0 2.1062232917756774e-06
populations O 0 8.903234265744686e-05
. O 0 1.5923720638966188e-05

To O 0 4.197639782432816e-07
facilitate O 0 4.432289131273137e-07
the O 0 4.953193766255026e-08
evaluation O 0 3.408858333386888e-07
of O 0 8.884758528893144e-08
ATM O 0 0.0013290907954797149
heterozygotes O 0 0.0017527679447084665
for O 0 5.818803856527666e-07
susceptibility O 0 0.0013370270607993007
to O 0 1.0211339258603402e-06
other O 0 1.4803244994254783e-05
diseases O 1 0.9981958270072937
, O 0 3.7307747788872803e-06
such O 0 1.7000284060486592e-05
as O 0 0.009661835618317127
breast B-Disease 1 0.9998302459716797
cancer I-Disease 1 0.9995668530464172
, O 0 1.0226240192423575e-06
we O 0 1.7394841123063998e-08
have O 0 3.394678982360233e-09
attempted O 0 1.784945453664477e-07
to O 0 1.4671747372574373e-08
define O 0 5.816140742354037e-07
the O 0 2.726454262358402e-08
most O 0 4.05511961787397e-08
common O 0 4.3710403474506165e-07
mutations O 0 4.0253863176076266e-07
and O 0 1.9469699186203115e-09
their O 0 3.957262073583934e-09
frequencies O 0 1.5458466862128262e-07
in O 0 3.0584726573579246e-06
ataxia B-Disease 1 0.9988675117492676
- I-Disease 1 0.9337016344070435
telangiectasia I-Disease 1 0.9973788261413574
( O 0 1.1885023923241533e-05
A B-Disease 0 0.00024050363572314382
- I-Disease 0 0.4862709641456604
T I-Disease 1 0.9928054213523865
) O 0 2.4870462311810115e-06
homozygotes O 0 0.00032740228925831616
from O 0 9.936005085364741e-08
10 O 0 2.3884155098130577e-07
ethnic O 0 2.571120376160252e-06
populations O 0 7.121743692550808e-05
. O 0 1.3541295629693195e-05

Both O 0 7.149157681851648e-06
genomic O 0 0.0002027739683398977
mutations O 0 2.9751598049188033e-05
and O 0 1.4900484757163213e-07
their O 0 6.063039847958862e-08
effects O 0 1.2215138667670544e-05
on O 0 1.283056150214179e-07
cDNA O 0 1.959176552190911e-05
were O 0 3.0423399266510387e-07
characterized O 0 0.0010556273628026247
. O 0 2.0093615603400394e-05

Protein O 0 2.7508001949172467e-05
- O 0 0.00014254284906201065
truncation O 0 2.01770308194682e-05
testing O 0 2.7892534149032144e-07
of O 0 5.8853819595583445e-09
the O 0 8.44177971970339e-09
entire O 0 1.1372993924396724e-07
ATM O 0 3.4751678867905866e-06
cDNA O 0 1.3745651585850283e-06
detected O 0 8.918475487007527e-07
92 O 0 1.0172751672143932e-06
( O 0 9.745051698928364e-08
66 O 0 6.322700301097939e-07
% O 0 2.4507368578952082e-08
) O 0 5.715996920230282e-08
truncating O 0 6.559693429153413e-05
mutations O 0 9.253797088604188e-07
in O 0 5.0713321542161793e-08
140 O 0 5.7660663514980115e-06
mutant O 0 0.00011555691162357107
alleles O 0 4.5788307033944875e-05
screened O 0 0.00012336188228800893
. O 0 2.0191197108943015e-05

The O 0 2.2432721380027942e-05
haplotyping O 0 0.04771968349814415
of O 0 1.1258898666710593e-05
patients O 0 0.08991769701242447
with O 0 4.678993718698621e-06
identical O 0 0.00011067415471188724
mutations O 0 0.0002132920635631308
indicates O 0 7.502231255784864e-06
that O 0 6.5729977016815155e-09
almost O 0 7.806714386049407e-09
all O 0 7.574985638747478e-10
of O 0 3.2055440524203505e-09
these O 0 7.247515032560159e-09
represent O 0 6.009698694242616e-08
common O 0 9.123894528784149e-07
ancestry O 0 2.317048711120151e-06
and O 0 3.874865583952669e-08
that O 0 2.2321406945025046e-08
very O 0 1.0111588721883891e-07
few O 0 8.655779879518377e-07
spontaneously O 0 0.0003322939737699926
recurring O 0 0.011625380255281925
ATM O 0 0.05018358305096626
mutations O 0 0.0002197029098169878
exist O 0 4.870183147431817e-06
. O 0 8.317029823956545e-06

Assays O 0 6.254261825233698e-05
requiring O 0 1.8012045984505676e-05
minimal O 0 3.5522152757039294e-06
amounts O 0 2.4046107682806905e-07
of O 0 2.7475758557216068e-08
genomic O 0 4.902401087747421e-06
DNA O 0 4.7157809035525133e-07
were O 0 6.098807237009396e-09
designed O 0 4.847810828323418e-07
to O 0 2.5613251963818584e-08
allow O 0 3.048683083761716e-07
rapid O 0 0.00019087883993051946
screening O 0 1.0446525266161188e-05
for O 0 1.4409424409222993e-07
common O 0 1.6244347307292628e-06
ethnic O 0 1.0374397788837086e-05
mutations O 0 0.0006511670653708279
. O 0 2.453861088724807e-05

These O 0 2.399772938588285e-06
rapid O 0 7.681708666495979e-05
assays O 0 1.6658868844388053e-05
detected O 0 1.1473033737274818e-05
mutations O 0 1.4283214113675058e-06
in O 0 2.8213294811507694e-08
76 O 0 1.910746732391999e-06
% O 0 1.8063431639347982e-08
of O 0 1.561996043619729e-08
Costa O 0 1.751080526446458e-05
Rican O 0 4.718822310678661e-05
patients O 0 0.0014238957082852721
( O 0 3.399333365905477e-07
3 O 0 8.232573378563757e-08
) O 0 1.0091778079868163e-08
, O 0 1.6614577491580462e-09
50 O 0 4.162628020054626e-09
% O 0 2.031766088705922e-09
of O 0 5.502986510919072e-09
Norwegian O 0 1.4080966138863005e-05
patients O 0 0.0009582886123098433
( O 0 3.7940930042168475e-07
1 O 0 6.127726948079726e-08
) O 0 9.227218100704704e-09
, O 0 1.269219951360867e-09
25 O 0 6.3321592413956296e-09
% O 0 5.2971595998485554e-09
of O 0 1.8415029501284153e-08
Polish O 0 0.0016626818105578423
patients O 0 0.004161372780799866
( O 0 6.981764499869314e-07
4 O 0 2.4513639118595165e-07
) O 0 1.563417839633985e-08
, O 0 1.959292950104441e-09
and O 0 1.625649947989416e-09
14 O 0 1.4358993105645368e-08
% O 0 6.2798268807284785e-09
of O 0 2.5164359485074783e-08
Italian O 0 0.0008482945268042386
patients O 0 0.011075450107455254
( O 0 8.154370334523264e-07
1 O 0 3.472006824267737e-07
) O 0 6.165418398040856e-08
, O 0 5.631638266834216e-09
as O 0 3.6162641769976744e-09
well O 0 5.990389961851861e-09
as O 0 1.2723060827113386e-08
in O 0 8.976210352784619e-08
patients O 0 0.00011168747732881457
of O 0 1.9511276150296908e-07
Amish O 0 0.0021960523445159197
/ O 0 0.015656856819987297
Mennonite O 0 0.00047150166938081384
and O 0 2.544235826462682e-07
Irish O 0 8.874358172761276e-06
English O 0 3.423477210162673e-06
backgrounds O 0 3.816209209617227e-05
. O 0 2.3619693820364773e-05

Additional O 0 2.1194868168095127e-05
mutations O 0 1.8170945622841828e-05
were O 0 5.776594846906846e-08
observed O 0 1.723540066222995e-07
in O 0 5.0656861816378296e-08
Japanese O 0 1.4381516848516185e-06
, O 0 6.925609596919458e-08
Utah O 0 1.7323079646303086e-06
Mormon O 0 2.0687423329945887e-06
, O 0 1.7496937232408527e-07
and O 0 3.544077173955884e-07
African O 0 5.1312574214534834e-05
American O 0 0.00032598950201645494
patients O 1 0.5043953061103821
. O 0 9.967906953534111e-05

These O 0 8.775051014708879e-07
assays O 0 3.4878612495958805e-06
should O 0 1.31196301822456e-07
facilitate O 0 5.080544838165224e-07
screening O 0 4.457129762158729e-06
for O 0 1.6555817694552388e-07
A B-Disease 0 0.00014590054342988878
- I-Disease 1 0.6216502785682678
T I-Disease 1 0.9974505305290222
heterozygotes O 0 0.003236232092604041
in O 0 1.8407098423267598e-07
the O 0 2.5478533416389837e-07
populations O 0 5.599386895482894e-06
studied O 0 1.960399004019564e-06
. O 0 6.960145242373983e-07
. O 0 4.762667686009081e-06

The O 0 7.78026005718857e-05
von B-Disease 1 0.7876847386360168
Hippel I-Disease 1 0.9874057173728943
- I-Disease 1 0.9871307015419006
Lindau I-Disease 1 0.9973297119140625
tumor I-Disease 1 0.9970411658287048
suppressor O 0 0.16964952647686005
gene O 0 1.7282558474107645e-05
is O 0 3.362043088372957e-08
required O 0 4.5517172253539684e-08
for O 0 5.9114963590900516e-08
cell O 0 2.9779757824144326e-05
cycle O 0 4.1310959204565734e-05
exit O 0 3.403529626666568e-05
upon O 0 2.478222086210735e-06
serum O 0 0.0034415735863149166
withdrawal O 0 0.0001495385222369805
. O 0 1.783329753379803e-05

The O 0 4.6151503738656174e-06
inactivation O 0 0.00017655902775004506
of O 0 3.3922282227649703e-07
the O 0 5.330687145033153e-06
von B-Disease 0 0.3760697543621063
Hippel I-Disease 1 0.9897361993789673
- I-Disease 1 0.7786433100700378
Lindau I-Disease 1 0.9907971620559692
( I-Disease 0 0.0012802843702957034
VHL I-Disease 1 0.9926010966300964
) I-Disease 0 0.00031234382186084986
tumor I-Disease 1 0.990395724773407
suppressor O 0 0.41633060574531555
gene O 0 0.0021337142679840326
predisposes O 1 0.8409437537193298
affected O 0 5.044064164394513e-05
individuals O 0 7.409346949316387e-07
to O 0 6.010461106598086e-07
the O 0 8.38838896015659e-05
human O 1 0.979236364364624
VHL B-Disease 1 0.9997888207435608
cancer I-Disease 1 0.9998939037322998
syndrome I-Disease 1 0.9998806715011597
and O 0 2.1309377189027146e-05
is O 0 2.602832410047995e-06
associated O 0 4.597452061716467e-05
with O 0 4.235039159539156e-05
sporadic B-Disease 1 0.901343047618866
renal I-Disease 1 0.9996834993362427
cell I-Disease 1 0.9977783560752869
carcinomas I-Disease 1 0.9993950128555298
( O 0 0.06065843999385834
RCC B-Disease 1 0.9980839490890503
) O 0 5.0700968131422997e-05
and O 0 1.5547071598120965e-05
brain B-Disease 0 0.4230698347091675
hemangioblastomas I-Disease 0 0.2675745189189911
. O 0 6.276278145378456e-05

VHL O 1 0.7927348613739014
- O 0 0.002221215283498168
negative O 0 7.044056837912649e-05
786 O 0 0.014916869811713696
- O 0 0.004895513877272606
0 O 0 0.00022577965864911675
RCC B-Disease 1 0.951563835144043
cells O 0 1.5054610230436083e-05
are O 0 4.1062630629085106e-08
tumorigenic O 0 0.0006797991809435189
in O 0 7.297064144040633e-07
nude O 0 0.0033608016092330217
mice O 0 0.0003351778141222894
which O 0 1.916592040629439e-08
is O 0 1.4477437026982898e-08
suppressed O 0 2.088605015160283e-06
by O 0 2.455298719894472e-08
the O 0 8.041942578529415e-08
reintroduction O 0 0.0001869965490186587
of O 0 3.896146154147573e-06
VHL B-Disease 1 0.9828457236289978
. O 0 4.98448389407713e-05

Remarkably O 0 0.0017490606987848878
, O 0 2.6037212137453025e-06
this O 0 2.488184520643699e-07
occurs O 0 2.7174573915544897e-06
without O 0 1.6733184793338296e-07
affecting O 0 4.658476882468676e-06
the O 0 8.54251425153052e-08
growth O 0 6.837929959147004e-06
rate O 0 5.483594804900349e-07
and O 0 7.753978081836976e-08
cell O 0 1.3110168765706476e-05
cycle O 0 1.1194551916560158e-05
profile O 0 2.714745278353803e-06
of O 0 1.4618674271105192e-08
these O 0 8.384816396755923e-08
cells O 0 1.806027466955129e-05
in O 0 3.6633426248045e-07
culture O 0 1.3075007700535934e-05
. O 0 1.0629536518536042e-05

The O 0 6.427589141821954e-06
786 O 0 0.0014241887256503105
- O 0 0.00022447951778303832
0 O 0 6.991531790845329e-06
cell O 0 2.538643457228318e-05
line O 0 1.7484571799286641e-06
, O 0 3.8130022517179896e-07
like O 0 6.274540737649659e-06
many O 0 1.5332934708567336e-05
cancer B-Disease 1 0.9985495209693909
cells O 0 0.00016018997121136636
, O 0 3.2988623388519045e-07
fails O 0 1.2140879334765486e-05
to O 0 1.6626250598505976e-08
exit O 0 2.4603486963314936e-06
the O 0 5.05537798289879e-08
cell O 0 1.2475147741497494e-05
cycle O 0 1.7564529116498306e-05
upon O 0 2.5579820430721156e-06
serum O 0 0.005087388213723898
withdrawal O 0 0.00018600835755933076
. O 0 1.4383175766852219e-05

Here O 0 1.08131653178134e-05
, O 0 5.37559401436738e-07
it O 0 2.5118037427773743e-08
is O 0 9.32911525808322e-09
shown O 0 1.4160908001770167e-08
that O 0 2.1638475455887374e-09
reintroduction O 0 5.91339130551205e-07
of O 0 2.4886452898442712e-09
the O 0 2.9423933511907308e-08
wild O 0 4.324987003201386e-06
- O 0 0.001801550853997469
type O 0 0.0004065705870743841
VHL B-Disease 0 0.40129774808883667
gene O 0 3.1354963994090213e-06
restores O 0 8.211061867768876e-06
the O 0 2.4988921154545096e-08
ability O 0 4.346743480709847e-07
of O 0 5.762684622823144e-07
VHL O 1 0.9933634996414185
- O 1 0.7521284818649292
negative O 0 0.10166589170694351
RCC B-Disease 1 0.99921715259552
cancer I-Disease 1 0.9959319233894348
cells O 0 1.2469652574509382e-05
to O 0 3.9791828498891846e-08
exit O 0 1.8185431827077991e-06
the O 0 2.1304517261455658e-08
cell O 0 2.482532181602437e-06
cycle O 0 8.001395030987624e-07
and O 0 3.2308349773302325e-08
enter O 0 3.0889345907780807e-06
G0 O 1 0.7688400149345398
/ O 0 0.007437494117766619
quiescence O 0 0.0035641680005937815
in O 0 1.1019568546544178e-06
low O 0 0.00015736257773824036
serum O 0 0.010145838372409344
. O 0 9.22510662348941e-06

Both O 0 8.778465416980907e-05
VHL O 1 0.8188884258270264
- O 0 0.0005713696009479463
positive O 0 3.6915957934979815e-06
and O 0 7.612935860379366e-06
VHL O 1 0.9907492995262146
- O 0 0.03946753218770027
negative O 0 0.00026752386474981904
RCC B-Disease 1 0.9704982042312622
cells O 0 1.8563921912573278e-05
exit O 0 7.124641797418008e-06
the O 0 9.879595808115482e-08
cell O 0 2.8883301638416015e-05
cycle O 0 1.1208204341528472e-05
by O 0 3.383665898581967e-07
contact O 0 1.6031677660066634e-05
inhibition O 0 0.00014495717186946422
. O 0 1.1856202945637051e-05

The O 0 1.6903883079066873e-05
cyclin O 0 0.004961868282407522
- O 0 0.00022909023391548544
dependent O 0 1.0123384527105372e-05
kinase O 0 9.446837793802842e-05
inhibitor O 0 7.005283259786665e-05
, O 0 5.629922270600218e-07
p27 O 0 0.0005261642509140074
, O 0 2.311697642198851e-07
accumulates O 0 3.718525113072246e-05
upon O 0 4.1377043658030743e-07
serum O 0 0.0004588234587572515
withdrawal O 0 5.179309937375365e-06
, O 0 7.632086074238487e-09
only O 0 6.719339529226431e-10
in O 0 2.314978653217281e-09
the O 0 4.224512295536442e-09
presence O 0 7.626108811109589e-08
of O 0 1.5389510110708216e-07
VHL B-Disease 1 0.8865761756896973
, O 0 1.1360960883166626e-07
as O 0 9.599438577367891e-09
a O 0 2.013358013641664e-08
result O 0 2.9621073593943947e-08
of O 0 3.2799094551450025e-09
the O 0 2.0572780812244673e-08
stabilization O 0 9.874904208118096e-06
of O 0 1.1868564797623549e-08
the O 0 1.0183938314867191e-07
protein O 0 5.2363548093126155e-06
. O 0 3.3377880299667595e-06

We O 0 1.8477675212125177e-06
propose O 0 7.40026234780089e-06
that O 0 3.4177443097860305e-08
the O 0 6.794078899474698e-08
loss O 0 1.3217528248787858e-05
of O 0 1.387894172921733e-07
wild O 0 8.154677198035643e-05
- O 0 0.09442222863435745
type O 0 0.005742656532675028
VHL B-Disease 1 0.8671430349349976
gene O 0 2.9954578621982364e-06
results O 0 8.869553624890614e-08
in O 0 6.737438162929266e-09
a O 0 3.3318102055091003e-08
specific O 0 1.6824330373310659e-07
cellular O 0 0.00011902936967089772
defect O 0 0.011339523829519749
in O 0 1.6370802313758759e-06
serum O 0 0.018461918458342552
- O 0 0.001659950241446495
dependent O 0 7.726643161731772e-06
growth O 0 8.465843166050036e-06
control O 0 5.465665822157462e-07
, O 0 6.449383960216437e-08
which O 0 5.6434476647382326e-08
may O 0 3.662856897790334e-06
initiate O 0 0.0010981628438457847
tumor B-Disease 1 0.9328532218933105
formation O 0 0.0007329400978051126
. O 0 2.5067005481105298e-05

This O 0 1.73892885868554e-06
is O 0 5.169698624740704e-07
corrected O 0 1.1315906704112422e-05
by O 0 1.0918184578656565e-08
the O 0 9.883662777099289e-09
reintroduction O 0 5.963379862805596e-06
of O 0 4.086869864750042e-08
wild O 0 1.606988371349871e-05
- O 0 0.018701782450079918
type O 0 0.006066787522286177
VHL B-Disease 1 0.9859030246734619
, O 0 5.30429224454565e-06
implicating O 0 0.04964147508144379
VHL B-Disease 1 0.5562117099761963
as O 0 5.448024609222557e-08
the O 0 4.1849766319046466e-08
first O 0 1.7466539929955616e-06
tumor B-Disease 1 0.6594345569610596
suppressor O 0 0.00023254554253071547
involved O 0 2.676852872696145e-08
in O 0 3.735058484721776e-09
the O 0 3.3623046569175585e-09
regulation O 0 1.8530815282247204e-07
of O 0 1.103412294867212e-08
cell O 0 1.6580146620981395e-05
cycle O 0 2.654035597515758e-05
exit O 0 1.3047506399743725e-05
, O 0 5.316018203416206e-08
which O 0 5.040202033512742e-09
is O 0 2.9461884043513464e-09
consistent O 0 1.1963750878862811e-08
with O 0 9.662703526203131e-09
its O 0 7.919151556734505e-08
gatekeeper O 0 0.0003285300626885146
function O 0 2.6217284698759613e-07
in O 0 4.454230406736315e-07
the O 0 1.0518071576370858e-05
kidney O 1 0.9978424310684204
. O 0 1.005001013254514e-05
. O 0 2.5131101210718043e-05

Piebaldism B-Disease 1 0.9699393510818481
with O 0 0.013528767973184586
deafness B-Disease 1 0.9974850416183472
: O 0 0.00013331077934708446
molecular O 0 8.576486288802698e-05
evidence O 0 2.8336905870673945e-06
for O 0 2.011887772823684e-06
an O 0 3.319475581520237e-05
expanded O 0 0.22739559412002563
syndrome O 1 0.9984809756278992
. O 0 0.00033369430457241833

In O 0 1.7864077790363808e-06
a O 0 6.519492217194056e-07
South O 0 3.6455508052313235e-06
African O 0 4.314432317187311e-06
girl O 0 4.597478255163878e-05
of O 0 8.87759085799189e-07
Xhosa O 0 0.4669662117958069
stock O 0 0.0008709361427463591
with O 0 0.0001624979340704158
severe O 1 0.9981520771980286
piebaldism B-Disease 1 0.9954018592834473
and O 0 0.01290185283869505
profound O 1 0.9979261159896851
congenital O 1 0.9998195767402649
sensorineural B-Disease 1 0.9997718930244446
deafness I-Disease 1 0.9997485280036926
we O 0 3.1489362299907953e-06
identified O 0 1.6208817896767869e-06
a O 0 1.8994390416082751e-07
novel O 0 2.7972714633506257e-06
missense O 0 2.093827788485214e-05
substitution O 0 3.871933245136461e-07
at O 0 4.097672601233171e-08
a O 0 1.3690240052710578e-08
highly O 0 5.0006093488264014e-08
conserved O 0 3.166170259305545e-08
residue O 0 9.38444344456002e-08
in O 0 1.3585405023164299e-09
the O 0 2.5074944343117522e-09
intracellular O 0 8.48133879571833e-07
kinase O 0 2.5911671741596365e-07
domain O 0 4.4221279971168315e-09
of O 0 1.5075436454736746e-09
the O 0 5.485289733542231e-08
KIT O 0 0.012054300867021084
proto O 0 0.10241522639989853
- O 0 0.051795653998851776
oncogene O 0 0.022097080945968628
, O 0 1.933056182679138e-06
R796G O 0 0.0010228280443698168
. O 0 7.835650649212766e-06

Though O 0 0.00018689478747546673
auditory B-Disease 0 0.08170679211616516
anomalies I-Disease 0 0.006614611949771643
have O 0 9.202457107448936e-08
been O 0 3.1416689694196975e-08
observed O 0 1.4161440731186303e-07
in O 0 1.7478525649039511e-07
mice O 0 0.00010620481771184132
with O 0 3.9627479964110535e-07
dominant O 0 8.119796984829009e-05
white O 0 0.005654651205986738
spotting O 0 0.14135867357254028
( O 0 0.00010139083315152675
W O 0 0.424588680267334
) O 0 5.54035523236962e-07
due O 0 5.177247430765419e-07
to O 0 5.599272867584659e-07
KIT O 1 0.8581961393356323
mutations O 0 0.0028668066952377558
, O 0 9.883489838102832e-05
deafness B-Disease 1 0.9994609951972961
is O 0 4.4960549416828144e-07
not O 0 7.032471671664098e-08
typical O 0 9.042019883054309e-06
in O 0 1.1743566119548632e-06
human O 0 4.948796413373202e-05
piebaldism B-Disease 0 0.20740991830825806
. O 0 4.544140028883703e-05

Thus O 0 7.842812919989228e-06
, O 0 1.1898823686351534e-06
the O 0 5.301498617882316e-07
occurrence O 0 9.79260221356526e-05
of O 0 3.244110484956764e-05
sensorineural B-Disease 1 0.9991704225540161
deafness I-Disease 1 0.9996305704116821
in O 0 8.239544513344299e-06
this O 0 1.984532673304784e-06
patient O 0 0.008710544556379318
extends O 0 3.607117469073273e-05
considerably O 0 3.788473804888781e-06
the O 0 9.415492385755897e-09
phenotypic O 0 7.087005542416591e-07
range O 0 1.412305579151507e-07
of O 0 3.011107807537883e-08
piebaldism B-Disease 0 0.002034284407272935
due O 0 1.5951346767906216e-06
to O 0 1.828380788992945e-07
KIT O 0 0.0849275290966034
gene O 0 1.8461367290001363e-05
mutation O 0 8.834568689053413e-06
in O 0 1.4882930088333524e-07
humans O 0 1.6621644363112864e-06
and O 0 2.6205236736132065e-07
tightens O 0 0.010296688415110111
the O 0 1.6788844448001328e-07
clinical O 0 0.0001852119603427127
similarity O 0 1.8704151898418786e-06
between O 0 4.988863224753004e-07
piebaldism B-Disease 0 0.0015558921732008457
and O 0 1.855071829481858e-08
the O 0 1.5407065845352008e-08
various O 0 6.864352286584108e-08
forms O 0 8.041646651690826e-05
of O 0 0.005970966070890427
Waardenburg B-Disease 1 0.9994027614593506
syndrome I-Disease 1 0.9995083808898926
. O 0 5.852252070326358e-05
. O 0 6.006900730426423e-05

Cycloheximide O 0 0.006134832743555307
facilitates O 0 4.0740160329733044e-05
the O 0 2.5509484657959547e-07
identification O 0 2.2091720097705547e-07
of O 0 3.7653745010857165e-08
aberrant O 0 4.588525553117506e-05
transcripts O 0 1.5136519095904077e-06
resulting O 0 1.200587803396047e-06
from O 0 1.6887689469058387e-08
a O 0 2.4631695794141706e-08
novel O 0 1.6432414895461989e-06
splice O 0 5.933368083788082e-05
- O 0 0.00011726904631359503
site O 0 9.060681804839987e-07
mutation O 0 1.921715011121705e-06
in O 0 9.412676860165448e-08
COL17A1 O 0 0.007180001121014357
in O 0 4.025720272693434e-07
a O 0 1.1530200936249457e-05
patient O 0 0.039588563144207
with O 0 0.0002945058513432741
generalized O 1 0.9900904893875122
atrophic B-Disease 1 0.9978169202804565
benign I-Disease 1 0.9972169399261475
epidermolysis I-Disease 1 0.9964991807937622
bullosa I-Disease 1 0.9926992058753967
. O 0 0.0025970120914280415

Patients O 1 0.9061524271965027
with O 0 0.004887692164629698
generalized O 1 0.9885772466659546
atrophic B-Disease 1 0.9975128173828125
benign I-Disease 1 0.9978469610214233
epidermolysis I-Disease 1 0.9981474876403809
bullosa I-Disease 1 0.9968559741973877
often O 0 3.3141423045890406e-05
show O 0 6.566198408108903e-06
decreased O 0 3.0651117413071916e-05
expression O 0 5.01674492170423e-07
of O 0 5.225232939665148e-07
type O 0 0.11361227929592133
XVII O 1 0.9991099238395691
collagen O 0 0.4365770220756531
, O 0 2.5616554921725765e-07
a O 0 5.641047096105467e-07
transmembrane O 0 0.00019222180708311498
hemidesmosomal O 0 0.0003010138461831957
protein O 0 3.0261179517765413e-07
encoded O 0 1.4403407533336576e-07
by O 0 5.571765200329537e-07
COL17A1 O 0 0.02547398768365383
. O 0 1.2721075108856894e-05

This O 0 1.1797717434092192e-06
report O 0 7.712706064921804e-07
documents O 0 1.5209374737423786e-07
a O 0 1.1547290057478676e-07
novel O 0 2.7792534638138022e-06
splice O 0 0.00010167965228902176
- O 0 0.00013812851102557033
site O 0 1.0058015504910145e-06
mutation O 0 4.0212412386608776e-06
in O 0 1.6055724927355186e-07
COL17A1 O 0 0.010779399424791336
in O 0 2.1521267967727908e-07
a O 0 5.082360075903125e-06
patient O 0 0.046684324741363525
with O 0 0.00021517620189115405
generalized O 1 0.9915580749511719
atrophic B-Disease 1 0.9991160035133362
benign I-Disease 1 0.9991835951805115
epidermolysis I-Disease 1 0.9993916749954224
bullosa I-Disease 1 0.9988883137702942
, O 0 6.1101432038412895e-06
and O 0 2.447733606913971e-07
applies O 0 3.157317962632078e-07
a O 0 4.435257139334681e-08
new O 0 1.1881548545034093e-07
methodology O 0 2.7718024853129464e-07
to O 0 1.3974589485599154e-08
define O 0 4.421995924985822e-07
and O 0 3.512065660515873e-08
characterize O 0 4.686724423663691e-06
the O 0 2.9021181902066928e-08
resulting O 0 2.5535605345794465e-06
mRNA O 0 2.5074104996747337e-06
splice O 0 8.425900887232274e-05
variants O 0 1.7562419088790193e-05
. O 0 4.345435627328698e-06

Mutational O 0 0.003057817928493023
analysis O 0 4.1955290726036765e-06
of O 0 7.476109544768406e-07
COL17A1 O 0 0.01565208099782467
identified O 0 2.6604025151755195e-06
a O 0 2.1886055492359446e-06
maternally O 0 0.010094164870679379
inherited O 0 0.13477164506912231
G O 0 0.0016623146366328
- O 0 0.0001796060532797128
to O 0 6.583828167094907e-07
- O 0 0.0040680584497749805
T O 0 0.06511817127466202
transversion O 0 5.784516906714998e-05
at O 0 1.6784866829766543e-08
the O 0 7.3982735493416385e-09
- O 0 2.659276333361049e-06
1 O 0 2.2621296835723115e-08
position O 0 7.659195944142994e-09
of O 0 1.1462866211786604e-08
exon O 0 6.430157372960821e-05
32 O 0 5.1914994401158765e-06
. O 0 3.7771897041238844e-06

This O 0 3.95094730265555e-06
acceptor O 0 0.0002175894333049655
splice O 0 0.00024661936913616955
- O 0 0.0001513956522103399
site O 0 6.73221222768916e-07
mutation O 0 9.171877195512934e-07
led O 0 6.562753185335168e-08
to O 0 3.3376155172959443e-09
the O 0 7.554501024742422e-09
formation O 0 5.37792175236973e-07
of O 0 2.0099470532386476e-08
aberrant O 0 4.758416980621405e-05
transcripts O 0 1.7439177781852777e-06
present O 0 1.9478889612400963e-07
at O 0 6.5051892761403e-07
extremely O 0 1.0514229870750569e-05
low O 0 5.8238809288013726e-05
levels O 0 2.5464361897320487e-05
. O 0 4.271526904631173e-06

Based O 0 2.1422476947918767e-06
on O 0 1.3129869103067904e-07
our O 0 8.099236481484695e-08
recent O 0 5.115203407513036e-07
finding O 0 4.2537479316706595e-07
that O 0 1.2608869326413696e-07
cycloheximide O 0 0.00858230423182249
stabilized O 0 0.0021507414057850838
mutant O 0 0.0001093130704248324
COL17A1 O 0 0.002436175011098385
transcripts O 0 1.2670553815041785e-06
in O 0 1.4445707563481847e-07
keratinocytes O 0 0.0006922982283867896
homozygous O 0 1.9408512343943585e-06
for O 0 2.9031147263935964e-08
a O 0 1.476657757848443e-06
frameshift O 0 0.05741720274090767
mutation O 0 1.8833146896213293e-05
, O 0 2.3468697207817968e-08
the O 0 6.2899445651964925e-09
effects O 0 2.2350424444539385e-07
of O 0 2.0486505825090262e-09
the O 0 3.0215552726531314e-08
splice O 0 6.464027683250606e-05
- O 0 3.5608540201792493e-05
site O 0 1.1973594382652664e-07
mutation O 0 4.132553144131634e-08
on O 0 8.236618054269229e-10
splicing O 0 5.591205720634207e-08
of O 0 5.0517896532653594e-09
COL17A1 O 0 0.00021859235130250454
transcripts O 0 1.018104427430444e-07
were O 0 9.629527175647468e-10
determined O 0 8.128234973980852e-09
using O 0 9.85371606532226e-09
reverse O 0 1.2207930012664292e-05
transcriptase O 0 0.00036359805380925536
polymerase O 0 8.925111615099013e-06
chain O 0 5.277859145280672e-07
reaction O 0 2.3712027896749532e-08
of O 0 6.57443655072143e-10
total O 0 3.6718252882650404e-09
RNA O 0 1.1565099811150503e-07
from O 0 4.439480605356039e-08
keratinocytes O 0 6.591170676983893e-05
incubated O 0 1.928114443217055e-06
for O 0 1.3014590649618185e-07
2 O 0 5.826816504850285e-06
. O 0 5.006448645872297e-06

5 O 0 3.0367617000592873e-05
h O 0 8.757678733672947e-05
in O 0 1.2915602098928503e-07
the O 0 3.8623067410981093e-08
presence O 0 2.053691474657171e-07
or O 0 4.68415422005819e-08
absence O 0 1.8773368992697215e-07
of O 0 2.4291802347420344e-08
10 O 0 1.545806981084752e-06
microg O 0 0.006779026240110397
cycloheximide O 0 0.0027068171184509993
per O 0 1.6266297961919918e-06
ml O 0 0.0063010831363499165
. O 0 1.1625022125372197e-05

Using O 0 1.4273464330472052e-06
this O 0 1.3214902594427258e-07
approach O 0 7.420860015372455e-07
, O 0 1.6018452697608154e-07
an O 0 2.9502169240913645e-07
abnormally O 0 0.0028391999658197165
spliced O 0 6.452030356740579e-05
transcript O 0 2.197437424911186e-05
was O 0 8.279562280222308e-08
identified O 0 3.527688008375662e-08
that O 0 9.293945057997632e-10
contains O 0 2.686416200603503e-09
an O 0 9.089167751774596e-10
extra O 0 1.2007483007892006e-08
264 O 0 1.533989575364103e-07
bases O 0 9.157455238550938e-09
upstream O 0 4.795894170683823e-08
from O 0 7.920190725485554e-09
exon O 0 3.1575880257150857e-06
32 O 0 1.1372842578794007e-07
, O 0 1.5599923131048854e-08
resulting O 0 1.4010517190854443e-07
in O 0 8.246682448032061e-09
a O 0 1.2808726523871883e-07
premature O 0 0.0002944092557299882
termination O 0 2.5214258130290546e-05
codon O 0 1.1146698852826376e-06
27 O 0 5.756581913374248e-07
bp O 0 3.07685081679665e-06
downstream O 0 2.4278330101878964e-07
from O 0 2.3972599905164316e-08
the O 0 7.957974190730965e-08
cryptic O 0 8.734609582461417e-05
splice O 0 0.00018885596364270896
site O 0 9.077271897695027e-06
. O 0 6.9540678850898985e-06

Three O 0 5.418633577392029e-07
other O 0 1.653991006378419e-07
splice O 0 7.064196688588709e-05
variants O 0 3.649955033324659e-06
, O 0 3.211285815041265e-08
including O 0 8.048782973446578e-09
one O 0 2.264917586813908e-09
derived O 0 6.7153966831767775e-09
from O 0 2.5907744838349345e-09
the O 0 1.8944681379196027e-09
skipping O 0 3.878733423334779e-07
of O 0 9.269235157205458e-09
exon O 0 4.61313065898139e-05
32 O 0 7.527506227233971e-07
, O 0 4.606899750569937e-08
were O 0 1.0890230939253343e-08
also O 0 1.0226762015008717e-07
identified O 0 2.036133309957222e-06
. O 0 5.963783223705832e-06

These O 0 6.418667908292264e-07
results O 0 8.313948001159588e-07
indicate O 0 3.104671009168669e-07
the O 0 4.243921480906465e-08
usefulness O 0 6.4785081121954136e-06
of O 0 3.592459449919261e-07
cycloheximide O 0 0.42045485973358154
treatment O 0 0.00041236699325963855
in O 0 3.533007841838298e-08
evaluating O 0 1.0942721928586252e-06
the O 0 2.845410840279783e-08
abnormal O 0 4.18563013226958e-06
processing O 0 1.625669376892347e-08
of O 0 1.8179731053891146e-09
mRNA O 0 4.49122055101725e-08
due O 0 3.935465642257441e-08
to O 0 5.7552567156449186e-09
splice O 0 2.3753917048452422e-05
- O 0 0.00012390603660605848
site O 0 1.2994354392503737e-06
mutations O 0 4.9764216782932635e-06
, O 0 6.515718808941529e-08
because O 0 9.823114055507176e-08
( O 0 1.678343295452578e-07
i O 0 4.139250364687541e-08
) O 0 1.7634194549032145e-08
aberrant O 0 9.368486644234508e-07
splicing O 0 2.119981985515551e-07
often O 0 1.1866934990223399e-08
generates O 0 9.286050328682904e-08
a O 0 9.553504298764892e-08
premature O 0 0.0003376264648977667
termination O 0 0.00010670843039406464
codon O 0 2.4245850909210276e-06
, O 0 1.1588748805024807e-07
( O 0 4.46304511569906e-07
ii O 0 2.3027187125990167e-05
) O 0 6.318276035699455e-08
transcripts O 0 3.3680322530926787e-07
with O 0 2.955550542083074e-07
premature O 0 0.005300129763782024
termination O 0 0.0008493232307955623
codons O 0 9.694617801869754e-06
can O 0 6.431682209040446e-08
occur O 0 1.3572311274856474e-07
at O 0 9.808341872030724e-08
low O 0 4.793827883986523e-06
or O 0 5.8573982641974e-07
undetectable O 0 0.0017931832699105144
levels O 0 6.297798336163396e-07
due O 0 6.176917821676398e-08
to O 0 1.0676378003893205e-08
nonsense O 0 1.6923696648518671e-06
- O 0 2.5182857825711835e-06
mediated O 0 1.3527280771086225e-06
mRNA O 0 1.56901364789519e-07
decay O 0 1.7887672356664552e-06
, O 0 2.3015253702851624e-08
and O 0 3.488119304506654e-08
( O 0 6.17132513980323e-07
iii O 0 8.654997509438545e-05
) O 0 1.6918640710628097e-08
the O 0 3.158665107250158e-09
levels O 0 2.6951731513236155e-08
of O 0 7.58001494904903e-10
these O 0 1.7122830930915711e-09
transcripts O 0 1.7920679340477363e-07
can O 0 5.1694390990064676e-09
be O 0 2.585305081126421e-09
increased O 0 3.302170341612509e-07
by O 0 5.314608984008373e-07
cycloheximide O 0 0.02195722796022892
. O 0 1.505906129750656e-05

A O 0 1.5743928088340908e-05
deletion O 0 0.0003551251138560474
mutation O 0 3.0439985494012944e-05
in O 0 7.224840601338656e-07
COL17A1 O 0 0.00442013842985034
in O 0 1.7398565432813484e-07
five O 0 4.21279111151307e-07
Austrian O 0 0.00020418640633579344
families O 0 8.94083859748207e-06
with O 0 0.00010226785525446758
generalized O 1 0.9914570450782776
atrophic B-Disease 1 0.9991446733474731
benign I-Disease 1 0.9987823367118835
epidermolysis I-Disease 1 0.9991344809532166
bullosa I-Disease 1 0.997848391532898
represents O 0 7.449731492670253e-05
propagation O 0 6.050337560736807e-06
of O 0 1.7022746590100724e-07
an O 0 2.2232045466807904e-06
ancestral O 0 0.0013177896616980433
allele O 0 0.0004978027427569032
. O 0 1.876713395176921e-05

Patients O 1 0.8893417716026306
with O 0 0.0017797379987314343
generalized O 1 0.9841603636741638
atrophic B-Disease 1 0.9975029826164246
benign I-Disease 1 0.9979307651519775
epidermolysis I-Disease 1 0.9980941414833069
bullosa I-Disease 1 0.9970869421958923
, O 0 1.0963374734274112e-05
a O 0 7.25709696780541e-07
usually O 0 5.955407118563016e-07
nonlethal O 0 7.568691944470629e-05
form O 0 4.168361556367017e-06
of O 0 1.498472374805715e-05
junctional B-Disease 1 0.996624231338501
epidermolysis I-Disease 1 0.9982617497444153
bullosa I-Disease 1 0.9965014457702637
, O 0 2.9498726235033246e-06
have O 0 3.297462569662457e-07
generalized O 0 0.002994891256093979
blistering B-Disease 1 0.7037706971168518
, O 0 0.0011594886891543865
nail B-Disease 1 0.9977076053619385
dystrophy I-Disease 1 0.9991369843482971
, O 0 0.03931116685271263
patchy B-Disease 1 0.9980809688568115
alopecia I-Disease 1 0.9993513226509094
, O 0 0.0007685364689677954
and O 0 0.0011184653267264366
dental B-Disease 1 0.9972430467605591
abnormalities I-Disease 1 0.9946883916854858
. O 0 0.00032566735171712935

Skin B-Disease 1 0.9942293167114258
fragility I-Disease 1 0.9749597311019897
in O 0 1.0612418918753974e-05
most O 0 2.044948587354156e-06
cases O 0 8.858901310304645e-06
is O 0 1.4935925207737455e-07
due O 0 4.637735173673718e-07
to O 0 2.12389927867207e-08
mutations O 0 7.620669748575892e-07
in O 0 6.822228559855148e-09
the O 0 2.0566346847772365e-08
gene O 0 2.276438408443937e-06
encoding O 0 6.091368504712591e-06
type O 0 0.015712112188339233
XVII O 1 0.9980432987213135
collagen O 1 0.9522194862365723
( O 0 5.693808998330496e-05
COL17A1 O 0 0.06284049153327942
) O 0 5.555653842748143e-06
. O 0 4.075356628163718e-06

Recently O 0 0.0001555361959617585
, O 0 1.5885855191299925e-06
we O 0 1.5805717623607052e-07
reported O 0 1.0711112281569513e-06
five O 0 2.7202241881241207e-07
Austrian O 0 0.00021249188284855336
families O 0 1.4306895536719821e-05
with O 0 0.00011001495295204222
generalized O 1 0.991913914680481
atrophic B-Disease 1 0.9987710118293762
benign I-Disease 1 0.9983227849006653
epidermolysis I-Disease 1 0.9985346794128418
bullosa I-Disease 1 0.9965410828590393
who O 0 1.5081307537911925e-05
share O 0 2.2011690816725604e-06
the O 0 7.13477447789046e-07
same O 0 5.742666417063447e-06
COL17A1 O 0 0.4625363051891327
mutation O 0 0.0007887305691838264
. O 0 2.1463341909111477e-05

Affected O 0 0.000513323990162462
individuals O 0 2.8824904347857228e-06
in O 0 1.097296973284756e-07
three O 0 3.3730202630977146e-08
families O 0 2.9479417662514606e-07
are O 0 1.260093185351252e-08
homozygous O 0 3.5412767829257064e-06
for O 0 4.075544381976215e-07
4003delTC O 0 0.030012255534529686
, O 0 5.142192662788148e-07
whereas O 0 4.882162443209381e-07
those O 0 7.108786448384308e-09
in O 0 7.284295833187571e-09
two O 0 1.0944642525601012e-08
others O 0 2.6252087081957143e-07
are O 0 6.454848744397168e-08
compound O 0 0.00020432955352589488
heterozygotes O 0 0.10400062799453735
. O 0 3.776537414523773e-05

To O 0 1.4783429378439905e-06
determine O 0 6.435903969759238e-07
if O 0 1.3122559039402404e-07
the O 0 5.665168245627683e-08
occurrence O 0 2.5678123165562283e-06
of O 0 6.752338066462471e-08
4003delTC O 0 0.0011774455197155476
in O 0 1.161705327490381e-07
these O 0 3.9022559406021173e-08
unrelated O 0 1.3924714039603714e-05
families O 0 1.470550046178687e-06
signifies O 0 1.606301884748973e-05
propagation O 0 2.71746785074356e-07
of O 0 5.403532288283941e-09
an O 0 2.9434094273028677e-08
ancestral O 0 7.106848443072522e-06
allele O 0 1.5027681001811288e-06
or O 0 3.554244187853328e-08
a O 0 2.8112745553698915e-07
mutational O 0 0.010096785612404346
hot O 0 4.6100081817712635e-05
spot O 0 1.6934933455559076e-06
, O 0 1.0771678660148609e-07
haplotypes O 0 1.8531272871769033e-05
were O 0 4.028936295696894e-09
determined O 0 8.113430993716975e-08
for O 0 2.571511892313083e-08
polymorphisms O 0 3.3676867587928427e-06
both O 0 1.229260782054098e-08
within O 0 4.707647605073362e-08
and O 0 6.318625196399807e-07
flanking O 0 0.010198892094194889
COL17A1 O 1 0.7294226288795471
. O 0 5.206335481489077e-05

Five O 0 1.720038017083425e-05
intragenic O 0 0.0063135153613984585
polymorphisms O 0 2.3264958144864067e-05
were O 0 2.7306851890784856e-08
chosen O 0 2.255137943052432e-08
based O 0 2.2542003819125966e-08
on O 0 4.105135786858227e-08
their O 0 5.162102070244146e-07
informativeness O 0 0.03694882616400719
. O 0 2.579945976322051e-05

One O 0 6.803525138820987e-07
of O 0 1.0633338831667061e-07
these O 0 5.67180684640789e-08
, O 0 4.9791569978197003e-08
not O 0 8.66987193148816e-09
previously O 0 1.2730505716262996e-07
reported O 0 6.334565227916755e-07
, O 0 3.7628186788651874e-08
was O 0 7.372990040721561e-08
2988 O 0 0.00011802775406977162
A O 0 2.0825855528983084e-07
or O 0 1.4142518978133012e-07
C O 0 3.690951643875451e-06
that O 0 2.2531676524550903e-09
introduces O 0 1.8785870281590178e-07
a O 0 2.0602074712883223e-08
new O 0 9.6147786621259e-08
restriction O 0 5.446849513646157e-07
site O 0 3.3371659924341657e-07
for O 0 2.693041381007788e-07
Eco0109 O 0 0.0019147651037201285
I O 0 1.9337130652274936e-05
. O 0 7.063860721245874e-06

All O 0 2.955285935968277e-07
the O 0 5.732613885811588e-07
4003delTC O 0 0.0005386341363191605
alleles O 0 1.1175851795997005e-05
showed O 0 5.011561370338313e-07
the O 0 2.993659009575822e-08
same O 0 1.1297129276499618e-07
haplotype O 0 0.00025033089332282543
for O 0 3.152425520625002e-08
these O 0 3.2173677055880034e-08
five O 0 1.2819813264286495e-06
polymorphic O 0 0.002292262390255928
markers O 0 0.0006968476227484643
. O 0 2.128382766386494e-05

Fourteen O 0 6.732502515660599e-05
microsatellite O 0 0.0053320713341236115
polymorphisms O 0 3.939814996556379e-05
were O 0 3.214791277628137e-08
selected O 0 2.260327036651688e-08
based O 0 9.298967817983339e-09
on O 0 4.912517503896652e-09
their O 0 1.201339383527511e-08
high O 0 4.137185442232294e-06
heterozygosity O 0 0.0004290480865165591
and O 0 1.252810211127553e-08
their O 0 4.317779023210733e-09
location O 0 3.298405459872811e-08
within O 0 1.0641352332640963e-07
10q23 O 0 0.00213488913141191
- O 0 0.0015983438352122903
q25 O 0 0.002688835607841611
near O 0 6.22965453658253e-05
COL17A1 O 0 0.05569753795862198
. O 0 1.702701956673991e-05

Three O 0 2.2475453533843393e-06
families O 0 5.34104810867575e-06
shared O 0 2.896259729823214e-06
microsatellite O 0 0.012616806663572788
polymorphisms O 0 0.0002128087799064815
covering O 0 1.7232163372682407e-05
at O 0 2.777028385025915e-07
most O 0 8.13743668004463e-08
19 O 0 6.538354227814125e-06
cM O 0 0.001356853055767715
, O 0 6.472725289086156e-08
whereas O 0 1.0964767938048681e-07
the O 0 6.507444805237128e-09
others O 0 1.9614590840433266e-08
shared O 0 3.2527111670788145e-08
smaller O 0 2.381056134481696e-07
regions O 0 1.410239605093011e-07
consistent O 0 1.579462889367278e-07
with O 0 1.0050501231262388e-07
cross O 0 2.312152673766832e-06
- O 0 2.4689448764547706e-05
over O 0 5.7400217912118023e-08
events O 0 3.331860654043339e-08
during O 0 4.515106866165297e-08
passage O 0 1.1455854576070124e-07
of O 0 5.3382369635812665e-09
this O 0 1.759579149052115e-08
mutation O 0 7.845451364119072e-07
through O 0 3.207894394563482e-08
several O 0 1.716175717092483e-07
generations O 0 5.071073246654123e-05
. O 0 9.125825272349175e-06

These O 0 1.1196239029231947e-06
results O 0 2.654092440934619e-06
indicate O 0 2.216187112935586e-06
that O 0 1.2482419720072357e-07
4003delTC O 0 0.0004301312437746674
occurs O 0 4.1942143980122637e-07
on O 0 1.1048527426282817e-08
a O 0 5.197937014145282e-08
single O 0 2.0050983096098207e-07
ancestral O 0 5.28263408341445e-05
allele O 0 2.648887675604783e-05
. O 0 7.204351391010277e-07
. O 0 4.202981472190004e-06

The O 0 2.43404592765728e-05
haptoglobin O 0 0.014580564573407173
- O 0 0.0025663573760539293
gene O 0 5.909369792789221e-05
deletion O 0 0.0003747984883375466
responsible O 0 1.057614827004727e-05
for O 0 4.898232418781845e-06
anhaptoglobinemia B-Disease 0 0.31764766573905945
. O 0 4.405941945151426e-05

We O 0 6.791836426600639e-07
have O 0 4.2906073360882147e-08
found O 0 2.818979005780875e-08
an O 0 1.7932949347709837e-08
allelic O 0 3.8623184082098305e-05
deletion O 0 5.709524884878192e-06
of O 0 2.1008052186743953e-08
the O 0 2.5567572947693407e-07
haptoglobin O 0 0.007954119704663754
( O 0 1.814712618397607e-06
Hp O 0 2.5865432689897716e-05
) O 0 1.651585677109324e-07
gene O 0 1.3015373667712993e-07
from O 0 1.1347854211862796e-08
an O 0 1.205625022038248e-08
individual O 0 1.0876701139750367e-07
with O 0 2.959091716547846e-06
anhaptoglobinemia B-Disease 0 0.12287741899490356
. O 0 3.0127963327686302e-05

The O 0 4.8911283556662966e-06
Hp O 0 0.00011542024731170386
gene O 0 8.655476449348498e-06
cluster O 0 1.3204173228587024e-05
consists O 0 5.569109973180275e-08
of O 0 1.3376090457484224e-08
coding O 0 4.448169875104213e-06
regions O 0 2.6698161903482287e-08
of O 0 1.2390336534551238e-09
the O 0 5.5588342817713965e-09
alpha O 0 4.048381754273578e-07
chain O 0 1.2508783129305812e-06
and O 0 1.9201486622932862e-08
beta O 0 6.616003815906879e-07
chain O 0 1.9564808440009074e-07
of O 0 2.626468598165843e-09
the O 0 4.751235493927197e-08
haptoglobin O 0 0.0008006422431208193
gene O 0 1.6745187849664944e-06
( O 0 2.1603788979973615e-07
Hp O 0 2.7919249987462536e-06
) O 0 9.655150456922001e-09
and O 0 6.19635898146953e-10
of O 0 4.38248520806539e-10
the O 0 4.12467660027005e-09
alpha O 0 2.8538360652419215e-07
chain O 0 4.595666780460306e-07
and O 0 6.252684148222443e-09
beta O 0 6.313788389888941e-07
chain O 0 2.1003729955282324e-07
of O 0 3.4940170756669886e-09
the O 0 1.0204296074789454e-07
haptoglobin O 0 0.004906942136585712
- O 0 0.00011349718261044472
related O 0 5.200780833547469e-06
gene O 0 1.0547190868237521e-05
( O 0 3.3322569379379274e-06
Hpr O 0 0.0037618486676365137
) O 0 9.654767296751743e-08
, O 0 1.4754900412583538e-08
in O 0 1.330256171883093e-08
tandem O 0 2.7865810352523113e-06
from O 0 2.8089049308732683e-08
the O 0 6.628433624200625e-08
5 O 0 2.7892585876543308e-06
side O 0 7.681856004637666e-06
. O 0 5.423326001618989e-06

Southern O 0 3.8782851333962753e-05
blot O 0 0.0007164556300267577
and O 0 9.151772246696055e-07
PCR O 0 4.891755452263169e-05
analyses O 0 3.7045954286440974e-06
have O 0 2.53437395514311e-08
indicated O 0 1.4558328587099822e-07
that O 0 1.6402824654093706e-09
the O 0 2.259618936406582e-09
individual O 0 1.2884729727602462e-08
with O 0 1.049785680606874e-07
anhaptoglobinemia B-Disease 0 0.006605394184589386
was O 0 1.6059937024692772e-07
homozygous O 0 5.282683446239389e-07
for O 0 1.0427030794346592e-08
the O 0 2.4909546425533335e-08
gene O 0 2.248149939987343e-06
deletion O 0 2.2336020265356638e-05
and O 0 1.1046483727739087e-08
that O 0 2.077588767690486e-09
the O 0 8.544532192900078e-09
gene O 0 8.051916893236921e-07
deletion O 0 4.2315245991630945e-06
was O 0 1.1806903010835867e-08
included O 0 9.080387108895138e-09
at O 0 1.6838447081113372e-08
least O 0 3.731128295214603e-09
from O 0 8.769695192256677e-09
the O 0 1.2912112268281817e-08
promoter O 0 1.703549969533924e-05
region O 0 1.0432684405259351e-07
of O 0 1.2344392175123176e-08
Hp O 0 1.5718364011263475e-05
to O 0 5.139407477372515e-08
Hpr O 0 0.0009517790749669075
alpha O 0 4.828008286494878e-07
but O 0 9.28000876143642e-09
not O 0 5.002571690226887e-09
to O 0 9.129467315460715e-08
Hpr O 0 0.03167664632201195
beta O 0 0.0001075739783118479
( O 0 1.1947389793931507e-05
Hpdel O 0 0.004200989380478859
) O 0 1.7110064618464094e-06
. O 0 2.4241967366833705e-06

In O 0 3.585276317608077e-06
addition O 0 1.8338359950575978e-06
, O 0 1.4621554100813228e-07
we O 0 7.19742665467038e-09
found O 0 8.270720108782825e-09
seven O 0 2.6013427856241833e-08
individuals O 0 2.6058419422270163e-08
with O 0 1.0465748090382476e-07
hypohaptoglobinemia B-Disease 0 0.0037948430981487036
in O 0 3.3526490028634726e-08
three O 0 2.3603774934599642e-08
families O 0 2.117252222433308e-07
, O 0 2.4121158404000198e-08
and O 0 7.667278367762265e-09
the O 0 1.6132553071201983e-08
genotypes O 0 1.3037430107942782e-05
of O 0 2.220644335082511e-09
six O 0 1.2073440025517357e-08
of O 0 3.1269489220164814e-09
the O 0 1.6799823754354293e-08
seven O 0 9.358470975939781e-08
individuals O 0 7.148437219939296e-08
were O 0 3.645336033031299e-09
found O 0 2.433372436883019e-08
to O 0 3.047490793051111e-08
be O 0 2.1735222333063575e-07
Hp2 O 0 0.12794604897499084
/ O 0 0.20615337789058685
Hpdel O 0 0.0388411246240139
. O 0 1.3842361113347579e-05

The O 0 6.295699677139055e-06
phenotypes O 0 0.0008341753273271024
and O 0 1.4714422604811261e-06
genotypes O 0 0.00046983337961137295
in O 0 6.029664945117474e-08
one O 0 4.926714591846348e-09
of O 0 2.5995110508603148e-09
these O 0 1.4766012856881616e-09
three O 0 8.565057996179348e-09
families O 0 2.3226183998303895e-07
showed O 0 3.858537809264817e-07
the O 0 1.465259114041828e-08
father O 0 3.12699285132112e-07
to O 0 1.2508976077185707e-08
be O 0 1.318864661925545e-08
hypohaptoglobinemic B-Disease 0 0.0010587101569399238
( O 0 1.1676548865580116e-06
Hp2 O 0 0.00024342193501070142
) O 0 1.2502469814990036e-07
and O 0 1.6636616351206612e-07
Hp2 O 0 0.02561376616358757
/ O 0 0.0020800239872187376
Hpdel O 0 0.0007154376362450421
, O 0 2.119270092748593e-08
the O 0 6.348025216595943e-09
mother O 0 1.517037730991433e-07
to O 0 3.0810078932574925e-09
be O 0 4.331669689605633e-09
Hp2 O 0 9.0250869106967e-05
- O 0 9.214264537149575e-06
1 O 0 1.1549052914006097e-07
and O 0 6.899780657931842e-08
Hp1 O 0 0.02347424067556858
/ O 0 0.0030388087034225464
Hp2 O 0 0.00025530127459205687
, O 0 4.200753078720254e-09
one O 0 4.2969086622157704e-10
of O 0 4.3629605483985756e-10
the O 0 1.6832852889336891e-09
two O 0 2.5427491223695142e-09
children O 0 8.980816801340552e-08
to O 0 7.350787090132371e-09
be O 0 1.0699515051726394e-08
hypohaptoglobinemic B-Disease 0 0.0004310258664190769
( O 0 8.729477372071415e-07
Hp2 O 0 0.0003117940213996917
) O 0 1.6831889126933675e-07
and O 0 1.8847546812139626e-07
Hp2 O 0 0.037323445081710815
/ O 0 0.0036629566457122564
Hpdel O 0 0.0012254774337634444
, O 0 2.0932816369167995e-08
and O 0 4.502780370785331e-09
the O 0 3.1467826122622e-09
other O 0 8.566382270203121e-09
child O 0 5.393669653130928e-07
to O 0 1.343833311295839e-08
be O 0 1.546140993013978e-08
Hp1 O 0 0.0007362684700638056
and O 0 5.83486382765841e-07
Hp1 O 0 0.2325325459241867
/ O 0 0.016799872741103172
Hpdel O 0 0.0018027337500825524
, O 0 6.234632365931247e-08
showing O 0 2.0430410074823158e-07
an O 0 1.746242261901898e-08
anomalous O 0 2.5597055355319753e-05
inheritance O 0 9.458608474233188e-06
of O 0 1.844273356255144e-07
Hp O 0 0.0026474795304238796
phenotypes O 0 0.0006294900667853653
in O 0 2.686023776732327e-07
the O 0 2.536393708396645e-07
child O 0 6.502246105810627e-05
with O 0 1.364789204671979e-05
Hp1 O 0 0.42933836579322815
. O 0 4.207416350254789e-05

The O 0 6.851362559245899e-05
Hp2 O 1 0.6705130934715271
/ O 0 0.49975231289863586
Hpdel O 0 0.16290602087974548
individuals O 0 1.7298677903454518e-06
had O 0 1.385243990625895e-07
an O 0 5.264406865990168e-08
extremely O 0 1.157864630840777e-06
low O 0 5.517186991710332e-07
level O 0 4.5828429051653075e-08
of O 0 1.4163420658519499e-08
Hp O 0 2.6137646273127757e-05
( O 0 2.26586138296625e-07
mean O 0 3.2989473197631014e-07
+ O 0 8.551913197152317e-06
/ O 0 1.0561422641330864e-05
- O 0 3.0831956792098936e-06
SD O 0 9.2267428044579e-06
= O 0 6.749929752913886e-07
0 O 0 3.466953657493832e-08
. O 0 1.6595519625184352e-08
049 O 0 0.00034715377842076123
+ O 0 1.1723283932951745e-05
/ O 0 7.494851161027327e-06
- O 0 1.2907674999951269e-06
0 O 0 7.554115200036904e-08
. O 0 1.885036304827281e-08
043 O 0 9.35074349399656e-05
mg O 0 5.433271508081816e-05
/ O 0 6.558279710588977e-05
ml O 0 4.6976125304354355e-05
; O 0 9.302234360575312e-08
n O 0 7.354603894782485e-07
= O 0 1.5943437574605923e-06
6 O 0 6.534088470289134e-08
) O 0 1.1837863134189774e-08
, O 0 2.7131308311112434e-09
compared O 0 1.0062754185469203e-08
with O 0 1.4064052145101869e-09
the O 0 1.705740992896665e-09
level O 0 2.4689926547694085e-08
( O 0 2.5791205615632862e-08
1 O 0 7.663433443383383e-09
. O 0 2.391746356522617e-09
64 O 0 2.3767501033944427e-07
+ O 0 8.34896036394639e-06
/ O 0 5.336286903911969e-06
- O 0 7.493269436054106e-07
1 O 0 2.038140145543821e-08
. O 0 1.1791172482844559e-08
07 O 0 1.7639056750340387e-05
mg O 0 0.0001036417088471353
/ O 0 6.590529665118083e-05
ml O 0 3.288202060502954e-05
) O 0 9.936133693599913e-09
obtained O 0 4.909660678009686e-09
from O 0 1.4462891329003469e-08
52 O 0 1.476129682487226e-06
healthy O 0 1.1313768482068554e-05
volunteers O 0 2.081050070046331e-06
having O 0 9.951174888556125e-07
phenotype O 0 0.0015236615436151624
Hp2 O 0 0.0012910091318190098
, O 0 5.322602802948495e-08
whereas O 0 2.2843603630917642e-07
the O 0 6.115875095247247e-08
serum O 0 0.00013480664347298443
Hp O 0 3.0362841698661214e-06
level O 0 1.1719780701469062e-08
of O 0 8.666892203912369e-10
an O 0 3.176972684926227e-09
individual O 0 2.4605164128388424e-08
with O 0 4.2393830312903447e-07
Hp1 O 0 0.4441927671432495
/ O 0 0.05066588148474693
Hpdel O 0 0.004383801482617855
was O 0 7.33840579414391e-07
0 O 0 9.785049769561738e-06
. O 0 4.440685188455973e-06

50 O 0 4.797757719643414e-05
mg O 0 0.011950717307627201
/ O 0 0.013307887129485607
ml O 0 0.0017902870895341039
, O 0 1.1936586474803335e-07
which O 0 5.976546813002415e-09
was O 0 2.522653197445379e-09
approximately O 0 4.3553800566087375e-09
half O 0 2.2320074677395496e-09
the O 0 9.744003381939592e-10
level O 0 5.644478218158611e-09
of O 0 2.9483917529660175e-09
Hp O 0 2.8281128834350966e-06
in O 0 2.18198081824994e-08
control O 0 3.450949179750751e-07
sera O 0 4.85884265799541e-05
from O 0 2.4721451552522922e-08
the O 0 8.430970410699956e-08
Hp1 O 0 0.006770167965441942
phenotype O 0 0.00015082088066264987
( O 0 1.3854118208200816e-07
1 O 0 3.0898188896344436e-08
. O 0 7.337171759047578e-09
26 O 0 1.7582631528512138e-07
+ O 0 1.2323298506089486e-05
/ O 0 5.316512215358671e-06
- O 0 5.978864123790117e-07
0 O 0 2.3366368395727477e-08
. O 0 3.26001381445451e-09
33 O 0 1.4503879697258526e-07
mg O 0 1.9477904061204754e-05
/ O 0 3.428784111747518e-05
ml O 0 2.7165166102349758e-05
; O 0 8.94148826091623e-08
n O 0 8.532254014426144e-07
= O 0 1.4023258927409188e-06
9 O 0 3.692630201612701e-08
) O 0 8.427991637915966e-09
, O 0 3.995318742511245e-09
showing O 0 7.456884532075492e-08
a O 0 1.4184053043209133e-07
gene O 0 1.900077586469706e-05
- O 0 0.0012152546551078558
dosage O 0 0.0008843779214657843
effect O 0 1.1992205145361368e-05
. O 0 5.497499387274729e-06

The O 0 1.9504668671288528e-06
other O 0 7.754626949463272e-07
allele O 0 2.2281894416664727e-05
( O 0 3.0142332434479613e-06
Hp2 O 0 0.0005431555910035968
) O 0 5.0991399547228866e-08
of O 0 7.102646470968921e-09
individuals O 0 8.84085693542147e-08
with O 0 1.1055568620577105e-06
Hp2 O 1 0.5927942991256714
/ O 0 0.15670782327651978
Hpdel O 0 0.018608316779136658
was O 0 1.0736664535215823e-07
found O 0 1.933548254839934e-08
to O 0 4.759305394230751e-09
have O 0 2.6960560450817184e-09
, O 0 5.209248143955847e-09
in O 0 2.3784534342041752e-09
all O 0 1.8639592092029034e-09
exons O 0 1.1480412922537653e-06
, O 0 1.8385760469641355e-08
no O 0 3.637808987377866e-08
mutation O 0 4.535009736628126e-07
, O 0 1.632262502937465e-08
by O 0 4.3467760946214185e-08
DNA O 0 2.6280995371052995e-06
sequencing O 0 7.303786787815625e-06
. O 0 3.977562755608233e-06

On O 0 2.2476366723367391e-07
the O 0 3.449191154913933e-08
basis O 0 1.2906054003281042e-08
of O 0 1.0138931472170043e-08
the O 0 3.196899811541698e-08
present O 0 2.222135151441762e-07
study O 0 1.7714501154841855e-07
, O 0 1.6302431404824347e-08
the O 0 4.5636503465118494e-09
mechanism O 0 5.447141404602007e-08
of O 0 1.6329693153238622e-08
anhaptoglobinemia B-Disease 0 0.0003309433814138174
and O 0 1.1361498408746229e-08
the O 0 4.4268877452680044e-09
mechanism O 0 4.579042212071727e-08
of O 0 1.2975906571455198e-08
anomalous O 0 2.508934267098084e-05
inheritance O 0 1.038448499457445e-05
of O 0 2.7951276138082903e-07
Hp O 0 0.009990953840315342
phenotypes O 0 0.0006039757863618433
were O 0 5.1870621575744735e-08
well O 0 4.1745252588043513e-07
explained O 0 2.6353543944424018e-05
. O 0 8.478576091874857e-06

However O 0 5.598650204774458e-06
, O 0 4.6178661250451114e-07
the O 0 9.890210606045002e-08
mechanism O 0 1.2442477554941433e-06
of O 0 1.0645062502590008e-06
hypohaptoglobinemia B-Disease 0 0.17064134776592255
remains O 0 0.00026065396377816796
unknown O 0 0.00020648959616664797

ATM O 0 0.0023330794647336006
mutations O 0 0.00019306271860841662
and O 0 7.340649517573183e-06
phenotypes O 0 0.039012935012578964
in O 0 0.0009168254327960312
ataxia B-Disease 1 0.9994162321090698
- I-Disease 1 0.9981244206428528
telangiectasia I-Disease 1 0.9988687634468079
families O 0 9.931825843523256e-06
in O 0 1.014773687302295e-07
the O 0 1.0714365572539464e-07
British O 0 3.3774222174542956e-06
Isles O 0 1.5708263163105585e-05
: O 0 2.0746523432535469e-07
expression O 0 1.52125601005082e-08
of O 0 7.766348453230876e-09
mutant O 0 9.499203770246822e-06
ATM O 0 2.4004868464544415e-05
and O 0 9.680380230747687e-08
the O 0 8.931821184887667e-07
risk O 0 0.015466027893126011
of O 0 0.00028799238498322666
leukemia B-Disease 1 0.999713122844696
, O 1 0.8597587943077087
lymphoma B-Disease 1 0.9998562335968018
, O 0 0.023506201803684235
and O 0 0.18009933829307556
breast B-Disease 1 0.9992934465408325
cancer I-Disease 1 0.9983377456665039
. O 0 0.0004305853508412838

We O 0 1.566736500535626e-06
report O 0 6.582736205018591e-07
the O 0 3.705095963368876e-08
spectrum O 0 5.683544941348373e-07
of O 0 3.7974121624984036e-08
59 O 0 1.2875002539658453e-05
ATM O 0 0.00015503291797358543
mutations O 0 7.910191015980672e-06
observed O 0 1.8180749066232238e-06
in O 0 9.630885870137718e-06
ataxia B-Disease 1 0.9991511106491089
- I-Disease 1 0.9740248918533325
telangiectasia I-Disease 1 0.9984139204025269
( O 0 4.3265201384201646e-05
A B-Disease 0 0.001649393467232585
- I-Disease 1 0.9750273823738098
T I-Disease 1 0.9991059899330139
) O 0 3.576092785806395e-05
patients O 0 0.0004032221913803369
in O 0 4.8930974827499085e-08
the O 0 1.4480535526217864e-07
British O 0 2.4749986550887115e-05
Isles O 0 0.00038370362017303705
. O 0 1.4733922398590948e-05

Of O 0 3.012081151609891e-06
51 O 0 0.00013170020247343928
ATM O 0 0.0028223656117916107
mutations O 0 5.36334264324978e-05
identified O 0 6.227026574379124e-07
in O 0 5.7351076776512855e-08
families O 0 2.8538087804008683e-07
native O 0 1.1710992708913182e-07
to O 0 4.3239434255326614e-09
the O 0 1.5561884225689937e-08
British O 0 1.6338157138306997e-06
Isles O 0 7.772835488140117e-06
, O 0 4.554591370720118e-08
11 O 0 7.99929154027268e-08
were O 0 9.405817458230104e-09
founder O 0 1.3938903975940775e-05
mutations O 0 1.528957909613382e-06
, O 0 1.0933292493575664e-08
and O 0 3.3261764453840215e-09
2 O 0 1.0260989391497333e-08
of O 0 1.4500394218686097e-09
these O 0 4.385740215440137e-09
11 O 0 5.802600639981392e-07
conferred O 0 1.8674705643206835e-05
a O 0 1.050025184667902e-05
milder O 1 0.8376776576042175
clinical O 0 0.1327030062675476
phenotype O 0 0.0032001936342567205
with O 0 1.2564193241360044e-07
respect O 0 2.0901104846871021e-07
to O 0 3.026836736808036e-07
both O 0 1.8390534023637883e-05
cerebellar B-Disease 1 0.9989131689071655
degeneration I-Disease 1 0.9990676045417786
and O 0 1.935761065396946e-05
cellular O 0 0.0012555639259517193
features O 0 6.876982661196962e-05
. O 0 2.2606458514928818e-05

We O 0 2.0373374809423694e-06
report O 0 1.0164750392505084e-06
, O 0 7.242170596555297e-08
in O 0 2.0876397499591803e-08
two O 0 3.785732616279347e-08
A B-Disease 0 9.044341277331114e-05
- I-Disease 0 0.33215031027793884
T I-Disease 1 0.9791578650474548
families O 0 5.738614277106535e-07
, O 0 1.176107478073618e-08
an O 0 8.508476589952352e-09
ATM O 0 9.029284228745382e-06
mutation O 0 1.064879825207754e-06
( O 0 1.5800895880602184e-07
7271T O 0 7.738114072708413e-05
- O 0 0.00021183343778830022
- O 0 0.0008714432478882372
> O 0 0.0017121505225077271
G O 0 0.00012690876610577106
) O 0 8.162837161762582e-08
that O 0 5.591821228279059e-09
may O 0 4.1795598093585795e-08
be O 0 1.0044111098395092e-09
associated O 0 3.716902696737634e-08
with O 0 1.1297189850267841e-08
an O 0 1.3939985876731953e-07
increased O 0 5.379570575314574e-05
risk O 0 0.03875506669282913
of O 0 0.00013576859782915562
breast B-Disease 1 0.9997603297233582
cancer I-Disease 1 0.9984267950057983
in O 0 6.035810429239064e-07
both O 0 6.543616564158583e-07
homozygotes O 0 0.2080162614583969
and O 0 2.7562527975533158e-06
heterozygotes O 0 0.08998921513557434
( O 0 6.4599876168358605e-06
relative O 0 9.86280974757392e-06
risk O 0 3.374861626070924e-05
12 O 0 6.935073315617046e-08
. O 0 1.2684413519536974e-08
7 O 0 2.783503134651255e-07
; O 0 7.710940508331987e-07
P O 0 0.0004472614382393658
= O 0 3.6741465009981766e-05
. O 0 2.2346843309151154e-07
0025 O 0 0.020233571529388428
) O 0 1.1917431663732714e-07
, O 0 1.6536652935883467e-08
although O 0 1.0296750119209719e-08
there O 0 3.2926461557281073e-09
is O 0 7.666590917665417e-09
a O 0 1.397829976212961e-07
less O 0 7.430033747368725e-06
severe O 1 0.9664309620857239
A B-Disease 0 0.03737397491931915
- I-Disease 1 0.9963622689247131
T I-Disease 1 0.9992303848266602
phenotype O 0 0.0011427989229559898
in O 0 1.5825047938733405e-08
terms O 0 1.4745785037462156e-08
of O 0 9.440614512357115e-09
the O 0 9.969397041231787e-08
degree O 0 8.474809874314815e-06
of O 0 2.8276974262553267e-05
cerebellar B-Disease 1 0.995931088924408
degeneration I-Disease 1 0.9974785447120667
. O 0 0.0013246816815808415

This O 0 1.5903469829936512e-06
mutation O 0 1.0737564480223227e-05
( O 0 2.5642245873314096e-06
7271T O 0 0.0007302482263185084
- O 0 0.000671625544782728
- O 0 0.0010130535811185837
> O 0 0.0007113712490536273
G O 0 4.92521830892656e-05
) O 0 1.9458681776995945e-08
also O 0 1.1676021260953462e-09
allows O 0 3.3458249504292326e-09
expression O 0 1.9316157562343506e-09
of O 0 8.374691495838249e-10
full O 0 3.5241171758571e-08
- O 0 6.057462087483145e-06
length O 0 1.707220462776604e-07
ATM O 0 2.510286549295415e-06
protein O 0 2.399071341585568e-08
at O 0 4.424439925543311e-09
a O 0 7.753027553292213e-09
level O 0 7.484656805445411e-08
comparable O 0 3.965969028740801e-07
with O 0 4.2623277352049627e-08
that O 0 6.611386993427004e-08
in O 0 1.3006801964365877e-06
unaffected O 0 0.0014873004984110594
individuals O 0 3.899127023032634e-06
. O 0 1.7926278815139085e-05

In O 0 2.738478315222892e-06
addition O 0 1.0311498499504523e-06
, O 0 9.049165328178788e-08
we O 0 4.195164216014291e-09
have O 0 3.0621256641438777e-09
studied O 0 1.0529801386383042e-07
18 O 0 1.5987959613994462e-06
A B-Disease 0 0.0016296958783641458
- I-Disease 1 0.9867798686027527
T I-Disease 1 0.9993201494216919
patients O 0 0.04624629020690918
, O 0 1.2358530909750698e-07
in O 0 7.122864076336555e-08
15 O 0 5.367454036786512e-07
families O 0 1.2063160284014884e-06
, O 0 1.5375559314634302e-06
who O 0 7.379830640275031e-05
developed O 0 0.4812120795249939
leukemia B-Disease 1 0.9996607303619385
, O 0 0.06047353148460388
lymphoma B-Disease 1 0.9997584223747253
, O 0 0.0002425827697152272
preleukemic O 1 0.9775121808052063
T O 1 0.9879665970802307
- O 0 0.10935301333665848
cell O 0 0.035050638020038605
proliferation O 0 0.495923787355423
, O 0 0.00018104241462424397
or O 0 0.19046904146671295
Hodgkin B-Disease 1 0.9997771382331848
lymphoma I-Disease 1 0.9998051524162292
, O 0 1.66869031090755e-05
mostly O 0 2.2939582322578644e-06
in O 0 9.749077435117215e-06
childhood O 0 0.3067212998867035
. O 0 0.00010520661453483626

A O 0 3.992433448729571e-06
wide O 0 2.410958131804364e-06
variety O 0 3.178241456680553e-07
of O 0 9.28923853393826e-08
ATM O 0 0.00032620711135677993
mutation O 0 1.149094805441564e-05
types O 0 6.963132364035118e-07
, O 0 3.552407434881388e-08
including O 0 1.3839289181305503e-07
missense O 0 6.405798922060058e-05
mutations O 0 1.2792700090358267e-06
and O 0 1.7398489760012126e-08
in O 0 6.979608002666282e-08
- O 0 0.0001318774011451751
frame O 0 4.442534191184677e-05
deletions O 0 9.927242899721023e-06
, O 0 3.5083498772792154e-08
were O 0 6.325399759532502e-09
seen O 0 6.814063908677781e-07
in O 0 2.3125619463826297e-07
these O 0 1.5210027868306497e-06
patients O 0 0.10724815726280212
. O 0 5.3957126510795206e-05

We O 0 9.906576678986312e-07
also O 0 1.2294418638703064e-07
show O 0 3.886968258370871e-08
that O 0 2.019915346096468e-09
25 O 0 8.13623834972077e-09
% O 0 2.7045026218530666e-09
of O 0 9.819751678463717e-10
all O 0 1.8985421235129252e-08
A B-Disease 0 0.00034101205528713763
- I-Disease 1 0.9627331495285034
T I-Disease 1 0.9991173148155212
patients O 0 0.0012415158562362194
carried O 0 9.496748276660583e-08
in O 0 4.197983827225471e-08
- O 0 2.8463326088967733e-05
frame O 0 1.6280346244457178e-05
deletions O 0 1.4383985217136797e-05
or O 0 7.407170983242395e-07
missense O 0 0.0005047557642683387
mutations O 0 6.27155577603844e-06
, O 0 1.3027189993408683e-08
many O 0 1.9600705503108884e-09
of O 0 1.7842222144182074e-09
which O 0 5.667478042425955e-09
were O 0 1.8172485738432442e-09
also O 0 1.7574659949559646e-08
associated O 0 8.762174985577076e-08
with O 0 1.2880160049633105e-08
expression O 0 9.169623638172197e-08
of O 0 3.29682698918532e-08
mutant O 0 0.00011490181350382045
ATM O 0 0.0004532353486865759
protein O 0 1.069429526978638e-05
. O 0 4.943712156091351e-06

The O 0 2.4718945496715605e-05
DMPK O 0 0.1189502701163292
gene O 0 0.00016776146367192268
of O 0 4.984674524166621e-05
severely O 1 0.9974374771118164
affected O 1 0.995974600315094
myotonic B-Disease 1 0.9996836185455322
dystrophy I-Disease 1 0.9998030066490173
patients O 1 0.9966261386871338
is O 0 2.6911593522527255e-05
hypermethylated O 1 0.5213946104049683
proximal O 0 0.004188158083707094
to O 0 1.7453589862270746e-07
the O 0 1.3483872862707358e-07
largely O 0 1.965528326763888e-06
expanded O 0 3.916088826372288e-05
CTG O 0 0.37035682797431946
repeat O 0 0.004322544671595097
. O 0 2.9352855563047342e-05

Using O 0 2.4909843432396883e-06
methylation O 0 3.2587082387181e-05
- O 0 0.0005840968224219978
sensitive O 0 9.618100193620194e-06
restriction O 0 5.171975317352917e-06
enzymes O 0 2.1866883344046073e-06
, O 0 4.8273360420125755e-08
we O 0 8.241744176018528e-09
characterized O 0 1.0291447551935562e-06
the O 0 3.660148184536638e-09
methylation O 0 1.3191444736548874e-07
pattern O 0 1.598376684341929e-07
on O 0 1.574456343078623e-09
the O 0 2.315923675055842e-09
5 O 0 1.4166392503511815e-08
side O 0 1.7084412107237767e-08
of O 0 2.237518836878394e-09
the O 0 3.2270289551661335e-08
CTG O 0 0.003330651903524995
repeat O 0 1.1175266990903765e-05
in O 0 1.061416554648531e-08
the O 0 4.20265457989899e-08
DMPK O 0 0.006853669416159391
gene O 0 3.431023287703283e-07
of O 0 1.164393470531877e-08
normal O 0 5.0837195431086e-07
individuals O 0 1.170037648989819e-07
and O 0 2.0204178952099028e-07
of O 0 5.963095645711292e-06
patients O 1 0.9643400311470032
affected O 0 0.02579919807612896
with O 0 0.08909234404563904
myotonic B-Disease 1 0.9997981190681458
dystrophy I-Disease 1 0.9996856451034546
, O 0 8.674557648191694e-06
showing O 0 1.8295409972779453e-05
expansions O 0 1.2616206731763668e-05
of O 0 5.290335991503525e-08
the O 0 5.295990490594704e-07
repetitive O 0 0.002187642501667142
sequence O 0 6.110108188295271e-06
. O 0 1.1411749255785253e-05

The O 0 2.8915264920215122e-06
gene O 0 7.542361800005892e-06
segment O 0 2.4162293357221643e-06
analyzed O 0 2.8618845249184233e-07
corresponds O 0 1.1188794957206483e-07
to O 0 9.561156311121977e-09
the O 0 2.428846634927595e-08
genomic O 0 1.0605862371448893e-05
SacI O 0 0.0035858354531228542
- O 0 9.021240111906081e-05
HindIII O 0 0.00037955911830067635
fragment O 0 1.4742445273441263e-06
carrying O 0 2.1033918073953828e-07
exons O 0 4.778883067046991e-06
11 O 0 2.5008957891259342e-06
- O 0 0.0001666287862462923
15 O 0 5.932290150667541e-06
. O 0 4.6996906348795164e-06

There O 0 1.0175118632105296e-06
is O 0 1.4427769201574847e-07
constitutive O 0 3.2538207506149774e-06
methylation O 0 7.572716071990726e-07
in O 0 5.2351886381529766e-08
intron O 0 0.0002154549874830991
12 O 0 5.4070611099632515e-08
at O 0 2.8585366962374792e-08
restriction O 0 8.131246431730688e-08
sites O 0 7.889854991560696e-09
of O 0 7.230449572404041e-09
SacII O 0 0.0002738806651905179
and O 0 7.684953828857033e-08
HhaI O 0 0.0009760890388861299
, O 0 3.5945422638405944e-08
localized O 0 4.433397862158017e-06
1 O 0 7.469112972557923e-08
, O 0 1.4874482090476704e-08
159 O 0 8.570117415729328e-07
- O 0 2.5269609977840446e-06
1 O 0 2.2969864232891268e-08
, O 0 4.530157138304958e-09
232 O 0 2.8877985869257827e-07
bp O 0 1.9258931160948123e-07
upstream O 0 1.9419861274627692e-08
of O 0 1.140189276327419e-09
the O 0 3.2175275777035495e-08
CTG O 0 0.0139429597184062
repeat O 0 0.00011607274791458622
, O 0 9.250147314787682e-08
whereas O 0 2.581897149411816e-07
most O 0 1.1729823334860612e-08
, O 0 3.3464587545495306e-08
if O 0 5.3884754436239746e-09
not O 0 4.619222226942554e-10
all O 0 2.5800034331169286e-10
, O 0 8.840528309406182e-10
of O 0 2.436807144956532e-10
the O 0 5.754792753442928e-10
other O 0 6.561358123491345e-10
sites O 0 7.119614231498872e-09
of O 0 1.5854746848731338e-08
SacII O 0 0.004137538373470306
, O 0 4.219529898819019e-07
HhaI O 0 0.0038933486212044954
, O 0 9.293562897028096e-08
and O 0 6.62868586687182e-08
HpaII O 0 0.0010405703214928508
in O 0 2.227258377729413e-08
this O 0 1.1735864724471412e-08
region O 0 5.356134238354571e-07
are O 0 1.0768017588702605e-08
unmethylated O 0 0.0006060282466933131
, O 0 1.4459973840530438e-07
in O 0 5.5433261536563805e-08
normal O 0 5.259790327727387e-07
individuals O 0 6.438015276444276e-08
and O 0 2.0549054013940804e-08
most O 0 1.8641520327378203e-08
of O 0 1.4748462717761868e-07
the O 0 8.355428690265398e-06
patients O 1 0.5642203688621521
. O 0 6.792099884478375e-05

In O 0 1.0915164239122532e-06
a O 0 1.918787404520117e-07
number O 0 3.634306722233305e-08
of O 0 2.1919842652096122e-07
young O 0 0.0006648063426837325
and O 0 0.0003187018446624279
severely O 1 0.997032642364502
affected O 0 0.16779226064682007
patients O 0 0.2794332802295685
, O 0 3.8349122633007937e-07
however O 0 4.486742355425122e-08
, O 0 1.1126881638290342e-08
complete O 0 7.929429557407275e-08
methylation O 0 7.65870211694164e-08
of O 0 1.7283744435658832e-09
these O 0 3.459105002434626e-09
restriction O 0 1.7627004922360356e-07
sites O 0 3.04172438347905e-08
was O 0 1.843017471969688e-08
found O 0 1.209727518158843e-08
in O 0 2.391163711479294e-08
the O 0 2.5646551193858613e-07
mutated O 0 0.000441738375229761
allele O 0 6.487994687631726e-05
. O 0 6.111524726293283e-06

In O 0 2.1318924154911656e-06
most O 0 1.6616588993656478e-07
of O 0 1.6332970176335948e-07
these O 0 1.2409664122969843e-06
patients O 0 0.07143134623765945
, O 0 1.8301809632248478e-06
the O 0 5.841071015311172e-06
onset O 1 0.9917011857032776
of O 0 1.6717103790142573e-05
the O 0 0.009090873412787914
disease O 1 0.9992832541465759
was O 0 0.046797946095466614
congenital O 1 0.9983280301094055
. O 0 0.0020270044915378094

Preliminary O 0 1.779979356797412e-05
in O 0 5.031117780163186e-06
vivo O 0 0.00022433635604102165
footprinting O 0 0.031466055661439896
data O 0 1.7077674385745922e-07
gave O 0 1.2229143919739727e-07
evidence O 0 3.9660214667947e-08
for O 0 1.3389338526792471e-08
protein O 0 5.804160991829121e-07
- O 0 4.9964866775553674e-05
DNA O 0 7.431497124343878e-07
contact O 0 1.7776915228751022e-07
in O 0 1.4923729807492236e-08
normal O 0 1.0159899943573691e-07
genes O 0 8.756879310567456e-08
at O 0 3.689208938340016e-08
an O 0 4.6438294987183326e-08
Sp1 O 0 0.0016505259554833174
consensus O 0 5.877756237282483e-08
binding O 0 1.984773057017719e-08
site O 0 1.3849185798164854e-08
upstream O 0 1.7792748607803333e-08
of O 0 1.1101881636221833e-09
the O 0 2.2930773724283426e-08
CTG O 0 0.016217509284615517
repeat O 0 1.3577179743151646e-05
and O 0 5.9681060093907945e-09
for O 0 3.097116119121779e-09
a O 0 1.0607850597921242e-08
significant O 0 3.7517821738219936e-08
reduction O 0 4.895001666227472e-07
of O 0 1.6899700527872596e-09
this O 0 2.9910833809765336e-09
interaction O 0 6.502583715928267e-08
in O 0 7.070723739843743e-08
cells O 0 1.9824933588097338e-06
with O 0 7.642096022664191e-08
a O 0 4.142108537052991e-06
hypermethylated O 0 0.2786634862422943
DMPK O 0 0.413725346326828
gene O 0 3.164094960084185e-05
. O 0 1.0989459724441986e-06
. O 0 5.056273494119523e-06

The O 0 0.00014770742563996464
hemochromatosis B-Disease 1 0.9925686717033386
gene O 0 7.607301813550293e-05
product O 0 1.2916853847855236e-05
complexes O 0 1.8716622435022146e-05
with O 0 8.998048883768206e-08
the O 0 2.956063838155387e-07
transferrin O 0 0.007468825206160545
receptor O 0 1.1776665814977605e-05
and O 0 5.609642528270342e-08
lowers O 0 8.971791248768568e-05
its O 0 1.0633192104592126e-08
affinity O 0 3.34549525859984e-07
for O 0 4.2263920363438956e-08
ligand O 0 1.0344611837354023e-05
binding O 0 8.009174962353427e-06
. O 0 8.243025149567984e-06

We O 0 3.131611492790398e-06
recently O 0 5.970231086394051e-06
reported O 0 6.88153704686556e-07
the O 0 2.5102712797320237e-08
positional O 0 1.9808567230938934e-06
cloning O 0 1.4203858427208615e-06
of O 0 7.721623340728456e-09
a O 0 1.9047033106289746e-07
candidate O 0 3.165788939440972e-06
gene O 0 8.628856448922306e-05
for O 0 6.900315202074125e-05
hereditary B-Disease 1 0.9981928467750549
hemochromatosis I-Disease 1 0.9993416666984558
called O 0 0.15452124178409576
HFE O 1 0.9924941062927246
. O 0 0.00043975800508633256

The O 0 3.170169748045737e-06
gene O 0 1.3162533832655754e-05
product O 0 1.477429577789735e-06
, O 0 6.134217045428159e-08
a O 0 1.88451867444428e-08
member O 0 1.8612279717444835e-08
of O 0 6.099307725548897e-09
the O 0 6.993587220449626e-08
major O 0 1.9113855159957893e-05
histocompatibility O 1 0.9869198799133301
complex O 0 2.5398176148883067e-05
class O 0 6.989363464526832e-05
I O 0 1.0835266039066482e-05
- O 0 0.00025059544714167714
like O 0 1.2753451983371633e-06
family O 0 2.250035322504118e-06
, O 0 4.000216335953155e-08
was O 0 1.5473800019094597e-08
found O 0 4.332198155765354e-09
to O 0 1.185360476441133e-09
have O 0 1.070761479482485e-09
a O 0 1.115203662749309e-08
mutation O 0 4.757048088777083e-07
, O 0 9.053361083033451e-08
Cys O 0 0.01582854986190796
- O 0 9.355880320072174e-05
282 O 0 0.00010054223821498454
- O 0 0.000678607146255672
- O 0 0.0021284865215420723
> O 0 0.002777156187221408
Tyr O 0 0.030347004532814026
( O 0 8.493593668390531e-07
C282Y O 0 5.491905540111475e-05
) O 0 4.609035642033632e-08
, O 0 2.8936930629441804e-09
in O 0 3.197581310843134e-09
85 O 0 6.130837277851242e-07
% O 0 6.163477905829495e-08
of O 0 1.2588564857196616e-07
patient O 0 0.00246712495572865
chromosomes O 0 0.00013448244135361165
. O 0 3.2196941901929677e-05

This O 0 2.913876869570231e-06
mutation O 0 4.291804725653492e-05
eliminates O 0 6.856486288597807e-05
the O 0 9.60389243687132e-08
ability O 0 3.746133643289795e-07
of O 0 6.23569107460753e-08
HFE O 0 0.0636928379535675
to O 0 5.3979416492211385e-08
associate O 0 8.080456268544367e-07
with O 0 4.173625711700879e-07
beta2 O 0 0.0496448315680027
- O 0 0.009400677867233753
microglobulin O 0 0.08881678432226181
( O 0 4.849438028031727e-06
beta2m O 0 0.0015359313692897558
) O 0 2.2391044751657319e-07
and O 0 8.102805537646418e-08
prevents O 0 8.292479469673708e-05
cell O 0 0.00016487526590935886
- O 0 0.0006519680609926581
surface O 0 1.860035990830511e-05
expression O 0 3.389024641364813e-06
. O 0 3.6892515709041618e-06

A O 0 7.655074114154559e-06
second O 0 2.7810456231236458e-06
mutation O 0 1.386479470966151e-05
that O 0 3.790118086044458e-08
has O 0 2.163188383974557e-08
no O 0 1.718021991337082e-08
effect O 0 1.7557111675614578e-07
on O 0 1.0492450996935077e-07
beta2m O 0 0.03515161946415901
association O 0 2.2803455067332834e-05
, O 0 3.9896181647236517e-07
H63D O 0 0.01544957049190998
, O 0 4.344297721559087e-08
was O 0 7.653383704564476e-09
found O 0 4.942036557764595e-09
in O 0 1.9874086820692582e-09
eight O 0 4.077034709837335e-09
out O 0 3.895702427314518e-09
of O 0 1.2011194705507933e-08
nine O 0 3.5802261209028075e-06
patients O 0 0.0014613686362281442
heterozygous O 0 2.4133689748850884e-06
for O 0 7.895985021377783e-08
the O 0 5.866779133611999e-07
C282Y O 0 0.012513263151049614
mutant O 0 0.00228843349032104
. O 0 1.5264551620930433e-05

In O 0 1.3834475112162181e-06
this O 0 1.5844534573261626e-07
report O 0 8.575161132284848e-07
, O 0 2.4601130022006146e-08
we O 0 4.679686416153572e-09
demonstrate O 0 6.369446481357954e-08
in O 0 3.948419902144451e-08
cultured O 0 1.475760291214101e-05
293 O 0 0.0005156042170710862
cells O 0 0.0001284672471228987
overexpressing O 0 0.028162488713860512
wild O 0 1.5514307960984297e-05
- O 0 0.0008569500641897321
type O 0 1.746457564877346e-05
or O 0 3.4959793993039057e-07
mutant O 0 8.060094842221588e-05
HFE O 0 0.023087894544005394
proteins O 0 2.4754669425419706e-08
that O 0 7.681912328472151e-10
both O 0 1.012269490452411e-09
the O 0 8.53881321205563e-09
wild O 0 2.0139070784352953e-06
- O 0 0.0001017440517898649
type O 0 7.97055872681085e-06
and O 0 2.8478439162427094e-07
H63D O 0 0.06928426772356033
HFE O 0 0.06471224874258041
proteins O 0 1.70381113662188e-07
form O 0 1.990965330378458e-07
stable O 0 5.624342975352192e-06
complexes O 0 8.194610018108506e-06
with O 0 1.7106103200603684e-07
the O 0 1.1673142807921977e-06
transferrin O 0 0.18256863951683044
receptor O 0 0.0005802621017210186
( O 0 1.4968069990572985e-05
TfR O 0 0.011462370865046978
) O 0 2.192173496951e-06
. O 0 5.253170911601046e-06

The O 0 2.0931571270921268e-05
C282Y O 0 0.016639819368720055
mutation O 0 0.00018132505647372454
nearly O 0 6.341441348922672e-06
completely O 0 1.1779653505072929e-05
prevents O 0 2.2161357264849357e-05
the O 0 6.446936851034479e-08
association O 0 6.376253054440895e-07
of O 0 8.403144846624855e-09
the O 0 1.5249476348344615e-07
mutant O 0 0.00018469982023816556
HFE O 0 0.10079440474510193
protein O 0 1.1106737929367227e-06
with O 0 3.9858795730651764e-07
the O 0 3.9644824028073344e-06
TfR O 0 0.21341846883296967
. O 0 1.3070394743408542e-05

Studies O 0 1.8045193428406492e-05
on O 0 1.1779548003687523e-06
cell O 0 0.0001333869295194745
- O 0 0.00047503827954642475
associated O 0 6.28744328423636e-06
transferrin O 0 0.0006037168786861002
at O 0 1.2503495838700474e-07
37 O 0 7.814761602276121e-07
degrees O 0 6.204998044267995e-07
C O 0 9.445637260796502e-06
suggest O 0 6.988533129970165e-08
that O 0 2.222406925156406e-09
the O 0 1.983085518020289e-08
overexpressed O 0 0.00013759480498265475
wild O 0 2.638914111230406e-06
- O 0 0.00032491781166754663
type O 0 3.757863669306971e-05
HFE O 0 0.026919079944491386
protein O 0 6.422960723284632e-07
decreases O 0 5.05537798289879e-07
the O 0 3.7471679092959675e-09
affinity O 0 1.1139180600139298e-07
of O 0 1.1258385335111143e-08
the O 0 4.528367014700052e-07
TfR O 0 0.011471020057797432
for O 0 2.2895692382007837e-06
transferrin O 0 0.06067964434623718
. O 0 2.2023023120709695e-05

The O 0 2.682601370906923e-05
overexpressed O 0 0.06505327671766281
H63D O 0 0.24985097348690033
protein O 0 1.7847538401838392e-05
does O 0 6.287560267992376e-07
not O 0 7.473355267961779e-09
have O 0 2.6058404323237028e-09
this O 0 3.895100242345961e-09
effect O 0 8.192878908630519e-08
, O 0 8.681439567226334e-09
providing O 0 9.269748524332044e-09
the O 0 1.508179359177575e-09
first O 0 1.7354071513153713e-09
direct O 0 1.0240069236999716e-08
evidence O 0 3.918567870186962e-08
for O 0 6.300690635896444e-09
a O 0 1.0981051445924095e-07
functional O 0 1.1753480748666334e-06
consequence O 0 1.1263817896178807e-06
of O 0 2.784012131940017e-08
the O 0 2.018984105234267e-06
H63D O 1 0.5529894828796387
mutation O 0 0.00036543107125908136
. O 0 1.953303763002623e-05

Addition O 0 3.002676976393559e-06
of O 0 5.769844619862852e-07
soluble O 0 0.0004692975780926645
wild O 0 4.6741657570237294e-05
- O 0 0.007289591711014509
type O 0 0.003965283744037151
HFE O 1 0.933327317237854
/ O 0 0.04192550107836723
beta2m O 0 0.037969909608364105
heterodimers O 0 0.01057428028434515
to O 0 2.802916867494787e-07
cultured O 0 8.964342850958928e-05
cells O 0 1.0879396540985908e-05
also O 0 4.567510458741708e-08
decreased O 0 1.9805129340966232e-06
the O 0 6.673464891804315e-09
apparent O 0 9.852739140114863e-07
affinity O 0 2.545050961089146e-07
of O 0 3.3431331036837264e-09
the O 0 2.7321595652551878e-08
TfR O 0 0.00018978057778440416
for O 0 2.4122710495788624e-09
its O 0 7.090680931298721e-09
ligand O 0 5.424662390396406e-07
under O 0 1.4043692431187083e-07
steady O 0 1.5047289707581513e-05
- O 0 3.6992947570979595e-05
state O 0 6.559437082387376e-08
conditions O 0 8.275037544080988e-07
, O 0 8.762738978873585e-09
both O 0 3.2529576809992022e-09
in O 0 3.28087459422477e-08
293 O 0 0.00010496380855329335
cells O 0 1.9116507701255614e-06
and O 0 4.874095083096108e-08
in O 0 1.4477072909357958e-06
HeLa O 0 0.36648619174957275
cells O 0 0.00015216716565191746
. O 0 6.266049240366556e-06

Furthermore O 0 1.9508126570144668e-05
, O 0 3.9449389532819623e-07
at O 0 2.1393739757513686e-07
4 O 0 5.862562488800904e-07
degrees O 0 6.844766176072881e-07
C O 0 9.07463163457578e-06
, O 0 1.0902119207401029e-08
the O 0 7.135261714807939e-09
added O 0 1.25400248407459e-07
soluble O 0 4.76410332339583e-06
complex O 0 5.380809966482047e-07
of O 0 2.9975674920024176e-07
HFE O 1 0.7815144658088684
/ O 0 0.006932585034519434
beta2m O 0 0.0005342562799341977
inhibited O 0 2.924583895946853e-06
binding O 0 3.6098846578624944e-08
of O 0 2.0682746182387746e-08
transferrin O 0 0.00026245444314554334
to O 0 2.3572445684294507e-07
HeLa O 0 0.018389351665973663
cell O 0 6.859567656647414e-05
TfR O 0 0.0017806750256568193
in O 0 3.0804098827275084e-08
a O 0 3.346637811318942e-07
concentration O 0 0.00011343787627993152
- O 0 0.0006477151764556766
dependent O 0 1.0838449270522688e-05
manner O 0 5.78225535718957e-06
. O 0 5.407661319623003e-06

Scatchard O 0 0.00028794846730306745
plots O 0 4.264265498932218e-06
of O 0 7.471078333765035e-08
these O 0 2.192652814869689e-08
data O 0 9.949621215810112e-08
indicate O 0 1.6028492666464444e-07
that O 0 5.6871645170986085e-09
the O 0 1.7788948980523855e-08
added O 0 5.441149255602795e-07
heterodimer O 0 0.0010869172401726246
substantially O 0 1.920345312100835e-05
reduced O 0 4.7311914386227727e-07
the O 0 1.3708059576345022e-08
affinity O 0 9.59726094151847e-07
of O 0 2.3457334918930428e-07
TfR O 0 0.03624308481812477
for O 0 5.9304406931914855e-06
transferrin O 0 0.07890283316373825
. O 0 2.9437875127769075e-05

These O 0 1.2935278164150077e-06
results O 0 7.880252610448224e-07
establish O 0 3.979012888066791e-07
a O 0 3.3705128998917644e-07
molecular O 0 1.534582224849146e-05
link O 0 1.092539241653867e-05
between O 0 1.1863697864100686e-06
HFE O 0 0.0361771285533905
and O 0 3.4400851944837996e-08
a O 0 3.194894304670015e-08
key O 0 1.3779840912775398e-07
protein O 0 1.31566295635821e-07
involved O 0 3.2657904824873185e-08
in O 0 5.604039188256138e-08
iron O 0 0.0007990485755726695
transport O 0 2.2562580852536485e-06
, O 0 5.458509022560065e-08
the O 0 9.111602139455499e-08
TfR O 0 0.013191722333431244
, O 0 4.622117799613079e-08
and O 0 1.0388122362314789e-08
raise O 0 2.085837280674241e-07
the O 0 9.682389112697365e-09
possibility O 0 3.1269746614270844e-07
that O 0 1.0947419859519414e-08
alterations O 0 2.9599893878184957e-06
in O 0 1.8538054646910496e-08
this O 0 1.8821944891556086e-08
regulatory O 0 1.5406105376314372e-05
mechanism O 0 8.913229407880863e-07
may O 0 4.8422013065874125e-08
play O 0 3.1547453538394166e-09
a O 0 9.015344026863659e-09
role O 0 5.325771468278617e-08
in O 0 3.984134622214697e-08
the O 0 5.019453510612948e-07
pathogenesis O 1 0.55009526014328
of O 0 0.0001432653225492686
hereditary B-Disease 1 0.9987878203392029
hemochromatosis I-Disease 1 0.9995125532150269
. O 0 0.00017126034072134644
. O 0 0.00011283728235866874

Genomic O 0 0.00011326343519613147
organization O 0 3.0487401545542525e-06
of O 0 3.18249391284553e-07
the O 0 1.668008167143853e-06
UBE3A O 1 0.6598244905471802
/ O 0 0.02984500303864479
E6 O 0 0.0729844942688942
- O 0 0.01881919801235199
AP O 0 0.0010306774638593197
gene O 0 8.84870041772956e-06
and O 0 4.259658226146712e-07
related O 0 6.229215068742633e-05
pseudogenes O 0 0.002148939296603203
. O 0 4.390009416965768e-05

The O 0 4.440583325049374e-06
UBE3A O 0 0.003513985313475132
gene O 0 2.255363142467104e-06
encodes O 0 8.319436801684787e-07
the O 0 1.5845955658733146e-07
E6 O 0 0.0003789412439800799
- O 0 0.00022822209575679153
AP O 0 6.927387585164979e-05
ubiquitin O 0 3.340698094689287e-05
- O 0 3.302381082903594e-05
protein O 0 5.049220703767787e-07
ligase O 0 8.790036190475803e-06
and O 0 2.6446977940963734e-08
has O 0 4.776504525239034e-08
recently O 0 2.9374430710049637e-07
been O 0 3.983008145524991e-09
shown O 0 2.346175875800327e-08
to O 0 4.0614359875235095e-08
be O 0 1.0169530924031278e-06
mutated O 0 0.44032832980155945
in O 0 0.40834593772888184
Angelman B-Disease 1 0.9998251795768738
syndrome I-Disease 1 0.9999161958694458
patients O 1 0.9921749234199524
who O 0 7.116244523786008e-05
lack O 0 0.000684092054143548
15q11 O 0 0.4682682454586029
- O 0 0.08085308969020844
q13 O 0 0.02086705155670643
deletions O 0 0.00010856357403099537
or O 0 1.378888782710419e-06
chromosome O 0 0.00012767357111442834
15 O 0 1.762594183674082e-05
paternal O 0 0.01185243297368288
uniparental B-Disease 1 0.9860068559646606
disomy I-Disease 1 0.6721614003181458
. O 0 0.00010296093387296423

Previous O 0 4.788606020156294e-05
UBE3A O 0 0.008027835749089718
cDNA O 0 3.19270184263587e-05
analysis O 0 1.8154153167415643e-06
has O 0 2.3844285124141607e-07
shown O 0 1.94881039305983e-07
a O 0 2.0192582894651423e-07
coding O 0 1.4964201909606345e-05
region O 0 2.620551242671354e-07
of O 0 2.3876726373828205e-08
approximately O 0 4.038979852794e-07
2 O 0 4.192225787846837e-06
. O 0 4.513584372034529e-06

6 O 0 3.030865264008753e-05
kb O 0 7.883983926149085e-05
and O 0 2.2415723321955738e-07
a O 0 1.660977630990601e-07
3 O 0 2.3207064714370063e-06
- O 0 0.0003549859975464642
untranslated O 0 0.0008709675748832524
region O 0 1.5842766742935055e-06
( O 0 2.988513472246268e-07
UTR O 0 2.654967101989314e-05
) O 0 7.298119886200993e-09
of O 0 3.173859619565178e-09
< O 0 3.265738996560685e-05
50 O 0 1.3887678562696237e-07
bp O 0 2.3412553673551884e-06
, O 0 1.1292214274760681e-08
whereas O 0 5.235637701161977e-08
Northern O 0 9.737913586604918e-09
analysis O 0 6.579520039906583e-09
has O 0 4.79188688728982e-09
indicated O 0 1.4385501678759738e-08
mRNA O 0 8.381455529615778e-09
sizes O 0 1.419078543563046e-08
of O 0 2.7920776801693137e-09
5 O 0 2.515213282094919e-07
- O 0 5.024878919357434e-05
8 O 0 4.071483544976218e-06
kb O 0 0.0003846762119792402
. O 0 3.736397047759965e-06

We O 0 7.527764296355599e-07
have O 0 8.101353188294524e-08
analyzed O 0 1.9257626604485267e-07
additional O 0 9.572053727424645e-08
cDNA O 0 5.780987521575298e-06
clones O 0 6.191443389980122e-05
and O 0 4.041252310571508e-08
provide O 0 4.1414615736812266e-08
evidence O 0 3.4332025222738594e-08
for O 0 7.49073780781373e-09
an O 0 1.6219559029195807e-08
additional O 0 5.597265158030496e-07
0 O 0 9.611507266527042e-06
. O 0 4.303271452954505e-06

5 O 0 1.162832722911844e-05
kb O 0 4.704780440079048e-05
of O 0 2.6515704121266026e-07
5 O 0 2.1400812784122536e-06
- O 0 8.230919775087386e-05
UTR O 0 0.00020456132187973708
and O 0 1.1178321557281379e-07
> O 0 9.278219295083545e-06
2 O 0 1.2871126386926335e-07
kb O 0 9.088756996789016e-06
of O 0 6.668823004929436e-08
3 O 0 8.065557267400436e-06
- O 0 0.0019849829841405153
UTR O 0 0.01478044968098402
. O 0 1.0695376658986788e-05

We O 0 1.5319470776375965e-06
have O 0 1.0681026196834864e-07
established O 0 8.204122536881187e-08
the O 0 3.152557681573853e-08
genomic O 0 3.457943876128411e-06
organization O 0 1.5368917161140416e-07
of O 0 3.139937732044018e-08
UBE3A O 0 0.002480987459421158
and O 0 9.11201603059908e-09
the O 0 3.2079050527045183e-09
sequence O 0 3.1381532039631566e-08
of O 0 9.900024622311321e-08
intron O 0 0.10923442989587784
- O 0 0.0030776397325098515
exon O 0 0.000724890676792711
borders O 0 1.5830284610274248e-05
. O 0 6.013189704390243e-06

We O 0 1.2166065062046982e-06
have O 0 8.344674995441892e-08
also O 0 1.524084680681881e-08
mapped O 0 1.4514104407226114e-07
two O 0 4.780658091618761e-09
highly O 0 1.5113425888557686e-07
homologous O 0 2.473547056069947e-06
processed O 0 4.8226331728074e-07
pseudogenes O 0 1.4358480257214978e-05
, O 0 4.4021101075486513e-07
UBE3AP1 O 0 0.0060036806389689445
and O 0 4.0267727285936417e-07
UBE3AP2 O 0 0.0013467168901115656
, O 0 1.825984163872363e-08
to O 0 3.5605527415327742e-09
chromosomes O 0 1.0870790134731578e-07
2 O 0 5.6061555397945995e-08
and O 0 6.5466729815000235e-09
21 O 0 1.028534910574308e-07
, O 0 1.888836997920862e-08
respectively O 0 6.963093568401746e-08
, O 0 8.535296025513617e-09
and O 0 5.2815920525972615e-09
determined O 0 3.702807305216993e-08
their O 0 2.822998190765702e-08
genomic O 0 5.844478073413484e-05
organization O 0 1.3929242413723841e-05
. O 0 1.035675268212799e-05

These O 0 2.1322134671208914e-06
results O 0 1.197674009745242e-06
will O 0 5.503786937310906e-08
form O 0 4.549825050048639e-08
the O 0 4.826173682914714e-09
basis O 0 4.007614240464363e-09
for O 0 8.626869885119959e-09
studies O 0 5.7133267006292954e-08
of O 0 1.3807855303582528e-08
mutation O 0 1.9122780940961093e-06
and O 0 1.4839292816759553e-07
imprinting O 0 7.031184213701636e-05
of O 0 2.1344189917726908e-06
UBE3A O 1 0.8543501496315002
. O 0 6.180612399475649e-05

Mutation O 0 0.0002358540950808674
spectrum O 0 6.68612847221084e-05
and O 0 7.099457889125915e-06
genotype O 0 0.0032259065192192793
- O 0 0.03171855956315994
phenotype O 0 0.049289751797914505
analyses O 0 0.0005773227312602103
in O 0 0.0010174231138080359
Cowden B-Disease 1 0.9981145858764648
disease I-Disease 1 0.9983924031257629
and O 0 0.0012254390167072415
Bannayan B-Disease 1 0.9973002076148987
- I-Disease 1 0.9982103109359741
Zonana I-Disease 1 0.9991255402565002
syndrome I-Disease 1 0.999415397644043
, O 0 6.491787644336e-05
two O 0 0.00010235673835268244
hamartoma B-Disease 1 0.9973477125167847
syndromes I-Disease 1 0.9968787431716919
with O 0 0.0016753210220485926
germline O 1 0.9927264451980591
PTEN O 1 0.9921918511390686
mutation O 0 0.010688149370253086
. O 0 9.678655624156818e-05

The O 0 0.00024699445930309594
tumour B-Disease 1 0.9919473528862
suppressor O 0 0.3492482304573059
gene O 0 0.0017157656839117408
PTEN O 0 0.2743663191795349
, O 0 4.1948143802983395e-07
which O 0 6.591091050722753e-08
maps O 0 1.3026888154854532e-06
to O 0 8.660197750032239e-07
10q23 O 0 0.0049449182115495205
. O 0 2.3432265152223408e-05

3 O 0 2.46751073973428e-06
and O 0 8.35990547898291e-08
encodes O 0 1.498609094596759e-07
a O 0 2.692141976012863e-08
403 O 0 3.9516604033451586e-07
amino O 0 2.5431335259895604e-08
acid O 0 2.9857898198315524e-07
dual O 0 1.4396485426004801e-07
specificity O 0 4.7612917342121364e-07
phosphatase O 0 0.0001282163430005312
( O 0 8.613423574388435e-08
protein O 0 6.174644795464701e-08
tyrosine O 0 1.5048559589558863e-06
phosphatase O 0 0.0006777839735150337
; O 0 8.866286407283042e-07
PTPase O 0 0.000548903422895819
) O 0 1.0268080075093167e-07
, O 0 1.1677608213744861e-08
was O 0 1.1283494139036065e-08
shown O 0 1.380672287609741e-08
recently O 0 2.8582803679455537e-08
to O 0 1.4482235410895328e-09
play O 0 3.4245810631716722e-09
a O 0 4.211987203461831e-08
broad O 0 1.4881122297083493e-05
role O 0 1.8274323565492523e-06
in O 0 4.3408299461589195e-06
human O 0 0.0005158789572305977
malignancy B-Disease 1 0.9962562322616577
. O 0 9.231692820321769e-05

Somatic O 0 0.01938154734671116
PTEN O 0 0.3422541320323944
deletions O 0 0.0002057392557617277
and O 0 1.718765020086721e-06
mutations O 0 7.709963938395958e-06
were O 0 2.9231451037503575e-08
observed O 0 5.180151561035018e-07
in O 0 1.3140634109731764e-06
sporadic B-Disease 0 0.05793372169137001
breast I-Disease 1 0.9989281296730042
, I-Disease 0 0.007557394448667765
brain I-Disease 1 0.998187243938446
, I-Disease 0 0.12233057618141174
prostate I-Disease 1 0.9997426867485046
and I-Disease 1 0.8779320120811462
kidney I-Disease 1 0.9998718500137329
cancer I-Disease 1 0.9996891021728516
cell O 0 0.02391701377928257
lines O 0 1.4829668543825392e-05
and O 0 1.130352060840778e-07
in O 0 9.965385316945685e-08
several O 0 7.603943004141911e-07
primary O 0 0.0008975446107797325
tumours B-Disease 1 0.9970033764839172
such O 0 2.7160322133568116e-05
as O 0 0.0068160416558384895
endometrial B-Disease 1 0.9986610412597656
carcinomas I-Disease 1 0.9993909597396851
, O 1 0.9925123453140259
malignant B-Disease 1 0.9997076392173767
melanoma I-Disease 1 0.9997813105583191
and O 1 0.9928597807884216
thyroid B-Disease 1 0.9993864297866821
tumours I-Disease 1 0.9980263113975525
. O 0 0.0029862725641578436

In O 0 8.99663154996233e-06
addition O 0 1.4985481357143726e-05
, O 0 1.50804735312704e-05
PTEN O 0 0.18521648645401
was O 0 3.41486497745791e-07
identified O 0 2.9052924332972907e-07
as O 0 1.8769460652379166e-08
the O 0 8.03240780555825e-08
susceptibility O 0 0.0002677877200767398
gene O 0 3.874119556712685e-06
for O 0 1.4291935030996683e-06
two O 0 0.00027185690123587847
hamartoma B-Disease 1 0.9992104768753052
syndromes I-Disease 1 0.9995138645172119
Cowden B-Disease 1 0.9995129108428955
disease I-Disease 1 0.9992572665214539
( O 0 0.00012112236436223611
CD B-Disease 0 0.00035985480644740164
; O 0 2.0736504666274413e-05
MIM O 0 0.09594845771789551
158350 O 0 0.0008406581473536789
) O 0 2.0786389143268025e-07
and O 0 1.5063666580772406e-07
Bannayan B-Disease 0 0.00478534959256649
- I-Disease 0 0.006611338816583157
Zonana I-Disease 1 0.7200701832771301
( I-Disease 0 6.7980845415149815e-06
BZS I-Disease 0 0.013207699172198772
) I-Disease 0 5.580290007856092e-07
or I-Disease 0 1.1672841537802014e-06
Ruvalcaba I-Disease 0 0.3804774880409241
- I-Disease 0 0.0413421206176281
Riley I-Disease 0 0.08512812107801437
- I-Disease 1 0.9554682374000549
Smith I-Disease 1 0.8969154357910156
syndrome I-Disease 1 0.9991125464439392
( O 0 0.0004857434832956642
MIM O 1 0.9149830937385559
153480 O 0 0.04918398708105087
) O 0 9.093490916711744e-06
. O 0 5.23702419741312e-06

Constitutive O 0 0.0002217398287029937
DNA O 0 9.050785592989996e-06
from O 0 6.109335117798764e-07
37 O 0 2.6756947590911295e-06
CD B-Disease 0 4.53842903880286e-06
families O 0 4.254603709341609e-07
and O 0 6.612749103851456e-08
seven O 0 1.5401710697915405e-06
BZS B-Disease 0 0.17390532791614532
families O 0 1.1908120995940408e-06
was O 0 3.2149853268492734e-07
screened O 0 1.3676084563485347e-05
for O 0 6.357033726089867e-06
germline O 1 0.6468189358711243
PTEN O 1 0.9690551161766052
mutations O 0 0.0014441594248637557
. O 0 2.473719541740138e-05

PTEN O 0 0.4320003390312195
mutations O 0 6.573444989044219e-05
were O 0 1.0325822330514711e-07
identified O 0 1.2082473688224127e-07
in O 0 1.472018418269272e-08
30 O 0 2.8684551622859544e-08
of O 0 7.444305172299437e-09
37 O 0 6.64309538933594e-07
( O 0 2.697269394502655e-07
81 O 0 2.7081100597570185e-06
% O 0 7.471392393654241e-08
) O 0 4.168597200759905e-08
CD B-Disease 0 6.139461561360804e-07
families O 0 8.949558605308994e-08
, O 0 9.049213822720503e-09
including O 0 4.3937887994616176e-08
missense O 0 1.766525201674085e-05
and O 0 8.274684404341315e-08
nonsense O 0 8.110851922538131e-06
point O 0 1.1824441514818318e-07
mutations O 0 1.2509868838606053e-06
, O 0 2.1229233482245036e-08
deletions O 0 1.2896380212623626e-06
, O 0 3.4176462548884956e-08
insertions O 0 1.7570069985595183e-06
, O 0 4.621800542281562e-08
a O 0 1.789780981198419e-07
deletion O 0 0.00017839235079009086
/ O 0 0.0004651906492654234
insertion O 0 5.481589596456615e-06
and O 0 1.983309232400643e-07
splice O 0 0.00012453932140488178
site O 0 5.688420515070902e-06
mutations O 0 4.27106351708062e-05
. O 0 6.355081495712511e-06

These O 0 1.5945020095387008e-06
mutations O 0 7.539945272583282e-06
were O 0 1.6740647978963352e-08
scattered O 0 2.3300241025481228e-07
over O 0 4.17502654670443e-08
the O 0 1.2804104443375763e-08
entire O 0 9.670211653656224e-08
length O 0 1.7119516826369363e-07
of O 0 4.428157041047598e-08
PTEN O 0 0.02361399680376053
, O 0 2.372491891833306e-08
with O 0 1.0562524188628686e-08
the O 0 7.94703503004257e-09
exception O 0 4.2902879471284905e-08
of O 0 1.1738588989729237e-09
the O 0 2.948701283145283e-09
first O 0 8.693817221683275e-09
, O 0 1.689893558420863e-08
fourth O 0 1.2083857825473387e-07
and O 0 5.4766548629459066e-08
last O 0 1.1027768778149039e-06
exons O 0 4.8265254008583724e-05
. O 0 5.648623300658073e-06

A O 0 9.250142284145113e-06
hot O 0 2.7427924578660168e-05
spot O 0 2.595510068204021e-06
for O 0 7.256785465870053e-07
PTEN O 0 0.1584993600845337
mutation O 0 4.410188466863474e-06
in O 0 3.7950876219383645e-08
CD B-Disease 0 3.4271749882464064e-06
was O 0 3.942768245224215e-08
identified O 0 4.287040766826067e-08
in O 0 1.3395009546002257e-08
exon O 0 8.732726200832985e-06
5 O 0 3.7785547135626985e-08
that O 0 7.669658796949363e-10
contains O 0 6.6844965118662e-09
the O 0 8.791466221680366e-09
PTPase O 0 0.0001392435806337744
core O 0 3.9044266486598644e-07
motif O 0 7.775583981128875e-07
, O 0 2.514496610928063e-09
with O 0 1.7896207848977497e-09
13 O 0 6.8816663478799e-09
of O 0 1.406297966966008e-09
30 O 0 3.754230348818055e-08
( O 0 3.675463489116737e-08
43 O 0 6.469996804980838e-08
% O 0 1.4258885627782547e-08
) O 0 3.567869200082896e-08
CD B-Disease 0 2.432273959129816e-06
mutations O 0 6.685123707939056e-07
identified O 0 4.117101326528427e-08
in O 0 2.32514434372888e-08
this O 0 1.591805158795978e-07
exon O 0 0.0005903231212869287
. O 0 1.0482182005944196e-05

Seven O 0 7.913803869996627e-07
of O 0 1.3901087925205502e-07
30 O 0 6.496899800367828e-07
( O 0 7.015122491793591e-07
23 O 0 2.007763697520204e-07
% O 0 3.1815829970582854e-08
) O 0 4.355571014968973e-09
were O 0 1.3158982237193584e-10
within O 0 2.5485646926171057e-10
the O 0 1.907768609754612e-09
core O 0 3.4972532603205764e-07
motif O 0 1.2848870483139763e-06
, O 0 5.762704091694104e-09
the O 0 3.924601976734721e-09
majority O 0 3.2593874266240164e-08
( O 0 1.2029696350168706e-08
five O 0 1.0782624793037598e-09
of O 0 1.4791720071016812e-09
seven O 0 1.8004509882985076e-08
) O 0 6.9497958499198376e-09
of O 0 8.137134299701643e-10
which O 0 4.336646153291213e-09
were O 0 9.136902789919077e-09
missense O 0 0.00013841580948792398
mutations O 0 5.272303042147541e-06
, O 0 6.64618156065444e-08
possibly O 0 6.246679049581871e-07
pointing O 0 8.981045311884372e-07
to O 0 3.6354486088185922e-09
the O 0 4.82902784426642e-09
functional O 0 1.955807391595954e-07
significance O 0 9.095870012743035e-08
of O 0 2.1454784615571043e-08
this O 0 2.5522794544485805e-07
region O 0 3.436450788285583e-05
. O 0 1.8682063455344178e-05

Germline O 1 0.9216445684432983
PTEN O 1 0.9181396961212158
mutations O 0 7.98624096205458e-05
were O 0 5.9277891040210307e-08
identified O 0 1.0547591244858268e-07
in O 0 4.717091606210033e-09
four O 0 2.8695208431628316e-09
of O 0 3.8550114211943765e-09
seven O 0 9.848345428054017e-08
( O 0 5.779415914730635e-07
57 O 0 4.514487955020741e-06
% O 0 5.223090511208284e-07
) O 0 1.6500537185493158e-06
BZS B-Disease 0 0.041679270565509796
families O 0 2.64787558990065e-06
studied O 0 8.991056347440463e-06
. O 0 8.057692866714206e-06

Interestingly O 0 0.0006187921389937401
, O 0 1.4722058949701022e-06
none O 0 2.782712158477807e-07
of O 0 1.8196566031747352e-08
these O 0 7.472689134147004e-08
mutations O 0 4.769949555338826e-06
was O 0 6.697555221535367e-08
observed O 0 9.510252141353703e-08
in O 0 3.824247585271223e-08
the O 0 1.7115991113314521e-07
PTPase O 0 0.004209491424262524
core O 0 3.97433977923356e-05
motif O 0 0.00016878338647074997
. O 0 1.2065439477737527e-05

It O 0 8.673098932376888e-07
is O 0 1.4157646432977344e-07
also O 0 6.02313647846131e-08
worthy O 0 4.4022783640684793e-07
of O 0 8.815881358259503e-09
note O 0 3.389382356999704e-07
that O 0 2.5069015752166024e-09
a O 0 6.52838050285709e-09
single O 0 2.2299790458646385e-08
nonsense O 0 3.7870652249694103e-06
point O 0 1.229462895935285e-07
mutation O 0 1.7997631402977277e-06
, O 0 8.534973972018634e-08
R233X O 0 0.00019780549337156117
, O 0 3.434604423091514e-08
was O 0 1.2923567993539109e-08
observed O 0 1.5856985058348982e-08
in O 0 2.863495662808191e-09
the O 0 2.263748477560057e-08
germline O 0 4.20977667090483e-05
DNA O 0 1.0410381889869313e-07
from O 0 6.554019105209363e-09
two O 0 1.0119379112438764e-08
unrelated O 0 1.1980408999079373e-05
CD B-Disease 0 1.8102158719557337e-05
families O 0 7.527225989178987e-07
and O 0 1.97120911593629e-07
one O 0 1.2565049019030994e-06
BZS B-Disease 1 0.5992785692214966
family O 0 8.244430500781164e-05
. O 0 2.4542636310798116e-05

Genotype O 0 0.22703218460083008
- O 0 0.09559793770313263
phenotype O 0 0.006821705028414726
studies O 0 2.4945693439804018e-06
were O 0 1.833998197753317e-08
not O 0 5.97427884940771e-09
performed O 0 1.1333340488306476e-08
on O 0 2.871590298880733e-09
this O 0 5.52393464303691e-09
small O 0 7.27306783687709e-08
group O 0 3.785696947034012e-07
of O 0 7.008167699495971e-07
BZS B-Disease 1 0.678484320640564
families O 0 3.802658829954453e-05
. O 0 2.31019457714865e-05

However O 0 1.0565269803919364e-05
, O 0 8.343929948750883e-06
genotype O 0 0.0009566948865540326
- O 0 0.0014845187542960048
phenotype O 0 0.0003327967715449631
analysis O 0 1.0137944173038704e-06
inthe O 0 0.00016446686640847474
group O 0 2.089412873829133e-07
of O 0 2.6087759508186537e-08
CD B-Disease 0 2.522921931813471e-05
families O 0 1.012339566841547e-06
revealed O 0 8.095883003989002e-07
two O 0 4.619885807244373e-09
possible O 0 4.9673566593355645e-08
associations O 0 1.2776858682173042e-07
worthy O 0 2.1522706106225087e-07
of O 0 9.362662645173714e-09
follow O 0 5.174157422516146e-07
- O 0 1.95338943740353e-05
up O 0 9.859096650188803e-08
in O 0 7.132203450055385e-08
independent O 0 2.866235604415124e-07
analyses O 0 1.030801831802819e-05
. O 0 7.026852017588681e-06

The O 0 1.1787089988501975e-06
first O 0 4.6437497758233803e-07
was O 0 3.9439649412997824e-07
an O 0 2.0056661753642402e-07
association O 0 1.9905523004126735e-05
noted O 0 3.9946053220774047e-07
in O 0 1.0393573113276489e-08
the O 0 8.68044569557469e-09
group O 0 9.344986295900526e-08
of O 0 5.7307776302195634e-08
CD B-Disease 0 0.00030059946584515274
families O 0 0.0002142845478374511
with O 0 0.05595703050494194
breast B-Disease 1 0.9993709921836853
disease I-Disease 1 0.9990079998970032
. O 0 0.0008737238822504878

A O 0 4.910262305202195e-06
correlation O 0 3.199955472155125e-06
was O 0 1.4692336947064177e-07
observed O 0 1.4005387072302256e-07
between O 0 4.682278031964415e-08
the O 0 7.484171504756887e-08
presence O 0 3.633988853835035e-06
/ O 0 0.0005559137789532542
absence O 0 5.460789225253393e-07
of O 0 2.0556816693328983e-08
a O 0 3.2310620099451626e-06
PTEN O 0 0.4730129837989807
mutation O 0 2.9844738946849247e-06
and O 0 1.4225038924564615e-08
the O 0 4.5784656066416574e-08
type O 0 1.6284788216580637e-05
of O 0 1.5331280565078487e-06
breast O 1 0.9953586459159851
involvement O 0 0.001275116577744484
( O 0 0.0007248823530972004
unaffected O 0 0.14719857275485992
versus O 1 0.7525860071182251
benign O 1 0.9970797896385193
versus O 1 0.9927256107330322
malignant O 1 0.9985377788543701
) O 0 0.00016196361684706062
. O 0 3.402082438697107e-05

Specifically O 0 1.1270016329945065e-05
and O 0 3.566842394775449e-07
more O 0 6.220296455694552e-08
directly O 0 2.4286669031425845e-07
, O 0 2.7697760174305586e-07
an O 0 2.101679399402201e-07
association O 0 1.7017639038385823e-05
was O 0 8.59233892924749e-08
also O 0 1.278341077437517e-08
observed O 0 1.3209718652262836e-08
between O 0 7.999318540896638e-09
the O 0 4.283376764391278e-09
presence O 0 4.140687437370616e-08
of O 0 3.933589454163666e-08
a O 0 3.3133332181023434e-05
PTEN O 1 0.9928985834121704
mutation O 0 0.14789263904094696
and O 0 0.06979383528232574
malignant B-Disease 1 0.9994215965270996
breast I-Disease 1 0.9992474317550659
disease I-Disease 1 0.9986411929130554
. O 0 0.004112090449780226

Secondly O 0 0.0011940429685637355
, O 0 6.137539912742795e-06
there O 0 5.238334779278375e-07
appeared O 0 1.3288533864397323e-06
to O 0 3.898907863231216e-08
be O 0 8.302552423344878e-09
an O 0 7.041276717245637e-08
interdependent O 0 0.00046646504779346287
association O 0 9.698732355900574e-06
between O 0 1.5941203912461788e-07
mutations O 0 1.8589593082651845e-06
upstream O 0 2.731808592670859e-07
and O 0 2.4582824664776126e-09
within O 0 1.6297014848731806e-09
the O 0 1.275939265354964e-08
PTPase O 0 0.0004101371159777045
core O 0 1.2087078857803135e-06
motif O 0 3.6674950933957007e-06
, O 0 7.422187753292064e-09
the O 0 2.4992246050459244e-09
core O 0 1.604911119557073e-07
motif O 0 4.132262461098435e-07
containing O 0 2.093241668887913e-08
the O 0 6.383478634575113e-09
majority O 0 3.865416786652531e-08
of O 0 2.6138909703377067e-08
missense O 0 0.000320115388603881
mutations O 0 4.795803306478774e-06
, O 0 2.828776324292903e-08
and O 0 7.790115219563631e-09
the O 0 5.745133702106386e-09
involvement O 0 1.6824009207994095e-07
of O 0 4.4403845045337675e-09
all O 0 2.562825329732732e-08
major O 0 4.0339033148484305e-05
organ O 0 0.2143554836511612
systems O 0 0.0005433213082142174
( O 0 7.6173364504938945e-06
central O 0 1.0964504326693714e-05
nervous O 0 0.042729806154966354
system O 0 0.0004364165070001036
, O 0 0.0011816307669505477
thyroid O 1 0.9996304512023926
, O 0 0.007277831435203552
breast O 1 0.9995157718658447
, O 0 0.023898109793663025
skin O 1 0.9993102550506592
and O 0 0.0578971728682518
gastrointestinal O 1 0.999283492565155
tract O 1 0.9977098703384399
) O 0 0.00029358940082602203
. O 0 4.995123890694231e-05

However O 0 3.853268026432488e-06
, O 0 2.3565141304970894e-07
these O 0 2.053455716577446e-08
observations O 0 1.1069625571735742e-07
would O 0 2.0023707136829216e-08
need O 0 3.5974299095187234e-08
to O 0 4.486414795223936e-09
be O 0 1.6586966244958035e-09
confirmed O 0 3.6499368860631876e-08
by O 0 3.115191660185701e-09
studying O 0 3.513257951226478e-08
a O 0 1.9686890340153695e-08
larger O 0 8.017376984525981e-08
number O 0 6.871501589955642e-09
of O 0 3.4348072830425735e-08
CD B-Disease 0 9.822408901527524e-05
families O 0 1.354766391159501e-05
. O 0 1.137413528340403e-05

Molecular O 0 0.013727271929383278
defects O 0 0.44312140345573425
leading O 0 1.1567736692086328e-05
to O 0 5.876163982065918e-07
human O 0 1.2458122910175007e-05
complement B-Disease 0 0.00045145326294004917
component I-Disease 0 0.1553654670715332
C6 I-Disease 1 0.9992974996566772
deficiency I-Disease 1 0.9993075132369995
in O 0 3.8920208567105874e-07
an O 0 4.117157175187458e-07
African O 0 4.463571895030327e-05
- O 0 0.005656243301928043
American O 0 2.3422146114171483e-05
family O 0 5.86294372624252e-05
. O 0 1.8271732187713496e-05

Complement B-Disease 0 0.0019471843261271715
component I-Disease 0 0.30515894293785095
C6 I-Disease 1 0.9968157410621643
deficiency I-Disease 1 0.9987548589706421
( O 0 0.0006929311784915626
C6D B-Disease 1 0.7555933594703674
) O 0 2.4724840841372497e-05
was O 0 1.0802908946061507e-05
diagnosed O 0 0.36852285265922546
in O 0 2.658788744724916e-08
a O 0 6.427095655681114e-08
16 O 0 6.671971277683042e-07
- O 0 7.571037713205442e-05
year O 0 1.6482356386404717e-06
- O 0 7.936135079944506e-05
old O 0 1.179469472845085e-05
African O 0 1.4098288374952972e-05
- O 0 0.0016146117122843862
American O 0 1.5873250958975405e-05
male O 0 0.00015936711861286312
with O 0 0.0014509836910292506
meningococcal B-Disease 1 0.9980525970458984
meningitis I-Disease 1 0.9975011944770813
. O 0 0.0005634360713884234

The O 0 0.00010776833369163796
patients O 0 0.03802467882633209
father O 0 1.3434226275421679e-05
and O 0 2.6698475608100125e-07
two O 0 7.618287156674342e-08
brothers O 0 1.5154577340581454e-05
also O 0 2.7979442052128434e-07
had O 0 8.677054097461223e-07
C6D B-Disease 0 0.08106474578380585
, O 0 1.0037913966698397e-07
but O 0 2.0755697605068235e-08
gave O 0 1.1899851415364537e-07
no O 0 8.700224185531624e-08
history O 0 1.10039843548293e-06
of O 0 3.7460877138073556e-06
meningitis B-Disease 1 0.9985823631286621
or O 0 1.899970811791718e-05
other O 0 2.8607119020307437e-05
neisserial B-Disease 1 0.9956165552139282
infection I-Disease 1 0.995093822479248
. O 0 0.00015645708481315523

By O 0 8.667154247632425e-07
using O 0 5.23431026522303e-07
exon O 0 6.228656275197864e-05
- O 0 2.589070390968118e-05
specific O 0 1.884188662870656e-07
polymerase O 0 2.5232371626771055e-05
chain O 0 1.3847417903889436e-05
reaction O 0 3.6063793231733143e-06
( O 0 3.164643089803576e-07
PCR O 0 4.001955403509783e-06
) O 0 9.537518508295761e-08
/ O 0 2.6197515126114013e-06
single O 0 1.0393909732897555e-08
- O 0 2.9463581086019985e-06
strand O 0 6.092067224017228e-07
conformation O 0 1.8645827992713748e-07
polymorphism O 0 1.3989262015456916e-07
as O 0 1.5936112429670857e-09
a O 0 6.875080060808614e-09
screening O 0 1.9155145025706588e-07
step O 0 1.0574236597449271e-08
and O 0 7.372968902075172e-10
nucleotide O 0 4.221709204443869e-09
sequencing O 0 5.903651789651576e-09
of O 0 6.582466793858543e-10
target O 0 3.607448206821573e-08
exons O 0 7.718960546299058e-07
, O 0 7.508475619033561e-09
we O 0 1.1669253341395347e-09
determined O 0 4.973525591367434e-09
that O 0 1.7829668852442637e-09
the O 0 1.1175950831443515e-08
proband O 0 6.786253652535379e-05
was O 0 1.3626154427015535e-08
a O 0 2.4649555285805036e-08
compound O 0 2.213479092461057e-06
heterozygote O 0 4.989272929378785e-05
for O 0 6.249229045351967e-08
two O 0 6.566796741935832e-07
C6 O 1 0.7581451535224915
gene O 0 0.00017184740863740444
mutations O 0 6.664422835456207e-05
. O 0 6.897858838783577e-06

The O 0 5.721864795305009e-07
first O 0 1.8274586466304754e-07
, O 0 2.502293341422046e-07
1195delC O 0 5.195850462769158e-05
located O 0 9.890965912973115e-08
in O 0 3.6593053920341845e-08
exon O 0 3.633358937804587e-05
7 O 0 6.123158868831524e-07
, O 0 2.0706943715254056e-08
is O 0 3.1736659966696834e-09
a O 0 1.8518337085993153e-08
novel O 0 9.460965770813345e-07
mutation O 0 5.022393452236429e-07
, O 0 2.8488034153895114e-09
while O 0 1.9464427847282195e-09
the O 0 1.2379044456167776e-09
second O 0 8.358530756424898e-09
, O 0 3.526308844925552e-08
1936delG O 0 3.523017221596092e-05
in O 0 4.070921377774539e-08
exon O 0 1.9889394025085494e-05
12 O 0 1.339005848421948e-07
, O 0 2.697019318986804e-08
has O 0 1.4616611032636229e-08
been O 0 3.6737448638746173e-09
described O 0 2.3570918017412623e-07
before O 0 1.0899129421204634e-07
to O 0 9.575961712471326e-08
cause O 0 4.404526771395467e-05
C6D B-Disease 0 0.010551424697041512
in O 0 8.559656805573468e-08
an O 0 1.5881114734384028e-07
unrelated O 0 6.444466271204874e-05
African O 0 4.8251404223265126e-05
- O 0 0.0020496314391493797
American O 0 3.902858225046657e-06
individual O 0 1.7899104705065838e-06
. O 0 9.418668923899531e-06

Both O 0 7.785529305692762e-06
mutations O 0 8.742093632463366e-05
result O 0 8.764589438214898e-06
in O 0 2.491122131687007e-06
premature O 0 0.017513995990157127
termination O 0 0.0015119776362553239
codons O 0 8.212401007767767e-05
and O 0 3.815741365542635e-06
C6 O 0 0.36188557744026184
null O 0 9.93362336885184e-05
alleles O 0 0.00012274595792405307
. O 0 1.5435856766998768e-05

Allele O 0 0.00022753399389330298
- O 0 0.00011051617184421048
specific O 0 1.0495989499759162e-06
PCR O 0 4.897468170383945e-05
indicated O 0 9.276788546230819e-07
that O 0 9.493013486405744e-09
the O 0 2.339508675675006e-08
probands O 0 0.0001818536693463102
two O 0 4.1410114448581226e-08
brothers O 0 1.9611503375926986e-05
also O 0 3.595249324916949e-07
inherited O 0 0.0015543632907792926
the O 0 2.1890345180963777e-07
1195delC O 0 0.0028296136297285557
mutation O 0 2.8967981506866636e-06
from O 0 1.328058196747861e-08
their O 0 8.629288394956802e-09
heterozygous O 0 4.4186290324432775e-06
mother O 0 3.306756980236969e-06
and O 0 2.131858245491003e-08
the O 0 6.957504439242257e-08
1936delG O 0 0.0014512034831568599
mutation O 0 2.163759518225561e-06
from O 0 2.6076664383367643e-08
their O 0 5.170950956312481e-08
homozygous O 0 3.52682254742831e-05
father O 0 1.9913288269890472e-05
. O 0 1.733663225422788e-06
. O 0 1.1336775060044602e-05

PAX6 O 1 0.9228482246398926
mutations O 0 0.008351970463991165
reviewed O 0 0.0011644436744973063
. O 0 0.00024566444335505366

Mutations O 0 0.0006621941574849188
in O 0 6.226829100342002e-06
PAX6 O 0 0.37398314476013184
are O 0 2.454381728966837e-07
responsible O 0 2.7382432108424837e-06
for O 0 5.673417717844131e-07
human O 0 3.031047344848048e-05
aniridia B-Disease 1 0.8588226437568665
and O 0 2.1580007114607724e-07
have O 0 3.109067492346185e-08
also O 0 1.763503476581718e-08
been O 0 1.3092227746369645e-08
found O 0 1.745061126712244e-07
in O 0 3.1572417356073856e-06
patients O 0 0.15745705366134644
with O 0 0.00013756660337094218
Peters B-Disease 1 0.998018741607666
anomaly I-Disease 1 0.9974006414413452
, O 0 0.0023656690027564764
with O 1 0.5125797986984253
congenital B-Disease 1 0.9998725652694702
cataracts I-Disease 1 0.9997691512107849
, O 0 0.00045204017078503966
with O 0 0.0017726091900840402
autosomal B-Disease 1 0.9980596899986267
dominant I-Disease 1 0.8982342481613159
keratitis I-Disease 1 0.9986183643341064
, O 0 3.206609471817501e-05
and O 0 6.035618753230665e-06
with O 0 0.00011761565110646188
isolated B-Disease 1 0.6436005234718323
foveal I-Disease 1 0.9966603517532349
hypoplasia I-Disease 1 0.996720016002655
. O 0 0.0007621547556482255

No O 0 9.88933152257232e-06
locus O 0 2.9116685254848562e-05
other O 0 1.4908771106547647e-07
than O 0 5.517797490028897e-07
chromosome O 0 0.0001469193957746029
11p13 O 0 0.0014209630899131298
has O 0 1.9448371801900066e-07
been O 0 5.1608910922595896e-08
implicated O 0 4.1058192437049e-05
in O 0 1.2726163731713314e-06
aniridia B-Disease 0 0.4098089337348938
, O 0 4.942265832141857e-07
and O 0 7.773908237140859e-07
PAX6 O 0 0.32253164052963257
is O 0 8.377686810945306e-08
clearly O 0 1.5737703051854623e-07
the O 0 2.707290924774952e-08
major O 0 1.6229698758252198e-06
, O 0 1.1096853569370069e-07
if O 0 2.3471248056239347e-08
not O 0 2.5127322444973288e-09
only O 0 8.920276961532636e-09
, O 0 1.3935466824932519e-07
gene O 0 4.081225597474258e-06
responsible O 0 5.783579126728e-06
. O 0 9.483256690145936e-06

Twenty O 0 1.3944141755928285e-05
- O 0 3.540402394719422e-05
eight O 0 4.6822694343973126e-07
percent O 0 5.02252760270494e-07
of O 0 4.46884129701175e-08
identified O 0 4.820885806111619e-06
PAX6 O 0 0.22873733937740326
mutations O 0 1.035594232234871e-05
are O 0 4.753347226937876e-08
C O 0 0.00035996714723296463
- O 0 0.0026429619174450636
T O 0 0.008624296635389328
changes O 0 9.579962068073655e-08
at O 0 1.1796080912063189e-07
CpG O 0 6.658044731011614e-05
dinucleotides O 0 0.00010347708303015679
, O 0 1.1913676267738538e-08
20 O 0 7.848967698009801e-09
% O 0 3.0802380646122174e-09
are O 0 4.092466643346171e-10
splicing O 0 1.767855337675428e-07
errors O 0 2.079957539535826e-07
, O 0 5.629265054096777e-09
and O 0 1.6119102719258649e-09
more O 0 9.669244294130408e-10
than O 0 5.0611252966348275e-09
30 O 0 5.4140890881626547e-08
% O 0 1.471965038746248e-08
are O 0 3.3456271086862444e-09
deletion O 0 9.572887393005658e-06
or O 0 2.4846633550623665e-07
insertion O 0 2.1151841792743653e-05
events O 0 2.7380708615964977e-06
. O 0 7.833483323338442e-06

There O 0 2.331345285710995e-06
is O 0 5.165430820852634e-07
a O 0 1.6481051261507673e-06
noticeably O 0 0.0014242097968235612
elevated O 0 0.0007774626137688756
level O 0 2.649540533639083e-07
of O 0 1.5904994654647453e-08
mutation O 0 1.1676048643494141e-06
in O 0 6.956028641980083e-09
the O 0 1.196194876484924e-08
paired O 0 2.2429737782658776e-06
domain O 0 1.1835407320859304e-07
compared O 0 1.2546065875085333e-07
with O 0 8.548150631781937e-09
the O 0 7.706336013768578e-09
rest O 0 4.504947526129399e-08
of O 0 1.4315512331108948e-08
the O 0 3.488865161216381e-07
gene O 0 4.5150562073104084e-05
. O 0 6.022796242177719e-06

Increased O 0 1.7810014469432645e-05
mutation O 0 7.812697731424123e-06
in O 0 9.400924483315976e-08
the O 0 9.923144972390219e-08
homeodomain O 0 0.00045336241601035
is O 0 1.9926172711848267e-08
accounted O 0 9.680287149649303e-08
for O 0 4.711283363434404e-09
by O 0 8.68100880069278e-09
the O 0 7.77186386358153e-08
hypermutable O 0 0.0030226572416722775
CpG O 0 0.0003564509970601648
dinucleotide O 0 0.00012910287478007376
in O 0 1.0069958022995706e-07
codon O 0 2.9846960387658328e-06
240 O 0 6.8074009504925925e-06
. O 0 2.665130978130037e-06

Very O 0 2.8379474770190427e-06
nearly O 0 7.97311997757788e-07
all O 0 1.20350719612361e-07
mutations O 0 5.176444028620608e-05
appear O 0 3.035632516912301e-06
to O 0 3.96568566429778e-07
cause O 0 0.0005663127521984279
loss O 0 2.6980103939422406e-05
of O 0 1.0649734427659041e-08
function O 0 1.9772425474684496e-08
of O 0 4.110916052013636e-09
the O 0 3.3812071364991425e-08
mutant O 0 1.6882953786989674e-05
allele O 0 1.4588307521989918e-06
, O 0 6.554131903868665e-09
and O 0 7.97151789022621e-10
more O 0 5.615182208096314e-10
than O 0 2.919711139526271e-09
80 O 0 4.0216523444769336e-08
% O 0 7.198964535604091e-09
of O 0 7.015374503538396e-09
exonic O 0 0.00016487417451571673
substitutions O 0 2.680235695606825e-07
result O 0 2.7317071271681925e-07
in O 0 1.5914028494989907e-07
nonsense O 0 7.549941801698878e-05
codons O 0 6.286516145337373e-05
. O 0 9.997433153330348e-06

In O 0 1.191028900393576e-06
a O 0 6.688950406896765e-07
gene O 0 2.8549568469316e-06
with O 0 9.092297403867633e-08
such O 0 1.7951126096704684e-07
extraordinarily O 0 3.408119300729595e-05
high O 0 7.225612534966785e-07
sequence O 0 7.036496896262179e-08
conservation O 0 5.273683427731157e-07
throughout O 0 1.8048968541961585e-08
evolution O 0 1.0887078616406143e-07
, O 0 2.4595030012619645e-08
there O 0 7.314675087854994e-09
are O 0 6.1021583341869245e-09
presumed O 0 1.4523408026434481e-05
undiscovered O 0 0.0028568219859153032
missense O 0 0.0008829171420074999
mutations O 0 5.88892680752906e-06
, O 0 2.1039610942352738e-08
these O 0 1.8599957130049916e-09
are O 0 1.7472009394836618e-09
hypothesized O 0 1.1017551742042997e-06
to O 0 8.380800053942039e-09
exist O 0 2.6997932778272116e-08
in O 0 1.1331264815339637e-08
as O 0 5.2259306215773904e-08
- O 0 0.00020171416690573096
yet O 0 2.176342150050914e-06
unidentified O 0 3.821853897534311e-05
phenotypes O 0 0.002872233046218753
. O 0 2.886936044887989e-06
. O 0 1.5222945876303129e-05

Genetic O 0 0.0009922116296365857
heterogeneity O 0 0.0007928884588181973
and O 0 1.6545698144909693e-06
penetrance O 0 0.0016724858433008194
analysis O 0 3.558694743333035e-07
of O 0 5.788484713775688e-08
the O 0 1.3004037100472488e-06
BRCA1 O 0 0.017762504518032074
and O 0 9.158101420325693e-06
BRCA2 O 0 0.2730077803134918
genes O 0 0.000633705232758075
in O 0 0.010617425665259361
breast B-Disease 1 0.9995587468147278
cancer I-Disease 1 0.9991412162780762
families O 0 0.0019994396716356277
. O 0 0.0002252498088637367

The O 0 0.353260338306427
Breast B-Disease 1 0.9962815642356873
Cancer I-Disease 1 0.9959321618080139
Linkage O 0 0.2634114921092987
Consortium O 0 0.011255073361098766
. O 0 0.00021171875414438546

The O 0 1.8121600078302436e-06
contribution O 0 4.01510214942391e-06
of O 0 1.2906825759273488e-06
BRCA1 O 0 0.04024740681052208
and O 0 4.185661964584142e-05
BRCA2 O 1 0.9444034695625305
to O 0 0.014206930994987488
inherited B-Disease 1 0.9996532201766968
breast I-Disease 1 0.9998352527618408
cancer I-Disease 1 0.9997798800468445
was O 0 1.3316848708200268e-05
assessed O 0 1.8910210201283917e-05
by O 0 1.7606272706416348e-07
linkage O 0 7.159548113122582e-05
and O 0 9.820022484063884e-08
mutation O 0 2.9911245746916393e-06
analysis O 0 9.975160253361537e-08
in O 0 7.426410775224213e-08
237 O 0 4.3742544221458957e-05
families O 0 1.4328193742585427e-07
, O 0 4.500745109936588e-09
each O 0 2.8708549426603724e-10
with O 0 3.780513679885189e-09
at O 0 2.1109995529400294e-08
least O 0 1.769095980819202e-08
four O 0 1.1016798850960186e-07
cases O 0 1.9146584236295894e-05
of O 0 0.00010734279203461483
breast B-Disease 1 0.9997456669807434
cancer I-Disease 1 0.9983876943588257
, O 0 8.014622494556534e-07
collected O 0 5.63448736556893e-07
by O 0 1.0047834621218499e-05
the O 0 0.0029848814010620117
Breast B-Disease 1 0.9994284510612488
Cancer I-Disease 1 0.9990085959434509
Linkage O 0 0.1277785301208496
Consortium O 0 0.006879974156618118
. O 0 6.140927143860608e-05

Families O 0 1.7305334040429443e-05
were O 0 1.4397227232620935e-07
included O 0 1.8952177072151244e-07
without O 0 1.200595391992465e-07
regard O 0 2.0230901043305494e-07
to O 0 2.333149851097005e-08
the O 0 1.8345446051171166e-07
occurrence O 0 9.655306348577142e-05
of O 0 1.9020319086848758e-05
ovarian B-Disease 1 0.9993225336074829
or I-Disease 0 0.00026086304569616914
other I-Disease 0 0.00014071984332986176
cancers I-Disease 1 0.9966566562652588
. O 0 0.00015662306395824999

Overall O 0 0.02973717637360096
, O 0 0.0026140930131077766
disease O 1 0.995621383190155
was O 0 2.4792245767457644e-06
linked O 0 3.179848863510415e-05
to O 0 5.124246058585413e-07
BRCA1 O 0 0.0006910331430844963
in O 0 2.7894868637190484e-08
an O 0 1.5031657696340517e-08
estimated O 0 6.876577458569955e-07
52 O 0 6.145975817162252e-07
% O 0 1.5883683701645168e-08
of O 0 4.731400604640612e-09
families O 0 1.4254676727887272e-07
, O 0 3.758091793315543e-08
to O 0 3.518945135283502e-08
BRCA2 O 0 7.69018879509531e-05
in O 0 1.0949257500669773e-08
32 O 0 1.643468863221642e-07
% O 0 1.868826338125018e-08
of O 0 1.0120942306457437e-08
families O 0 3.3833237012004247e-07
, O 0 2.0762033869914376e-08
and O 0 5.1598645356421e-09
to O 0 4.426296662529694e-09
neither O 0 7.071748342468709e-08
gene O 0 9.470194584082492e-08
in O 0 6.073477720747178e-09
16 O 0 4.1344925705288915e-08
% O 0 1.634371393777201e-08
( O 0 2.356589767771311e-08
95 O 0 3.164467798910664e-08
% O 0 6.78813094623365e-09
confidence O 0 1.5251511342739832e-07
interval O 0 3.7885430970163725e-07
[ O 0 4.208255631965585e-06
CI O 0 0.0018360558897256851
] O 0 5.042791144660441e-07
6 O 0 7.252786815570289e-08
% O 0 3.013020588582549e-08
- O 0 5.707983746106038e-06
28 O 0 2.718328460105113e-07
% O 0 9.878559836806744e-08
) O 0 1.1907570751645835e-07
, O 0 5.074573650176717e-08
suggesting O 0 2.2227700355870184e-06
other O 0 2.27627708682121e-07
predisposition O 0 0.06171133369207382
genes O 0 3.270769593655132e-05
. O 0 1.5077772332006134e-05

The O 0 2.0101290374441305e-06
majority O 0 2.8548072350531584e-06
( O 0 1.5101106782822171e-06
81 O 0 5.8984260249417275e-06
% O 0 1.3822379685279884e-07
) O 0 9.599881423127954e-08
of O 0 2.243180432515146e-07
the O 0 0.0004274535458534956
breast B-Disease 1 0.9996534585952759
- I-Disease 1 0.9997181296348572
ovarian I-Disease 1 0.9999163150787354
cancer I-Disease 1 0.9997158646583557
families O 0 2.219581074314192e-05
were O 0 8.765384507114504e-08
due O 0 3.965601536037866e-06
to O 0 5.617158080895024e-07
BRCA1 O 0 0.010478000156581402
, O 0 3.514431057283218e-08
with O 0 1.3162285483758751e-08
most O 0 2.1740296674011006e-08
others O 0 1.152592403741437e-07
( O 0 2.392546605278767e-07
14 O 0 2.106065437601501e-07
% O 0 2.032639798699165e-07
) O 0 2.218364159034536e-07
due O 0 1.0684055951060145e-06
to O 0 1.164073637482943e-06
BRCA2 O 0 0.03218130022287369
. O 0 2.2898815586813726e-05

Conversely O 0 0.00029861394432373345
, O 0 1.0724993444455322e-06
the O 0 1.6147335202276736e-07
majority O 0 1.7306770416780637e-07
of O 0 2.8349338876410002e-08
families O 0 1.457790517633839e-06
with O 0 9.875335535980412e-07
male B-Disease 0 0.00012803713616449386
and I-Disease 0 0.00012736774806398898
female I-Disease 1 0.5241271257400513
breast I-Disease 1 0.9996340274810791
cancer I-Disease 1 0.9991156458854675
were O 0 2.872008906251722e-07
due O 0 6.529810889333021e-06
to O 0 9.907295179800713e-07
BRCA2 O 0 0.035351987928152084
( O 0 4.056129000673536e-06
76 O 0 0.00011684968922054395
% O 0 1.9595838693931e-06
) O 0 2.177288706661784e-06
. O 0 4.453841029317118e-06

The O 0 2.226272499683546e-06
largest O 0 7.376882422249764e-06
proportion O 0 3.467828264547279e-06
( O 0 7.281312264240114e-07
67 O 0 2.070313257718226e-06
% O 0 8.154761133027932e-08
) O 0 3.024016947961172e-08
of O 0 7.525020606635735e-09
families O 0 4.338634198575164e-07
due O 0 4.634750894183526e-07
to O 0 7.988675498893372e-09
other O 0 1.144667738373073e-08
genes O 0 3.326888986521226e-07
was O 0 5.412550763139734e-08
found O 0 3.7833792987385095e-08
in O 0 2.4420344857389864e-08
families O 0 5.7194213809452776e-08
with O 0 1.5030884981115378e-08
four O 0 1.4318161767334914e-08
or O 0 8.247550908890844e-08
five O 0 1.1182778081320066e-07
cases O 0 3.869116426358232e-06
of O 0 8.86594170879107e-06
female O 1 0.6705722212791443
breast B-Disease 1 0.9995809197425842
cancer I-Disease 1 0.9988806843757629
only O 0 8.328079275088385e-06
. O 0 9.097062138607726e-05

These O 0 2.9451837235683342e-06
estimates O 0 2.0729150492115878e-05
were O 0 1.0257334537300267e-07
not O 0 1.0125078375722296e-07
substantially O 0 3.349595863255672e-05
affected O 0 1.4965538639444276e-06
either O 0 2.055371872700107e-08
by O 0 1.780442815402239e-08
changing O 0 4.920195237900771e-07
the O 0 3.778410473387339e-08
assumed O 0 1.5929820165183628e-06
penetrance O 0 0.0009149191901087761
model O 0 1.3919197954237461e-06
for O 0 2.0062840633272572e-07
BRCA1 O 0 0.001805744832381606
or O 0 7.897023834857464e-08
by O 0 1.9210608215303182e-08
including O 0 1.3812417876124528e-07
or O 0 1.1018602208423545e-06
excluding O 0 5.904103454668075e-05
BRCA1 O 0 0.039430130273103714
mutation O 0 1.932035775098484e-05
data O 0 1.1377478585927747e-06
. O 0 4.859628006670391e-06

Among O 0 2.7020631023333408e-05
those O 0 9.214748388330918e-06
families O 0 0.0002841793466359377
with O 0 0.00458848150447011
disease O 1 0.9994778037071228
due O 0 0.000153301254613325
to O 0 2.972691163449781e-06
BRCA1 O 0 0.04008439555764198
that O 0 5.048160645060307e-08
were O 0 1.0566292729663473e-08
tested O 0 3.854646308809606e-07
by O 0 1.5571703926298142e-09
one O 0 6.806978869455804e-10
of O 0 1.2341466737453288e-09
the O 0 1.0941574757339367e-08
standard O 0 1.2345072946118307e-06
screening O 0 2.24908717427752e-06
methods O 0 8.550485830483012e-08
, O 0 8.058510303499133e-08
mutations O 0 6.427084144888795e-07
were O 0 2.7439506222748378e-09
detected O 0 1.459628009570224e-07
in O 0 1.3291978628870993e-09
the O 0 1.4540747494962147e-09
coding O 0 2.681063904219627e-07
sequence O 0 3.4133254001034175e-09
or O 0 4.943695675052595e-09
splice O 0 6.085157338020508e-07
sites O 0 8.213639546283957e-09
in O 0 1.5967207556144558e-09
an O 0 2.377038565981593e-09
estimated O 0 1.6197105878745788e-07
63 O 0 6.206927309904131e-07
% O 0 1.5452123136583396e-08
( O 0 2.6650692319662994e-08
95 O 0 1.1445077063854114e-07
% O 0 4.381486817806035e-08
CI O 0 0.00063484744168818
51 O 0 4.3668282501130307e-07
% O 0 1.1430145008262116e-07
- O 0 1.9013752535101958e-05
77 O 0 6.239984486455796e-06
% O 0 3.474481218290748e-07
) O 0 8.36211995647318e-07
. O 0 2.6759548745758366e-06

The O 0 4.613892087945715e-06
estimated O 0 1.9236302250646986e-05
sensitivity O 0 5.940414212091127e-06
was O 0 6.147346454099534e-08
identical O 0 8.042571408850563e-08
for O 0 6.338333857769385e-09
direct O 0 2.509888297197449e-08
sequencing O 0 1.9669556650114828e-07
and O 0 2.1327000609971947e-08
other O 0 4.362382455269653e-08
techniques O 0 3.338672740937909e-06
. O 0 8.582830560044385e-06

The O 0 4.195085239189211e-06
penetrance O 0 0.0014980221167206764
of O 0 1.1334786904626526e-06
BRCA2 O 0 0.004122492391616106
was O 0 1.799651556666504e-07
estimated O 0 1.4573107876003633e-07
by O 0 7.211126806794255e-09
maximizing O 0 3.0949419738135475e-07
the O 0 3.347997079572451e-08
LOD O 0 0.0005406267591752112
score O 0 5.864407981448494e-08
in O 0 4.4708107793667295e-07
BRCA2 O 0 0.05301002040505409
- O 0 0.0035681959707289934
mutation O 0 8.033684025576804e-06
families O 0 1.7616619629734487e-07
, O 0 2.2259504461885626e-08
over O 0 3.4379468161205295e-08
all O 0 2.1938658889553153e-08
possible O 0 2.851041699614143e-06
penetrance O 0 0.006538483779877424
functions O 0 1.7183962199851521e-06
. O 0 8.456820978608448e-06

The O 0 6.984021183598088e-06
estimated O 0 0.00011655722482828423
cumulative O 0 0.0016105474205687642
risk O 0 0.017397195100784302
of O 0 0.00011136981629533693
breast B-Disease 1 0.999297022819519
cancer I-Disease 1 0.9898533225059509
reached O 0 1.928114443217055e-06
28 O 0 8.54503809932794e-07
% O 0 7.989685002485203e-08
( O 0 6.03113718966597e-08
95 O 0 8.791051442358366e-08
% O 0 4.826553379189136e-08
CI O 0 0.0005827256245538592
9 O 0 1.1251992049210457e-07
% O 0 1.4810388471175884e-08
- O 0 7.961160122249566e-07
44 O 0 7.240388555374011e-08
% O 0 9.542828749431465e-09
) O 0 5.12716624712084e-09
by O 0 1.4430397987652555e-09
age O 0 7.4398364802164e-08
50 O 0 1.2701384832780604e-08
years O 0 3.0337517387124535e-08
and O 0 1.2048503528205856e-08
84 O 0 8.908775726013118e-07
% O 0 1.820628625637255e-08
( O 0 2.413427502290233e-08
95 O 0 9.517782473267289e-08
% O 0 4.588764213053764e-08
CI O 0 0.00042958444100804627
43 O 0 1.0638228076231826e-07
% O 0 2.1381620030069826e-08
- O 0 3.211315743101295e-06
95 O 0 2.1701318075884046e-07
% O 0 1.6797004676050165e-08
) O 0 8.828771491664611e-09
by O 0 6.092970128435127e-09
age O 0 2.1385592390288366e-06
70 O 0 3.2985869893309427e-06
years O 0 4.0555719351687e-06
. O 0 4.636944595404202e-06

The O 0 0.0010373939294368029
corresponding O 1 0.9780246019363403
ovarian B-Disease 1 0.9995766282081604
cancer I-Disease 1 0.999545156955719
risks O 1 0.690725564956665
were O 0 1.7864554138213862e-06
0 O 0 9.690476872492582e-05
. O 0 1.914588938234374e-05

4 O 0 3.484619810478762e-06
% O 0 5.521640673578077e-07
( O 0 2.0089090924102493e-07
95 O 0 2.392519320437714e-07
% O 0 1.3845757962371863e-07
CI O 0 0.0015287608839571476
0 O 0 1.2456447961994854e-07
% O 0 2.2806462496305357e-08
- O 0 1.0338537776988233e-06
1 O 0 1.9669363027219333e-08
% O 0 9.741183859546254e-09
) O 0 5.085490695222461e-09
by O 0 1.48361101182104e-09
age O 0 6.004325570074798e-08
50 O 0 1.1637164121225396e-08
years O 0 8.798411776922421e-09
and O 0 2.3423651906995246e-09
27 O 0 5.236277189624161e-08
% O 0 4.253562835287994e-09
( O 0 1.0067573441574496e-08
95 O 0 5.531328284291703e-08
% O 0 2.367045404128021e-08
CI O 0 0.00034525187220424414
0 O 0 7.582596595057112e-08
% O 0 1.0984817500059307e-08
- O 0 1.8569836583992583e-06
47 O 0 2.1884564205265633e-07
% O 0 2.3225693368544853e-08
) O 0 1.319783127229357e-08
by O 0 1.3523468567200325e-08
age O 0 1.530168788121955e-06
70 O 0 2.1222285795374773e-06
years O 0 4.766984602611046e-06
. O 0 6.887084964546375e-06

The O 0 4.255175372236408e-05
lifetime O 0 0.05985619127750397
risk O 0 0.23534955084323883
of O 0 0.0026285655330866575
breast B-Disease 1 0.9996151924133301
cancer I-Disease 1 0.9994476437568665
appears O 0 0.0002641698229126632
similar O 0 1.280926653635106e-06
to O 0 1.6975150174403097e-07
the O 0 8.282751196020399e-07
risk O 0 0.007215759716928005
in O 0 4.04028469347395e-06
BRCA1 O 1 0.6127135753631592
carriers O 0 0.0007414002320729196
, O 0 1.6991411655453703e-07
but O 0 1.0195556399139605e-08
there O 0 2.5958692972949393e-09
was O 0 3.365178802283708e-09
some O 0 1.3904444262635707e-09
suggestion O 0 1.1032885538497794e-07
of O 0 6.209494696207685e-09
a O 0 3.2974375585581583e-07
lower O 0 9.638121991883963e-05
risk O 0 0.0015822122804820538
in O 0 2.7695750759448856e-06
BRCA2 O 0 0.07044202089309692
carriers O 0 0.0002948376059066504
< O 0 0.0006696879281662405
50 O 0 1.2142309913087956e-07
years O 0 1.426648168489919e-07
of O 0 1.264007636336828e-07
age O 0 5.499075268744491e-05
. O 0 1.2033241546305362e-05

Eye B-Disease 1 0.8695365786552429
movement I-Disease 0 0.003934514243155718
abnormalities I-Disease 1 0.7553361654281616
correlate O 0 0.00040615376201458275
with O 0 5.7363518862985075e-05
genotype O 0 0.3782918453216553
in O 0 0.00039504384039901197
autosomal O 1 0.9947210550308228
dominant O 1 0.9700998663902283
cerebellar B-Disease 1 0.998938262462616
ataxia I-Disease 1 0.9986740350723267
type I-Disease 1 0.759381115436554
I I-Disease 0 0.00427144393324852
. O 0 0.00028805420151911676

We O 0 3.7837151012354298e-06
compared O 0 1.5090486158442218e-05
horizontal O 0 0.0001346828939858824
eye O 0 0.004870041739195585
movements O 0 3.873687091981992e-06
( O 0 1.9802146198344417e-06
visually O 0 1.4924198694643565e-05
guided O 0 1.3529331226891372e-05
saccades O 0 0.15652701258659363
, O 0 4.0919562138697074e-07
antisaccades O 0 0.00033347870339639485
, O 0 2.147890221237958e-08
and O 0 7.793028444780248e-09
smooth O 0 1.3663835716215544e-06
pursuit O 0 2.074348913083668e-06
) O 0 3.7996073842805345e-08
in O 0 8.395598882771083e-09
control O 0 1.319310456437961e-07
subjects O 0 3.399528054615075e-07
( O 0 3.764865255106997e-07
n O 0 3.973763796238927e-06
= O 0 1.0078322702611331e-05
14 O 0 3.0911456860849285e-07
) O 0 2.8549905550789845e-07
and O 0 1.0232986369373975e-07
patients O 0 2.7131818569614552e-05
with O 0 7.994834128055572e-09
three O 0 8.37632541106359e-09
forms O 0 4.209987594094855e-07
of O 0 3.114261062364676e-07
autosomal O 0 0.419076532125473
dominant O 0 0.014562404714524746
cerebellar B-Disease 1 0.9980694651603699
ataxias I-Disease 1 0.9876811504364014
type I-Disease 0 0.012855617329478264
I I-Disease 0 0.0003245097759645432
spinocerebellar B-Disease 1 0.9906678795814514
ataxias I-Disease 0 0.002529412042349577
1 I-Disease 0 3.9312124044954544e-07
and I-Disease 0 3.8621816855766156e-08
2 I-Disease 0 3.0925787086744094e-07
( O 0 4.0738191842137894e-07
SCA1 B-Disease 0 0.0001248479966307059
, O 0 1.7805277252591623e-08
n O 0 5.092103378956381e-07
= O 0 1.1550697536222287e-06
11 O 0 3.085019528725752e-08
; O 0 6.853820622154672e-08
SCA2 B-Disease 0 5.565251558437012e-05
, O 0 1.582097297614382e-08
n O 0 3.622769781941315e-07
= O 0 7.738884164609772e-07
10 O 0 1.2169015128904448e-08
) O 0 2.983472313644597e-08
and O 0 1.0316765752804713e-07
SCA3 B-Disease 0 0.3022276759147644
/ O 0 0.0033686370588839054
Machado B-Disease 0 0.002580872271209955
- I-Disease 0 0.04357141628861427
Joseph I-Disease 0 0.011403250508010387
disease I-Disease 1 0.9946371912956238
( O 0 2.102419784932863e-05
MJD B-Disease 0 0.32463401556015015
) O 0 7.408485203086457e-07
( O 0 4.464360188194405e-07
n O 0 7.07981780578848e-06
= O 0 1.4187641681928653e-05
16 O 0 4.60157849602183e-07
) O 0 6.634972464780731e-07
. O 0 1.3784049315290758e-06

In O 0 1.3017576748097781e-05
SCA1 B-Disease 0 0.008889720775187016
, O 0 2.1272537651384482e-06
saccade O 0 0.00040979107143357396
amplitude O 0 6.466354079748271e-06
was O 0 8.590861284574203e-07
significantly O 0 2.819489782268647e-05
increased O 0 3.5037937777815387e-06
, O 0 3.7755978610221064e-07
resulting O 0 1.4226798157324083e-05
in O 0 3.1355918963527074e-06
hypermetria B-Disease 0 0.06338512897491455
. O 0 2.467824197083246e-05

The O 0 5.493861863214988e-06
smooth O 0 6.718642544001341e-05
pursuit O 0 0.00014850759180262685
gain O 0 7.374849519692361e-05
was O 0 2.2851867470308207e-05
decreased O 0 0.0013533286983147264
. O 0 3.1228584703058004e-05

In O 0 1.9058885300182737e-05
SCA2 B-Disease 0 0.014178935438394547
, O 0 7.758933861623518e-06
saccade O 0 0.0016776337288320065
velocity O 0 2.9410824936348945e-05
was O 0 1.3259013940114528e-05
markedly O 0 0.003121356712654233
decreased O 0 0.0008357354090549052
. O 0 1.7337693861918524e-05

The O 0 1.2782310250258888e-06
percentage O 0 2.2897024791745935e-06
of O 0 1.280034922501727e-07
errors O 0 9.28733788896352e-06
in O 0 9.039157475854154e-07
antisaccades O 0 0.024391133338212967
was O 0 8.978211099019973e-07
greatly O 0 6.41984570393106e-06
increased O 0 7.396512273771805e-07
and O 0 5.26811341217126e-08
was O 0 2.7541983627088484e-07
significantly O 0 2.6157944375881925e-05
correlated O 0 3.326085425214842e-05
with O 0 5.218731985223712e-06
age O 0 0.007128489203751087
at O 0 0.019174281507730484
disease O 1 0.998931348323822
onset O 1 0.9970096349716187
. O 0 0.00038158244569785893

In O 0 2.2784408884035656e-06
addition O 0 8.1886435054912e-07
, O 0 6.423517362463826e-08
a O 0 3.249622793077833e-08
correlation O 0 2.167569022049065e-07
between O 0 5.3215476469858913e-08
smooth O 0 4.993545644538244e-06
pursuit O 0 3.2864663808140904e-06
gain O 0 1.988418887322041e-07
and O 0 6.740651592451741e-09
the O 0 5.234387145947039e-09
number O 0 1.0658513183159357e-08
of O 0 2.1984867260016472e-07
trinucleotide O 1 0.9772770404815674
repeats O 0 0.0005710314726457
was O 0 6.710124011988228e-07
found O 0 1.4660832903246046e-06
. O 0 4.0144323065760545e-06

In O 0 5.153835809323937e-05
SCA3 B-Disease 1 0.5857149362564087
, O 0 3.4927361411973834e-05
gaze B-Disease 0 0.044099483639001846
- I-Disease 0 0.18240873515605927
evoked I-Disease 0 0.17921046912670135
nystagmus I-Disease 1 0.6769064664840698
was O 0 6.203571842888778e-07
often O 0 1.7006455266255216e-07
present O 0 7.138122981587003e-08
as O 0 3.177107998908468e-08
was O 0 1.5331616509683954e-07
saccade O 0 0.0003364119620528072
hypometria O 0 0.00039158182335086167
and O 0 3.796043301917962e-08
smooth O 0 8.492560482409317e-06
pursuit O 0 4.602843546308577e-05
gain O 0 2.8029700843035243e-05
was O 0 7.415521849907236e-06
markedly O 0 0.006182029377669096
decreased O 0 0.0006698478246107697
. O 0 1.386257372359978e-05

Three O 0 2.2282031295617344e-06
major O 0 6.4332680267398246e-06
criteria O 0 2.2750755306333303e-06
, O 0 2.672776986401004e-07
saccade O 0 4.211624036543071e-05
amplitude O 0 8.247801019933831e-07
, O 0 1.0698560259925216e-07
saccade O 0 1.9881710613844916e-05
velocity O 0 1.993762310803504e-07
, O 0 8.62431903669858e-09
and O 0 2.8548519104276693e-09
presence O 0 2.275844401822269e-08
of O 0 2.2721144077308963e-08
gaze B-Disease 0 0.0020148116163909435
- I-Disease 0 0.011872800998389721
evoked I-Disease 0 0.010058633983135223
nystagmus I-Disease 0 0.06848841905593872
, O 0 7.244049271548647e-08
permitted O 0 3.272237592000238e-08
the O 0 7.497899190411772e-09
correct O 0 1.981452726340649e-07
assignment O 0 5.018830862013601e-08
of O 0 1.6045056394631274e-09
90 O 0 2.070666660358711e-08
% O 0 2.4947333088221058e-09
of O 0 9.789455912567746e-10
the O 0 1.6571732430747943e-08
SCA1 B-Disease 0 0.0006974103744141757
, O 0 1.1812219646856192e-08
90 O 0 1.5248350138108435e-08
% O 0 2.200557513987178e-09
of O 0 7.788744094128219e-10
the O 0 1.373546165694961e-08
SCA2 B-Disease 0 0.0010534434113651514
, O 0 1.6339818387223204e-08
and O 0 7.653996547674069e-09
93 O 0 3.9944603713593096e-07
% O 0 7.298926796295291e-09
of O 0 5.168562022817014e-09
the O 0 4.305962875150726e-07
patients O 0 0.0018555799033492804
with O 0 1.2362273764665588e-06
SCA3 B-Disease 1 0.8721295595169067
to O 0 9.87238166771931e-08
their O 0 9.576820048096124e-08
genetically O 0 0.00013690977357327938
confirmed O 0 2.20376459765248e-05
patient O 0 0.002234108280390501
group O 0 7.315710490729543e-07
and O 0 1.2338512078713393e-07
, O 0 1.3908447726862505e-07
therefore O 0 5.275866143961139e-08
, O 0 8.037082466216816e-08
may O 0 3.6926869029230147e-07
help O 0 1.6434875078630284e-06
orient O 0 0.00021270877914503217
diagnoses O 0 0.0046459101140499115
of O 0 2.249918509278359e-07
SCA1 B-Disease 0 0.20486392080783844
, O 0 1.210918298966135e-06
SCA2 B-Disease 0 0.033461328595876694
, O 0 1.597556860133409e-07
and O 0 1.4902602174515778e-07
SCA3 B-Disease 0 0.11379215121269226
at O 0 4.852140023103857e-07
early O 0 1.8594274706629221e-06
clinical O 0 0.00019953784067183733
stages O 0 9.783631867321674e-06
of O 0 5.32303943145962e-07
the O 0 0.00010550399019848555
diseases O 1 0.9983110427856445
. O 0 9.924232472258154e-06
. O 0 2.9304663257789798e-05

Genetic O 0 0.00012452089868020266
basis O 0 1.0385625728304149e-06
and O 0 1.696665094641503e-06
molecular O 0 0.00039136968553066254
mechanism O 0 0.001269213273189962
for O 0 0.009516285732388496
idiopathic B-Disease 1 0.998909592628479
ventricular I-Disease 1 0.9975807666778564
fibrillation I-Disease 1 0.9968976974487305
. O 0 0.012507637962698936

Ventricular B-Disease 1 0.9874393343925476
fibrillation I-Disease 1 0.9920656085014343
causes O 0 0.004077024292200804
more O 0 2.530235292397265e-07
than O 0 2.4508682372470503e-07
300 O 0 1.6618251947875251e-06
, O 0 5.984511517453939e-07
000 O 0 3.374192237970419e-05
sudden O 0 0.002662187209352851
deaths O 0 9.081548341782764e-06
each O 0 9.29570465046936e-09
year O 0 3.0364961389750533e-07
in O 0 9.050891947026685e-08
the O 0 6.046088287803286e-07
USA O 0 0.00024392375780735165
alone O 0 2.762712028925307e-05
. O 0 6.053362085367553e-06

In O 0 9.372374734084588e-07
approximately O 0 7.924483043098007e-07
5 O 0 1.2681482530751964e-06
- O 0 1.0136445780517533e-05
12 O 0 9.006478762785264e-08
% O 0 1.2464369092413108e-08
of O 0 4.654840957130091e-09
these O 0 1.8424831438323963e-08
cases O 0 7.687635275033244e-07
, O 0 4.505617567929221e-08
there O 0 9.324987892966874e-09
are O 0 7.008059021984536e-09
no O 0 6.844100539638021e-07
demonstrable O 0 0.11037185043096542
cardiac O 1 0.9798822402954102
or O 0 4.3379146518418565e-05
non O 0 0.02627742290496826
- O 1 0.9901826977729797
cardiac O 1 0.9991576671600342
causes O 0 0.002141049597412348
to O 0 6.084228232339228e-08
account O 0 8.639651127850811e-08
for O 0 1.3091604245119015e-08
the O 0 4.1476752699054487e-08
episode O 0 2.6498132683627773e-06
, O 0 1.5215178450489475e-07
which O 0 6.391814366679682e-08
is O 0 1.9252098582001054e-07
therefore O 0 9.375690979140927e-07
classified O 0 0.0006657866761088371
as O 0 0.001415643491782248
idiopathic B-Disease 1 0.9995198249816895
ventricular I-Disease 1 0.9990137815475464
fibrillation I-Disease 1 0.9990193843841553
( O 0 0.0713408812880516
IVF B-Disease 1 0.9928684830665588
) O 0 0.00013457622844725847
. O 0 3.9507634937763214e-05

A O 0 5.078755293652648e-06
distinct O 0 4.889561296295142e-06
group O 0 1.6299843991873786e-05
of O 0 3.794790609390475e-05
IVF B-Disease 1 0.9991938471794128
patients O 1 0.9394468069076538
has O 0 1.4105639820627403e-06
been O 0 4.0163094183753856e-08
found O 0 1.8519854094734e-08
to O 0 4.727179092611777e-09
present O 0 5.179587958537013e-08
with O 0 7.551219738388681e-08
a O 0 2.554037791924202e-06
characteristic O 0 0.000533160986378789
electrocardiographic O 0 0.46707621216773987
pattern O 0 0.00201296154409647
. O 0 3.858482159557752e-05

Because O 0 1.9166600395692512e-06
of O 0 5.568461958205262e-08
the O 0 4.8944041708409713e-08
small O 0 1.1421187195992388e-07
size O 0 1.7035739574566833e-07
of O 0 4.595234415205596e-09
most O 0 1.2761096179758624e-08
pedigrees O 0 1.0752782145573292e-05
and O 0 2.4725176572815144e-08
the O 0 6.157555532126935e-08
high O 0 3.160844062222168e-05
incidence O 0 0.027523867785930634
of O 0 1.1559072845557239e-06
sudden B-Disease 0 0.329494833946228
death I-Disease 0 7.539940270362422e-05
, O 0 3.163804365158285e-07
however O 0 1.0490690272035863e-07
, O 0 1.0367106284547845e-07
molecular O 0 1.2402551874401979e-05
genetic O 0 2.354731441300828e-05
studies O 0 5.809998242511938e-07
of O 0 2.55196312082262e-07
IVF B-Disease 1 0.5487334132194519
have O 0 5.753569354283172e-08
not O 0 2.14297966039112e-08
yet O 0 1.4917276303094695e-07
been O 0 5.602457520126336e-08
done O 0 9.29543887195905e-07
. O 0 4.4864355004392564e-06

Because O 0 0.013247745111584663
IVF B-Disease 1 0.9913862943649292
causes O 1 0.9931973218917847
cardiac O 1 0.997497022151947
rhythm O 1 0.5210621356964111
disturbance O 0 0.4365493357181549
, O 0 2.585425590950763e-06
we O 0 9.634457853735512e-08
investigated O 0 5.947567842667922e-06
whether O 0 3.730148421254853e-07
malfunction O 0 0.0003061239840462804
of O 0 1.9416750873801902e-08
ion O 0 1.7212654711329378e-05
channels O 0 1.4587278656108538e-06
could O 0 2.0256629795767367e-06
cause O 0 0.00042127963388338685
the O 0 6.10744018558762e-06
disorder O 1 0.9841369390487671
by O 0 1.3948044852440944e-07
studying O 0 2.1503001335076988e-06
mutations O 0 1.3339741599338595e-05
in O 0 1.0857777255068868e-07
the O 0 7.883372745709494e-07
cardiac O 0 0.36120936274528503
sodium O 0 4.821984839509241e-05
channel O 0 8.488010280416347e-06
gene O 0 4.9262471293332055e-05
SCN5A O 0 0.03049504943192005
. O 0 1.2923323083668947e-05

We O 0 1.406671003678639e-06
have O 0 1.4430878536586533e-07
now O 0 1.5706410749771749e-07
identified O 0 9.370509701511764e-08
a O 0 1.0891648827282552e-07
missense O 0 4.120473386137746e-05
mutation O 0 2.4450275759591023e-06
, O 0 3.0418227936479525e-08
a O 0 1.680398185044396e-07
splice O 0 0.0003894536930602044
- O 0 0.005447706673294306
donor O 0 0.0004126363783143461
mutation O 0 8.806297955743503e-06
, O 0 2.7416499293053676e-08
and O 0 9.7764738526962e-09
a O 0 1.7438398458580195e-07
frameshift O 0 0.0012095492566004395
mutation O 0 8.111416605061095e-07
in O 0 5.161262084385498e-09
the O 0 1.8419841651962088e-08
coding O 0 1.541811434435658e-05
region O 0 2.1119383575296524e-07
of O 0 3.267036774445842e-08
SCN5A O 0 0.003982909023761749
in O 0 2.2600991655963298e-07
three O 0 1.234822889273346e-06
IVF B-Disease 1 0.9103408455848694
families O 0 4.1188155591953546e-05
. O 0 2.1977517462801188e-05

We O 0 1.272092163162597e-06
show O 0 3.0429782782448456e-07
that O 0 1.622621148555936e-08
sodium O 0 2.1830928176314046e-07
channels O 0 2.4240845775125308e-08
with O 0 1.2952490635598224e-08
the O 0 5.744753295289229e-08
missense O 0 0.00024017594114411622
mutation O 0 5.780094215879217e-05
recover O 0 0.0008515493827871978
from O 0 7.89211355822772e-07
inactivation O 0 0.004305217415094376
more O 0 5.326909402469937e-08
rapidly O 0 1.4944124814064708e-05
than O 0 1.5226262917167332e-08
normal O 0 5.1355563357446954e-08
and O 0 4.238402073752923e-09
that O 0 4.434882683312935e-09
the O 0 5.568547223333553e-08
frameshift O 0 0.0038743342738598585
mutation O 0 8.644017725600861e-06
causes O 0 3.945630396628985e-06
the O 0 7.957257963653319e-09
sodium O 0 3.553068950168381e-07
channel O 0 5.235987288187971e-08
to O 0 4.866586689189489e-09
be O 0 6.797174378903037e-09
non O 0 3.152869794575963e-06
- O 0 0.00023940776009112597
functional O 0 2.510614285711199e-05
. O 0 7.271095000760397e-06

Our O 0 3.910850409738487e-06
results O 0 2.141694267265848e-06
indicate O 0 9.018991704579093e-07
that O 0 3.7529847674022676e-08
mutations O 0 5.826972483191639e-06
in O 0 4.1999942368420307e-07
cardiac O 0 0.13841478526592255
ion O 0 0.0001338611909886822
- O 0 8.988575427792966e-05
channel O 0 2.81588171446856e-07
genes O 0 7.329985152182417e-08
contribute O 0 1.7115208095219714e-07
to O 0 7.633760290559621e-09
the O 0 6.905665372869407e-08
risk O 0 2.9292255931068212e-05
of O 0 1.537369769266661e-07
developing O 0 0.0018017328111454844
IVF B-Disease 1 0.9018552899360657
. O 0 4.162784080108395e-06
. O 0 9.76454157353146e-06

Molecular O 0 0.00011365875252522528
heterogeneity O 0 0.00047985013225115836
in O 0 8.605083166912664e-06
mucopolysaccharidosis B-Disease 0 0.1804920881986618
IVA I-Disease 1 0.5150213241577148
in O 0 5.478409548231866e-07
Australia O 0 3.3503931717859814e-07
and O 0 2.6307215961196562e-08
Northern O 0 9.532317335469997e-08
Ireland O 0 2.677885220236931e-07
: O 0 1.3365411177801434e-07
nine O 0 6.028434995641874e-08
novel O 0 2.034739509326755e-06
mutations O 0 2.1004141217417782e-06
including O 0 1.4307643425581773e-07
T312S O 0 0.0009703074465505779
, O 0 9.166248560177337e-08
a O 0 1.3683497002148215e-07
common O 0 1.8810962956194999e-06
allele O 0 1.6957988918875344e-05
that O 0 3.0794177519055665e-07
confers O 0 0.004785389639437199
a O 0 0.00023523739946540445
mild O 1 0.994056224822998
phenotype O 1 0.6166653037071228
. O 0 9.084231714950874e-05

Mucopolysaccharidosis B-Disease 1 0.8479065895080566
IVA I-Disease 1 0.9789136648178101
( O 0 0.0011628213105723262
MPS B-Disease 0 0.06570648401975632
IVA I-Disease 1 0.9937912821769714
) O 0 1.2552720363601111e-05
is O 0 1.8041382645606063e-06
an O 0 4.832969716517255e-05
autosomal B-Disease 1 0.9973390698432922
recessive I-Disease 1 0.9988800883293152
lysosomal I-Disease 1 0.9995176792144775
storage I-Disease 1 0.9989506006240845
disorder I-Disease 1 0.9997003078460693
caused O 0 0.10115835815668106
by O 0 3.549458824636531e-06
a O 0 3.878081770380959e-05
genetic B-Disease 0 0.298530638217926
defect I-Disease 1 0.6760047674179077
in O 0 1.0577664397715125e-06
N O 0 0.00013507530093193054
- O 0 0.00045799885992892087
acetylgalactosamine O 0 0.004432918969541788
- O 0 0.0004524393880274147
6 O 0 1.962454552995041e-05
- O 0 0.00440492806956172
sulfate O 0 0.10328425467014313
sulfatase O 1 0.7448328137397766
( O 0 2.185039375035558e-05
GALNS O 0 0.027523530647158623
) O 0 3.3224548587895697e-06
. O 0 4.373740466689924e-06

Previous O 0 1.4798473785049282e-05
studies O 0 6.610961463593412e-06
of O 0 1.4069124745219597e-06
patients O 0 0.005075069610029459
from O 0 4.5460603814717615e-07
a O 0 7.139320814530947e-07
British O 0 3.0705530662089586e-05
- O 0 0.00246313470415771
Irish O 0 1.4224016922526062e-05
population O 0 1.5183317714217992e-07
showed O 0 1.877011044371102e-07
that O 0 3.2892062407086087e-09
the O 0 3.4616146393773306e-08
I113F O 0 0.0021040416322648525
mutation O 0 3.3713852189976024e-06
is O 0 4.546387266657348e-09
the O 0 3.277082827324307e-09
most O 0 9.542355350333764e-09
common O 0 1.2585863373715256e-07
single O 0 1.1749464334798176e-07
mutation O 0 8.761622666497715e-06
among O 0 5.22061327501433e-06
MPS B-Disease 0 0.44003841280937195
IVA I-Disease 1 0.9996379613876343
patients O 1 0.6019749641418457
and O 0 4.412964699440636e-06
produces O 0 0.0013786604395136237
a O 0 0.0008608153439126909
severe O 1 0.9978504180908203
clinical O 1 0.9635677337646484
phenotype O 1 0.8066783547401428
. O 0 0.00018568089581094682

We O 0 2.128398136846954e-06
studied O 0 4.998586518922821e-06
mutations O 0 5.694114406651352e-06
in O 0 5.9557137888077705e-08
the O 0 9.074175011392072e-08
GALNS O 0 0.001124689937569201
gene O 0 4.5246588342706673e-07
from O 0 5.084252308051873e-08
23 O 0 5.964597562524432e-07
additional O 0 1.5103123587323353e-06
MPS B-Disease 0 0.010798855684697628
IVA I-Disease 1 0.9985995888710022
patients O 0 0.02701306715607643
( O 0 6.281782134465175e-07
15 O 0 5.12917388562073e-08
from O 0 1.3890083749856785e-08
Australia O 0 3.717554974969062e-08
, O 0 4.500427586151545e-09
8 O 0 1.5103879036360013e-08
from O 0 5.84067239017827e-09
Northern O 0 6.039886102371383e-08
Ireland O 0 1.728544134493859e-07
) O 0 2.2530398879894165e-08
, O 0 3.977784768238735e-09
with O 0 1.7138361840807192e-08
various O 0 3.517607183312066e-07
clinical O 0 0.3655093312263489
phenotypes O 1 0.669282853603363
( O 0 0.0027291958685964346
severe O 1 0.8885691165924072
, O 0 4.6174392309694667e-07
16 O 0 1.143062831943098e-06
cases O 0 1.6153818478414905e-06
; O 0 9.026028919834062e-07
intermediate O 0 3.484094577288488e-06
, O 0 1.487658778387413e-07
4 O 0 4.241123860992957e-06
cases O 0 2.4289302018587478e-05
; O 0 3.3923763112397864e-05
mild O 0 0.11400409042835236
, O 0 9.049628602042503e-07
3 O 0 5.497709480550839e-06
cases O 0 1.1535403245943598e-05
) O 0 3.860318884107983e-06
. O 0 4.20618562202435e-06

We O 0 1.5047655779198976e-06
found O 0 3.4320248687436106e-07
two O 0 7.423493286751182e-08
common O 0 1.257401436305372e-06
mutations O 0 1.2526032833193312e-06
that O 0 3.351394495254567e-09
together O 0 8.937784734541765e-09
accounted O 0 8.285012853548324e-08
for O 0 3.409044380120463e-09
32 O 0 4.405738707191631e-08
% O 0 2.72550648716674e-09
of O 0 1.0920219173371493e-09
the O 0 1.2851227637611373e-08
44 O 0 1.5573812106595142e-06
unrelated O 0 2.514366315153893e-05
alleles O 0 2.0239895093254745e-05
in O 0 9.520304047327954e-07
these O 0 4.173771685600514e-06
patients O 0 0.43617260456085205
. O 0 8.833248284645379e-05

One O 0 1.14813985874207e-06
is O 0 2.222048323119452e-07
the O 0 2.948445114725473e-07
T312S O 0 0.0009707313147373497
mutation O 0 9.408811820321716e-06
, O 0 6.596800972147321e-08
a O 0 1.245168590457979e-07
novel O 0 6.2178501138987485e-06
mutation O 0 8.561216418456752e-06
found O 0 2.9519816280298983e-07
exclusively O 0 1.6500474657732411e-06
in O 0 4.079303835169412e-05
milder O 1 0.9801871180534363
patients O 1 0.7308507561683655
. O 0 0.0001615575165487826

The O 0 6.845484676887281e-07
other O 0 8.002053419886579e-08
is O 0 3.9123317918665634e-08
the O 0 3.342662679983732e-08
previously O 0 7.161920052567439e-07
described O 0 1.0396792276878841e-05
I113F O 0 0.0037247296422719955
that O 0 5.847765010003059e-07
produces O 0 0.00022095305030234158
a O 0 0.0003202362859155983
severe O 1 0.995570719242096
phenotype O 1 0.5965121388435364
. O 0 0.00015719323710072786

The O 0 4.8931992751022335e-06
I113F O 0 0.0004365438362583518
and O 0 1.308054265791725e-06
T312S O 0 0.0003860860597342253
mutations O 0 6.329562893370166e-06
accounted O 0 4.3698361196220503e-07
for O 0 1.997716658763693e-08
8 O 0 3.2481176504006726e-07
( O 0 1.0460718868898766e-07
18 O 0 4.224328975510616e-08
% O 0 1.3919150276819892e-08
) O 0 6.4071676852961446e-09
and O 0 2.5951514270872167e-09
6 O 0 4.853611557109616e-08
( O 0 2.1236319369677403e-08
14 O 0 1.744634303690873e-08
% O 0 7.159063564188273e-09
) O 0 3.494350364618981e-09
of O 0 1.6900345567449904e-09
44 O 0 6.083045605009829e-07
unrelated O 0 1.1088471183029469e-05
alleles O 0 7.452699719578959e-06
, O 0 4.394488541947794e-07
respectively O 0 5.232860530668404e-06
. O 0 6.082968411647016e-06

The O 0 2.7395440156396944e-06
relatively O 0 5.802439773106016e-06
high O 0 1.2104900633858051e-05
residual O 0 0.0012718538055196404
GALNS O 0 0.03058238886296749
activity O 0 4.3420035922281386e-07
seen O 0 1.4773296186376683e-07
when O 0 1.006797667457704e-08
the O 0 7.193090123536194e-09
T312S O 0 1.6197496734093875e-05
mutant O 0 2.1222892883088207e-06
cDNA O 0 1.1683021057251608e-06
is O 0 7.011123415168186e-08
overexpressed O 0 3.989920878666453e-05
in O 0 6.431032772979961e-08
mutant O 0 3.533987182890996e-05
cells O 0 2.4083108201011783e-06
provides O 0 6.738828517427464e-08
an O 0 7.686973724219115e-09
explanation O 0 2.6344832804170437e-07
for O 0 8.839727883014348e-08
the O 0 7.693914994888473e-06
mild O 1 0.9850670099258423
phenotype O 0 0.3059736490249634
in O 0 1.7881593521451578e-05
patients O 0 0.05612749233841896
with O 0 1.4347215255838819e-06
this O 0 2.8021627258567605e-06
mutation O 0 0.0005159950233064592
. O 0 2.8920258046127856e-05

The O 0 4.198208216621424e-07
distribution O 0 2.018832674366422e-07
and O 0 1.777131330982229e-08
relative O 0 2.9317998695432834e-08
frequencies O 0 4.461693681179213e-09
of O 0 2.165788215435782e-09
the O 0 2.0115079379934286e-08
I113F O 0 3.711372482939623e-05
and O 0 7.480432628881317e-08
T312S O 0 0.0004746630147565156
mutations O 0 2.2604081095778383e-06
in O 0 2.065267068473986e-08
Australia O 0 1.8178982941208233e-07
corresponded O 0 2.866153749891964e-07
to O 0 4.269542941415239e-09
those O 0 4.218046800730235e-09
observed O 0 1.9584048160936618e-08
in O 0 8.717029764682138e-09
Northern O 0 7.727593498429997e-08
Ireland O 0 3.5156250532963895e-07
and O 0 1.1804359267841846e-08
are O 0 9.900318342914716e-10
unique O 0 5.118938606329948e-09
to O 0 1.7100800775438074e-09
these O 0 1.5288093013765547e-09
two O 0 2.6444606504583135e-08
populations O 0 7.330289918172639e-06
, O 0 1.3039674229275988e-07
suggesting O 0 1.4116930060481536e-06
that O 0 7.008179370160406e-09
both O 0 2.5875758424831474e-08
mutations O 0 2.040479785136995e-06
were O 0 3.66745789293077e-09
probably O 0 8.5547277706155e-08
introduced O 0 3.368461776176446e-08
to O 0 4.88571805234983e-09
Australia O 0 4.8630262483584374e-08
by O 0 1.2449660857782874e-08
Irish O 0 1.1960622714468627e-06
migrants O 0 2.4503401618858334e-07
during O 0 1.1234086372269303e-07
the O 0 6.677911557062544e-08
19th O 0 4.653787527786335e-06
century O 0 1.6576954294578172e-05
. O 0 9.111703548114747e-06

Haplotype O 0 0.0005973122897557914
analysis O 0 1.4443038480749237e-06
using O 0 4.400897353207256e-07
6 O 0 5.755430265708128e-06
RFLPs O 0 0.00047661352436989546
provides O 0 1.4357929956076987e-07
additional O 0 3.873542908650052e-08
data O 0 1.4464850650597327e-08
that O 0 3.692832262203183e-09
the O 0 4.870712544402522e-08
I113F O 0 0.00031726309680379927
mutation O 0 3.885996648023138e-06
originated O 0 2.786918855690601e-07
from O 0 4.152978760885162e-08
a O 0 3.337070211273385e-07
common O 0 4.429742602951592e-06
ancestor O 0 7.718525012023747e-05
. O 0 2.8742097128997557e-05

The O 0 1.5169438256634749e-06
other O 0 3.0724123689651606e-07
9 O 0 4.464591711439425e-06
novel O 0 1.2546759535325691e-05
mutations O 0 1.4631900739914272e-05
identified O 0 4.1468376821285347e-07
in O 0 7.870529117326441e-08
these O 0 1.3366722839691647e-07
23 O 0 3.041178388230037e-05
patients O 0 0.0004309660289436579
were O 0 1.1878682482091563e-09
each O 0 1.0293091934343579e-09
limited O 0 2.4304178225520445e-08
to O 0 5.319454210450658e-09
a O 0 9.593529881612994e-08
single O 0 6.465697879320942e-07
family O 0 1.786131178960204e-05
. O 0 1.6390988093917258e-05

These O 0 5.271752456792456e-07
data O 0 3.086108790739672e-07
provide O 0 1.234394915172743e-07
further O 0 4.111145557317286e-08
evidence O 0 5.0842032806031057e-08
for O 0 2.0868196060064292e-08
extensive O 0 5.113426141178934e-06
allelic O 0 0.0004947491688653827
heterogeneity O 0 0.00019063259242102504
in O 0 8.165381473190791e-07
MPS B-Disease 0 0.001962093636393547
IVA I-Disease 1 0.9896398782730103
in O 0 3.6215167256159475e-06
British O 0 0.00048062330461107194
- O 1 0.5662020444869995
Irish O 0 0.00611926568672061
patients O 0 0.006658672820776701
and O 0 1.0855126220121747e-07
provide O 0 9.174504356224134e-08
evidence O 0 3.8739639052209895e-08
for O 0 3.353095356928293e-09
their O 0 3.579257112917844e-09
transmission O 0 5.839183359057643e-07
to O 0 6.939490759805267e-09
Australia O 0 1.0489129209645398e-07
by O 0 2.855093050868618e-08
British O 0 3.1145275443122955e-06
- O 0 0.00014123792061582208
Irish O 0 8.489872016070876e-06
migrants O 0 3.980105248047039e-06
. O 0 8.453963005194964e-07
. O 0 3.973976163251791e-06

Identification O 0 6.509510058094747e-06
of O 0 9.800858151720604e-07
constitutional O 0 8.686301589477807e-05
WT1 O 1 0.9605920314788818
mutations O 0 0.0003790535847656429
, O 0 3.2396894766861806e-06
in O 0 1.2319210327405017e-05
patients O 0 0.1881268173456192
with O 0 0.0003632217994891107
isolated O 1 0.9671343564987183
diffuse B-Disease 1 0.9990697503089905
mesangial I-Disease 1 0.9997082352638245
sclerosis I-Disease 1 0.9998255372047424
, O 0 1.0899731023528147e-05
and O 0 3.013831531006872e-07
analysis O 0 4.7014160031721985e-07
of O 0 6.776903660465905e-07
genotype O 0 0.144006609916687
/ O 0 0.18079006671905518
phenotype O 0 0.00032635763636790216
correlations O 0 1.1585426591409487e-06
by O 0 8.630934189568507e-09
use O 0 9.836721659439718e-09
of O 0 1.6675128833298913e-08
a O 0 1.4681540960737038e-06
computerized O 0 0.002801555674523115
mutation O 0 0.0001872651046141982
database O 0 4.6760382247157395e-05
. O 0 1.5819690815987997e-05

Constitutional O 0 1.8714961697696708e-05
mutations O 0 9.711162419989705e-06
of O 0 1.2913716318507795e-07
the O 0 3.6551554671859776e-07
WT1 O 0 0.05270126089453697
gene O 0 9.441460520065448e-07
, O 0 2.1223037549589208e-08
encoding O 0 1.1996888815701823e-07
a O 0 5.452878895084723e-07
zinc O 0 0.002012066077440977
- O 0 0.0005327906692400575
finger O 0 0.00011720298789441586
transcription O 0 6.125242634880124e-06
factor O 0 1.509399339738593e-06
involved O 0 6.249795205803821e-07
in O 0 1.5087292013049591e-05
renal O 1 0.9993520379066467
and O 0 1.5622214050381444e-05
gonadal O 1 0.9481634497642517
development O 0 9.076751666725613e-06
, O 0 1.3152903477475775e-07
are O 0 3.3279026201427087e-09
found O 0 2.1484515499992085e-08
in O 0 4.249161733582696e-08
most O 0 7.900170544417051e-07
patients O 0 0.021150054410099983
with O 0 0.00018556194845587015
Denys B-Disease 1 0.997129499912262
- I-Disease 1 0.9981895089149475
Drash I-Disease 1 0.9987418055534363
syndrome I-Disease 1 0.9996155500411987
( O 0 0.007782031316310167
DDS B-Disease 1 0.9985565543174744
) O 0 8.018552762223408e-06
, O 0 4.358608293841826e-06
or O 0 0.0002372431627009064
diffuse B-Disease 1 0.9969520568847656
mesangial I-Disease 1 0.999509334564209
sclerosis I-Disease 1 0.999769389629364
( O 0 0.029485246166586876
DMS B-Disease 1 0.9955915212631226
) O 0 2.167551656384603e-06
associated O 0 1.987788664337131e-06
with O 0 1.242100665876933e-06
pseudohermaphroditism B-Disease 1 0.71465665102005
and O 0 3.104283314314671e-05
/ O 1 0.7814768552780151
or O 0 0.002345980843529105
Wilms B-Disease 1 0.9986911416053772
tumor I-Disease 1 0.9973580241203308
( O 0 0.0006888463394716382
WT B-Disease 1 0.9865303635597229
) O 0 1.677609543548897e-05
. O 0 7.603212907270063e-06

Most O 0 5.61344604648184e-05
mutations O 0 0.0034452390391379595
in O 0 0.0004483548691496253
DDS B-Disease 1 0.9986918568611145
patients O 0 0.23430711030960083
lie O 0 1.160997726401547e-05
in O 0 1.1826436718820332e-07
exon O 0 2.320689964108169e-05
8 O 0 1.4367216749633371e-07
or O 0 2.120102848834904e-08
exon O 0 4.158157480560476e-06
9 O 0 6.908326355414829e-08
, O 0 6.763317461633278e-09
encoding O 0 1.3500213924544369e-07
zinc O 0 3.276932693552226e-05
finger O 0 8.756310307944659e-06
2 O 0 2.4453561309201177e-07
or O 0 1.625679431072058e-07
zinc O 0 0.00018349423771724105
finger O 0 8.515852641721722e-06
3 O 0 9.338126005786762e-08
, O 0 1.0318867538217091e-08
respectively O 0 2.257836584362849e-08
, O 0 2.9405629042855708e-09
with O 0 3.940045179007257e-09
a O 0 4.115719676178742e-08
hot O 0 8.184511898434721e-06
spot O 0 1.9136534774588654e-06
( O 0 7.929426715236332e-07
R394W O 0 6.428654887713492e-05
) O 0 1.4230717226837442e-07
in O 0 1.1532213051168583e-07
exon O 0 0.00010559316433500499
9 O 0 1.1381524927855935e-05
. O 0 4.461050593818072e-06

We O 0 1.3402084277913673e-06
analyzed O 0 1.2434672953531845e-06
a O 0 1.0578094133961713e-07
series O 0 2.2383488840205246e-07
of O 0 9.307363768584764e-08
24 O 0 7.413216735585593e-06
patients O 0 0.00031609891448169947
, O 0 5.2574026909724125e-08
10 O 0 1.4177209095578291e-07
with O 0 8.309755230584415e-07
isolated B-Disease 0 0.0024274634197354317
DMS I-Disease 1 0.99580979347229
( O 0 6.477751594502479e-05
IDMS B-Disease 1 0.9621295928955078
) O 0 3.888756054948317e-07
, O 0 3.914085766609787e-08
10 O 0 7.617299502271635e-08
with O 0 5.181663595976715e-07
DDS B-Disease 1 0.9849599003791809
, O 0 6.495158544339574e-08
and O 0 3.850288265994095e-08
4 O 0 2.171907453885069e-06
with O 0 1.3116370610077865e-05
urogenital B-Disease 1 0.9970695972442627
abnormalities I-Disease 1 0.9723660945892334
and O 0 4.571613681036979e-05
/ O 0 0.3161492645740509
or O 0 0.00010179850505664945
WT B-Disease 1 0.9796664118766785
. O 0 5.55769911443349e-05

We O 0 1.103991235140711e-05
report O 0 1.9534712919266894e-05
WT1 O 0 0.07120181620121002
heterozygous O 0 7.118959911167622e-05
mutations O 0 4.418434400577098e-05
in O 0 1.7542829482408706e-06
16 O 0 6.330002361210063e-05
patients O 0 0.013342362828552723
, O 0 1.8118110745035665e-07
4 O 0 3.7133179375814507e-07
of O 0 4.371828410398848e-08
whom O 0 1.3114020475768484e-05
presented O 0 1.854463516792748e-05
with O 0 8.931892807595432e-05
IDMS B-Disease 1 0.9935804605484009
. O 0 0.00012268114369362593

One O 0 2.3954057724040467e-06
male O 0 7.96231506683398e-06
and O 0 6.421557827707147e-07
two O 0 2.5206620648532407e-06
female O 0 0.0196369681507349
IDMS B-Disease 1 0.9983479976654053
patients O 1 0.8846497535705566
with O 0 0.0018512160750105977
WT1 O 1 0.9968820810317993
mutations O 0 0.17215467989444733
underwent O 1 0.9166536331176758
normal O 0 0.0013848782982677221
puberty O 0 0.48412373661994934
. O 0 0.00017199496505782008

Two O 0 6.336139904306037e-06
mutations O 0 0.00047612996422685683
associated O 0 4.9274829507339746e-05
with O 0 2.7501364456838928e-05
IDMS B-Disease 1 0.9905175566673279
are O 0 2.1613201894865597e-08
different O 0 1.1343980865774483e-08
from O 0 2.2123259668660467e-07
those O 0 7.412923537231109e-07
described O 0 0.0002791265433188528
in O 0 0.0009998059831559658
DDS B-Disease 1 0.9985606074333191
patients O 1 0.9806930422782898
. O 0 0.0003965648065786809

No O 0 0.00012353928468655795
WT1 O 0 0.2128130942583084
mutations O 0 3.34787109750323e-05
were O 0 8.535836570899846e-08
detected O 0 1.9082281141891144e-06
in O 0 1.0100713154770347e-08
the O 0 2.7484356124318765e-08
six O 0 1.3342770444069174e-06
other O 0 2.7300107831251808e-05
IDMS B-Disease 1 0.9995226860046387
patients O 1 0.7818514704704285
, O 0 7.748514690320008e-06
suggesting O 0 0.0002004613634198904
genetic O 0 0.000458466267446056
heterogeneity O 0 0.002649205271154642
of O 0 5.6807448345352896e-06
this O 0 0.0002870174066629261
disease O 1 0.9974575638771057
. O 0 0.0002762787917163223

We O 0 1.0511463187867776e-05
analyzed O 0 0.00019082098151557148
genotype O 0 0.04451863095164299
/ O 0 0.16751925647258759
phenotype O 0 0.0011731777340173721
correlations O 0 6.706095064146211e-06
, O 0 2.861984604862755e-08
on O 0 1.76108250204976e-09
the O 0 8.556872987952602e-10
basis O 0 5.188184881710356e-10
of O 0 5.190599616788916e-10
the O 0 3.269129411620497e-09
constitution O 0 1.5232913597174047e-08
of O 0 2.6946986864118117e-09
a O 0 3.290357142304856e-07
WT1 O 0 0.014404082670807838
mutation O 0 6.887931931487401e-07
database O 0 9.510488041541976e-08
of O 0 2.1640138569978262e-08
84 O 0 0.00014717556769028306
germ O 0 0.3001549243927002
- O 0 0.0003158199542667717
line O 0 1.67401253747812e-06
mutations O 0 1.7588093896847568e-06
, O 0 6.196752000420247e-09
to O 0 2.4041411084141373e-09
compare O 0 1.6039074068885384e-07
the O 0 1.9889634383929433e-09
distribution O 0 1.2316663244860138e-08
and O 0 1.5284806309523447e-08
type O 0 1.2967738030056353e-06
of O 0 2.5928770241989696e-08
mutations O 0 6.223492164281197e-06
, O 0 3.7317423817739837e-08
according O 0 5.004130088082093e-08
to O 0 2.311031188639845e-08
the O 0 1.2909875124478276e-07
different O 0 1.3091275832266547e-06
symptoms O 1 0.9823102355003357
. O 0 6.466580089181662e-05

This O 0 1.3710199482375174e-06
demonstrated O 0 5.9163180594623554e-06
( O 0 1.353448283225589e-06
1 O 0 2.7732119178836e-07
) O 0 6.920697614987148e-08
the O 0 1.942152927369989e-08
association O 0 5.584666382674186e-07
between O 0 2.4292035050166305e-08
mutations O 0 1.882500271221943e-07
in O 0 7.2273196316530175e-09
exons O 0 3.811460942415579e-07
8 O 0 8.110877303124653e-08
and O 0 1.5446641299377006e-08
9 O 0 4.4256242404117074e-07
and O 0 2.7359070031707233e-07
DMS B-Disease 0 0.36069464683532715
; O 0 6.955592652957421e-07
( O 0 3.943167428133165e-07
2 O 0 6.226646860341134e-07
) O 0 5.819846933263761e-07
among O 0 1.2278756003070157e-06
patients O 0 0.0029290467500686646
with O 0 1.857840970842517e-06
DMS B-Disease 1 0.783788800239563
, O 0 1.3321630021323472e-08
a O 0 3.3660134679536213e-09
higher O 0 5.50527490261743e-09
frequency O 0 1.9973269704820495e-09
of O 0 1.6257368784522441e-09
exon O 0 5.247863100521499e-06
8 O 0 1.8776377430640423e-07
mutations O 0 5.187270062378957e-07
among O 0 9.252018173810939e-08
46 O 0 5.5439036259485874e-06
, O 0 7.1872213993628975e-06
XY O 1 0.9117571711540222
patients O 0 0.005972404032945633
with O 0 7.936220640658576e-07
female O 0 1.2381419765006285e-05
phenotype O 0 0.0003811874194070697
than O 0 1.5422553190092003e-07
among O 0 1.2581306236825185e-06
46 O 0 0.00010454596485942602
, O 0 2.802205563057214e-05
XY O 1 0.9942154288291931
patients O 0 0.022670350968837738
with O 0 6.659009841314401e-07
sexual O 0 3.5565444704843685e-05
ambiguity O 0 0.0001902280346257612
or O 0 3.149083340758807e-06
male O 0 5.329453415470198e-05
phenotype O 0 0.0029662479646503925
; O 0 1.091613285097992e-06
and O 0 8.198428957939541e-08
( O 0 6.843369533271471e-07
3 O 0 2.4918725216593884e-07
) O 0 3.442533369479861e-08
statistically O 0 1.718146513951524e-08
significant O 0 1.410637295862216e-08
evidence O 0 1.685258510519816e-08
that O 0 1.9389354566357042e-09
mutations O 0 7.104356569698211e-08
in O 0 3.606882348350382e-09
exons O 0 3.9728737988298235e-07
8 O 0 9.214839735705027e-08
and O 0 1.4331276609880206e-08
9 O 0 1.511801031028881e-07
preferentially O 0 1.911652987018897e-07
affect O 0 6.979807665175031e-08
amino O 0 1.1629553320346986e-08
acids O 0 1.3056144609890907e-08
with O 0 3.6777902945317464e-09
different O 0 4.365326766730959e-09
functions O 0 5.106585732050917e-08
. O 0 4.1324517496832414e-07
. O 0 3.234067889934522e-06

The O 0 3.163588189636357e-05
185delAG O 0 0.1578981578350067
BRCA1 O 0 0.0911208912730217
mutation O 0 4.633473145077005e-05
originated O 0 8.584956390222942e-07
before O 0 3.519179969657671e-08
the O 0 1.0574821018849434e-08
dispersion O 0 5.028211944591021e-07
of O 0 8.023981479254871e-09
Jews O 0 1.9447556098839414e-07
in O 0 2.368766338634032e-08
the O 0 6.115093498237911e-08
diaspora O 0 3.347794745423016e-06
and O 0 3.114789492997261e-08
is O 0 1.4364745837269766e-08
not O 0 5.934879698799023e-09
limited O 0 2.602705819754192e-07
to O 0 5.051079483564536e-07
Ashkenazim O 0 0.006149024702608585
. O 0 1.305596833844902e-05

The O 0 1.4356098290591035e-05
185delAG O 0 0.00374430138617754
mutation O 0 0.00011147882469231263
in O 0 3.2390712476626504e-06
BRCA1 O 0 0.015874119475483894
is O 0 9.651855634729145e-07
detected O 0 1.5535037164227106e-05
in O 0 3.5023731470573694e-07
Ashkenazi O 0 0.0001886504323920235
Jews O 0 1.0031959618572728e-06
both O 0 4.2219693341394304e-07
in O 0 7.433366408804432e-05
familial B-Disease 1 0.9992480874061584
breast I-Disease 1 0.9997736811637878
and I-Disease 1 0.9850236177444458
ovarian I-Disease 1 0.9999196529388428
cancer I-Disease 1 0.9997900128364563
and O 0 2.8172189558972605e-06
in O 0 3.547039284512721e-07
the O 0 3.9150197039816703e-07
general O 0 6.246730663406197e-06
population O 0 5.4626875680696685e-06
. O 0 7.577059932373231e-06

All O 0 4.015255399281159e-06
tested O 0 0.00020734760619234294
Ashkenazi O 0 0.0012566730147227645
mutation O 0 2.9689021175727248e-05
carriers O 0 6.2998792600410525e-06
share O 0 4.142875908996757e-08
the O 0 7.1913066612694365e-09
same O 0 3.808204951383232e-08
allelic O 0 6.339722312986851e-05
pattern O 0 6.933460099389777e-06
at O 0 7.104017072379065e-07
the O 0 2.2732210709364153e-06
BRCA1 O 0 0.028965961188077927
locus O 0 0.0011878438526764512
. O 0 2.1335365090635605e-05

Our O 0 3.207098416169174e-06
previous O 0 3.262664449721342e-06
study O 0 4.524694759311387e-06
showed O 0 1.6622309431113536e-06
that O 0 2.654096853405008e-08
this O 0 1.2250224301624257e-07
Ashkenazi O 0 0.0007005391526035964
mutation O 0 1.2112511285522487e-05
also O 0 5.5411696564533486e-08
occurs O 0 3.2451205811412365e-07
in O 0 1.8788981037687336e-08
Iraqi O 0 3.342045147292083e-07
Jews O 0 1.8625530628924025e-07
with O 0 4.215949545027797e-08
a O 0 3.164932991239766e-07
similar O 0 5.239511665422469e-06
allelic O 0 0.015488524921238422
pattern O 0 0.000947126536630094
. O 0 3.8451922591775656e-05

We O 0 9.973806527341367e-07
extended O 0 6.412561788238236e-07
our O 0 7.396343448817788e-08
analysis O 0 5.292940485901454e-08
to O 0 7.1112542521234445e-09
other O 0 1.105381830512897e-08
non O 0 1.21073242098646e-06
- O 0 6.195163587108254e-05
Ashkenazi O 0 9.176897037832532e-06
subsets O 0 2.8036279786647356e-07
354 O 0 2.981808790991636e-07
of O 0 3.6693750260496927e-09
Moroccan O 0 4.027356226288248e-07
origin O 0 1.4314283980354503e-08
, O 0 1.4806152748292334e-08
200 O 0 1.04379786591835e-07
Yemenites O 0 4.824537973036058e-05
and O 0 2.610075000575307e-08
150 O 0 2.5598410502425395e-07
Iranian O 0 8.28603845093312e-07
Jews O 0 3.610002977438853e-06
. O 0 5.435006187326508e-06

Heteroduplex O 0 0.0026789207477122545
analysis O 0 4.736708433483727e-06
complemented O 0 2.4224079879786586e-06
by O 0 5.35076800645129e-08
direct O 0 7.172378957420733e-08
DNA O 0 4.364979417914583e-07
sequencing O 0 4.536601352356229e-07
of O 0 1.1761257923126323e-07
abnormally O 0 0.0009907305939123034
migrating O 0 3.3384499147359747e-06
bands O 0 6.615852612412709e-07
were O 0 5.248175583005832e-08
employed O 0 4.117693151783897e-06
. O 0 6.669835784123279e-06

Four O 0 4.881031259174051e-07
of O 0 1.80056488829905e-07
Moroccan O 0 3.326246542201261e-06
origin O 0 1.5717513690560736e-07
( O 0 1.468082331257392e-07
1 O 0 5.6416503468881274e-08
. O 0 5.9841323007958636e-09
1 O 0 3.792417757608746e-08
% O 0 3.091198408355922e-08
) O 0 1.2592810350042782e-08
and O 0 1.4951073712410334e-09
none O 0 4.807321651867369e-09
of O 0 2.131446352748867e-09
the O 0 3.8146239944580884e-08
Yemenites O 0 0.0005736335297115147
or O 0 5.637326339069659e-08
Iranians O 0 7.027068704701378e-08
was O 0 1.2583926789488942e-08
a O 0 3.998492204004833e-08
carrier O 0 4.411534064274747e-06
of O 0 2.797452403058287e-08
the O 0 1.0694434422475751e-06
185delAG O 0 0.021131642162799835
mutation O 0 0.0002178322902182117
. O 0 1.1481746696517803e-05

BRCA1 O 0 0.2263776808977127
allelic O 0 0.006076479330658913
patterns O 0 1.933840394485742e-05
were O 0 3.3024846857188095e-08
determined O 0 1.3974221246826346e-07
for O 0 7.3919825815949025e-09
four O 0 8.132374773595075e-09
of O 0 6.49725029333581e-09
these O 0 4.077267856672506e-09
individuals O 0 1.3432618573006039e-08
and O 0 4.214926629941829e-09
for O 0 4.525355645768059e-09
12 O 0 6.42761079916454e-08
additional O 0 1.609523252454892e-07
non O 0 8.036075087147765e-06
- O 0 0.0023243906907737255
Ashkenazi O 0 0.0028578450437635183
185delAG O 0 0.006456747651100159
mutation O 0 0.00014343031216412783
carriers O 0 0.0009782578563317657
who O 0 8.480538235744461e-05
had O 0 0.007303921971470118
breast B-Disease 1 0.9990353584289551
/ I-Disease 1 0.999032735824585
ovarian I-Disease 1 0.9995959401130676
cancer I-Disease 1 0.9987558126449585
. O 0 0.0012809161562472582

Six O 0 2.4731678422540426e-05
non O 0 0.00039192818803712726
- O 0 0.021752269938588142
Ashkenazi O 0 0.0016457134624943137
individuals O 0 4.667592463647452e-07
shared O 0 6.523143269987486e-07
the O 0 3.2281775474984897e-07
common O 0 2.9793165595037863e-05
Ashkenazi O 0 0.015357067808508873
haplotype O 0 0.011752627789974213
, O 0 9.255018795784054e-08
four O 0 1.4841777584706506e-08
had O 0 2.5925505298118878e-08
a O 0 7.159353287988779e-08
closely O 0 4.594501206156565e-07
related O 0 7.048786301311338e-06
pattern O 0 9.789941032067873e-06
, O 0 3.6505916511941905e-08
and O 0 7.643375710131295e-09
the O 0 1.0659549687375147e-08
rest O 0 2.197767656753058e-07
( O 0 1.990088378533983e-07
n O 0 2.64739855992957e-06
= O 0 4.974333933205344e-06
6 O 0 1.0849910125898532e-07
) O 0 1.7047465661335082e-08
displayed O 0 5.471184039151922e-08
a O 0 8.273059393104631e-08
distinct O 0 2.676976009752252e-06
BRCA1 O 0 0.006141307298094034
allelic O 0 0.002217126777395606
pattern O 0 0.00023426600091625005
. O 0 2.2054991859477013e-05

We O 0 1.2302949699005694e-06
conclude O 0 2.590257963674958e-06
that O 0 2.981589730666201e-08
the O 0 2.1338765066047927e-07
185delAG O 0 0.03352218493819237
BRCA1 O 0 0.04872233420610428
mutation O 0 2.4880520868464373e-05
occurs O 0 3.72571861362303e-07
in O 0 1.3124430431332712e-08
some O 0 5.9329135382313325e-08
non O 0 3.403743903618306e-05
- O 0 0.04478801041841507
Ashkenazi O 0 0.004129196982830763
populations O 0 4.139052180107683e-06
at O 0 3.910265888862341e-07
rates O 0 2.2174258447194006e-06
comparable O 0 8.128592980938265e-07
with O 0 4.749341542265029e-08
that O 0 4.889085758463807e-08
of O 0 6.474681981671893e-07
Ashkenazim O 0 0.021559014916419983
. O 0 3.2435102184535936e-05

The O 0 5.701057261831011e-07
majority O 0 7.92616049238859e-07
of O 0 1.7290518883328332e-07
Jewish O 0 1.966364106920082e-05
185delAG O 0 0.06534172594547272
mutation O 0 0.00016463021165691316
carriers O 0 3.507038127281703e-05
have O 0 1.2011423855540215e-08
a O 0 1.0735845279441492e-07
common O 0 4.653898940887302e-06
allelic O 0 0.001634643878787756
pattern O 0 3.545288200257346e-05
, O 0 1.6886312437236484e-07
supporting O 0 5.998344363433716e-07
the O 0 4.078109938632224e-08
founder O 0 2.889013194362633e-05
effect O 0 1.1634632528512157e-06
notion O 0 6.893702106935962e-07
, O 0 6.327393009541993e-08
but O 0 1.7754407721781718e-08
dating O 0 8.651818461657967e-07
the O 0 2.266085630253656e-08
mutations O 0 5.553717983275419e-07
origin O 0 5.619877896378966e-09
to O 0 3.3089775364203433e-09
an O 0 5.71351943534637e-09
earlier O 0 9.711763482300739e-08
date O 0 1.394397486365051e-07
than O 0 8.857145417096035e-08
currently O 0 8.273893854493508e-07
estimated O 0 8.479288226226345e-06
. O 0 1.0072635632241145e-05

However O 0 2.1075252334412653e-06
, O 0 1.0227093127923581e-07
the O 0 1.7687010966938033e-08
different O 0 1.0177410025846712e-08
allelic O 0 6.453716923715547e-05
pattern O 0 5.999980203341693e-06
at O 0 1.321476332805105e-07
the O 0 1.5445529299995542e-07
BRCA1 O 0 0.003107768716290593
locus O 0 1.0358688996348064e-05
even O 0 6.100671612330189e-08
in O 0 1.851932474039586e-08
some O 0 2.5426825089880367e-08
Jewish O 0 6.022842171660159e-06
mutation O 0 0.00011827720300061628
carriers O 0 0.0002737963222898543
, O 0 2.5221405053343915e-07
might O 0 2.2372690011707164e-07
suggest O 0 1.9720269506251498e-07
that O 0 6.891609949377653e-09
the O 0 5.405586733786549e-08
mutation O 0 1.3314614079718012e-05
arose O 0 4.7313765207945835e-06
independently O 0 4.1293316144219716e-07
. O 0 7.827919148439832e-07
. O 0 7.102640211087419e-06

Crystal O 0 0.0011546551249921322
structure O 0 9.969574421120342e-06
of O 0 9.877595630314318e-07
the O 0 2.628344554977957e-05
hemochromatosis B-Disease 1 0.9978659749031067
protein O 0 0.0001357266737613827
HFE O 0 0.2823411226272583
and O 0 1.4943432802283496e-07
characterization O 0 1.3073496347715263e-06
of O 0 6.631453164374079e-09
its O 0 3.245070701041186e-08
interaction O 0 5.714753683605522e-07
with O 0 2.897212880270672e-06
transferrin O 0 0.2474014163017273
receptor O 0 0.0007303811726160347
. O 0 8.429815352428705e-06

HFE O 0 0.3839704990386963
is O 0 5.659541784552857e-06
an O 0 8.416913260589354e-06
MHC O 1 0.7364521026611328
- O 0 0.003186493180692196
related O 0 7.0505479925486725e-06
protein O 0 3.5347034099686425e-07
that O 0 8.390476757824672e-09
is O 0 2.6946333164801217e-08
mutated O 0 1.0229439794784412e-05
in O 0 2.3403751470141287e-07
the O 0 7.16987324267393e-06
iron B-Disease 1 0.9796335697174072
- I-Disease 1 0.9979396462440491
overload I-Disease 1 0.9984244108200073
disease I-Disease 1 0.9991948008537292
hereditary B-Disease 1 0.9977355003356934
hemochromatosis I-Disease 1 0.9986928105354309
. O 0 0.006991804111748934

HFE O 0 0.07388868182897568
binds O 0 8.379171777050942e-05
to O 0 4.5420488277159166e-06
transferrin O 0 0.013894758187234402
receptor O 0 0.00016811152454465628
( O 0 7.72505154600367e-06
TfR O 0 0.0018937266431748867
) O 0 8.100812465272611e-08
and O 0 9.708815085218703e-09
reduces O 0 7.859845254643005e-07
its O 0 3.5625091765467687e-09
affinity O 0 1.9437359810581256e-07
for O 0 2.3295433138059707e-08
iron O 0 0.0001644301664782688
- O 0 7.872647984186187e-05
loaded O 0 5.413192866399186e-06
transferrin O 0 0.006150814238935709
, O 0 2.403898406555527e-06
implicating O 0 0.028642360121011734
HFE O 1 0.7715500593185425
in O 0 6.799497896281537e-06
iron O 0 0.09365767985582352
metabolism O 0 0.001941473106853664
. O 0 2.0923409465467557e-05

The O 0 3.517639197525568e-05
2 O 0 0.00011091376654803753
. O 0 5.564307139138691e-05

6 O 0 2.3285154384211637e-05
A O 0 6.37567245576065e-06
crystal O 0 0.00032760645262897015
structure O 0 4.849854121857788e-06
of O 0 6.251970603443624e-07
HFE O 0 0.40909630060195923
reveals O 0 1.9081764548900537e-05
the O 0 4.364904526710234e-08
locations O 0 2.0481795104387857e-07
of O 0 3.188425580447074e-06
hemochromatosis B-Disease 1 0.9992355108261108
mutations O 0 6.888258212711662e-05
and O 0 1.9645523252620478e-07
a O 0 2.001673692575423e-06
patch O 0 0.2751709520816803
of O 0 4.908661708213913e-07
histidines O 0 0.0711696594953537
that O 0 4.0129631173613234e-08
could O 0 4.62809879309134e-08
be O 0 4.916201223892358e-09
involved O 0 1.5381088758203987e-07
in O 0 1.0241641348329722e-06
pH O 0 0.01647368259727955
- O 0 0.002382142934948206
dependent O 0 1.9092722141067497e-05
interactions O 0 7.945035576994997e-06
. O 0 8.135672032949515e-06

We O 0 1.6705487269064179e-06
also O 0 3.3511025776533643e-07
demonstrate O 0 1.6127650042108144e-06
that O 0 3.7307853517631884e-07
soluble O 0 0.0023101007100194693
TfR O 0 0.03679746761918068
and O 0 1.1988944379481836e-06
HFE O 0 0.47738251090049744
bind O 0 8.501312549924478e-06
tightly O 0 8.873578281054506e-07
at O 0 3.655308233874166e-08
the O 0 6.325231005632759e-09
basic O 0 1.0149537388315366e-07
pH O 0 3.781475015784963e-06
of O 0 3.5043954405011846e-09
the O 0 2.974477908423978e-08
cell O 0 1.568389416206628e-05
surface O 0 3.3712888125592144e-06
, O 0 2.4609716930967807e-08
but O 0 2.196724580016962e-09
not O 0 7.324723605428574e-10
at O 0 1.3105944773883493e-08
the O 0 3.860156638779699e-08
acidic O 0 0.00021246231335680932
pH O 0 5.435277125798166e-05
of O 0 1.411892185387842e-07
intracellular O 0 0.00016385404160246253
vesicles O 0 0.000469349033664912
. O 0 6.143201517261332e-06

TfR O 1 0.5501242876052856
HFE O 0 0.4131615161895752
stoichiometry O 0 0.0006721711833961308
( O 0 4.832997092307778e-06
2 O 0 9.395885172125418e-07
1 O 0 3.18400282139919e-07
) O 0 9.742895912268068e-08
differs O 0 7.879291388235288e-07
from O 0 2.3441234020538104e-07
TfR O 0 0.0059040626510977745
transferrin O 0 0.00126385479234159
stoichiometry O 0 1.7430766092729755e-05
( O 0 7.452747041725161e-08
2 O 0 8.162510312104132e-08
2 O 0 1.4209695109457243e-07
) O 0 2.7691781312455532e-08
, O 0 4.33579439018672e-09
implying O 0 4.368327566339758e-08
a O 0 1.1658441989581547e-09
different O 0 2.948457866747134e-10
mode O 0 1.4497194555929127e-08
of O 0 1.6501672250868182e-09
binding O 0 8.333540790772531e-08
for O 0 1.2825911710478977e-07
HFE O 0 0.05125914886593819
and O 0 2.3175029184585583e-07
transferrin O 0 0.0042283497750759125
to O 0 3.5018720723201113e-07
TfR O 0 0.03017423301935196
, O 0 2.8802038087860637e-08
consistent O 0 3.009632010275709e-08
with O 0 1.0977780462440023e-08
our O 0 1.3967073719811651e-08
demonstration O 0 4.856852910961607e-07
that O 0 8.014075092432904e-08
HFE O 0 0.0944661945104599
, O 0 9.575749118084786e-07
transferrin O 0 0.020028559491038322
, O 0 1.6694865223598754e-07
and O 0 2.100689613371287e-07
TfR O 0 0.003106032032519579
form O 0 4.870281031799095e-07
a O 0 8.714512773622118e-07
ternary O 0 0.0006470521911978722
complex O 0 0.0001871918939286843
. O 0 2.483477146597579e-05

Identification O 0 2.1541936803259887e-06
of O 0 8.236405335537711e-08
three O 0 1.601596295586205e-07
novel O 0 7.13096324034268e-06
mutations O 0 3.1041195143188816e-06
and O 0 8.960691744164251e-09
a O 0 1.8758472108970636e-08
high O 0 7.765626008904292e-08
frequency O 0 7.504838528404889e-09
of O 0 3.281661609122466e-09
the O 0 1.8761018338864233e-07
Arg778Leu O 0 0.020231397822499275
mutation O 0 4.070222348673269e-05
in O 0 4.260680270817829e-06
Korean O 0 0.12429241836071014
patients O 1 0.9131702184677124
with O 0 0.0017512401100248098
Wilson B-Disease 1 0.9781895279884338
disease I-Disease 1 0.9977389574050903
. O 0 0.00040990413981489837

Four O 0 6.856336767668836e-06
mutations O 0 0.0001324327604379505
- O 0 0.0008113454096019268
- O 0 0.00043128992547281086
R778L O 0 0.0003793071664404124
, O 0 3.5198317505091836e-07
A874V O 0 0.0001007914324873127
, O 0 1.3085268335544242e-07
L1083F O 0 1.959479232027661e-05
, O 0 3.251476954346799e-08
and O 0 3.1685445378570876e-08
2304delC O 0 0.00014778561308048666
- O 0 3.9650341932429e-05
- O 0 3.354298314661719e-06
in O 0 4.85417395168497e-09
the O 0 8.475046442413259e-09
copper O 0 3.3530252494529122e-06
- O 0 3.62408036380657e-06
transporting O 0 4.7101983113861934e-07
enzyme O 0 4.776431410391524e-07
, O 0 3.7267486874270617e-08
P O 0 2.8614324037334882e-05
- O 0 2.8379468858474866e-05
type O 0 7.145286417653551e-06
ATPase O 0 0.00036309193819761276
( O 0 6.902182008161617e-07
ATP7B O 0 0.001792561961337924
) O 0 3.823270233738185e-08
, O 0 6.32472385575511e-09
were O 0 2.819198208214857e-09
identified O 0 2.2679324729324435e-07
in O 0 1.107251478060789e-06
Korean O 0 0.07270260900259018
Patients O 1 0.8452740907669067
with O 0 0.0033801121171563864
Wilson B-Disease 1 0.9925498962402344
disease I-Disease 1 0.9983202815055847
. O 0 0.00045729411067441106

Arg778Leu O 0 0.034146253019571304
, O 0 1.796121068764478e-06
the O 0 1.1597726512491136e-07
most O 0 7.027590953612162e-08
frequently O 0 4.94335893108655e-07
reported O 0 1.423914909537416e-06
mutation O 0 5.643780696118483e-07
of O 0 4.80175010864059e-09
this O 0 2.1379703341040113e-08
enzyme O 0 1.4267802725953516e-06
, O 0 1.583685360628806e-08
was O 0 4.9512829392028834e-09
found O 0 1.6727872420574386e-09
in O 0 1.2797944926035143e-09
six O 0 9.547853174751708e-09
of O 0 2.309629998364926e-08
eight O 0 4.862961304752389e-06
unrelated O 0 0.016244668513536453
patients O 0 0.05790222808718681
studied O 0 1.711745767352113e-06
, O 0 8.862215139515683e-08
an O 0 2.299870871524945e-08
allele O 0 6.617070198444708e-07
frequency O 0 3.978150786565493e-08
of O 0 5.052987361864325e-08
37 O 0 1.2920218068757094e-05
. O 0 7.746113624307327e-06

5 O 0 2.6345453079557046e-05
% O 0 2.6326149509259267e-06
, O 0 2.8746393354595057e-07
which O 0 5.481943077256801e-08
is O 0 6.875096403291536e-08
considerably O 0 2.9967320642754203e-06
higher O 0 1.3894249661916547e-07
than O 0 1.3137278820352094e-08
those O 0 2.26143530568379e-08
in O 0 5.9455100398508876e-08
other O 0 2.92191998596536e-07
Asian O 0 0.00018242972146254033
populations O 0 8.440794772468507e-05
. O 0 1.1999183698208071e-05

The O 0 6.751964178874914e-07
novel O 0 1.267571406060597e-06
single O 0 1.8381031452463503e-07
nucleotide O 0 1.6358892480639042e-06
deletion O 0 0.0001159480816568248
, O 0 8.055941407292266e-07
2304delC O 0 0.00096366205252707
, O 0 1.3072470039787731e-07
was O 0 8.176098020840072e-08
found O 0 6.287596221454805e-08
in O 0 1.4653575419742992e-07
one O 0 7.685567879889277e-07
patient O 0 0.004119362682104111
. O 0 4.360917955636978e-05

Since O 0 4.832374997931765e-06
a O 0 5.85982377288019e-07
mutation O 0 1.0647560202414752e-06
at O 0 1.16964265828301e-07
cDNA O 0 2.313904133188771e-06
nucleotide O 0 3.153462103000493e-06
2302 O 0 0.08620651066303253
( O 0 1.734369334371877e-06
2302insC O 0 0.0001623202842893079
) O 0 1.2953050543274003e-07
had O 0 1.9902396175552894e-08
been O 0 8.990068245395832e-09
previously O 0 9.335650474895374e-08
described O 0 3.577491440864833e-07
, O 0 1.1202200056459333e-08
this O 0 2.0845589698836875e-09
region O 0 4.347372950519457e-08
of O 0 4.993334190572796e-09
the O 0 3.221332178782177e-07
ATP7B O 1 0.7664055824279785
gene O 0 0.0001368342200294137
may O 0 4.524133601080393e-06
be O 0 9.779405729659629e-08
susceptible O 0 0.0006885627517476678
to O 0 1.0627655910866451e-06
gene O 0 0.0008065273286774755
rearrangements O 0 0.4455778896808624
causing O 1 0.9607646465301514
Wilson B-Disease 1 0.9663569331169128
disease I-Disease 1 0.997718095779419
. O 0 0.00045476912055164576

Disruption O 0 9.671912266639993e-05
of O 0 3.7436549860103696e-07
splicing O 0 5.428567419585306e-06
regulated O 0 7.752009310024732e-07
by O 0 1.0950681428312237e-07
a O 0 8.623053986411833e-07
CUG O 0 0.020376279950141907
- O 0 0.0005680166068486869
binding O 0 1.0422483683214523e-05
protein O 0 3.3566753700142726e-05
in O 0 9.778168168850243e-05
myotonic B-Disease 1 0.9973747730255127
dystrophy I-Disease 1 0.9973863959312439
. O 0 0.0008874492486938834

Myotonic B-Disease 1 0.9914845824241638
dystrophy I-Disease 1 0.9969393014907837
( O 1 0.8397561311721802
DM B-Disease 1 0.9984782338142395
) O 0 8.276901644421741e-05
is O 0 1.394566538692743e-06
caused O 0 3.7483714550035074e-05
by O 0 4.2528267130137465e-08
a O 0 1.9136265905217442e-07
CTG O 0 0.0010644920403137803
expansion O 0 1.470659412916575e-06
in O 0 1.5177114676134806e-08
the O 0 1.3259649378483118e-08
3 O 0 5.532277214115311e-07
untranslated O 0 0.00014542318240273744
region O 0 3.1128001864999533e-07
of O 0 4.894627991802736e-08
the O 0 5.572537702391855e-06
DM B-Disease 1 0.9971655011177063
gene O 0 0.0002203973854193464
. O 0 1.5998934031813405e-05

One O 0 2.9259342682053102e-06
model O 0 1.9536408217391e-05
of O 0 1.9453398635960184e-05
DM B-Disease 1 0.9984729886054993
pathogenesis O 1 0.758272647857666
suggests O 0 2.1349533199099824e-05
that O 0 5.327925478582074e-08
RNAs O 0 4.9279856284556445e-06
from O 0 9.96220794746705e-09
the O 0 5.430561778041465e-09
expanded O 0 1.1152190637631065e-07
allele O 0 1.6325246576798236e-07
create O 0 2.2616120531893102e-08
a O 0 1.6251858525606622e-08
gain O 0 4.348327138359309e-07
- O 0 7.124913281586487e-06
of O 0 4.243063500553035e-08
- O 0 8.909758616937324e-05
function O 0 8.102172444068856e-08
mutation O 0 2.2888110606800183e-07
by O 0 1.5729015867549379e-09
the O 0 3.4488081279704375e-09
inappropriate O 0 7.578012883868723e-08
binding O 0 9.824983493444961e-09
of O 0 1.5333152525442983e-09
proteins O 0 1.9586513744229705e-08
to O 0 1.3144648036700346e-08
the O 0 2.640122147568036e-07
CUG O 0 0.023299546912312508
repeats O 0 0.00015568725939374417
. O 0 6.012163339619292e-06

Data O 0 1.5153017557167914e-05
presented O 0 3.920309154636925e-06
here O 0 3.488525806005782e-07
indicate O 0 2.0420300472778763e-07
that O 0 5.661233259957044e-09
the O 0 1.478738376192723e-08
conserved O 0 1.046564307216613e-06
heterogeneous O 0 8.553951920475811e-05
nuclear O 0 7.60374023229815e-05
ribonucleoprotein O 0 0.054821621626615524
, O 0 2.3045569719215564e-07
CUG O 0 0.0004916485631838441
- O 0 5.440756922325818e-06
binding O 0 1.2544893479571328e-07
protein O 0 3.2966292451419577e-07
( O 0 4.1318921262245567e-07
CUG O 0 0.0008953937795013189
- O 0 8.632363460492343e-05
BP O 0 4.910628194920719e-05
) O 0 7.210606867147362e-08
, O 0 1.7769279381241176e-08
may O 0 2.3249715042084063e-08
mediate O 0 1.4142143527351436e-06
the O 0 5.1032753134450104e-08
trans O 0 0.0001345404307357967
- O 0 9.395934466738254e-05
dominant O 0 8.273980256490177e-07
effect O 0 6.608210156855421e-08
of O 0 8.360204084567613e-09
the O 0 1.3228873285697773e-07
RNA O 0 6.309776836133096e-06
. O 0 2.084040943373111e-06

CUG O 0 0.32949215173721313
- O 0 0.008714511059224606
BP O 0 0.0005000641103833914
was O 0 2.856155845165631e-07
found O 0 5.666572633344913e-08
to O 0 1.6137846614583395e-08
bind O 0 1.347752572655736e-06
to O 0 3.9664527662353066e-08
the O 0 2.714220102006948e-07
human O 0 7.573218317702413e-05
cardiac O 1 0.9946117401123047
troponin O 1 0.9972835779190063
T O 1 0.7718694806098938
( O 0 4.883233032160206e-06
cTNT O 0 0.00019936876196879894
) O 0 1.4604133014017862e-07
pre O 0 6.535349257319467e-06
- O 0 1.4666856259282213e-05
messenger O 0 1.5499314258704544e-06
RNA O 0 1.1959853907228535e-07
and O 0 7.303188276353012e-09
regulate O 0 1.4507739365399175e-07
its O 0 2.2923339670910536e-08
alternative O 0 7.98875305463298e-07
splicing O 0 1.2059113032591995e-05
. O 0 4.09423091696226e-06

Splicing O 0 2.0555327864713036e-05
of O 0 1.0265941909892717e-06
cTNT O 0 0.0013462180504575372
was O 0 2.7497837891132804e-06
disrupted O 0 0.00021742208627983928
in O 0 3.629895581980236e-05
DM B-Disease 1 0.9990754127502441
striated O 1 0.9956537485122681
muscle O 0 0.31393566727638245
and O 0 4.659369210457953e-07
in O 0 2.3381041103220923e-07
normal O 0 4.4655712372332346e-06
cells O 0 9.401384886587039e-06
expressing O 0 2.3894097012089333e-06
transcripts O 0 1.998171910599922e-06
that O 0 6.896372184428401e-08
contain O 0 1.1644217011053115e-05
CUG O 0 0.16263501346111298
repeats O 0 0.0006104768835939467
. O 0 1.4621661648561712e-05

Altered O 0 3.229694630135782e-05
expression O 0 9.930356554832542e-07
of O 0 8.84915749566062e-08
genes O 0 1.7422720475224196e-06
regulated O 0 4.967824224877404e-06
posttranscriptionally O 0 0.000813300721347332
by O 0 1.101521888813295e-06
CUG O 0 0.28003382682800293
- O 0 0.01659262552857399
BP O 0 0.0011179258581250906
therefore O 0 5.061505135017796e-07
may O 0 1.2082422244930058e-06
contribute O 0 1.406066439813003e-05
to O 0 1.3584418411483057e-05
DM B-Disease 1 0.998603880405426
pathogenesis O 1 0.8256232738494873
. O 0 7.729908247711137e-06
. O 0 2.443544326524716e-05

Identification O 0 3.3116896247520344e-06
of O 0 1.6241948230799608e-07
a O 0 7.732251674497093e-07
novel O 0 1.0693275726225693e-05
nonsense O 0 6.868423224659637e-05
mutation O 0 1.2929308468301315e-06
and O 0 8.541158003083638e-09
a O 0 2.972345569673962e-08
missense O 0 2.6173242986260448e-06
substitution O 0 5.07978334951531e-08
in O 0 1.1247975884032257e-08
the O 0 3.8855151984762415e-08
vasopressin O 0 9.568598034093156e-05
- O 0 0.0013241947162896395
neurophysin O 0 0.021814430132508278
II O 0 0.0008102718857116997
gene O 0 3.5137415466124367e-07
in O 0 1.1717188996840378e-08
two O 0 2.0714763238061096e-08
Spanish O 0 4.759897819894832e-06
kindreds O 0 0.0035194980446249247
with O 0 0.0002121552242897451
familial B-Disease 1 0.9966740608215332
neurohypophyseal I-Disease 1 0.9977189898490906
diabetes I-Disease 1 0.9990273714065552
insipidus I-Disease 1 0.9963339567184448
. O 0 0.002796351909637451

Familial B-Disease 1 0.9749719500541687
neurohypophyseal I-Disease 1 0.9899300932884216
diabetes I-Disease 1 0.9986469149589539
insipidus I-Disease 1 0.997283935546875
( O 0 0.04981635883450508
FNDI B-Disease 1 0.9944537281990051
) O 0 2.9859897040296346e-05
is O 0 3.1275046694645425e-06
an O 0 9.233586024492979e-05
autosomal B-Disease 1 0.9980955719947815
dominant I-Disease 1 0.9980407357215881
disease I-Disease 1 0.9997560381889343
caused O 1 0.9863911867141724
by O 0 0.0027103594038635492
deficiency O 1 0.9993683695793152
in O 0 1.3273993317852728e-06
the O 0 2.4780613330221968e-06
antidiuretic O 0 0.29348239302635193
hormone O 0 0.0011755062732845545
arginine O 0 4.6115557779558e-05
vasopressin O 0 0.00024054905225057155
( O 0 1.4321705066322465e-06
AVP O 0 0.0002128195483237505
) O 0 1.2135405569324575e-08
encoded O 0 2.680054622672401e-09
by O 0 4.9610950902945206e-09
the O 0 5.527763491386395e-08
AVP O 0 0.008584754541516304
- O 0 0.0005522819701582193
neurophysin O 0 0.00970856286585331
II O 0 0.007300123572349548
( O 0 8.672522199049126e-06
AVP O 0 0.09086010605096817
- O 0 0.003489942057058215
NPII O 0 0.027489282190799713
) O 0 3.3263182785958634e-07
gene O 0 7.709683131906786e-07
on O 0 2.191919463712111e-07
chromosome O 0 0.00025903177447617054
20p13 O 0 0.002903657266870141
. O 0 1.1750728845072445e-05

In O 0 2.5891069981298642e-06
this O 0 2.501167557511508e-07
study O 0 1.0376962791269762e-06
, O 0 8.36204208098934e-08
we O 0 5.459860119572113e-09
analyzed O 0 5.77580152594237e-08
two O 0 3.2772080604814846e-09
families O 0 8.509486804086919e-08
with O 0 1.0082199963790117e-07
FNDI B-Disease 0 0.0058493115939199924
using O 0 7.441607774438808e-09
direct O 0 1.598360732657511e-08
automated O 0 3.4075387134180346e-07
fluorescent O 0 2.679596718735411e-06
, O 0 1.348717226790086e-08
solid O 0 1.545672745351112e-07
phase O 0 4.3483686340550776e-07
, O 0 1.0701903363496967e-08
single O 0 1.573256369624687e-08
- O 0 2.343019787076628e-06
stranded O 0 1.843942669665921e-07
DNA O 0 3.619668476062543e-08
sequencing O 0 2.7683332959327345e-08
of O 0 1.4167067519110788e-08
PCR O 0 1.7333544747089036e-05
- O 0 0.00011221719614695758
amplified O 0 0.00013206955918576568
AVP O 0 0.03915996849536896
- O 0 0.0017236777348443866
NPII O 0 0.01692325808107853
DNA O 0 6.526622746605426e-05
. O 0 1.0286629731126595e-05

In O 0 8.131042932291166e-07
one O 0 8.774835436042849e-08
of O 0 5.080752529806887e-08
the O 0 2.7029525995203585e-07
families O 0 4.6219029172789305e-06
, O 0 1.1084473499067826e-06
affected O 0 4.722315679828171e-06
individuals O 0 6.525058893203095e-08
presented O 0 1.644348373019966e-07
a O 0 1.2026053752833832e-07
novel O 0 3.4452580166544067e-06
nonsense O 0 3.1167888664640486e-05
mutation O 0 6.744910479028476e-07
in O 0 1.3594458891930117e-08
exon O 0 3.703927859532996e-06
3 O 0 2.9004080914774022e-08
of O 0 1.0794251048551473e-09
the O 0 9.416337043433032e-09
gene O 0 1.2873631760612625e-07
, O 0 4.345439119646244e-09
consisting O 0 7.616918651365268e-09
in O 0 4.583399881852301e-09
a O 0 5.036975281313971e-08
G O 0 2.140914511983283e-05
to O 0 3.590068331504881e-08
T O 0 0.0005844722036272287
transition O 0 2.9870088269490225e-07
at O 0 3.9884533009626466e-08
nucleotide O 0 3.7269836639097775e-07
2101 O 0 0.000610771297942847
, O 0 7.19106019175797e-09
which O 0 2.267364074270972e-09
produces O 0 4.709757916998569e-08
a O 0 6.589328638284542e-09
stop O 0 5.856728790831767e-08
signal O 0 3.298292483577825e-08
in O 0 6.9807235547614255e-09
codon O 0 5.741499080613721e-07
82 O 0 3.830515197478235e-06
( O 0 1.6995039686662494e-06
Glu O 0 0.008761432953178883
) O 0 1.740185098242364e-07
of O 0 2.66258552983345e-07
NPII O 0 0.04257318377494812
. O 0 1.5019604688859545e-05

The O 0 2.1862108042114414e-05
premature O 0 0.01509066205471754
termination O 0 0.0005526079330593348
eliminates O 0 4.720910874311812e-05
part O 0 9.002855705375623e-08
of O 0 1.5913217410457037e-08
the O 0 1.6700758465049148e-07
C O 0 0.00019262601563241333
- O 0 0.00013623363338410854
terminal O 0 5.401327143772505e-06
domain O 0 2.939605536766976e-08
of O 0 8.810570051309696e-09
NPII O 0 0.00041294493712484837
, O 0 7.923862455072594e-09
including O 0 2.550734734541038e-09
a O 0 6.818469344693767e-09
cysteine O 0 2.779150634069083e-07
residue O 0 6.456991172854032e-07
in O 0 1.0059703292597533e-08
position O 0 4.1571475151158666e-08
85 O 0 2.2785691271565156e-06
, O 0 2.6979092737633437e-08
which O 0 3.997529418597878e-09
could O 0 5.530481406168519e-09
be O 0 5.271012515351003e-10
involved O 0 6.7433774120218e-09
in O 0 7.626047349162945e-09
the O 0 1.4965175765269123e-08
correct O 0 1.5271670008587535e-06
folding O 0 3.421950532356277e-05
of O 0 1.0855457333036611e-07
the O 0 2.9259063012432307e-06
prohormone O 1 0.5757178664207458
. O 0 2.0320603653090075e-05

In O 0 9.648946388551849e-07
the O 0 1.1775376407285876e-07
second O 0 1.53369683175697e-07
family O 0 7.219317126327951e-07
, O 0 1.9137646134481656e-08
a O 0 1.7830629417403543e-08
G279A O 0 9.511061762168538e-06
substitution O 0 6.615853465063992e-08
at O 0 2.5250713520108548e-08
position O 0 2.4453811420244165e-08
- O 0 1.5957159575918922e-06
1 O 0 6.467502089435584e-09
of O 0 5.737607611244755e-10
the O 0 3.376919632813724e-09
signal O 0 7.083627906467882e-08
peptide O 0 5.379194476518023e-07
was O 0 7.637503074420238e-09
observed O 0 1.805075733329886e-08
in O 0 7.588901063115827e-09
all O 0 2.8281235131544236e-08
affected O 0 1.2465586223697755e-05
individuals O 0 2.382624188612681e-06
. O 0 1.1254196579102427e-05

This O 0 4.074140633747447e-06
missense O 0 0.0003857119008898735
mutation O 0 2.129109634552151e-05
, O 0 3.578153382477467e-07
which O 0 2.428504615181737e-07
replaces O 0 0.004523790907114744
Ala O 0 0.4956797659397125
with O 0 1.4853232642053626e-05
Thr O 1 0.9303573369979858
, O 0 5.805943601444596e-07
is O 0 2.2253141196415527e-07
frequent O 0 2.8825103072449565e-05
among O 0 9.029261127579957e-05
FNDI B-Disease 1 0.9994202852249146
patients O 0 0.18539610505104065
and O 0 2.8150145681138383e-07
is O 0 7.407312807572453e-08
thought O 0 7.928234424525726e-08
to O 0 9.77617542474718e-09
reduce O 0 4.863388198828034e-07
the O 0 4.5601789011584515e-09
efficiency O 0 1.8940505697173649e-07
of O 0 1.6622825782519612e-08
cleavage O 0 6.828572077210993e-05
by O 0 1.4534550984990346e-07
signal O 0 3.779957069127704e-06
peptidases O 0 0.00020956834487151355
. O 0 4.5484628685699136e-07
. O 0 2.615101038827561e-06

Genetic O 0 0.0004192388732917607
heterogeneity O 0 0.0011151114013046026
of O 0 8.961462299339473e-05
Saethre B-Disease 1 0.9916567802429199
- I-Disease 1 0.9973836541175842
Chotzen I-Disease 1 0.9987836480140686
syndrome I-Disease 1 0.9996234178543091
, O 0 1.1088756764365826e-05
due O 0 8.888655429473147e-06
to O 0 4.992089657207543e-07
TWIST O 0 0.002507345750927925
and O 0 1.202385828946717e-05
FGFR O 1 0.7977544069290161
mutations O 0 0.0006847835611552
. O 0 1.9271037672297098e-05

Thirty O 0 0.00011173979146406054
- O 0 0.0002947091998066753
two O 0 8.637786095277988e-07
unrelated O 0 0.0010025912197306752
patients O 0 0.0012833713553845882
with O 0 2.7029861371374864e-07
features O 0 2.7777377908932976e-06
of O 0 6.229810878721764e-06
Saethre B-Disease 1 0.9971044659614563
- I-Disease 1 0.998810887336731
Chotzen I-Disease 1 0.9994643330574036
syndrome I-Disease 1 0.9997881054878235
, O 0 1.6366870113415644e-05
a O 0 2.0681209207396023e-05
common O 0 0.001993634505197406
autosomal B-Disease 1 0.9914178848266602
dominant I-Disease 0 0.19250094890594482
condition I-Disease 0 0.4180293083190918
of O 0 0.00016209107707254589
craniosynostosis B-Disease 1 0.999345600605011
and O 0 0.0032045510597527027
limb B-Disease 1 0.9987335801124573
anomalies I-Disease 0 0.3704475462436676
, O 0 3.553187468696706e-07
were O 0 2.0975260639488624e-08
screened O 0 2.0136978946538875e-06
for O 0 5.5332172621547215e-08
mutations O 0 4.005831215181388e-06
in O 0 1.332049066604668e-07
TWIST O 0 0.00025096870376728475
, O 0 1.4797958556300728e-06
FGFR2 O 0 0.05977019667625427
, O 0 9.234649382960924e-07
and O 0 2.7869823497894686e-06
FGFR3 O 0 0.21410834789276123
. O 0 2.3684066036366858e-05

Nine O 0 6.037161710992223e-06
novel O 0 9.590869922249112e-06
and O 0 6.19326328887837e-07
three O 0 8.114109277812531e-07
recurrent O 1 0.5324127078056335
TWIST O 0 0.012257527559995651
mutations O 0 3.336880763527006e-05
were O 0 2.427573164709429e-08
found O 0 1.2600648346960952e-07
in O 0 1.4080210064548737e-07
12 O 0 3.592898792703636e-06
families O 0 1.2180449630250223e-05
. O 0 2.6311230612918735e-05

Seven O 0 9.672749001765624e-06
families O 0 3.2450695925945183e-06
were O 0 4.928634567136214e-08
found O 0 3.4537340098950153e-08
to O 0 7.657121159354574e-09
have O 0 7.678737645733236e-09
the O 0 1.2792659731530875e-07
FGFR3 O 0 0.09242445230484009
P250R O 0 0.005284017417579889
mutation O 0 6.619047780986875e-06
, O 0 2.0000843647949296e-08
and O 0 4.1797969529966394e-09
one O 0 2.396129739068442e-09
individual O 0 1.5068515324401233e-08
was O 0 1.8062468853941027e-08
found O 0 7.036936811033456e-09
to O 0 2.1539814376581035e-09
have O 0 4.7946935310960725e-09
an O 0 1.2818868810882122e-07
FGFR2 O 0 0.09170065075159073
VV269 O 0 0.010716638527810574
- O 0 0.002015909878537059
270 O 0 7.046757673379034e-05
deletion O 0 0.0005424620467238128
. O 0 1.12715215436765e-05

To O 0 7.742302159385872e-07
date O 0 6.182175411595381e-07
, O 0 6.314035516652439e-08
our O 0 3.206585219572844e-08
detection O 0 1.8154742065235041e-06
rate O 0 9.835130754254351e-08
for O 0 2.1554415141622485e-08
TWIST O 0 4.631724004866555e-05
or O 0 6.821703664172674e-07
FGFR O 0 0.039192479103803635
mutations O 0 2.7709832011169055e-06
is O 0 1.2241507363341952e-08
68 O 0 6.52825860925077e-07
% O 0 3.083413702142934e-08
in O 0 5.440039529958085e-08
our O 0 7.141832156776218e-06
Saethre B-Disease 1 0.9895423650741577
- I-Disease 1 0.9985670447349548
Chotzen I-Disease 1 0.9995309114456177
syndrome I-Disease 1 0.999871015548706
patients O 0 0.3265168070793152
, O 0 4.39715080347014e-07
including O 0 3.890584707733069e-07
our O 0 5.138662686476891e-07
five O 0 1.5528399671893567e-05
patients O 0 0.48276397585868835
elsewhere O 0 3.970445322920568e-05
reported O 0 1.5572117263218388e-05
with O 0 7.68415611673845e-06
TWIST O 0 0.03132861480116844
mutations O 0 0.0020274536218494177
. O 0 3.370419653947465e-05

More O 0 8.322293751916732e-07
than O 0 2.8012172492708487e-07
35 O 0 5.764256343354646e-07
different O 0 5.485572529551064e-08
TWIST O 0 0.00037452057586051524
mutations O 0 1.409499418514315e-05
are O 0 1.519197212473955e-08
now O 0 2.2162200252751063e-07
known O 0 1.1444956982131771e-07
in O 0 3.4705330165252235e-08
the O 0 9.546563717321987e-08
literature O 0 4.439033546077553e-06
. O 0 1.3578887774201576e-05

The O 0 1.7407043060302385e-06
most O 0 4.910946245217929e-07
common O 0 2.5832073333731387e-06
phenotypic O 0 1.7427108105039224e-05
features O 0 2.4611042590549914e-06
, O 0 1.4520389868266648e-07
present O 0 7.443343008617376e-08
in O 0 1.010624384178982e-08
more O 0 4.160500832739444e-09
than O 0 5.317770224166907e-09
a O 0 1.4188321628694212e-08
third O 0 7.991376804739048e-08
of O 0 4.933563246822814e-08
our O 0 2.3346492525888607e-06
patients O 0 0.0047117057256400585
with O 0 1.1052110266973614e-06
TWIST O 0 0.0038795641157776117
mutations O 0 1.1824226021417417e-05
, O 0 3.681364191265857e-08
are O 0 1.1902843155553455e-08
coronal B-Disease 0 0.0002744551748037338
synostosis I-Disease 0 0.005326475016772747
, O 0 8.902856620807142e-07
brachycephaly B-Disease 0 0.0036380153615027666
, O 0 3.9678866414760705e-06
low B-Disease 0 0.004292420577257872
frontal I-Disease 1 0.9972215890884399
hairline I-Disease 1 0.9993523955345154
, O 0 0.001089389668777585
facial B-Disease 1 0.9972547888755798
asymmetry I-Disease 0 0.33483627438545227
, O 0 0.0005083689466118813
ptosis B-Disease 1 0.9990504384040833
, O 0 7.071192521834746e-05
hypertelorism B-Disease 1 0.9768163561820984
, O 0 1.990408463825588e-06
broad B-Disease 0 0.00018010646454058588
great I-Disease 0 6.088395093684085e-05
toes I-Disease 0 0.007347120437771082
, O 0 1.1494128102640389e-06
and O 0 2.895561010518577e-06
clinodactyly B-Disease 0 0.0800057128071785
. O 0 2.3923781554913148e-05

Significant O 0 2.837865577021148e-05
intra O 0 0.0007371057290583849
- O 0 0.0005741918575949967
and O 0 2.10851248994004e-06
interfamilial O 0 0.02503732591867447
phenotypic O 0 0.00026061045355163515
variability O 0 0.00015713540778961033
is O 0 6.606119029584079e-08
present O 0 1.1432990021376099e-07
for O 0 4.98775918345018e-08
either O 0 6.483227252829238e-07
TWIST O 0 0.003179119899868965
mutations O 0 0.00019843077461700886
or O 0 8.858783075993415e-06
FGFR O 1 0.767548680305481
mutations O 0 0.001240837387740612
. O 0 2.2371190425474197e-05

The O 0 3.7004606383561622e-06
overlap O 0 2.036318437603768e-05
in O 0 1.6154989452843438e-06
clinical O 0 0.00013080373173579574
features O 0 7.202730216704367e-07
and O 0 3.595529918243301e-08
the O 0 2.9166237425215513e-08
presence O 0 2.2141031763567298e-07
, O 0 1.5726623558975916e-08
in O 0 2.7774074151665218e-09
the O 0 2.4526340958175297e-09
same O 0 9.671278000666916e-09
genes O 0 8.039412335847373e-08
, O 0 4.087670646413244e-09
of O 0 2.376004948345667e-09
mutations O 0 2.5766235012270045e-07
for O 0 2.1972861308228175e-09
more O 0 3.0380176152533522e-09
than O 0 1.9456678046481102e-08
one O 0 2.6892737992056936e-07
craniosynostotic B-Disease 0 0.2642092704772949
condition I-Disease 0 0.0008116500684991479
- O 0 2.1124929844518192e-05
such O 0 3.43243655720471e-08
as O 0 1.4871778830638505e-07
Saethre B-Disease 0 0.0049261674284935
- I-Disease 0 0.0011917356168851256
Chotzen I-Disease 0 0.016961950808763504
, I-Disease 0 9.154976510217239e-07
Crouzon I-Disease 0 0.004551609046757221
, I-Disease 0 8.992092261905782e-07
and I-Disease 0 1.7518606910016388e-05
Pfeiffer I-Disease 1 0.9981246590614319
syndromes I-Disease 1 0.998793363571167
- O 0 0.0012138346210122108
support O 0 2.2994682069565897e-07
the O 0 2.8102659754836168e-08
hypothesis O 0 9.433162517780147e-07
that O 0 1.4632902001210368e-08
TWIST O 0 3.092632323387079e-05
and O 0 1.6492404597556742e-07
FGFRs O 0 0.0014059090754017234
are O 0 1.6640964162206728e-09
components O 0 1.0320009735664826e-08
of O 0 7.012079805690519e-10
the O 0 3.248512125963998e-09
same O 0 5.761209287413749e-09
molecular O 0 4.5739443521597423e-07
pathway O 0 1.8106969434938947e-07
involved O 0 7.290105852320039e-09
in O 0 2.7326012563833046e-09
the O 0 1.3961346745361425e-08
modulation O 0 4.152372184762498e-06
of O 0 1.430873680874356e-06
craniofacial O 1 0.99880051612854
and O 0 3.9955481042852625e-05
limb O 1 0.9609419107437134
development O 0 3.2705949706723914e-05
in O 0 2.23501342588861e-06
humans O 0 6.344125722534955e-05
. O 0 4.074614480487071e-06
. O 0 1.8881630239775404e-05

Mutation O 0 0.0002853086916729808
analysis O 0 4.059139973833226e-05
of O 0 0.00020318756287451833
UBE3A O 1 0.9878904819488525
in O 1 0.9624363780021667
Angelman B-Disease 1 0.9990457892417908
syndrome I-Disease 1 0.9996145963668823
patients O 1 0.9952600598335266
. O 0 0.005404116120189428

Angelman B-Disease 1 0.9973266124725342
syndrome I-Disease 1 0.9988987445831299
( O 0 0.0021479649003595114
AS B-Disease 0 0.00015863892622292042
) O 0 6.0671864048345014e-06
is O 0 3.6925109725416405e-07
caused O 0 2.1950536392978393e-05
by O 0 8.943261775584688e-08
chromosome O 0 4.437910683918744e-05
15q11 O 0 0.001561286742798984
- O 0 0.0003821426653303206
q13 O 0 0.0001550230081193149
deletions O 0 2.2276485651673283e-06
of O 0 3.3974529856095614e-08
maternal O 0 5.291396882967092e-05
origin O 0 5.184737972285802e-08
, O 0 6.108285788286594e-08
by O 0 2.1207463873906818e-07
paternal O 0 0.0013892203569412231
uniparental B-Disease 1 0.9402604699134827
disomy I-Disease 0 0.4788986146450043
( O 0 8.072795026237145e-05
UPD B-Disease 1 0.9387257099151611
) O 0 4.106506708012603e-07
15 O 0 2.195325095044609e-07
, O 0 1.0999938382383334e-07
by O 0 3.2689320050849346e-07
imprinting O 0 0.10789543390274048
defects O 1 0.6073799133300781
, O 0 1.4702540340749692e-07
and O 0 2.0588206695038025e-08
by O 0 7.110823219136364e-08
mutations O 0 2.785877086353139e-06
in O 0 1.1127543331213019e-07
the O 0 1.5702337350376183e-06
UBE3A O 1 0.5162889957427979
gene O 0 0.00010879218461923301
. O 0 1.3683365068573039e-05

UBE3A O 0 0.004709684289991856
encodes O 0 1.6102039808174595e-05
a O 0 2.401208348601358e-06
ubiquitin O 0 0.0001996415521716699
- O 0 0.000173146283486858
protein O 0 2.9261575491545955e-06
ligase O 0 6.958836456760764e-05
and O 0 2.742639253483503e-07
shows O 0 7.139523859223118e-06
brain O 0 0.040399566292762756
- O 0 0.0003213997988495976
specific O 0 2.0400789253471885e-06
imprinting O 0 0.0010176373180001974
. O 0 1.9781891751335934e-05

Here O 0 7.1533245318278205e-06
we O 0 5.244353360467358e-07
describe O 0 1.7992353605222888e-05
UBE3A O 0 0.1770266890525818
coding O 0 0.0007332739769481122
- O 0 0.00153638469055295
region O 0 9.011270776682068e-06
mutations O 0 1.1267985428276006e-05
detected O 0 2.2209942471818067e-06
by O 0 9.070748774320236e-08
SSCP O 0 0.0023685586638748646
analysis O 0 1.855290179264557e-07
in O 0 6.339679003986021e-08
13 O 0 1.6025145441744826e-06
AS B-Disease 0 1.725966058074846e-06
individuals O 0 1.0501215683689225e-06
or O 0 2.991312612721231e-06
families O 0 2.030574432865251e-05
. O 0 2.472899177519139e-05

Two O 0 4.863694016421505e-07
identical O 0 1.3540291092795087e-06
de O 0 3.623164275268209e-06
novo O 0 4.1684329517011065e-06
5 O 0 6.84984684085066e-07
- O 0 5.128096745465882e-05
bp O 0 9.667491212894674e-06
duplications O 0 4.525566509983037e-06
in O 0 4.156299127089369e-08
exon O 0 1.7269408999709412e-05
16 O 0 2.0149492740983987e-07
were O 0 2.05644639095226e-08
found O 0 5.945237830928818e-07
. O 0 3.9216292861965485e-06

Among O 0 3.587875653465744e-06
the O 0 1.5916958773232182e-07
other O 0 4.0501188180996905e-08
11 O 0 4.6488278826473106e-07
unique O 0 1.7014080810895393e-07
mutations O 0 2.199888967879815e-06
, O 0 2.66154902561766e-08
8 O 0 3.312029051016907e-08
were O 0 1.503084767762175e-09
small O 0 3.2267891469928145e-08
deletions O 0 9.117441095440881e-07
or O 0 6.376240690997292e-08
insertions O 0 1.8594044377095997e-05
predicted O 0 3.984331851825118e-05
to O 0 3.81425365958421e-07
cause O 0 0.00027932808734476566
frameshifts O 0 0.005537564400583506
, O 0 8.33966282698384e-08
1 O 0 8.385088534623719e-08
was O 0 9.259640165737437e-09
a O 0 8.860639333363451e-09
mutation O 0 6.973380095587345e-08
to O 0 7.782953170831775e-10
a O 0 3.832453021601623e-09
stop O 0 5.907777023139715e-08
codon O 0 7.784994693338376e-08
, O 0 4.610123838233449e-09
1 O 0 1.4221810396009005e-08
was O 0 5.560000904125673e-09
a O 0 3.246599789008542e-08
missense O 0 2.1723113604821265e-05
mutation O 0 4.655358623040229e-07
, O 0 8.046480814982715e-09
and O 0 6.0424656389557185e-09
1 O 0 1.0002271011444464e-07
was O 0 5.3389424437000343e-08
predicted O 0 3.011096168847871e-06
to O 0 1.5765637684239664e-08
cause O 0 1.9709186744876206e-06
insertion O 0 4.1764445768421865e-07
of O 0 3.9892120717865964e-09
an O 0 2.5825366734011368e-08
isoleucine O 0 3.118759923381731e-05
in O 0 9.368058329073392e-09
the O 0 8.296283660058634e-09
hect O 0 1.8221284335595556e-05
domain O 0 1.100761526373617e-08
of O 0 2.7497972787671188e-09
the O 0 3.759984679163608e-08
UBE3A O 0 0.0018015243113040924
protein O 0 6.169629784835706e-08
, O 0 2.6302888755935783e-09
which O 0 1.0459613175584082e-09
functions O 0 2.194764592289289e-09
in O 0 1.281326600377497e-08
E2 O 0 5.49251344637014e-05
binding O 0 2.0361669328394782e-07
and O 0 7.390843848043005e-08
ubiquitin O 0 1.9592886019381694e-05
transfer O 0 2.6077666461787885e-06
. O 0 5.000884812034201e-06

Eight O 0 2.169963181586354e-06
of O 0 2.3949206706674886e-07
the O 0 5.811106689179724e-07
cases O 0 5.2387822506716475e-06
were O 0 1.7013577746638475e-07
familial O 0 0.03734598681330681
, O 0 4.296487361443724e-07
and O 0 5.808979253174584e-08
five O 0 1.2669451621150074e-07
were O 0 1.3130095055657875e-07
sporadic O 0 9.2196227342356e-05
. O 0 2.893603959819302e-05

In O 0 7.197558261395898e-06
two O 0 1.7377153653796995e-06
familial O 0 0.40005818009376526
cases O 0 2.91486630885629e-05
and O 0 2.1358086144118715e-07
one O 0 7.470237761708631e-08
sporadic O 0 1.6253370631602593e-05
case O 0 8.830879778543022e-06
, O 0 2.6987486307916697e-06
mosaicism O 0 0.17092879116535187
for O 0 3.1834031233302085e-06
UBE3A O 1 0.9163591265678406
mutations O 0 6.849258352303877e-05
was O 0 2.6522909024606633e-07
detected O 0 1.9669942048494704e-06
in O 0 1.500324486869431e-08
the O 0 7.226354625800013e-09
mother O 0 4.904702564090258e-07
of O 0 3.2961460227909356e-09
three O 0 2.757156636334912e-08
AS B-Disease 0 2.4662685973453335e-06
sons O 0 7.203158020274714e-05
, O 0 1.035665135873387e-07
in O 0 3.3631785356647015e-08
the O 0 8.460433775780984e-08
maternal O 0 0.0001457812322769314
grandfather O 0 3.103391236436437e-06
of O 0 3.642125490088688e-09
two O 0 3.642389279079339e-09
AS B-Disease 0 1.0224577096096255e-07
first O 0 3.5794364805497025e-08
cousins O 0 3.6510377867671195e-06
, O 0 3.180236163302652e-08
and O 0 1.0748196110910158e-08
in O 0 1.7936677920715738e-08
the O 0 4.030744804595088e-08
mother O 0 2.41611178353196e-06
of O 0 4.3290370399518e-08
an O 0 5.721319098483946e-07
AS B-Disease 0 2.8564427339006215e-05
daughter O 0 0.003940597176551819
. O 0 4.791091487277299e-05

The O 0 8.095905741356546e-07
frequencies O 0 2.8449395017560164e-07
with O 0 8.082384539420673e-08
which O 0 2.2696887924666953e-08
we O 0 2.1378847137043522e-08
detected O 0 8.288757271657232e-07
mutations O 0 1.2767212353992363e-07
were O 0 1.0986341836272118e-09
5 O 0 5.060896413056071e-08
( O 0 2.5317746121800155e-08
14 O 0 1.7684582687138573e-08
% O 0 4.6657473440347985e-09
) O 0 1.542478922367252e-09
of O 0 4.6342951698363777e-10
35 O 0 3.3042553582163237e-08
in O 0 1.247090875011736e-08
sporadic O 0 1.3670210137206595e-06
cases O 0 1.6493191878907965e-07
and O 0 9.53031431549789e-09
8 O 0 9.339604645219879e-08
( O 0 3.865365272304189e-08
80 O 0 4.250766849622778e-08
% O 0 7.934555235067364e-09
) O 0 3.932769665482283e-09
of O 0 2.2318329406800785e-09
10 O 0 1.363793842301675e-07
in O 0 9.410285883859615e-07
familial O 0 0.30926626920700073
cases O 0 0.00011228065704926848
. O 0 5.535318905458553e-06
. O 0 2.468935417709872e-05

The O 0 8.637896098662168e-05
hemochromatosis B-Disease 1 0.9873933792114258
845 O 0 0.06521157175302505
G O 0 0.009820698760449886
- O 0 0.002891632728278637
- O 0 0.0002134786336682737
> O 0 1.4138651749817654e-05
A O 0 3.9097283632827384e-08
and O 0 2.5440989759317745e-08
187 O 0 2.4157616280717775e-06
C O 0 3.581342025427148e-05
- O 0 8.114022784866393e-05
- O 0 0.00021406973246484995
> O 0 0.0008509896579198539
G O 0 0.0007943794480524957
mutations O 0 1.7697155271889642e-05
: O 0 5.32758713234216e-06
prevalence O 0 0.0015536854043602943
in O 0 2.106511374222464e-07
non O 0 3.892483437084593e-05
- O 0 0.02455104887485504
Caucasian O 0 0.009739239700138569
populations O 0 6.901473534526303e-05
. O 0 8.76657031767536e-06

Hemochromatosis B-Disease 1 0.9874812960624695
, O 0 0.0005825695698149502
the O 0 0.0053336163982748985
inherited B-Disease 1 0.9987183809280396
disorder I-Disease 1 0.9988664388656616
of I-Disease 0 1.4209700566425454e-05
iron I-Disease 1 0.7385740876197815
metabolism I-Disease 0 0.011447742581367493
, O 0 2.49970344157191e-06
leads O 0 3.137539533781819e-05
, O 0 2.0891627627861453e-06
if O 0 4.708977030531969e-06
untreated O 1 0.5048642754554749
, O 0 4.395566293169395e-07
to O 0 1.167812001767743e-06
progressive O 0 0.05098022148013115
iron B-Disease 1 0.9636344909667969
overload I-Disease 1 0.9927940368652344
and O 0 6.395708624040708e-05
premature B-Disease 1 0.87491774559021
death I-Disease 0 0.006124250125139952
. O 0 9.367512393509969e-05

The O 0 0.00023922249965835363
hemochromatosis B-Disease 1 0.9928159713745117
gene O 0 0.0008979906560853124
, O 0 8.535610686521977e-05
HFE O 1 0.9674803614616394
, O 0 6.092594503570581e-06
recently O 0 1.2035973668389488e-05
has O 0 2.096354876357509e-07
been O 0 1.8966129999853365e-08
identified O 0 1.2970851059890265e-07
, O 0 2.556137523868074e-08
and O 0 1.3131917775410784e-08
characterization O 0 2.6862439881369937e-06
of O 0 1.3861394698722052e-08
this O 0 4.248059681799532e-08
gene O 0 2.1184289380471455e-06
has O 0 5.5609369553621946e-08
shown O 0 2.954168820679115e-08
that O 0 1.2906071766849436e-09
it O 0 9.297722036727407e-10
contains O 0 8.788499705758568e-09
two O 0 3.903482426181881e-09
mutations O 0 2.8659621875704033e-07
that O 0 1.1636004382253873e-09
result O 0 6.307809830019551e-09
in O 0 1.1441759761865455e-09
amino O 0 4.928462971065528e-09
acid O 0 7.589830630649885e-08
substitutions O 0 2.389649900180757e-08
- O 0 2.5139900117210345e-07
cDNA O 0 2.054674723694916e-07
nucleotides O 0 2.073046374562182e-07
845 O 0 3.150064731016755e-05
G O 0 4.607384471455589e-05
- O 0 2.8798174753319472e-05
- O 0 2.0703879272332415e-05
> O 0 7.788217772031203e-06
A O 0 4.572121525825423e-08
( O 0 1.0428367147596873e-07
C282Y O 0 3.38167978952697e-06
) O 0 7.612356967001688e-09
and O 0 3.6898122335315975e-09
187 O 0 7.727120987510716e-07
C O 0 1.5041478945931885e-05
- O 0 0.00016750158101785928
- O 0 0.0007150328019633889
> O 0 0.001239639357663691
G O 0 0.00023977072851266712
( O 0 4.613337296177633e-06
H63D O 0 0.004901334177702665
) O 0 1.6676708582963329e-06
. O 0 1.8666124788069283e-06

Although O 0 0.003931377548724413
hemochromatosis B-Disease 1 0.9947454929351807
is O 0 5.342882104741875e-06
common O 0 5.768788923887769e-06
in O 0 1.2908068356409785e-06
Caucasians O 0 0.0006709823501296341
, O 0 8.168021281562687e-07
affecting O 0 4.929216447635554e-05
> O 0 0.00146720209158957
= O 0 6.844793097116053e-05
1 O 0 1.2484732678785804e-06
/ O 0 3.229577487218194e-05
300 O 0 4.386010488133252e-08
individuals O 0 4.385539487117285e-09
of O 0 3.335960618855438e-09
northern O 0 1.259937505437847e-07
European O 0 2.673985477485985e-07
origin O 0 5.645643952334467e-08
, O 0 7.318781314324951e-08
it O 0 1.1989540915635644e-08
has O 0 3.290124084287527e-08
not O 0 5.9072107205793145e-09
been O 0 1.0430133201566605e-08
recognized O 0 1.1842475089451909e-07
in O 0 5.654890600226281e-08
other O 0 3.2807690786285093e-07
populations O 0 6.252185994526371e-05
. O 0 9.641546057537198e-06

The O 0 1.0947836699415348e-06
present O 0 5.433588512460119e-07
study O 0 3.157101104989124e-07
used O 0 5.024079641202661e-08
PCR O 0 4.951926712237764e-06
and O 0 6.291206489095202e-08
restriction O 0 2.324143906662357e-06
- O 0 7.805302448105067e-05
enzyme O 0 1.6816514971651486e-06
digestion O 0 1.5764396721351659e-06
to O 0 1.1905901819986298e-09
analyze O 0 5.331053820611942e-09
the O 0 3.5907563034065504e-10
frequency O 0 6.262539931078948e-10
of O 0 3.8044112304902455e-10
the O 0 5.2725437349465665e-09
845 O 0 0.00010191582987317815
G O 0 8.078870450844988e-05
- O 0 6.631963333347812e-05
- O 0 2.0014860638184473e-05
> O 0 3.469445573500707e-06
A O 0 7.13733117052584e-09
and O 0 4.744531434397459e-09
187 O 0 8.966770224105858e-07
C O 0 1.2263354619790334e-05
- O 0 4.465632082428783e-05
- O 0 7.249071495607495e-05
> O 0 5.3040217608213425e-05
G O 0 2.3855844119680114e-05
mutations O 0 7.451466785823868e-07
in O 0 4.567510458741708e-08
HLA O 0 0.005355774890631437
- O 0 4.198386704956647e-06
typed O 0 1.1140263467268596e-07
samples O 0 2.0137806089337573e-08
from O 0 2.5216541743589005e-08
non O 0 3.817626748059411e-06
- O 0 0.0010921732755377889
Caucasian O 0 0.0006378456018865108
populations O 0 8.725348834559554e-07
, O 0 1.8546757019066717e-08
comprising O 0 1.1552015166671481e-07
Australian O 0 1.570191784594499e-06
Aboriginal O 0 1.8212592749478063e-06
, O 0 6.110337125164733e-08
Chinese O 0 2.8784361916223133e-07
, O 0 2.86014625316966e-07
and O 0 4.5482545374397887e-07
Pacific O 0 0.00016534377937205136
Islanders O 0 0.000156649955897592
. O 0 8.184176294889767e-06

Results O 0 9.795974619919434e-06
showed O 0 2.1070047750981757e-06
that O 0 5.349645348928789e-08
the O 0 1.2704127527740638e-07
845 O 0 0.0009075249545276165
G O 0 0.0011385584948584437
- O 0 0.0020844500977545977
- O 0 0.0015025464817881584
> O 0 0.0002639178710523993
A O 0 7.463194151569041e-07
mutation O 0 2.9282623472681735e-06
was O 0 2.105900342996847e-08
present O 0 1.8040536176044952e-08
in O 0 4.8416444187182606e-09
these O 0 3.3617917338801817e-09
populations O 0 8.299912224174477e-08
( O 0 1.3657169617431464e-08
allele O 0 2.7053348006234046e-08
frequency O 0 2.9771214382634525e-09
0 O 0 1.2586759190469365e-08
. O 0 1.5380867690595323e-09
32 O 0 2.1345313072629324e-08
% O 0 1.1643003006156505e-08
) O 0 2.340785343335483e-08
, O 0 4.076031512312284e-09
and O 0 5.4321152020975205e-09
, O 0 2.8940091212348307e-08
furthermore O 0 2.416150266526529e-07
, O 0 1.1118904907903016e-08
it O 0 2.372956942053861e-09
was O 0 6.860291446031397e-09
always O 0 1.0114805881755728e-08
seen O 0 2.3152447070629023e-08
in O 0 7.390516199023978e-09
conjunction O 0 1.026285758598533e-06
with O 0 2.572125822553062e-06
HLA O 1 0.9232789874076843
haplotypes O 0 0.0015872432850301266
common O 0 1.5164548585744342e-06
in O 0 2.760962161119096e-07
Caucasians O 0 0.00035745828063227236
, O 0 1.5220199145460356e-07
suggesting O 0 9.97630877463962e-07
that O 0 5.028422478403627e-08
845 O 0 0.003909336403012276
G O 0 0.0038010203279554844
- O 0 0.009972702711820602
- O 0 0.008401473984122276
> O 0 0.0007685972959734499
A O 0 6.072472729101719e-07
may O 0 1.0331928734785834e-07
have O 0 1.5865446734153466e-09
been O 0 2.24808927029585e-09
introduced O 0 1.7852578082511172e-08
into O 0 5.446120443508562e-09
these O 0 1.3812043064831414e-08
populations O 0 2.083228309857077e-06
by O 0 1.1608121894823853e-06
Caucasian O 0 0.006107928231358528
admixture O 0 0.03424854204058647
. O 0 3.961002221331e-05

187 O 0 0.0003106602525804192
C O 0 0.00097090337658301
- O 0 0.0022918458562344313
- O 0 0.0018095390405505896
> O 0 0.0011808376293629408
G O 0 0.00010872871644096449
was O 0 5.2374758752193884e-08
present O 0 3.688575489491086e-08
at O 0 1.9698273234780572e-08
an O 0 7.991983075328335e-09
allele O 0 2.5568962769284553e-07
frequency O 0 2.6736024949514103e-08
of O 0 3.294959682875742e-08
2 O 0 3.3672465633571846e-06
. O 0 3.606310883697006e-06

68 O 0 5.948358739260584e-05
% O 0 9.442757118449663e-07
in O 0 6.362985516261688e-08
the O 0 2.6942272413066348e-08
two O 0 2.7576668060191878e-08
populations O 0 4.091381470061606e-06
analyzed O 0 1.8800543557517813e-06
( O 0 1.2400837476889137e-06
Australian O 0 1.4764013940293808e-06
Aboriginal O 0 2.2293170331977308e-06
and O 0 1.514990657369708e-07
Chinese O 0 2.450796500852448e-06
) O 0 2.978894826810574e-06
. O 0 4.645952230930561e-06

In O 0 1.0468509117345093e-06
the O 0 1.503028812521734e-07
Australian O 0 9.919262993207667e-07
Aboriginal O 0 6.683389415229612e-07
samples O 0 9.651213872530207e-08
, O 0 4.443495882355819e-08
187 O 0 2.4452981506328797e-06
C O 0 5.217234865995124e-05
- O 0 0.00018468625785317272
- O 0 0.00026309731765650213
> O 0 0.00016351568046957254
G O 0 1.6881989722605795e-05
was O 0 1.58725672605442e-08
found O 0 4.368625017292516e-09
to O 0 1.626803802778909e-09
be O 0 1.4475911580547063e-09
associated O 0 1.7167191401767923e-07
with O 0 8.095211683212256e-07
HLA O 1 0.9696283936500549
haplotypes O 0 0.012512091547250748
common O 0 2.7979331207461655e-06
in O 0 1.4931210898794234e-06
Caucasians O 0 0.024496810510754585
, O 0 1.7391826077073347e-06
suggesting O 0 6.14968485024292e-06
that O 0 7.409528102186869e-09
it O 0 4.862457991805513e-09
was O 0 2.4390878650137893e-08
introduced O 0 1.802845019938104e-07
by O 0 1.3261703202260833e-07
recent O 0 1.9005414287676103e-05
admixture O 0 0.018769679591059685
. O 0 4.6396995458053425e-05

In O 0 5.893989509786479e-07
the O 0 6.857965928475096e-08
Chinese O 0 1.0660692595365617e-07
samples O 0 1.1733653337842043e-07
analyzed O 0 1.4588319174890785e-07
, O 0 2.618172345592029e-08
187 O 0 2.5160916266031563e-06
C O 0 3.6983565223636106e-05
- O 0 0.00017638450663071126
- O 0 0.0004414561262819916
> O 0 0.00018615616136230528
G O 0 2.4356988433282822e-05
was O 0 2.5780090950888734e-08
present O 0 2.8834028498181397e-08
in O 0 1.4087443211963091e-08
association O 0 4.1404751982554444e-07
with O 0 4.927710683944042e-09
a O 0 1.498008295186537e-08
wide O 0 2.2480311656636331e-07
variety O 0 1.3588527281171991e-07
of O 0 1.763063579574009e-07
HLA O 1 0.9491727948188782
haplotypes O 0 0.002757719485089183
, O 0 2.585090328466322e-07
showing O 0 8.397890951528098e-07
this O 0 2.3810509119925882e-08
mutation O 0 1.0659051667971653e-06
to O 0 1.3081320027197307e-08
be O 0 8.195673473210263e-09
widespread O 0 2.8050744731444865e-06
and O 0 9.87036727906343e-08
likely O 0 4.02986898961899e-07
to O 0 4.163566913462091e-08
predate O 0 3.522801853250712e-05
the O 0 7.488237585562274e-09
more O 0 1.460535248298811e-08
genetically O 0 2.1828066110174404e-06
restricted O 0 9.52429957123968e-07
845 O 0 0.0021373433992266655
G O 0 0.0019340935396030545
- O 0 0.002440523589029908
- O 0 0.0019594894256442785
> O 0 0.0003566875820979476
A O 0 3.0444141430052696e-06
mutation O 0 4.2259376641595736e-05
. O 0 3.4137033253500704e-06

Genotype O 0 0.05911003425717354
- O 0 0.06907030194997787
phenotype O 0 0.046949777752161026
correlations O 0 0.005651006009429693
in O 0 0.0026638032868504524
attenuated B-Disease 1 0.9918606877326965
adenomatous I-Disease 1 0.9975000023841858
polyposis I-Disease 1 0.9978506565093994
coli I-Disease 1 0.9943760633468628
. O 0 0.0018847370520234108

Germ O 0 0.48153427243232727
- O 0 0.0007869865512475371
line O 0 5.048020284448285e-06
mutations O 0 2.0176983070996357e-06
of O 0 7.063080431635171e-08
the O 0 3.37536471306521e-06
tumor B-Disease 1 0.9088734984397888
suppressor O 0 0.019358066841959953
APC O 0 0.0013347738422453403
are O 0 1.6124914736792562e-07
implicated O 0 0.0016671171179041266
in O 0 0.0002500847040209919
attenuated B-Disease 1 0.9964266419410706
adenomatous I-Disease 1 0.9994137287139893
polyposis I-Disease 1 0.9995983242988586
coli I-Disease 1 0.9990276098251343
( O 0 0.030210528522729874
AAPC B-Disease 1 0.9973307847976685
) O 0 5.419851277110865e-06
, O 0 3.8216231246224197e-07
a O 0 1.964021748790401e-06
variant O 0 0.007214967627078295
of O 0 0.00012658473860938102
familial B-Disease 1 0.9983413219451904
adenomatous I-Disease 1 0.9988831877708435
polyposis I-Disease 1 0.9990538954734802
( O 0 0.23336657881736755
FAP B-Disease 1 0.9939777851104736
) O 0 0.00023675845295656472
. O 0 4.6230612497311085e-05

AAPC B-Disease 1 0.9806407690048218
is O 0 2.0934328404109692e-06
recognized O 0 4.2708160208349e-07
by O 0 3.086243793859467e-08
the O 0 2.28115499822934e-08
occurrence O 0 1.140924950959743e-06
of O 0 8.154045616493022e-08
< O 0 0.002375561511144042
100 O 0 4.378364337753737e-06
colonic B-Disease 1 0.9576197266578674
adenomas I-Disease 0 0.30763018131256104
and O 0 7.453258632494908e-08
a O 0 5.296536187415768e-07
later O 0 3.686286436277442e-05
onset O 1 0.9985476136207581
of O 0 0.11157585680484772
colorectal B-Disease 1 0.9999047517776489
cancer I-Disease 1 0.999745786190033
( O 0 8.213263208745047e-05
age O 0 0.000134441681439057
> O 0 0.002186229219660163
40 O 0 1.3586211480287602e-06
years O 0 3.460140533206868e-06
) O 0 1.9458368569758022e-06
. O 0 4.3778550207207445e-06

The O 0 1.4386208704308956e-06
aim O 0 1.1533481938386103e-06
of O 0 2.9467797091342618e-08
this O 0 2.1747387890513892e-08
study O 0 2.09300267783874e-07
was O 0 5.426391780360973e-08
to O 0 8.03014046368844e-08
assess O 0 0.00021020470012445003
genotype O 0 0.007726744282990694
- O 0 0.02560652419924736
phenotype O 0 0.003451853059232235
correlations O 0 0.00013229202886577696
in O 0 2.011692959058564e-05
AAPC B-Disease 1 0.993937611579895
families O 0 8.551513747079298e-05
. O 0 6.0512113122968e-05

By O 0 1.7544904267197126e-06
protein O 0 2.9332318263186608e-06
- O 0 1.97805911739124e-05
truncation O 0 1.4043939700059127e-05
test O 0 4.080079065715836e-07
( O 0 1.7224817838723538e-07
PTT O 0 1.3949816093372647e-06
) O 0 2.3549318939330988e-08
assay O 0 6.404042096619378e-08
, O 0 2.022818357261258e-09
the O 0 1.5220446014652111e-09
entire O 0 7.628131015735562e-08
coding O 0 2.4580667741247453e-06
region O 0 4.442538426019382e-08
of O 0 3.1708342618230745e-09
the O 0 4.290279775887029e-08
APC B-Disease 0 0.00010978083446389064
gene O 0 5.842090331498184e-07
was O 0 4.408537890299158e-08
screened O 0 1.153394464381563e-06
in O 0 7.363953358208164e-08
affected O 0 1.7697998373478185e-06
individuals O 0 6.039022082404699e-08
from O 0 4.542931151263474e-07
11 O 0 0.00011330922279739752
AAPC B-Disease 1 0.9982818365097046
kindreds O 0 0.05153492093086243
, O 0 1.5116251006475068e-07
and O 0 2.2515921571653053e-08
their O 0 2.417500155615926e-08
phenotypic O 0 2.185783341701608e-05
differences O 0 1.0506351827643812e-05
were O 0 7.190911333054828e-07
examined O 0 0.0006011130171827972
. O 0 5.318715557223186e-05

Five O 0 1.1421091585361864e-05
novel O 0 0.00013790556113235652
germ O 0 0.3700391948223114
- O 0 0.001854629721492529
line O 0 3.061710958718322e-05
APC B-Disease 0 0.00397578626871109
mutations O 0 7.95949836174259e-06
were O 0 2.2299959212546128e-08
identified O 0 1.8911626398221415e-07
in O 0 1.0787077542318002e-07
seven O 0 7.124220246623736e-06
kindreds O 0 0.06619998067617416
. O 0 3.2043357350630686e-05

Mutations O 0 6.775668589398265e-05
were O 0 9.152202551376831e-08
located O 0 8.10759814839912e-08
in O 0 5.304357841851015e-09
three O 0 2.079087346729125e-09
different O 0 1.2260241710748687e-09
regions O 0 1.306262120692736e-08
of O 0 3.6928042845829623e-09
the O 0 4.848744694641027e-08
APC B-Disease 0 0.00018222563085146248
gene O 0 8.874780519363412e-07
( O 0 5.930797897235607e-08
1 O 0 3.3847882718873734e-08
) O 0 3.8067216046044905e-09
at O 0 1.2711315333646667e-09
the O 0 5.81697801038672e-10
5 O 0 1.0143418549546368e-08
end O 0 1.9544009077776536e-08
spanning O 0 2.952837689917942e-07
exons O 0 3.004338680057117e-07
4 O 0 3.6076684750696586e-08
and O 0 5.154336069068677e-09
5 O 0 4.7088242638437805e-08
, O 0 6.5959677719718e-09
( O 0 9.414253376860415e-09
2 O 0 8.001607376684206e-09
) O 0 2.253683462072331e-09
within O 0 1.5477039649880453e-09
exon O 0 9.039226256390975e-07
9 O 0 6.089871362746635e-08
, O 0 4.100219275215977e-09
and O 0 3.2859959198106026e-09
( O 0 2.1830880214679382e-08
3 O 0 2.8856476319560898e-08
) O 0 5.944758907361347e-09
at O 0 2.8699915777252727e-09
the O 0 2.830944811904601e-09
3 O 0 1.16361697166667e-07
distal O 0 2.1660391212208197e-05
end O 0 1.258165127637767e-07
of O 0 1.496332124872879e-08
the O 0 3.244934987378656e-07
gene O 0 2.772754851321224e-05
. O 0 6.331186796160182e-06

Variability O 0 0.0004854444705415517
in O 0 9.722992899696692e-07
the O 0 3.1135127187553735e-07
number O 0 1.2468266277210205e-06
of O 0 0.0002728405233938247
colorectal B-Disease 1 0.9996926784515381
adenomas I-Disease 1 0.9989711046218872
was O 0 6.810998456785455e-06
most O 0 6.221150101737294e-07
apparent O 0 4.664516382035799e-05
in O 0 2.1927620252881752e-07
individuals O 0 2.181431995040839e-07
with O 0 3.1431019920091785e-07
mutations O 0 7.252673185575986e-06
in O 0 8.959550257259252e-08
region O 0 8.628680348010676e-07
1 O 0 4.359762613148632e-07
, O 0 1.061283327885576e-07
and O 0 1.3961101785753272e-06
upper O 0 0.2251085489988327
- O 1 0.9969925880432129
gastrointestinal O 1 0.9993147850036621
manifestations O 0 0.011564550921320915
were O 0 3.1180650239548413e-07
more O 0 2.7712026167137083e-06
severe O 1 0.823764979839325
in O 0 1.4026495591679122e-06
them O 0 1.1886450010933913e-06
. O 0 1.7668789951130748e-05

In O 0 2.7502137527335435e-06
individuals O 0 7.182521812865161e-07
with O 0 4.456801150354295e-07
mutations O 0 7.502245352952741e-06
in O 0 6.360826176887713e-08
either O 0 1.4261665626236208e-07
region O 0 1.210913751492626e-06
2 O 0 6.151839784251933e-07
or O 0 1.35049276650534e-07
region O 0 3.556204433152743e-07
3 O 0 5.1076671780947436e-08
, O 0 2.5061557273886592e-09
the O 0 1.5993846247397414e-09
average O 0 2.4334559256544708e-08
number O 0 3.4985516705887676e-09
of O 0 7.140437929820109e-08
adenomas B-Disease 0 0.4703165590763092
tended O 0 3.9074466258171014e-06
to O 0 1.276720773546458e-08
be O 0 4.801804731613402e-09
lower O 0 8.791467962510069e-07
than O 0 8.873035639567206e-09
those O 0 1.2868838439317187e-08
in O 0 2.1819641204956497e-08
individuals O 0 4.502619432855681e-08
with O 0 1.633942190437665e-07
mutations O 0 8.311448254971765e-06
in O 0 9.823450852763926e-08
region O 0 1.8041778275801335e-06
1 O 0 1.3356227555050282e-06
, O 0 3.016914433828788e-07
although O 0 7.37351001589559e-07
age O 0 3.995921724708751e-05
at O 0 2.479896465956699e-05
diagnosis O 1 0.6507421731948853
was O 0 2.8424058200471336e-06
similar O 0 1.0386684152763337e-05
. O 0 1.847040039137937e-05

In O 0 5.821839749842184e-06
all O 0 2.569080834291526e-06
AAPC B-Disease 1 0.9846336245536804
kindreds O 0 0.0037497307639569044
, O 0 3.558331798103609e-07
a O 0 3.29314474356579e-07
predominance O 0 0.00022792723029851913
of O 0 1.5688672192482045e-06
right O 0 0.0009280054946430027
- O 1 0.9904155731201172
sided O 1 0.9976664781570435
colorectal B-Disease 1 0.9996127486228943
adenomas I-Disease 1 0.9986124038696289
and O 0 0.008228716440498829
rectal B-Disease 1 0.9987107515335083
polyp I-Disease 1 0.9982220530509949
sparing O 0 0.04528183862566948
was O 0 1.3143792784831021e-05
observed O 0 2.0668196157203056e-05
. O 0 2.051756928267423e-05

No O 0 0.0011150037171319127
desmoid B-Disease 1 0.9901838898658752
tumors I-Disease 1 0.9956828355789185
were O 0 2.476471081536147e-07
found O 0 6.147124622657429e-07
in O 0 3.3896475315486896e-07
these O 0 1.1975848792644683e-06
kindreds O 0 0.010833492502570152
. O 0 4.26960141339805e-05

Our O 0 1.663788339101302e-06
data O 0 7.71754685047199e-07
suggest O 0 2.9803384222759632e-06
that O 0 6.749878878054005e-08
, O 0 3.1691737945038767e-07
in O 0 2.8324316190264653e-06
AAPC B-Disease 1 0.9975422620773315
families O 0 1.919253691085032e-06
, O 0 3.433281037246161e-08
the O 0 4.0867744743877665e-09
location O 0 8.831247733098735e-09
of O 0 8.185706334984388e-09
the O 0 4.2316193571423355e-07
APC B-Disease 0 0.0326879657804966
mutation O 0 0.00021295534679666162
may O 0 5.858588792762021e-06
partially O 0 3.3955548133235425e-05
predict O 0 2.084257357637398e-05
specific O 0 4.208662858218304e-07
phenotypic O 0 4.8559340939391404e-05
expression O 0 1.2661526852753013e-05
. O 0 1.870809319370892e-05

This O 0 1.2489282426031423e-06
should O 0 3.6964286209695274e-07
help O 0 3.8481854858218867e-07
in O 0 1.2047629560640871e-08
the O 0 1.2265019222468254e-08
design O 0 4.78006370485673e-07
of O 0 2.611908200833568e-07
tailored O 0 0.01605183258652687
clinical O 0 0.14012660086154938
- O 0 0.07114856690168381
management O 0 7.180595275713131e-05
protocols O 0 4.975348929292522e-06
in O 0 2.9386860944669024e-08
this O 0 1.8949604552176424e-08
subset O 0 4.040111434733262e-06
of O 0 5.2431360018090345e-06
FAP B-Disease 1 0.9983053207397461
patients O 0 0.4426952600479126
. O 0 7.837338671379257e-06
. O 0 2.6366566089564003e-05

Wilms B-Disease 1 0.9815342426300049
' I-Disease 0 0.00655948743224144
tumor I-Disease 0 0.0517130121588707
1 O 0 1.0774950851555332e-06
and O 0 2.7290278126201883e-07
Dax O 0 0.0003453695389907807
- O 0 1.9092685761279427e-05
1 O 0 2.3736831167298078e-07
modulate O 0 5.410075573308859e-06
the O 0 1.1409647271420909e-07
orphan O 0 0.0018722579116001725
nuclear O 0 3.140691478620283e-05
receptor O 0 0.00010448117973282933
SF O 0 0.07570067048072815
- O 0 1.5086313396750484e-05
1 O 0 1.0059169142095925e-07
in O 0 3.113833102474928e-08
sex O 0 1.2470120509533444e-06
- O 0 3.752634802367538e-05
specific O 0 1.7081127623441716e-07
gene O 0 2.8358886083879042e-06
expression O 0 3.2697475944587495e-06
. O 0 4.640098723029951e-06

Products O 0 1.7893484255182557e-05
of O 0 1.5394471120089293e-06
steroidogenic O 0 0.1390439122915268
factor O 0 1.3095922440697905e-05
1 O 0 2.750313569777063e-06
( O 0 4.422064648679225e-06
SF O 0 0.07727190852165222
- O 0 3.285173806943931e-05
1 O 0 4.4183872205394437e-07
) O 0 3.251440148233087e-07
and O 0 1.4704800150866504e-06
Wilms B-Disease 1 0.9979419112205505
tumor I-Disease 1 0.5988644957542419
1 O 0 4.308864845370408e-06
( O 0 8.597741725679953e-06
WT1 O 0 0.11912867426872253
) O 0 6.86602774635503e-08
genes O 0 2.5159369698712908e-08
are O 0 7.55047802059039e-10
essential O 0 9.983607718311305e-09
for O 0 2.2443074954026088e-08
mammalian O 0 1.2817568858736195e-05
gonadogenesis O 0 0.0013555454788729548
prior O 0 3.4370688695162244e-07
to O 0 1.0950138573662116e-07
sexual O 0 1.6874777429620735e-05
differentiation O 0 0.0007440512999892235
. O 0 2.407359534117859e-05

In O 0 4.5803094508301e-06
males O 0 2.1839581677340902e-05
, O 0 5.933302873017965e-06
SF O 0 0.44150829315185547
- O 0 8.817896741675213e-05
1 O 0 5.871380039934593e-07
participates O 0 2.6161612822761526e-06
in O 0 2.7240266931016777e-08
sexual O 0 8.202148933378339e-07
development O 0 2.4443698976028827e-07
by O 0 1.7923408535125418e-08
regulating O 0 7.888667141742189e-07
expression O 0 2.6607775538423084e-08
of O 0 7.226313769592707e-09
the O 0 1.8944660951092374e-07
polypeptide O 0 0.0023419910576194525
hormone O 0 0.007242003921419382
Mullerian O 1 0.7129263877868652
inhibiting O 0 0.004614383447915316
substance O 0 0.0020403340458869934
( O 0 6.052434764569625e-05
MIS O 0 0.13066014647483826
) O 0 5.258403689367697e-06
. O 0 3.481975454633357e-06

Here O 0 5.208205948292743e-06
, O 0 5.028058467360097e-07
we O 0 3.776379031705801e-08
show O 0 9.153563951258548e-08
that O 0 6.69796378360843e-08
WT1 O 0 0.02932976372539997
- O 0 0.00045491132186725736
KTS O 0 0.1056026890873909
isoforms O 0 1.0909211596299428e-06
associate O 0 9.224368682225759e-07
and O 0 1.1333430904869601e-07
synergize O 0 0.005012086592614651
with O 0 4.165063728578389e-06
SF O 1 0.8918472528457642
- O 0 0.00010515947360545397
1 O 0 3.4683830563153606e-07
to O 0 5.979045880621925e-08
promote O 0 6.883375135657843e-06
MIS O 0 0.036587487906217575
expression O 0 6.4240839492413215e-06
. O 0 6.766236310795648e-06

In O 0 6.425400897569489e-06
contrast O 0 7.489835115848109e-05
, O 0 1.8164033463108353e-05
WT1 O 1 0.8620471358299255
missense O 0 0.005034852307289839
mutations O 0 5.769939161837101e-05
, O 0 3.6772314615518553e-07
associated O 0 1.4491962474494358e-06
with O 0 4.6024032940295e-07
male B-Disease 0 0.00010480009950697422
pseudohermaphroditism I-Disease 1 0.9548189640045166
in O 0 0.00015322685067076236
Denys B-Disease 1 0.9980981945991516
- I-Disease 1 0.9986960291862488
Drash I-Disease 1 0.9993652701377869
syndrome I-Disease 1 0.999660849571228
, O 0 9.84564030659385e-06
fail O 0 0.000110514389234595
to O 0 3.717654806223436e-07
synergize O 0 0.09003841876983643
with O 0 1.3528247109206859e-05
SF O 1 0.9929888844490051
- O 0 0.005343402270227671
1 O 0 1.608426646271255e-05
. O 0 8.88803606358124e-06

Additionally O 0 1.9814460756606422e-05
, O 0 5.843372150593495e-07
the O 0 2.6317962920074933e-07
X O 0 0.000662907725200057
- O 0 0.00019858010637108237
linked O 0 3.992901838500984e-06
, O 0 7.381531474948133e-08
candidate O 0 4.7317101348198776e-07
dosage O 0 0.00012065654300386086
- O 0 3.834068411379121e-05
sensitive O 0 8.74605973422149e-07
sex O 0 1.6545603784834384e-06
- O 0 8.223638724302873e-05
reversal O 0 2.6486350179766305e-05
gene O 0 5.693874527423759e-07
, O 0 1.0617976897719927e-07
Dax O 0 9.227098053088412e-05
- O 0 6.903294433868723e-06
1 O 0 3.309635587811499e-08
, O 0 1.8272176660616424e-08
antagonizes O 0 2.1826275769853964e-05
synergy O 0 4.309365976951085e-06
between O 0 2.653647186434682e-07
SF O 0 0.45443740487098694
- O 0 8.991362119559199e-05
1 O 0 3.319409813684615e-07
and O 0 1.6420149506757298e-07
WT1 O 0 0.04439368471503258
, O 0 2.199950266401629e-08
most O 0 2.939475107766043e-09
likely O 0 8.352012415002719e-09
through O 0 9.367892017664303e-10
a O 0 2.8586060185631368e-09
direct O 0 8.68367511230872e-09
interaction O 0 1.5451158219548233e-07
with O 0 1.7741716646924033e-06
SF O 1 0.9249637126922607
- O 0 0.0010342993773519993
1 O 0 7.5892030508839525e-06
. O 0 5.472787961480208e-06

We O 0 2.065911303361645e-06
propose O 0 1.754524237185251e-05
that O 0 4.2022216462100914e-07
WT1 O 0 0.005750259850174189
and O 0 7.200779350569064e-07
Dax O 0 0.0034291998017579317
- O 0 0.00011183688911842182
1 O 0 5.207875801716e-07
functionally O 0 2.273255859108758e-06
oppose O 0 1.5015130827578105e-07
each O 0 1.331948884519818e-09
other O 0 2.3199999699130558e-09
in O 0 4.5170274631800567e-08
testis O 0 0.0004950189613737166
development O 0 1.67848739351939e-07
by O 0 1.4860054875498463e-07
modulating O 0 0.003352239029482007
SF O 1 0.8158909678459167
- O 0 0.00018451253708917648
1 O 0 3.798451871261932e-06
- O 0 0.0007525531109422445
mediated O 0 0.0002389206929365173
transactivation O 0 0.005172081757336855
. O 0 1.5437386764460825e-06
. O 0 7.467846899089636e-06

A O 0 5.744191003032029e-05
mouse O 0 0.0014195984695106745
model O 0 0.00033743272069841623
for O 0 0.0007818807498551905
Prader B-Disease 1 0.9965019226074219
- I-Disease 1 0.9973300695419312
Willi I-Disease 1 0.9986276626586914
syndrome I-Disease 1 0.9988653659820557
imprinting O 1 0.9332287907600403
- O 1 0.7639881372451782
centre O 0 0.003938041627407074
mutations O 0 0.002169633749872446
. O 0 5.238658195594326e-05

Imprinting O 0 0.00016873929416760802
in O 0 1.216335022036219e-06
the O 0 1.228512928719283e-06
15q11 O 0 0.010568419471383095
- O 0 0.002924619009718299
q13 O 0 0.0014768947148695588
region O 0 1.4418046703212894e-06
involves O 0 4.3889977519029344e-07
an O 0 6.997162671495971e-08
imprinting O 0 5.4836375056765974e-05
centre O 0 6.11164159636246e-06
( O 0 1.8160005765821552e-06
IC O 0 0.0006479930016212165
) O 0 6.223167758889758e-08
, O 0 4.129832475996409e-09
mapping O 0 3.03818161739855e-08
in O 0 1.5776908668385659e-09
part O 0 6.837926669334138e-09
to O 0 2.527883902203598e-09
the O 0 7.613258468097683e-09
promoter O 0 5.601176326308632e-06
and O 0 1.4767231881762655e-08
first O 0 5.513516398991669e-08
exon O 0 3.992097845184617e-05
of O 0 1.0583941048025736e-06
SNRPN O 0 0.29444026947021484
. O 0 3.90072564186994e-05

Deletion O 0 0.0001542759855510667
of O 0 5.93386346281477e-07
this O 0 7.679750524403062e-07
IC O 0 0.0033928081393241882
abolishes O 0 0.0005761052016168833
local O 0 4.785779310623184e-07
paternally O 0 9.956069698091596e-05
derived O 0 3.143063054267259e-07
gene O 0 6.960052019167051e-07
expression O 0 2.416242068647989e-07
and O 0 2.1292864005317824e-07
results O 0 2.3389402485918254e-05
in O 0 0.0005111857899464667
Prader B-Disease 1 0.998736560344696
- I-Disease 1 0.9989134073257446
Willi I-Disease 1 0.9993250370025635
syndrome I-Disease 1 0.9996540546417236
( O 0 0.42515829205513
PWS B-Disease 1 0.9977337121963501
) O 0 0.00014070668839849532
. O 0 4.340248415246606e-05

We O 0 1.2024830766677042e-06
have O 0 1.1096937413412888e-07
created O 0 1.8659737577308988e-07
two O 0 7.038845950546602e-08
deletion O 0 0.0001405843795510009
mutations O 0 1.9216022337786853e-05
in O 0 1.0082870858241222e-06
mice O 0 0.0019392366521060467
to O 0 1.2006427141386666e-06
understand O 0 0.00015647751570213586
PWS B-Disease 1 0.9986542463302612
and O 0 8.116835914506737e-08
the O 0 2.666498133407913e-08
mechanism O 0 3.22366474847513e-07
of O 0 5.034362615674581e-08
this O 0 5.845869281984051e-07
IC O 0 0.012445591390132904
. O 0 1.7393240341334604e-05

Mice O 0 0.06898505240678787
harbouring O 0 0.017061429098248482
an O 0 4.552925474854419e-06
intragenic O 0 0.040899794548749924
deletion O 0 0.0009011066285893321
in O 0 3.2450450362375705e-06
Snrpn O 0 0.06927099078893661
are O 0 2.039696482825093e-07
phenotypically O 0 0.0019658436067402363
normal O 0 4.624252596840961e-06
, O 0 2.980424369525281e-07
suggesting O 0 3.1036752261570655e-06
that O 0 1.3873933113472958e-08
mutations O 0 7.999731792551756e-07
of O 0 4.392104457906498e-08
SNRPN O 0 0.01993405446410179
are O 0 1.3372824625434987e-08
not O 0 1.5892288374175223e-08
sufficient O 0 7.287689527402108e-07
to O 0 1.0573610325081972e-06
induce O 0 0.018505414947867393
PWS B-Disease 1 0.9932777285575867
. O 0 6.904976180521771e-05

Mice O 0 0.0008349111885763705
with O 0 6.538844559145218e-07
a O 0 6.591267265321221e-07
larger O 0 2.8557849418575643e-06
deletion O 0 2.7341484383214265e-05
involving O 0 9.225090025211102e-07
both O 0 1.0698192909330828e-07
Snrpn O 0 0.001421191729605198
and O 0 1.620920500045031e-07
the O 0 9.54082679527346e-07
putative O 0 0.08204300701618195
PWS O 1 0.998671293258667
- O 0 0.08049038052558899
IC O 0 0.007833677344024181
lack O 0 5.200956820772262e-07
expression O 0 2.7709376126949792e-08
of O 0 3.953912308674035e-09
the O 0 6.479012171212162e-08
imprinted O 0 0.0001396544394083321
genes O 0 3.185498371749418e-06
Zfp127 O 0 0.0034376417752355337
( O 0 1.0174750286751078e-06
mouse O 0 9.97010738501558e-06
homologue O 0 9.468960342928767e-06
of O 0 7.584895911350031e-08
ZNF127 O 0 0.020537178963422775
) O 0 8.387453931391065e-07
, O 0 5.535644049814437e-07
Ndn O 0 0.02002173662185669
and O 0 3.1369930297842075e-07
Ipw O 0 0.0013903486542403698
, O 0 1.6482341891332908e-07
and O 0 1.0526628813067873e-07
manifest O 0 1.2125189641665202e-05
several O 0 6.190434760355856e-07
phenotypes O 0 0.013680433854460716
common O 0 0.00012009798956569284
to O 0 0.0002565434842836112
PWS B-Disease 1 0.9982684850692749
infants O 1 0.9365044236183167
. O 0 0.00021337995713111013

These O 0 1.0364026366005419e-06
data O 0 9.703151135909138e-07
demonstrate O 0 6.529005531774601e-07
that O 0 5.82956571903992e-09
both O 0 1.8723826933353394e-09
the O 0 2.1844823727690255e-09
position O 0 4.067767900295394e-09
of O 0 2.7359492449363643e-09
the O 0 6.786942208236724e-08
IC O 0 0.0005248654633760452
and O 0 1.009637884408221e-08
its O 0 7.632973364479767e-09
role O 0 2.2222893747425587e-08
in O 0 3.306908080702442e-09
the O 0 3.7195249102950356e-09
coordinate O 0 1.5169335654263705e-07
expression O 0 1.4788795077436134e-08
of O 0 1.4842818085725185e-09
genes O 0 2.879264471289389e-08
is O 0 2.980069968572252e-09
conserved O 0 2.8511259131391853e-08
between O 0 1.2461543974495726e-07
mouse O 0 0.0001997576910071075
and O 0 6.775973560024795e-08
human O 0 4.911910878035997e-07
, O 0 4.473574222174648e-08
and O 0 1.743393518438552e-08
indicate O 0 7.992657202748887e-08
that O 0 2.8218556380465998e-09
the O 0 1.2174772301420944e-08
mouse O 0 9.515670171822421e-06
is O 0 6.946561992293709e-09
a O 0 3.138811877079206e-08
suitable O 0 3.514099944368354e-07
model O 0 2.2850269942864543e-07
system O 0 1.3806254628434544e-07
in O 0 2.464930703993673e-09
which O 0 1.4244960766518489e-09
to O 0 2.433250712030599e-09
investigate O 0 7.548425884351673e-08
the O 0 5.288598448061066e-09
molecular O 0 4.1068906853070075e-07
mechanisms O 0 1.3461863090924453e-07
of O 0 1.516137615453772e-08
imprinting O 0 2.8610256777028553e-05
in O 0 2.9499798159804413e-08
this O 0 4.141531118051489e-09
region O 0 4.6821174493061335e-08
of O 0 5.573719263907151e-09
the O 0 1.0216584200861689e-07
genome O 0 1.8605893274070695e-05
. O 0 3.914571777841047e-07
. O 0 3.580779321055161e-06

Mutations O 0 1.4742579878657125e-05
of O 0 1.1566577740040884e-07
the O 0 2.3897098344605183e-07
ATM O 0 8.387821435462683e-05
gene O 0 1.3096572729409672e-05
detected O 0 1.1270779395999853e-05
in O 0 3.4665681596379727e-06
Japanese O 0 0.11363887786865234
ataxia B-Disease 1 0.9993999004364014
- I-Disease 1 0.9991303086280823
telangiectasia I-Disease 1 0.9996356964111328
patients O 1 0.8815245628356934
: O 0 2.3013048121356405e-05
possible O 0 9.510739005236246e-07
preponderance O 0 3.834894596366212e-05
of O 0 4.2650829534807144e-09
the O 0 1.8158669234935587e-08
two O 0 7.214939756750027e-08
founder O 0 0.0001685310562606901
mutations O 0 5.8605288359103724e-05
4612del165 O 0 0.0025794105604290962
and O 0 3.998350166511955e-06
7883del5 O 0 0.010371444746851921
. O 0 2.1953113900963217e-05

The O 0 6.753033630957361e-06
ATM O 0 0.0003855152754113078
( O 0 1.7722959455568343e-05
A O 0 8.799971692496911e-05
- O 0 0.278636634349823
T O 1 0.9916772842407227
, O 0 2.5042011202458525e-06
mutated O 0 0.0001017157337628305
) O 0 2.8716721089949715e-07
gene O 0 9.192298193738679e-07
on O 0 1.0200228928169963e-07
human O 0 9.501523891231045e-06
chromosome O 0 0.0011379658244550228
11q22 O 0 0.014402574859559536
. O 0 3.1463903724215925e-05

3 O 0 4.238231122144498e-05
has O 0 3.839310920739081e-06
recently O 0 7.002682650636416e-06
been O 0 5.4895600953841495e-08
identified O 0 7.255263767547149e-08
as O 0 6.64078170231619e-09
the O 0 1.0441299380659075e-08
gene O 0 6.440337187996192e-07
responsible O 0 2.888649532906129e-07
for O 0 2.488424399871292e-07
the O 0 3.281147655798122e-05
human O 0 0.45062294602394104
recessive B-Disease 1 0.9992387294769287
disease I-Disease 1 0.9997809529304504
ataxia B-Disease 1 0.9996739625930786
- I-Disease 1 0.9987549781799316
telangiectasia I-Disease 1 0.999054491519928
( O 0 0.0009262555395253003
A B-Disease 0 0.017757486552000046
- I-Disease 1 0.97296541929245
T I-Disease 1 0.9966405630111694
) O 0 2.2576125047635287e-05
. O 0 1.0213082532573026e-05

In O 0 1.4742656730959425e-06
order O 0 2.5956560989470745e-07
to O 0 7.500577225982852e-08
define O 0 9.327327461505774e-07
the O 0 1.9589957389598567e-07
types O 0 9.750211575010326e-06
of O 0 1.1685912795655895e-05
disease O 1 0.9985590577125549
- O 0 0.02664555422961712
causing O 0 0.001345470896922052
ATM O 0 0.00018789773457683623
mutations O 0 4.559730314213084e-06
in O 0 7.905523347062626e-08
Japanese O 0 6.134364957688376e-05
A B-Disease 0 0.014204940758645535
- I-Disease 1 0.9986304044723511
T I-Disease 1 0.9996011853218079
patients O 0 0.07847455143928528
as O 0 2.6125103858021248e-08
well O 0 8.764009074013757e-09
as O 0 3.3916243147302794e-09
to O 0 2.78626832717066e-09
look O 0 1.4172289297675889e-07
for O 0 1.3186181924140783e-08
possible O 0 7.583455499116099e-07
mutational O 0 0.006424751132726669
hotspots O 0 6.500635208794847e-05
, O 0 6.746622460696017e-08
reverse O 0 5.213006261328701e-06
- O 0 9.49096374824876e-06
transcribed O 0 3.637674126366619e-07
RNA O 0 1.2255435422048322e-07
derived O 0 1.747151756603671e-08
from O 0 1.9014812835393968e-08
ten O 0 1.5860742053064314e-07
patients O 0 5.3943644161336124e-05
belonging O 0 4.751090187937734e-08
to O 0 3.659833991420669e-09
eight O 0 8.540022378156209e-08
unrelated O 0 1.8875869500334375e-05
Japanese O 0 4.139504017075524e-05
A B-Disease 0 0.003095964202657342
- I-Disease 1 0.8962409496307373
T I-Disease 1 0.995029628276825
families O 0 1.4386470184035716e-06
was O 0 9.309423631975733e-08
analyzed O 0 2.0680543855178257e-07
for O 0 1.6716080963874447e-08
mutations O 0 7.129346499823441e-07
by O 0 1.5865092350964005e-08
the O 0 6.624919279829555e-08
restriction O 0 1.0569422556727659e-05
endonuclease O 0 0.0010640581604093313
fingerprinting O 0 5.6774242693791166e-05
method O 0 1.5409526668008766e-06
. O 0 4.118926426599501e-06

As O 0 3.3831347536761314e-06
has O 0 6.05890193128289e-07
been O 0 1.704103738120466e-07
reported O 0 1.3930033446740708e-06
by O 0 6.306416366896883e-08
others O 0 1.956212116738243e-07
, O 0 7.527793854933407e-08
mutations O 0 4.4573067725650617e-07
that O 0 4.924347152268638e-09
lead O 0 1.6283544823636475e-07
to O 0 4.169559275624124e-08
exon O 0 7.627226295880973e-05
skipping O 0 3.53442519553937e-05
or O 0 9.04174385141232e-07
premature O 0 0.0013975483598187566
protein O 0 1.1097366723333835e-06
truncation O 0 6.888799816806568e-06
were O 0 5.343146813885369e-09
also O 0 1.3638635110169162e-08
predominant O 0 4.3218761902608094e-07
in O 0 7.914772481854015e-08
our O 0 8.011168119992362e-07
mutants O 0 0.0002838665677700192
. O 0 8.067173439485487e-06

Six O 0 2.123645799656515e-06
different O 0 1.5146106591146236e-07
mutations O 0 3.7190557122812606e-06
were O 0 7.133724277963438e-09
identified O 0 2.83228018815862e-08
on O 0 3.6481044851655042e-09
12 O 0 1.6997724117118196e-08
of O 0 4.36491065514133e-09
the O 0 3.101054701915018e-08
16 O 0 2.1383837065513944e-06
alleles O 0 4.496292967814952e-05
examined O 0 0.0001803355262381956
. O 0 1.3745620890404098e-05

Four O 0 7.951569500619371e-07
were O 0 1.2267106797025917e-07
deletions O 0 5.204908575251466e-06
involving O 0 1.4258105238695862e-06
a O 0 1.6916648348797025e-07
loss O 0 3.0282076295407023e-06
of O 0 4.0197485340343064e-09
a O 0 1.746961864057539e-08
single O 0 4.227714711646513e-08
exon O 0 1.1917393749172334e-05
exon O 0 8.647118193039205e-06
7 O 0 8.78672707926853e-08
, O 0 1.5798809371858624e-08
exon O 0 3.519285201036837e-06
16 O 0 5.756390564215508e-08
, O 0 3.402225701165662e-08
exon O 0 8.503404387738556e-06
33 O 0 3.460453683601372e-07
or O 0 1.2144951710979512e-07
exon O 0 5.688762030331418e-05
35 O 0 4.932000592816621e-06
. O 0 3.812689328697161e-06

The O 0 1.071775386662921e-06
others O 0 2.4309701984748244e-07
were O 0 1.4063684439236113e-08
minute O 0 6.009194208900226e-08
deletions O 0 1.4278964499681024e-06
, O 0 7.549837022224892e-08
4649delA O 0 2.6248477297485806e-05
in O 0 4.715052170922718e-08
exon O 0 1.2916570085508283e-05
33 O 0 4.6021401090001746e-07
and O 0 3.2072030364815873e-08
7883del5 O 0 6.873717211419716e-05
in O 0 2.2759317630516307e-07
exon O 0 0.00019818950386252254
55 O 0 1.6501688151038252e-05
. O 0 5.1315796554263216e-06

The O 0 6.678995305264834e-06
mutations O 0 7.196072692750022e-05
4612del165 O 0 0.0008193818503059447
and O 0 1.4110563597569126e-06
7883del5 O 0 0.0003097865846939385
were O 0 1.3723154168587826e-08
found O 0 1.5010428455752844e-08
in O 0 3.1180868997893185e-09
more O 0 1.8199680651420636e-09
than O 0 6.340329150589241e-09
two O 0 8.585979038855385e-09
unrelated O 0 5.269035682431422e-06
families O 0 4.0658781585989345e-07
; O 0 1.5205864656309132e-07
44 O 0 3.5223368399783794e-07
% O 0 2.3782959601703624e-08
( O 0 1.5381873552655634e-08
7 O 0 7.48469641820293e-09
of O 0 8.128602235757398e-10
16 O 0 1.5923115270766175e-08
) O 0 2.0432262548553126e-09
of O 0 3.4715025298837077e-10
the O 0 6.57970877782077e-09
mutant O 0 6.182792731124209e-06
alleles O 0 4.422299468842539e-07
had O 0 2.7122306622828773e-09
one O 0 1.0299768815613675e-09
of O 0 1.7756295322968185e-09
the O 0 1.5060356517437867e-08
two O 0 1.2637521251690487e-07
mutations O 0 9.325765131507069e-05
. O 0 9.910290827974677e-06

The O 0 2.029979987128172e-05
4612del165 O 0 0.00467940978705883
mutations O 0 1.8629474652698264e-05
in O 0 3.701684647694492e-08
three O 0 1.0363602420682128e-08
different O 0 4.555180233012379e-09
families O 0 3.6444550488567984e-08
were O 0 8.86971440738904e-10
all O 0 1.0493983459980427e-09
ascribed O 0 1.881419677829399e-07
to O 0 2.583776970155327e-09
the O 0 8.866945400143322e-09
same O 0 2.1241042702513369e-07
T O 0 0.2510164976119995
- O 0 0.00024831859627738595
- O 0 3.717174331541173e-05
> O 0 2.637253601278644e-06
A O 0 6.400425522912201e-09
substitution O 0 1.6675382852326948e-08
at O 0 9.334632622426398e-09
the O 0 1.5427739086248948e-08
splice O 0 1.1446967619122006e-05
donor O 0 8.472587069263682e-06
site O 0 3.1748243145557353e-07
in O 0 3.3356130302308884e-07
intron O 0 0.011952146887779236
33 O 0 3.054513945244253e-05
. O 0 7.4523936746118125e-06

Microsatellite O 0 0.006852959282696247
genotyping O 0 0.0003882180026266724
around O 0 5.50040738289681e-07
the O 0 2.409591957075463e-07
ATM O 0 0.00013118857168592513
locus O 0 3.0518873245455325e-05
also O 0 1.1789894927005662e-07
indicated O 0 1.0508910008866224e-06
that O 0 1.2975560181871515e-08
a O 0 2.8654810080297466e-07
common O 0 4.369258476799587e-06
haplotype O 0 0.0018376450752839446
was O 0 4.0801719336514e-08
shared O 0 1.4607859810666923e-08
by O 0 8.738254564377712e-09
the O 0 2.938355336823406e-08
mutant O 0 1.2506573511927854e-05
alleles O 0 2.3793065793142887e-06
in O 0 1.1335927752043062e-07
both O 0 6.286744564931723e-07
mutations O 0 0.0002624574408400804
. O 0 1.6454510841867886e-05

This O 0 1.9617698399088113e-06
suggests O 0 6.0089246289862785e-06
that O 0 3.353359190327865e-08
these O 0 1.62480748855387e-08
two O 0 1.0530143157438943e-07
founder O 0 0.0017823659582063556
mutations O 0 0.0003198649501428008
may O 0 5.803950671179336e-07
be O 0 1.0066459665836192e-08
predominant O 0 1.1367023944330867e-06
among O 0 2.621760870624712e-07
Japanese O 0 1.6310837963828817e-05
ATM O 0 0.0012101259781047702
mutant O 0 0.0004641245468519628
alleles O 0 0.00021210729028098285
. O 0 1.591908949194476e-05

W474C O 0 0.00044951995369046926
amino O 0 3.756146725208964e-06
acid O 0 2.2209849703358486e-05
substitution O 0 3.588957042666152e-06
affects O 0 1.1319759323669132e-05
early O 0 5.526213442408334e-08
processing O 0 2.1866762622835267e-08
of O 0 1.352518874675468e-09
the O 0 2.2602137939031763e-09
alpha O 0 5.472216813018349e-08
- O 0 2.3321180719904078e-07
subunit O 0 2.4809642340528626e-08
of O 0 6.589931711431518e-09
beta O 0 9.808809409150854e-06
- O 0 0.00021008809562772512
hexosaminidase O 0 0.0003472877142485231
A O 0 8.38129921021391e-08
and O 0 1.978902730570553e-08
is O 0 2.3527903181275178e-08
associated O 0 7.836478630451893e-07
with O 0 2.77581011687289e-06
subacute O 1 0.9969455599784851
G B-Disease 0 0.23578251898288727
( I-Disease 0 6.922341708559543e-05
M2 I-Disease 0 0.061761993914842606
) I-Disease 0 8.132135917549022e-06
gangliosidosis I-Disease 0 0.0052595301531255245
. O 0 1.6335805412381887e-05

Mutations O 0 4.7959551011445e-05
in O 0 5.114061991662311e-07
the O 0 6.465303385994048e-07
HEXA O 0 0.19472914934158325
gene O 0 8.993944788926456e-07
, O 0 9.360110020395496e-09
encoding O 0 1.4795875635797984e-08
the O 0 3.5396563458078845e-09
alpha O 0 8.540055063122054e-08
- O 0 3.648879385309556e-07
subunit O 0 3.126956471533049e-08
of O 0 3.611742460662981e-09
beta O 0 3.849543645628728e-06
- O 0 4.690762943937443e-05
hexosaminidase O 0 0.00014044276031199843
A O 0 9.899193997853217e-08
( O 0 1.7344855507417378e-07
Hex O 0 1.098098437068984e-06
A O 0 2.8085780812148187e-08
) O 0 1.1979529368488784e-08
, O 0 2.4086483918495105e-09
that O 0 1.188067644264379e-09
abolish O 0 1.0044691407529172e-06
Hex O 0 2.1521689177461667e-06
A O 0 2.2884204042838974e-07
enzyme O 0 1.9797820641542785e-05
activity O 0 3.2752705010352656e-05
cause O 0 0.32711395621299744
Tay B-Disease 1 0.9989927411079407
- I-Disease 1 0.9986739158630371
Sachs I-Disease 1 0.9994227886199951
disease I-Disease 1 0.9993828535079956
( O 0 0.00029270481900312006
TSD B-Disease 1 0.9911792874336243
) O 0 8.982201507024001e-07
, O 0 1.174813135662589e-07
the O 0 6.676891644019634e-07
fatal O 0 0.2692919671535492
infantile B-Disease 0 0.45492011308670044
form I-Disease 0 6.468331434916763e-07
of I-Disease 0 2.450639158269041e-07
G I-Disease 0 0.003908222541213036
( I-Disease 0 1.0729723726399243e-05
M2 I-Disease 0 0.023054033517837524
) I-Disease 0 1.5896100649115397e-06
gangliosidosis I-Disease 0 0.0004888472030870616
, I-Disease 0 2.6806446840055287e-07
Type I-Disease 0 1.292002070840681e-05
1 I-Disease 0 4.041101419716142e-06
. O 0 4.163022367720259e-06

Less O 0 0.002838094951584935
severe O 1 0.9881816506385803
, O 0 0.001600697636604309
subacute O 1 0.9965630173683167
( O 0 0.024366242811083794
juvenile O 1 0.9963011741638184
- O 1 0.9913815855979919
onset O 1 0.9982883334159851
) O 0 0.0005820594960823655
and O 0 0.000414486596127972
chronic O 1 0.9995737671852112
( O 0 0.0003603037621360272
adult O 0 0.0059716119430959225
- O 1 0.9411934614181519
onset O 1 0.9979409575462341
) O 0 2.8604840736079495e-06
variants O 0 2.601105279609328e-06
are O 0 7.292498160893501e-09
characterized O 0 3.144602942484198e-06
by O 0 1.2125457082845514e-08
a O 0 7.709382998655201e-08
broad O 0 1.6672951460350305e-05
spectrum O 0 1.1493972124299034e-05
of O 0 6.252627144931466e-07
clinical O 0 0.08239401131868362
manifestations O 0 0.006609187461435795
and O 0 3.9874575463727524e-07
are O 0 1.9433718634331854e-08
associated O 0 9.052304221768281e-07
with O 0 1.6076839415291033e-07
residual O 0 7.534435280831531e-05
levels O 0 4.0049806671049737e-07
of O 0 1.9155869779297063e-08
Hex O 0 2.1997833755449392e-05
A O 0 1.0003793704527197e-06
enzyme O 0 1.0191463843511883e-05
activity O 0 2.1587509309028974e-06
. O 0 4.322760105424095e-06

We O 0 2.150593218175345e-06
identified O 0 1.3263894516057917e-06
a O 0 1.2106665963074192e-06
1422 O 0 0.046498093754053116
G O 0 0.0013070437125861645
- O 0 0.0013493680162355304
- O 0 0.00034300395054742694
> O 0 0.00013767550990451127
C O 0 6.8031431510462426e-06
( O 0 4.055839042393927e-08
amino O 0 1.2613002198236245e-08
acid O 0 3.485140496195527e-07
W474C O 0 3.935288987122476e-06
) O 0 4.437218148467537e-09
substitution O 0 5.659689605863605e-09
in O 0 3.624714972616516e-10
the O 0 2.2314615433227658e-10
first O 0 4.367765038537641e-10
position O 0 1.1304578384496722e-09
of O 0 1.3792660347178298e-09
exon O 0 2.0982997739338316e-06
13 O 0 3.283215832539099e-08
of O 0 1.3436359580509816e-08
HEXA O 0 0.005384667310863733
of O 0 5.256778567996889e-09
a O 0 1.1580727488080811e-07
non O 0 2.9731847916991683e-06
- O 0 0.00019397976575419307
Jewish O 0 9.844391570368316e-06
proband O 0 0.050304166972637177
who O 0 4.705408628069563e-06
manifested O 0 0.0005467286100611091
a O 0 1.3085211321595125e-05
subacute O 1 0.996278703212738
variant O 0 0.0012102522887289524
of O 0 1.04895457297971e-06
G B-Disease 0 0.012756545096635818
( I-Disease 0 3.622847725637257e-05
M2 I-Disease 0 0.058067139238119125
) I-Disease 0 8.32420391816413e-06
gangliosidosis I-Disease 0 0.002786233788356185
. O 0 1.1487069059512578e-05

On O 0 6.960755740692548e-07
the O 0 3.468502143277874e-07
second O 0 4.777880803885637e-06
maternally O 0 0.06276297569274902
inherited O 0 0.1811521202325821
allele O 0 6.4413710788358e-05
, O 0 1.9545804263998434e-07
we O 0 5.404957192922666e-08
identified O 0 1.0779483545775292e-06
the O 0 1.7815792716646683e-06
common O 0 0.017626885324716568
infantile O 1 0.9993472695350647
disease O 1 0.9993769526481628
- O 0 0.08422039449214935
causing O 0 0.0014265396166592836
4 O 0 1.0101339285029098e-05
- O 0 0.0005630184314213693
bp O 0 2.9135964723536745e-05
insertion O 0 7.959407412272412e-06
, O 0 6.2075076812107e-07
+ O 0 0.0002666252839844674
TATC O 0 0.022041194140911102
1278 O 0 0.0023090983740985394
, O 0 1.1448166503669199e-07
in O 0 1.434941623301711e-07
exon O 0 0.0001054642561939545
11 O 0 1.0211329026788007e-05
. O 0 4.7055300456122495e-06

Pulse O 0 0.0012856272514909506
- O 0 0.00031018731533549726
chase O 0 3.4055232390528545e-05
analysis O 0 1.1099813264081604e-06
using O 0 5.58255749183445e-07
proband O 0 0.0047382148914039135
fibroblasts O 0 0.0004519415379036218
revealed O 0 9.923095376507263e-07
that O 0 6.193952017952142e-09
the O 0 1.3422885913882965e-08
W474C O 0 2.4708504497539252e-05
- O 0 2.449083694955334e-06
containing O 0 5.519587631397371e-08
alpha O 0 2.871064168630255e-07
- O 0 2.3194406821858138e-06
subunit O 0 2.7102470312456717e-07
precursor O 0 3.846992910894187e-07
was O 0 7.1959171954461e-09
normally O 0 1.1722687709436741e-08
synthesized O 0 9.573697212772458e-08
, O 0 3.83770482059731e-09
but O 0 1.1915125552874883e-09
not O 0 1.4633730893720553e-09
phosphorylated O 0 1.7049295308879664e-07
or O 0 1.6013206760590037e-08
secreted O 0 1.496723740501693e-07
, O 0 4.226357930292579e-09
and O 0 5.074522579917584e-09
the O 0 2.7714873951367736e-08
mature O 0 4.187082959106192e-05
lysosomal O 0 0.00899149477481842
alpha O 0 3.057585900023696e-06
- O 0 2.7448857508716173e-05
subunit O 0 1.711341042209824e-06
was O 0 1.5679039222504798e-07
not O 0 9.063623451766034e-08
detected O 0 1.170527593785664e-05
. O 0 1.926265667862026e-06

When O 0 1.5702457858424168e-06
the O 0 4.0991429273162794e-07
W474C O 0 7.534751057391986e-05
- O 0 6.332467364700278e-06
containing O 0 1.8361933484811743e-07
alpha O 0 8.108369229375967e-07
- O 0 4.7538460421492346e-06
subunit O 0 4.799683210876537e-07
was O 0 1.3201575654875342e-07
transiently O 0 0.00012085447815479711
co O 0 1.4652678146376275e-05
- O 0 4.793425432580989e-06
expressed O 0 1.1666588584091642e-08
with O 0 2.9981657156952224e-09
the O 0 3.0272129247777002e-09
beta O 0 3.6002450087835314e-07
- O 0 6.839096613475704e-07
subunit O 0 2.461802672826252e-08
to O 0 1.0725643706521737e-09
produce O 0 1.8857555517115543e-08
Hex O 0 6.542312576129916e-07
A O 0 3.986992780369292e-08
( O 0 1.889486043182842e-07
alphabeta O 0 4.3165142415091395e-05
) O 0 2.6409827214024517e-08
in O 0 2.878484828272576e-08
COS O 0 0.005607143510133028
- O 0 3.882488454109989e-05
7 O 0 8.1394989592809e-07
cells O 0 4.170109093593055e-07
, O 0 1.6965521210110523e-09
the O 0 2.9310436300278297e-09
mature O 0 3.7756268511657254e-07
alpha O 0 2.0999124217269127e-07
- O 0 2.9875923246436287e-06
subunit O 0 3.531862944328168e-07
was O 0 7.594722184478542e-09
present O 0 1.0197463318206701e-08
, O 0 2.8941786744951514e-09
but O 0 8.797333417298603e-10
its O 0 1.5869895397813139e-09
level O 0 2.267014842516346e-08
was O 0 4.4934633791626766e-09
much O 0 8.644625459908184e-09
lower O 0 1.0956384954852183e-07
than O 0 1.4891023969454409e-09
that O 0 4.945938103517733e-10
from O 0 2.03523753405932e-09
normal O 0 1.3444948265828316e-08
alpha O 0 1.3115865726831544e-07
- O 0 4.0345471461478155e-06
subunit O 0 1.286809833800362e-06
transfections O 0 0.00015063761384226382
, O 0 8.077141622209183e-09
although O 0 7.852516858974923e-09
higher O 0 1.1180300241164787e-08
than O 0 3.943638748893363e-09
in O 0 6.312864897495274e-09
those O 0 1.9355075764337926e-08
cells O 0 2.660349309735466e-06
transfected O 0 2.8248321541468613e-05
with O 0 9.187493432705196e-09
an O 0 1.527818938029668e-08
alpha O 0 2.009331637964351e-06
- O 0 8.07374162832275e-05
subunit O 0 7.882614227128215e-06
associated O 0 4.543530394585105e-06
with O 0 1.8143155102734454e-05
infantile O 1 0.9915093183517456
TSD B-Disease 1 0.9901463389396667
. O 0 0.00010757704149000347

Furthermore O 0 2.6825708118849434e-05
, O 0 4.104236097646208e-07
the O 0 4.447574397659082e-08
precursor O 0 1.0890209978242638e-06
level O 0 1.6800401070327098e-08
of O 0 1.3637770912566793e-09
the O 0 5.2665134475660125e-09
W474C O 0 7.369014383584727e-06
alpha O 0 3.1116485388338333e-07
- O 0 2.046339659500518e-06
subunit O 0 1.6303060590416862e-07
was O 0 5.161902016936892e-09
found O 0 3.281048321923663e-09
to O 0 4.768782702058161e-09
accumulate O 0 2.5042083962034667e-06
in O 0 3.2887421674843154e-09
comparison O 0 3.1645644327227274e-08
to O 0 9.617705520881259e-10
the O 0 6.044678979577611e-09
normal O 0 1.032773297993117e-07
alpha O 0 1.4631334579462418e-06
- O 0 3.873664536513388e-05
subunit O 0 6.924658009666018e-06
precursor O 0 3.234669929952361e-05
levels O 0 6.773926088499138e-06
. O 0 2.3180389234767063e-06

We O 0 1.1614389450187446e-06
conclude O 0 2.1120160909049446e-06
that O 0 3.9836788090497066e-08
the O 0 1.6691555515535583e-07
1422 O 0 0.015353566035628319
G O 0 0.0009643036173656583
- O 0 0.0006863698363304138
- O 0 0.0017613155068829656
> O 0 0.0034377165138721466
C O 0 8.013200567802414e-05
mutation O 0 4.899803229818644e-07
is O 0 3.891603039818392e-09
the O 0 9.184672578044228e-09
cause O 0 8.484494173899293e-07
of O 0 3.8267941704361874e-08
Hex B-Disease 0 0.0005441842367872596
A I-Disease 0 0.00010927085531875491
enzyme I-Disease 1 0.7692509293556213
deficiency I-Disease 1 0.9990352392196655
in O 0 5.787832719761354e-07
the O 0 1.845995825533464e-06
proband O 0 0.0466943234205246
. O 0 1.4206149899109732e-05

The O 0 3.1763613606017316e-06
resulting O 0 1.8380260371486656e-05
W474C O 0 0.00017125168233178556
substitution O 0 2.396465788478963e-06
clearly O 0 4.0864262018658337e-07
interferes O 0 4.39648965766537e-06
with O 0 2.6430438282432078e-08
alpha O 0 1.0736945341704995e-06
- O 0 9.162731657852419e-06
subunit O 0 3.896715270457207e-07
processing O 0 7.754998421205528e-08
, O 0 8.071043389179522e-09
but O 0 1.7072903091275293e-09
because O 0 1.7535943808155707e-09
the O 0 1.1510338238096551e-09
base O 0 1.3026718370667822e-08
substitution O 0 1.3761035688730772e-07
falls O 0 3.28292662743479e-06
at O 0 2.4759141403762897e-09
the O 0 5.498765887068657e-10
first O 0 1.0020306806524104e-09
position O 0 1.4553593885580085e-09
of O 0 1.7423987808129482e-09
exon O 0 4.657721547118854e-06
13 O 0 9.907958542498818e-08
, O 0 4.339908343808929e-08
aberrant O 0 1.6984275134745985e-05
splicing O 0 2.4306905288540293e-06
may O 0 1.410637793242131e-07
also O 0 9.126174482787519e-09
contribute O 0 2.8012919983666507e-07
to O 0 1.2931316462072573e-07
Hex B-Disease 0 0.001282079960219562
A I-Disease 0 0.00025897324667312205
deficiency I-Disease 1 0.997883141040802
in O 0 3.263994585722685e-07
this O 0 4.929362944494642e-07
proband O 0 0.011314639821648598
. O 0 1.2607611097337212e-06
. O 0 6.260500413191039e-06

Two O 0 2.37680123973405e-05
frequent O 0 0.0013460270129144192
missense O 0 0.07753737270832062
mutations O 0 0.03282665088772774
in O 0 0.00869838148355484
Pendred B-Disease 1 0.9958409667015076
syndrome I-Disease 1 0.9985835552215576
. O 0 0.003295180620625615

Pendred B-Disease 1 0.9900598526000977
syndrome I-Disease 1 0.998339056968689
is O 0 0.03422025218605995
an O 1 0.878200113773346
autosomal B-Disease 1 0.9994109869003296
recessive I-Disease 1 0.9995380640029907
disorder I-Disease 1 0.9997578263282776
characterized O 1 0.9913213849067688
by O 0 0.0035596867091953754
early O 1 0.7757093906402588
childhood O 1 0.9986866116523743
deafness B-Disease 1 0.9995018243789673
and O 1 0.5618690848350525
goiter B-Disease 1 0.9987377524375916
. O 0 0.002351907780393958

A O 0 5.0623721108422615e-06
century O 0 3.64010361408873e-06
after O 0 9.02482497622259e-07
its O 0 1.374534832621066e-07
recognition O 0 2.483152456989046e-06
as O 0 9.575228432368021e-07
a O 0 0.00017316891171503812
syndrome O 1 0.9994205236434937
by O 0 5.169070846022805e-06
Vaughan O 0 0.0709705576300621
Pendred O 1 0.676527202129364
, O 0 1.2461188816814683e-05
the O 0 3.776926314458251e-05
disease O 1 0.9977737069129944
gene O 0 0.0001720851578284055
( O 0 1.5423231161548756e-05
PDS O 0 0.0552661195397377
) O 0 1.8476534080491547e-07
was O 0 3.763263478617773e-08
mapped O 0 5.235822868598916e-07
to O 0 6.864365076353351e-08
chromosome O 0 7.362622272921726e-05
7q22 O 0 0.006689124274998903
- O 0 0.004742160905152559
q31 O 0 0.007779991719871759
. O 0 1.1766899660869967e-05

1 O 0 1.8834223737940192e-05
and O 0 1.8740254290605662e-06
, O 0 1.2368924444672302e-06
recently O 0 1.9046102579522994e-06
, O 0 3.1870854400040116e-08
found O 0 5.852426543384581e-09
to O 0 5.3341051575728216e-09
encode O 0 1.2983883834749577e-07
a O 0 7.460226925104507e-07
putative O 0 0.0016722820000723004
sulfate O 0 0.24084626138210297
transporter O 0 0.0207503791898489
. O 0 1.776817771315109e-05

We O 0 1.2988457456231117e-06
performed O 0 5.003504952583171e-07
mutation O 0 7.625627631568932e-07
analysis O 0 4.6677527620886394e-08
of O 0 2.505143648079411e-08
the O 0 6.685633593406237e-07
PDS B-Disease 0 0.1635177880525589
gene O 0 2.9644459573319182e-05
in O 0 2.0708582724182634e-06
patients O 0 0.007292528636753559
from O 0 8.32896319025167e-07
14 O 0 1.9575369151425548e-05
Pendred B-Disease 0 0.1200183629989624
families O 0 1.4139782251731958e-06
originating O 0 4.2595326021910296e-07
from O 0 2.021600487012165e-08
seven O 0 6.566234134197657e-08
countries O 0 4.1071874790077345e-08
and O 0 4.784482499076148e-08
identified O 0 5.137476932759455e-07
all O 0 1.250867143198775e-07
mutations O 0 6.218875932972878e-05
. O 0 8.307762982440181e-06

The O 0 1.9957494714617496e-06
mutations O 0 5.537225206353469e-06
include O 0 7.412541691564911e-08
three O 0 7.138706070719536e-09
single O 0 3.6776445000441527e-08
base O 0 1.5328137692449673e-07
deletions O 0 1.2044938557664864e-06
, O 0 1.3167582579853843e-08
one O 0 8.837346854306816e-09
splice O 0 9.576858246873599e-06
site O 0 5.015702413402323e-07
mutation O 0 1.632314365451748e-06
and O 0 8.059663514359272e-08
10 O 0 1.991207682294771e-06
missense O 0 0.0008865285199135542
mutations O 0 0.00013579943333752453
. O 0 1.217758017446613e-05

One O 0 7.57153429731261e-06
missense O 0 0.0006668147980235517
mutation O 0 9.043504542205483e-05
( O 0 6.803935320931487e-06
L236P O 0 0.001000820891931653
) O 0 3.4674107496357465e-07
was O 0 1.8624000119871198e-08
found O 0 7.730303508424186e-09
in O 0 4.806753217678761e-09
a O 0 3.165892792367231e-08
homozygous O 0 5.042079465056304e-07
state O 0 7.07679204126066e-09
in O 0 5.7358597871370876e-09
two O 0 1.098569768487323e-08
consanguineous O 0 0.0005939736147411168
families O 0 4.0063483197627647e-07
and O 0 1.1767334662238227e-08
in O 0 8.56339266164241e-09
a O 0 4.530263097990428e-08
heterozygous O 0 2.994624423990899e-07
state O 0 6.234915694847132e-09
in O 0 3.6822120907942235e-09
five O 0 1.997598531033873e-08
additional O 0 3.8664279600197915e-07
non O 0 6.373874930432066e-05
- O 0 0.03569646179676056
consanguineous O 0 0.03890875726938248
families O 0 5.7323275541421026e-05
. O 0 1.8592252672533505e-05

Another O 0 3.942825787817128e-05
missense O 0 0.0017866402631625533
mutation O 0 0.0001789542438928038
( O 0 8.719362085685134e-06
T416P O 0 0.000846495502628386
) O 0 2.8004907903778076e-07
was O 0 2.4748249671802114e-08
found O 0 8.910006066287224e-09
in O 0 5.40474864862972e-09
a O 0 3.5862633751548856e-08
homozygous O 0 7.878892915869073e-07
state O 0 2.3103922330847126e-08
in O 0 1.8637004828292447e-08
one O 0 8.321625166729518e-09
family O 0 9.359113306572908e-08
and O 0 5.176444606291852e-09
in O 0 6.306486000084988e-09
a O 0 3.2723686871349855e-08
heterozygous O 0 4.944462261846638e-07
state O 0 2.2957992840133556e-08
in O 0 2.9089957109817988e-08
four O 0 2.529458527078532e-07
families O 0 2.0568388208630495e-05
. O 0 2.200291055487469e-05

Pendred B-Disease 1 0.9434582591056824
patients O 0 0.020984161645174026
in O 0 6.347742669277068e-07
three O 0 3.7330877944441454e-07
non O 0 0.00010729573114076629
- O 0 0.03449130803346634
consanguineous O 0 0.07041420042514801
families O 0 1.2149415624662652e-06
were O 0 4.938851549951551e-09
shown O 0 3.322031361108202e-08
to O 0 6.797614471309998e-09
be O 0 7.876352015045995e-09
compound O 0 7.58228679842432e-06
heterozygotes O 0 0.0004172018088866025
for O 0 6.038919195816561e-07
L236P O 0 0.0016302249860018492
and O 0 3.199186494384776e-06
T416P O 0 0.006518857087939978
. O 0 1.4896485481585842e-05

In O 0 1.333339582743065e-06
total O 0 3.7543313169408066e-07
, O 0 1.2098674062599457e-07
one O 0 2.0169942160919163e-08
or O 0 1.5492730653932085e-08
both O 0 1.987871200981317e-09
of O 0 2.9572115867182447e-09
these O 0 6.662197016282789e-09
mutations O 0 5.07018171447271e-07
were O 0 1.7345864744555684e-09
found O 0 5.78925485328341e-09
in O 0 2.6911546324726032e-09
nine O 0 9.12993503021653e-09
of O 0 5.7655076268758876e-09
the O 0 5.0683635066661736e-08
14 O 0 1.992942088691052e-06
families O 0 3.828937224170659e-06
analyzed O 0 2.5183308025589213e-05
. O 0 1.207121749757789e-05

The O 0 6.912464414199349e-07
identification O 0 2.61490896491523e-07
of O 0 2.9951323199384206e-08
two O 0 9.880650964078086e-08
frequent O 0 0.00021806669246871024
PDS B-Disease 0 0.4365997016429901
mutations O 0 1.63080076163169e-05
will O 0 5.41387201735688e-08
facilitate O 0 7.35690548481216e-07
the O 0 1.8846211560230586e-06
molecular O 0 0.006640275940299034
diagnosis O 1 0.9931683540344238
of O 0 0.004000644665211439
Pendred B-Disease 1 0.9981789588928223
syndrome I-Disease 1 0.9989394545555115
. O 0 0.003413519822061062

Insertional O 0 0.0066185020841658115
mutation O 0 3.3852149499580264e-05
by O 0 6.008272066537756e-07
transposable O 0 0.0004901878419332206
element O 0 2.6511959276831476e-06
, O 0 5.690432658411737e-07
L1 O 0 0.00039438719977624714
, O 0 7.807939539361541e-08
in O 0 7.310271143978753e-08
the O 0 1.2510191709225182e-06
DMD B-Disease 1 0.996996283531189
gene O 0 1.5151802472246345e-05
results O 0 3.681361476992606e-06
in O 0 5.619340754492441e-06
X B-Disease 1 0.7413980960845947
- I-Disease 1 0.9673389792442322
linked I-Disease 1 0.7418051362037659
dilated I-Disease 1 0.9955392479896545
cardiomyopathy I-Disease 1 0.9983110427856445
. O 0 0.0006353374337777495

X B-Disease 1 0.5219688415527344
- I-Disease 1 0.9344355463981628
linked I-Disease 1 0.8803837299346924
dilated I-Disease 1 0.9960365891456604
cardiomyopathy I-Disease 1 0.9990002512931824
( O 0 0.0034966564271599054
XLDCM B-Disease 1 0.9016693830490112
) O 0 3.1474382922169752e-06
is O 0 1.1029645463622728e-07
a O 0 7.160888912949304e-07
clinical O 0 0.0013650364708155394
phenotype O 0 0.00026523612905293703
of O 0 1.2881736211056705e-07
dystrophinopathy B-Disease 0 0.028755858540534973
which O 0 1.1282153167258002e-07
is O 0 2.487124106664851e-07
characterized O 0 0.0002593720855657011
by O 0 6.8989506871730555e-06
preferential O 0 0.0936911404132843
myocardial B-Disease 1 0.999396800994873
involvement I-Disease 0 0.00032591584022156894
without O 0 8.633759875920077e-07
any O 0 6.039662139301072e-07
overt O 0 0.0020252070389688015
clinical O 0 0.17853866517543793
signs O 0 0.03332425653934479
of O 0 0.0006341535481624305
skeletal B-Disease 1 0.9977890253067017
myopathy I-Disease 1 0.9979361295700073
. O 0 0.003862785641103983

To O 0 1.1226027254451765e-06
date O 0 7.224089699775504e-07
, O 0 1.2963629103524e-07
several O 0 1.0533155858638565e-07
mutations O 0 1.1400263247196563e-05
in O 0 1.5031464499770664e-06
the O 0 0.0003954443382099271
Duchenne B-Disease 1 0.999323844909668
muscular I-Disease 1 0.99945467710495
dystrophy I-Disease 1 0.9995077848434448
gene O 0 0.08243976533412933
, O 0 0.001074710045941174
DMD O 1 0.9994004964828491
, O 0 2.1906018901063362e-06
have O 0 2.974818436030091e-08
been O 0 4.855657920188605e-08
identified O 0 1.6897280374905677e-06
in O 0 4.3475829443195835e-06
patients O 0 0.12891824543476105
with O 0 8.95965968084056e-06
XLDCM B-Disease 1 0.8840562105178833
, O 0 3.4926401326629275e-07
but O 0 2.1276173711726187e-08
a O 0 3.834970385696579e-08
pathogenic O 0 1.4025451946508838e-06
correlation O 0 3.613721943906967e-08
of O 0 4.387112451098574e-09
these O 0 7.316813110946896e-08
cardiospecific O 0 0.026928886771202087
mutations O 0 4.489479761105031e-05
in O 0 2.002742803597357e-06
DMD O 1 0.9967817068099976
with O 0 5.149367439116759e-07
the O 0 6.566473530256189e-06
XLDCM B-Disease 1 0.9933266639709473
phenotype O 0 0.0727512538433075
has O 0 3.6829695204687596e-07
remained O 0 6.464692887675483e-07
to O 0 8.961480801872312e-08
be O 0 2.0171333403595781e-07
elucidated O 0 0.0004961134400218725
. O 0 9.515442798146978e-06

We O 0 2.1580924567388138e-06
report O 0 9.620500804885523e-07
here O 0 7.469667906434552e-08
the O 0 7.789461520246732e-09
identification O 0 1.191790399701631e-08
of O 0 1.6327598162391155e-09
a O 0 1.2760560608171545e-08
unique O 0 6.476380320918906e-08
de O 0 8.764127983340586e-07
novo O 0 4.96563188789878e-06
L1 O 0 3.685913543449715e-05
insertion O 0 6.900753533045645e-07
in O 0 1.3591217040698211e-08
the O 0 3.8631469578831457e-08
muscle O 0 0.00024678115732967854
exon O 0 3.4690976463025436e-05
1 O 0 1.3279196764415246e-06
in O 0 9.517617627352593e-07
DMD O 1 0.9927356243133545
in O 0 2.827320884080109e-07
three O 0 1.8974055819853675e-06
XLDCM B-Disease 1 0.98235023021698
patients O 0 0.007343803066760302
from O 0 2.2377298591891304e-07
two O 0 1.4292518812908384e-07
unrelated O 0 0.00021326016576495022
Japanese O 0 0.00028904734062962234
families O 0 9.963970660464838e-05
. O 0 5.223452899372205e-05

The O 0 1.8956745861942181e-06
insertion O 0 1.2114960554754362e-05
was O 0 2.1659634796833416e-07
a O 0 2.1487348078608193e-07
5 O 0 1.12840518795565e-06
- O 0 2.6771220291266218e-05
truncated O 0 2.4006267267395742e-06
form O 0 2.431488788090519e-08
of O 0 5.396363800258541e-09
human O 0 1.4290378658188274e-07
L1 O 0 4.779791925102472e-05
inversely O 0 2.8155514542049787e-07
integrated O 0 1.2612454725058342e-07
in O 0 3.235187229222447e-09
the O 0 4.2084198348391055e-09
5 O 0 2.8597972345778544e-07
- O 0 6.679494981653988e-05
untranslated O 0 0.00018336798530071974
region O 0 2.06145017500603e-07
in O 0 1.0836525454749335e-08
the O 0 6.908023664209395e-08
muscle O 0 0.0014680343447253108
exon O 0 6.836533430032432e-05
1 O 0 2.371678249346587e-07
, O 0 1.7808027052979014e-08
which O 0 3.2259688254043795e-09
affected O 0 1.0850489928770912e-07
the O 0 3.483569654960661e-09
transcription O 0 3.649728341770242e-07
or O 0 1.4229299516443916e-08
the O 0 4.616168780557928e-09
stability O 0 1.5798981678472046e-07
of O 0 4.87496665257936e-09
the O 0 1.3473641047312412e-07
muscle O 0 0.0007670116610825062
form O 0 1.1867777516272326e-07
of O 0 8.848954990980928e-08
dystrophin O 0 0.07351940870285034
transcripts O 0 3.238796580262715e-06
but O 0 2.3310546382049324e-08
not O 0 1.7736223600905987e-09
that O 0 9.341449835886806e-10
of O 0 6.207055314177978e-09
the O 0 4.2176151282546925e-07
brain O 0 0.03156613931059837
or O 0 4.258145509083988e-06
Purkinje O 1 0.8166890740394592
cell O 0 0.0002769119164440781
form O 0 2.505039674360887e-06
, O 0 4.83824976527103e-07
probably O 0 4.841619443141099e-07
due O 0 6.999004398267061e-08
to O 0 2.8836377730101503e-09
its O 0 6.034218902328803e-09
unique O 0 2.0026496017067075e-08
site O 0 6.253449669202382e-08
of O 0 7.143216862459667e-08
integration O 0 4.5009597670286894e-05
. O 0 9.610269444237929e-06

We O 0 2.325686864423915e-06
speculate O 0 5.593356036115438e-06
that O 0 1.5258095231729385e-08
this O 0 4.577913159664604e-09
insertion O 0 2.5010243120959785e-07
of O 0 2.790746522762788e-09
an O 0 2.5284931481905915e-08
L1 O 0 0.0003522499755490571
sequence O 0 4.4378384700394236e-07
in O 0 1.9718061139428755e-06
DMD O 1 0.9987560510635376
is O 0 4.517760032740625e-08
responsible O 0 3.3307994584674816e-08
for O 0 2.2757653539429157e-09
some O 0 1.2151102346535936e-09
of O 0 1.5519457940982306e-09
the O 0 1.1355475670882242e-08
population O 0 3.965665840155452e-08
of O 0 1.1030823543478618e-07
Japanese O 0 0.0013545622350648046
patients O 0 0.14902150630950928
with O 0 2.6705232812673785e-05
XLDCM B-Disease 1 0.9247000813484192
. O 0 1.1848889698740095e-05
. O 0 1.6886659068404697e-05

Severe O 1 0.9791402816772461
early O 0 0.12104877829551697
- O 1 0.9955407977104187
onset O 1 0.9984808564186096
obesity B-Disease 1 0.9989217519760132
, O 0 0.29098719358444214
adrenal B-Disease 1 0.9983620047569275
insufficiency I-Disease 1 0.9986659288406372
and O 0 0.001453140750527382
red O 1 0.9785072803497314
hair O 1 0.9971246123313904
pigmentation O 1 0.9969778060913086
caused O 0 0.17614436149597168
by O 0 0.00011597052798606455
POMC O 1 0.9960779547691345
mutations O 0 0.0005375002510845661
in O 0 5.318469447956886e-06
humans O 0 0.0001422612403985113
. O 0 3.513776391628198e-05

Sequential O 0 1.3878790923627093e-05
cleavage O 0 4.1141836845781654e-05
of O 0 9.910284148872961e-08
the O 0 8.219346625537582e-08
precursor O 0 2.185251787523157e-06
protein O 0 3.0518046401084575e-07
pre O 0 2.1621612177114002e-05
- O 0 9.565232176100835e-05
pro O 0 3.5028431739192456e-05
- O 0 0.0011515723308548331
opiomelanocortin O 0 0.009223133325576782
( O 0 3.992254278273322e-06
POMC O 0 0.00488280551508069
) O 0 4.576396150923756e-08
generates O 0 1.0933547400782118e-07
the O 0 3.307042106825975e-08
melanocortin O 0 0.0038575984071940184
peptides O 0 1.572331166244112e-05
adrenocorticotrophin O 0 0.0020087824668735266
( O 0 2.9882703529438004e-06
ACTH O 0 0.0010293567320331931
) O 0 1.9322843058944272e-07
, O 0 1.8343381213981047e-07
melanocyte O 0 0.023244496434926987
- O 0 0.0007672093925066292
stimulating O 0 0.0008983865263871849
hormones O 0 0.00016313443484250456
( O 0 3.143514277326176e-06
MSH O 0 0.1507633477449417
) O 0 4.4262652210136366e-08
alpha O 0 8.031825871057663e-08
, O 0 5.949284620498929e-09
beta O 0 1.2226578860463633e-07
and O 0 3.07050074255244e-09
gamma O 0 2.6569239253149135e-07
as O 0 1.1603690230899133e-09
well O 0 6.740699109997195e-10
as O 0 2.020801526114724e-09
the O 0 1.767881663283788e-08
opioid O 0 0.00044175059883855283
- O 0 0.00010868890967685729
receptor O 0 6.8690669650095515e-06
ligand O 0 6.787668098695576e-06
beta O 0 8.005974814295769e-05
- O 0 0.001976101193577051
endorphin O 0 0.15264064073562622
. O 0 6.350677267619176e-06

While O 0 2.532403414079454e-06
a O 0 9.394809694640571e-07
few O 0 9.982627489080187e-07
cases O 0 4.895892743661534e-06
of O 0 6.658224265265744e-06
isolated O 1 0.8987292647361755
ACTH B-Disease 1 0.999075174331665
deficiency I-Disease 1 0.9991877675056458
have O 0 1.9760518910061364e-07
been O 0 2.2733243554284854e-07
reported O 0 2.253293314424809e-05
( O 0 2.6465595510671847e-05
OMIM O 1 0.9816446304321289
201400 O 0 0.036656804382801056
) O 0 1.5385620599772665e-06
, O 0 4.134485607210081e-07
an O 0 7.274480140040396e-06
inherited O 1 0.9969795942306519
POMC O 1 0.9991707801818848
defect O 1 0.9791425466537476
has O 0 2.017430688283639e-06
not O 0 5.127892421796787e-08
been O 0 9.02957921766756e-08
described O 0 2.194382432207931e-06
so O 0 4.329037324168894e-07
far O 0 3.0703436095791403e-06
. O 0 8.821207302389666e-06

Recent O 0 5.369012797018513e-05
studies O 0 7.008675765973749e-06
in O 0 9.326589065494773e-07
animal O 0 1.141732354881242e-05
models O 0 1.7925070778801455e-06
elucidated O 0 1.025499113893602e-05
a O 0 4.16576746431474e-08
central O 0 3.813256554963118e-08
role O 0 2.0966341551797996e-08
of O 0 1.5154553167917584e-08
alpha O 0 1.112310383177828e-05
- O 0 0.004473667126148939
MSH O 1 0.582934558391571
in O 0 9.43953448739876e-09
the O 0 4.035088707610157e-09
regulation O 0 1.3522260644549533e-07
of O 0 7.074416608077172e-09
food O 0 7.936985184642253e-07
intake O 0 7.220363613669178e-07
by O 0 4.192348690423842e-09
activation O 0 9.482539553573588e-08
of O 0 4.291145216939185e-09
the O 0 1.0068632150250778e-07
brain O 0 0.0017215687548741698
melanocortin O 0 0.01483230385929346
- O 0 4.041392094222829e-05
4 O 0 1.4636482319474453e-06
- O 0 3.525329157127999e-05
receptor O 0 7.553374871349661e-06
( O 0 6.219833608156478e-07
MC4 O 0 0.013634403236210346
- O 0 4.912338044960052e-05
R O 0 0.0001203807260026224
; O 0 1.7782002714739065e-07
refs O 0 1.1986533536401112e-05
3 O 0 2.877887368413212e-07
- O 0 9.169496479444206e-06
5 O 0 9.415801116574585e-08
) O 0 6.254091911017667e-09
and O 0 9.155214919509547e-10
the O 0 2.301366208712352e-09
linkage O 0 2.9094285309838597e-06
of O 0 5.862461804895247e-08
human O 0 2.2853304471937008e-05
obesity B-Disease 1 0.9583526253700256
to O 0 7.3612994810901e-08
chromosome O 0 3.1524848509434378e-06
2 O 0 8.92834961518929e-08
in O 0 4.434865807922961e-09
close O 0 2.0842776393692475e-08
proximity O 0 8.763194614402892e-08
to O 0 8.155955022459693e-09
the O 0 7.653795108808481e-08
POMC O 0 0.22723513841629028
locus O 0 4.092220478923991e-06
, O 0 1.9813915841382368e-08
led O 0 3.9855862610238546e-08
to O 0 2.3699309181779427e-09
the O 0 2.8369826488017225e-09
proposal O 0 1.3817371780078247e-07
of O 0 9.32372490325406e-09
an O 0 9.89945831975092e-08
association O 0 1.870754022093024e-05
of O 0 1.9117765077680815e-06
POMC O 1 0.9923498034477234
with O 0 0.00010589830344542861
human O 0 0.03416881337761879
obesity B-Disease 1 0.9975239634513855
. O 0 0.00022737783729098737

The O 0 1.116508201448596e-06
dual O 0 1.95689835891244e-06
role O 0 5.023322842134803e-07
of O 0 1.5975263067957712e-07
alpha O 0 4.179518873570487e-05
- O 0 0.009588994085788727
MSH O 1 0.9261026382446289
in O 0 2.6773949457492563e-07
regulating O 0 1.4315711268864106e-05
food O 0 7.054731668176828e-06
intake O 0 1.834742579376325e-05
and O 0 3.631130311987363e-07
influencing O 0 0.00023758067982271314
hair O 1 0.5256203413009644
pigmentation O 1 0.7143871784210205
predicts O 0 0.0026307529769837856
that O 0 4.4488469796988284e-08
the O 0 3.1675722311774734e-07
phenotype O 0 0.0008464902639389038
associated O 0 1.4922412674422958e-06
with O 0 1.2789294601134316e-07
a O 0 8.815278306428809e-06
defect O 0 0.43748944997787476
in O 0 6.872139692859491e-06
POMC O 1 0.9784533977508545
function O 0 1.7597019450477092e-06
would O 0 5.883723019906029e-07
include O 0 0.0001639989495743066
obesity B-Disease 1 0.9985426664352417
, O 0 8.34903221402783e-06
alteration O 0 0.002148994244635105
in O 0 4.7389621613547206e-05
pigmentation O 1 0.9905705451965332
and O 0 0.004557671025395393
ACTH B-Disease 1 0.996591329574585
deficiency I-Disease 1 0.9975391626358032
. O 0 0.000145939236972481

The O 0 3.076751227126806e-06
observation O 0 1.3443479474517517e-05
of O 0 3.681473401684343e-07
these O 0 1.1343697678967146e-06
symptoms O 0 0.19523465633392334
in O 0 1.60794456860458e-07
two O 0 2.036986614939451e-07
probands O 0 0.03964345157146454
prompted O 0 3.7666319258278236e-05
us O 0 5.315501425684488e-07
to O 0 9.633701836264663e-09
search O 0 4.85494489055327e-08
for O 0 3.17816848394159e-08
mutations O 0 1.2171009302619495e-06
within O 0 8.064061063350891e-08
their O 0 9.841508017416345e-07
POMC O 1 0.7709867358207703
genes O 0 3.476963684079237e-05
. O 0 1.0142973223992158e-05

Patient O 0 0.005223347805440426
1 O 0 5.437183062895201e-06
was O 0 2.212853615901622e-07
found O 0 3.0937581385614976e-08
to O 0 3.6334522057757113e-09
be O 0 7.880164853979466e-10
a O 0 1.0009959083845388e-08
compound O 0 1.2102672144465032e-06
heterozygote O 0 2.7821926778415218e-05
for O 0 4.356584870635061e-09
two O 0 5.629812616092522e-09
mutations O 0 4.587810735756648e-07
in O 0 2.67668944786692e-08
exon O 0 2.6706506105256267e-05
3 O 0 8.080911015895254e-07
( O 0 1.0630393489918788e-06
G7013T O 0 0.00012013554805889726
, O 0 3.113298987500457e-07
C7133delta O 0 0.0009304206469096243
) O 0 5.4569269991588953e-08
which O 0 4.011461385289294e-09
interfere O 0 3.860090203033906e-08
with O 0 3.574924578586547e-09
appropriate O 0 1.079151878968787e-08
synthesis O 0 6.900991422753577e-08
of O 0 4.863258240561663e-08
ACTH O 0 0.001234860741533339
and O 0 3.3514862707306747e-07
alpha O 0 6.0980637499596924e-05
- O 0 0.025236593559384346
MSH O 1 0.9717069268226624
. O 0 1.2067717761965469e-05

Patient O 0 0.0020763741340488195
2 O 0 7.706405995122623e-06
was O 0 4.206528103622986e-07
homozygous O 0 1.4519272326651844e-06
for O 0 1.70067728788581e-08
a O 0 6.209331360196302e-08
mutation O 0 7.482258297386579e-07
in O 0 3.10053991370296e-08
exon O 0 3.128841126454063e-05
2 O 0 1.6131494930959889e-06
( O 0 3.11748726744554e-06
C3804A O 0 0.00012915358820464462
) O 0 2.455163610193267e-07
which O 0 1.5765914440635242e-07
abolishes O 0 0.005746548064053059
POMC O 0 0.465110182762146
translation O 0 1.4529005056829192e-05
. O 0 1.3158567526261322e-05

These O 0 1.2832754237024346e-06
findings O 0 1.55638645082945e-06
represent O 0 3.86757044168462e-08
the O 0 1.1845837200041842e-08
first O 0 2.049933733871967e-08
examples O 0 6.672499353044259e-08
of O 0 4.499666417245862e-08
a O 0 7.802067557349801e-06
genetic B-Disease 0 0.05306577682495117
defect I-Disease 0 0.39488938450813293
within O 0 3.1727782356938405e-07
the O 0 1.51842004925129e-06
POMC O 1 0.6921201348304749
gene O 0 2.29083184422052e-06
and O 0 3.6688657445438366e-08
define O 0 2.0978498014301294e-06
a O 0 7.069103958201595e-06
new O 0 0.006180767901241779
monogenic B-Disease 1 0.9991025924682617
endocrine I-Disease 1 0.9995262622833252
disorder I-Disease 1 0.9992362260818481
resulting O 0 0.00045549951028078794
in O 0 1.1828714377770666e-05
early O 0 0.00520270224660635
- O 1 0.9984381794929504
onset O 1 0.9994198083877563
obesity B-Disease 1 0.9995891451835632
, O 0 0.05144130438566208
adrenal B-Disease 1 0.9991146922111511
insufficiency I-Disease 1 0.9990383386611938
and O 0 0.0006626121466979384
red O 1 0.9581499695777893
hair O 1 0.9941732287406921
pigmentation O 1 0.9599083065986633
. O 0 1.1871113201777916e-05
. O 0 2.5014705897774547e-05

A O 0 3.460543302935548e-05
European O 0 6.805767043260857e-05
multicenter O 0 0.04852758347988129
study O 0 2.3960017642821185e-05
of O 0 2.28943390538916e-05
phenylalanine B-Disease 1 0.993973433971405
hydroxylase I-Disease 1 0.9978821873664856
deficiency I-Disease 1 0.999583899974823
: O 0 2.134379064955283e-05
classification O 0 1.8762051695375703e-05
of O 0 2.6182771506455538e-08
105 O 0 6.044005203875713e-06
mutations O 0 2.695970351851429e-06
and O 0 8.720189015321012e-09
a O 0 2.5775223733148778e-08
general O 0 1.7771152727164008e-07
system O 0 4.7146116344265465e-07
for O 0 9.272988421571426e-08
genotype O 0 0.00016462738858535886
- O 0 0.00016893731663003564
based O 0 6.544914867845364e-07
prediction O 0 7.672607898712158e-05
of O 0 2.4447431314911228e-06
metabolic O 1 0.6848419904708862
phenotype O 0 0.07935221493244171
. O 0 4.824947609449737e-05

Phenylketonuria B-Disease 1 0.972865879535675
( O 0 0.0035857295151799917
PKU B-Disease 1 0.9835642576217651
) O 0 8.451080066151917e-05
and O 0 7.177513907663524e-05
mild B-Disease 1 0.9940063953399658
hyperphenylalaninemia I-Disease 1 0.9969995617866516
( O 0 0.011860299855470657
MHP B-Disease 1 0.9983459711074829
) O 0 4.250495112501085e-05
are O 0 9.186459465126973e-06
allelic B-Disease 1 0.9977346658706665
disorders I-Disease 1 0.9997349381446838
caused O 0 0.015234199352562428
by O 0 3.791275275943917e-07
mutations O 0 4.507510311668739e-06
in O 0 2.5178284346338842e-08
the O 0 2.8259073303615878e-08
gene O 0 1.6931317077251151e-06
encoding O 0 3.81711333830026e-06
phenylalanine O 0 0.0024662483483552933
hydroxylase O 0 0.22291262447834015
( O 0 0.0008753263391554356
PAH O 1 0.9969040751457214
) O 0 5.75457443119376e-06
. O 0 6.47701335765305e-06

Previous O 0 3.183277294738218e-05
studies O 0 5.585232429439202e-06
have O 0 1.1895335205736046e-07
suggested O 0 5.53240397493937e-07
that O 0 1.353177569995978e-08
the O 0 8.870822654216681e-08
highly O 0 9.772329576662742e-06
variable O 0 0.0001668270124355331
metabolic O 1 0.7356868386268616
phenotypes O 0 0.3336234986782074
of O 0 0.01594555750489235
PAH B-Disease 1 0.9994850158691406
deficiency I-Disease 1 0.9989138841629028
correlate O 0 0.07139158993959427
with O 0 0.008700340054929256
PAH O 1 0.9977814555168152
genotypes O 1 0.6428421139717102
. O 0 0.00010588517034193501

We O 0 2.0110512650717283e-06
identified O 0 1.9308192804601276e-06
both O 0 5.254195230008918e-07
causative O 0 0.001260528457351029
mutations O 0 0.00014816557813901454
in O 0 1.4946375813451596e-05
686 O 1 0.9690752625465393
patients O 0 0.08013437688350677
from O 0 1.2374894140521064e-06
seven O 0 4.028557214041939e-06
European O 0 6.048310024198145e-05
centers O 0 6.15956014371477e-05
. O 0 2.248459350084886e-05

On O 0 3.772175318772497e-07
the O 0 2.526439324412877e-08
basis O 0 7.47039141657524e-09
of O 0 6.615800351994494e-09
the O 0 2.1136949968081353e-08
phenotypic O 0 2.4669743652339093e-06
characteristics O 0 3.955830720769882e-07
of O 0 2.410102126759739e-07
297 O 0 0.018608812242746353
functionally O 0 0.1886366456747055
hemizygous O 1 0.9701642990112305
patients O 0 0.0228490699082613
, O 0 1.2890104983398487e-07
105 O 0 3.817943934336654e-07
of O 0 5.060661667499744e-09
the O 0 2.6680345044383103e-08
mutations O 0 4.6742030690438696e-07
were O 0 5.623456145187333e-10
assigned O 0 4.7984904938402906e-09
to O 0 5.584464557450985e-10
one O 0 5.355142440599536e-10
of O 0 1.6336133557004473e-09
four O 0 3.3122375953098526e-08
arbitrary O 0 1.0700514394557104e-06
phenotype O 0 0.0015149434329941869
categories O 0 1.7364334780722857e-05
. O 0 6.9412067205121275e-06

We O 0 1.6302840322168777e-06
proposed O 0 3.043807510039187e-06
and O 0 1.6189832763302547e-07
tested O 0 1.186292820420931e-06
a O 0 2.6525635021812377e-08
simple O 0 8.817079333311995e-08
model O 0 1.7130476237525727e-07
for O 0 3.417822469486964e-08
correlation O 0 6.208005061125732e-07
between O 0 3.7127830410099705e-07
genotype O 0 6.01929277763702e-05
and O 0 3.9421300357389555e-07
phenotypic O 0 5.031908949604258e-05
outcome O 0 3.155627200612798e-05
. O 0 2.183254218834918e-05

The O 0 2.7761120691138785e-06
observed O 0 8.720659025129862e-06
phenotype O 0 0.00018276541959494352
matched O 0 5.0766147978720255e-06
the O 0 5.049856213190651e-07
predicted O 0 0.00035963187110610306
phenotype O 0 0.000341406324878335
in O 0 1.6151048498613818e-07
79 O 0 1.637920649955049e-05
% O 0 2.3398746051839225e-08
of O 0 4.46919701246884e-09
the O 0 3.692848693503947e-08
cases O 0 5.209142273088219e-07
, O 0 2.263796083923353e-08
and O 0 4.70252992101905e-09
in O 0 2.267684262591274e-09
only O 0 1.4517415047876625e-09
5 O 0 7.36473992901665e-08
of O 0 5.1793115574128024e-08
184 O 0 0.004293733276426792
patients O 0 0.008376197889447212
was O 0 8.103084070398836e-08
the O 0 4.204241932370678e-08
observed O 0 4.655691725474753e-07
phenotype O 0 8.447761501884088e-06
more O 0 4.165614519990868e-09
than O 0 9.05375419080201e-09
one O 0 9.26324439376458e-09
category O 0 5.655170411955623e-07
away O 0 6.934676832770492e-08
from O 0 5.6971991568843805e-08
that O 0 8.491019798384514e-08
expected O 0 2.7772241537604714e-06
. O 0 4.761101081385277e-06

Among O 0 3.3387366329407087e-06
the O 0 1.7952015696209855e-07
seven O 0 5.722650371353666e-07
contributing O 0 1.3402197510004044e-05
centers O 0 1.6141159449034603e-06
, O 0 6.527224627461692e-08
the O 0 3.7628186788651874e-08
proportion O 0 2.1544649371207925e-06
of O 0 4.0950635593617335e-07
patients O 0 0.009958157315850258
for O 0 2.2458111459400243e-07
whom O 0 2.454779860272538e-06
the O 0 2.952406816802977e-07
observed O 0 4.524202722677728e-06
phenotype O 0 0.00019440232426859438
did O 0 4.83845283838491e-08
not O 0 2.061247839080238e-09
match O 0 5.09023898587202e-08
the O 0 1.351738188049012e-08
predicted O 0 9.420573405805044e-06
phenotype O 0 1.2228867490193807e-05
was O 0 9.050370231022953e-09
4 O 0 5.398126745603804e-08
% O 0 2.3220376732524528e-08
- O 0 3.948235189454863e-06
23 O 0 1.3557615829995484e-07
% O 0 4.560729038871614e-08
( O 0 2.900193294408382e-07
P O 0 0.0001975968189071864
< O 0 0.00022512143186759204
. O 0 2.973270625261648e-07
0001 O 0 0.002228538040071726
) O 0 9.958602475990119e-08
, O 0 3.2221212364902385e-08
suggesting O 0 3.534545101047115e-07
that O 0 3.3250475706125826e-09
differences O 0 4.288864730028763e-08
in O 0 3.90535159766614e-09
methods O 0 1.2026049489577417e-08
used O 0 1.1210237182979199e-08
for O 0 6.57217285038314e-08
mutation O 0 2.8210659365868196e-05
detection O 0 0.00011931539484066889
or O 0 5.936274192208657e-06
phenotype O 0 0.02419418841600418
classification O 0 0.001230114372447133
may O 0 5.89271905937494e-07
account O 0 2.5515147328292187e-08
for O 0 6.4825700363257965e-09
a O 0 4.2419387114023266e-08
considerable O 0 1.481190793128917e-06
proportion O 0 2.3075617718859576e-06
of O 0 1.3440482007354149e-06
genotype O 0 0.11663131415843964
- O 0 0.41445392370224
phenotype O 0 0.05858312174677849
inconsistencies O 0 0.0011045470600947738
. O 0 3.288151856395416e-05

Our O 0 2.436167051200755e-06
data O 0 1.053556275110168e-06
indicate O 0 1.28446322378295e-06
that O 0 1.7296819976309052e-07
the O 0 1.0098353413923178e-05
PAH O 1 0.9986844658851624
- O 0 0.008285080082714558
mutation O 0 1.2208943189762067e-05
genotype O 0 3.805790811384213e-06
is O 0 2.1737549538158873e-09
the O 0 2.690846878650177e-09
main O 0 5.112550383046255e-08
determinant O 0 3.8129549011500785e-06
of O 0 4.963047786077368e-07
metabolic O 1 0.7501195669174194
phenotype O 0 0.08677264302968979
in O 0 7.892806934250984e-06
most O 0 9.762822446646169e-05
patients O 1 0.9887682795524597
with O 1 0.6013490557670593
PAH B-Disease 1 0.9994420409202576
deficiency I-Disease 1 0.998802661895752
. O 0 0.0005727741518057883

In O 0 8.235924724431243e-07
the O 0 1.6383360446070583e-07
present O 0 1.6956931858658209e-07
study O 0 3.747863104308635e-07
, O 0 2.521620245943268e-08
the O 0 1.9137610607344868e-08
classification O 0 1.9854598576785065e-05
of O 0 3.48483496281915e-07
105 O 0 0.009752963669598103
PAH O 1 0.999502420425415
mutations O 0 4.6832632506266236e-05
may O 0 1.2343195976427523e-07
allow O 0 6.518551032286268e-09
the O 0 2.5212341103753033e-09
prediction O 0 2.2493779283649928e-07
of O 0 1.4881370580255293e-09
the O 0 2.4325649050638276e-08
biochemical O 0 2.960953861474991e-05
phenotype O 0 4.3343083234503865e-05
in O 0 5.525096824499087e-08
> O 0 4.012012141174637e-05
10 O 0 9.837006587076758e-08
, O 0 1.1259054844003913e-07
000 O 0 8.11839709058404e-06
genotypes O 0 0.0001301743759540841
, O 0 7.144321045871038e-08
which O 0 1.613433830982558e-08
may O 0 4.196262537448092e-08
be O 0 5.797693991560493e-10
useful O 0 3.5025511380126773e-09
for O 0 2.9838864712417035e-09
the O 0 3.30912435231312e-08
management O 0 6.908556770213181e-06
of O 0 3.964350696605834e-07
hyperphenylalaninemia B-Disease 1 0.902793288230896
in O 0 4.7623841965105385e-05
newborns O 1 0.670261025428772
. O 0 4.266357427695766e-05

Somatic O 0 0.000753470987547189
instability O 0 0.00015200822963379323
of O 0 2.7695355697687773e-07
the O 0 1.322095613431884e-06
CTG O 0 0.029891962185502052
repeat O 0 0.00012221910583321005
in O 0 7.231844847410684e-07
mice O 0 0.0004938732599839568
transgenic O 0 0.000135846043122001
for O 0 2.7440937628853135e-06
the O 0 0.0012737868819385767
myotonic B-Disease 1 0.9997616410255432
dystrophy I-Disease 1 0.9998088479042053
region O 0 0.0031438369769603014
is O 0 2.5006547730299644e-06
age O 0 3.087778532062657e-05
dependent O 0 3.1545089314022334e-06
but O 0 3.471387088893607e-08
not O 0 6.963143839300301e-09
correlated O 0 2.5099294020947127e-07
to O 0 3.3686082812067752e-09
the O 0 1.2104684365965568e-08
relative O 0 1.5119393310669693e-06
intertissue O 0 0.006047938019037247
transcription O 0 9.662194497650489e-05
levels O 0 2.5838930014288053e-05
and O 0 8.67328344611451e-06
proliferative O 1 0.983747661113739
capacities O 0 0.0009365477599203587
. O 0 2.724959449551534e-05

A O 0 2.464947829139419e-05
( O 0 2.853758451237809e-05
CTG O 0 0.008259453810751438
) O 0 1.7880372524814447e-06
nexpansion O 0 5.28153104824014e-05
in O 0 3.981445217959845e-08
the O 0 3.622195876573642e-08
3 O 0 1.0144597126782173e-06
- O 0 0.0001518506178399548
untranslated O 0 0.0005667036166414618
region O 0 9.6880239652819e-07
( O 0 2.832483687598142e-07
UTR O 0 1.4973081306379754e-05
) O 0 4.434831613053802e-09
of O 0 1.2818588412955023e-09
the O 0 6.731403345838771e-08
DM O 1 0.9585129022598267
protein O 0 1.9744065866689198e-06
kinase O 0 2.870763637474738e-05
gene O 0 6.090526312618749e-06
( O 0 2.0157997369096847e-06
DMPK O 0 0.003908274695277214
) O 0 1.5287319854451198e-07
is O 0 4.521880470065298e-08
responsible O 0 1.0588040595393977e-06
for O 0 1.3949995263828896e-05
causing O 1 0.9896774291992188
myotonic B-Disease 1 0.999294638633728
dystrophy I-Disease 1 0.9994813799858093
( O 0 0.287916898727417
DM B-Disease 1 0.9985870122909546
) O 0 0.0001233705843333155
. O 0 2.916031371569261e-05

Major O 0 0.0010116931516677141
instability O 0 0.00948572251945734
, O 0 1.1219026418984868e-06
with O 0 1.8814053248661367e-07
very O 0 1.1659185616963441e-07
large O 0 3.5248672247689683e-07
expansions O 0 1.0091835974890273e-05
between O 0 1.3764264394922066e-07
generations O 0 1.726644313748693e-06
and O 0 5.011675696664497e-08
high O 0 1.0666891512300936e-06
levels O 0 5.781918730463076e-07
of O 0 6.438114041884546e-08
somatic O 0 0.001311178901232779
mosaicism O 0 0.30209895968437195
, O 0 4.3212827449679025e-07
is O 0 1.1484536344141816e-07
observed O 0 1.6920823782129446e-06
in O 0 6.760328233212931e-06
patients O 0 0.1054077222943306
. O 0 7.345456106122583e-05

There O 0 1.5728866173958522e-06
is O 0 1.0977323228189562e-07
a O 0 6.299047328184315e-08
good O 0 8.18791150436482e-08
correlation O 0 2.2426009138598602e-07
between O 0 1.77001481915795e-07
repeat O 0 4.764936966239475e-05
size O 0 1.7844989770310349e-06
( O 0 1.1651360409814515e-07
at O 0 1.2492834322586077e-08
least O 0 1.0727940313870477e-08
in O 0 1.0402759897942815e-07
leucocytes O 0 0.018498102203011513
) O 0 1.7958898297365522e-06
, O 0 3.954422936658375e-06
clinical O 0 0.08387716114521027
severity O 0 0.11617188155651093
and O 0 1.0718777048168704e-06
age O 0 7.914264278952032e-05
of O 0 1.0189442036789842e-05
onset O 1 0.9924275279045105
. O 0 0.00013730238424614072

The O 0 0.00015799433458596468
trinucleotide O 1 0.9791560173034668
repeat O 0 0.0341389961540699
instability O 0 0.0057945954613387585
mechanisms O 0 3.610607382142916e-05
involved O 0 9.556814802635927e-06
in O 0 8.545187301933765e-05
DM B-Disease 1 0.9989112615585327
and O 0 1.0642367669788655e-05
other O 0 2.4375836801482365e-05
human O 0 0.17816118896007538
genetic B-Disease 1 0.9984731078147888
diseases I-Disease 1 0.9993712306022644
are O 0 2.9584148251160514e-06
unknown O 0 5.781147046945989e-05
. O 0 4.4956796045880765e-05

We O 0 2.5861456833808916e-06
studied O 0 5.08336825078004e-06
somatic O 0 0.00034425369813106954
instability O 0 0.0003399020351935178
by O 0 1.5903424355201423e-07
measuring O 0 1.0743853636085987e-05
the O 0 5.191011496208375e-07
CTG O 0 0.10320988297462463
repeat O 0 8.044821151997894e-05
length O 0 5.61999797810131e-07
at O 0 5.577359019071082e-08
several O 0 1.4507511636452364e-08
ages O 0 1.3229381465862389e-06
in O 0 1.212635947211993e-08
various O 0 1.0339888945054554e-08
tissues O 0 4.318441824580077e-06
of O 0 4.6467711456443794e-08
transgenic O 0 0.0002528302720747888
mice O 0 2.3387796318274923e-05
carrying O 0 8.79395329889121e-08
a O 0 1.3643584395595099e-07
( O 0 1.688581164671632e-06
CTG O 0 0.002186592435464263
) O 0 1.383680796607223e-07
55expansion O 0 3.5732839023694396e-05
surrounded O 0 2.4346917371076415e-07
by O 0 7.71338015681522e-09
45 O 0 5.903192601408591e-08
kb O 0 3.512204330036184e-06
of O 0 6.123354712173068e-09
the O 0 8.209993040964036e-08
human O 0 3.351199484313838e-05
DM B-Disease 1 0.9989271759986877
region O 0 2.8563786145241465e-06
, O 0 2.6388425666823423e-08
using O 0 3.134468329335505e-08
small O 0 7.313728929148056e-07
- O 0 0.00041454387246631086
pool O 0 0.00026149407494813204
PCR O 0 9.070174564840272e-05
. O 0 5.408816832641605e-06

These O 0 7.054927209537709e-06
mice O 0 0.0006685212720185518
have O 0 1.2117115488763375e-07
been O 0 2.7186390028077767e-08
shown O 0 2.9710646387570705e-08
to O 0 1.0709275244380478e-08
reproduce O 0 1.2370835520414403e-06
the O 0 3.214901767023548e-08
intergenerational O 0 6.474687688751146e-05
and O 0 9.338518225376902e-08
somatic O 0 1.6968278941931203e-05
instability O 0 1.0166651918552816e-05
of O 0 7.423433867614904e-09
the O 0 5.678691294974669e-08
55 O 0 1.4243809346226044e-05
CTG O 0 0.3163434863090515
repeat O 0 0.00028171800659038126
suggesting O 0 1.931219003381557e-06
that O 0 5.356545429435755e-09
surrounding O 0 5.640800537776158e-08
sequences O 0 4.2404582956123704e-08
and O 0 1.1882268502461102e-08
the O 0 4.0285002000928216e-08
chromatin O 0 7.072601874824613e-05
environment O 0 2.679990302567603e-06
are O 0 8.933404238575804e-09
involved O 0 6.03807848165161e-07
in O 0 1.805964643608604e-06
instability O 0 0.016447974368929863
mechanisms O 0 0.00016931304708123207
. O 0 4.223706491757184e-05

As O 0 1.115373720494972e-06
observed O 0 3.772916556954442e-07
in O 0 1.3449565017253917e-08
some O 0 3.830435968410484e-09
of O 0 6.5279071037593894e-09
the O 0 4.2162878344242927e-07
tissues O 0 0.006301959976553917
of O 0 0.00032536263461224735
DM B-Disease 1 0.999859094619751
patients O 1 0.9336763620376587
, O 0 8.594482778789825e-07
there O 0 4.8906713345786557e-08
is O 0 1.543792294000923e-08
a O 0 1.4758762745259446e-07
tendency O 0 7.014988113951404e-06
for O 0 4.98976682195007e-08
repeat O 0 4.675079617300071e-05
length O 0 7.516158007092599e-07
and O 0 1.4251264701670152e-07
somatic O 0 0.00012204067752463743
mosaicism O 0 0.02390337735414505
to O 0 2.7490017373565934e-08
increase O 0 1.0298560226829068e-07
with O 0 1.6294441351760725e-08
the O 0 1.5889076721009587e-08
age O 0 4.229222838603164e-07
of O 0 2.30355858832354e-08
the O 0 6.452226557485119e-07
mouse O 0 0.0040239072404801846
. O 0 2.0285267964936793e-05

Furthermore O 0 0.00022016066941432655
, O 0 1.3183914688852383e-06
we O 0 6.5786316838512e-08
observed O 0 7.172283034151405e-08
no O 0 1.2995721831998708e-08
correlation O 0 4.279948839780445e-08
between O 0 1.0487825718996646e-08
the O 0 4.9574371274729856e-08
somatic O 0 0.00010798631410580128
mutation O 0 2.163052158721257e-05
rate O 0 5.084919848741265e-06
and O 0 4.43209637523978e-06
tissue O 0 0.33173421025276184
proliferation O 0 0.37156233191490173
capacity O 0 8.051806798903272e-05
. O 0 1.0028754331870005e-05

The O 0 6.866276635264512e-06
somatic O 0 0.0006005337345413864
mutation O 0 0.00018275390902999789
rates O 0 8.065034307946917e-06
in O 0 5.235388300661725e-08
different O 0 2.260223652683635e-08
tissues O 0 2.3425764084095135e-05
were O 0 4.584554069708702e-09
also O 0 5.027259941670081e-09
not O 0 2.6072324299519778e-09
correlated O 0 2.2319069614695763e-07
to O 0 2.951497712899709e-09
the O 0 7.265618773288907e-09
relative O 0 1.4293871117843082e-06
inter O 0 0.00014003623800817877
- O 0 0.007702633738517761
tissue O 0 0.0005322927027009428
difference O 0 1.793622175227938e-07
in O 0 1.008944838787329e-08
transcriptional O 0 4.6384653273889853e-07
levels O 0 1.8338408125373462e-08
of O 0 4.517522744773572e-10
the O 0 1.2060913379130511e-09
three O 0 6.66024035922419e-09
genes O 0 3.7615780001942767e-07
( O 0 7.167543571995338e-07
DMAHP O 0 0.002489169593900442
, O 0 1.9250410332460888e-07
DMPK O 0 0.0008784035453572869
and O 0 5.4311648511884414e-08
59 O 0 4.031585831398843e-06
) O 0 7.921099864915959e-08
surrounding O 0 3.0419741392506694e-07
the O 0 7.700168680457864e-08
repeat O 0 0.0002340722130611539
. O 0 1.1731264066838776e-06
. O 0 4.669552254199516e-06

A O 0 3.0875427910359576e-05
novel O 0 9.114940621657297e-05
missense O 0 0.00378972920589149
mutation O 0 0.000368417298886925
in O 0 9.047523235494737e-06
patients O 0 0.037295062094926834
from O 0 1.6341865602953476e-06
a O 0 4.830195757676847e-05
retinoblastoma B-Disease 1 0.9941098690032959
pedigree O 0 0.09593851864337921
showing O 0 6.380571721820161e-05
only O 0 5.322659148987441e-07
mild O 0 0.030567308887839317
expression O 0 1.2440176533345948e-06
of O 0 3.7878422176618187e-07
the O 0 8.432741742581129e-05
tumor B-Disease 1 0.9966756105422974
phenotype O 0 0.17653684318065643
. O 0 6.859259883640334e-05

We O 0 6.555184199896757e-07
have O 0 3.131755121899005e-08
used O 0 1.2547951122598988e-08
single O 0 1.907431190772968e-08
strand O 0 6.73102420023497e-07
conformation O 0 6.450922569456452e-07
polymorphism O 0 3.3576540658941667e-07
analysis O 0 2.079187311210262e-08
to O 0 2.8075215485756644e-09
study O 0 1.0165052799493424e-08
the O 0 2.096481210855927e-09
27 O 0 3.241853718805032e-08
exons O 0 1.0339893918853704e-07
of O 0 5.7232156791542366e-09
the O 0 2.126562890225614e-07
RB1 O 0 0.2345687597990036
gene O 0 1.2510203077908955e-06
in O 0 2.6208303083308238e-08
individuals O 0 3.374229962105346e-08
from O 0 7.14850543204193e-08
a O 0 1.1579926422200515e-06
family O 0 3.093979830737226e-05
showing O 0 0.00023052850156091154
mild O 0 0.12012722343206406
expression O 0 8.099149795270932e-07
of O 0 1.6069327557488577e-07
the O 0 1.0637740160746034e-05
retinoblastoma B-Disease 1 0.993224561214447
phenotype O 0 0.47695958614349365
. O 0 6.113499694038182e-05

In O 0 8.823193638818339e-06
this O 0 3.0966800750320544e-06
family O 0 0.0001506318658357486
affected O 0 0.0005658493028022349
individuals O 0 4.811098915524781e-05
developed O 0 0.013402240350842476
unilateral B-Disease 1 0.9063896536827087
tumors I-Disease 1 0.9994701743125916
and O 0 1.2245919833731023e-06
, O 0 1.45519976513242e-07
as O 0 9.364574005132908e-09
a O 0 2.4287540867362623e-08
result O 0 4.707019130023582e-08
of O 0 1.6016292292420076e-08
linkage O 0 4.246257958584465e-05
analysis O 0 1.380519051963347e-06
, O 0 1.9622732452262426e-06
unaffected O 0 0.001419431995600462
mutation O 0 3.1254090572474524e-05
carriers O 0 5.648273145197891e-06
were O 0 3.787196778404223e-09
also O 0 1.3405078824746397e-08
identified O 0 7.159503212506024e-08
within O 0 4.893004046380156e-08
the O 0 9.975804005080136e-07
pedigree O 0 0.00926136877387762
. O 0 3.66802305507008e-05

A O 0 1.5769763876960496e-06
single O 0 3.7869537550250243e-07
band O 0 6.693940690638556e-07
shift O 0 8.518610457031173e-07
using O 0 1.3715100521949353e-07
SSCP O 0 0.002868221839889884
was O 0 9.10814463850329e-08
identified O 0 6.841791133638253e-08
in O 0 2.3551878669536563e-08
exon O 0 1.5473155144718476e-05
21 O 0 1.1938908528463799e-07
which O 0 6.291516196910152e-09
resulted O 0 1.14049697685914e-07
in O 0 6.080571601785323e-09
a O 0 2.719956349039876e-08
missense O 0 6.036131253495114e-06
mutation O 0 2.197258339720065e-07
converting O 0 7.744754526584074e-08
a O 0 3.8720440898032393e-07
cys O 0 0.1340092420578003
- O 0 0.00045076091191731393
- O 0 0.00023068193695507944
> O 0 0.00012125248758820817
arg O 0 2.4111370294122025e-05
at O 0 1.0500655456269214e-08
nucleotide O 0 2.1966544139218058e-08
position O 0 5.923717516509441e-09
28 O 0 2.6686045373480738e-08
in O 0 7.884859876128303e-09
the O 0 9.281801283123059e-08
exon O 0 0.00020868919091299176
. O 0 6.103410669311415e-06

The O 0 1.7047379515133798e-05
mutation O 0 0.00013809240772388875
destroyed O 0 3.687608113978058e-05
an O 0 1.5087775864230935e-06
NdeI O 0 0.014512184076011181
restriction O 0 4.978973083780147e-05
enzyme O 0 5.396376582211815e-05
site O 0 1.2243968740222044e-05
. O 0 7.301057394215604e-06

Analysis O 0 3.2710545383451972e-06
of O 0 1.0915523063204091e-07
all O 0 6.850108746903061e-08
family O 0 9.999215535572148e-07
members O 0 2.416504329971758e-08
demonstrated O 0 2.2174123159857118e-07
that O 0 4.877142689707625e-09
the O 0 3.117594715718042e-08
missense O 0 0.00010711119830375537
mutation O 0 0.00012412613432388753
co O 0 0.0024827441666275263
- O 0 0.03367100656032562
segregated O 0 0.0016809448134154081
with O 0 0.0001436400052625686
patients O 1 0.9591423273086548
with O 0 0.006330679636448622
tumors B-Disease 1 0.9997332692146301
or O 0 1.525167408544803e-05
who O 0 1.6736357792979106e-06
, O 0 8.011537744323505e-08
as O 0 5.977470074469693e-09
a O 0 1.8736123763574142e-08
result O 0 7.455263784095223e-08
of O 0 2.1249162429626267e-08
linkage O 0 2.3007605705060996e-05
analysis O 0 1.7360146387090936e-07
had O 0 3.6029714323149165e-08
been O 0 2.1702719621430333e-08
predicted O 0 1.3976128911963315e-06
to O 0 1.527629578390588e-08
carry O 0 2.0607701856079075e-07
the O 0 5.845824375683151e-07
predisposing O 0 0.007130325306206942
mutation O 0 0.00026900143711827695
. O 0 1.2095128113287501e-05

These O 0 5.357794634619495e-07
observations O 0 5.429325824479747e-07
point O 0 1.2224130330196203e-07
to O 0 2.3827137596299508e-08
another O 0 8.569818277237573e-08
region O 0 2.0257813559965143e-07
of O 0 2.2982222347422976e-08
the O 0 1.0986535698975786e-06
RB1 O 1 0.9077644944190979
gene O 0 4.820279173145536e-06
where O 0 8.232369452798594e-08
mutations O 0 5.117208843330445e-07
only O 0 2.2251809284057344e-09
modify O 0 5.637551225845527e-07
the O 0 2.0824288959886417e-09
function O 0 2.9183024885526265e-09
of O 0 1.2307123098409534e-09
the O 0 1.039765784582869e-08
gene O 0 4.781686584465206e-07
and O 0 2.4682721644353478e-08
raise O 0 6.664778879894584e-07
important O 0 1.3591658465372802e-08
questions O 0 2.3284246708499268e-07
for O 0 1.72364210015985e-07
genetic O 0 0.00041843531653285027
counseling O 0 0.00036618244484998286
in O 0 3.778930022235727e-07
families O 0 9.093672588278423e-07
with O 0 3.4694215855779476e-07
these O 0 5.354934273782419e-07
distinctive O 0 0.00047873397124931216
phenotypes O 0 0.01114187017083168
. O 0 4.284782789909514e-06
. O 0 2.0263301848899573e-05

Maternal B-Disease 0 0.0650855153799057
disomy I-Disease 1 0.7831554412841797
and O 0 0.012476756237447262
Prader B-Disease 1 0.9972450733184814
- I-Disease 1 0.9983704686164856
Willi I-Disease 1 0.9994044303894043
syndrome I-Disease 1 0.9992606043815613
consistent O 0 9.057330316863954e-05
with O 0 2.2183898181538098e-05
gamete O 0 0.22552728652954102
complementation O 1 0.6113678812980652
in O 0 2.511483501166367e-07
a O 0 1.992513460891132e-07
case O 0 4.341295607446227e-07
of O 0 1.5561089128368621e-07
familial O 0 0.08205059915781021
translocation O 0 0.0009002922452054918
( O 0 1.2323523606028175e-06
3 O 0 2.2105714947429078e-07
; O 0 1.1196714666539265e-07
15 O 0 5.768953670326482e-08
) O 0 6.961619192225044e-08
( O 0 2.892106181207055e-07
p25 O 0 0.0002498482645023614
; O 0 7.085978381837776e-07
q11 O 0 6.63432219880633e-05
. O 0 8.181619648439664e-08
2 O 0 1.1018664736184292e-06
) O 0 1.1206857379875146e-06
. O 0 2.1066050521767465e-06

Maternal B-Disease 0 0.4464800953865051
uniparental I-Disease 1 0.9690755605697632
disomy I-Disease 1 0.8610367774963379
( I-Disease 0 0.0013387236976996064
UPD I-Disease 1 0.9754525423049927
) I-Disease 0 2.3019240416033426e-06
for I-Disease 0 1.517771579528926e-07
chromosome I-Disease 0 1.0192979061685037e-05
15 I-Disease 0 1.8942492374662834e-07
is O 0 1.9401571904609227e-08
responsible O 0 3.428765893431773e-08
for O 0 4.480113169336164e-09
an O 0 8.324053446528978e-09
estimated O 0 1.6765324062362197e-07
30 O 0 4.5830088168941074e-08
% O 0 1.578745312258434e-08
of O 0 2.307982960303434e-08
cases O 0 2.0073008272447623e-05
of O 0 0.00039424418355338275
Prader B-Disease 1 0.9993113279342651
- I-Disease 1 0.9992914199829102
Willi I-Disease 1 0.9995678067207336
syndrome I-Disease 1 0.9996373653411865
( O 0 0.33390340209007263
PWS B-Disease 1 0.997255265712738
) O 0 8.19166743895039e-05
. O 0 3.0752424208913e-05

We O 0 2.7255809982307255e-06
report O 0 1.0716119049902773e-06
on O 0 3.967443973351692e-08
an O 0 1.9899170311532544e-08
unusual O 0 2.308032236442159e-07
case O 0 1.7009344333018817e-07
of O 0 1.2238780300322105e-07
maternal B-Disease 0 0.0034646412823349237
disomy I-Disease 0 0.04088769480586052
15 I-Disease 0 8.282473572762683e-06
in O 0 9.218193554261234e-06
PWS B-Disease 1 0.9984132051467896
that O 0 2.6835444089101657e-08
is O 0 5.5273705612535196e-09
most O 0 2.0064374606221236e-09
consistent O 0 1.8281623326288354e-08
with O 0 1.0226309576921722e-08
adjacent O 0 3.9061214351931994e-07
- O 0 2.059172220469918e-05
1 O 0 6.161691601391794e-08
segregation O 0 8.76352601153485e-07
of O 0 3.0096303227367116e-09
a O 0 1.8974058946241712e-07
paternal O 0 0.0002703451318666339
t O 0 0.013494124636054039
( O 0 1.796996826897157e-07
3 O 0 6.009412345520104e-08
; O 0 4.251350915751573e-08
15 O 0 5.3428948376677e-08
) O 0 6.227217141940855e-08
( O 0 2.0826611546453933e-07
p25 O 0 0.00012510240776464343
; O 0 1.5554383026028518e-07
q11 O 0 1.1023437764379196e-05
. O 0 4.460323221877616e-09
2 O 0 2.0251626153822144e-08
) O 0 3.436909201681715e-09
with O 0 2.6622737347992143e-09
simultaneous O 0 1.3691263234250073e-07
maternal O 0 0.00014140017447061837
meiotic O 0 0.018100377172231674
nondisjunction O 0 0.008941588923335075
for O 0 7.682709792788955e-07
chromosome O 0 8.384454849874601e-05
15 O 0 7.179836302384501e-06
. O 0 8.95700304681668e-06

The O 0 4.336057463660836e-05
patient O 0 0.01159212738275528
( O 0 4.3395695684012026e-05
J O 0 0.04464628919959068
. O 0 7.73459703395929e-07
B O 0 1.6508203771081753e-05
. O 0 1.4381742907687567e-08
) O 0 9.02084895670896e-09
, O 0 2.346693950272538e-09
a O 0 9.527078681514922e-09
17 O 0 3.6847436035714054e-07
- O 0 3.224426109227352e-05
year O 0 2.1734424535679864e-06
- O 0 0.00036490961792878807
old O 0 5.343688098946586e-05
white O 0 0.0002444653073325753
male O 0 2.163011049560737e-05
with O 0 1.9011977201444097e-05
PWS B-Disease 1 0.9992029070854187
, O 0 3.8186138340279285e-07
was O 0 4.8429864563104275e-08
found O 0 9.062478767418725e-09
to O 0 1.9659265326765762e-09
have O 0 1.6079184650408251e-09
47 O 0 1.0393497262839446e-07
chromosomes O 0 7.375297172984574e-08
with O 0 1.4239454060316348e-08
a O 0 2.6082742010657967e-07
supernumerary O 0 0.0004337947757449001
, O 0 5.620877345791087e-07
paternal O 0 0.0001776029821485281
der O 0 0.000630672147963196
( O 0 1.630302932653649e-07
15 O 0 2.6301847810827894e-08
) O 0 4.469154379904694e-09
consisting O 0 1.925785086953624e-09
of O 0 1.1721854598079062e-09
the O 0 1.1259308152489211e-08
short O 0 2.8730876238114433e-06
arm O 0 0.00012489930668380111
and O 0 4.419996812998761e-08
the O 0 1.40362217848633e-07
proximal O 0 0.004654032178223133
long O 0 5.2580271585611627e-05
arm O 0 7.519017526647076e-05
of O 0 5.1992852689863867e-08
chromosome O 0 1.902093572425656e-05
15 O 0 5.418116870714584e-07
, O 0 1.6662417579027533e-07
and O 0 1.0110718449141132e-06
distal O 0 0.174489364027977
chromosome O 0 0.014554770663380623
arm O 0 0.14877037703990936
3p O 1 0.8169481158256531
. O 0 5.902099292143248e-05

The O 0 1.553099173179362e-05
t O 0 0.0029260264709591866
( O 0 2.4656853838678217e-06
3 O 0 5.50532433862827e-07
; O 0 2.395994442849769e-07
15 O 0 7.621484598985262e-08
) O 0 1.7476351032996718e-08
was O 0 2.4084552130432257e-09
present O 0 3.292037087376798e-09
in O 0 1.6769562405372085e-09
the O 0 2.300584833747621e-09
balanced O 0 2.393961722191307e-07
state O 0 3.187614794342153e-08
in O 0 1.1059600524276902e-07
the O 0 2.9460657060553785e-06
patients O 0 0.02140142023563385
father O 0 1.6961159417405725e-05
and O 0 4.7209420017679804e-07
a O 0 4.413175247464096e-06
sister O 0 0.0004261231515556574
. O 0 3.315780122647993e-05

Fluorescent O 0 0.00010266456956742331
in O 0 1.0135179309145315e-06
situ O 0 6.784629658795893e-05
hybridization O 0 3.4194376894447487e-06
analysis O 0 9.018071409627737e-07
demonstrated O 0 1.5144127019084408e-06
that O 0 5.487162724193695e-08
the O 0 1.003360466711456e-06
PWS B-Disease 1 0.9984523057937622
critical O 0 1.3399016097537242e-05
region O 0 2.5337610622955253e-06
resided O 0 1.1605575309658889e-06
on O 0 8.109219074015073e-09
the O 0 4.451801061122751e-08
derivative O 0 3.857459432765609e-06
chromosome O 0 4.089072263013804e-06
3 O 0 7.240388555374011e-08
and O 0 7.768452547907145e-09
that O 0 2.215719607789879e-09
there O 0 2.624055195354913e-09
was O 0 6.584365941364467e-09
no O 0 9.790507071727461e-09
deletion O 0 1.3272068599690101e-06
of O 0 2.66544031291005e-08
the O 0 2.018081204369082e-06
PWS B-Disease 1 0.998245358467102
region O 0 7.230465257634933e-07
on O 0 5.495790933451872e-09
the O 0 5.099730859825513e-09
normal O 0 5.1587651483941954e-08
pair O 0 9.444867998809059e-08
of O 0 9.169588821578145e-08
15s O 0 0.007818000391125679
present O 0 3.227619117751601e-06
in O 0 7.1442646003561094e-06
J O 1 0.5140348076820374
. O 0 1.943759707501158e-05

B O 0 0.013145893812179565
. O 0 0.00032988781458698213

Methylation O 0 1.0545923942117952e-05
analysis O 0 1.0279950402036775e-06
at O 0 2.893281418892002e-07
exon O 0 9.302177204517648e-06
alpha O 0 2.2035412428067502e-07
of O 0 5.515365053554433e-09
the O 0 1.1296672930427576e-08
small O 0 2.2430070600876206e-07
nuclear O 0 4.675944728660397e-05
ribonucleoprotein O 0 0.20739959180355072
- O 0 8.668048394611105e-05
associated O 0 2.1627529349643737e-06
polypeptide O 0 3.9740138163324445e-05
N O 0 3.081031172769144e-05
( O 0 1.1207552006453625e-06
SNRPN O 0 0.0030904910527169704
) O 0 8.875883139580765e-08
gene O 0 1.8785905808726966e-07
showed O 0 1.3037362123213825e-07
a O 0 3.672730741755004e-08
pattern O 0 1.7894616348712589e-06
characteristic O 0 1.8816494673501438e-07
of O 0 4.015143328928161e-09
only O 0 6.378221062419698e-09
the O 0 9.481797746957454e-08
maternal O 0 0.00027090011280961335
chromosome O 0 2.5908835596055724e-05
15 O 0 2.2450283267971827e-06
in O 0 3.18421689371462e-06
J O 0 0.2286757379770279
. O 0 2.3040805899654515e-05

B O 0 0.020518681034445763
. O 0 0.0004898426705040038

Maternal B-Disease 0 0.03926697000861168
disomy I-Disease 0 0.059689268469810486
was O 0 3.7195025015535066e-06
confirmed O 0 9.751687457537628e-07
by O 0 9.17039244541229e-08
polymerase O 0 2.9170187190175056e-05
chain O 0 6.758807103324216e-06
reaction O 0 4.367065855603869e-07
analysis O 0 2.7486819931255013e-08
of O 0 1.2849560526717596e-08
microsatellite O 0 0.00023299829626921564
repeats O 0 1.7732260175762349e-06
at O 0 1.6363740584779407e-08
the O 0 1.2498054147158655e-08
gamma O 0 3.977578217018163e-06
- O 0 7.586285937577486e-05
aminobutyric O 0 0.00042234701686538756
acid O 0 6.910237061674707e-06
receptor O 0 8.534550943295471e-06
beta3 O 0 0.00012331105244811624
subunit O 0 6.494492481579073e-06
( O 0 3.4415927530062618e-06
GABRB3 O 0 0.002317547332495451
) O 0 1.1851100225612754e-06
locus O 0 4.0726372390054166e-05
. O 0 3.603677214414347e-06

A O 0 4.0436858398607e-05
niece O 0 0.003398754633963108
( O 0 1.8363125491305254e-05
B O 0 8.008861186681315e-05
. O 0 1.4605109299736796e-07
B O 0 9.849923117144499e-06
. O 0 7.537373392096924e-09
) O 0 4.721016466646688e-09
with O 0 2.0935002620348087e-09
45 O 0 2.3783277569577876e-08
chromosomes O 0 2.612654981248852e-08
and O 0 2.161117285126579e-09
the O 0 3.106979118427944e-09
derivative O 0 2.523685225241934e-07
3 O 0 3.041649065949059e-08
but O 0 2.8558051479166124e-09
without O 0 7.933313561636623e-09
the O 0 3.9983550692568315e-08
der O 0 0.00018431984062772244
( O 0 1.9263008255165914e-07
15 O 0 8.840402188070584e-08
) O 0 3.570633211325003e-08
demonstrated O 0 1.3712119084630103e-07
a O 0 1.7682499731108692e-07
phenotype O 0 3.7659927329514176e-05
consistent O 0 5.18311615849143e-08
with O 0 1.0509392467383805e-08
that O 0 6.88735202203361e-09
reported O 0 2.5578208351362264e-07
for O 0 3.734291098567155e-08
haploinsufficiency O 0 0.00037423952016979456
of O 0 2.1499154456705583e-07
distal O 0 0.007830738089978695
3 O 0 4.457722752704285e-05
p O 0 0.001670761383138597
. O 0 9.404416232428048e-06

Uniparental B-Disease 1 0.9778193831443787
disomy I-Disease 1 0.8699098825454712
associated O 0 8.148636698024347e-05
with O 0 3.602364586186013e-06
unbalanced O 0 0.0017052817856892943
segregation O 0 0.00014098994142841548
of O 0 2.1578935616162198e-07
non O 0 3.6503632145468146e-05
- O 0 0.013217441737651825
Robertsonian O 0 0.17411798238754272
translocations O 0 0.0011578607372939587
has O 0 3.6954489246454614e-07
been O 0 6.669293384220509e-08
reported O 0 2.3507730020355666e-06
previously O 0 3.4673050208766654e-07
but O 0 4.583087687137777e-08
has O 0 2.668858911647476e-08
not O 0 3.6946008474814107e-09
, O 0 9.47362366332527e-09
to O 0 2.4957949040782523e-09
our O 0 7.013474689898658e-09
knowledge O 0 2.6714461753840624e-08
, O 0 8.311869414967532e-09
been O 0 2.3790887038188657e-09
observed O 0 1.9799031747425033e-08
in O 0 9.435501269194901e-09
a O 0 1.1984185732671904e-07
case O 0 4.286160219635349e-06
of O 0 1.1031661415472627e-05
PWS B-Disease 1 0.997307538986206
. O 0 0.000118763062346261

Furthermore O 0 0.00016432703705504537
, O 0 3.0966477879701415e-06
our O 0 4.1782411130952823e-07
findings O 0 1.0751291483757086e-06
are O 0 8.908884296943143e-09
best O 0 3.9942086971223034e-08
interpreted O 0 4.7216129672733587e-08
as O 0 1.7507010952044766e-08
true O 0 9.749771834322019e-07
gamete O 0 0.004068995360285044
complementation O 0 0.468598872423172
resulting O 0 0.00011734075815184042
in O 0 9.936894457496237e-06
maternal B-Disease 0 0.12612175941467285
UPD I-Disease 1 0.9911518692970276
15 I-Disease 0 0.00011581095168367028
and O 0 0.00011218980216654018
PWS B-Disease 1 0.9862924814224243

Schwartz B-Disease 1 0.7973124980926514
- I-Disease 1 0.9736555218696594
Jampel I-Disease 1 0.9930716156959534
syndrome I-Disease 1 0.9980577826499939
type I-Disease 0 0.0013626865111291409
2 I-Disease 0 6.44218162051402e-05
and O 0 0.00012366606097202748
Stuve B-Disease 1 0.9961942434310913
- I-Disease 1 0.9988477230072021
Wiedemann I-Disease 1 0.9994975328445435
syndrome I-Disease 1 0.9996687173843384
: O 0 2.6604113372741267e-05
a O 0 6.746506073795899e-07
case O 0 3.029940899068606e-06
for O 0 3.9990041500459483e-07
" O 0 2.3145773866417585e-06
lumping O 0 0.0032486121635884047
" O 0 7.35708408683422e-06
. O 0 9.60230863711331e-06

Recent O 0 8.81241649040021e-05
studies O 0 1.1983539479842875e-05
demonstrated O 0 3.6970318433304783e-06
the O 0 6.391887552581466e-08
existence O 0 3.0772218906349735e-07
of O 0 2.649458963333018e-08
a O 0 8.251656140600971e-07
genetically O 0 3.3200478355865926e-05
distinct O 0 9.38902360303473e-07
, O 0 1.269552853955247e-07
usually O 0 7.790193023993197e-08
lethal O 0 1.165637740996317e-06
form O 0 3.420228722461616e-08
of O 0 3.14827310887722e-08
the O 0 3.173139930368052e-06
Schwartz B-Disease 1 0.6727361083030701
- I-Disease 1 0.9936208128929138
Jampel I-Disease 1 0.9977689981460571
syndrome I-Disease 1 0.9994663596153259
( O 0 0.0037481170147657394
SJS B-Disease 1 0.9968374967575073
) O 0 1.4689649106003344e-06
of O 0 3.506096845740103e-06
myotonia B-Disease 1 0.9985987544059753
and O 0 0.0009643022785894573
skeletal B-Disease 1 0.999163031578064
dysplasia I-Disease 1 0.9994217157363892
, O 0 4.2993747229047585e-06
which O 0 2.2653644293768593e-07
we O 0 3.8066585261731234e-07
called O 0 0.0001365006173728034
SJS B-Disease 1 0.9961622953414917
type I-Disease 0 0.00032445439137518406
2 I-Disease 0 1.578132651047781e-05
. O 0 7.514210665249266e-06

This O 0 0.0005740065244026482
disorder O 1 0.9947670698165894
is O 0 1.3721997902393923e-06
reminiscent O 0 0.0001723799796309322
of O 0 4.252774203905574e-07
another O 0 1.5684910977142863e-05
rare O 0 0.0020397487096488476
condition O 0 0.0017830304568633437
, O 0 3.418798769416753e-06
the O 0 2.1095254851388745e-05
Stuve B-Disease 1 0.9956419467926025
- I-Disease 1 0.9985450506210327
Wiedemann I-Disease 1 0.9993973970413208
syndrome I-Disease 1 0.9995868802070618
( O 0 0.0009612587164156139
SWS B-Disease 1 0.9357720613479614
) O 0 2.3690515149610292e-07
, O 0 1.6417542880731162e-08
which O 0 8.135866202962916e-09
comprises O 0 3.1916911780172086e-07
campomelia B-Disease 0 0.0005943251890130341
at O 0 1.4234477703212178e-06
birth O 0 0.000169287872267887
with O 0 0.00020888207654934376
skeletal B-Disease 1 0.9988275170326233
dysplasia I-Disease 1 0.9995571970939636
, O 0 0.0005828733555972576
contractures B-Disease 1 0.9952868223190308
, O 0 4.227249519317411e-06
and O 0 1.026196741804597e-06
early B-Disease 0 8.599102329753805e-06
death I-Disease 0 0.00036622537299990654
. O 0 3.589777406887151e-05

To O 0 1.2640103932426427e-06
test O 0 1.7334747326458455e-06
for O 0 1.9184543020855926e-07
possible O 0 2.756363301159581e-06
nosologic O 0 0.058594271540641785
identity O 0 8.918925232137553e-06
between O 0 1.0829460734385066e-05
these O 0 3.274908158346079e-05
disorders O 1 0.9992916584014893
, O 0 5.881052516087948e-07
we O 0 1.5893258265009536e-08
reviewed O 0 9.401623657367963e-08
the O 0 4.217443283494049e-09
literature O 0 1.4011527937896062e-08
and O 0 3.5557001787367426e-09
obtained O 0 6.0235247900664035e-09
a O 0 5.139316527902338e-09
follow O 0 3.60293057610761e-08
- O 0 1.514575956207409e-06
up O 0 5.752907927814022e-09
of O 0 5.602558417194814e-10
the O 0 2.7222435416973667e-09
only O 0 2.469636495305849e-09
two O 0 3.5825440392045493e-08
surviving O 0 0.0015736253699287772
patients O 0 0.0033160545863211155
, O 0 7.994792383669846e-08
one O 0 2.928765141518852e-08
with O 0 4.29381452704547e-06
SJS B-Disease 1 0.998785674571991
type I-Disease 0 1.6475141819682904e-05
2 I-Disease 0 3.6238066059013363e-07
at O 0 8.04979976010145e-08
age O 0 4.163282198987872e-07
10 O 0 2.570486934416749e-08
years O 0 5.13445961303205e-08
and O 0 1.230276414077025e-08
another O 0 9.920911736571725e-08
with O 0 8.283083161586546e-07
SWS B-Disease 0 0.2215253710746765
at O 0 1.2103341759939212e-06
age O 0 9.96622839011252e-06
7 O 0 6.161284545669332e-06
years O 0 7.022805675660493e-06
. O 0 1.0042574103863444e-05

Patients O 1 0.6038351058959961
reported O 0 8.626923954579979e-05
as O 0 2.4354305878659943e-06
having O 0 1.6773376046330668e-05
either O 0 0.00039228814421221614
neonatal O 1 0.9987125396728516
SJS B-Disease 1 0.9984288811683655
or O 0 4.5142980525270104e-05
SWS B-Disease 1 0.6171050071716309
presented O 0 1.0036925459644408e-06
a O 0 1.953823840494806e-07
combination O 0 4.415515832079109e-06
of O 0 3.8681022829223366e-07
a O 0 0.00010223002755083144
severe O 1 0.9967460632324219
, O 0 0.006351831369102001
prenatal O 1 0.9981430768966675
- O 1 0.9990895986557007
onset O 1 0.9996546506881714
neuromuscular B-Disease 1 0.9997653365135193
disorder I-Disease 1 0.9996991157531738
( O 0 0.07564271241426468
with O 0 0.10791025310754776
congenital B-Disease 1 0.999624490737915
joint I-Disease 1 0.9974426031112671
contractures I-Disease 1 0.9993557333946228
, O 1 0.6157724857330322
respiratory O 1 0.9995068311691284
and O 0 0.00013632146874442697
feeding O 0 0.06043609604239464
difficulties O 0 0.0418396070599556
, O 0 9.409063750354107e-06
tendency O 0 0.0017659375444054604
to O 0 8.202061508200131e-06
hyperthermia B-Disease 1 0.9956459403038025
, O 0 9.117370609601494e-07
and O 0 5.336753474693978e-07
frequent O 0 4.688974513555877e-05
death O 0 6.638758350163698e-05
in O 0 2.065227590719587e-06
infancy O 0 0.048481907695531845
) O 0 2.719910128234915e-07
with O 0 5.733674868224625e-08
a O 0 3.480815564671502e-07
distinct O 0 2.315424535481725e-05
campomelic B-Disease 1 0.8523554801940918
- I-Disease 1 0.9742656946182251
metaphyseal I-Disease 1 0.9943615198135376
skeletal I-Disease 1 0.9966797828674316
dysplasia I-Disease 1 0.9975311160087585
. O 0 0.0011253602569922805

The O 0 7.580548526675557e-07
similarity O 0 1.3667407756656758e-06
of O 0 1.1847072300952277e-07
the O 0 1.061005491465039e-06
clinical O 0 0.0013045661617070436
and O 0 4.979763616574928e-06
radiographic O 1 0.5199438333511353
findings O 0 3.575595110305585e-05
is O 0 1.8556104919298377e-07
so O 0 2.3345792499185336e-07
extensive O 0 3.393644874449819e-05
that O 0 1.138681341217307e-06
these O 0 1.2816457456210628e-05
disorders O 1 0.9984437823295593
appear O 0 2.33833225138369e-06
to O 0 3.7490927695671417e-08
be O 0 8.955873376237378e-09
a O 0 1.2720373376851057e-07
single O 0 7.243662025757658e-07
entity O 0 2.436079921608325e-05
. O 0 1.290027103095781e-05

The O 0 1.2008717931166757e-06
follow O 0 1.6573081893511699e-06
- O 0 3.587514947867021e-05
up O 0 9.666376143968591e-08
observation O 0 1.4737496201178146e-07
of O 0 2.6703648181580775e-09
an O 0 6.591943435552139e-09
identical O 0 1.0243394399367389e-07
and O 0 1.568010965513622e-08
unique O 0 8.402747653235565e-08
pattern O 0 9.177580068353564e-06
of O 0 3.2915102110564476e-06
progressive O 1 0.9854711294174194
bone B-Disease 1 0.9996002316474915
dysplasia I-Disease 1 0.9994701743125916
in O 0 1.219024625243037e-06
the O 0 4.4315873992673005e-07
two O 0 1.5155555956880562e-06
patients O 0 0.08031854033470154
( O 0 1.11668714453117e-06
one O 0 5.184777407407637e-08
with O 0 5.544009127333993e-06
SJS B-Disease 1 0.9988460540771484
type I-Disease 0 1.0469732842466328e-05
2 I-Disease 0 1.5800684138866927e-07
, O 0 9.442900683609423e-09
one O 0 4.1168166653449134e-09
with O 0 2.7564738047658466e-07
SWS B-Disease 0 0.4662018120288849
) O 0 4.998950089429854e-07
surviving O 0 1.2624873306776863e-05
beyond O 0 4.530428668658715e-06
infancy O 0 0.0028897514566779137
adds O 0 3.4970089473063126e-05
to O 0 8.031897813509659e-09
the O 0 8.785130845012645e-09
evidence O 0 3.7247236406301454e-08
in O 0 1.2903641710693137e-08
favor O 0 1.102731062019302e-07
of O 0 1.243054157384904e-07
identity O 0 6.495483830804005e-06
. O 0 1.131973749579629e-05

The O 0 4.220465598336887e-06
hypothesis O 0 3.406770701985806e-05
that O 0 3.200987066520611e-06
SWS B-Disease 1 0.8627889752388
and O 0 7.897692557889968e-05
SJS B-Disease 1 0.9976786971092224
type I-Disease 0 0.0001237977558048442
2 I-Disease 0 1.2549791108540376e-06
are O 0 1.1198931559874836e-08
the O 0 3.259580694248143e-07
same O 0 1.389423050568439e-05
disorder O 1 0.9866483807563782
should O 0 1.5449653290033893e-07
be O 0 6.619296222254434e-09
testable O 0 1.2588795925694285e-06
by O 0 4.507044693013995e-08
molecular O 0 2.400308630967629e-06
methods O 0 3.809454938163981e-07
. O 0 6.697260914734215e-07
. O 0 4.276601430319715e-06

A O 0 6.445327016990632e-05
mouse O 0 0.0023575443774461746
model O 0 0.000587677932344377
of O 0 0.004037164617329836
severe O 1 0.9987550973892212
von B-Disease 1 0.999288022518158
Willebrand I-Disease 1 0.9996906518936157
disease I-Disease 1 0.9997555613517761
: O 1 0.9628087282180786
defects O 1 0.998790442943573
in O 0 0.008427509106695652
hemostasis O 1 0.9984129667282104
and O 0 0.024685615673661232
thrombosis B-Disease 1 0.9982865452766418
. O 0 0.0011417974019423127

von B-Disease 1 0.9457383155822754
Willebrand I-Disease 1 0.9802563190460205
factor I-Disease 0 0.1828058511018753
( I-Disease 0 0.15426576137542725
vWf I-Disease 1 0.9901266098022461
) I-Disease 1 0.9482226371765137
deficiency I-Disease 1 0.9988489151000977
causes O 1 0.9981209635734558
severe O 1 0.9995192289352417
von B-Disease 1 0.9995054006576538
Willebrand I-Disease 1 0.9996449947357178
disease I-Disease 1 0.9996181726455688
in O 0 0.0070749372243881226
humans O 0 0.020473869517445564
. O 0 0.00025376028497703373

We O 0 5.632134616462281e-07
generated O 0 7.746733672320261e-07
a O 0 5.126240694153239e-07
mouse O 0 0.00022203708067536354
model O 0 3.380219141035923e-06
for O 0 6.51192351597274e-07
this O 0 2.6338352654420305e-06
disease O 1 0.8270954489707947
by O 0 1.06177736824975e-07
using O 0 3.6994407537349616e-07
gene O 0 1.8148675735574216e-05
targeting O 0 1.4500019460683689e-05
. O 0 1.6997915736283176e-05

vWf B-Disease 1 0.9555469155311584
- I-Disease 1 0.9714898467063904
deficient I-Disease 1 0.9837606549263
mice O 0 0.014224417507648468
appeared O 0 1.4244991689338349e-05
normal O 0 4.953305506205652e-06
at O 0 4.353179065219592e-06
birth O 0 5.213073018239811e-05
; O 0 5.088511443318566e-07
they O 0 6.7281917814909775e-09
were O 0 6.748936076661494e-09
viable O 0 1.6293561202473938e-06
and O 0 7.215999744403234e-07
fertile O 0 0.00046771354391239583
. O 0 1.827605410653632e-05

Neither O 0 0.001132776727899909
vWf O 0 0.43601125478744507
nor O 0 0.0029364353977143764
vWf O 1 0.8394771218299866
propolypeptide O 1 0.8023946285247803
( O 0 0.004287031013518572
von B-Disease 1 0.9876526594161987
Willebrand I-Disease 1 0.9971802234649658
antigen O 1 0.9183779358863831
II O 0 0.010109026916325092
) O 0 2.2596466919821978e-07
were O 0 6.958629672482175e-09
detectable O 0 2.8627653136936715e-06
in O 0 4.9990070749572624e-08
plasma O 0 6.186408427311108e-05
, O 0 8.534304356544453e-07
platelets O 0 0.004661291837692261
, O 0 1.7779153438368667e-07
or O 0 7.748830626042036e-07
endothelial O 0 0.013385679572820663
cells O 0 1.1943593563046306e-06
of O 0 1.8159674652906688e-08
the O 0 4.990023967366142e-07
homozygous O 0 7.055458263494074e-05
mutant O 0 0.001476498320698738
mice O 0 0.005315791815519333
. O 0 1.5364566934295e-05

The O 0 5.540490383282304e-05
mutant O 0 0.030016327276825905
mice O 1 0.5762990117073059
exhibited O 0 0.04921590909361839
defects O 1 0.9839584827423096
in O 0 2.729245534283109e-05
hemostasis O 1 0.961287260055542
with O 0 3.755322723009158e-06
a O 0 2.3305237846216187e-05
highly O 0 0.001897342735901475
prolonged O 1 0.9974817633628845
bleeding O 1 0.9958315491676331
time O 0 1.1478748547233408e-06
and O 0 1.7444916693420964e-06
spontaneous O 0 0.0008767210529185832
bleeding O 1 0.865626871585846
events O 0 1.4498279199415265e-07
in O 0 1.7635708005059314e-08
approximately O 0 6.182481371297399e-08
10 O 0 1.0535667627209477e-07
% O 0 1.7813606234540202e-07
of O 0 5.610038442682708e-07
neonates O 0 0.2127162516117096
. O 0 3.469206785666756e-05

As O 0 5.094015705253696e-06
in O 0 3.6439657833398087e-06
the O 0 1.7591079085832462e-05
human O 0 0.006508273538202047
disease O 1 0.9974812865257263
, O 0 4.949746426063939e-07
the O 0 3.0690975449942925e-07
factor O 0 3.715256752911955e-05
VIII O 0 0.07771917432546616
level O 0 7.261105565703474e-07
in O 0 3.508342771851858e-08
these O 0 4.3341344735381426e-08
mice O 0 6.314947677310556e-05
was O 0 6.808699026805698e-08
reduced O 0 1.1776246537920088e-06
strongly O 0 1.7374954097704176e-07
as O 0 7.209586705414495e-09
a O 0 1.666234616948259e-08
result O 0 3.888822064368469e-08
of O 0 4.149026011646129e-09
the O 0 4.284588328573591e-08
lack O 0 8.605505854575313e-07
of O 0 5.6163770523198764e-08
protection O 0 5.111652717459947e-05
provided O 0 1.7513993952888995e-06
by O 0 8.856704880599864e-06
vWf O 0 0.4226825535297394
. O 0 2.135238355549518e-05

Defective O 1 0.9780660271644592
thrombosis B-Disease 1 0.9927629828453064
in O 0 4.125671330257319e-05
mutant O 0 0.059399597346782684
mice O 0 0.005748777650296688
was O 0 8.233183734773775e-07
also O 0 1.1618848816397076e-07
evident O 0 9.455364420318801e-07
in O 0 1.7136040142418096e-08
an O 0 2.1709551489834666e-08
in O 0 3.667704788767878e-07
vivo O 0 0.00018485098553355783
model O 0 1.7001450032694265e-05
of O 0 5.391767990658991e-05
vascular B-Disease 1 0.9986372590065002
injury I-Disease 1 0.9786428213119507
. O 0 0.00024502817541360855

In O 0 8.422024393439642e-07
this O 0 8.536569851003151e-08
model O 0 3.5822370136884274e-07
, O 0 5.5325838133057914e-08
the O 0 9.036867254508252e-08
exteriorized O 0 0.002984925638884306
mesentery O 0 0.0015033328672870994
was O 0 2.3785098335338262e-07
superfused O 0 0.00047800803440622985
with O 0 5.827567406413436e-07
ferric O 1 0.5267164707183838
chloride O 0 9.530360694043338e-05
and O 0 2.973411561413286e-08
the O 0 4.536073561212106e-08
accumulation O 0 3.41207705787383e-05
of O 0 3.125436478512711e-07
fluorescently O 0 0.31476926803588867
labeled O 0 0.0021126512438058853
platelets O 0 0.01231516245752573
was O 0 1.8816135138877144e-07
observed O 0 2.4701731149434636e-07
by O 0 7.752645387881785e-07
intravital O 0 0.008741618134081364
microscopy O 0 0.0002929591864813119
. O 0 1.0117361853190232e-05

We O 0 3.72268232240458e-06
conclude O 0 1.7486609067418613e-05
that O 0 1.6331600249941403e-07
these O 0 2.1221059398612852e-07
mice O 0 0.0011474043130874634
very O 0 3.832813490589615e-06
closely O 0 0.0007210922776721418
mimic O 1 0.996925413608551
severe O 1 0.9993464350700378
human O 1 0.9971868395805359
von B-Disease 1 0.9997783303260803
Willebrand I-Disease 1 0.9998962879180908
disease I-Disease 1 0.9998582601547241
and O 0 1.874756344477646e-05
will O 0 3.01366497978961e-07
be O 0 7.96667354308056e-09
very O 0 1.1296478419353662e-08
useful O 0 1.1177953673779939e-08
for O 0 6.226477999859981e-09
investigating O 0 1.5430718747211358e-07
the O 0 7.90414933504735e-09
role O 0 6.028837162830314e-08
of O 0 2.3795307413365663e-07
vWf O 0 0.10297294706106186
in O 0 5.338158644008217e-07
normal O 0 2.672428854566533e-05
physiology O 0 0.0031448653899133205
and O 0 1.7505728919786634e-06
in O 0 4.062966399942525e-05
disease O 1 0.9973567724227905
models O 0 7.546543929493055e-05
. O 0 3.2217574243986746e-06
. O 0 9.339521056972444e-06

Oral O 0 0.013189515098929405
contraceptives O 0 0.048243872821331024
and O 0 8.407094355789013e-06
the O 0 2.8538182959891856e-05
risk O 0 0.19580647349357605
of O 0 0.002165209036320448
hereditary B-Disease 1 0.9978971481323242
ovarian I-Disease 1 0.999626874923706
cancer I-Disease 1 0.9992619156837463
. O 0 0.00795577559620142

Hereditary B-Disease 1 0.9878467917442322
Ovarian I-Disease 1 0.9978310465812683
Cancer I-Disease 1 0.9970818161964417
Clinical O 1 0.944644033908844
Study O 0 0.0017428320134058595
Group O 0 0.00034503487404435873
. O 0 0.00013995599874760956

BACKGROUND O 0 0.00016443754429928958
Women O 0 7.737187843304127e-06
with O 0 7.52330038267246e-07
mutations O 0 1.2527176295407116e-05
in O 0 7.273595059587024e-08
either O 0 1.0567566732788691e-07
the O 0 2.748929261997546e-07
BRCA1 O 0 0.001756784738972783
or O 0 1.709488230972056e-07
the O 0 2.433709767046821e-07
BRCA2 O 0 0.008367754518985748
gene O 0 3.6041585644852603e-06
have O 0 2.4891832595130836e-08
a O 0 8.210648161366407e-07
high O 0 0.0003082866023760289
lifetime O 0 0.1877945065498352
risk O 1 0.7903140783309937
of O 0 0.060473229736089706
ovarian B-Disease 1 0.9996970891952515
cancer I-Disease 1 0.9992427825927734
. O 0 0.004235700238496065

Oral O 0 0.16905748844146729
contraceptives O 1 0.9286341071128845
protect O 1 0.6954192519187927
against O 1 0.9936059713363647
ovarian B-Disease 1 0.9997701048851013
cancer I-Disease 1 0.9995369911193848
in O 0 1.0122467756445985e-05
general O 0 7.998488399607595e-06
, O 0 6.561726308973448e-07
but O 0 6.637441174461856e-08
it O 0 1.360037149567006e-08
is O 0 1.2860962961269706e-08
not O 0 4.474476789084747e-09
known O 0 6.91448320822019e-08
whether O 0 1.7534615537329046e-08
they O 0 6.078553660415764e-09
also O 0 1.3105461960094544e-07
protect O 0 1.909432467073202e-05
against O 0 2.3009317374089733e-05
hereditary B-Disease 0 0.26544588804244995
forms I-Disease 0 0.0022216695360839367
of I-Disease 0 0.14084959030151367
ovarian I-Disease 1 0.9996305704116821
cancer I-Disease 1 0.9991043210029602
. O 0 0.0013825208880007267

METHODS O 0 1.4726407243870199e-05
We O 0 2.5632466531533282e-06
enrolled O 0 8.972440991783515e-05
207 O 0 0.002361598890274763
women O 0 0.0002096650714520365
with O 0 0.002756536938250065
hereditary B-Disease 1 0.999006450176239
ovarian I-Disease 1 0.9998666048049927
cancer I-Disease 1 0.9996029734611511
and O 0 2.6912696284853155e-06
161 O 0 1.757639074639883e-05
of O 0 2.2586462478102476e-08
their O 0 3.967973682961201e-08
sisters O 0 4.074090156791499e-06
as O 0 2.485444561273198e-08
controls O 0 5.144223109709856e-07
in O 0 2.995989589749115e-08
a O 0 2.996858370352129e-07
case O 0 7.2027701207844075e-06
- O 0 0.0011642727768048644
control O 0 1.29512054627412e-05
study O 0 1.749673356243875e-05
. O 0 1.1211219316464849e-05

All O 0 1.8365943788012373e-06
the O 0 3.2989833016472403e-06
patients O 0 0.0012831147760152817
carried O 0 3.8000860058673425e-07
a O 0 5.440381301013986e-07
pathogenic O 0 5.9142235841136426e-05
mutation O 0 3.7943025290587684e-06
in O 0 7.888337449912797e-08
either O 0 4.214084867726342e-07
BRCA1 O 0 0.006295484025031328
( O 0 2.2355634428095073e-06
179 O 0 1.7199494322994724e-05
women O 0 1.3128583304933272e-06
) O 0 3.01251532164315e-07
or O 0 6.657670041931851e-07
BRCA2 O 0 0.0017922156257554889
( O 0 1.3862606920156395e-06
28 O 0 2.4805488010315457e-06
women O 0 4.211250598018523e-06
) O 0 2.4529640541004483e-06
. O 0 4.193756922177272e-06

The O 0 3.851967449008953e-06
control O 0 7.366604222625028e-06
women O 0 1.6071579693743843e-06
were O 0 4.0875949736118855e-08
enrolled O 0 3.6295450627221726e-06
regardless O 0 2.861794428099529e-07
of O 0 1.829152829202485e-08
whether O 0 2.4896064587665023e-07
or O 0 2.3030409579405386e-07
not O 0 8.3381479498712e-09
they O 0 7.828141690424673e-09
had O 0 9.946794676807258e-08
either O 0 1.1794061265391065e-06
mutation O 0 7.868916145525873e-05
. O 0 7.490649750252487e-06

Lifetime O 0 0.0012364507419988513
histories O 0 0.00012826501915697008
of O 0 1.6629635410936316e-06
oral O 0 0.0022082426585257053
- O 0 0.035030562430620193
contraceptive O 0 0.007418811786919832
use O 0 5.3772765795656596e-08
were O 0 5.020676319134054e-09
obtained O 0 1.689816109262665e-08
by O 0 1.3412905452980795e-08
interview O 0 9.908891343002324e-07
or O 0 4.3174594566153246e-08
by O 0 7.036735638621394e-09
written O 0 2.001599419543254e-08
questionnaire O 0 3.27260522681172e-06
and O 0 2.205121596432491e-08
were O 0 1.3568397960739276e-08
compared O 0 1.110101948142983e-05
between O 0 7.594502676511183e-06
patients O 0 0.06447513401508331
and O 0 4.5417181127049844e-07
control O 0 4.076394361618441e-06
women O 0 2.104271743519348e-06
, O 0 1.3582670987943857e-07
after O 0 6.475206646427978e-07
adjustment O 0 5.196655365580227e-06
for O 0 1.7625282566768874e-08
year O 0 1.3540507382003852e-07
of O 0 4.673195519444562e-08
birth O 0 3.4610744478413835e-05
and O 0 1.1031281701434636e-06
parity O 0 0.0003397497639525682
. O 0 1.7250413293368183e-05

RESULTS O 0 1.1539023944351356e-05
The O 0 1.093802666218835e-06
adjusted O 0 0.00013415623106993735
odds O 0 0.02897152490913868
ratio O 0 0.004287907388061285
for O 0 0.14465680718421936
ovarian B-Disease 1 0.9998766183853149
cancer I-Disease 1 0.9997661709785461
associated O 0 3.892364475177601e-05
with O 0 1.0298207087089395e-07
any O 0 2.4805666853922048e-08
past O 0 6.619248438255454e-08
use O 0 2.9068102591622846e-08
of O 0 1.0627864099888029e-07
oral O 0 0.0013202588306739926
contraceptives O 0 0.012976162135601044
was O 0 2.827551952577778e-06
0 O 0 2.51571909757331e-05
. O 0 6.618997758778278e-06

5 O 0 7.57576663090731e-06
( O 0 1.2168884495622478e-06
95 O 0 5.865179559805256e-07
percent O 0 4.111099372039462e-07
confidence O 0 4.394250083805673e-07
interval O 0 1.8192336881384108e-07
, O 0 1.227445078910705e-08
0 O 0 2.352247463477397e-08
. O 0 1.2811719463101667e-09
3 O 0 8.382110117111097e-09
to O 0 1.84910087241974e-09
0 O 0 4.1941500938946774e-08
. O 0 7.275437141629482e-09
8 O 0 2.1163620544939477e-07
) O 0 4.235737662838801e-07
. O 0 7.364851626334712e-07

The O 0 8.901613182388246e-05
risk O 0 0.007911309599876404
decreased O 0 2.923644206020981e-05
with O 0 1.2522563963557332e-07
increasing O 0 9.254837891603529e-07
duration O 0 9.108471772378834e-07
of O 0 5.926870549899377e-09
use O 0 4.796424946107436e-08
( O 0 3.004212487667246e-07
P O 0 7.346483471337706e-06
for O 0 8.962947717350289e-09
trend O 0 1.374364728690125e-06
, O 0 3.572581519506457e-08
< O 0 2.0985618903068826e-05
0 O 0 1.8249612310228258e-07
. O 0 1.8155795089569438e-08
001 O 0 2.7910071366932243e-05
) O 0 2.2513043873573224e-08
; O 0 8.574800425265039e-09
use O 0 1.3109587859716498e-09
for O 0 1.2286085482315912e-09
six O 0 1.1435177249552453e-08
or O 0 1.807273619647276e-08
more O 0 7.8643731526995e-09
years O 0 1.6265897784251138e-07
was O 0 3.5995441294289776e-08
associated O 0 5.899410737697508e-08
with O 0 1.162287865952294e-08
a O 0 1.2688194317433954e-07
60 O 0 2.492362682460225e-06
percent O 0 1.8769889720715582e-05
reduction O 0 0.0004646601446438581
in O 0 5.960184807918267e-06
risk O 0 0.005525186192244291
. O 0 1.913172673084773e-05

Oral O 0 0.009318958036601543
- O 0 0.0600355863571167
contraceptive O 0 0.10551434010267258
use O 0 4.4583815906662494e-05
protected O 0 0.04345198720693588
against O 1 0.9227876663208008
ovarian B-Disease 1 0.9998347759246826
cancer I-Disease 1 0.9994366765022278
both O 0 3.1692158586338337e-07
for O 0 1.2456149534045835e-07
carriers O 0 8.261110451712739e-06
of O 0 1.7434832244589415e-08
the O 0 2.4762846351222834e-07
BRCA1 O 0 0.010478870943188667
mutation O 0 1.135253842221573e-05
( O 0 4.097751400422567e-07
odds O 0 7.254637694131816e-06
ratio O 0 1.213285401036046e-07
, O 0 4.4962922274294215e-09
0 O 0 2.500312845654662e-08
. O 0 2.0688735169471784e-09
5 O 0 7.263124768286389e-09
; O 0 7.963847359349074e-09
95 O 0 4.787349183743572e-08
percent O 0 5.348839593466437e-08
confidence O 0 6.61557564285431e-08
interval O 0 2.182854963450609e-08
, O 0 2.4741910742420714e-09
0 O 0 1.1749594186483137e-08
. O 0 9.267975831228625e-10
3 O 0 2.9258935274611986e-09
to O 0 8.024039210852152e-10
0 O 0 2.144128607994844e-08
. O 0 1.7729391288412444e-09
9 O 0 3.742348297919307e-08
) O 0 5.2561768271175424e-09
and O 0 8.522375027908424e-10
for O 0 1.923655679192393e-09
carriers O 0 2.779757437565422e-07
of O 0 2.2787924880418586e-09
the O 0 5.2160022079306145e-08
BRCA2 O 0 0.0026402685325592756
mutation O 0 6.113570634624921e-06
( O 0 4.3158954099453695e-07
odds O 0 1.6037136447266676e-05
ratio O 0 2.713627509365324e-07
, O 0 9.104111242663748e-09
0 O 0 2.4509754226187397e-08
. O 0 1.4448932050825647e-09
4 O 0 1.569252461308679e-08
; O 0 1.198759758125334e-08
95 O 0 3.0322649280378755e-08
percent O 0 2.889739825207016e-08
confidence O 0 6.808711816574942e-08
interval O 0 4.390094332507033e-08
, O 0 3.671853265885261e-09
0 O 0 1.3032831702730618e-08
. O 0 9.29084309486683e-10
2 O 0 4.396695452157928e-09
to O 0 1.357923884448553e-09
1 O 0 3.8467799612362796e-08
. O 0 1.5363898597797743e-08
1 O 0 1.7147883113466378e-07
) O 0 3.6620568266698683e-07
. O 0 9.607664424038376e-07

CONCLUSIONS O 0 0.00014188693603500724
Oral O 0 0.0019182784017175436
- O 0 0.03707602992653847
contraceptive O 0 0.048989590257406235
use O 0 1.3838551922162878e-06
may O 0 4.493792403081898e-06
reduce O 0 0.00014218786964192986
the O 0 3.889133495249553e-06
risk O 0 0.20615622401237488
of O 0 0.014994662255048752
ovarian B-Disease 1 0.9999091625213623
cancer I-Disease 1 0.9997467398643494
in O 0 9.944554221874569e-06
women O 0 1.6715635865693912e-05
with O 0 3.1889151159703033e-06
pathogenic O 0 0.0023264673072844744
mutations O 0 2.359398058615625e-05
in O 0 2.0710939452328603e-07
the O 0 2.3986883661564207e-06
BRCA1 O 0 0.14634031057357788
or O 0 5.2696730563184246e-05
BRCA2 O 0 0.2676880359649658
gene O 0 0.0009597468306310475

A O 0 2.1117837604833767e-05
Japanese O 0 0.0001331041130470112
family O 0 5.804121246910654e-05
with O 0 1.496488675911678e-05
adrenoleukodystrophy B-Disease 1 0.9961431622505188
with O 0 2.6327302293793764e-07
a O 0 4.2706528802227695e-07
codon O 0 1.8719674699241295e-05
291 O 0 0.00016906623204704374
deletion O 0 0.00012042321759508923
: O 0 3.4032168514386285e-06
a O 0 2.0747129383380525e-06
clinical O 0 0.0016918047331273556
, O 0 1.2244190656929277e-06
biochemical O 0 0.00045866603613831103
, O 0 4.218212325213244e-06
pathological O 0 0.0242225993424654
, O 0 1.677966906754591e-06
and O 0 1.4111641348790727e-06
genetic O 0 0.0004367115907371044
report O 0 3.729665695573203e-05
. O 0 1.5149534192460123e-05

We O 0 3.567615067368024e-06
report O 0 1.976188741537044e-06
a O 0 9.459341754336492e-07
Japanese O 0 3.3814496418926865e-05
family O 0 8.831706509226933e-05
with O 0 0.0012323040282353759
adrenoleukodystrophy B-Disease 1 0.9995494484901428
( O 0 0.09931184351444244
ALD B-Disease 1 0.9992826581001282
) O 0 4.717904289464059e-07
with O 0 1.1208697081599439e-08
a O 0 1.1264506660779716e-08
three O 0 5.050383222737764e-09
base O 0 5.936060176736646e-08
pair O 0 6.237630145733419e-07
deletion O 0 2.331559699086938e-05
( O 0 1.3138102303855703e-06
delGAG O 0 0.0005748277762904763
291 O 0 1.8707558410824277e-05
) O 0 1.7238754423942737e-07
in O 0 1.7060744994523702e-07
the O 0 3.961477432312677e-06
ALD B-Disease 1 0.9972803592681885
gene O 0 0.00046219342038966715
. O 0 1.9999462892883457e-05

A O 0 5.980516561976401e-06
variety O 0 1.8556045233708574e-06
of O 0 3.3722554348969425e-07
phenotypes O 0 0.00035735894925892353
were O 0 4.261637087665804e-08
observed O 0 3.002408277552604e-07
within O 0 1.070084536536342e-07
this O 0 2.4192533487621404e-07
family O 0 3.785818989854306e-05
. O 0 2.2827518478152342e-05

While O 0 5.788881935586687e-06
the O 0 3.894095243595075e-06
proband O 0 0.08512452989816666
( O 0 4.904881279799156e-05
patient O 0 0.0010547658894211054
1 O 0 2.994172518810956e-06
) O 0 4.13876989568962e-07
was O 0 6.891796999752842e-08
classified O 0 7.659635912204976e-07
as O 0 1.3431670886632219e-08
having O 0 4.943566622728213e-08
a O 0 8.633177372985301e-08
rare O 0 6.621408829232678e-06
intermediate O 0 1.0840662071132101e-05
type O 0 6.342669166770065e-06
of O 0 1.6669474689479102e-07
adult O 0 0.00047478522174060345
cerebral O 1 0.9568864107131958
and O 0 2.6139814508496784e-05
cerebello O 1 0.9904534816741943
- O 1 0.9727576971054077
brain O 1 0.9220523238182068
stem O 0 0.005739341024309397
forms O 0 1.1208247769900481e-06
, O 0 9.232168451944744e-08
his O 0 5.002612510907056e-07
younger O 0 2.9713719413848594e-05
brother O 0 3.44759137078654e-05
( O 0 5.258513738226611e-06
patient O 0 9.24985361052677e-05
2 O 0 1.189480713037483e-06
) O 0 2.7645876343740383e-07
and O 0 1.7927858664279483e-07
nephew O 0 0.0006566205993294716
( O 0 1.474592681915965e-05
patient O 0 0.0005610347143374383
3 O 0 1.9296485334052704e-06
) O 0 3.8668665069963026e-07
had O 0 3.2080296819003706e-07
a O 0 2.4878243493731134e-05
childhood O 1 0.9919993281364441
ALD B-Disease 1 0.9990611672401428
type O 0 0.039731837809085846
. O 0 8.216302376240492e-05

Another O 0 5.63054891244974e-05
nephew O 0 0.010115742683410645
( O 0 7.447855750797316e-05
patient O 0 0.0008201539749279618
4 O 0 4.4823896132584196e-06
) O 0 4.6570372091991885e-07
of O 0 1.6789708467968012e-07
patient O 0 0.002323699649423361
1 O 0 3.5083946841041325e-06
was O 0 5.949991077613959e-07
classified O 0 4.967076165485196e-06
as O 0 4.220141391897414e-08
having O 0 1.8044772787106922e-07
an O 0 6.003031671752979e-07
adolescent O 0 0.10835488885641098
form O 0 4.5108990889275447e-05
. O 0 3.413860758882947e-05

The O 0 2.4004641545616323e-06
tau O 0 4.426447776495479e-05
level O 0 7.969759963089018e-07
in O 0 6.876040714587361e-08
the O 0 3.8713645267307584e-07
cerebrospinal O 0 0.1377364993095398
fluid O 0 0.0005492524360306561
( O 0 3.319949610158801e-05
CSF O 0 0.22001983225345612
) O 0 3.5746953130910697e-07
in O 0 1.4540081849645503e-07
patient O 0 0.00014558009570464492
1 O 0 2.0342318407529092e-07
was O 0 9.537151512972741e-09
as O 0 3.185090635682286e-09
high O 0 1.3678017296570033e-07
as O 0 7.195312790031494e-09
that O 0 2.1964533303275857e-08
of O 0 2.352831870666705e-06
patients O 1 0.9852096438407898
with O 0 0.41206836700439453
Alzheimers B-Disease 1 0.9998407363891602
disease I-Disease 1 0.9995427131652832
( O 0 0.000792462844401598
AD B-Disease 0 0.017716895788908005
) O 0 1.2233277630002704e-05
. O 0 7.490192274417495e-06

His O 0 0.0001010144769679755
brain O 0 0.005257255397737026
magnetic O 0 2.2434860511566512e-05
resonance O 0 0.00010203738929703832
image O 0 0.0006141715566627681
( O 0 5.1083781727356836e-05
MRI O 0 0.012530574575066566
) O 0 3.366196551723988e-06
showed O 0 2.0561641576932743e-05
abnormalities B-Disease 0 0.002654296113178134
in I-Disease 0 4.4583863711977756e-08
the I-Disease 0 2.2219890638552897e-07
bilateral I-Disease 0 0.00032612873474135995
cerebellar I-Disease 1 0.9800918102264404
hemispheres I-Disease 0 0.005974578205496073
and O 0 0.00017503999697510153
brain O 1 0.9820315837860107
stem O 0 0.06479479372501373
, O 0 3.782694477649784e-07
but O 0 3.687640059979458e-08
not O 0 4.945940546008387e-09
in O 0 1.211170825854424e-07
the O 0 6.285153176577296e-06
cerebral O 1 0.9938740134239197
white O 0 0.0004774475237354636
matter O 0 4.067188967837865e-07
, O 0 4.059228686514871e-08
where O 0 1.8140426050194947e-08
marked O 0 4.80141352454666e-07
reductions O 0 2.180208184654475e-06
of O 0 2.0958143664984163e-08
the O 0 4.829269528272562e-06
cerebral O 1 0.9950627684593201
blood O 0 0.0036689757835119963
flow O 0 5.525756478164112e-06
and O 0 1.9269513984454534e-07
oxygen O 0 2.450500505801756e-05
metabolism O 0 2.7489497824717546e-06
were O 0 3.1541738110263395e-09
clearly O 0 5.442489126039618e-08
demonstrated O 0 8.885233171440632e-08
by O 0 6.655315587522637e-08
positron O 0 0.00030127394711598754
emission O 0 2.5739031116245314e-05
tomography O 0 0.0001552417961647734
( O 0 5.6078520174196456e-06
PET O 0 0.0010257512331008911
) O 0 2.355593323954963e-06
. O 0 2.649828502399032e-06

In O 0 4.317650382290594e-05
patients O 0 0.0049022408202290535
2 O 0 2.535941575843026e-06
and O 0 9.867223838000427e-08
3 O 0 2.1622710733026906e-07
, O 0 2.224006756534891e-08
the O 0 1.7310012978555278e-08
autopsy O 0 1.4639870641985908e-05
findings O 0 4.551292931864737e-06
showed O 0 1.9266628441982903e-05
massive O 0 0.063389852643013
demyelination B-Disease 1 0.9970627427101135
of I-Disease 0 1.1141936511194217e-06
the I-Disease 0 2.669810055522248e-05
cerebral I-Disease 1 0.996657133102417
white I-Disease 0 0.00023712919210083783
matter I-Disease 0 9.499972719595462e-08
with O 0 5.248916323807862e-08
sparing O 0 7.081424428179162e-06
of O 0 3.788513680547112e-08
the O 0 5.494116521731485e-07
U O 0 0.028427984565496445
- O 0 0.012183517217636108
fibers O 0 0.0007764587644487619
, O 0 4.885720628067247e-08
compatible O 0 1.7209809755058814e-07
with O 0 3.408298354656836e-08
the O 0 1.0517657500486166e-07
findings O 0 6.563787792401854e-06
of O 0 8.043803973123431e-06
childhood O 1 0.9721549153327942
ALD B-Disease 1 0.9980410933494568
. O 0 0.0003609434061218053

Oleic O 0 0.002778786001726985
and O 0 1.0105404726346023e-05
erucic O 0 0.038325294852256775
acids O 0 1.0037777428806294e-05
( O 0 3.935679160349537e-06
Lorenzos O 0 0.0005650981911458075
Oil O 0 1.3725218650506577e-06
) O 0 4.124041552699964e-08
were O 0 3.4356375522293092e-09
administered O 0 2.749757754827442e-07
to O 0 1.5983340517777833e-07
patients O 0 0.0003244918480049819
1 O 0 2.3686651218213228e-07
and O 0 3.423524930212807e-08
4 O 0 3.043982417239022e-07
, O 0 4.346113158248954e-08
but O 0 1.9456306787901667e-08
sufficient O 0 5.390954811446136e-07
effectiveness O 0 1.2839014743804e-05
was O 0 5.62052413499714e-08
not O 0 2.2088258333496924e-08
obtained O 0 5.416050612438994e-07
. O 0 4.232129867887124e-06

The O 0 3.926861154468497e-06
findings O 0 1.0506041689950507e-05
in O 0 2.857022423086164e-07
this O 0 8.018677277732422e-08
family O 0 3.214030357412412e-06
suggest O 0 2.960440951937926e-06
that O 0 5.954918691486455e-08
delGAG291 O 0 0.000487425277242437
is O 0 1.8087703779201547e-08
part O 0 1.0317489973488136e-08
of O 0 8.20033285720001e-09
the O 0 1.1854927350896105e-07
cause O 0 4.613223427440971e-05
of O 0 7.390687528641138e-07
Japanese O 0 0.013970743864774704
ALD B-Disease 1 0.9989857077598572
with O 0 1.1188009921170305e-05
phenotypic O 0 0.0009276482742279768
variations O 0 0.00022309791529551148
. O 0 4.541913222055882e-05

Moreover O 0 0.00018589416868053377
, O 0 7.187393862295721e-07
although O 0 8.855371191884842e-08
the O 0 1.7282895115044994e-08
scale O 0 5.945146881458641e-07
of O 0 5.348285814221754e-09
the O 0 2.6016405030304668e-08
study O 0 2.195210129229963e-07
is O 0 2.171054447330789e-08
limited O 0 9.56294812226588e-08
, O 0 2.5644732559726435e-08
there O 0 5.946561909553338e-09
is O 0 3.3945948274549664e-09
a O 0 3.488784372507325e-08
possibility O 0 2.1362518509704387e-06
that O 0 2.084306203187225e-07
PET O 0 0.0021556448191404343
can O 0 5.36576010290446e-07
detect O 0 0.0001735590340103954
an O 0 1.6004831877580727e-06
insidious B-Disease 1 0.9262394309043884
lesion I-Disease 1 0.9289281964302063
which O 0 1.1425915147356136e-07
is O 0 4.099642580968066e-08
undetectable O 0 4.780502786161378e-05
by O 0 2.3524448167222545e-08
computed O 0 1.1237788157814066e-06
tomogram O 0 0.003021706361323595
( O 0 5.9951585171802435e-06
CT O 0 0.04156596586108208
) O 0 1.1294157076235933e-07
or O 0 9.962534619489816e-08
MRI O 0 6.202133954502642e-05
analysis O 0 7.052230444060115e-08
, O 0 9.308141812880422e-09
and O 0 1.3742452731335675e-09
that O 0 4.23453772047111e-10
the O 0 1.2415081185324084e-09
higher O 0 1.1333945337810292e-08
level O 0 9.654248067647586e-09
of O 0 2.555604616816254e-09
tau O 0 3.919225036952412e-06
reflects O 0 5.876657738212998e-08
the O 0 4.6497743433349115e-09
process O 0 5.2696911723160156e-08
of O 0 9.84269036052865e-07
neuronal B-Disease 0 0.34528183937072754
degeneration I-Disease 1 0.9983559250831604
in O 0 0.001994834281504154
ALD B-Disease 1 0.9977220892906189
. O 0 0.0004785893252119422

Lorenzos O 0 0.037028782069683075
Oil O 0 3.015613583556842e-05
should O 0 2.0809298462154402e-07
be O 0 9.268652512162134e-09
given O 0 1.3281924005070778e-08
in O 0 8.585863575660824e-09
the O 0 1.6698871618814337e-08
early O 0 5.02305454119778e-07
stage O 0 3.1943036447046325e-05
. O 0 1.7593159782336443e-06
. O 0 6.739381660736399e-06

Nonsense O 0 0.00026535673532634974
mutation O 0 1.6694542864570394e-05
in O 0 4.3924106307713373e-07
exon O 0 2.720963311730884e-05
4 O 0 3.095591409874032e-07
of O 0 3.148867833147051e-08
human O 0 1.5220707609842066e-06
complement O 0 3.127635864075273e-05
C9 O 1 0.6909109950065613
gene O 0 2.3191732907434925e-06
is O 0 1.7861536250052268e-08
the O 0 1.9487652380689724e-08
major O 0 2.210829507021117e-06
cause O 0 2.4790948373265564e-05
of O 0 3.63472310027646e-07
Japanese O 0 0.0015341099351644516
complement B-Disease 0 0.03877190127968788
C9 I-Disease 1 0.9965946078300476
deficiency I-Disease 1 0.9970107078552246
. O 0 0.00015227356925606728

Deficiency B-Disease 1 0.9835699200630188
of I-Disease 0 2.974269079913938e-07
the I-Disease 0 2.100745604138865e-07
ninth I-Disease 0 2.5472975266893627e-06
component I-Disease 0 3.042804053166037e-07
of I-Disease 0 1.92709777024902e-08
human I-Disease 0 7.0782380134915e-07
complement I-Disease 0 4.875866579823196e-06
( O 0 7.090763574524317e-06
C9 O 0 0.3580480217933655
) O 0 1.2591517872806435e-07
is O 0 5.079276998998239e-09
the O 0 8.83431372500354e-09
most O 0 8.770535231406029e-08
common O 0 2.776621113298461e-05
complement B-Disease 0 0.2767256200313568
deficiency I-Disease 1 0.9996682405471802
in O 0 1.259309442502854e-06
Japan O 0 0.00020418816711753607
but O 0 2.264034009158422e-07
is O 0 1.0992912535812138e-07
rare O 0 3.4849454095819965e-06
in O 0 7.010387292893938e-08
other O 0 7.557257220014435e-08
countries O 0 1.2849139920945163e-06
. O 0 1.2775151844834909e-05

We O 0 1.0952725233437377e-06
studied O 0 6.637326350755757e-07
the O 0 4.7974129557815104e-08
molecular O 0 5.602552732852928e-07
basis O 0 4.413653442725263e-08
of O 0 2.209021204180317e-06
C9 B-Disease 1 0.9979579448699951
deficiency I-Disease 1 0.9977765679359436
in O 0 2.4207352566918416e-07
four O 0 1.28621115891292e-06
Japanese O 0 0.014897949062287807
C9 B-Disease 1 0.9977351427078247
- I-Disease 1 0.9976174235343933
deficient I-Disease 1 0.9987496137619019
patients O 1 0.9386923313140869
who O 0 0.0004984171246178448
had O 0 0.0012181700440123677
suffered O 1 0.9963541030883789
from O 0 0.052859220653772354
meningococcal B-Disease 1 0.9986264705657959
meningitis I-Disease 1 0.9983355402946472
. O 0 0.001245318097062409

Direct O 0 1.9228186829423066e-06
sequencing O 0 1.4184096244207467e-06
of O 0 2.2192062942849589e-07
amplified O 0 2.7338615836924873e-05
C9 O 0 0.008484496735036373
cDNA O 0 4.169395197095582e-06
and O 0 5.999688568181227e-08
DNA O 0 4.977424055141455e-07
revealed O 0 1.9903578163393831e-07
a O 0 1.9420749453047392e-08
nonsense O 0 1.2827591717723408e-06
substitution O 0 1.6346450593118789e-07
( O 0 1.457387241998731e-07
CGA O 0 3.2184598239837214e-05
- O 0 9.539253369439393e-05
- O 0 0.0002459634852129966
> O 0 0.0002577861014287919
TGA O 0 0.004576882813125849
) O 0 1.5688604193542233e-08
at O 0 6.3959100238264455e-09
codon O 0 4.610486570300054e-08
95 O 0 1.890246181801558e-08
in O 0 2.986648039993156e-09
exon O 0 6.010570245962299e-07
4 O 0 1.7788202910651307e-08
in O 0 2.8492976866800745e-09
the O 0 2.0370947595438338e-08
four O 0 1.6858521121321246e-06
C9 B-Disease 1 0.9930194020271301
- I-Disease 1 0.8056212067604065
deficient I-Disease 1 0.669650673866272
individuals O 0 9.042416422744282e-06
. O 0 2.0445650079636835e-05

An O 0 3.019187488462194e-06
allele O 0 2.7866057280334644e-05
- O 0 5.154533209861256e-05
specific O 0 3.5684141153069504e-07
polymerase O 0 0.00010077789193019271
chain O 0 6.037516868673265e-05
reaction O 0 8.158740456565283e-06
system O 0 9.620774790164432e-07
designed O 0 2.095636091326014e-06
to O 0 5.069755459885528e-08
detect O 0 4.777292815560941e-06
exclusively O 0 6.574163879946582e-09
only O 0 4.653897822670672e-10
one O 0 3.889018274083611e-10
of O 0 8.397035844431855e-10
the O 0 2.9139641810616013e-09
normal O 0 6.28751166686925e-08
and O 0 4.058470182144447e-08
mutant O 0 2.438655064906925e-05
alleles O 0 2.933326868514996e-06
indicated O 0 3.3150379863400303e-07
that O 0 1.1535481458935237e-09
all O 0 7.501185228520058e-10
the O 0 8.060751177652037e-09
four O 0 1.0117800997022641e-07
patients O 0 0.00026920437812805176
were O 0 4.66183358582839e-09
homozygous O 0 2.830347796134447e-07
for O 0 3.7826772825155786e-09
the O 0 1.53195376384474e-08
mutation O 0 8.578236929679406e-07
in O 0 2.0065265005086985e-08
exon O 0 4.412543785292655e-05
4 O 0 2.318537610790372e-07
and O 0 6.667574048435654e-09
that O 0 1.941018679119111e-09
the O 0 6.993904566598985e-09
parents O 0 1.1346906347853292e-07
of O 0 4.525564989421582e-08
patient O 0 0.0004698877455666661
2 O 0 1.1761296718759695e-06
were O 0 1.4396046310594102e-07
heterozygous O 0 4.241639544488862e-05
. O 0 1.0763308637251612e-05

The O 0 3.449798214205657e-06
common O 0 1.8883489474319504e-06
mutation O 0 1.4827539871475892e-06
at O 0 9.103906251084481e-08
codon O 0 3.901631373537384e-07
95 O 0 1.925529318214103e-07
in O 0 3.3589603987138617e-08
exon O 0 2.9275499400682747e-05
4 O 0 6.529353981932218e-07
might O 0 6.317829814861398e-08
be O 0 1.8351311581454866e-09
responsible O 0 3.299494011343995e-08
for O 0 4.1700765507357573e-08
most O 0 2.2401711703423643e-06
Japanese O 0 0.1271885633468628
C9 B-Disease 1 0.9989773035049438
deficiency I-Disease 1 0.9992057681083679
. O 0 2.550653152866289e-05
. O 0 2.7843476345879026e-05

BRCA1 O 0 0.0023425861727446318
required O 0 2.2386016098607797e-06
for O 0 9.056432190845953e-07
transcription O 0 0.00024112955725286156
- O 0 0.02246306836605072
coupled O 0 0.0038529837038367987
repair O 0 0.11993351578712463
of O 0 6.487707651103847e-06
oxidative O 1 0.5693893432617188
DNA O 0 0.003703920403495431
damage O 0 0.10896031558513641
. O 0 7.493170414818451e-05

The O 0 0.00514040095731616
breast B-Disease 1 0.9951127171516418
and I-Disease 1 0.9221881628036499
ovarian I-Disease 1 0.9994933605194092
cancer I-Disease 1 0.9993442893028259
susceptibility O 1 0.8821381330490112
gene O 0 0.0004715320246759802
BRCA1 O 0 0.0044736098498106
encodes O 0 4.448174422577722e-06
a O 0 1.6263412589978543e-06
zinc O 0 0.0038734772242605686
finger O 0 0.00012653791054617614
protein O 0 3.499261822526023e-07
of O 0 6.09804189366514e-08
unknown O 0 1.0750696901595802e-06
function O 0 2.8324398044787813e-06
. O 0 7.311257377295988e-06

Association O 0 4.0415114199277014e-05
of O 0 2.2631294882557995e-07
the O 0 2.8244130589882843e-07
BRCA1 O 0 0.000220134636037983
protein O 0 1.8185572514539672e-07
with O 0 1.3414747535023253e-08
the O 0 3.788253621905824e-08
DNA O 0 6.684896106889937e-06
repair O 0 0.03244500234723091
protein O 0 1.060777412931202e-05
Rad51 O 0 0.012993298470973969
and O 0 1.7013098485563205e-08
changes O 0 1.1057508686462825e-08
in O 0 9.506762044253492e-10
the O 0 1.1011116463066628e-09
phosphorylation O 0 1.1895852303211996e-08
and O 0 5.3802389210488855e-09
cellular O 0 2.0931385336098174e-07
localization O 0 7.013785108256343e-08
of O 0 8.783752614149876e-10
the O 0 4.639320927424251e-09
protein O 0 1.1385061071678138e-07
after O 0 2.026971941404554e-07
exposure O 0 1.7055948774213903e-05
to O 0 2.316326863649465e-08
DNA O 0 1.9466946469037794e-05
- O 0 0.0038261788431555033
damaging O 0 0.001265883562155068
agents O 0 3.4290934536329587e-07
are O 0 1.3821207511810485e-09
consistent O 0 2.3403389448617418e-08
with O 0 1.1386338094609982e-08
a O 0 6.573664990128236e-08
role O 0 3.9469151147386583e-07
for O 0 3.9296830323110044e-07
BRCA1 O 0 0.009666678495705128
in O 0 1.379587160954543e-06
DNA O 0 0.0003999391046818346
repair O 1 0.5202900767326355
. O 0 4.695346069638617e-05

Here O 0 9.34993749979185e-06
, O 0 7.161141297729046e-07
it O 0 3.4741226784262835e-08
is O 0 2.52428620228784e-08
shown O 0 7.253451173028225e-08
that O 0 7.941886082107885e-08
mouse O 0 0.001094524166546762
embryonic O 0 0.025542106479406357
stem O 0 0.34287264943122864
cells O 0 0.010140649974346161
deficient B-Disease 0 0.2897963225841522
in I-Disease 0 9.342167572867766e-07
BRCA1 I-Disease 0 0.003634988097473979
are O 0 1.4155291161443984e-08
defective O 0 0.0001525479310657829
in O 0 1.5784051399236887e-08
the O 0 1.088416823336047e-08
ability O 0 4.950039311779619e-08
to O 0 2.14608331106092e-09
carry O 0 9.784626442410627e-09
out O 0 1.482124023510778e-08
transcription O 0 4.288891432224773e-06
- O 0 0.0005648389342240989
coupled O 0 0.0002251824043923989
repair O 0 0.01176455244421959
of O 0 4.203981518458022e-07
oxidative O 0 0.045611415058374405
DNA O 0 0.0003712180186994374
damage O 0 0.0067143975757062435
, O 0 1.6016696235965355e-07
and O 0 3.531660297539929e-08
are O 0 1.8053649242233405e-08
hypersensitive O 0 0.001182197011075914
to O 0 6.923415867277072e-07
ionizing O 0 0.007000569254159927
radiation O 0 0.0003244506660848856
and O 0 2.945547237231949e-07
hydrogen O 0 2.4244778614956886e-05
peroxide O 0 0.0022368705831468105
. O 0 7.2973957685462665e-06

These O 0 2.084422476400505e-06
results O 0 2.8623614980460843e-06
suggest O 0 5.75646254219464e-06
that O 0 4.4804571075474087e-07
BRCA1 O 0 0.014227506704628468
participates O 0 3.0376533686649054e-05
, O 0 1.8465928519617592e-07
directly O 0 6.062300172970936e-08
or O 0 1.0352918167200187e-07
indirectly O 0 3.6521240076581307e-07
, O 0 1.4464409225922736e-08
in O 0 2.106860286232859e-08
transcription O 0 1.234600040334044e-05
- O 0 0.0021877672988921404
coupled O 0 0.000725770543795079
repair O 0 0.011718428693711758
of O 0 1.094203298634966e-06
oxidative O 0 0.32123345136642456
DNA O 0 0.0021530543453991413
damage O 0 0.04494686797261238
. O 0 3.323659029774717e-06
. O 0 1.0340862900193315e-05

Truncation O 0 0.0017622815212234855
mutations O 0 7.454009755747393e-05
in O 0 6.473626399383647e-07
the O 0 6.451906529036933e-07
transactivation O 0 0.002746300306171179
region O 0 3.4918948585982434e-06
of O 0 4.379047595648444e-07
PAX6 O 1 0.5497675538063049
result O 0 4.918698778055841e-06
in O 0 1.072976033356099e-06
dominant O 0 0.00021231347636785358
- O 0 0.017970306798815727
negative O 0 9.091199899557978e-05
mutants O 0 0.004466450773179531
. O 0 2.279814907524269e-05

PAX6 O 0 0.13067694008350372
is O 0 7.386276479337539e-07
a O 0 2.50231011023061e-07
transcription O 0 5.0299086069571786e-06
factor O 0 3.9614934621567954e-07
with O 0 8.617232261087793e-09
two O 0 7.904284338167145e-09
DNA O 0 1.1394146213206113e-06
- O 0 1.6858115486684255e-05
binding O 0 2.629247717322869e-07
domains O 0 1.0261438774250564e-06
( O 0 1.8444438865117263e-07
paired O 0 2.2313226963888155e-06
box O 0 2.760664528977941e-06
and O 0 1.435286520745649e-07
homeobox O 0 0.0038431589491665363
) O 0 1.8241220089976196e-08
and O 0 1.904620017256775e-09
a O 0 1.0447574361194256e-08
proline O 0 2.3020490971248364e-06
- O 0 6.156655672384659e-06
serine O 0 1.5670474340367946e-06
- O 0 2.0162298824288882e-05
threonine O 0 3.940524038625881e-06
( O 0 1.983843731068191e-06
PST O 0 0.0004168048326391727
) O 0 6.149481919237587e-07
- O 0 3.324436329421587e-05
rich O 0 7.123615887394408e-06
transactivation O 0 0.0004973108880221844
domain O 0 8.331900062330533e-06
. O 0 7.780452506267466e-06

PAX6 O 1 0.959283173084259
regulates O 0 0.13961836695671082
eye O 0 0.24323275685310364
development O 0 3.278283111285418e-05
in O 0 1.1942021274080616e-06
animals O 0 2.6594082100928063e-06
ranging O 0 5.431700174085563e-06
from O 0 4.022059556518798e-07
jellyfish O 0 5.6925713579403237e-05
to O 0 1.272518943551404e-07
Drosophila O 0 7.73796909925295e-06
to O 0 4.022742245979316e-07
humans O 0 2.0218056306475773e-05
. O 0 6.755056347174104e-06

Heterozygous O 0 0.0005185036570765078
mutations O 0 7.835117867216468e-05
in O 0 4.79043649193045e-07
the O 0 9.458656222705031e-07
human O 0 3.790652408497408e-05
PAX6 O 1 0.8702214956283569
gene O 0 1.572680594108533e-05
result O 0 4.457545230707183e-07
in O 0 3.207056309406653e-08
various O 0 7.783583555465157e-08
phenotypes O 0 0.001096373307518661
, O 0 4.956529551236599e-07
including O 0 7.35889489078545e-06
aniridia B-Disease 1 0.9970222115516663
, O 0 0.0005099477129988372
Peters B-Disease 1 0.9935842156410217
anomaly I-Disease 1 0.9841793179512024
, O 0 0.0002434722991893068
autosomal B-Disease 1 0.938471794128418
dominant I-Disease 0 0.38127586245536804
keratitis I-Disease 1 0.997880220413208
, O 0 0.00016005118959583342
and O 0 0.00034868635702878237
familial B-Disease 1 0.9968420267105103
foveal I-Disease 1 0.996217668056488
dysplasia I-Disease 1 0.9977555871009827
. O 0 0.006406816188246012

It O 0 2.1321159238141263e-06
is O 0 3.6683277926385927e-07
believed O 0 1.5370764572253393e-07
that O 0 6.5164624807323435e-09
the O 0 2.476718385935328e-08
mutated O 0 1.3173105799069162e-05
allele O 0 1.1771318213504856e-06
of O 0 8.653042726791682e-08
PAX6 O 0 0.17069582641124725
produces O 0 7.186563379946165e-06
an O 0 1.1320985748852763e-07
inactive O 0 2.2105086827650666e-05
protein O 0 1.6753605223129853e-06
and O 0 1.8234178469356266e-06
aniridia B-Disease 1 0.8047625422477722
is O 0 1.57662009314663e-06
caused O 0 0.0002668406814336777
due O 0 4.798964710062137e-06
to O 0 1.2836831047025044e-06
genetic O 0 0.0015704681864008307
haploinsufficiency O 0 0.3431173264980316
. O 0 7.496908801840618e-05

However O 0 7.389091479126364e-06
, O 0 7.595347710775968e-07
several O 0 2.4017344912863337e-07
truncation O 0 0.0005844136467203498
mutations O 0 2.703248719626572e-05
have O 0 2.2162447876894475e-08
been O 0 7.900078813349865e-09
found O 0 1.341961031187111e-08
to O 0 3.7071514746855883e-09
occur O 0 2.0599440375690392e-08
in O 0 4.202516112883359e-09
the O 0 3.1819411105971085e-08
C O 0 7.339629519265145e-05
- O 0 4.1437098843744025e-05
terminal O 0 4.280318535165861e-06
half O 0 3.2288145490610987e-08
of O 0 9.71474634070546e-08
PAX6 O 1 0.8405919075012207
in O 0 5.460952706926037e-06
patients O 0 0.017472533509135246
with O 0 2.7651201435219264e-06
Aniridia B-Disease 1 0.8880060911178589
resulting O 0 1.466716275899671e-05
in O 0 6.932098273182419e-08
mutant O 0 5.044973477197345e-06
proteins O 0 2.026855128178795e-08
that O 0 1.4261598568765521e-09
retain O 0 9.875395079461669e-08
the O 0 8.847044874471521e-09
DNA O 0 1.4455164318860625e-06
- O 0 1.6739977581892163e-05
binding O 0 2.0449104454201006e-07
domains O 0 4.248469451795245e-07
but O 0 7.4307147102103954e-09
have O 0 2.1638475455887374e-09
lost O 0 7.507046007049212e-08
most O 0 2.6156603549765123e-09
of O 0 6.2634981645715015e-09
the O 0 1.8414860392113042e-07
transactivation O 0 0.0023497582878917456
domain O 0 1.1398459719202947e-05
. O 0 9.423179108125623e-06

It O 0 3.527894705257495e-06
is O 0 2.991125143125828e-07
not O 0 2.738179993855283e-08
clear O 0 8.558350828025141e-08
whether O 0 4.4659866915708335e-08
such O 0 6.943108132873022e-08
mutants O 0 0.00024395166838075966
really O 0 3.410211775189964e-06
behave O 0 3.5980388020107057e-06
as O 0 8.669975670727581e-08
loss O 0 6.418977136490867e-05
- O 0 5.764675734099001e-05
of O 0 7.762723441828712e-08
- O 0 0.00026047209394164383
function O 0 5.225392101237958e-07
mutants O 0 2.3865766706876457e-05
as O 0 1.1912375441625045e-07
predicted O 0 2.549293640186079e-05
by O 0 1.373642703583755e-06
haploinsufficiency O 0 0.014862441457808018
. O 0 2.2495016310131177e-05

Contrary O 0 1.0915644452325068e-05
to O 0 2.475061364748399e-07
this O 0 4.34158913265037e-08
theory O 0 1.497451762588753e-07
, O 0 3.481611798861195e-08
our O 0 1.3454465985773822e-08
data O 0 2.6223954563420193e-08
showed O 0 4.8378442585317316e-08
that O 0 1.7111175809603196e-09
these O 0 2.015531963550643e-09
mutants O 0 8.741406531953544e-07
are O 0 2.267956711321517e-09
dominant O 0 1.2753354212691193e-06
- O 0 3.7674511986551806e-05
negative O 0 5.856035727447306e-07
in O 0 9.851069648902921e-08
transient O 0 0.00011507836461532861
transfection O 0 0.0007573553593829274
assays O 0 8.738563792576315e-07
when O 0 4.843928991249413e-08
they O 0 4.899538552649574e-09
are O 0 8.930320483102605e-09
coexpressed O 0 0.0001418919418938458
with O 0 4.826028998650145e-07
wild O 0 5.138984852237627e-05
- O 0 0.02821393311023712
type O 0 0.0035034334287047386
PAX6 O 1 0.8062821626663208
. O 0 3.433077290537767e-05

We O 0 1.1673665767375496e-06
found O 0 1.7240891736491903e-07
that O 0 2.1158649943231467e-08
the O 0 1.1928733556487714e-07
dominant O 0 5.196360871195793e-05
- O 0 0.005257933400571346
negative O 0 1.677324871707242e-05
effects O 0 5.006569699617103e-05
result O 0 1.4987490715157037e-07
from O 0 1.5658262242368437e-08
the O 0 1.5385658969080396e-08
enhanced O 0 1.4762929367861943e-06
DNA O 0 5.159149054634327e-07
binding O 0 1.4857390340239363e-07
ability O 0 9.530862854489897e-08
of O 0 1.4288179528421097e-08
these O 0 1.3610029725441564e-07
mutants O 0 0.0004177404334768653
. O 0 1.2318176231929101e-05

Kinetic O 0 2.334024611627683e-05
studies O 0 1.7704868469081703e-06
of O 0 6.660889795284675e-08
binding O 0 4.946462013322162e-07
and O 0 1.7662712537003245e-07
dissociation O 0 4.0190163417719305e-05
revealed O 0 5.89525939176383e-07
that O 0 3.3681839539667635e-09
various O 0 7.260091638983113e-09
truncation O 0 1.2515246453403961e-05
mutants O 0 3.5932139326178003e-06
have O 0 3.6077698606362674e-09
3 O 0 1.0645860015756625e-07
- O 0 6.8018134697922505e-06
5 O 0 2.5923881707967666e-07
- O 0 1.0963751265080646e-05
fold O 0 2.0793595467694104e-06
higher O 0 2.0870743355771992e-08
affinity O 0 2.9245896371321578e-08
to O 0 6.86174062014544e-10
various O 0 1.3585715885611194e-09
DNA O 0 1.8247244781832705e-07
- O 0 2.1316359379852656e-06
binding O 0 3.1393145860647564e-08
sites O 0 9.827775926396498e-09
when O 0 1.0131642191879564e-08
compared O 0 7.768766607796351e-08
with O 0 1.6995812757159e-08
the O 0 1.2036173302476527e-07
wild O 0 4.1153292841045186e-05
- O 0 0.01838562823832035
type O 0 0.0020551320631057024
PAX6 O 1 0.6190269589424133
. O 0 2.9480608645826578e-05

These O 0 9.71098302215978e-07
results O 0 5.217231091592112e-07
provide O 0 7.154275039056301e-08
a O 0 2.850788760611067e-08
new O 0 6.833209909018478e-08
insight O 0 7.063746352287126e-07
into O 0 7.182464845101322e-09
the O 0 6.648233519257474e-09
role O 0 5.950627013362464e-08
of O 0 1.7124349938058003e-07
mutant O 0 0.001510715577751398
PAX6 O 1 0.933262050151825
in O 0 2.8248025046195835e-05
causing O 0 0.09861134737730026
aniridia B-Disease 1 0.9363018274307251
. O 0 6.965045486140298e-06
. O 0 1.6521085854037665e-05

Reversal O 0 0.1110544204711914
of O 0 0.013739708811044693
severe O 1 0.9981687068939209
hypertrophic B-Disease 1 0.9991288781166077
cardiomyopathy I-Disease 1 0.9992994070053101
and O 0 4.882834036834538e-05
excellent O 0 0.0002994920942001045
neuropsychologic O 0 0.04946587607264519
outcome O 0 5.1897368393838406e-06
in O 0 2.4122405761772825e-07
very B-Disease 0 8.958974717643287e-07
- I-Disease 0 0.000671402201987803
long I-Disease 0 0.00014130391355138272
- I-Disease 0 0.0024310166481882334
chain I-Disease 0 0.0005585832404904068
acyl I-Disease 0 0.016287488862872124
- I-Disease 0 0.02303018793463707
coenzyme I-Disease 0 0.04464215040206909
A I-Disease 0 0.0038620864506810904
dehydrogenase I-Disease 1 0.9898087978363037
deficiency I-Disease 1 0.9964285492897034
. O 0 0.00011091757187386975

Very B-Disease 0 1.7639998986851424e-05
- I-Disease 0 0.0006699442747049034
long I-Disease 0 3.33131683873944e-05
- I-Disease 0 0.0003596376918721944
chain I-Disease 0 8.672561671119183e-05
acyl I-Disease 0 0.0010001898044720292
- I-Disease 0 0.0004906890098936856
coenzyme I-Disease 0 0.00028946538805030286
A I-Disease 0 1.6607524230494164e-05
dehydrogenase I-Disease 0 0.3772830665111542
( I-Disease 0 0.0002316985628567636
VLCAD I-Disease 1 0.9824705719947815
) I-Disease 0 0.001523230574093759
deficiency I-Disease 1 0.9989584684371948
is O 0 6.497061235677393e-07
a O 0 1.4046404430700932e-05
disorder O 1 0.9697510004043579
of O 0 2.7845439376505965e-07
fatty O 0 0.0015668782871216536
acid O 0 0.00011181023728568107
beta O 0 3.171006392221898e-05
oxidation O 0 1.6067002434283495e-05
that O 0 3.735944176241901e-08
reportedly O 0 3.291281018391601e-06
has O 0 6.706119393129484e-08
high O 0 1.263375224880292e-06
rates O 0 3.1271913485397818e-06
of O 0 8.195503369279322e-07
morbidity O 1 0.8425830602645874
and O 0 1.5240594620991033e-05
mortality O 0 0.12678924202919006
. O 0 2.004695124924183e-05

We O 0 1.1384012168491608e-06
describe O 0 9.032823982124683e-07
the O 0 2.3483337940888305e-08
outcome O 0 5.99709224502476e-08
of O 0 6.434060395577035e-09
a O 0 5.75335015184919e-08
5 O 0 5.419057060862542e-07
- O 0 3.2358424505218863e-05
year O 0 8.76188835263747e-07
- O 0 0.00014320333139039576
old O 0 7.335159170906991e-05
girl O 0 0.0026361257769167423
with O 0 0.0012993966229259968
VLCAD B-Disease 1 0.9995086193084717
deficiency I-Disease 1 0.9996832609176636
who O 0 1.6184319520107238e-06
was O 0 7.760873188544792e-08
first O 0 2.827233558377884e-08
seen O 0 2.6195365876446886e-07
at O 0 7.320470984950589e-08
5 O 0 3.737070528586628e-07
months O 0 8.644906870358682e-07
of O 0 2.2919280695532507e-07
age O 0 0.01036288496106863
with O 0 0.09718374907970428
severe O 1 0.9996335506439209
hypertrophic B-Disease 1 0.9997134804725647
cardiomyopathy I-Disease 1 0.9997714161872864
, O 1 0.9661177396774292
hepatomegaly B-Disease 1 0.9994897842407227
, O 1 0.5952870845794678
encephalopathy B-Disease 1 0.9988768696784973
, O 0 0.0002489432517904788
and O 0 0.0003389642224647105
hypotonia B-Disease 1 0.9926700592041016
. O 0 0.0002489235484972596

Biochemical O 0 0.02233123779296875
studies O 0 0.008901315741240978
indicated O 1 0.9519258737564087
VLCAD B-Disease 1 0.9984385371208191
deficiency I-Disease 1 0.9994887113571167
caused O 0 0.09065593779087067
by O 0 2.2605267986364197e-06
a O 0 8.448453627352137e-06
stable O 0 0.0005765891983173788
yet O 0 2.905948531406466e-05
inactive O 0 0.0013039911864325404
enzyme O 0 0.0001812408590922132
. O 0 9.654989298724104e-06

Molecular O 0 0.00015171746781561524
genetic O 0 2.4882228899514303e-05
analysis O 0 5.476001092574734e-07
of O 0 1.5984285539616394e-07
her O 0 2.2484464352601208e-05
VLCAD O 1 0.5100439786911011
gene O 0 2.4993862098199315e-05
revealed O 0 7.615360573254293e-06
a O 0 8.426145541307051e-07
T1372C O 0 0.0032330118119716644
( O 0 5.8221285144099966e-06
F458L O 0 0.0007827533991076052
) O 0 8.962529705058842e-07
missense O 0 2.9506565624615178e-05
mutation O 0 1.656424842622073e-06
and O 0 9.716561777395327e-08
a O 0 4.2833976294787135e-06
1668 O 0 0.498862087726593
ACAG O 1 0.763565719127655
1669 O 0 0.08852653205394745
splice O 0 0.0009305354906246066
site O 0 2.338097147003282e-05
mutation O 0 9.349182073492557e-05
. O 0 7.885411832830869e-06

After O 0 0.00011486862058518454
initial O 0 0.00015569022798445076
treatment O 0 0.0012337368680164218
with O 0 2.6251586859871168e-06
intravenous O 0 0.0036714377347379923
glucose O 0 0.00047935181646607816
and O 0 2.7393086838856107e-06
carnitine O 1 0.5554194450378418
, O 0 3.035899567294109e-07
the O 0 2.0583462401191355e-07
patient O 0 0.0001291854860028252
has O 0 6.534686747272644e-08
thrived O 0 4.35660967923468e-06
on O 0 6.23441653857526e-09
a O 0 7.05025371416923e-08
low O 0 6.238372407096904e-06
- O 0 0.00015067339700181037
fat O 0 1.7558599211042747e-05
diet O 0 3.6704730064229807e-06
supplemented O 0 1.789250205774806e-07
with O 0 3.371019730025182e-08
medium O 0 5.145624982105801e-06
- O 0 6.587387179024518e-05
chain O 0 1.0099672181240749e-05
triglyceride O 0 2.0089666577405296e-05
oil O 0 2.899325011185283e-07
and O 0 1.6484543152728293e-07
carnitine O 0 0.024151500314474106
and O 0 2.089153952056222e-07
avoidance O 0 0.00011030161840608343
of O 0 3.9255550632333325e-07
fasting O 0 0.0001602576521690935
. O 0 2.0835379473282956e-05

Her O 0 0.006724138744175434
ventricular O 1 0.9865018725395203
hypertrophy O 1 0.9888181090354919
resolved O 0 0.00037062005139887333
significantly O 0 3.201464278390631e-05
over O 0 5.665924049935711e-07
1 O 0 1.1041533980460372e-06
year O 0 8.811251746010385e-07
, O 0 2.2806990784829395e-07
and O 0 3.6341961617836205e-07
cognitively O 0 0.001955434214323759
, O 0 1.6301615346492326e-07
she O 0 8.773764648140059e-08
is O 0 4.597759506452803e-09
in O 0 3.392089942266807e-09
the O 0 2.1600508048891243e-08
superior O 0 4.409935627336381e-06
range O 0 1.177029503196536e-06
for O 0 4.232249182223313e-07
age O 0 0.00011714577703969553
. O 0 1.2794635040336289e-05

Clinical O 0 0.016477283090353012
recognition O 0 0.00023550557671114802
of O 0 0.0019263530848547816
VLCAD B-Disease 1 0.9994414448738098
deficiency I-Disease 1 0.9996494054794312
is O 0 2.3376587705570273e-06
important O 0 3.3330312021462305e-07
because O 0 1.1157509760550965e-07
it O 0 3.6636822464686247e-09
is O 0 1.681308536838344e-09
one O 0 5.432299055030398e-10
of O 0 1.6092961407920825e-09
the O 0 6.119889661704292e-08
few O 0 6.15860562902526e-06
directly O 0 0.0009349376778118312
treatable O 1 0.9992995262145996
causes O 0 0.15636251866817474
of O 0 0.00032902753446251154
cardiomyopathy B-Disease 1 0.9995843768119812
in O 0 5.039352618041448e-05
children O 0 0.000302893080515787
. O 0 1.188867463497445e-05
. O 0 5.41926892765332e-05

Cloning O 0 6.339135870803148e-05
of O 0 2.0740193917845318e-07
a O 0 2.561665439770877e-07
novel O 0 7.072192715895653e-07
member O 0 4.223112526346995e-08
of O 0 7.953221192735782e-09
the O 0 9.917449972363102e-08
low O 0 3.496421777526848e-05
- O 0 0.004694448783993721
density O 0 0.00011927376181120053
lipoprotein O 1 0.5006951689720154
receptor O 0 0.00020883709657937288
family O 0 1.8098775399266742e-05
. O 0 6.116136773925973e-06

A O 0 2.455386265864945e-06
gene O 0 1.287585746467812e-06
encoding O 0 4.873621151091356e-07
a O 0 2.347206020658632e-07
novel O 0 7.5438506428326946e-06
transmembrane O 0 0.0001888829719973728
protein O 0 5.341274800230167e-07
was O 0 1.4333244813258261e-08
identified O 0 7.859305206636691e-09
by O 0 1.0343356171560458e-09
DNA O 0 1.5940770481392974e-08
sequence O 0 5.4321982467797625e-09
analysis O 0 1.233137858491773e-08
within O 0 1.7987176192946208e-08
the O 0 7.158642461035924e-07
insulin B-Disease 0 0.46313104033470154
- I-Disease 1 0.9617339372634888
dependent I-Disease 1 0.8786829113960266
diabetes I-Disease 1 0.999769389629364
mellitus I-Disease 1 0.9993834495544434
( O 0 0.000302995671518147
IDDM B-Disease 1 0.5703304409980774
) O 0 5.660735041601583e-06
locus O 0 0.00015219140914268792
IDDM4 O 0 0.004346626810729504
on O 0 1.1086863196396735e-06
chromosome O 0 0.00034344239975325763
11q13 O 0 0.0036601785104721785
. O 0 2.8677535738097504e-05

Based O 0 2.1120442852406995e-06
on O 0 1.890088014988578e-07
its O 0 3.00483151249864e-07
chromosomal O 0 0.00017879459483083338
position O 0 1.6454229978535295e-07
, O 0 3.3507184582504124e-08
this O 0 4.782336304742785e-09
gene O 0 1.8179537164542126e-07
is O 0 3.6925718038816058e-09
a O 0 2.8296668119764945e-08
candidate O 0 2.847360462965298e-07
for O 0 6.513532753160689e-07
conferring O 0 0.012010258622467518
susceptibility O 1 0.8614556789398193
to O 0 0.0009608475957065821
diabetes B-Disease 1 0.9982836246490479
. O 0 0.0005540676065720618

The O 0 3.4255410810146714e-06
gene O 0 6.960105110920267e-06
, O 0 6.189301302583772e-07
termed O 0 2.069904439849779e-05
low O 0 1.9616816643974744e-05
- O 0 0.00036533985985442996
density O 0 1.918533416755963e-05
lipoprotein O 0 0.01945711113512516
receptor O 0 4.915706540487008e-06
related O 0 2.7852505013470363e-07
protein O 0 9.178022253308882e-08
5 O 0 2.6503795425014687e-07
( O 0 5.037206278757367e-07
LRP5 O 0 0.00028534242301248014
) O 0 9.346301510504418e-09
, O 0 1.298592677834165e-09
encodes O 0 5.191771013102198e-09
a O 0 1.4961286654013861e-09
protein O 0 5.846011230659087e-09
of O 0 1.3603996817934672e-09
1615 O 0 5.515111297427211e-06
amino O 0 9.17157905178101e-09
acids O 0 4.7130268576722756e-09
that O 0 5.287384974295151e-10
contains O 0 2.9092659392659925e-09
conserved O 0 1.7346104996818212e-08
modules O 0 4.0098111497854916e-08
which O 0 1.086122636273501e-09
are O 0 3.708776064037522e-10
characteristic O 0 1.0278893292081648e-08
of O 0 8.563894038360331e-10
the O 0 2.1535223382329605e-08
low O 0 1.0975772056553978e-05
- O 0 0.0007144259288907051
density O 0 5.866444917046465e-05
lipoprotein O 1 0.6806089878082275
( O 0 3.6115365219302475e-05
LDL O 0 0.24490176141262054
) O 0 8.82823428582924e-07
receptor O 0 2.457137088640593e-05
family O 0 4.315971636970062e-06
. O 0 4.523874849837739e-06

These O 0 7.916552249298547e-07
modules O 0 2.204341171818669e-06
include O 0 2.8135787033534143e-07
a O 0 9.620136154353531e-08
putative O 0 4.395404175738804e-06
signal O 0 1.0520687254711447e-07
peptide O 0 2.0267901845727465e-07
for O 0 4.7734056707327e-09
protein O 0 2.801922072137586e-08
export O 0 4.301751133084508e-08
, O 0 7.341231178514818e-09
four O 0 4.5798806524999236e-08
epidermal O 0 0.020451074466109276
growth O 0 1.8284177713212557e-05
factor O 0 1.2771544788847677e-05
( O 0 4.188792900094995e-06
EGF O 0 0.07731062173843384
) O 0 5.392961099914828e-08
repeats O 0 4.161488220688625e-07
with O 0 1.4356118072100799e-08
associated O 0 3.203425364972645e-07
spacer O 0 1.926199911395088e-05
domains O 0 2.766687146049662e-07
, O 0 1.4286680283248643e-08
three O 0 8.998786427127925e-08
LDL O 0 0.23104770481586456
- O 0 0.0002824614057317376
receptor O 0 2.217040309915319e-05
( O 0 7.829502237655106e-07
LDLR O 0 0.0016826021019369364
) O 0 6.650125783380645e-08
repeats O 0 6.157404186524218e-07
, O 0 2.636959539614736e-09
a O 0 3.7511367345643976e-09
single O 0 1.6650655965122496e-08
transmembrane O 0 6.389306690834928e-06
spanning O 0 1.0560429473116528e-06
domain O 0 1.4370696987953124e-07
, O 0 1.3575931490095172e-08
and O 0 9.186003957495359e-09
a O 0 1.0945669970396921e-07
cytoplasmic O 0 2.590184158179909e-05
domain O 0 3.989841388829518e-06
. O 0 4.430934041010914e-06

The O 0 8.147467838170996e-07
encoded O 0 4.548081165012263e-07
protein O 0 5.677781018675887e-07
has O 0 2.8051571732135017e-08
a O 0 3.133691350853951e-08
unique O 0 7.943280166955446e-08
organization O 0 2.416933568838431e-07
of O 0 1.2238032809364086e-07
EGF O 0 0.3966328501701355
and O 0 6.770753770979354e-07
LDLR O 0 0.155244842171669
repeats O 0 0.00010568775178398937
; O 0 6.284526534727775e-07
therefore O 0 8.971468901108892e-08
, O 0 2.787806749893207e-07
LRP5 O 0 0.020146343857049942
likely O 0 3.932989898203232e-07
represents O 0 1.487576497538612e-07
a O 0 1.587562614702165e-08
new O 0 1.0434953168214633e-07
category O 0 5.041781605541473e-07
of O 0 2.8169688803814097e-08
the O 0 9.388288617628859e-07
LDLR O 0 0.19494938850402832
family O 0 6.213186134118587e-05
. O 0 2.5522760552121326e-05

Both O 0 3.5249349821242504e-06
human O 0 5.841784059157362e-06
and O 0 3.96259247281705e-06
mouse O 0 0.026949109509587288
LRP5 O 1 0.9596679210662842
cDNAs O 0 0.09150668233633041
have O 0 9.221221830557624e-08
been O 0 2.3458403219933643e-08
isolated O 0 6.157468419587531e-07
and O 0 4.105055406711244e-09
the O 0 2.7329869478620594e-09
encoded O 0 1.7859184353596902e-08
mature O 0 5.786828296550084e-07
proteins O 0 6.4093801377396176e-09
are O 0 5.301705185978278e-10
95 O 0 6.803168872693277e-08
% O 0 1.153621198568544e-08
identical O 0 4.333093173158886e-08
, O 0 1.895148393771251e-08
indicating O 0 1.874953596825435e-07
a O 0 2.7820426851121738e-08
high O 0 3.2127260851666506e-07
degree O 0 1.6983311468266038e-07
of O 0 2.854722680467603e-08
evolutionary O 0 1.8526607163948938e-05
conservation O 0 3.129939068458043e-05
. O 0 1.0441887070555822e-06
. O 0 7.317898507608334e-06

The O 0 7.83063023845898e-06
APC B-Disease 0 0.0010028744582086802
variants O 0 2.591439442767296e-05
I1307K O 0 0.0006333133787848055
and O 0 2.0730319647555007e-06
E1317Q O 0 0.0026917115319520235
are O 0 1.1995165323241963e-06
associated O 0 0.0033651043195277452
with O 1 0.7961997985839844
colorectal B-Disease 1 0.9999417066574097
tumors I-Disease 1 0.9999018907546997
, O 0 2.081716593238525e-05
but O 0 2.8664541673606436e-07
not O 0 1.2569078222668395e-08
always O 0 4.732811120788938e-08
with O 0 7.387165368299975e-08
a O 0 9.93208118416078e-07
family O 0 1.865482408902608e-05
history O 0 3.877582275890745e-05
. O 0 4.060897481394932e-05

Classical O 0 0.07262064516544342
familial B-Disease 1 0.9927430152893066
adenomatous I-Disease 1 0.9967657327651978
polyposis I-Disease 1 0.9980254173278809
( O 0 0.02514737844467163
FAP B-Disease 1 0.984875500202179
) O 0 5.9620947467919905e-06
is O 0 2.0286815072267927e-07
a O 0 1.5034747775644064e-06
high O 0 0.0014594800304621458
- O 1 0.9728421568870544
penetrance O 1 0.9983240962028503
autosomal B-Disease 1 0.9984604120254517
dominant I-Disease 1 0.9841780066490173
disease I-Disease 1 0.9994040727615356
that O 0 6.812453648308292e-06
predisposes O 0 0.18058191239833832
to O 0 3.728810895609058e-07
hundreds O 0 5.3077778829901945e-06
or O 0 2.8340582503005862e-06
thousands O 0 0.0001060563517967239
of O 0 0.0035874920431524515
colorectal B-Disease 1 0.9998644590377808
adenomas I-Disease 1 0.9996565580368042
and I-Disease 0 0.03565029054880142
carcinoma I-Disease 1 0.9997671246528625
and O 0 4.047771540172107e-07
that O 0 3.5688628940988565e-08
results O 0 2.9712890636801603e-07
from O 0 3.2658255122441915e-07
truncating O 0 0.004499686881899834
mutations O 0 8.085720764938742e-06
in O 0 8.5567187113611e-08
the O 0 5.762431669609214e-07
APC B-Disease 0 0.009297351352870464
gene O 0 0.0001148284281953238
. O 0 1.444285771867726e-05

A O 0 4.812723636860028e-05
variant O 0 0.0009163057547993958
of O 0 1.155549762188457e-05
FAP B-Disease 1 0.9904539585113525
is O 0 0.002071486320346594
attenuated B-Disease 1 0.9957926273345947
adenomatous I-Disease 1 0.9990861415863037
polyposis I-Disease 1 0.9991925358772278
coli I-Disease 1 0.9968330264091492
, O 0 2.401448909949977e-06
which O 0 1.7651767336701596e-07
results O 0 6.757014148206508e-07
from O 0 1.2988085700271768e-06
germ O 0 0.274141788482666
- O 0 0.0004812348634004593
line O 0 1.2090167729184031e-06
mutations O 0 5.228831696513225e-07
in O 0 2.4909345697210483e-09
the O 0 2.4773265661082178e-09
5 O 0 4.3388411086198175e-08
and O 0 4.683008203443251e-09
3 O 0 3.525609315602196e-08
regions O 0 2.0125364486034414e-08
of O 0 7.1205517038208654e-09
the O 0 2.6882790393756295e-07
APC B-Disease 0 0.0010094273602589965
gene O 0 4.051668292959221e-05
. O 0 8.328380317834672e-06

Attenuated B-Disease 1 0.9775057435035706
adenomatous I-Disease 1 0.9941018223762512
polyposis I-Disease 1 0.9973621964454651
coli I-Disease 1 0.9976373910903931
patients O 1 0.9892314076423645
have O 0 6.9340089794422965e-06
" O 0 1.8419599655317143e-05
multiple O 0 0.003272424219176173
" O 0 0.07666732370853424
colorectal B-Disease 1 0.999788224697113
adenomas I-Disease 1 0.9992996454238892
( O 0 1.9058121324633248e-05
typically O 0 4.66454878278455e-07
fewer O 0 2.087198396338863e-07
than O 0 1.8274475266366608e-08
100 O 0 7.092943121733697e-08
) O 0 3.410743687481954e-08
without O 0 1.7708412514139127e-08
the O 0 1.1528342014344162e-07
florid O 0 0.00884078536182642
phenotype O 0 0.0002204041084041819
of O 0 4.1418178398089367e-07
classical O 0 0.00012397224782034755
FAP B-Disease 1 0.949445366859436
. O 0 8.816416811896488e-05

Another O 0 1.4460692909779027e-05
group O 0 1.2300778507778887e-05
of O 0 4.858297870669048e-06
patients O 0 0.13118717074394226
with O 0 9.886522093438543e-06
multiple O 0 0.0020225930493324995
adenomas B-Disease 1 0.9943529367446899
has O 0 1.0210910659225192e-06
no O 0 1.4126976566330995e-07
mutations O 0 1.264701268155477e-06
in O 0 1.2270120031132592e-08
the O 0 5.6860393726765324e-08
APC B-Disease 0 0.0007265477906912565
gene O 0 1.72106786067161e-06
, O 0 2.949900768101088e-08
and O 0 1.4856703423049566e-08
their O 0 2.7680217229431037e-08
phenotype O 0 9.208042320096865e-05
probably O 0 1.583073014899128e-07
results O 0 1.9930583405880498e-08
from O 0 5.863420859952839e-09
variation O 0 8.472060386566227e-08
at O 0 3.3016785749850897e-08
a O 0 6.85037022662982e-08
locus O 0 1.1436655768193305e-05
, O 0 5.139006020726811e-08
or O 0 8.399815243365083e-08
loci O 0 1.5184692756520235e-06
, O 0 6.614541092631043e-08
elsewhere O 0 1.2338982458004466e-07
in O 0 3.635728162976193e-08
the O 0 2.749526970546867e-07
genome O 0 9.020990546559915e-05
. O 0 1.0131053386430722e-05

Recently O 0 0.00010681756248231977
, O 0 1.207274635817157e-06
however O 0 1.5538370234935428e-07
, O 0 4.1295198371926745e-08
a O 0 1.1340286221184215e-07
missense O 0 3.67737484339159e-05
variant O 0 2.7014189981855452e-05
of O 0 1.5456816981895827e-07
APC B-Disease 0 0.0022580407094210386
( O 0 1.0139230653294362e-05
I1307K O 0 0.0016410484677180648
) O 0 3.0673680839754525e-07
was O 0 4.3101618274477005e-08
described O 0 2.6223960958304815e-07
that O 0 4.491391791816568e-08
confers O 0 0.00012622711074072868
an O 0 1.0846056284208316e-06
increased O 0 0.000810236029792577
risk O 0 0.43128207325935364
of O 0 0.01855030655860901
colorectal B-Disease 1 0.9998956918716431
tumors I-Disease 1 0.9997592568397522
, O 0 1.4163862033456098e-05
including O 0 2.090416273858864e-05
multiple O 0 0.026434753090143204
adenomas B-Disease 1 0.9978744983673096
, O 0 8.694617463333998e-06
in O 0 1.2865195458289236e-05
Ashkenazim O 0 0.1824563890695572
. O 0 5.280714685795829e-05

We O 0 7.838571036700159e-07
have O 0 7.576943517051404e-08
studied O 0 1.0656850690793362e-07
a O 0 2.5649526946835977e-08
set O 0 3.5473629367288595e-08
of O 0 1.9564826914120204e-07
164 O 0 0.0025006188079714775
patients O 0 0.05143018811941147
with O 0 6.38419805909507e-05
multiple O 1 0.7934530973434448
colorectal B-Disease 1 0.9997991919517517
adenomas I-Disease 1 0.9993366599082947
and I-Disease 0 0.0003538605524227023
/ I-Disease 1 0.9587534070014954
or I-Disease 0 0.0014464325504377484
carcinoma I-Disease 1 0.9994407296180725
and O 0 3.60414759370542e-07
analyzed O 0 4.456020633369917e-06
codons O 0 2.1130974346306175e-05
1263 O 0 0.00966489315032959
- O 0 0.0005248639499768615
1377 O 0 0.004801290109753609
( O 0 7.120648888303549e-07
exon O 0 2.065932858386077e-05
15G O 0 2.6102321498910896e-05
) O 0 6.798419160958247e-09
of O 0 1.1927359100383228e-09
the O 0 3.2496043189667034e-08
APC B-Disease 0 5.439965025288984e-05
gene O 0 2.3543896077171667e-06
for O 0 6.827737593084748e-07
germ O 1 0.6888099908828735
- O 0 0.001138911466114223
line O 0 1.007376704365015e-05
variants O 0 2.48696087510325e-05
. O 0 6.7796199800795875e-06

Three O 0 1.532180976937525e-05
patients O 0 0.0017805190291255713
with O 0 4.0322908034795546e-07
the O 0 6.325184926936345e-07
I1307K O 0 0.003425533650442958
allele O 0 1.5410145351779647e-05
were O 0 3.310513108090163e-08
detected O 0 1.6729688923078356e-06
, O 0 8.9816358794792e-09
each O 0 2.7059474660973137e-09
of O 0 1.1021317192216884e-07
Ashkenazi O 0 0.0006604766822420061
descent O 0 8.062793494900689e-05
. O 0 1.8424942027195357e-05

Four O 0 5.495112418429926e-05
patients O 0 0.004788065794855356
had O 0 8.725698421585548e-07
a O 0 1.5318389614549233e-06
germ O 0 0.0903746709227562
- O 0 0.0002989047789014876
line O 0 6.2494123085343745e-06
E1317Q O 0 0.0008784670499153435
missense O 0 0.00013481704809237272
variant O 0 3.2264804758597165e-05
of O 0 8.903266035531487e-08
APC O 0 0.0006537233712151647
that O 0 2.654268982382746e-08
was O 0 2.693415446231029e-08
not O 0 2.096025353282016e-09
present O 0 2.064884796482147e-08
in O 0 1.777060276708653e-08
controls O 0 1.2167782870164956e-06
; O 0 8.506598447866054e-08
one O 0 2.2415898026650893e-09
of O 0 2.4695798739315933e-09
these O 0 6.424397458459907e-09
individuals O 0 3.2680151917929834e-08
had O 0 1.4320100660825119e-08
an O 0 1.4745671350624434e-08
unusually O 0 4.285657269065268e-06
large O 0 6.288112075480967e-08
number O 0 1.6786371404009515e-08
of O 0 1.5232717487378977e-07
metaplastic B-Disease 1 0.6441633701324463
polyps I-Disease 0 0.06188807636499405
of I-Disease 0 1.6650790257699555e-07
the I-Disease 0 3.337800535518909e-06
colorectum I-Disease 0 0.17298346757888794
. O 0 2.373091410845518e-05

There O 0 9.419512934982777e-06
is O 0 8.502232731188997e-07
increasing O 0 3.0520566269842675e-06
evidence O 0 3.7945017083984567e-07
that O 0 1.9339466916790116e-08
there O 0 2.84076335788086e-08
exist O 0 3.2849769127096806e-07
germ O 0 0.02430274523794651
- O 0 2.284066977153998e-05
line O 0 1.2945851324275282e-07
variants O 0 7.835554072244122e-08
of O 0 3.8732235196903275e-09
the O 0 4.984839208077574e-08
APC B-Disease 0 0.0002679338213056326
gene O 0 1.0100136478286004e-06
that O 0 1.2652590974937539e-08
predispose O 0 1.577157854626421e-05
to O 0 5.941868330694433e-09
the O 0 2.104840213235093e-08
development O 0 9.615142744223704e-07
of O 0 2.9068105504848063e-06
multiple O 1 0.585090696811676
colorectal B-Disease 1 0.999858021736145
adenomas I-Disease 1 0.9997095465660095
and I-Disease 0 0.2014215886592865
carcinoma I-Disease 1 0.9998487234115601
, O 0 2.3521902221546043e-06
but O 0 5.536014668905409e-08
without O 0 4.823930410680077e-08
the O 0 9.217336582878488e-08
florid O 0 0.012375744059681892
phenotype O 0 9.65083236224018e-05
of O 0 5.7317723900496276e-08
classical O 0 4.336309575592168e-05
FAP B-Disease 1 0.8245965838432312
, O 0 1.9732986800136132e-07
and O 0 4.86423239465239e-08
possibly O 0 1.0818639566423371e-06
with O 0 8.164704468072159e-07
importance O 0 0.0006954047130420804
for O 1 0.7052683234214783
colorectal B-Disease 1 0.9999480247497559
cancer I-Disease 1 0.9999045133590698
risk O 0 0.13212493062019348
in O 0 3.2225088375525957e-07
the O 0 2.8529163387247536e-07
general O 0 4.023404926556395e-06
population O 0 2.318392716915696e-06
. O 0 1.3766012898486224e-06
. O 0 9.716867680253927e-06

Genomic O 0 0.00030171143589541316
structure O 0 2.2478548999060877e-05
of O 0 1.7178701909870142e-06
the O 0 0.00011639141303021461
human O 1 0.7277941107749939
congenital B-Disease 1 0.9994945526123047
chloride I-Disease 1 0.9985741376876831
diarrhea I-Disease 1 0.9996296167373657
( O 0 0.2679217755794525
CLD B-Disease 1 0.997165858745575
) O 0 6.567711534444243e-05
gene O 0 0.0002020804677158594
. O 0 2.9705302949878387e-05

Congenital B-Disease 1 0.9962912797927856
chloride I-Disease 1 0.9943767786026001
diarrhea I-Disease 1 0.9990922212600708
( O 1 0.5088573694229126
CLD B-Disease 1 0.9976763129234314
) O 0 0.00010822454351000488
is O 0 2.8717345230688807e-06
caused O 0 0.0001998626539716497
by O 0 2.0636275621654931e-07
mutations O 0 2.814286517605069e-06
in O 0 1.2193084764078321e-08
a O 0 7.861167006240066e-08
gene O 0 1.5294057220671675e-06
which O 0 6.772459215653726e-08
encodes O 0 8.20329751149984e-06
an O 0 1.611011612112634e-05
intestinal O 1 0.9940815567970276
anion O 0 0.18332520127296448
transporter O 0 0.04553909972310066
. O 0 2.420112105028238e-05

We O 0 3.1153415420703823e-06
report O 0 1.06293998669571e-06
here O 0 7.339974672504468e-08
the O 0 1.6474194453053315e-08
complete O 0 2.381642190130151e-07
genomic O 0 4.673588591685984e-06
organization O 0 1.0572667008545977e-07
of O 0 1.012362638164177e-08
the O 0 1.4800059489061823e-07
human O 0 2.6721740141510963e-05
CLD B-Disease 1 0.9842830300331116
gene O 0 4.644911314244382e-06
which O 0 7.308249649895515e-08
spans O 0 9.964726814359892e-06
approximately O 0 6.236464287212584e-07
39kb O 0 0.0011226460337638855
, O 0 4.9194493811910434e-08
and O 0 1.6752306208900336e-08
comprises O 0 2.525394791064173e-07
21 O 0 2.7680698622134514e-06
exons O 0 4.192660708213225e-05
. O 0 6.0016909628757276e-06

All O 0 2.7352364213584224e-06
exon O 0 0.0007412031409330666
/ O 0 0.0011407226556912065
intron O 0 0.000768535363022238
boundaries O 0 3.8071522112659295e-07
conform O 0 1.9545259419828653e-06
to O 0 6.859784207335906e-08
the O 0 7.99052145339374e-07
GT O 0 0.2162451595067978
/ O 0 0.22726546227931976
AG O 0 0.45560184121131897
rule O 0 2.5150809960905463e-05
. O 0 1.2882642295153346e-05

An O 0 5.555344273489027e-07
analysis O 0 2.090018824674189e-07
of O 0 2.5427503658193018e-08
the O 0 6.569628396846383e-08
putative O 0 3.149254189338535e-05
promoter O 0 4.59735601907596e-05
region O 0 3.202771665655746e-07
sequence O 0 1.928255954908309e-08
shows O 0 3.5182271318490166e-08
a O 0 1.2330325205311965e-07
putative O 0 0.00014876612112857401
TATA O 0 0.006049537565559149
box O 0 1.6081841749837622e-05
and O 0 1.6850341921781364e-07
predicts O 0 0.00034443658660165966
multiple O 0 1.579060608492e-06
transcription O 0 1.452892229281133e-05
factor O 0 3.1059612410899717e-06
binding O 0 9.01903376870905e-07
sites O 0 1.307797333538474e-06
. O 0 2.6362679363955976e-06

The O 0 4.098457338841399e-06
genomic O 0 6.106426735641435e-05
structure O 0 5.239421625446994e-06
was O 0 1.1742900341005225e-07
determined O 0 5.319294515970796e-08
using O 0 1.142920247332313e-08
DNA O 0 9.291223790341974e-08
from O 0 7.57449836186197e-09
several O 0 4.841755441020723e-09
sources O 0 1.1182603287807069e-08
including O 0 1.371114510817506e-08
multiple O 0 2.583394689281704e-07
large O 0 8.102633728412911e-07
- O 0 0.0001415808219462633
insert O 0 0.00011858776269946247
libaries O 0 0.0001795849675545469
and O 0 4.3607851551996646e-08
genomic O 0 5.436426363303326e-06
DNA O 0 1.786128336789261e-06
from O 0 4.177952632744564e-06
Finnish O 0 0.30275261402130127
CLD B-Disease 1 0.9981812238693237
patients O 0 0.2061847448348999
and O 0 4.907537459075684e-06
controls O 0 0.00015414775407407433
. O 0 2.8434677005861886e-05

Exon O 0 0.0012065654154866934
- O 0 0.00018653018923942
specific O 0 1.4737679521203972e-06
primers O 0 0.00012728797446470708
developed O 0 4.6415370889008045e-06
in O 0 4.0661568334598996e-08
this O 0 1.1128897803303062e-08
study O 0 1.0519723758761756e-07
will O 0 1.9917472116048884e-08
facilitate O 0 8.400518254347844e-07
mutation O 0 1.8585074940347113e-05
screening O 0 1.5903826351859607e-05
studies O 0 1.915464736157446e-06
of O 0 1.6792891983641312e-06
patients O 0 0.356575071811676
with O 0 4.695104144047946e-05
the O 0 0.0016577630303800106
disease O 1 0.9985672235488892
. O 0 0.000592260155826807

Genomic O 0 1.925288961501792e-05
sequencing O 0 2.048425130851683e-06
of O 0 1.218139686898212e-07
a O 0 2.238840806967346e-06
BAC O 0 0.014865192584693432
clone O 0 0.30722615122795105
H O 0 0.2737754285335541
_ O 0 3.216845652787015e-05
RG364P16 O 0 0.0015079057775437832
revealed O 0 2.125242190231802e-06
the O 0 1.7495461079874985e-08
presence O 0 4.387533181215986e-08
of O 0 5.227493105053327e-09
another O 0 7.120079459355111e-08
, O 0 2.6727407842486173e-08
highly O 0 4.329119462909148e-08
homologous O 0 6.767319291611784e-07
gene O 0 3.085997093421611e-07
3 O 0 4.323367974734538e-08
of O 0 9.376549314765725e-09
the O 0 5.04862327943556e-07
CLD B-Disease 1 0.9835023283958435
gene O 0 2.144050540664466e-06
, O 0 1.5246371276589343e-08
with O 0 6.0065565854472425e-09
a O 0 2.1420602180910464e-08
similar O 0 2.377806822551065e-07
genomic O 0 4.963552419212647e-05
structure O 0 1.5016668839962222e-05
, O 0 3.579153542432323e-07
recently O 0 4.47580305262818e-06
identified O 0 5.560660838455078e-07
as O 0 3.872598028920038e-07
the O 0 0.0001235460804309696
Pendred B-Disease 1 0.9993197917938232
syndrome I-Disease 1 0.999760091304779
gene O 0 0.005673427600413561
( O 0 0.00027748203137889504
PDS B-Disease 0 0.48108938336372375
) O 0 3.852867394016357e-06
. O 0 1.0551972309258417e-06
. O 0 6.025335551385069e-06

The O 0 4.6653392928419635e-05
APCI1307K O 1 0.7725880146026611
allele O 0 0.02549838460981846
and O 0 0.0020987738389521837
cancer B-Disease 1 0.998877227306366
risk O 0 0.006140096578747034
in O 0 2.0107874831865047e-07
a O 0 5.977689170322265e-07
community O 0 1.709173375274986e-06
- O 0 0.00013076294271741062
based O 0 2.297271777251808e-07
study O 0 8.986348234429897e-07
of O 0 3.8988008554952103e-07
Ashkenazi O 0 0.0060539087280631065
Jews O 0 2.7356347345630638e-05
. O 0 1.5451110812136903e-05

Mutations O 0 0.0009079323499463499
in O 0 1.6945283277891576e-05
APC O 0 0.015896989032626152
are O 0 1.814944539546559e-06
classically O 0 0.04306606948375702
associated O 0 0.0005935718072578311
with O 0 0.004951017443090677
familial B-Disease 1 0.9991894364356995
adenomatous I-Disease 1 0.9995309114456177
polyposis I-Disease 1 0.9995531439781189
( O 0 0.2653188407421112
FAP B-Disease 1 0.9967721104621887
) O 0 1.3439377653412521e-05
, O 0 1.4453620451604365e-06
a O 0 2.435373971820809e-05
highly O 0 0.029701728373765945
penetrant O 1 0.9989112615585327
autosomal B-Disease 1 0.9994961023330688
dominant I-Disease 1 0.9985712766647339
disorder I-Disease 1 0.9998185038566589
characterized O 1 0.9822711944580078
by O 0 0.0019064194057136774
multiple O 1 0.9691601991653442
intestinal O 1 0.9997199177742004
polyps B-Disease 1 0.9981391429901123
and O 0 5.7731640481506474e-06
, O 0 3.1633262551622465e-06
without O 0 4.335285666456912e-06
surgical O 0 0.20313535630702972
intervention O 0 8.887839067028835e-05
, O 0 2.426027663204877e-07
the O 0 4.147414927047066e-07
development O 0 0.0002957681135740131
of O 0 0.017654582858085632
colorectal B-Disease 1 0.9998477697372437
cancer I-Disease 1 0.999710738658905
( O 0 0.024445755407214165
CRC B-Disease 1 0.9375810623168945
) O 0 3.9922957512317225e-05
. O 0 1.3620352547150105e-05

APC B-Disease 0 0.0040359338745474815
is O 0 5.7816268963506445e-06
a O 0 6.129605753812939e-05
tumour O 1 0.9960513710975647
- O 0 0.0385720431804657
suppressor O 0 0.02321573905646801
gene O 0 1.0196741641266271e-05
, O 0 2.477063958394865e-07
and O 0 7.664889949410281e-07
somatic O 0 0.00306492461822927
loss O 0 0.02671915665268898
occurs O 0 0.00024299642245750874
in O 0 3.897245187545195e-05
tumours B-Disease 1 0.9958664178848267
. O 0 0.00014722903142683208

The O 0 1.982663343369495e-05
germline O 0 0.058521248400211334
T O 0 0.1451389044523239
- O 0 0.00014049591845832765
to O 0 1.7652945416557486e-07
- O 0 2.5266830562031828e-05
A O 0 5.528015663003316e-07
transversion O 0 0.0003477601567283273
responsible O 0 6.831047016930825e-08
for O 0 5.857429208333542e-09
the O 0 2.0672768386020834e-08
APC O 0 5.4537969845114276e-05
I1307K O 0 2.387623862887267e-05
allele O 0 1.9705079523646418e-07
converts O 0 2.173818103301528e-08
the O 0 6.924246065409534e-09
wild O 0 3.575254368115566e-07
- O 0 5.1561664804467e-06
type O 0 2.1830490481988818e-07
sequence O 0 8.146860075441964e-09
to O 0 1.4195739694855547e-08
a O 0 2.2723845631844597e-06
homopolymer O 1 0.7108697891235352
tract O 1 0.9452113509178162
( O 0 0.00010761326848296449
A8 O 1 0.7837512493133545
) O 0 9.804242608879576e-07
that O 0 3.502646350739269e-08
is O 0 2.8134957119618775e-07
genetically O 0 0.00014739450125489384
unstable O 0 0.004759639035910368
and O 0 1.0078083505504765e-06
prone O 0 0.003535575233399868
to O 0 9.801531177799916e-07
somatic O 0 0.001504168496467173
mutation O 0 0.00018020006245933473
. O 0 1.1663177247100975e-05

The O 0 1.0179051059822086e-05
I1307K O 0 0.0016529937274754047
allele O 0 4.447705941856839e-05
was O 0 4.0005298274081724e-07
found O 0 2.728345975810953e-07
in O 0 2.831621941368212e-07
6 O 0 1.1894673662027344e-05
. O 0 1.030031398840947e-05

1 O 0 4.211804935039254e-06
% O 0 5.28919656517246e-07
of O 0 4.1470431710877165e-07
unselected O 0 0.052375584840774536
Ashkenazi O 0 0.002268571872264147
Jews O 0 1.5235143564495957e-06
and O 0 1.6687798165548884e-07
higher O 0 2.6561990580376005e-06
proportions O 0 0.00015829215408302844
of O 0 2.0425696334314125e-07
Ashkenazim O 0 0.004951050505042076
with O 0 7.481315833501867e-07
family O 0 5.3791204663866665e-06
or O 0 3.1752182394484407e-07
personal O 0 2.162521695936448e-06
histories O 0 8.491834887536243e-05
of O 0 2.822836904670112e-06
CRC B-Disease 1 0.8081349730491638
( O 0 4.869275289820507e-05
ref O 0 0.0276125967502594
. O 0 1.735895409638033e-07
2 O 0 1.2729149148071883e-06
) O 0 1.3245187346910825e-06
. O 0 2.4263408704428002e-06

To O 0 8.220300742323161e-07
evaluate O 0 2.158195229640114e-06
the O 0 3.749428856281156e-08
role O 0 1.808194838304189e-07
of O 0 2.289103520070057e-07
I1307K O 0 0.1744484007358551
in O 0 7.33538981876336e-05
cancer B-Disease 1 0.9752728939056396
, O 0 3.242726336338819e-07
we O 0 6.710815370070122e-08
genotyped O 0 0.000921665399800986
5 O 0 1.735638534228201e-06
, O 0 1.064346861312515e-06
081 O 0 0.10050490498542786
Ashkenazi O 0 0.00012823910219594836
volunteers O 0 4.913893008051673e-07
in O 0 2.4490919514619236e-08
a O 0 1.9217650049085933e-07
community O 0 2.935560360128875e-06
survey O 0 1.9838245862047188e-05
. O 0 5.841015081387013e-06

Risk O 0 0.026265982538461685
of O 0 8.791550499154255e-05
developing O 1 0.9781558513641357
colorectal B-Disease 1 0.9994402527809143
, I-Disease 0 0.020510336384177208
breast I-Disease 1 0.998399555683136
and I-Disease 0 7.527903562731808e-06
other I-Disease 0 5.4847687351866625e-06
cancers I-Disease 1 0.6603831648826599
were O 0 4.348658677599815e-08
compared O 0 3.929003923985874e-06
between O 0 2.1746034235547995e-06
genotyped O 0 0.16637185215950012
I1307K O 0 0.021613627672195435
carriers O 0 6.320960528682917e-05
and O 0 1.360520229809481e-07
non O 0 3.554695922503015e-06
- O 0 0.0002025324502028525
carriers O 0 2.2120568701211596e-06
and O 0 4.994515467870997e-09
their O 0 4.007943310568862e-09
first O 0 9.63570840895045e-08
- O 0 0.00014009341248311102
degree O 0 4.723955044028116e-06
relatives O 0 3.128232492599636e-05
. O 0 9.137181223195512e-06

Sperm O 0 3.612287764553912e-05
DNA O 0 4.276805611880263e-06
analysis O 0 1.0405562989035388e-06
in O 0 7.788125913066324e-07
a O 0 0.00010383370681665838
Friedreich B-Disease 1 0.9970777034759521
ataxia I-Disease 1 0.9971954822540283
premutation O 1 0.853263258934021
carrier O 0 0.0009725313866510987
suggests O 0 3.786147772188997e-06
both O 0 6.90693013893906e-08
meiotic O 0 0.00030347236315719783
and O 0 1.844185533173004e-07
mitotic O 0 0.00013125414261594415
expansion O 0 8.762423931329977e-06
in O 0 2.356078141474427e-07
the O 0 1.8101633258993388e-06
FRDA B-Disease 0 0.15725399553775787
gene O 0 0.0001193695716210641
. O 0 1.1134183296235278e-05

Friedreich B-Disease 1 0.9897047877311707
ataxia I-Disease 1 0.9940927624702454
is O 0 4.178741801297292e-05
usually O 0 1.1654949048534036e-05
caused O 0 8.178796269930899e-05
by O 0 3.3081711592330976e-08
an O 0 1.495701340559208e-08
expansion O 0 2.8025107212670264e-07
of O 0 1.1600089777630274e-08
a O 0 1.0060375643661246e-06
GAA O 0 0.003350073006004095
trinucleotide O 1 0.7007279396057129
repeat O 0 5.889269232284278e-05
in O 0 1.5140719256123703e-07
intron O 0 0.0003658111672848463
1 O 0 1.2029448726025294e-07
of O 0 1.7877452407333294e-08
the O 0 5.103854618937476e-07
FRDA B-Disease 0 0.05027252435684204
gene O 0 4.357741272542626e-05
. O 0 6.537656190630514e-06

Occasionally O 0 3.8612801290582865e-05
, O 0 6.796709044465388e-07
a O 0 4.1277957052443526e-07
fully O 0 2.0336028683232144e-06
expanded O 0 2.8896520234411582e-06
allele O 0 6.753240086254664e-06
has O 0 6.781831274338401e-08
been O 0 1.0219991075643975e-08
found O 0 2.1747263545535134e-08
to O 0 2.37929853597052e-08
arise O 0 1.5722506532256375e-06
from O 0 1.796667170594901e-08
a O 0 8.393185169097706e-08
premutation O 0 0.00018986019131261855
of O 0 1.5598317304466036e-08
100 O 0 7.922928801917806e-08
or O 0 1.2625282863609755e-07
less O 0 9.33445562623092e-07
triplet O 0 0.003701681038364768
repeats O 0 0.0005196213023737073
. O 0 7.651512532902416e-06

We O 0 8.884179578672047e-07
have O 0 1.0900646429945482e-07
examined O 0 1.142520090979815e-06
the O 0 3.3487125961073616e-08
sperm O 0 9.87829253062955e-07
DNA O 0 2.511924321879633e-07
of O 0 4.755342075668523e-08
a O 0 7.856564479880035e-06
premutation O 0 0.2215145081281662
carrier O 0 0.0030579259619116783
. O 0 2.1710977307520807e-05

This O 0 2.070751861538156e-06
mans O 0 0.000131826353026554
leucocyte O 0 0.0026183058507740498
DNA O 0 5.574196165980538e-06
showed O 0 6.051591299183201e-07
one O 0 1.691857498542504e-08
normal O 0 1.572864078980274e-07
allele O 0 5.628945132230001e-07
and O 0 3.730637132548509e-09
one O 0 3.213980415139872e-09
allele O 0 5.04591781691488e-08
of O 0 4.724240998399409e-09
approximately O 0 1.0422679963539849e-07
100 O 0 6.381375214914442e-07
repeats O 0 0.00010188881424255669
. O 0 5.006057563150534e-06

His O 0 8.10551591712283e-06
sperm O 0 2.6917241484625265e-05
showed O 0 1.3420144568954129e-06
an O 0 3.9213567504248203e-08
expanded O 0 6.523703177663265e-07
allele O 0 6.169665311972494e-07
in O 0 7.68983277055213e-09
a O 0 2.5488882116064815e-08
tight O 0 7.407834914374689e-07
range O 0 1.1339572125734776e-07
centering O 0 1.5598085667534178e-07
on O 0 4.7299391070509955e-09
a O 0 2.1838335584334345e-08
size O 0 1.2353959277788817e-07
of O 0 2.4053026237425e-08
approximately O 0 1.9350923139427323e-06
320 O 0 0.00037707420415244997
trinucleotide O 0 0.46466928720474243
repeats O 0 0.00035813948488794267
. O 0 1.2527725630206987e-05

His O 0 0.00012687222624663264
affected O 0 0.0006609439151361585
son O 0 0.0007619056850671768
has O 0 2.6559662273939466e-06
repeat O 0 7.182443368947133e-05
sizes O 0 2.1336861664167373e-06
of O 0 1.022059947786147e-07
1040 O 0 0.000814343336969614
and O 0 1.3290916740515968e-06
540 O 0 0.0002512210630811751
. O 0 9.325164683104958e-06

These O 0 1.2032355698465835e-06
data O 0 1.0571835673545138e-06
suggest O 0 1.9766559944400797e-06
that O 0 4.182008339626009e-08
expansion O 0 3.1985825899027986e-06
occurs O 0 3.079535133565514e-07
in O 0 4.4846610869342385e-09
two O 0 2.6054627344507253e-09
stages O 0 6.778280408070714e-07
, O 0 9.617472152001483e-09
the O 0 1.42763223465181e-09
first O 0 3.955571870051244e-09
during O 0 8.18667800217554e-08
meiosis O 0 1.5167324818321504e-06
followed O 0 2.909933449757318e-08
by O 0 3.855459951296325e-09
a O 0 4.123010910461744e-08
second O 0 3.5357047067918757e-07
mitotic O 0 0.000467602105345577
expansion O 0 0.00016756067634560168
. O 0 1.754397089825943e-05

We O 0 9.53397830016911e-07
also O 0 1.5830201505195873e-07
show O 0 7.570023541347837e-08
that O 0 3.3283023004315737e-09
in O 0 2.163146106681779e-09
all O 0 1.8720898165014432e-09
informative O 0 2.0328873233665945e-06
carrier O 0 0.00010609367018332705
father O 0 3.4070226320181973e-06
to O 0 2.5817988102971867e-07
affected O 0 2.9677297789021395e-05
child O 0 2.9059317967039533e-05
transmissions O 0 5.00041733175749e-06
, O 0 1.3558153710846454e-08
with O 0 5.186188811734382e-09
the O 0 3.3845801716836377e-09
notable O 0 4.464811453885886e-08
exception O 0 3.849818597245758e-08
of O 0 4.332545433527457e-09
the O 0 1.442168695575674e-07
premutation O 0 0.015080204233527184
carrier O 0 4.6220695367082953e-05
, O 0 3.7608668179700544e-08
the O 0 3.610249521557307e-08
expansion O 0 4.814950443687849e-06
size O 0 1.010328469419619e-05
decreases O 0 5.655615677824244e-05
. O 0 5.087589443064644e-07
. O 0 4.79780692330678e-06

The O 0 1.4191499758453574e-05
R496H O 0 0.0011400122893974185
mutation O 0 3.358372487127781e-05
of O 0 6.626157755817985e-07
arylsulfatase O 0 0.07744807749986649
A O 0 2.5811148589127697e-05
does O 0 1.9938430341426283e-05
not O 0 7.123962404875783e-06
cause O 0 0.07158990949392319
metachromatic B-Disease 1 0.9942553639411926
leukodystrophy I-Disease 1 0.9954806566238403
. O 0 0.00047249827184714377

Deficiency B-Disease 1 0.9853640198707581
of I-Disease 0 5.79523430133122e-06
arylsulfatase I-Disease 0 0.040002819150686264
A I-Disease 0 7.478131010429934e-05
( O 0 0.00021291252051014453
ARSA O 1 0.9374811053276062
) O 0 7.975774678925518e-06
enzyme O 0 0.00012037487613270059
activity O 0 4.704049206338823e-05
causes O 0 0.2691345512866974
metachromatic B-Disease 1 0.9969820380210876
leukodystrophy I-Disease 1 0.998581051826477
( O 0 0.006975844502449036
MLD B-Disease 1 0.9947841763496399
) O 0 3.021826341864653e-05
. O 0 1.4770387679163832e-05

A O 0 1.4060929061088245e-06
number O 0 1.2311407715515088e-07
of O 0 6.592121621906699e-07
ARSA O 1 0.9895414710044861
gene O 0 0.00026068754959851503
mutations O 0 8.849460573401302e-05
responsible O 0 3.571196202756255e-06
for O 0 5.457037786982255e-06
MLD B-Disease 1 0.9977772831916809
have O 0 2.4572037204961816e-07
been O 0 2.9936592227386427e-07
identified O 0 7.141695732570952e-06
. O 0 1.5175287444435526e-05

Recently O 0 4.0187249396694824e-05
, O 0 8.611474413555698e-07
the O 0 3.517134246067144e-07
R496H O 0 0.0006214239401742816
mutation O 0 1.1731985068763606e-05
of O 0 3.3503548024782503e-07
ARSA O 1 0.8601697683334351
was O 0 2.759035453436809e-07
proposed O 0 4.1768390701690805e-07
to O 0 1.1179765557756127e-08
be O 0 2.6326074653582054e-09
a O 0 6.211913472498054e-08
cause O 0 9.933502042258624e-06
of O 0 9.350652590001118e-07
MLD B-Disease 1 0.9977479577064514
( O 0 2.915552795457188e-05
Draghia O 0 0.018370481207966805
et O 0 0.00026414869353175163
al O 0 1.773619806044735e-05
. O 0 1.1603811600480185e-07
, O 0 2.104465153252022e-07
1997 O 0 8.092956704786047e-06
) O 0 1.6154896229636506e-06
. O 0 3.0950620839576004e-06

We O 0 1.5872512904024916e-06
have O 0 1.0427034879967323e-07
investigated O 0 1.097617769119097e-06
the O 0 1.2866094323271682e-07
R496H O 0 0.0025712591595947742
mutation O 0 7.77153854869539e-06
and O 0 2.1782591730357126e-08
found O 0 1.28208190730561e-08
this O 0 4.652808360816607e-09
mutation O 0 3.9632845982850995e-07
at O 0 1.6501145339020695e-08
a O 0 2.099795715082564e-08
relatively O 0 7.059067286263598e-08
high O 0 9.791164501393723e-08
frequency O 0 1.3647015073559032e-08
in O 0 2.6212838566408436e-09
an O 0 5.051211449114135e-09
African O 0 8.781449167827304e-08
American O 0 5.3058077043033336e-08
population O 0 3.3453929404458904e-08
( O 0 8.058817257960982e-08
f O 0 2.0086285985598806e-06
= O 0 1.4832291981292656e-06
0 O 0 3.2485818479699446e-08
. O 0 4.679490572812028e-09
09 O 0 1.2104819688829593e-06
, O 0 2.0032034697692325e-08
n O 0 1.222560399583017e-06
= O 0 9.519273589830846e-06
61 O 0 1.3717444744543172e-06
subjects O 0 9.689446187621797e-07
) O 0 7.711875014138059e-07
. O 0 1.5559099892925587e-06

The O 0 1.7400290744262747e-05
ARSA O 1 0.5534833669662476
enzyme O 0 2.6142806746065617e-05
activity O 0 9.4153313057177e-07
in O 0 6.163995180941129e-08
subjects O 0 2.8618435976568435e-07
with O 0 4.741385595252723e-08
and O 0 2.2023222356892802e-08
without O 0 3.40079822080952e-08
the O 0 1.4917745261300297e-07
R496H O 0 0.006923376582562923
mutation O 0 1.0541790288698394e-05
was O 0 8.136242257705817e-08
determined O 0 1.7391863593729795e-07
and O 0 3.600505138479093e-08
found O 0 3.477065746437802e-08
to O 0 2.054438930088054e-08
be O 0 4.647240814392717e-08
normal O 0 5.995764240651624e-06
. O 0 3.825174189842073e-06

It O 0 2.0179156763333594e-06
is O 0 3.6029618399879837e-07
therefore O 0 1.2648469294163078e-07
concluded O 0 6.985314371377171e-07
that O 0 6.469254465457652e-09
the O 0 3.778209034521751e-08
R496H O 0 0.00030738243367522955
mutation O 0 5.32397052666056e-06
of O 0 4.0426331793241843e-07
ARSA O 1 0.9851329326629639
does O 0 3.495906071293575e-07
not O 0 7.0112808892019984e-09
negatively O 0 7.823621928082503e-08
influence O 0 2.2665956223022476e-08
the O 0 4.912292350667258e-09
activity O 0 6.11341448575331e-08
of O 0 8.475906554394896e-08
ARSA O 1 0.9209821820259094
and O 0 1.217080694004835e-07
is O 0 3.9402799245635833e-08
not O 0 2.2541531308206686e-08
a O 0 1.504012402619992e-06
cause O 0 0.0004127174324821681
of O 0 5.963233707007021e-05
MLD B-Disease 1 0.9933673739433289

Down O 0 6.82146564940922e-05
- O 0 9.484396287007257e-05
regulation O 0 5.107991910335841e-06
of O 0 8.005158065316209e-07
transmembrane O 0 0.00961905438452959
carbonic O 1 0.5800503492355347
anhydrases O 1 0.7987114191055298
in O 0 0.002485747914761305
renal B-Disease 1 0.9991397857666016
cell I-Disease 1 0.9834532141685486
carcinoma I-Disease 1 0.9994812607765198
cell O 0 0.0004514094034675509
lines O 0 4.044093202537624e-06
by O 0 4.3285584183649917e-07
wild O 0 4.269475175533444e-05
- O 0 0.018890494480729103
type O 0 0.009715475142002106
von B-Disease 1 0.8429339528083801
Hippel I-Disease 1 0.9889886975288391
- I-Disease 1 0.7975614666938782
Lindau I-Disease 1 0.9778462052345276
transgenes O 0 0.0754447728395462
. O 0 9.334492642665282e-05

To O 0 4.705844276031712e-06
discover O 0 3.396656029508449e-05
genes O 0 1.9598194285208592e-06
involved O 0 2.2013916805008193e-06
in O 0 7.99286863184534e-06
von B-Disease 1 0.7299879193305969
Hippel I-Disease 1 0.9916770458221436
- I-Disease 1 0.7506544589996338
Lindau I-Disease 1 0.9880048632621765
( O 0 0.00033605899079702795
VHL B-Disease 1 0.9425498843193054
) O 0 8.4638240878121e-06
- O 0 0.001321581657975912
mediated O 0 0.0009462707093916833
carcinogenesis O 0 0.32418888807296753
, O 0 6.015226290401188e-07
we O 0 4.890914055977191e-07
used O 0 3.934056076104753e-05
renal B-Disease 1 0.999337375164032
cell I-Disease 1 0.9890512824058533
carcinoma I-Disease 1 0.9994773268699646
cell O 0 0.0019978685304522514
lines O 0 3.028571154573001e-05
stably O 0 0.0007612467161379755
transfected O 0 0.0022216083016246557
with O 0 1.6504470750078326e-06
wild O 0 0.00018082470342051238
- O 0 0.133559450507164
type O 0 0.016465872526168823
VHL O 1 0.9864696264266968
- O 0 0.01354687288403511
expressing O 0 0.000809216289781034
transgenes O 0 0.03993910551071167
. O 0 2.875778045563493e-05

Large O 0 1.3974362445878796e-05
- O 0 4.5386004785541445e-05
scale O 0 6.1898367675894406e-06
RNA O 0 1.7893677295433008e-06
differential O 0 2.0193904219922842e-06
display O 0 7.489082918255008e-07
technology O 0 2.4683627088961657e-06
applied O 0 7.904257159907502e-08
to O 0 8.103235416001553e-09
these O 0 7.593969009178636e-09
cell O 0 3.719956794157042e-06
lines O 0 4.94613175305858e-07
identified O 0 7.147469460733191e-08
several O 0 1.8562257508847324e-08
differentially O 0 1.1325687410135288e-05
expressed O 0 1.7457702483625326e-07
genes O 0 7.249647637763701e-08
, O 0 1.0666791006030962e-08
including O 0 1.175239550121887e-08
an O 0 9.089175989629439e-08
alpha O 0 3.949061283492483e-05
carbonic O 0 0.2156408131122589
anhydrase O 0 0.056877151131629944
gene O 0 2.005559508688748e-05
, O 0 2.3019790660328e-06
termed O 0 0.0018854207592085004
CA12 O 0 0.3242323100566864
. O 0 3.191508585587144e-05

The O 0 9.17767806640768e-07
deduced O 0 2.407961801509373e-06
protein O 0 2.779757437565422e-07
sequence O 0 1.159162223984822e-07
was O 0 4.919683860293844e-08
classified O 0 3.934509038572287e-07
as O 0 3.0336979595091407e-09
a O 0 1.673911675936779e-08
one O 0 2.1331189259399252e-08
- O 0 4.5065822632750496e-05
pass O 0 1.2978451877643238e-06
transmembrane O 0 0.00040691817412152886
CA O 0 1.3563965694629587e-05
possessing O 0 2.8225630899214593e-07
an O 0 1.2825124073856387e-08
apparently O 0 2.044557447788975e-07
intact O 0 8.887213880370837e-07
catalytic O 0 3.791723770518729e-07
domain O 0 3.720534280660104e-08
in O 0 1.1368651797738494e-08
the O 0 5.954782267281189e-08
extracellular O 0 3.403094888199121e-05
CA O 0 0.00013132725143805146
module O 0 8.074750076048076e-05
. O 0 5.4043257478042506e-06

Reintroduced O 0 0.0005365394172258675
wild O 0 0.0002860620734281838
- O 0 0.0337689183652401
type O 0 0.006863781251013279
VHL B-Disease 1 0.8786881566047668
strongly O 0 4.951445134793175e-06
inhibited O 0 5.5890795920277014e-06
the O 0 1.983845976383236e-08
overexpression O 0 2.1139182990737027e-06
of O 0 5.7747633341875826e-09
the O 0 8.101275739136327e-08
CA12 O 0 0.005116674583405256
gene O 0 1.947743612618069e-06
in O 0 1.281742640912853e-07
the O 0 4.326801899878774e-06
parental O 1 0.6158450841903687
renal B-Disease 1 0.9994854927062988
cell I-Disease 1 0.9980092644691467
carcinoma I-Disease 1 0.9995043277740479
cell O 0 0.15634788572788239
lines O 0 0.0002968396001961082
. O 0 4.8214427806669846e-05

Similar O 0 7.72079420130467e-06
results O 0 1.034426873047778e-06
were O 0 2.3686668626510254e-08
obtained O 0 1.816279819877309e-07
with O 0 1.50082451000344e-06
CA9 O 1 0.8023996949195862
, O 0 1.0992933141551475e-07
encoding O 0 2.2866142046495952e-07
another O 0 6.27566237199062e-07
transmembrane O 0 0.0009176968014799058
CA O 0 1.4593592823075596e-05
with O 0 4.6115069096686057e-08
an O 0 7.619057384999905e-08
intact O 0 2.113480331900064e-05
catalytic O 0 2.2924687073100358e-05
domain O 0 1.0730521353252698e-05
. O 0 6.4165101321123075e-06

Although O 0 1.7320982124147122e-06
both O 0 1.2215319600272778e-07
domains O 0 6.651355874964793e-07
of O 0 3.3601008198047566e-08
the O 0 7.879718850745121e-07
VHL B-Disease 0 0.324533611536026
protein O 0 4.796589792022132e-07
contribute O 0 1.4817683791079617e-07
to O 0 5.475691011724848e-09
regulation O 0 2.3876094701336115e-07
of O 0 3.434145767755581e-08
CA12 O 0 0.008509532548487186
expression O 0 1.9336262369051838e-07
, O 0 2.17821352066494e-08
the O 0 2.5835319661382528e-08
elongin O 0 9.632830187911168e-05
binding O 0 2.8072400937162456e-07
domain O 0 4.661284549456468e-07
alone O 0 1.6295518889819505e-06
could O 0 2.2883025962983083e-07
effectively O 0 6.570990535692545e-06
regulate O 0 0.00039518243283964694
CA9 O 1 0.9057595729827881
expression O 0 1.3923120604886208e-05
. O 0 8.369065653823782e-06

We O 0 7.023790658422513e-06
mapped O 0 9.185853559756652e-05
CA12 O 0 0.0339103601872921
and O 0 1.2064910151821095e-05
CA9 O 1 0.8484072685241699
loci O 0 2.6082292606588453e-05
to O 0 3.4579562679937226e-07
chromosome O 0 7.020478369668126e-05
bands O 0 1.4002884199726395e-05
15q22 O 0 0.001021988457068801
and O 0 4.480253210203955e-06
17q21 O 0 0.00700550340116024
. O 0 2.5505825760774314e-05

2 O 0 4.234179141349159e-05
respectively O 0 3.009491592820268e-05
, O 0 3.66472977475496e-06
regions O 0 9.724747542350087e-06
prone O 0 0.0009885374456644058
to O 0 2.3464316711852007e-07
amplification O 0 9.56221338128671e-05
in O 0 4.4773730678571155e-07
some O 0 2.226444394182181e-06
human O 0 0.000825595750939101
cancers B-Disease 1 0.9833958148956299
. O 0 9.501306340098381e-05

Additional O 0 5.569143013417488e-06
experiments O 0 2.186423444072716e-06
are O 0 3.9400546825163474e-08
needed O 0 1.812848182680682e-07
to O 0 1.4561292616122046e-08
define O 0 1.7013528008646972e-07
the O 0 1.0457942956065835e-08
role O 0 2.3035549645555875e-07
of O 0 3.896265639014018e-07
CA O 0 0.019878655672073364
IX O 1 0.6527873277664185
and O 0 4.3680379349098075e-06
CA O 0 0.003863345133140683
XII O 0 0.3705528974533081
enzymes O 0 3.4201707421743777e-07
in O 0 3.8685943337668505e-09
the O 0 2.3555370987082824e-09
regulation O 0 7.935587831298108e-08
of O 0 4.607539239032121e-09
pH O 0 9.820611921895761e-06
in O 0 5.839580818900458e-09
the O 0 1.272997973700285e-08
extracellular O 0 7.894922418927308e-06
microenvironment O 0 0.000199271846213378
and O 0 1.1838608315883903e-08
its O 0 3.0954996788068456e-08
potential O 0 4.07851803174708e-06
impact O 0 1.8522121536079794e-05
on O 0 6.074828888813499e-06
cancer B-Disease 1 0.995751142501831
cell O 0 0.0078078326769173145
growth O 0 0.0012071036035194993
. O 0 2.672051778063178e-05

A O 0 1.6695324802640243e-06
gene O 0 1.6753590443840949e-06
encoding O 0 4.2368205299680994e-07
a O 0 2.948377471057029e-07
transmembrane O 0 0.0001563500118209049
protein O 0 3.3955241178773576e-06
is O 0 9.855521057033911e-07
mutated O 0 0.002618912374600768
in O 0 4.6865781769156456e-05
patients O 1 0.9798989295959473
with O 1 0.8369824290275574
diabetes B-Disease 1 0.9998148083686829
mellitus I-Disease 1 0.9996652603149414
and O 1 0.750906229019165
optic B-Disease 1 0.9993215799331665
atrophy I-Disease 1 0.9989022016525269
( O 1 0.9794963002204895
Wolfram B-Disease 1 0.9991674423217773
syndrome I-Disease 1 0.9996843338012695
) O 0 0.0005783130181953311
. O 0 7.349287625402212e-05

Wolfram B-Disease 1 0.9833914041519165
syndrome I-Disease 1 0.9977790713310242
( O 0 0.13679556548595428
WFS B-Disease 1 0.9906822443008423
; O 0 0.011141644790768623
OMIM O 1 0.9936793446540833
222300 O 1 0.5933020114898682
) O 0 2.6545038053882308e-05
is O 0 7.70165934227407e-06
an O 0 0.0007048558909446001
autosomal B-Disease 1 0.998917818069458
recessive I-Disease 1 0.9994350075721741
neurodegenerative I-Disease 1 0.9998241066932678
disorder I-Disease 1 0.9996509552001953
defined O 0 0.0008824158576317132
by O 0 7.356685091508552e-05
young O 0 0.10295923799276352
- O 1 0.9895786643028259
onset O 1 0.998414158821106
non O 0 0.24205359816551208
- O 1 0.9963436722755432
immune O 1 0.9980511665344238
insulin B-Disease 1 0.9937524199485779
- I-Disease 1 0.9965586066246033
dependent I-Disease 1 0.9889091849327087
diabetes I-Disease 1 0.999735414981842
mellitus I-Disease 1 0.999202311038971
and O 0 0.0031459254678338766
progressive O 1 0.993407130241394
optic B-Disease 1 0.9981305003166199
atrophy I-Disease 1 0.9956490397453308
. O 0 0.0004658731631934643

Linkage O 0 0.0002104325103573501
to O 0 2.263309397676494e-06
markers O 0 5.298965334077366e-05
on O 0 2.900115305237705e-06
chromosome O 0 0.0036361233796924353
4p O 1 0.9556848406791687
was O 0 1.001800001176889e-06
confirmed O 0 5.358346015782445e-07
in O 0 8.885690760962461e-08
five O 0 4.05010013082574e-07
families O 0 9.017579941428266e-06
. O 0 1.8344555428484455e-05

On O 0 2.921245823017671e-07
the O 0 5.706672112637534e-08
basis O 0 4.2776559183721474e-08
of O 0 3.9793809492039145e-07
meiotic O 1 0.6970704197883606
recombinants O 1 0.9835065007209778
and O 0 0.0013434700667858124
disease O 1 0.9992293119430542
- O 0 0.21054121851921082
associated O 0 6.66067426209338e-05
haplotypes O 0 0.0006282305694185197
, O 0 3.9574308630108135e-07
the O 0 1.0999997357430402e-06
WFS B-Disease 1 0.96859210729599
gene O 0 3.960121830459684e-06
was O 0 9.64490212140845e-08
localized O 0 4.654124950320693e-06
to O 0 2.617977479246747e-08
a O 0 7.570586149086012e-07
BAC O 0 0.013637924566864967
/ O 0 0.0034034322015941143
P1 O 0 0.0036035499069839716
contig O 0 4.492302468861453e-05
of O 0 6.908758454216013e-09
less O 0 8.883741742238271e-08
than O 0 1.758278216357212e-07
250 O 0 8.955327757576015e-06
kb O 0 0.0011597455013543367
. O 0 1.1083268873335328e-05

Mutations O 0 5.157203122507781e-05
in O 0 2.88931062186748e-07
a O 0 3.796652094933961e-07
novel O 0 8.359652383660432e-06
gene O 0 7.090155122568831e-06
( O 0 1.5032626379252179e-06
WFS1 O 0 0.0008297251770272851
) O 0 2.0761241614764003e-08
encoding O 0 3.3777201480234e-08
a O 0 3.9550528185827716e-08
putative O 0 1.0079793355544098e-05
transmembrane O 0 1.4895632375555579e-05
protein O 0 6.610000724549536e-08
were O 0 1.4284057270330663e-09
found O 0 7.903244281237676e-09
in O 0 5.503217437308194e-09
all O 0 6.6421623756696135e-09
affected O 0 1.8312266547582112e-06
individuals O 0 6.233134541844265e-08
in O 0 1.1717103376440718e-07
six O 0 1.2208407497382723e-05
WFS B-Disease 1 0.9963908791542053
families O 0 4.7994267333706375e-06
, O 0 1.3821193078911165e-07
and O 0 4.022595945230023e-08
these O 0 2.45503173346151e-08
mutations O 0 2.7103553748020204e-06
were O 0 1.5214766335702734e-08
associated O 0 3.589723974073422e-06
with O 0 8.990421520138625e-06
the O 0 0.0029350381810218096
disease O 1 0.9989396929740906
phenotype O 1 0.6968322992324829
. O 0 0.0001786291104508564

WFS1 O 0 0.35871660709381104
appears O 0 3.3692147553665563e-05
to O 0 3.071820913191914e-07
function O 0 2.652483317433507e-07
in O 0 1.6227053833972604e-07
survival O 0 0.00013055774616077542
of O 0 3.2029123531174264e-07
islet O 0 0.006243559997528791
beta O 0 0.0025029152166098356
- O 0 0.013586475513875484
cells O 0 4.58170470665209e-05
and O 0 5.53460949959117e-07
neurons O 0 5.6935485190479085e-05
. O 0 8.336941732522973e-07
. O 0 2.922487283285591e-06

Stable O 0 0.00015332757902797312
interaction O 0 1.8672926671570167e-06
between O 0 3.4562978612484585e-07
the O 0 4.9466979845647074e-08
products O 0 2.5508975909360743e-07
of O 0 1.7164923704626744e-08
the O 0 3.3193464332725853e-07
BRCA1 O 0 0.036153726279735565
and O 0 1.1497546438477002e-05
BRCA2 O 1 0.7586085200309753
tumor B-Disease 1 0.8443990349769592
suppressor O 0 0.0019399324664846063
genes O 0 9.725654308567755e-07
in O 0 3.044778225103073e-07
mitotic O 0 0.0008259285241365433
and O 0 3.985244347859407e-06
meiotic O 0 0.3020089864730835
cells O 0 0.0007045107195153832
. O 0 2.0867793864454143e-05

BRCA1 O 0 0.07477796077728271
and O 0 1.2016567779937759e-05
BRCA2 O 0 0.007889363914728165
account O 0 1.4983503433541046e-06
for O 0 1.3411248289685318e-07
most O 0 1.0211577716745524e-07
cases O 0 2.150843556592008e-06
of O 0 3.372011008195841e-07
familial O 1 0.6386019587516785
, O 0 4.543095928966068e-05
early O 0 0.0060006254352629185
onset O 1 0.9995631575584412
breast B-Disease 1 0.9993463158607483
and I-Disease 0 0.005147062707692385
/ I-Disease 1 0.998507559299469
or I-Disease 1 0.8575514554977417
ovarian I-Disease 1 0.9998894929885864
cancer I-Disease 1 0.999581515789032
and O 0 4.97277483191283e-07
encode O 0 6.105071861384204e-07
products O 0 5.516529881788301e-07
that O 0 4.148630328160152e-09
each O 0 7.764453080483236e-09
interact O 0 6.750560714863241e-07
with O 0 1.4926995390851516e-06
hRAD51 O 0 0.025168566033244133
. O 0 2.3872413294157013e-05

Results O 0 1.7515149011160247e-05
presented O 0 3.921360075764824e-06
here O 0 4.2878832573478576e-07
show O 0 5.109050675855542e-07
that O 0 2.49488778081286e-07
BRCA1 O 0 0.00286131352186203
and O 0 1.2278815120225772e-06
BRCA2 O 0 0.022604385390877724
coexist O 0 8.729395631235093e-06
in O 0 2.709631274910862e-08
a O 0 1.9912464210847247e-07
biochemical O 0 1.486393011873588e-05
complex O 0 1.1707692237905576e-06
and O 0 1.004676377647229e-07
colocalize O 0 0.0012507560895755887
in O 0 4.351828692961135e-07
subnuclear O 0 0.01038116030395031
foci O 0 0.00024164644128177315
in O 0 2.5347324594804377e-07
somatic O 0 5.8069112128578126e-05
cells O 0 1.323969286204374e-06
and O 0 3.226621192453649e-09
on O 0 1.0908686176591686e-09
the O 0 3.701068562733667e-09
axial O 0 6.929863616278453e-07
elements O 0 2.536153509424821e-08
of O 0 1.0169613062771532e-07
developing O 0 0.0003498297301121056
synaptonemal O 0 0.2634567320346832
complexes O 0 0.002433727728202939
. O 0 2.337820660613943e-05

Like O 0 0.00014696031576022506
BRCA1 O 0 0.004485228564590216
and O 0 7.413428647851106e-06
RAD51 O 0 0.4579237103462219
, O 0 6.451183253375348e-06
BRCA2 O 0 0.0032549749594181776
relocates O 0 0.00032834848389029503
to O 0 1.1217272231078823e-06
PCNA O 0 0.17120055854320526
+ O 0 0.00010947674309136346
replication O 0 3.1730007776786806e-06
sites O 0 1.211797098221723e-07
following O 0 3.7971264532643545e-07
exposure O 0 2.053332718787715e-05
of O 0 3.465102693667177e-08
S O 0 0.0018250950379297137
phase O 0 3.5770954127656296e-05
cells O 0 1.2085834896424785e-05
to O 0 5.709273409593152e-07
hydroxyurea O 0 0.07100700587034225
or O 0 2.0640816728700884e-05
UV O 0 0.18910066783428192
irradiation O 0 0.00048468337627127767
. O 0 7.767514944134746e-06

Thus O 0 2.3322356355492957e-05
, O 0 9.683990356279537e-06
BRCA1 O 0 0.004300635773688555
and O 0 1.7505494724900927e-06
BRCA2 O 0 0.0010837502777576447
participate O 0 2.8520676664811617e-07
, O 0 6.180665934607532e-08
together O 0 3.121366987102192e-08
, O 0 1.777456759555207e-08
in O 0 7.745756036570128e-09
a O 0 8.940788376321507e-08
pathway O 0 7.509976967412513e-06
( O 0 2.2510096187033923e-06
s O 0 0.000382949918275699
) O 0 8.502235004925751e-08
associated O 0 1.82679240623429e-08
with O 0 1.2471829125004774e-09
the O 0 1.4393287672831434e-09
activation O 0 6.579058720035391e-08
of O 0 1.9265418149672087e-09
double O 0 9.370095312988269e-07
- O 0 0.00011854049080284312
strand O 0 1.6843843695824035e-05
break O 0 2.2011179680703208e-05
repair O 0 0.008268484845757484
and O 0 7.141458695514302e-07
/ O 0 0.00041409398545511067
or O 0 3.8029682514206797e-07
homologous O 0 2.2854917915537953e-05
recombination O 0 0.0002130865614162758
. O 0 1.1485863069538027e-05

Dysfunction O 1 0.871883749961853
of O 0 1.9902829535567435e-06
this O 0 1.3224802160038962e-06
pathway O 0 2.641476021381095e-05
may O 0 4.5161917228142556e-07
be O 0 3.2846299014011038e-09
a O 0 8.634132342422163e-08
general O 0 6.982696731938631e-07
phenomenon O 0 7.766662747599185e-06
in O 0 1.0457283927678418e-08
the O 0 9.131344569368594e-09
majority O 0 6.474947866763614e-08
of O 0 2.8932751305887905e-08
cases O 0 7.668241778446827e-06
of O 0 7.139966328395531e-06
hereditary B-Disease 1 0.9961035251617432
breast I-Disease 1 0.9992828965187073
and I-Disease 0 0.02457687072455883
/ I-Disease 1 0.9984965324401855
or I-Disease 1 0.9448632001876831
ovarian I-Disease 1 0.9998389482498169
cancer I-Disease 1 0.9995684027671814
. O 0 9.704755211714655e-05
. O 0 8.084966975729913e-05

A O 0 1.760185114108026e-05
novel O 0 3.648132042144425e-05
Arg362Ser O 0 0.0018450391944497824
mutation O 0 6.288978966040304e-06
in O 0 6.992746648393222e-08
the O 0 8.86343229922204e-08
sterol O 0 0.00010703606676543131
27 O 0 4.735331003757892e-06
- O 0 0.0004218950925860554
hydroxylase O 0 0.0004944198299199343
gene O 0 4.183582859695889e-06
( O 0 1.3829119325237116e-06
CYP27 O 0 0.004511677194386721
) O 0 1.233422892710223e-07
: O 0 5.869309305239767e-08
its O 0 7.994666262334249e-09
effects O 0 1.8302422688520892e-07
on O 0 2.2341968275441104e-09
pre O 0 1.1308744660709635e-06
- O 0 3.2111809105117572e-06
mRNA O 0 5.5093746453849235e-08
splicing O 0 1.6965003624136443e-07
and O 0 3.2703098895581206e-08
enzyme O 0 1.89068418876559e-06
activity O 0 1.1568181434995495e-06
. O 0 1.7865304471342824e-06

A O 0 7.806219400663394e-06
novel O 0 9.303330443799496e-06
C O 0 1.635473017813638e-05
to O 0 3.9411293784041845e-08
A O 0 9.86176686978979e-08
mutation O 0 3.9516228866887104e-07
in O 0 7.909382482296223e-09
the O 0 1.787936376729249e-08
sterol O 0 5.992962542222813e-05
27 O 0 2.8022402602800867e-06
- O 0 0.00017290754476562142
hydroxylase O 0 0.0003198716149199754
gene O 0 2.3269737994269235e-06
( O 0 7.841038609512907e-07
CYP27 O 0 0.0022589764557778835
) O 0 3.719292607229363e-08
was O 0 3.478099142029123e-09
identified O 0 3.3401501564611635e-09
by O 0 2.697496226389262e-09
sequencing O 0 1.2521775261120638e-07
amplified O 0 6.20255332250963e-06
CYP27 O 0 0.0015413344372063875
gene O 0 1.1772069683502195e-06
products O 0 3.097924548001174e-07
from O 0 4.7409425718569764e-08
a O 0 9.535978620078822e-07
patient O 0 0.0014580852584913373
with O 0 2.2778067432227544e-05
cerebrotendinous B-Disease 1 0.993477463722229
xanthomatosis I-Disease 1 0.9934796094894409
( O 0 0.0007957268971949816
CTX B-Disease 1 0.9908418655395508
) O 0 1.2366610462777317e-05
. O 0 7.1136560109152924e-06

The O 0 2.566950342952623e-06
mutation O 0 1.1063035344704986e-05
changed O 0 4.7453394813601335e-07
the O 0 7.021106540605615e-08
adrenodoxin O 0 9.006455366034061e-05
cofactor O 0 3.491951474643429e-06
binding O 0 2.001264078899112e-07
residue O 0 3.208107955288142e-06
362Arg O 0 2.0743544155266136e-05
to O 0 5.2940109185328765e-08
362Ser O 0 0.0001026700483635068
( O 0 1.0836379260581452e-06
CGT O 0 0.0008940105908550322
362Arg O 0 0.00020892370957881212
to O 0 8.351090059477428e-07
AGT O 1 0.9484797120094299
362Ser O 0 0.001054292661137879
) O 0 1.77790170141634e-07
, O 0 1.625923751191749e-08
and O 0 1.2883476507852265e-08
was O 0 5.15795832711774e-08
responsible O 0 7.916929689599783e-07
for O 0 1.6063444263636484e-06
deficiency O 1 0.9730701446533203
in O 0 1.790243153720894e-08
the O 0 3.296003114883206e-08
sterol O 0 0.0001728244824334979
27 O 0 3.409798864595359e-06
- O 0 0.00042947367182932794
hydroxylase O 0 6.295706407399848e-05
activity O 0 5.9397407881078834e-08
, O 0 9.1475573782418e-09
as O 0 2.906758833631784e-09
confirmed O 0 6.146289255326565e-09
by O 0 8.045433208536679e-10
expression O 0 4.24960555633902e-09
of O 0 2.657955855411842e-09
mutant O 0 1.8242701571580255e-06
cDNA O 0 2.9128043479431653e-06
into O 0 6.273232884268509e-07
COS O 0 0.21238747239112854
- O 0 0.001280249678529799
1 O 0 9.672693522588816e-06
cells O 0 6.40298385405913e-05
. O 0 3.9751284930389374e-06

Quantitative O 0 4.9785649025579914e-05
analysis O 0 3.5410537293500965e-06
showed O 0 1.0449009550939081e-06
that O 0 1.1432385704779335e-08
the O 0 4.718324841945787e-09
expression O 0 2.0931697264359173e-08
of O 0 1.3579349200654178e-08
CYP27 O 0 0.0010435126023367047
gene O 0 3.874884555443714e-07
mRNA O 0 6.725141332708517e-08
in O 0 1.579082642422236e-08
the O 0 1.4351195432027453e-07
patient O 0 0.00033559062285348773
represented O 0 1.2937301789861522e-06
52 O 0 3.617752008722164e-05
. O 0 9.96873768599471e-06

5 O 0 6.190899512148462e-06
% O 0 3.703281095113198e-07
of O 0 1.0423654828173312e-07
the O 0 4.615730517798511e-07
normal O 0 7.905892744020093e-06
level O 0 1.4643361282651313e-05
. O 0 1.2264348697499372e-05

As O 0 9.70172550296411e-07
the O 0 2.1278329143115116e-07
mutation O 0 1.7479121652286267e-06
occurred O 0 8.557354647109605e-08
at O 0 7.805851076625459e-09
the O 0 2.1191355337180084e-09
penultimate O 0 6.152250762170297e-07
nucleotide O 0 1.5408858189402963e-08
of O 0 3.213968424731206e-09
exon O 0 3.0860314836900216e-06
6 O 0 2.314084213139722e-07
( O 0 3.4570948770351606e-08
- O 0 5.432469833976938e-07
2 O 0 6.807579389089824e-09
position O 0 1.2954780581608816e-09
of O 0 1.1048479908737363e-09
exon O 0 3.518600806273753e-06
6 O 0 4.75449894565827e-07
- O 0 2.0911182218696922e-05
intron O 0 0.0002926844754256308
6 O 0 3.858114325794304e-07
splice O 0 3.912014108209405e-06
site O 0 4.760914507073721e-08
) O 0 5.5125672915323776e-09
of O 0 7.387045974915907e-10
the O 0 1.1815801670422843e-08
gene O 0 3.891449296133942e-07
, O 0 2.030140144881898e-08
we O 0 6.528555029916561e-09
hypothesized O 0 8.056172191572841e-07
that O 0 5.425612403797686e-09
the O 0 6.897135307326607e-08
mutation O 0 2.906264489865862e-05
may O 0 6.454885124185239e-07
partially O 0 1.619256408957881e-06
affect O 0 4.9152756531611885e-08
the O 0 1.3425901501662452e-09
normal O 0 1.0540286865534654e-08
splicing O 0 1.928455191091416e-07
efficiency O 0 2.3701950624399615e-07
in O 0 1.5084360427408683e-08
exon O 0 1.1781810826505534e-05
6 O 0 7.05909315001918e-07
and O 0 4.5097273471128574e-08
cause O 0 1.5533732948824763e-06
alternative O 0 1.1818308109923237e-07
splicing O 0 1.132844317908166e-06
elsewhere O 0 3.001211723585584e-07
, O 0 1.8261548717646292e-08
which O 0 9.322516092424848e-09
resulted O 0 6.205128215697187e-07
in O 0 9.39606721317432e-08
decreased O 0 2.821900307026226e-05
transcript O 0 8.156437615980394e-06
in O 0 2.518698352105275e-07
the O 0 1.2575932260006084e-06
patient O 0 0.00529124541208148
. O 0 3.6107208870816976e-05

Transfection O 0 0.0015034209936857224
of O 0 1.5217586906146607e-06
constructed O 0 0.00011642480967566371
minigenes O 0 0.032544706016778946
, O 0 5.419099124992499e-07
with O 0 6.914614658626306e-08
or O 0 5.440081451979495e-08
without O 0 2.454516767613768e-08
the O 0 8.649028160334638e-09
mutation O 0 1.8935844536827062e-07
, O 0 9.71993241449809e-09
into O 0 1.0186676746570811e-07
COS O 0 0.3529789447784424
- O 0 0.0002577413688413799
1 O 0 1.1580854106796323e-06
cells O 0 9.742391284817131e-07
confirmed O 0 2.4030923029272344e-08
that O 0 1.5389877150440157e-09
the O 0 1.1830572077542456e-08
mutant O 0 1.9934703232138418e-05
minigene O 0 0.000597247970290482
was O 0 2.530331144612319e-08
responsible O 0 1.476638544772868e-08
for O 0 2.111087082923291e-09
a O 0 1.27460637600052e-08
mRNA O 0 1.308287238543926e-07
species O 0 2.1469890754133303e-08
alternatively O 0 1.9452268418262975e-07
spliced O 0 6.740036155861162e-07
at O 0 3.206952214895864e-08
an O 0 1.5422207511051056e-08
activated O 0 1.6414120409535826e-06
cryptic O 0 1.8124503640137846e-06
5 O 0 4.8196262980582105e-08
splice O 0 9.87454427558987e-07
site O 0 4.491871763434574e-08
88 O 0 3.481838177776808e-07
bp O 0 6.889495693940262e-07
upstream O 0 4.1868847944215304e-08
from O 0 1.4846865958872968e-09
the O 0 1.1525539411749719e-09
3 O 0 1.36915980775143e-08
end O 0 3.9891226322197326e-08
of O 0 3.1222544549791564e-08
exon O 0 0.00013213040074333549
6 O 0 1.4333690160128754e-05
. O 0 4.566780262393877e-06

Our O 0 2.5275658117607236e-06
data O 0 7.894763029980822e-07
suggest O 0 6.632251938754052e-07
that O 0 1.3568968171284723e-08
the O 0 2.368291873722228e-08
C O 0 4.715241630037781e-06
to O 0 4.223456695484629e-09
A O 0 4.3858097598103996e-08
mutation O 0 1.7077283587241254e-07
at O 0 2.4210473625885243e-09
the O 0 5.812397785298629e-10
penultimate O 0 1.8786047917274118e-07
nucleotide O 0 3.4205336341130987e-09
of O 0 6.970953814189329e-10
exon O 0 1.395583012708812e-06
6 O 0 2.4464682724101294e-08
of O 0 1.919971959196687e-09
the O 0 5.4063804100223933e-08
CYP27 O 0 0.003926723264157772
gene O 0 1.2101403399356059e-06
not O 0 1.0049634902031812e-08
only O 0 2.354720862740578e-08
causes O 0 9.314975613960996e-05
the O 0 1.7164192058771732e-06
deficiency B-Disease 1 0.9715592861175537
in I-Disease 0 1.8829449999202552e-08
the I-Disease 0 3.6732352270973934e-08
sterol I-Disease 0 0.00015564287605229765
27 I-Disease 0 1.7922609458764782e-06
- I-Disease 0 0.0002671683032531291
hydroxylase I-Disease 0 0.00013072104775346816
activity I-Disease 0 9.337200168602067e-08
, O 0 1.2034148788586663e-08
but O 0 2.818757227629476e-09
also O 0 3.476878340791245e-09
partially O 0 1.1991788539944537e-07
leads O 0 3.308392138023919e-08
to O 0 1.486639145120705e-09
alternative O 0 3.059021480567026e-08
pre O 0 1.0868826620935579e-06
- O 0 1.0057498229798512e-06
mRNA O 0 2.148308198002269e-08
splicing O 0 2.6712118739169455e-08
of O 0 4.581381052304323e-09
the O 0 9.4920395099507e-08
gene O 0 7.6770511441282e-06
. O 0 5.533134299184894e-06

To O 0 1.6361983625756693e-06
our O 0 4.545973695257999e-07
knowledge O 0 2.589154064480681e-07
, O 0 6.133936381047533e-08
this O 0 9.95892079913574e-09
is O 0 5.576568984366759e-09
the O 0 3.6520868551548347e-09
first O 0 1.2363054580077915e-08
report O 0 5.632597321891808e-08
regarding O 0 4.098899708537829e-08
effects O 0 8.685465218150057e-07
on O 0 5.93633986412101e-09
pre O 0 3.8553334889002144e-06
- O 0 1.0517753707972588e-06
mRNA O 0 1.1633523477883045e-08
splicing O 0 1.6778336942024907e-08
of O 0 5.889713161622012e-10
a O 0 1.0179701526169538e-08
mutation O 0 1.273250944677784e-07
at O 0 5.407388314893069e-09
the O 0 4.611935278120427e-09
- O 0 1.9484589302010136e-06
2 O 0 2.273557875298593e-08
position O 0 3.21238702305493e-09
of O 0 2.0528672095565526e-09
a O 0 5.8798082847033584e-08
5 O 0 1.3747264802077552e-06
splice O 0 7.74889558670111e-05
site O 0 6.079941158532165e-06
. O 0 5.323188815964386e-06

ATM O 0 0.003970193676650524
germline O 0 0.022665970027446747
mutations O 0 0.000205797899980098
in O 0 1.4426090274355374e-05
classical O 0 0.06015762314200401
ataxia B-Disease 1 0.9991746544837952
- I-Disease 1 0.9989569187164307
telangiectasia I-Disease 1 0.9993939399719238
patients O 1 0.6858524680137634
in O 0 1.5600405731674982e-06
the O 0 1.5946083067319705e-06
Dutch O 0 0.0002497270761523396
population O 0 1.205561693495838e-05
. O 0 1.2715446246147621e-05

Germline O 0 0.023841485381126404
mutations O 0 3.8156485970830545e-05
in O 0 3.297890600606479e-07
the O 0 2.7336824359736056e-07
ATM O 0 0.00018747073772829026
gene O 0 3.3644603263383033e-06
are O 0 1.6977052652578095e-08
responsible O 0 1.9421142951614456e-06
for O 0 1.1997261935903225e-05
the O 0 0.03507380932569504
autosomal B-Disease 1 0.9994126558303833
recessive I-Disease 1 0.9996460676193237
disorder I-Disease 1 0.9998708963394165
ataxia B-Disease 1 0.9995759129524231
- I-Disease 1 0.9989343285560608
telangiectasia I-Disease 1 0.9989432692527771
( O 0 0.004047558642923832
A B-Disease 0 0.023595135658979416
- I-Disease 1 0.9824825525283813
T I-Disease 1 0.9956492781639099
) O 0 4.8862722906051204e-05
. O 0 1.5269939467543736e-05

In O 0 2.045725068455795e-06
our O 0 1.0180136769122328e-06
study O 0 2.1101759557495825e-06
, O 0 1.6350830378542014e-07
we O 0 6.493447557431864e-09
have O 0 1.5989881640976478e-09
determined O 0 1.1066876304255402e-08
the O 0 5.970314465031379e-09
ATM O 0 3.61247907676443e-06
mutation O 0 1.7957957254566281e-07
spectrum O 0 6.76481661798789e-08
in O 0 4.586093282910042e-09
19 O 0 1.0846206066617015e-07
classical O 0 1.3593520407084725e-06
A B-Disease 0 0.0010603463742882013
- I-Disease 1 0.9925788044929504
T I-Disease 1 0.9993972778320312
patients O 0 0.041402772068977356
, O 0 7.329285978130429e-08
including O 0 4.724567759240017e-08
some O 0 4.3766757329422035e-08
immigrant O 0 2.216516077169217e-05
populations O 0 1.9228041310270783e-06
, O 0 2.386634534445875e-08
as O 0 4.3049666054173485e-09
well O 0 5.306250105974186e-09
as O 0 2.1204495936899548e-09
12 O 0 1.1186314985422996e-08
of O 0 8.50140313701786e-09
Dutch O 0 2.4776268219284248e-06
ethnic O 0 6.220403179213463e-07
origin O 0 2.1998300780978752e-06
. O 0 1.2650882126763463e-05

Both O 0 4.909139192932344e-07
the O 0 1.441709542859826e-07
protein O 0 6.919772204128094e-07
truncation O 0 1.7738668248057365e-05
test O 0 5.620137244477519e-07
( O 0 1.955781243623278e-07
PTT O 0 1.1023079196093022e-06
) O 0 8.271587859098872e-09
and O 0 1.5990552215683351e-09
the O 0 3.9669121321139755e-09
restriction O 0 3.7559857446467504e-07
endonuclease O 0 0.00010780677985167131
fingerprinting O 0 4.50761363026686e-05
( O 0 9.897623840515735e-07
REF O 0 0.00622547185048461
) O 0 1.155087669957311e-08
method O 0 1.4954096849706389e-09
were O 0 3.8075761987776957e-10
used O 0 1.3962405676082312e-09
and O 0 3.581913654571167e-09
compared O 0 4.34331184351322e-08
for O 0 1.413585803966555e-09
their O 0 3.920255231548708e-09
detection O 0 1.9332439933350543e-06
efficiency O 0 3.7459125223904266e-07
, O 0 1.2581166330960514e-08
identifying O 0 2.4298736889249994e-07
76 O 0 2.3420548131980468e-06
% O 0 1.3686636712861855e-08
and O 0 4.196028413616659e-09
60 O 0 4.157892874445679e-08
% O 0 5.784950296572333e-09
of O 0 2.7338993291436964e-09
the O 0 6.376836836352595e-08
mutations O 0 5.813107691210462e-06
, O 0 4.0312755800187006e-07
respectively O 0 5.0663134061323944e-06
. O 0 4.6837931222398765e-06

Most O 0 0.00013669559848494828
patients O 0 0.015455801039934158
were O 0 7.505299493004713e-08
found O 0 2.01454952275526e-07
to O 0 8.12574256769949e-08
be O 0 1.2116780112592096e-07
compound O 0 7.2358590841759e-05
heterozygote O 0 0.009963175281882286
. O 0 2.1064455722807907e-05

Seventeen O 0 8.417195931542665e-05
mutations O 0 3.72619615518488e-05
were O 0 4.427835875731034e-08
distinct O 0 2.3196213305709534e-07
, O 0 1.9499847070392207e-08
of O 0 6.97979141150995e-09
which O 0 2.2226284812632002e-08
10 O 0 5.824367121931573e-08
were O 0 7.095443343985153e-09
not O 0 4.275314680057818e-08
reported O 0 3.922014457202749e-06
previously O 0 4.6093264245428145e-06
. O 0 1.0714038580772467e-05

Mutations O 0 0.00011043117410736158
are O 0 1.9497362302445254e-07
small O 0 1.0651256161509082e-06
deletions O 0 4.075679316883907e-05
or O 0 9.667884341979516e-07
point O 0 1.7929619389178697e-06
mutations O 0 4.119561708648689e-05
frequently O 0 3.8065604712755885e-06
affecting O 0 7.099082722561434e-05
splice O 0 0.00037415052065625787
sites O 0 7.62693207434495e-06
. O 0 1.155973041022662e-05

Moreover O 0 0.0003051836392842233
, O 0 5.285362021822948e-06
a O 0 3.0371850243682275e-06
16 O 0 2.1005240341764875e-05
. O 0 2.6527044610702433e-05

7 O 0 3.037033457076177e-05
- O 0 0.0002508476609364152
kb O 0 0.0002718766045290977
genomic O 0 1.437048013031017e-05
deletion O 0 6.303545433183899e-06
of O 0 8.799821316074485e-09
the O 0 1.0907776903934518e-08
3 O 0 4.319205970659823e-08
end O 0 3.410015025906432e-08
of O 0 5.155378346444195e-09
the O 0 4.621967875095834e-08
gene O 0 2.7970472729066387e-06
, O 0 4.212766313571592e-08
most O 0 1.7285763931340625e-08
likely O 0 8.066460566169553e-08
a O 0 1.3078576444058854e-08
result O 0 2.078778926772884e-08
of O 0 2.737176041378575e-09
recombination O 0 1.154052370111458e-06
between O 0 2.893374251300429e-08
two O 0 5.7154707633344515e-09
LINE O 0 1.0541974688749178e-06
elements O 0 1.2810973260002356e-07
, O 0 2.6609100700625277e-07
was O 0 6.42987970422837e-07
identified O 0 7.541901140939444e-06
. O 0 7.4344134191051126e-06

The O 0 1.3491259096554131e-06
most O 0 2.959567382276873e-07
frequently O 0 9.590307854523417e-07
found O 0 4.712067607215431e-07
mutation O 0 5.383497409638949e-06
, O 0 5.7002647935178175e-08
identified O 0 4.8694118959247135e-08
in O 0 6.852915568344997e-09
three O 0 1.8308771387864908e-08
unrelated O 0 1.071483529813122e-05
Turkish O 0 2.1203117285040207e-05
A B-Disease 0 0.002326296642422676
- I-Disease 1 0.9784382581710815
T I-Disease 1 0.9985812902450562
individuals O 0 1.303863427892793e-06
, O 0 1.9787599114806653e-07
was O 0 6.727732682065835e-08
previously O 0 7.482316277673817e-08
described O 0 1.3395194287113554e-07
to O 0 4.400487974010048e-09
be O 0 1.7841744748281485e-09
a O 0 5.490408483410647e-08
Turkish O 0 5.0081680456059985e-06
A B-Disease 0 0.0001353108382318169
- I-Disease 1 0.6075804233551025
T I-Disease 1 0.9959806203842163
founder O 0 0.0031322722788900137
mutation O 0 0.00030433866777457297
. O 0 1.6475330994580872e-05

The O 0 6.719589009662741e-07
presence O 0 4.331102161359013e-07
of O 0 4.9776758714870084e-08
a O 0 1.0025646588474046e-06
founder O 0 0.00039274804294109344
mutation O 0 2.053644129773602e-05
among O 0 1.5616214454894362e-07
relatively O 0 3.790711389228818e-07
small O 0 7.981764582609685e-08
ethnic O 0 1.0472717804077547e-07
population O 0 9.787299148911188e-08
groups O 0 1.5088820859432417e-08
in O 0 7.750562502906178e-08
Western O 0 3.663269353637588e-06
Europe O 0 2.4577595922892215e-06
could O 0 4.647178997174706e-08
indicate O 0 5.179143869327163e-08
a O 0 3.752612443008729e-08
high O 0 2.370188894929015e-06
carrier O 0 1.4579445632989518e-05
frequency O 0 9.056002880925007e-08
in O 0 3.7663514973473866e-08
such O 0 1.3723762037898268e-07
communities O 0 2.6431655442138435e-06
. O 0 8.19017986941617e-06

In O 0 3.4826851333491504e-05
patients O 0 0.0010489034466445446
of O 0 1.8071294505261903e-07
Dutch O 0 1.4663219189969823e-05
ethnic O 0 6.610289915442991e-07
origin O 0 4.855722863794654e-07
, O 0 2.736416035986622e-07
however O 0 2.1221221402356605e-07
, O 0 9.838845471676905e-08
no O 0 1.5182014578840608e-07
significant O 0 1.916773271659622e-06
founder O 0 0.0001905084791360423
effect O 0 8.865705240168609e-06
could O 0 3.090114262249699e-07
be O 0 5.64858453344641e-08
identified O 0 4.020267169835279e-06
. O 0 7.585873845528113e-06

The O 0 5.479692390508717e-06
observed O 0 1.3199389286455698e-05
genetic O 0 6.75065748509951e-05
heterogeneity O 0 7.215450750663877e-05
including O 0 1.1259957233278328e-07
the O 0 2.2974814939402677e-08
relative O 0 2.951241242499236e-07
high O 0 3.0444121534856095e-07
percentage O 0 1.3748783089795324e-07
of O 0 1.886028933029138e-08
splice O 0 0.00037594177410937846
- O 0 0.0013801566092297435
site O 0 2.7609830794972368e-06
mutations O 0 3.2559876217419514e-06
had O 0 2.0373125408923443e-08
no O 0 1.9946821083749455e-08
reflection O 0 3.421772589717875e-07
on O 0 4.5038564877586396e-08
the O 0 9.103816296374134e-07
phenotype O 0 0.004496422596275806
. O 0 1.6649801182211377e-05

All O 0 2.169785147998482e-05
patients O 0 0.025478167459368706
manifested O 0 0.0004597950028255582
classical O 0 1.1037300282623619e-05
A B-Disease 0 0.0002488103637006134
- I-Disease 0 0.36834412813186646
T I-Disease 1 0.9364538788795471
and O 0 2.1830115315424337e-07
increased O 0 1.8896819256042363e-06
cellular O 0 3.217195626348257e-05
radioresistant O 0 0.0006449131178669631
DNA O 0 4.996622919861693e-06
synthesis O 0 1.1355993592587765e-05
. O 0 7.119519978004973e-06

Determination O 0 1.1632186215138063e-05
of O 0 1.3291584366470488e-07
the O 0 1.9465834100174106e-07
genomic O 0 7.326998002099572e-06
structure O 0 4.468142549285403e-07
of O 0 2.61831214487529e-08
the O 0 2.1325256227555656e-07
COL4A4 O 0 0.011311288923025131
gene O 0 2.2654646727460204e-06
and O 0 9.605540896018283e-08
of O 0 6.77670982440759e-07
novel O 0 0.012984959408640862
mutations O 1 0.5617344975471497
causing O 1 0.9943576455116272
autosomal B-Disease 1 0.9977895021438599
recessive I-Disease 1 0.9983797073364258
Alport I-Disease 1 0.9989345669746399
syndrome I-Disease 1 0.9992207288742065
. O 0 0.059387627989053726

Autosomal B-Disease 1 0.991204559803009
recessive I-Disease 1 0.9970523118972778
Alport I-Disease 1 0.9985955357551575
syndrome I-Disease 1 0.9988805651664734
is O 0 2.9051947421976365e-05
a O 0 0.0001880227937363088
progressive O 1 0.9509786367416382
hematuric B-Disease 1 0.9979082345962524
glomerulonephritis I-Disease 1 0.9992027878761292
characterized O 1 0.8662152886390686
by O 0 0.0012302645482122898
glomerular B-Disease 1 0.9989983439445496
basement I-Disease 1 0.986722469329834
membrane I-Disease 0 0.3075152337551117
abnormalities I-Disease 1 0.8843342661857605
and O 0 1.0825409617609694e-06
associated O 0 3.075055701629026e-06
with O 0 1.9846848431370745e-07
mutations O 0 3.819236098934198e-06
in O 0 1.778090918946873e-08
either O 0 2.0104648612573328e-08
the O 0 6.397279150860413e-08
COL4A3 O 0 0.006043021101504564
or O 0 7.349051855953803e-08
the O 0 1.0420711760161794e-07
COL4A4 O 0 0.010498850606381893
gene O 0 3.645672279617429e-07
, O 0 5.095083466244432e-09
which O 0 1.077117506298464e-09
encode O 0 1.6114716672177565e-08
the O 0 2.605653115494988e-08
alpha3 O 0 0.0005724226939491928
and O 0 1.2115364143028273e-06
alpha4 O 0 0.15103314816951752
type O 0 0.011862832121551037
IV O 1 0.9769565463066101
collagen O 1 0.9188368320465088
chains O 0 0.00048585090553388
, O 0 1.8011195379585843e-06
respectively O 0 6.427239895856474e-06
. O 0 8.331097888003569e-06

To O 0 2.4300113636854803e-06
date O 0 2.2157560124469455e-06
, O 0 7.17046304998803e-07
mutation O 0 4.368837835500017e-06
screening O 0 1.0561708450040896e-06
in O 0 8.45644443359106e-09
the O 0 6.7027792205465175e-09
two O 0 9.804971057292278e-09
genes O 0 5.753151981480187e-07
has O 0 9.841097892149264e-08
been O 0 7.422105596788242e-08
hampered O 0 0.0001873910368885845
by O 0 3.230773515383589e-08
the O 0 1.9613169754961746e-08
lack O 0 6.713785296597052e-07
of O 0 5.9449774880704354e-08
genomic O 0 0.00010913974983850494
structure O 0 2.4621542252134532e-05
information O 0 3.4964336919074412e-06
. O 0 1.3107192899042275e-05

We O 0 1.8339724192628637e-06
report O 0 7.33034823952039e-07
here O 0 3.4596279618881454e-08
the O 0 8.999795575448388e-09
complete O 0 8.297521247868644e-08
characterization O 0 3.82513093200032e-07
of O 0 1.8435649673520516e-09
the O 0 2.836089807445319e-09
48 O 0 4.076204618286283e-08
exons O 0 1.0737749533973329e-07
of O 0 2.9906097598342285e-09
the O 0 6.776658523222068e-08
COL4A4 O 0 0.014832288958132267
gene O 0 1.0193173238803865e-06
, O 0 1.2405523719394296e-08
a O 0 2.2822517209419857e-08
comprehensive O 0 3.1176418815448415e-06
gene O 0 2.278221472806763e-06
screen O 0 2.0054264950886136e-06
, O 0 2.2215223438593057e-08
and O 0 2.5242223866683844e-09
the O 0 2.145420063826009e-09
subsequent O 0 8.176534294079829e-08
detection O 0 2.2581944847388513e-07
of O 0 4.960678978704891e-09
10 O 0 2.017822140487624e-07
novel O 0 9.700943337520584e-06
mutations O 0 3.061138704651967e-05
in O 0 5.899883035453968e-06
eight O 0 0.00853534322232008
patients O 1 0.9990090131759644
diagnosed O 1 0.9995679259300232
with O 1 0.9459137320518494
autosomal B-Disease 1 0.9989257454872131
recessive I-Disease 1 0.998812198638916
Alport I-Disease 1 0.9990031123161316
syndrome I-Disease 1 0.9989416003227234
. O 0 0.04357622563838959

Furthermore O 0 5.4736799938837066e-05
, O 0 3.8782636124778946e-07
we O 0 3.523915381720144e-08
identified O 0 3.1795387656075036e-08
a O 0 1.3686167754656253e-08
glycine O 0 3.2836925356605207e-07
to O 0 7.160648074489018e-09
alanine O 0 1.6156191122718155e-06
substitution O 0 7.274275048985146e-08
in O 0 1.2946438587846387e-08
the O 0 3.9491055758844595e-08
collagenous O 0 0.02092565782368183
domain O 0 3.112544959549268e-07
that O 0 5.489253940282879e-09
is O 0 9.497976627415028e-09
apparently O 0 1.5822790544461895e-07
silent O 0 3.066369799853419e-06
in O 0 1.5018418508816467e-08
the O 0 4.834495825889462e-08
heterozygous O 0 1.2424760825524572e-05
carriers O 0 3.513609044603072e-05
, O 0 9.638245046517113e-08
in O 0 1.35793555955388e-07
11 O 0 7.500400442950195e-06
. O 0 5.967543984297663e-06

5 O 0 4.6697305151610635e-06
% O 0 1.6616621678622323e-07
of O 0 1.8934251500013488e-08
all O 0 1.6356999310573883e-08
control O 0 1.2237454711794271e-06
individuals O 0 1.5313321455323603e-07
, O 0 4.4824659539699496e-08
and O 0 1.2791753434271413e-08
in O 0 1.122418602506059e-08
one O 0 4.991087543260164e-09
control O 0 1.1789399678718837e-07
individual O 0 1.888966671970138e-08
homozygous O 0 2.9316444738469727e-07
for O 0 1.1658579879281206e-08
this O 0 2.9248182542573886e-08
glycine O 0 1.5428526239702478e-05
substitution O 0 7.393201030936325e-06
. O 0 5.732773388444912e-06

There O 0 5.196219717618078e-06
has O 0 5.094624384582858e-07
been O 0 3.670762893648316e-08
no O 0 1.9717329990953658e-08
previous O 0 2.578220481552762e-08
finding O 0 2.1896561008816207e-08
of O 0 2.036619761724978e-09
a O 0 3.322348263168351e-08
glycine O 0 2.2703873128193663e-06
substitution O 0 2.925254420915735e-07
that O 0 8.44382519460396e-09
is O 0 1.8792528422295618e-08
not O 0 7.607945384791037e-09
associated O 0 1.420522437456384e-07
with O 0 2.7599400098665683e-08
any O 0 2.7989312911813613e-07
obvious O 0 0.00011417071073083207
phenotype O 0 0.002509496873244643
in O 0 2.051864157692762e-06
homozygous O 0 0.000300718704238534
individuals O 0 1.8269971405970864e-05
. O 0 7.503475353587419e-05

Founder O 0 0.0038484656251966953
BRCA1 O 0 0.021643687039613724
and O 0 1.7325330190942623e-05
BRCA2 O 0 0.046968087553977966
mutations O 0 6.832794315414503e-05
in O 0 4.931700004817685e-06
French O 0 0.005535306874662638
Canadian O 0 0.2072034776210785
breast B-Disease 1 0.9988231062889099
and I-Disease 1 0.9424294829368591
ovarian I-Disease 1 0.9997077584266663
cancer I-Disease 1 0.9993463158607483
families O 0 0.013137883506715298
. O 0 0.0006586292874999344

We O 0 1.257379835806205e-06
have O 0 1.0309704379096729e-07
identified O 0 7.9365712224444e-08
four O 0 1.937849347655174e-08
mutations O 0 2.3303752527681354e-07
in O 0 3.2124238824593476e-09
each O 0 2.422701150806006e-09
of O 0 1.6336896635493758e-07
the O 0 0.0005844576517120004
breast B-Disease 1 0.9996422529220581
cancer I-Disease 1 0.9996135830879211
- O 1 0.5124341249465942
susceptibility O 0 0.07190766930580139
genes O 0 6.163923444546526e-06
, O 0 1.2747116215905407e-06
BRCA1 O 0 0.001854326343163848
and O 0 7.750885515633854e-07
BRCA2 O 0 0.0012957778526470065
, O 0 2.3503196189267328e-07
in O 0 7.252316436279216e-07
French O 0 0.0009648812119849026
Canadian O 0 0.09743471443653107
breast B-Disease 1 0.9993442893028259
cancer I-Disease 1 0.9994736313819885
and O 1 0.964420735836029
breast B-Disease 1 0.9997462630271912
/ I-Disease 1 0.9996193647384644
ovarian I-Disease 1 0.9998683929443359
cancer I-Disease 1 0.9996581077575684
families O 0 0.0004074983298778534
from O 0 3.7977293686708435e-05
Quebec O 0 0.0018126975046470761
. O 0 7.902078505139798e-05

To O 0 2.152875458705239e-05
identify O 0 0.00017887046851683408
founder O 0 0.005308497231453657
effects O 0 0.0006909996154718101
, O 0 5.166564278624719e-07
we O 0 6.469355895433182e-08
examined O 0 7.42963629818405e-06
independently O 0 3.9871378021416604e-07
ascertained O 0 4.8415309720439836e-05
French O 0 0.00015329409507103264
Canadian O 0 0.0028896278236061335
cancer B-Disease 1 0.9907057881355286
families O 0 1.0021650496128132e-06
for O 0 1.522408332732539e-08
the O 0 9.101245979081796e-09
distribution O 0 2.4182472913025777e-08
of O 0 7.526915091204955e-09
these O 0 3.634784917494471e-08
eight O 0 2.68820167548256e-06
mutations O 0 0.00016080397472251207
. O 0 7.0823903115524445e-06

Mutations O 0 5.3528066928265616e-05
were O 0 1.1254181231379334e-07
found O 0 9.843368786732754e-08
in O 0 5.599765273700541e-08
41 O 0 9.104745686272508e-07
of O 0 1.4120416835794458e-07
97 O 0 6.88534855726175e-05
families O 0 1.6168265574378893e-05
. O 0 1.7402197045157664e-05

Six O 0 1.618623400645447e-06
of O 0 2.1630570756769885e-07
eight O 0 8.175566108548082e-07
mutations O 0 4.381284270493779e-06
were O 0 1.741917721176378e-08
observed O 0 2.622471129143378e-07
at O 0 3.15789918658993e-07
least O 0 6.508887508971384e-07
twice O 0 8.81606865732465e-06
. O 0 9.444150236959103e-06

The O 0 4.436006202013232e-05
BRCA1 O 0 0.08233346045017242
C4446T O 0 0.019231395795941353
mutation O 0 6.625502282986417e-05
was O 0 2.0882895057638962e-07
the O 0 6.880199521219765e-08
most O 0 5.095513344599567e-08
common O 0 1.0632967359924805e-06
mutation O 0 4.169797193753766e-06
found O 0 5.2078902967878093e-08
, O 0 2.323331216302904e-08
followed O 0 7.4747276812559e-08
by O 0 6.39040038663552e-08
the O 0 1.9862668523273896e-06
BRCA2 O 0 0.19809262454509735
8765delAG O 0 0.13016994297504425
mutation O 0 0.0007779792649671435
. O 0 2.2519485355587676e-05

Together O 0 4.69458836960257e-06
, O 0 7.306255724870425e-07
these O 0 4.1068584977210776e-08
mutations O 0 6.882344223413384e-07
were O 0 2.5767294964396115e-09
found O 0 8.587893951528258e-09
in O 0 7.098231780133801e-09
28 O 0 7.329398243882679e-08
of O 0 2.1539538153092508e-08
41 O 0 5.9381432038208e-06
families O 0 8.00803661604732e-07
identified O 0 1.5224060234686476e-07
to O 0 1.7929256301840724e-08
have O 0 4.788070384620369e-08
a O 0 1.9703772977663903e-06
mutation O 0 8.682475163368508e-05
. O 0 8.596380212111399e-06

The O 0 4.995164999854751e-06
odds O 0 5.869142114534043e-05
of O 0 7.877032004444118e-08
detection O 0 3.3293758860963862e-06
of O 0 6.497610005595789e-09
any O 0 3.7786969109276924e-09
of O 0 4.643082807120891e-09
the O 0 3.0474677004121986e-08
four O 0 8.471363912576635e-07
BRCA1 O 0 0.08548720180988312
mutations O 0 2.3849837816669606e-05
was O 0 3.660862830656697e-07
18 O 0 7.997161446837708e-06
. O 0 1.0310810466762632e-05

7x O 0 0.1094912439584732
greater O 0 8.362171683984343e-06
if O 0 5.07513561842643e-07
one O 0 6.208526315276686e-08
or O 0 3.185308514730423e-07
more O 0 4.29514329880476e-07
cases O 0 0.001690062927082181
of O 0 0.08683046698570251
ovarian B-Disease 1 0.9999135732650757
cancer I-Disease 1 0.9997298121452332
were O 0 2.433185102290736e-07
also O 0 1.3323362679784623e-07
present O 0 3.1628027841179573e-07
in O 0 1.648139971166529e-07
the O 0 3.9255178307939786e-07
family O 0 4.151237226324156e-05
. O 0 2.745079473243095e-05

The O 0 5.666200650011888e-06
odds O 0 6.75002665957436e-05
of O 0 1.4308720608369185e-07
detection O 0 2.4133644274115795e-06
of O 0 6.5985852337746564e-09
any O 0 4.896119509822938e-09
of O 0 4.956725696558806e-09
the O 0 5.165647465332768e-08
four O 0 1.003039074021217e-06
BRCA2 O 0 0.15613608062267303
mutations O 0 3.697475040098652e-05
was O 0 1.118108684750041e-06
5 O 0 7.828091838746332e-06
. O 0 7.719719178567175e-06

3x O 0 0.003152592806145549
greater O 0 6.6928892010764685e-06
if O 0 2.6995209623237315e-07
there O 0 1.4444310636463342e-08
were O 0 2.7031308302838397e-09
at O 0 4.492514094067701e-08
least O 0 3.1344921325171526e-08
five O 0 1.5884113224728935e-07
cases O 0 2.7928097551921383e-05
of O 0 0.00021330446179490536
breast B-Disease 1 0.9997078776359558
cancer I-Disease 1 0.9990943670272827
in O 0 5.453791345644277e-06
the O 0 5.3796693464391865e-06
family O 0 0.00017914305499289185
. O 0 5.6107375712599605e-05

Interestingly O 0 0.0002051384944934398
, O 0 6.206868192748516e-07
the O 0 5.829368632248588e-08
presence O 0 2.7817225145554403e-07
of O 0 4.120920493733138e-07
a O 0 0.003099107649177313
breast B-Disease 1 0.999572217464447
cancer I-Disease 1 0.9993201494216919
case O 0 0.0001747066853567958
< O 0 0.010260246694087982
36 O 0 8.667575457366183e-07
years O 0 8.695777609091238e-08
of O 0 1.2397836535171791e-08
age O 0 1.3382441466092132e-06
was O 0 3.014083915786614e-08
strongly O 0 1.0653314319597484e-07
predictive O 0 2.7127165935780795e-07
of O 0 2.379878516478584e-09
the O 0 5.573687289484042e-09
presence O 0 2.4687853539262505e-08
of O 0 1.201361787828148e-09
any O 0 1.882344280446091e-09
of O 0 3.7576675104844526e-09
the O 0 6.354424186838514e-08
eight O 0 2.234378371213097e-06
mutations O 0 9.695773769635707e-05
screened O 0 0.00011814317986136302
. O 0 1.1591722795856185e-05

Carriers O 0 7.09508967702277e-05
of O 0 1.6929219270878093e-07
the O 0 1.39766186180168e-07
same O 0 1.2025364526380145e-07
mutation O 0 2.9451894079102203e-06
, O 0 2.475844773641711e-08
from O 0 1.3836142898071557e-08
different O 0 5.952122350549871e-09
families O 0 3.118844347227423e-07
, O 0 9.32027859334994e-08
shared O 0 1.8810393953572202e-07
similar O 0 1.0831037116076914e-06
haplotypes O 0 0.0018163318745791912
, O 0 1.950178898368904e-07
indicating O 0 6.685990570076683e-07
that O 0 6.060367319093984e-09
the O 0 2.6417534826350675e-08
mutant O 0 2.2615620764554478e-05
alleles O 0 1.985327799047809e-06
were O 0 9.849319582144744e-09
likely O 0 9.675875389802968e-08
to O 0 2.9104425536274903e-09
be O 0 6.85240308939683e-10
identical O 0 2.7339371655443756e-08
by O 0 6.220068460294215e-09
descent O 0 3.051516443974833e-07
for O 0 1.3407840171453245e-08
a O 0 2.267889129825562e-07
mutation O 0 4.549609457171755e-06
in O 0 7.283215808229215e-08
the O 0 3.0998720035313454e-07
founder O 0 0.0001858656614786014
population O 0 5.6323888202314265e-06
. O 0 1.0951169315376319e-05

The O 0 1.306194462813437e-06
identification O 0 9.549146398057928e-07
of O 0 2.8724966227855475e-07
common O 0 2.4382039555348456e-05
BRCA1 O 0 0.03197262063622475
and O 0 6.8758758970943745e-06
BRCA2 O 0 0.06365016102790833
mutations O 0 6.955606295377947e-06
will O 0 3.312654328624376e-08
facilitate O 0 1.5335405123551027e-06
carrier O 0 5.553588198381476e-05
detection O 0 2.1598078092210926e-05
in O 0 6.009360618008941e-07
French O 0 0.0008398936479352415
Canadian O 0 0.13975319266319275
breast B-Disease 1 0.9992809891700745
cancer I-Disease 1 0.9994068145751953
and O 1 0.7838911414146423
breast B-Disease 1 0.9996036887168884
/ I-Disease 1 0.9994354844093323
ovarian I-Disease 1 0.999790608882904
cancer I-Disease 1 0.9994327425956726
families O 0 0.017996905371546745
. O 0 0.00101224216632545

Are O 0 1.4997704965935554e-05
Dp71 O 0 0.021267669275403023
and O 0 2.8976633984711953e-05
Dp140 O 0 0.3889119327068329
brain O 0 0.4456123113632202
dystrophin O 0 0.16467389464378357
isoforms O 0 5.826936467201449e-05
related O 0 0.0001213317082147114
to O 0 1.7710997781250626e-05
cognitive B-Disease 1 0.6941408514976501
impairment I-Disease 1 0.9972156286239624
in O 0 0.4451490342617035
Duchenne B-Disease 1 0.9985415935516357
muscular I-Disease 1 0.9983629584312439
dystrophy I-Disease 1 0.9981921315193176
? O 1 0.795081377029419

Molecular O 0 0.00031600185320712626
study O 0 1.8128021110896952e-05
and O 0 2.165365685868892e-06
neuropsychological O 0 0.0007524993270635605
analysis O 0 3.1756724183651386e-07
were O 0 7.0650041372744e-09
performed O 0 3.785068258821411e-08
concurrently O 0 2.0286427115934202e-07
on O 0 3.4770533829941996e-07
49 O 0 0.0010242316639050841
patients O 1 0.6060837507247925
with O 0 0.019152086228132248
Duchenne B-Disease 1 0.9994984865188599
muscular I-Disease 1 0.9995347261428833
dystrophy I-Disease 1 0.9996505975723267
( O 1 0.5632869005203247
DMD B-Disease 1 0.9995263814926147
) O 0 2.0230893369443947e-06
in O 0 2.9643567600601273e-08
order O 0 1.7101559279808498e-08
to O 0 4.142636900184016e-09
find O 0 3.3572693070027526e-08
a O 0 4.403277387154958e-08
molecular O 0 2.023137767537264e-06
explanation O 0 2.3738166987641307e-07
for O 0 4.8361833648868924e-08
the O 0 1.145043029282533e-06
cognitive B-Disease 0 0.035976510494947433
impairment I-Disease 1 0.8741967678070068
observed O 0 2.212237632193137e-05
in O 0 1.8569800886325538e-05
most O 0 0.0006967160734347999
DMD B-Disease 1 0.9988566637039185
patients O 1 0.9585855603218079
. O 0 0.00019109976710751653

Complete O 0 2.9266823275975185e-06
analysis O 0 5.626175720863102e-07
of O 0 9.539119361079429e-08
the O 0 1.3210533325036522e-06
dystrophin O 0 0.06593289226293564
gene O 0 3.735442305696779e-06
was O 0 5.6517528435051645e-08
performed O 0 2.4998218606242517e-08
to O 0 3.78634457121052e-09
define O 0 4.9140943758629874e-08
the O 0 5.154395577022797e-09
localization O 0 3.3402290000594803e-07
of O 0 8.416105146125119e-09
deletions O 0 3.2834525427460903e-06
and O 0 5.816518466872367e-08
duplications O 0 7.945983270474244e-06
in O 0 3.290099215291775e-08
relation O 0 1.778213771785886e-07
to O 0 2.3493059941870342e-08
the O 0 2.5095394562413276e-07
different O 0 2.998138597831712e-06
DMD B-Disease 1 0.9968159794807434
promoters O 0 0.009664537385106087
. O 0 4.633623393601738e-05

Qualitative O 0 7.146104053390445e-06
analysis O 0 7.374929964498733e-07
of O 0 5.2569316011386036e-08
the O 0 1.9144663099268655e-07
Dp71 O 0 0.0024084709584712982
transcript O 0 6.170268989080796e-06
and O 0 4.344115467347365e-08
testing O 0 1.5404458508783136e-07
for O 0 1.8238009991122794e-09
the O 0 1.2086289746804368e-09
specific O 0 1.717395448075365e-09
first O 0 3.060572462132427e-09
exon O 0 2.40997883338423e-06
of O 0 9.375475507056308e-09
Dp140 O 0 3.3569056540727615e-05
were O 0 3.6504850253749055e-09
also O 0 1.7983746047889326e-08
carried O 0 9.581277993220283e-08
out O 0 3.915288573352882e-07
. O 0 4.3068766899523325e-06

Neuropsychological O 0 0.0203799307346344
analysis O 0 2.5075181838474236e-05
assessed O 0 4.593613266479224e-05
verbal O 0 5.149591015651822e-05
and O 0 5.606253125733929e-06
visuospatial O 0 0.04984704405069351
intelligence O 0 1.7244987247977406e-05
, O 0 4.4370850105224235e-07
verbal O 0 1.9898576283594593e-05
memory O 0 9.131922706728801e-05
, O 0 2.143885637906351e-07
and O 0 2.8250377681615646e-07
reading O 0 2.2411637473851442e-05
skills O 0 2.0436333215911873e-05
. O 0 1.1309454748698045e-05

Comparison O 0 1.3886999113310594e-05
of O 0 4.505102424445795e-07
molecular O 0 1.6066253010649234e-05
and O 0 1.2117062624383834e-06
psychometric O 0 0.002404281171038747
findings O 0 7.695331078139134e-06
demonstrated O 0 1.6087466292447061e-06
that O 0 3.510424662067635e-08
deletions O 0 6.360514817060903e-06
and O 0 6.859718837404216e-08
duplications O 0 8.002975846466143e-06
that O 0 6.162371057882865e-09
were O 0 4.357989080716607e-09
localized O 0 1.181861080112867e-05
in O 0 2.7289408066621945e-08
the O 0 4.4275065391730095e-08
distal O 0 7.996406930033118e-05
part O 0 3.747362598005566e-08
of O 0 6.296894561330646e-09
the O 0 6.376739491997796e-08
gene O 0 3.9675423977314495e-06
seemed O 0 5.597089511866216e-07
to O 0 2.235809226647234e-08
be O 0 2.2996472281988645e-08
preferentially O 0 1.6525667888345197e-05
associated O 0 1.735976547934115e-05
with O 0 2.0801884602406062e-05
cognitive B-Disease 1 0.5095296502113342
impairment I-Disease 1 0.9938275218009949
. O 0 0.0001661090791458264

Two O 0 2.870381877073669e-06
altered O 0 7.190626638475806e-05
Dp71 O 0 0.0004626015725079924
transcripts O 0 1.2496478802859201e-06
and O 0 2.9360640141362637e-08
two O 0 1.1099833940875214e-08
deleted O 0 1.1113179425592534e-06
Dp140 O 0 9.745655916049145e-06
DNA O 0 1.0175764231235007e-07
sequences O 0 2.8155131559515212e-08
were O 0 3.235507861631959e-09
found O 0 6.28343599373693e-08
in O 0 1.653965711057026e-07
four O 0 2.0580710042850114e-05
patients O 1 0.9741551876068115
with O 0 0.11196266114711761
severe O 1 0.9994137287139893
cerebral B-Disease 1 0.9991223216056824
dysfunction I-Disease 1 0.9982004165649414
. O 0 0.005400149151682854

These O 0 1.3409780876827426e-06
findings O 0 5.54413600184489e-06
suggest O 0 9.283851341024274e-07
that O 0 7.863818041187187e-09
some O 0 2.1866917165880295e-09
sequences O 0 3.122534053545678e-08
located O 0 1.463393406453406e-08
in O 0 4.929026964362038e-09
the O 0 1.5913641959741653e-08
distal O 0 2.2398091459763236e-05
part O 0 2.4778570306693837e-08
of O 0 5.97952265479762e-09
the O 0 5.18589473585962e-08
gene O 0 1.422240075044101e-06
and O 0 2.2834841573171616e-08
, O 0 1.9882930857306746e-08
in O 0 1.3246808094891094e-08
particular O 0 4.086308535988792e-08
, O 0 5.407989434047522e-08
some O 0 1.615847367020251e-07
DMD B-Disease 1 0.9949522018432617
isoforms O 0 2.1349442249629647e-06
expressed O 0 8.435086442659667e-07
in O 0 4.810479481420771e-07
the O 0 1.2095785677956883e-05
brain O 1 0.8074071407318115
may O 0 4.291309323889436e-06
be O 0 2.4299030343399863e-08
related O 0 2.2446558887168067e-06
to O 0 2.1599443300601706e-07
the O 0 6.378749276336748e-06
cognitive B-Disease 0 0.3032855689525604
impairment I-Disease 1 0.994148850440979
associated O 0 0.002059022895991802
with O 0 0.002062974264845252
DMD B-Disease 1 0.9984826445579529
. O 0 3.5418277548160404e-05
. O 0 3.8765174394939095e-05

I1307K O 0 0.010680921375751495
APC O 0 0.0025050330441445112
and O 0 7.469257070624735e-06
hMLH1 O 0 0.003373614512383938
mutations O 0 1.0969682080030907e-05
in O 0 6.200904323350187e-08
a O 0 4.1950582385652524e-07
non O 0 1.4964544789108913e-05
- O 0 0.000542403373401612
Jewish O 0 9.984341886593029e-06
family O 0 1.6266320017166436e-05
with O 0 5.8587185776559636e-05
hereditary B-Disease 1 0.9902462959289551
non I-Disease 1 0.9718614816665649
- I-Disease 1 0.9988176226615906
polyposis I-Disease 1 0.9993389248847961
colorectal I-Disease 1 0.9996567964553833
cancer I-Disease 1 0.9990600943565369
. O 0 0.0068457773886621

We O 0 1.3910837424191413e-06
describe O 0 4.530740170594072e-06
a O 0 1.5562039834549068e-06
French O 0 4.897458711639047e-05
Canadian O 0 0.0003599000920075923
hereditary B-Disease 1 0.8856679797172546
non I-Disease 1 0.9138772487640381
- I-Disease 1 0.9987210631370544
polyposis I-Disease 1 0.9995929598808289
colorectal I-Disease 1 0.9998224377632141
cancer I-Disease 1 0.9997408986091614
( O 1 0.5033748745918274
HNPCC B-Disease 1 0.9991750121116638
) O 0 2.676738949958235e-05
kindred O 0 0.0006006416515447199
which O 0 5.4687532724528864e-08
carries O 0 8.427784905506996e-07
a O 0 4.098032775345928e-07
novel O 0 3.210557042621076e-05
truncating O 0 0.0579981654882431
mutation O 0 0.0002676376316230744
in O 0 5.275532203086186e-06
hMLH1 O 0 0.035802870988845825
. O 0 4.209303006064147e-05

Interestingly O 0 0.0001354808482574299
, O 0 9.250850325770443e-07
the O 0 3.278054236943717e-07
I1307K O 0 0.0008630508673377335
APC O 0 0.0013674143701791763
polymorphism O 0 2.4201350242947228e-05
, O 0 2.255986117916109e-07
associated O 0 2.946294728189969e-07
with O 0 1.0014029072635822e-07
an O 0 1.0760400073195342e-06
increased O 0 0.0010818152222782373
risk O 1 0.7825475931167603
of O 0 0.09114667773246765
colorectal B-Disease 1 0.9999456405639648
cancer I-Disease 1 0.9998594522476196
, O 0 5.423729362519225e-06
is O 0 2.833242831457028e-07
also O 0 6.806893537714132e-08
present O 0 2.296895047493308e-07
in O 0 1.0273506489966167e-07
this O 0 1.4540997028689162e-07
family O 0 4.1510236769681796e-05
. O 0 2.146733459085226e-05

The O 0 7.635592737642583e-06
I1307K O 0 0.00418845284730196
polymorphism O 0 7.755917613394558e-05
has O 0 7.067702085805649e-07
previously O 0 1.792020043467346e-07
only O 0 9.786175425574584e-09
been O 0 1.0726221688628357e-08
identified O 0 4.6456456459509354e-08
in O 0 1.4182694130226992e-08
individuals O 0 2.5817980642273142e-08
of O 0 6.819070108576852e-08
self O 0 7.884269143687561e-05
- O 0 0.0488511398434639
reported O 0 0.00023383353254757822
Ashkenazi O 0 0.001115727238357067
Jewish O 0 9.97760162135819e-06
origins O 0 4.754193651024252e-05
. O 0 1.6136826161528006e-05

In O 0 2.4418866360065294e-06
addition O 0 1.733077965582197e-06
, O 0 2.2503949992369598e-07
in O 0 7.759717846056446e-08
this O 0 4.3986943865093053e-08
family O 0 2.84896259472589e-06
, O 0 3.283382454810635e-07
there O 0 7.050065420344254e-08
appears O 0 1.4372604937307187e-06
to O 0 1.1817244072176436e-08
be O 0 1.9527715000577928e-09
no O 0 9.937896727763018e-09
relationship O 0 9.999962458095979e-08
between O 0 2.721985481457523e-08
the O 0 5.156168114694992e-08
I1307K O 0 0.00014533432840835303
polymorphism O 0 2.1176492737140507e-06
and O 0 1.3271642451684329e-08
the O 0 1.8349535224615465e-08
presence O 0 4.4826367684436264e-07
or O 0 5.833149998579756e-07
absence O 0 0.00011166863259859383
of O 0 6.531043618451804e-05
cancer B-Disease 1 0.9981318116188049
. O 0 1.3988013961352408e-05
. O 0 2.9251363230287097e-05

Identification O 0 2.019484782067593e-06
of O 0 1.1560027246559912e-07
a O 0 2.1775079517283302e-07
novel O 0 2.5100184757320676e-06
mutation O 0 1.0246711781292106e-06
of O 0 1.2226947454507808e-08
the O 0 4.696374134027792e-08
CPO O 0 3.789517722907476e-05
gene O 0 6.055932431081601e-07
in O 0 5.008092429648059e-08
a O 0 8.834230698084866e-07
Japanese O 0 0.0003751667100004852
hereditary B-Disease 0 0.3214089572429657
coproporphyria I-Disease 1 0.8238718509674072
family O 0 0.0005739917396567762
. O 0 9.262104867957532e-05

Hereditary B-Disease 1 0.728038489818573
coproporphyria I-Disease 1 0.9362747669219971
( O 0 0.010625909082591534
HCP B-Disease 1 0.9936912059783936
) O 0 2.8413753170752898e-05
is O 0 2.443822495479253e-06
an O 0 0.00010863637726288289
autosomal B-Disease 1 0.9981004595756531
dominant I-Disease 1 0.9973125457763672
disease I-Disease 1 0.9996863603591919
characterized O 0 0.24193242192268372
by O 0 2.3848679120419547e-05
a O 0 0.0008984892047010362
deficiency B-Disease 1 0.9990081191062927
of I-Disease 0 2.464488716213964e-06
coproporphyrinogen I-Disease 1 0.748650312423706
oxidase I-Disease 0 0.013091782107949257
( O 0 2.345430948480498e-05
CPO O 0 0.0013535150792449713
) O 0 6.304468342932523e-07
caused O 0 1.3993200127515593e-06
by O 0 3.3109346375681525e-09
a O 0 2.603541560119993e-08
mutation O 0 5.751122102992667e-07
in O 0 1.7678141617238907e-08
the O 0 2.0586877269579418e-07
CPO O 0 0.0005300245829857886
gene O 0 2.231285543530248e-05
. O 0 3.840607405436458e-06

Only O 0 6.408282615666394e-07
11 O 0 1.5312372170228628e-06
mutations O 0 1.4388527915798477e-06
of O 0 1.5990254453868147e-08
the O 0 6.444933120519636e-08
gene O 0 1.4087074760027463e-06
have O 0 3.516549540449887e-08
been O 0 1.9651518812224822e-07
reported O 0 7.956049375934526e-05
in O 0 9.177238098345697e-05
HCP B-Disease 1 0.9976809024810791
patients O 1 0.7678269743919373
. O 0 0.00011336694296915084

We O 0 3.4038466765196063e-06
report O 0 3.1727709028928075e-06
another O 0 8.668402529110608e-07
mutation O 0 6.196522463142173e-06
in O 0 1.8546708702160686e-07
a O 0 1.4497243228106527e-06
Japanese O 0 8.567985787522048e-05
family O 0 0.00010590244346531108
. O 0 4.494410677580163e-05

Polymerase O 0 0.0008896043291315436
chain O 0 0.0002546276373323053
reaction O 0 4.635188088286668e-05
- O 0 4.176706715952605e-05
single O 0 3.057464539324428e-07
strand O 0 3.4993558983842377e-06
conformational O 0 4.229298156133154e-06
polymorphism O 0 4.622725953140616e-07
and O 0 3.5269327458564703e-09
direct O 0 3.6463794206298417e-09
sequence O 0 1.4154696970081204e-08
analyses O 0 9.990964144890313e-08
demonstrated O 0 3.614983512534309e-08
a O 0 2.049652181312922e-08
C O 0 2.9097225251462078e-06
to O 0 9.85525705488044e-09
T O 0 2.6075676942127757e-05
substitution O 0 1.4367897094302862e-08
in O 0 1.898678769762796e-09
exon O 0 1.962934277344175e-07
1 O 0 2.2390600484811785e-09
of O 0 4.663769925805639e-10
the O 0 2.4047923652403824e-09
CPO O 0 1.6716769550839672e-06
gene O 0 2.911293606189247e-08
at O 0 4.6986117219205425e-09
nucleotide O 0 1.651594416784974e-08
position O 0 1.0269016748054582e-08
85 O 0 2.2493392748401675e-07
, O 0 6.310516997842797e-09
which O 0 1.8728183448502023e-09
lies O 0 3.586030672408924e-08
in O 0 2.721848968434415e-09
the O 0 8.85756357149603e-09
putative O 0 1.869510924734641e-05
presequence O 0 0.00019172905012965202
for O 0 2.5733223552037998e-08
targeting O 0 3.56670312839924e-07
to O 0 1.3326895498266822e-07
mitochondria O 0 4.4090858864365146e-05
. O 0 6.25028224021662e-06

This O 0 1.6113013998619863e-06
mutation O 0 3.6150156574876746e-06
changes O 0 6.138886732287574e-08
the O 0 1.0611331369148047e-08
codon O 0 9.945068057959361e-08
for O 0 5.509602996056628e-09
glutamine O 0 3.9748221070112777e-07
to O 0 2.991351388814678e-09
a O 0 2.532996568049839e-08
termination O 0 1.2189955668873154e-05
codon O 0 3.2050175491349364e-07
at O 0 3.325004271914622e-08
amino O 0 5.1406132683951e-08
acid O 0 1.455767801417096e-06
position O 0 2.0953655166522367e-07
29 O 0 4.355226337793283e-06
. O 0 2.905086830651271e-06

MaeI O 0 0.005743701942265034
restriction O 0 2.0646210032282397e-05
analysis O 0 1.818825808186375e-06
showed O 0 9.775038734005648e-07
two O 0 1.8202987561721784e-08
other O 0 7.566516302404125e-08
carriers O 0 1.4043806004337966e-05
in O 0 9.768556452627308e-08
the O 0 3.7726647406088887e-07
family O 0 2.071958442684263e-05
. O 0 2.0202831365168095e-05

The O 0 1.516834345238749e-05
C O 0 0.0067009455524384975
- O 0 0.11832308024168015
T O 1 0.581651508808136
mutation O 0 7.640450348844752e-06
is O 0 1.1640360675357897e-08
located O 0 1.2259874004882931e-08
within O 0 4.717379820107226e-09
a O 0 2.059728032577368e-08
recently O 0 1.468989978548052e-07
proposed O 0 1.193918137687433e-07
putative O 0 4.62768412035075e-07
alternative O 0 1.1726712934034822e-08
translation O 0 1.548717598609528e-08
initiation O 0 2.377103811568304e-07
codon O 0 1.252266429219162e-06
( O 0 9.391781645717856e-07
TIC O 0 0.007961711846292019
- O 0 1.1362514669599477e-05
1 O 0 8.936100925893697e-08
) O 0 1.127480242502088e-08
, O 0 5.3991024984156866e-09
supporting O 0 7.378898914112142e-08
that O 0 4.6897859817818244e-08
TIC O 0 0.06484146416187286
- O 0 1.6417661754530855e-05
1 O 0 5.1758156871528627e-08
is O 0 4.163914546495562e-09
the O 0 6.8709637979225135e-09
real O 0 9.756245162861887e-07
TIC O 0 0.022324753925204277
rather O 0 7.743100383095225e-08
than O 0 3.7586912071674305e-07
TIC O 1 0.5232795476913452
- O 0 0.0001530773297417909
2 O 0 2.382731054240139e-06
. O 0 2.9478937335625233e-07
. O 0 2.723923216763069e-06

Human B-Disease 0 0.0009742220281623304
complement I-Disease 0 0.005587632767856121
factor I-Disease 1 0.6017840504646301
H I-Disease 1 0.9941937327384949
deficiency I-Disease 1 0.9983119964599609
associated O 1 0.881850004196167
with O 1 0.9903597831726074
hemolytic B-Disease 1 0.9995348453521729
uremic I-Disease 1 0.9995707869529724
syndrome I-Disease 1 0.9991323351860046
. O 0 0.10091453045606613

This O 0 1.0208165122094215e-06
study O 0 1.77519723365549e-06
reports O 0 3.0942192097427323e-07
on O 0 5.3695284663035636e-08
six O 0 6.062566626496846e-07
cases O 0 1.707044975773897e-05
of O 0 1.424636229785392e-05
deficiency B-Disease 1 0.9994075298309326
in I-Disease 0 9.529717459599851e-08
the I-Disease 0 2.190650327804633e-08
human I-Disease 0 2.6796683982865943e-07
complement I-Disease 0 6.987972938077291e-07
regulatory I-Disease 0 1.073660132533405e-05
protein I-Disease 0 1.8237866470371955e-06
Factor I-Disease 0 1.653112303756643e-05
H I-Disease 0 0.015329830348491669
( O 0 4.752364020532696e-06
FH O 0 0.049563776701688766
) O 0 4.11018135082486e-08
in O 0 3.4780327506922504e-09
the O 0 8.481515045843935e-09
context O 0 4.5714850216427294e-07
of O 0 5.391559170675464e-06
an O 0 0.04357781633734703
acute B-Disease 1 0.9994303584098816
renal I-Disease 1 0.9997856020927429
disease I-Disease 1 0.9993370175361633
. O 0 0.015899138525128365

Five O 0 1.440832875232445e-06
of O 0 1.4546198201514926e-07
the O 0 1.9308217247271386e-07
cases O 0 8.162555218405032e-07
were O 0 1.867846322056721e-08
observed O 0 6.482633807536331e-07
in O 0 8.222402811952634e-07
children O 0 0.00017185347678605467
presenting O 0 0.08386166393756866
with O 1 0.9483357071876526
idiopathic O 1 0.9995629191398621
hemolytic B-Disease 1 0.9998125433921814
uremic I-Disease 1 0.9998481273651123
syndrome I-Disease 1 0.9997963309288025
( O 1 0.9893445372581482
HUS B-Disease 1 0.9979294538497925
) O 0 0.0033968526404350996
. O 0 0.00020518951350823045

Two O 0 2.646277721396473e-07
of O 0 1.0224147928283855e-07
the O 0 4.2793371335392294e-07
children O 0 2.69331612798851e-05
exhibited O 0 0.0003203599771950394
a O 0 0.0005878986557945609
homozygous O 1 0.9330081343650818
deficiency O 1 0.9997156262397766
characterized O 0 0.0015389753971248865
by O 0 8.339296897474924e-08
the O 0 2.6661826524332355e-08
absence O 0 2.7397427970754507e-07
of O 0 2.7853011008716066e-09
the O 0 2.03948182786462e-08
150 O 0 5.617399096990994e-07
- O 0 0.00011623302270891145
kD O 0 0.0008543712319806218
form O 0 2.9723228323064177e-08
of O 0 9.160686431641807e-09
Factor O 0 3.3184267067554174e-06
H O 0 0.00030096102273091674
and O 0 8.621605651626396e-09
the O 0 6.765988214141316e-09
presence O 0 4.4434024459860666e-08
, O 0 5.286238557999923e-09
upon O 0 1.2278945860089152e-08
immunoblotting O 0 1.4398547136806883e-05
, O 0 2.2632076213113805e-09
of O 0 7.751752573170734e-10
the O 0 4.947053877657481e-09
42 O 0 8.317302899740753e-07
- O 0 5.923412390984595e-05
kD O 0 0.00277928845025599
Factor O 0 1.2751955864587217e-06
H O 0 0.00012704812979791313
- O 0 1.5277424836313003e-06
like O 0 1.79594756843926e-08
protein O 0 2.5879609566459294e-08
1 O 0 5.646419509730549e-08
( O 0 3.7833149235666497e-07
FHL O 0 0.00653348071500659
- O 0 3.340290732012363e-06
1 O 0 3.134707426966088e-08
) O 0 8.767085724059598e-09
and O 0 4.142020948449954e-09
other O 0 5.0961158848394916e-08
FH O 0 0.4498938024044037
- O 0 0.00031576937180943787
related O 0 4.818137767870212e-06
protein O 0 2.5254214506276185e-06
( O 0 5.161086392035941e-06
FHR O 0 0.004254139959812164
) O 0 4.6474360715365037e-07
bands O 0 2.639009608174092e-06
. O 0 3.913357431883924e-06

Southern O 0 4.2733532609418035e-05
blot O 0 0.0005225526983849704
and O 0 2.923949296018691e-07
PCR O 0 3.0482169677270576e-06
analysis O 0 3.894180977681572e-08
of O 0 6.024397869452969e-09
DNA O 0 2.6934213792628725e-07
of O 0 2.249291419786914e-08
one O 0 3.290821553036949e-07
patient O 0 0.012805284932255745
with O 0 0.00012694191536866128
homozygous O 1 0.8976481556892395
deficiency O 1 0.9995843768119812
ruled O 0 5.221145784162218e-06
out O 0 2.593871251121982e-08
the O 0 5.757342602663584e-09
presence O 0 1.1378131326011953e-08
of O 0 7.973859905696656e-10
a O 0 9.522610255885411e-09
large O 0 5.479319042933639e-08
deletion O 0 1.2613600119948387e-06
of O 0 7.047709527085999e-09
the O 0 3.7183920653660607e-07
FH O 1 0.8661170601844788
gene O 0 4.841988356929505e-06
as O 0 4.4393537734777055e-08
the O 0 3.800861634317698e-07
underlying O 0 0.0041471729055047035
defect O 0 0.33687442541122437
for O 0 1.3677728929906152e-05
the O 0 0.0007111217710189521
deficiency O 1 0.998113751411438
. O 0 0.00012710786540992558

The O 0 7.390179916910711e-07
other O 0 8.077668667283433e-08
four O 0 1.7758242165655247e-07
children O 0 3.538123792168335e-06
presented O 0 1.0271885003021453e-05
with O 0 0.00010440639744047076
heterozygous O 1 0.5014247894287109
deficiency O 1 0.9993541836738586
and O 0 1.1781279454226024e-06
exhibited O 0 3.15981924359221e-05
a O 0 5.091084176456206e-07
normal O 0 4.773713044414762e-06
immunoblotting O 0 0.0028259484097361565
pattern O 0 1.2801317552657565e-06
of O 0 6.805372709806079e-09
proteins O 0 5.233860633779841e-08
of O 0 7.245237299002838e-08
the O 0 6.543157269334188e-06
FH O 1 0.9833299517631531
family O 0 0.00015031578368507326
. O 0 2.5583389287930913e-05

Factor B-Disease 1 0.7311522364616394
H I-Disease 1 0.994175910949707
deficiency I-Disease 1 0.996860146522522
is O 0 8.726946703063732e-07
the O 0 1.1913198250113055e-06
only O 0 1.0874562576645985e-05
complement B-Disease 1 0.8001109957695007
deficiency I-Disease 1 0.9995338916778564
associated O 0 0.0013482080539688468
with O 0 0.0003012067754752934
HUS B-Disease 1 0.9956088662147522
. O 0 0.0001888829719973728

These O 0 7.60326145154977e-07
observations O 0 1.0751957688626135e-06
suggest O 0 7.46946739127452e-07
a O 0 1.1156849666349444e-07
role O 0 5.936003049100691e-07
for O 0 8.616707987130212e-07
FH O 1 0.7926602959632874
and O 0 2.37177391682053e-06
/ O 0 0.0070869396440684795
or O 0 4.5157539716456085e-06
FH O 1 0.6736131310462952
receptors O 0 6.97013547323877e-06
in O 0 6.329106838620646e-08
the O 0 7.739009220131265e-07
pathogenesis O 0 0.4472804665565491
of O 0 0.00012493670510593802
idiopathic O 1 0.9991098046302795
HUS B-Disease 1 0.9981033802032471
. O 0 0.000113412577775307
. O 0 5.8004192396765575e-05

Further O 0 7.105153599695768e-06
evidence O 0 9.864190815278562e-07
for O 0 1.6165702731996134e-07
a O 0 3.964350696605834e-07
major O 0 7.11913344275672e-06
ancient O 0 0.00011456812353571877
mutation O 0 0.04526350647211075
underlying O 1 0.8869328498840332
myotonic B-Disease 1 0.9994853734970093
dystrophy I-Disease 1 0.999417781829834
from O 0 0.00013137685891706496
linkage O 0 0.09754548966884613
disequilibrium O 0 0.44391006231307983
studies O 0 3.602443484851392e-06
in O 0 1.4344955445722007e-07
the O 0 2.4572716483817203e-07
Japanese O 0 5.157749183126725e-05
population O 0 6.119415957073215e-06
. O 0 1.1273831660219003e-05

The O 0 0.01181773655116558
myotonic B-Disease 1 0.9962326884269714
dystrophy I-Disease 1 0.9987190961837769
( O 0 0.24903275072574615
DM B-Disease 1 0.9987016916275024
) O 0 2.674565439519938e-05
mutation O 0 2.4976778149721213e-05
is O 0 5.579657269549898e-08
an O 0 1.5403429642901756e-07
unstable O 0 0.002444195793941617
( O 0 4.96661641591345e-06
CTG O 0 0.007753437850624323
) O 0 3.7308669220692536e-07
n O 0 5.591969511442585e-06
repeat O 0 9.28420286072651e-06
, O 0 7.570656102018347e-09
present O 0 7.032683768670722e-09
at O 0 4.968130795646175e-09
a O 0 2.8763813553212003e-09
copy O 0 2.327478298980168e-08
number O 0 5.11619302479005e-10
of O 0 1.0319708421135942e-09
5 O 0 1.112385135115801e-07
- O 0 9.972788575396407e-06
37 O 0 1.3647566277086298e-07
repeats O 0 2.039820827803851e-07
on O 0 1.7706883737034218e-09
normal O 0 9.260188171822392e-09
chromosomes O 0 2.5221012833753775e-08
but O 0 1.5942983599970262e-09
amplified O 0 6.520119910646827e-08
to O 0 2.3300799067982325e-09
50 O 0 4.055831581695202e-08
- O 0 1.274047463084571e-05
3000 O 0 4.506358436628943e-06
copies O 0 2.1749094969436555e-07
on O 0 1.0870951427932596e-06
DM B-Disease 1 0.9915766716003418
chromosomes O 0 6.54840623610653e-05
. O 0 1.4604075659008231e-05

Previous O 0 2.6799241823027842e-05
findings O 0 1.4480715435638558e-05
in O 0 9.679047252575401e-07
Caucasian O 0 0.0005729598342441022
populations O 0 3.1872064027993474e-06
of O 0 1.4461187447523116e-07
a O 0 5.996764593874104e-05
DM B-Disease 1 0.9994074106216431
founder O 0 0.012432248331606388
chromosome O 0 0.00021599473257083446
raise O 0 3.6389928936841898e-06
a O 0 9.362506148136163e-08
question O 0 7.383868450006048e-08
about O 0 1.5225129601503795e-08
the O 0 1.0870101263549259e-08
molecular O 0 5.637572826344694e-07
events O 0 2.489819372897273e-08
involved O 0 3.192232611581858e-08
in O 0 3.2358673962562534e-08
the O 0 2.368671943031586e-07
expansion O 0 0.00015895115211606026
mutation O 0 0.00022015142894815654
. O 0 9.14769680093741e-06

To O 0 4.210439783491893e-06
investigate O 0 7.479656687792158e-06
whether O 0 3.8114973222036497e-07
a O 0 4.368769168650033e-07
founder O 0 2.7890620913240127e-05
chromosome O 0 1.0627773008309305e-05
for O 0 1.739491608532262e-07
the O 0 1.2262723430467304e-05
DM B-Disease 1 0.9993879795074463
mutation O 0 0.00013059806951787323
exists O 0 6.12180485859426e-07
in O 0 9.679120616112868e-09
the O 0 1.706832009062964e-08
Japanese O 0 3.290135509814718e-06
population O 0 1.738645636351066e-07
, O 0 2.31727703692286e-08
we O 0 1.364545276771878e-08
genotyped O 0 0.00010419086902402341
families O 0 4.8205915703647406e-08
using O 0 1.4041170004475134e-08
polymorphic O 0 4.944366810377687e-05
markers O 0 5.481505922944052e-06
near O 0 3.698417572195467e-07
the O 0 5.040598338723612e-08
( O 0 1.6492984968863311e-06
CTG O 0 0.003079520072788
) O 0 6.912609364917444e-07
n O 0 1.0996778655680828e-05
repeat O 0 2.8552878575283103e-05
region O 0 6.714336109325814e-07
and O 0 1.3575638035945303e-07
constructed O 0 1.6848727682372555e-05
haplotypes O 0 0.0013780973386019468
. O 0 1.6354762919945642e-05

Six O 0 1.6976265442281147e-06
different O 0 2.5165280703731696e-07
haplotypes O 0 8.781981887295842e-05
were O 0 6.400293273145508e-08
found O 0 6.620245471822273e-07
and O 0 4.765407084050821e-06
DM B-Disease 1 0.9981637597084045
alleles O 0 2.4016913812374696e-05
were O 0 5.3975302449771334e-08
always O 0 2.4722828584344825e-06
haplotype O 0 0.002929871203377843
A O 0 1.3769459656032268e-05
. O 0 2.6599091142998077e-05

To O 0 1.278495574297267e-06
find O 0 5.112677285978862e-07
an O 0 1.889352141404288e-08
origin O 0 9.478250184713488e-09
of O 0 5.5709983293183996e-09
the O 0 6.778934391604707e-08
( O 0 1.8667744825506816e-06
CTG O 0 0.009166711941361427
) O 0 3.3703071267154883e-07
n O 0 3.996139184891945e-06
repeat O 0 2.101497921103146e-05
mutation O 0 6.278111186475144e-07
and O 0 5.812234693536311e-09
to O 0 2.915843344553082e-09
investigate O 0 8.770668813440352e-08
the O 0 2.1488191226382014e-09
mechanism O 0 2.06898089771812e-08
of O 0 1.6598645791177091e-09
the O 0 6.827135745623991e-09
expansion O 0 2.5131178063020343e-06
mutation O 0 1.1921424629690591e-06
in O 0 7.08692216022655e-09
the O 0 1.2637082491551155e-08
Japanese O 0 7.836703161956393e-07
population O 0 1.8609583207762626e-08
we O 0 1.0021397045534286e-09
have O 0 9.84751058474842e-10
studied O 0 3.5470993253738925e-08
90 O 0 4.258086789832305e-07
Japanese O 0 5.327314283931628e-05
DM B-Disease 1 0.9978569149971008
families O 0 1.1125904393338715e-06
comprising O 0 1.1818099210358923e-06
190 O 0 1.4099968211667147e-05
affected O 0 3.422785084694624e-06
and O 0 1.58335083710881e-07
130 O 0 1.0351656783313956e-05
unaffected O 0 0.00017004481924232095
members O 0 8.710300676284533e-07
. O 0 8.911027180147357e-06

The O 0 2.996057901327731e-06
results O 0 6.59607349007274e-06
suggest O 0 4.360437742434442e-06
that O 0 3.0721132304734056e-08
a O 0 7.634884724438962e-08
few O 0 2.46283178739759e-07
common O 0 1.3902310911362292e-06
ancestral O 0 4.618315870175138e-05
mutations O 0 6.079917511669919e-06
in O 0 4.603544567771678e-08
both O 0 9.938545275645083e-08
Caucasian O 0 0.0010433690622448921
and O 0 3.4999092690668476e-07
Japanese O 0 3.6163550248602405e-05
populations O 0 2.2079427708376897e-06
have O 0 4.867598768498738e-09
originated O 0 2.7404055913393677e-08
by O 0 2.9093991660289475e-09
expansion O 0 1.063613765950322e-07
of O 0 2.0761270480562644e-09
an O 0 8.592170530619114e-09
ancestral O 0 3.752344809981878e-06
n O 0 5.144270744494861e-06
= O 0 5.466929906106088e-06
5 O 0 5.302570116327843e-08
repeat O 0 6.59432259908499e-07
to O 0 7.724215933535561e-09
n O 0 9.52222933392477e-07
= O 0 2.5740694127307506e-06
19 O 0 2.3127560666580393e-07
- O 0 7.479214218619745e-06
37 O 0 7.894402074271056e-07
copies O 0 1.1657889444904868e-06
. O 0 2.089615009026602e-06

These O 0 2.7999325880045944e-07
data O 0 2.6793208007802605e-07
support O 0 3.083581816554215e-07
multistep O 0 2.057140773104038e-05
models O 0 5.205219508752634e-07
of O 0 1.0628492930209177e-07
triplet O 0 0.00839205365628004
repeat O 0 0.0006484217010438442
expansion O 0 5.7966108215623535e-06
that O 0 1.3277921873111609e-08
have O 0 3.550705285348954e-09
been O 0 2.9223632402874955e-09
proposed O 0 1.05125437244169e-07
for O 0 9.55144514591666e-08
both O 0 3.1150739232543856e-06
DM B-Disease 1 0.9990180730819702
and O 0 0.00010296093387296423
Friedreichs B-Disease 1 0.9695862531661987
ataxia I-Disease 1 0.9960044026374817
. O 0 1.772701580193825e-05
. O 0 2.8582464437931776e-05

The O 0 1.435192302778887e-06
molecular O 0 6.156749805086292e-06
basis O 0 6.738417255292006e-07
of O 0 9.72375346464105e-05
C6 B-Disease 1 0.9989610910415649
deficiency I-Disease 1 0.9991872906684875
in O 0 5.75300362015696e-07
the O 0 2.0045359860887402e-07
western O 0 4.302598426875193e-06
Cape O 0 7.37874725018628e-05
, O 0 9.496944812781294e-07
South O 0 7.596487193950452e-06
Africa O 0 3.7257199437590316e-05
. O 0 7.914809430076275e-06

Deficiency B-Disease 1 0.9769569039344788
of I-Disease 0 2.6710139877650363e-07
the I-Disease 0 8.307276289087895e-08
sixth I-Disease 0 1.4498515383820632e-06
component I-Disease 0 3.3438749369452125e-07
of I-Disease 0 1.9838420683981894e-08
human I-Disease 0 6.787271900066116e-07
complement I-Disease 0 5.846337899129139e-06
( O 0 1.621189949219115e-05
C6 O 0 0.25067776441574097
) O 0 2.3485270617129572e-07
has O 0 1.9387478289445426e-08
been O 0 3.1006566203473085e-09
reported O 0 4.859734659135029e-08
in O 0 1.3636911599945734e-09
a O 0 3.785571855985381e-09
number O 0 1.496362700414977e-09
of O 0 2.4599708936534626e-09
families O 0 6.959547960150303e-08
from O 0 1.761311807513266e-08
the O 0 2.1952304862793426e-08
western O 0 1.0187371799474931e-06
Cape O 0 2.946506538137328e-05
, O 0 3.17975150210259e-07
South O 0 7.673288564546965e-06
Africa O 0 4.078031633980572e-05
. O 0 6.601410404982744e-06

Meningococcal B-Disease 1 0.9955410361289978
disease I-Disease 1 0.9981058835983276
is O 0 5.879550371901132e-05
endemic O 0 0.014201195910573006
in O 0 1.9631775671768992e-07
the O 0 1.9334640910528833e-07
Cape O 0 9.202031833410729e-06
and O 0 9.414200086155233e-09
almost O 0 3.6314431461903496e-09
all O 0 2.1996846566452177e-09
pedigrees O 0 4.2365154513390735e-06
of O 0 1.672463412205616e-07
total O 0 0.0003591662389226258
C6 B-Disease 1 0.9994063377380371
deficiency I-Disease 1 0.9996511936187744
( O 0 0.00013398491137195379
C6Q0 O 0 0.3083265721797943
) O 0 5.239994038674922e-07
have O 0 1.9698685349567313e-08
been O 0 8.668470741213241e-08
ascertained O 0 2.0492459952947684e-05
because O 0 3.0314492960314965e-06
of O 0 4.006919334642589e-05
recurrent O 1 0.9979436993598938
disease O 1 0.9981067180633545
. O 0 0.0007756031700409949

We O 0 4.5496426537283696e-07
have O 0 5.003595404673433e-08
sequenced O 0 2.2856765724554862e-07
the O 0 1.0104181491499276e-08
expressed O 0 3.989837793483275e-08
exons O 0 3.912884380952164e-07
of O 0 1.2152546524646368e-08
the O 0 1.7145301001164626e-07
C6 O 0 0.0438728928565979
gene O 0 8.744407864469395e-07
from O 0 2.0929903143951378e-08
selected O 0 4.3707277797011557e-08
cases O 0 3.716527601227426e-07
and O 0 1.7169835331287686e-08
have O 0 3.80663456311936e-09
found O 0 1.7859322909430375e-08
three O 0 3.655287628134829e-08
molecular O 0 0.00013558722275774926
defects O 0 0.21570011973381042
leading O 0 4.3116269807796925e-06
to O 0 7.280874569914886e-07
total O 0 0.0003269558947067708
deficiency O 1 0.9997397065162659
879delG O 0 0.17024818062782288
, O 0 2.384919639553118e-07
which O 0 1.965927332037154e-08
is O 0 1.333632404509899e-08
the O 0 5.4984987230000115e-08
common O 0 5.415459781943355e-06
defect O 0 0.005862842313945293
in O 0 3.74621897947236e-08
the O 0 7.062460838369589e-08
Cape O 0 7.314702997973654e-06
and O 0 5.8708543804186775e-08
hitherto O 0 6.756931270501809e-06
unreported O 0 1.4077301784709562e-05
, O 0 5.9426078280466754e-08
and O 0 5.936003688589153e-08
1195delC O 0 0.0013673269422724843
and O 0 3.795573206843983e-07
1936delG O 0 0.001060080830939114
, O 0 7.400661417023002e-08
which O 0 9.776567999608687e-09
have O 0 3.7057092949766e-09
been O 0 5.463683283579712e-09
previously O 0 1.3738716120315075e-07
reported O 0 1.4393016272151726e-06
in O 0 2.7261481250207e-07
African O 0 7.350865053012967e-05
- O 0 0.027384769171476364
Americans O 0 6.157632742542773e-05
. O 0 1.731938391458243e-05

We O 0 1.1737161003111396e-06
also O 0 1.8143788338420563e-07
show O 0 9.152377344889828e-08
that O 0 1.7340314073521768e-08
the O 0 8.495896253180035e-08
879delG O 0 0.00373935978859663
and O 0 7.203003406175412e-06
1195delC O 1 0.7316568493843079
defects O 1 0.6424834728240967
are O 0 3.986544072631659e-08
associated O 0 1.3601794535134104e-06
with O 0 6.76379670494498e-07
characteristic O 0 0.0003805134037975222
C6 O 1 0.9889707565307617
/ O 0 0.2661970257759094
C7 O 0 0.21964120864868164
region O 0 2.0797147044504527e-06
DNA O 0 5.04018453284516e-06
marker O 0 8.24579838081263e-05
haplotypes O 0 0.00037894086563028395
, O 0 1.6814063030778925e-07
although O 0 7.875289043113298e-08
small O 0 1.1014319767355119e-07
variations O 0 8.463546237180708e-07
were O 0 5.118843660056882e-08
observed O 0 2.89500599137682e-06
. O 0 1.0891594683926087e-05

The O 0 4.062648440594785e-05
1936delG O 0 0.3714918792247772
defect O 0 0.16284610331058502
was O 0 9.899323458739673e-07
observed O 0 1.7996583778767672e-07
only O 0 1.0198182742726658e-08
once O 0 8.632090242599588e-08
in O 0 1.7235327831599534e-08
the O 0 4.497504235700944e-08
Cape O 0 1.3281439350976143e-05
, O 0 6.254964546315023e-08
but O 0 2.913804664217423e-08
its O 0 9.784462662310034e-08
associated O 0 1.0357750397815835e-05
haplotype O 0 0.001677541178651154
could O 0 1.8523924438795802e-07
be O 0 6.401550933787803e-08
deduced O 0 8.679629900143482e-06
. O 0 4.714221176982392e-06

The O 0 1.0236620937575935e-06
data O 0 3.4155880257458193e-07
from O 0 9.429621883327854e-08
the O 0 1.8204798379883869e-07
haplotypes O 0 0.00011584463209146634
indicate O 0 2.32096226682188e-07
that O 0 3.5054852354221566e-09
these O 0 5.531335833808271e-09
three O 0 1.0052360721601872e-07
molecular O 0 0.0006992138223722577
defects O 0 0.3420345187187195
account O 0 2.976028099510586e-07
for O 0 6.807283625676064e-08
the O 0 8.494808980685775e-07
defects O 0 0.023756980895996094
in O 0 1.1135649735649622e-08
all O 0 2.8349325109644496e-09
the O 0 4.274817300142786e-08
38 O 0 9.106647667067591e-06
unrelated O 0 0.00032751529943197966
C6Q0 O 0 0.4852825403213501
individuals O 0 2.431470988994988e-07
we O 0 8.110363047819646e-09
have O 0 3.3526603715472447e-09
studied O 0 5.347900966512498e-08
from O 0 6.785841577539031e-08
the O 0 3.3793187981245865e-07
Cape O 0 0.00023004785180091858
. O 0 8.648108632769436e-06

We O 0 1.296922164328862e-06
have O 0 1.6658921708767593e-07
also O 0 4.275013054666488e-08
observed O 0 1.297893135188133e-07
the O 0 1.82562615691495e-07
879delG O 0 0.0020727375522255898
defect O 0 0.0008074289653450251
in O 0 7.366355703197769e-08
two O 0 2.5862024699563335e-07
Dutch O 0 0.004609476309269667
C6 B-Disease 1 0.9981743097305298
- I-Disease 1 0.8749048709869385
deficient I-Disease 1 0.9737962484359741
kindreds O 0 0.0013863284839317203
, O 0 5.52918706375749e-08
but O 0 1.8646426624968626e-08
the O 0 8.378038529599507e-08
879delG O 0 0.0039594657719135284
defect O 0 0.001804232713766396
in O 0 3.149744998154347e-08
the O 0 9.969644310103831e-08
Cape O 0 8.795775647740811e-05
probably O 0 8.00756311036821e-07
did O 0 1.873923416439993e-08
not O 0 1.4708164686183522e-09
come O 0 1.2760609457984629e-08
from O 0 9.859111749221938e-09
The O 0 4.173083922864862e-08
Netherlands O 0 1.2324991075729486e-05
. O 0 4.991284754396474e-07
. O 0 4.102336333744461e-06

Complement B-Disease 1 0.5512502193450928
C7 I-Disease 1 0.9926913380622864
deficiency I-Disease 1 0.9970816969871521
: O 0 5.652531035593711e-05
seven O 0 5.68783480048296e-06
further O 0 3.782477506319992e-05
molecular O 0 0.007228707429021597
defects O 1 0.794413149356842
and O 0 5.1785906407531e-07
their O 0 6.296789365478617e-07
associated O 0 9.779603715287521e-05
marker O 0 0.003444307716563344
haplotypes O 0 0.03525187075138092
. O 0 9.566827793605626e-05

Seven O 0 4.100024852959905e-06
further O 0 2.204370503022801e-06
molecular O 0 2.092462636937853e-05
bases O 0 6.678039881080622e-06
of O 0 0.00012149068061262369
C7 B-Disease 1 0.9984460473060608
deficiency I-Disease 1 0.99912029504776
are O 0 2.1788277990708593e-06
described O 0 0.00022021545737516135
. O 0 2.6835788958123885e-05

All O 0 4.1234403624912375e-07
these O 0 1.7070233582217043e-07
new O 0 2.17273372982163e-06
molecular O 0 0.0003659306385088712
defects O 0 0.04539547488093376
involve O 0 1.215110728480795e-06
single O 0 1.5289711541299766e-07
- O 0 1.2751707799907308e-05
nucleotide O 0 1.1391099263846627e-07
events O 0 2.525538533859617e-08
, O 0 1.1288983081669812e-08
deletions O 0 3.4254165370839473e-07
and O 0 7.310030802898382e-09
substitutions O 0 8.520741801021359e-08
, O 0 4.584466584134361e-09
some O 0 5.189372265235193e-10
of O 0 1.6958533466393533e-09
which O 0 1.666005822187344e-08
alter O 0 7.761532287986483e-06
splice O 0 9.898578355205245e-06
sites O 0 9.39140818445594e-08
, O 0 4.984639545568825e-08
and O 0 9.338054951513186e-08
others O 0 8.170943601726322e-07
codons O 0 9.690957085695118e-05
. O 0 1.2347837582638022e-05

They O 0 3.866029487653577e-07
are O 0 2.6406098641018616e-08
distributed O 0 4.131449671262999e-08
along O 0 7.479562214030011e-08
the O 0 2.1781227133033099e-07
C7 O 0 0.38550305366516113
gene O 0 2.637303850860917e-06
, O 0 2.3286149897217e-08
but O 0 6.764413917892398e-09
predominantly O 0 1.364998158948083e-08
towards O 0 2.875642302058168e-08
the O 0 3.707499729443953e-08
3 O 0 1.3630907460537856e-06
end O 0 1.0457728421897627e-05
. O 0 8.154664101311937e-06

All O 0 5.654771371155221e-07
were O 0 1.461486220932784e-07
found O 0 1.991451483718265e-07
in O 0 2.7360715648683254e-07
compound O 0 3.082070907112211e-05
heterozygous O 0 8.962898573372513e-05
individuals O 0 1.0048283911601175e-05
. O 0 3.253640534239821e-05

The O 0 7.241265120683238e-05
C6 O 1 0.9603444933891296
/ O 0 0.36733904480934143
C7 O 1 0.8405488133430481
marker O 0 0.0012740549864247441
haplotypes O 0 0.0038422623183578253
associated O 0 1.667268224991858e-05
with O 0 4.1241623875976074e-06
most O 0 5.986206451780163e-05
C7 B-Disease 1 0.9982360601425171
defects I-Disease 1 0.9765170812606812
are O 0 2.766375644114305e-07
tabulated O 0 2.310648596903775e-05
. O 0 1.3086581702737021e-06
. O 0 1.0227731763734482e-05

A O 0 9.261706509278156e-06
genome O 0 3.539396857377142e-05
- O 0 3.868116618832573e-05
wide O 0 1.085416897694813e-06
search O 0 5.047699005444883e-07
for O 0 3.944890067941742e-07
chromosomal O 0 0.002917305566370487
loci O 0 0.0004930402501486242
linked O 0 0.002573312260210514
to O 0 9.553034760756418e-05
mental O 1 0.9990496039390564
health O 1 0.9651067852973938
wellness O 1 0.6293161511421204
in O 0 4.812076440430246e-06
relatives O 0 6.90982342348434e-05
at O 0 3.632329753600061e-05
high O 0 0.023648304864764214
risk O 1 0.9417895674705505
for O 0 0.255098819732666
bipolar B-Disease 1 0.9998774528503418
affective I-Disease 1 0.999631404876709
disorder I-Disease 1 0.9996352195739746
among O 0 1.54423887579469e-05
the O 0 1.2164487088739406e-06
Old O 0 0.00010439245670568198
Order O 0 1.0299027053406462e-05
Amish O 0 0.001101681962609291
. O 0 3.1310617487179115e-05

Bipolar B-Disease 1 0.9956106543540955
affective I-Disease 1 0.9957329630851746
disorder I-Disease 1 0.9978787899017334
( O 1 0.5053918361663818
BPAD B-Disease 1 0.9964587092399597
; O 1 0.9659873247146606
manic B-Disease 1 0.999066174030304
- I-Disease 1 0.9993304014205933
depressive I-Disease 1 0.9997005462646484
illness I-Disease 1 0.9994288086891174
) O 0 0.0001241841382579878
is O 0 1.576072918396676e-06
characterized O 0 8.708577661309391e-05
by O 0 1.1806456967633494e-07
episodes O 0 3.1519557524006814e-06
of O 0 4.558817181532504e-06
mania B-Disease 1 0.9982292056083679
and O 0 2.6329327738494612e-05
/ O 0 0.2517438232898712
or O 0 1.9606362911872566e-05
hypomania B-Disease 1 0.9633877277374268
interspersed O 0 4.120320227229968e-05
with O 0 1.778153887244116e-06
periods O 0 0.00010175365605391562
of O 0 1.910995524667669e-05
depression B-Disease 1 0.9944186210632324
. O 0 0.00021767639555037022

Compelling O 0 5.063138814875856e-05
evidence O 0 5.6495118769817054e-06
supports O 0 1.0631523764459416e-05
a O 0 5.70674217215128e-07
significant O 0 9.164934908767464e-07
genetic O 0 1.8744236513157375e-05
component O 0 2.665349484232138e-06
in O 0 1.792520976096057e-07
the O 0 8.725348834559554e-07
susceptibility O 0 0.0046037170104682446
to O 0 3.4088752727257088e-06
develop O 0 0.005482778884470463
BPAD B-Disease 1 0.9881293773651123
. O 0 0.00011067342711612582

To O 0 2.204017391704838e-06
date O 0 2.2317781258607283e-06
, O 0 4.492677305734105e-07
however O 0 1.5664885211208457e-07
, O 0 1.1928676713068853e-07
linkage O 0 3.340230614412576e-05
studies O 0 1.824895008439853e-07
have O 0 4.625607896713291e-09
attempted O 0 8.177251942242947e-08
only O 0 5.626163090965974e-09
to O 0 3.3194407222936206e-08
identify O 0 3.1829113140702248e-06
chromosomal O 0 0.004947596229612827
loci O 0 5.218658407102339e-05
that O 0 3.0328496336551325e-07
cause O 0 0.0003175880992785096
or O 0 8.290733148896834e-07
increase O 0 5.4122483561513945e-06
the O 0 6.071685447750497e-07
risk O 0 0.0008038414525799453
of O 0 1.7799761735659558e-06
developing O 0 0.01942470297217369
BPAD B-Disease 1 0.9904413223266602
. O 0 0.00010992707393597811

To O 0 2.4119976842484903e-06
determine O 0 2.4599075914011337e-06
whether O 0 7.800331331964117e-07
there O 0 1.1477529682224485e-07
could O 0 1.7497271187494334e-07
be O 0 3.858330899220164e-08
protective O 0 0.0009777088416740298
alleles O 0 7.9640694821137e-06
that O 0 1.2119612335936836e-07
prevent O 0 2.8445254429243505e-05
or O 0 9.234138929059554e-07
reduce O 0 5.429387601907365e-05
the O 0 1.9369706194538594e-07
risk O 0 0.0001295302645303309
of O 0 1.788966983440332e-07
developing O 0 0.005643101874738932
BPAD B-Disease 1 0.9845908880233765
, O 0 2.0409788703545928e-07
similar O 0 5.087880339260664e-08
to O 0 1.2161867957161121e-08
what O 0 1.8973981497083514e-08
is O 0 1.126375526183665e-08
observed O 0 1.5741095182875142e-07
in O 0 5.727204097638605e-07
other O 0 3.9814978663343936e-05
genetic B-Disease 1 0.9986302852630615
disorders I-Disease 1 0.9998224377632141
, O 0 9.679014510766137e-06
we O 0 2.0201703136990545e-06
used O 0 0.0001545953709864989
mental O 1 0.999096155166626
health O 1 0.9928832054138184
wellness O 1 0.9769794344902039
( O 0 5.147361662238836e-05
absence O 0 3.9963637391338125e-05
of O 0 1.5795937997609144e-06
any O 0 0.0008086054003797472
psychiatric B-Disease 1 0.9996849298477173
disorder I-Disease 1 0.999705970287323
) O 0 7.626626484125154e-06
as O 0 8.150034602749656e-08
the O 0 7.533553514349478e-08
phenotype O 0 1.9706594684976153e-05
in O 0 1.6810338010486703e-08
our O 0 3.968041539792466e-08
genome O 0 4.496098426898243e-06
- O 0 1.1383685887267347e-05
wide O 0 4.742896351217496e-07
linkage O 0 4.9678624236548785e-06
scan O 0 2.0079755813640077e-06
of O 0 2.479236149710573e-09
several O 0 7.01785030088331e-09
large O 0 2.82263840745145e-07
multigeneration O 0 0.00042964849853888154
Old O 0 4.772870852320921e-06
Order O 0 4.024967950044811e-07
Amish O 0 0.00025481663760729134
pedigrees O 0 0.0008336988976225257
exhibiting O 0 6.593371654162183e-05
an O 0 3.8029429560992867e-07
extremely O 0 3.3970871299970895e-05
high O 0 0.00010809355444507673
incidence O 0 0.025212571024894714
of O 0 5.834768671775237e-06
BPAD B-Disease 1 0.984538197517395
. O 0 6.923932232894003e-05

We O 0 1.7732057813191204e-06
have O 0 8.044520427574753e-08
found O 0 7.915784294709738e-08
strong O 0 1.219181058331742e-07
evidence O 0 4.026964006698108e-08
for O 0 7.506728572082011e-09
a O 0 4.197183400833637e-08
locus O 0 3.804905418292037e-06
on O 0 8.785402627609074e-08
chromosome O 0 4.359894955996424e-05
4p O 0 0.4280238747596741
at O 0 4.977775347470015e-07
D4S2949 O 0 4.9871661758515984e-05
( O 0 5.328372765234235e-08
maximum O 0 9.161791325595914e-08
GENEHUNTER O 0 0.00013734522508457303
- O 0 3.731169726961525e-06
PLUS O 0 3.063593965180189e-07
nonparametric O 0 8.423879762631259e-07
linkage O 0 3.8874358665452746e-07
score O 0 1.316359021785729e-08
= O 0 7.502078460674966e-07
4 O 0 2.1262380300868244e-08
. O 0 5.080420528713603e-09
05 O 0 3.0260885068855714e-06
, O 0 1.2392304959973899e-08
P O 0 4.373239789856598e-06
= O 0 5.694814149137528e-07
5 O 0 7.432883641911303e-09
. O 0 1.1777073760654844e-09
22 O 0 1.129520743603507e-08
x O 0 2.6185622914454143e-07
10 O 0 1.5249511875481403e-08
( O 0 3.293363803891225e-08
- O 0 5.697676783711358e-07
4 O 0 4.129488218040933e-08
) O 0 1.761664414345887e-08
; O 0 4.261222485979488e-08
SIBPAL O 0 7.489677955163643e-05
Pempirical O 0 8.571159014536534e-06
value O 0 6.815868314191675e-09
< O 0 3.637844429249526e-06
3 O 0 3.62711141121963e-08
x O 0 1.0644504300216795e-06
10 O 0 2.1711661801759874e-08
( O 0 5.3629982232905604e-08
- O 0 1.672994471846323e-06
5 O 0 6.510936145787127e-08
) O 0 1.586872500070058e-08
) O 0 5.0761004288801814e-09
and O 0 1.5899284111497991e-09
suggestive O 0 3.5065809811385407e-07
evidence O 0 3.690628469499302e-09
for O 0 9.701905945291855e-10
a O 0 6.698356980194831e-09
locus O 0 9.973064152291045e-07
on O 0 4.546346232814358e-08
chromosome O 0 4.802756302524358e-05
4q O 0 0.2626487910747528
at O 0 2.483658931851096e-07
D4S397 O 0 5.5471944506280124e-05
( O 0 6.472564706427875e-08
maximum O 0 8.315028310335038e-08
GENEHUNTER O 0 0.000661658588796854
- O 0 7.420537713187514e-06
PLUS O 0 5.117731234349776e-07
nonparametric O 0 7.784234981045302e-07
linkage O 0 2.210969825000575e-07
score O 0 1.3441896484778226e-08
= O 0 4.3881442479687394e-07
3 O 0 9.48810807699374e-09
. O 0 2.0710411163804565e-09
29 O 0 1.9918232396776148e-08
, O 0 1.5018533972011028e-08
P O 0 7.551041562692262e-06
= O 0 9.328635428573762e-07
2 O 0 1.6700559157811767e-08
. O 0 3.9506105053987994e-09
57 O 0 7.954135128329654e-08
x O 0 3.26340654055457e-07
10 O 0 1.3229865203356894e-08
( O 0 3.3543251731771306e-08
- O 0 9.270500527236436e-07
3 O 0 4.16858121354835e-08
) O 0 1.9494901692951316e-08
; O 0 4.6512578677493366e-08
SIBPAL O 0 8.638967847218737e-05
Pempirical O 0 1.232148952112766e-05
value O 0 9.317431270972065e-09
< O 0 8.432661161350552e-06
1 O 0 5.528627866624447e-08
x O 0 7.749422366032377e-07
10 O 0 2.8241883498481002e-08
( O 0 9.504231712753608e-08
- O 0 2.9767707019345835e-06
3 O 0 1.279595522873933e-07
) O 0 4.842367928858948e-08
) O 0 1.21045911072315e-08
that O 0 2.8043316557813114e-09
are O 0 1.5788478080480672e-08
linked O 0 7.739132706774399e-05
to O 0 1.8272916349815205e-05
mental O 1 0.9969786405563354
health O 1 0.9859014749526978
wellness O 1 0.9378131031990051
. O 0 0.00019071092538069934

These O 0 2.334582177354605e-06
findings O 0 6.13431575402501e-06
are O 0 2.330605575195932e-08
consistent O 0 1.3108549978824158e-07
with O 0 2.997378345526158e-08
the O 0 4.022657407176666e-08
hypothesis O 0 8.914393561099132e-07
that O 0 8.24238988172965e-09
certain O 0 5.655073920252107e-08
alleles O 0 3.56702298631717e-06
could O 0 2.528595075546036e-07
prevent O 0 2.444711935822852e-05
or O 0 3.670364208119281e-07
modify O 0 4.840538531425409e-05
the O 0 6.519312023556267e-07
clinical O 0 0.0014650918310508132
manifestations O 0 0.0004532383754849434
of O 0 2.169210119973286e-06
BPAD B-Disease 1 0.9954898953437805
and O 0 5.994569164613495e-06
perhaps O 0 5.162099114386365e-05
other O 0 3.558331809472293e-05
related O 1 0.8025186657905579
affective B-Disease 1 0.9983415603637695
disorders I-Disease 1 0.9986757636070251
. O 0 0.002705069724470377

Segregation O 0 0.14179128408432007
distortion O 0 0.3770811855792999
in O 0 0.02388818934559822
myotonic B-Disease 1 0.992335855960846
dystrophy I-Disease 1 0.9945698380470276
. O 0 0.0077069103717803955

Myotonic B-Disease 1 0.9916967153549194
dystrophy I-Disease 1 0.9968180656433105
( O 1 0.6677610278129578
DM B-Disease 1 0.9980214834213257
) O 0 9.722696267999709e-05
is O 0 3.3285818972217385e-06
an O 0 4.3925763748120517e-05
autosomal B-Disease 1 0.9977203011512756
dominant I-Disease 1 0.9746825098991394
disease I-Disease 1 0.9994315505027771
which O 0 5.169235350876988e-07
, O 0 1.5724411639439495e-07
in O 0 2.83252319377425e-08
the O 0 5.90063713445943e-08
typical O 0 2.3050915842759423e-05
pedigree O 0 0.00014526641461998224
, O 0 2.2207979455401983e-08
shows O 0 1.6797388369127475e-08
a O 0 2.2183128223218773e-08
three O 0 8.584934363398133e-08
generation O 0 7.646103040315211e-05
anticipation O 0 0.00029841787181794643
cascade O 0 0.005563898477703333
. O 0 1.781538230716251e-05

This O 0 1.135282036557328e-05
results O 0 0.00010951891454169527
in O 0 0.00044026740943081677
infertility B-Disease 1 0.9974853992462158
and O 0 0.4748559594154358
congenital B-Disease 1 0.9995970129966736
myotonic I-Disease 1 0.9995740056037903
dystrophy I-Disease 1 0.9996916055679321
( O 0 0.008950254879891872
CDM B-Disease 1 0.5974240303039551
) O 0 8.82521192124841e-07
with O 0 7.180851469001936e-08
the O 0 6.8470654923658e-08
disappearance O 0 1.7419566574972123e-05
of O 0 2.927519744844176e-06
DM B-Disease 1 0.9981650710105896
in O 0 2.9465941224771086e-06
that O 0 1.0412719575469964e-06
pedigree O 0 0.0033202290069311857
. O 0 2.0551447960315272e-05

The O 0 1.2647386711250874e-06
concept O 0 1.0480646324140253e-06
of O 0 3.5688807997757976e-07
segregation O 0 0.0017304609064012766
distortion O 0 0.0004411181143950671
, O 0 1.899185662068703e-07
where O 0 2.8933190066027237e-08
there O 0 7.451407491032569e-09
is O 0 7.830276871345632e-09
preferential O 0 4.284588328573591e-07
transmission O 0 2.2227308704714233e-07
of O 0 1.3109738850047847e-09
the O 0 5.075026177081554e-09
larger O 0 6.436591348801812e-08
allele O 0 4.6333718728419626e-07
at O 0 9.34129715801646e-08
the O 0 8.218278821914282e-07
DM B-Disease 1 0.9989657402038574
locus O 0 0.00012269295984879136
, O 0 1.01898258719757e-07
has O 0 1.1276802602822045e-08
been O 0 1.380260794547894e-09
put O 0 9.80188552546224e-09
forward O 0 1.1818935163887545e-08
to O 0 1.2036742269572187e-08
explain O 0 1.1921219993382692e-06
partially O 0 2.115701136062853e-06
the O 0 4.588667934513069e-08
maintenance O 0 3.0375984351849183e-05
of O 0 1.0321022045900463e-06
DM B-Disease 1 0.9986374974250793
in O 0 5.524548214452807e-07
the O 0 6.603711995012418e-07
population O 0 4.767638984048972e-06
. O 0 7.323008958337596e-06

In O 0 1.3636082485390943e-06
a O 0 5.355699954634474e-07
survey O 0 2.9836940029781545e-06
of O 0 7.993265285222151e-07
DM B-Disease 1 0.9966320395469666
in O 0 3.6029652505931153e-07
Northern O 0 8.859516924530908e-07
Ireland O 0 2.788035317280446e-06
, O 0 5.08912251007132e-07
59 O 0 1.6748903362895362e-05
pedigrees O 0 0.0001257375697605312
were O 0 2.3062388265771006e-07
ascertained O 0 9.741666144691408e-05
. O 0 9.846964530879632e-06

Sibships O 0 0.011060867458581924
where O 0 8.280745191768801e-07
the O 0 1.2113972047700372e-07
status O 0 1.830245821565768e-07
of O 0 6.5196079646057115e-09
all O 0 4.259229413605681e-09
the O 0 1.1257805354603079e-08
members O 0 2.6676630682231917e-08
had O 0 5.569673433569733e-08
been O 0 9.59953005974512e-09
identified O 0 5.228771726706327e-08
were O 0 1.969679752633624e-09
examined O 0 2.854315255262918e-07
to O 0 2.1296380214863575e-09
determine O 0 5.443036688035363e-09
the O 0 3.656910108063016e-09
transmission O 0 2.538409376029449e-07
of O 0 1.101253044311079e-08
the O 0 9.761885166881257e-07
DM B-Disease 1 0.9987553358078003
expansion O 0 4.939060454489663e-05
from O 0 1.0052981451735832e-06
affected O 0 1.0460461453476455e-05
parents O 0 3.9928684714141127e-07
to O 0 2.8447542987919405e-08
their O 0 1.7550249253872607e-07
offspring O 0 0.00019030187104362994
. O 0 2.2318386982078664e-05

Where O 0 4.6350082811841276e-06
the O 0 1.5496328842345974e-06
transmitting O 0 0.00018639452173374593
parent O 0 5.6129803851945326e-05
was O 0 8.611400517111178e-07
male O 0 7.291968813660787e-06
, O 0 1.6721809288355871e-06
58 O 0 0.0001169589304481633
. O 0 1.5119930139917415e-05

3 O 0 7.563971394120017e-06
% O 0 2.4293223077620496e-07
of O 0 2.9267546608480188e-08
the O 0 1.026949050242365e-07
offspring O 0 7.0672299443685915e-06
were O 0 2.4676745979945736e-08
affected O 0 2.9735701900790446e-06
, O 0 3.3930753318145435e-08
and O 0 1.20357555033479e-08
in O 0 7.265618773288907e-09
the O 0 6.17272277736447e-09
case O 0 3.497252265560746e-08
of O 0 7.195477547128348e-09
a O 0 3.3099013307946734e-07
female O 0 1.1942377568630036e-05
transmitting O 0 0.00032833314617164433
parent O 0 5.003538535675034e-05
, O 0 1.4263504226619261e-06
68 O 0 0.00011003425606759265
. O 0 1.1585909305722453e-05

7 O 0 5.26978874404449e-05
% O 0 1.2597511158674024e-05
were O 0 1.7067072803911287e-06
affected O 0 0.00012826941383536905
. O 0 2.6706073185778223e-05

Studies O 0 6.521620434796205e-06
on O 0 4.966494770997087e-07
meiotic O 0 0.0023240603040903807
drive O 0 4.056926627526991e-05
in O 0 1.0029415534518193e-05
DM B-Disease 1 0.9985784292221069
have O 0 5.383515855328369e-08
shown O 0 1.0206495204556632e-07
increased O 0 1.330396202092743e-07
transmission O 0 1.5196761182778573e-07
of O 0 9.303682269035107e-10
the O 0 2.987383007635458e-09
larger O 0 1.6149645887253428e-07
allele O 0 5.511434437721618e-07
at O 0 4.2661344679117974e-08
the O 0 2.53649773185316e-07
DM B-Disease 1 0.99503493309021
locus O 0 3.4759224945446476e-05
in O 0 7.233306860143784e-07
non O 0 0.0002030738687608391
- O 0 0.4169577360153198
DM O 1 0.9978026747703552
heterozygotes O 0 0.023329947143793106
for O 0 7.039589945634361e-06
CTGn O 0 0.09026623517274857
. O 0 3.790059417951852e-05

This O 0 2.060598262687563e-06
study O 0 1.6731762570998399e-06
provides O 0 7.886575303928112e-07
further O 0 1.650458330004767e-07
evidence O 0 1.58746942702237e-07
that O 0 4.655962015931436e-08
the O 0 1.2102741493436042e-06
DM B-Disease 1 0.9980802536010742
expansion O 0 0.00018672342412173748
tends O 0 2.7864301955560222e-05
to O 0 1.0669806727037212e-07
be O 0 1.654481565083188e-07
transmitted O 0 0.00010603430564515293
preferentially O 0 5.265201980364509e-05
. O 0 5.856946245330619e-06

Diagnosis O 1 0.9621763229370117
of O 0 0.0010658203391358256
hemochromatosis B-Disease 1 0.9907376170158386
. O 0 0.0026671672239899635

If O 0 0.0059953005984425545
untreated O 1 0.9940569400787354
, O 0 0.09488799422979355
hemochromatosis B-Disease 1 0.9988095760345459
can O 0 0.03830128163099289
cause O 1 0.9898635745048523
serious O 1 0.9965971112251282
illness O 1 0.9991983771324158
and O 0 7.104137694113888e-06
early B-Disease 0 3.815324816969223e-05
death I-Disease 0 0.0010014561703428626
, O 0 6.643724191235378e-06
but O 0 4.920133960695239e-06
the O 0 0.0001148251467384398
disease O 1 0.9991577863693237
is O 0 2.9867062494304264e-06
still O 0 2.3452563254977576e-05
substantially O 0 0.013617550022900105
under O 0 0.0011940927943214774
- O 1 0.9910339713096619
diagnosed O 1 0.9979122281074524
. O 0 0.00014753540745005012

The O 0 4.344217359175673e-06
cornerstone O 0 0.0001102819514926523
of O 0 3.1295462576963473e-07
screening O 0 2.657388904481195e-05
and O 0 3.6808734193982673e-07
case O 0 1.192442709907482e-06
detection O 0 8.043006346269976e-06
is O 0 8.214296798314535e-09
the O 0 5.109418221849182e-09
measurement O 0 1.1208702233034273e-07
of O 0 2.997292725126499e-08
serum O 0 0.0006829553167335689
transferrin O 0 0.0010269969934597611
saturation O 0 6.388380370481173e-06
and O 0 4.677226073113161e-08
the O 0 2.385383481851022e-07
serum O 0 0.0009458068525418639
ferritin O 0 0.0013906472595408559
level O 0 5.442443580250256e-06
. O 0 3.4903400774055626e-06

Once O 0 0.00016163116379175335
the O 0 4.4624568545259535e-05
diagnosis O 1 0.7894641757011414
is O 0 2.2607143819186604e-06
suspected O 0 2.8497714083641768e-05
, O 0 1.2723978670692304e-06
physicians O 0 0.00010460319754201919
must O 0 2.0016571511405346e-07
use O 0 5.327397047949489e-07
serum O 0 0.009417765773832798
ferritin O 0 0.03183222934603691
levels O 0 7.868194188631605e-06
and O 0 1.3762021353613818e-06
hepatic O 1 0.8696522116661072
iron O 0 0.0017801040085032582
stores O 0 8.131887625495438e-06
on O 0 1.2998546480957884e-05
liver O 1 0.9971809387207031
biopsy O 0 0.1561945527791977
specimens O 0 8.032494952203706e-05
to O 0 1.8209709651273442e-06
assess O 0 0.006171211134642363
patients O 0 0.005587174091488123
for O 0 7.713693150890322e-08
the O 0 1.4550028026860673e-07
presence O 0 1.934472493303474e-06
of O 0 2.729134166656877e-06
iron B-Disease 1 0.9112744927406311
overload I-Disease 1 0.9760105013847351
. O 0 6.132647104095668e-05

Liver O 1 0.9947764873504639
biopsy O 0 0.34283700585365295
is O 0 7.012594096522662e-07
also O 0 5.3559755741616755e-08
used O 0 1.1280373968247659e-08
to O 0 5.478407505421501e-09
establish O 0 5.11928313073895e-08
the O 0 2.1000762018275054e-08
presence O 0 5.858560712113103e-07
or O 0 4.4379990526977053e-07
absence O 0 3.4859811421483755e-05
of O 0 1.2596249689522665e-05
cirrhosis B-Disease 1 0.9995368719100952
, O 0 4.6635623220936395e-06
which O 0 5.639546429847542e-07
can O 0 7.0589712777291425e-06
affect O 0 0.0036930665373802185
prognosis O 1 0.9942532181739807
and O 0 1.4011324310558848e-05
management O 0 0.001041644369252026
. O 0 3.49640213244129e-05

A O 0 6.284733899519779e-06
DNA O 0 8.310338671435602e-06
- O 0 3.348512836964801e-05
based O 0 1.0034258224322912e-07
test O 0 1.7929225748503086e-07
for O 0 1.55349848540709e-08
the O 0 1.1024282287053211e-07
HFE O 0 0.1171507015824318
gene O 0 8.10442713827797e-07
is O 0 8.996689615514697e-09
commercially O 0 4.132616027163749e-08
available O 0 9.148307000828027e-09
, O 0 3.4925580205680262e-09
but O 0 7.882810515447147e-10
its O 0 2.1824833051908854e-09
place O 0 1.167248697697687e-08
in O 0 4.5696889827695486e-08
the O 0 1.2100238109269412e-06
diagnosis O 1 0.8303447961807251
of O 0 6.364764703903347e-05
hemochromatosis B-Disease 1 0.9996471405029297
is O 0 3.398329226911301e-06
still O 0 2.833469125107513e-06
being O 0 1.1346304518156103e-06
evaluated O 0 4.283357338863425e-05
. O 0 7.703804840275552e-06

Currently O 0 7.378064765362069e-06
, O 0 4.720766639820795e-07
the O 0 3.3336405635964184e-08
most O 0 1.6262431401514732e-08
useful O 0 4.097477201980837e-08
role O 0 6.1637720705221e-08
for O 0 4.5145962523918115e-09
this O 0 3.4518552460838237e-09
test O 0 1.1324161164338875e-07
is O 0 2.9272890778031524e-09
in O 0 3.2681695127934063e-09
the O 0 1.5789289875556278e-08
detection O 0 7.931809705041815e-06
of O 0 3.6951388437955757e-07
hemochromatosis B-Disease 1 0.9986573457717896
in O 0 1.9863831823840883e-07
the O 0 7.316827321801611e-08
family O 0 1.4188696013661684e-06
members O 0 3.0463926492529936e-08
of O 0 2.897122328704427e-07
patients O 0 0.02835427038371563
with O 0 7.692489703003957e-07
a O 0 5.555891675612656e-06
proven O 0 8.468077430734411e-05
case O 0 5.7955935517384205e-06
of O 0 1.411489847669145e-06
the O 0 0.00024585702340118587
disease O 1 0.9971380233764648
. O 0 0.00022954084852244705

It O 0 2.70499185717199e-06
is O 0 1.3320482139533851e-06
crucial O 0 2.4563099941588007e-05
to O 0 0.0001612736814422533
diagnose O 1 0.9978266358375549
hemochromatosis B-Disease 1 0.9990189075469971
before O 1 0.584072470664978
hepatic B-Disease 1 0.9991843104362488
cirrhosis I-Disease 1 0.9994993209838867
develops O 1 0.9949796795845032
because O 0 0.01715743914246559
phlebotomy O 1 0.9969385862350464
therapy O 1 0.9958211183547974
can O 0 0.11241202801465988
avert O 1 0.9993810653686523
serious O 1 0.9997007846832275
chronic O 1 0.9999496936798096
disease O 1 0.9998028874397278
and O 0 1.540764787932858e-05
can O 0 8.490508207614766e-07
even O 0 5.101917963656888e-07
lead O 0 2.0723716716020135e-06
to O 0 1.948487096115059e-07
normal O 0 1.2313325896684546e-05
life O 0 6.258497887756675e-05
expectancy O 0 0.012576662003993988
. O 0 2.2758677005185746e-06
. O 0 1.0998571269738022e-05

Prevalence O 0 0.0026649334467947483
of O 0 9.107785672313184e-07
the O 0 1.6655903891660273e-06
I1307K O 0 0.009168409742414951
APC B-Disease 0 0.017812764272093773
gene O 0 4.0154649468604475e-05
variant O 0 0.0001558026415295899
in O 0 8.668801854128105e-08
Israeli O 0 7.222333238132705e-07
Jews O 0 1.0644925652059101e-07
of O 0 7.257392020676434e-09
differing O 0 6.878269687149441e-07
ethnic O 0 7.709778628850472e-07
origin O 0 1.9151561900798697e-06
and O 0 5.0957867642864585e-05
risk O 1 0.8728086948394775
for O 0 0.3112717568874359
colorectal B-Disease 1 0.9996981620788574
cancer I-Disease 1 0.9992601275444031
. O 0 0.004644250031560659

BACKGROUND O 0 0.00044090853771194816
& O 0 0.0005892832414247096
AIMS O 0 4.533444734988734e-05
Israeli O 0 3.776080347961397e-06
Jews O 0 7.14529448941903e-07
of O 0 3.190869080071934e-08
European O 0 3.821396603598259e-06
birth O 0 2.5014012862811796e-05
, O 0 3.0225473324207996e-07
i O 0 2.590228120880056e-07
. O 0 1.6748344933148474e-08
e O 0 5.650803700518736e-07
. O 0 1.8956438196937597e-08
, O 0 7.754717046282167e-08
Ashkenazim O 0 0.00012222284567542374
, O 0 7.43497139410465e-08
have O 0 5.1926154043258066e-08
the O 0 8.867472388374154e-06
highest O 1 0.9022324085235596
colorectal B-Disease 1 0.9999034404754639
cancer I-Disease 1 0.9998278617858887
incidence O 0 0.3473852276802063
of O 0 7.925437728317775e-08
any O 0 2.2921291531474708e-07
Israeli O 0 4.394486040837364e-06
ethnic O 0 3.0582509680243675e-06
group O 0 3.857334013446234e-05
. O 0 3.68103756045457e-05

The O 0 3.2598021789453924e-05
I1307K O 0 0.017699219286441803
APC B-Disease 0 0.03425891697406769
gene O 0 0.00015490582154598087
variant O 0 0.000693968147970736
was O 0 8.811537668407254e-07
found O 0 4.5458259023689607e-07
in O 0 4.426358657383389e-07
6 O 0 2.7513089662534185e-05
. O 0 1.2258152310096193e-05

1 O 0 3.2694920264475513e-06
% O 0 3.611028489558521e-07
of O 0 4.515563034601655e-08
American O 0 6.128680070105474e-07
Jews O 0 3.1462568017559533e-07
, O 0 3.9730402079385385e-08
28 O 0 1.7526029694181489e-07
% O 0 7.484371877808371e-08
of O 0 4.1580841525501455e-07
their O 0 0.0006824820302426815
familial O 1 0.9995218515396118
colorectal B-Disease 1 0.9999501705169678
cancer I-Disease 1 0.9999104738235474
cases O 0 0.014499219134449959
, O 0 6.108256002335111e-06
but O 0 2.8083030656489427e-07
not O 0 5.192377727780695e-08
in O 0 3.8614680875070917e-07
non O 0 6.576453597517684e-05
- O 0 0.009100348688662052
Jews O 0 3.141616616630927e-05
. O 0 1.634677937545348e-05

We O 0 3.057848516618833e-06
assessed O 0 1.994227022805717e-05
the O 0 2.24232348955411e-06
I1307K O 0 0.08350059390068054
prevalence O 0 0.05680728331208229
in O 0 1.2957821127201896e-07
Israeli O 0 1.234874730471347e-06
Jews O 0 1.1863160409575357e-07
of O 0 1.1637784957940767e-08
differing O 0 5.41973975032306e-07
ethnic O 0 9.387984505337954e-07
origin O 0 2.746486643445678e-06
and O 0 5.019788659410551e-05
risk O 1 0.9032286405563354
for O 0 0.34977811574935913
colorectal B-Disease 1 0.9997816681861877
cancer I-Disease 1 0.9992917776107788
. O 0 0.005007670260965824

METHODS O 0 6.807920271967305e-06
DNA O 0 4.594081019604346e-06
samples O 0 8.01537112238293e-07
from O 0 2.2790638354308612e-07
500 O 0 2.0933191535732476e-06
unrelated O 0 7.224355613288935e-06
Jews O 0 1.8457019734796631e-07
of O 0 3.118201163943013e-08
European O 0 1.650692752264149e-06
or O 0 4.286509351913992e-07
non O 0 8.147707376338076e-06
- O 0 0.00033963509486056864
European O 0 9.049870186572662e-07
origin O 0 1.8054270967127195e-08
, O 0 1.3043948143831585e-08
with O 0 1.904824387111148e-08
or O 0 5.815597603486822e-08
without O 0 2.102749441235119e-08
a O 0 6.330060386972036e-08
personal O 0 1.6434012195531977e-06
and O 0 8.394911787945603e-07
/ O 0 0.007779818028211594
or O 0 2.434633472603309e-07
family O 0 1.3304461390362121e-06
history O 0 6.513085395454254e-07
of O 0 6.929400910848926e-07
neoplasia B-Disease 1 0.9893929958343506
, O 0 1.6056796425800712e-07
were O 0 5.8025424465313336e-09
examined O 0 4.961571562489553e-07
for O 0 1.2735030807675685e-08
the O 0 7.925498124450314e-08
I1307K O 0 0.0007569830631837249
variant O 0 1.4249365449359175e-05
by O 0 7.187686446030739e-09
the O 0 1.4043071594471712e-08
allele O 0 1.7213370711033349e-06
- O 0 9.03643376659602e-06
specific O 0 1.4903056921866664e-07
oligonucleotide O 0 0.0005395873449742794
( O 0 7.8955854405649e-06
ASO O 0 0.032299693673849106
) O 0 4.90988782075874e-07
method O 0 4.877657033830474e-07
. O 0 3.1955762551660882e-06

RESULTS O 0 3.442151137278415e-05
In O 0 1.8716607428359566e-06
persons O 0 3.6315466331870994e-06
at O 0 1.3022867278777994e-05
average O 0 0.0019009128445759416
risk O 1 0.8703242540359497
for O 0 0.24279603362083435
colorectal B-Disease 1 0.9999170303344727
cancer I-Disease 1 0.9997474551200867
, O 0 7.423314673360437e-05
I1307K O 0 0.08565593510866165
was O 0 8.265438964372152e-07
found O 0 2.885230117044557e-07
in O 0 2.6486208071219153e-07
5 O 0 6.388855581462849e-06
. O 0 7.558923698525177e-06

0 O 0 4.679484845837578e-06
% O 0 3.0259275263233576e-07
of O 0 4.7277858072902745e-08
120 O 0 8.314852379953663e-07
European O 0 1.0112386235050508e-06
and O 0 2.6595705548970727e-07
1 O 0 3.6025915051141055e-06
. O 0 5.876438990526367e-06

6 O 0 5.456892267829971e-06
% O 0 2.1778485859158536e-07
of O 0 4.476254389373935e-08
188 O 0 1.4497833944915328e-05
non O 0 4.238495421304833e-06
- O 0 3.685010233311914e-05
European O 0 8.025927513699571e-07
Jews O 0 7.519757332374866e-07
( O 0 9.627732424632995e-07
P O 0 9.326601139036939e-05
= O 0 1.276630882784957e-05
0 O 0 3.3715608083184634e-07
. O 0 6.840591026957554e-08
08 O 0 1.470859660912538e-05
) O 0 6.871896971460956e-07
. O 0 1.4299896520242328e-06

It O 0 2.832334530467051e-06
occurred O 0 5.72782209928846e-06
in O 0 1.3156784461898496e-06
15 O 0 1.4148633454169612e-05
. O 0 1.608540151210036e-05

4 O 0 5.621463515126379e-06
% O 0 4.948198579768359e-07
of O 0 1.7814761577028548e-07
52 O 0 2.7223675715504214e-05
Ashkenazi O 0 0.0006526142824441195
Israelis O 0 1.5372876077890396e-05
with O 0 3.263590770075098e-05
familial O 1 0.9972935318946838
cancer B-Disease 1 0.9987325072288513
( O 0 3.423295493121259e-05
P O 0 0.011684900149703026
= O 0 6.242904782993719e-05
0 O 0 8.983452062238939e-07
. O 0 9.418801028004964e-08
02 O 0 0.00015132635599002242
) O 0 1.9629636582862986e-08
and O 0 3.815422200403873e-09
was O 0 4.503055262006228e-09
not O 0 1.3201424398090467e-09
detected O 0 9.95129241232462e-08
in O 0 9.56724921508112e-09
51 O 0 9.26087750485749e-07
non O 0 3.0137705380184343e-06
- O 0 0.00031007820507511497
European O 0 5.417577540356433e-06
Jews O 0 8.750434062676504e-06
at O 0 5.015739952796139e-05
increased O 0 0.021767083555459976
cancer B-Disease 1 0.9979058504104614
risk O 0 0.18319566547870636
. O 0 6.872084486531094e-05

Colorectal B-Disease 1 0.9942981600761414
neoplasia I-Disease 1 0.993298351764679
occurred O 0 0.0006626651156693697
personally O 0 0.0002101928839692846
or O 0 8.641593467473285e-07
in O 0 3.996502329073337e-08
the O 0 1.2227715728840849e-08
families O 0 4.078615489788717e-08
of O 0 3.2876132927128765e-09
13 O 0 4.147968013512582e-08
of O 0 1.032132868061808e-08
20 O 0 9.767435358298826e-07
Ashkenazi O 0 0.00026642376906238496
I1307K O 0 0.0004972483147867024
carriers O 0 1.0066998584079556e-05
, O 0 2.3029524953699365e-08
8 O 0 6.312216527248893e-08
of O 0 9.315228588491209e-09
whom O 0 4.54253267889726e-07
also O 0 2.4262538644848064e-08
had O 0 2.5608708043023398e-08
a O 0 9.47836298337279e-08
personal O 0 3.354109594511101e-06
or O 0 4.3847097686011693e-07
family O 0 4.310673375584884e-06
history O 0 6.8525332608260214e-06
of O 0 1.4129917872196529e-05
noncolonic O 1 0.9778183698654175
neoplasia B-Disease 1 0.9951424598693848
. O 0 0.00020577377290464938

CONCLUSIONS O 0 4.72992796858307e-05
The O 0 8.937036000133958e-06
I1307K O 0 0.034827739000320435
APC O 0 0.08004340529441833
variant O 0 0.0012238145573064685
may O 0 6.945431323401863e-07
represent O 0 9.526610256216372e-08
a O 0 8.057086233748123e-07
susceptibility O 0 0.011880164965987206
gene O 0 0.00011644169717328623
for O 0 5.8171150158159435e-05
colorectal B-Disease 1 0.9996649026870728
, I-Disease 0 3.2711388939787867e-06
or I-Disease 0 1.2332882306509418e-06
other I-Disease 0 4.259735817413457e-07
, I-Disease 0 3.1724190193926916e-05
cancers I-Disease 1 0.9231984615325928
in O 0 1.5722266653028782e-06
Ashkenazi O 0 0.004447649233043194
Jews O 0 1.3212675185059197e-06
, O 0 1.5592583224588452e-07
and O 0 1.9811240292710863e-07
partially O 0 2.0879977455479093e-05
explains O 0 9.051424967765342e-06
the O 0 4.85815007778001e-07
higher O 0 0.00016477548342663795
incidence O 1 0.9906744360923767
of O 0 0.0950666293501854
colorectal B-Disease 1 0.9998551607131958
cancer I-Disease 1 0.999541163444519
in O 0 2.2068350517656654e-05
European O 0 0.00020868421415798366
Israelis O 0 0.00013835773279424757
. O 0 5.700421388610266e-05

Systematic O 0 2.385707375651691e-05
analysis O 0 5.133645572641399e-06
of O 0 2.986085291922791e-06
coproporphyrinogen O 1 0.5595096349716187
oxidase O 0 0.2449759691953659
gene O 0 0.02150399051606655
defects O 1 0.9453619718551636
in O 0 1.900052302516997e-05
hereditary B-Disease 1 0.6096960306167603
coproporphyria I-Disease 1 0.5904125571250916
and O 0 2.600309016997926e-05
mutation O 0 0.002230570651590824
update O 0 0.0076110572554171085
. O 0 4.0327260649064556e-05

Hereditary B-Disease 1 0.5832920074462891
coproporphyria I-Disease 1 0.8768668174743652
( O 0 0.002219976857304573
HC B-Disease 1 0.9916287660598755
) O 0 0.00010979120270349085
is O 0 2.1513445972232148e-05
an O 0 0.0007948416750878096
acute O 1 0.9991369843482971
hepatic B-Disease 1 0.999416708946228
porphyria I-Disease 1 0.9991527795791626
with O 0 0.004269415978342295
autosomal O 1 0.9971170425415039
dominant O 0 0.20656590163707733
inheritance O 1 0.7842357754707336
caused O 0 0.36388930678367615
by O 0 1.832986527006142e-05
deficient B-Disease 0 0.21241724491119385
activity I-Disease 0 1.1572926723601995e-06
of I-Disease 0 6.72810415380809e-07
coproporphyrinogen I-Disease 0 0.49302324652671814
III I-Disease 0 0.46328815817832947
oxidase I-Disease 0 0.004984844475984573
( O 0 1.092368347599404e-05
CPO O 0 0.0005086277960799634
) O 0 2.07717152989062e-06
. O 0 3.168169087075512e-06

Clinical O 0 0.17407342791557312
manifestations O 0 0.010493827983736992
of O 0 1.7024358385242522e-05
the O 0 0.005076552741229534
disease O 1 0.9990637898445129
are O 0 5.515321845450671e-06
characterized O 0 0.19994737207889557
by O 0 0.0016502465587109327
acute O 1 0.9994223117828369
attacks O 0 0.2372286021709442
of O 0 0.08426842838525772
neurological B-Disease 1 0.9997767806053162
dysfunction I-Disease 1 0.9995617270469666
often O 0 0.0009983601048588753
precipitated O 1 0.5334619283676147
by O 0 1.04836717582657e-05
drugs O 0 0.0024531949311494827
, O 0 2.9919460757810157e-06
fasting O 0 9.448711352888495e-05
, O 0 2.364044848945923e-05
cyclical O 1 0.945643424987793
hormonal O 1 0.7118942141532898
changes O 0 0.00013069389387965202
, O 0 0.0001509526773588732
or O 0 0.03411875665187836
infectious B-Disease 1 0.9985944628715515
diseases I-Disease 1 0.9982255101203918
. O 0 0.00044509238796308637

Skin O 1 0.9941430687904358
photosensitivity O 1 0.9940685033798218
may O 0 0.00023110925394576043
also O 0 1.1205104328837479e-06
be O 0 2.5452013119320327e-07
present O 0 4.885906491836067e-06
. O 0 2.084476000163704e-05

The O 0 6.061872568352555e-07
seven O 0 3.708306621774682e-07
exons O 0 3.3839478419395164e-06
, O 0 7.927432932319789e-08
the O 0 4.550172150175058e-08
exon O 0 9.666739060776308e-05
/ O 0 0.00018408166943117976
intron O 0 0.0001188176465802826
boundaries O 0 1.1117016640582733e-08
and O 0 2.302103618845308e-09
part O 0 2.655361486247898e-09
of O 0 1.0416012496961002e-09
3 O 0 3.762926326089655e-08
noncoding O 0 3.690423454827396e-06
sequence O 0 2.2825772383328058e-09
of O 0 6.600218149799275e-10
the O 0 5.786980672439768e-09
CPO O 0 5.36553807251039e-06
gene O 0 8.588980193735551e-08
were O 0 1.2368801538542584e-09
systematically O 0 1.0642469305821578e-07
analyzed O 0 1.6772416344679186e-08
by O 0 1.4837864270589307e-09
an O 0 4.886146598437335e-09
exon O 0 7.484266006940743e-06
- O 0 5.300080374581739e-06
by O 0 4.142844289845016e-08
- O 0 3.2769356039352715e-05
exon O 0 4.320525113143958e-05
denaturing O 0 0.0013416078872978687
gradient O 0 2.420065902697388e-05
gel O 0 0.0007846443331800401
electrophoresis O 0 0.00018345857097301632
( O 0 1.4374414831763715e-06
DGGE O 0 0.0008727569947950542
) O 0 4.1613919421479295e-08
strategy O 0 9.98959208686756e-08
followed O 0 6.178329847728037e-09
by O 0 1.515856329348253e-09
direct O 0 4.912067641527074e-09
sequencing O 0 3.2932319982137415e-08
in O 0 8.460526501608001e-09
seven O 0 1.484014120478605e-07
unrelated O 0 0.000110537264845334
heterozygous O 0 0.0022167388815432787
HC B-Disease 1 0.998450517654419
patients O 0 0.11411304026842117
from O 0 2.1982907583151245e-06
France O 0 6.17075347690843e-05
, O 0 9.19170190627483e-07
Holland O 0 6.446323095588014e-05
, O 0 1.0585985421585065e-07
and O 0 1.3122934205966885e-07
Czech O 0 2.4015447706915438e-05
Republic O 0 6.992311682552099e-06
. O 0 7.272176844708156e-06

Seven O 0 1.1792906661867164e-05
novel O 0 3.063118856516667e-05
mutations O 0 1.2572128071042243e-05
and O 0 7.384643652130762e-08
two O 0 5.2454634413834356e-08
new O 0 3.2503596685273806e-06
polymorphisms O 0 0.00011903289123438299
were O 0 5.08460175296932e-07
detected O 0 8.167306805262342e-05
. O 0 8.503793651470914e-06

Among O 0 3.374517973497859e-06
these O 0 1.3276458332711627e-07
mutations O 0 9.992343166231876e-07
two O 0 9.888509566735593e-09
are O 0 1.527964599290499e-08
missense O 0 4.9454560212325305e-05
( O 0 2.0905222299916204e-06
G197W O 0 0.00024449979537166655
, O 0 2.3550448702280846e-07
W427R O 0 0.00016756354307290167
) O 0 4.614806314862108e-08
, O 0 2.6411373088564005e-09
two O 0 9.541075707275581e-10
are O 0 3.2546272343836335e-09
nonsense O 0 7.0866599344299175e-06
( O 0 5.948363082097785e-07
Q306X O 0 4.365865606814623e-05
, O 0 5.908205125138011e-08
Q385X O 0 3.969063618569635e-05
) O 0 2.0749128637476133e-08
, O 0 1.0597571709070053e-09
two O 0 2.6916049944425424e-10
are O 0 3.1138833178623315e-10
small O 0 1.5539075803872038e-08
deletions O 0 1.8987867633768474e-06
( O 0 7.35494097625633e-07
662de14bp O 0 0.00016392937686759979
; O 0 2.926627473698318e-07
1168del3bp O 0 8.065622387221083e-05
removing O 0 6.492235797850299e-07
a O 0 1.9649151639100637e-08
glycine O 0 1.0729023642852553e-06
at O 0 3.2837480290481835e-08
position O 0 5.3197815930161596e-08
390 O 0 3.743287606994272e-06
) O 0 3.384000990536151e-08
, O 0 3.24021387498874e-09
and O 0 7.523652811869397e-10
one O 0 4.5036371854045854e-10
is O 0 4.84803697187175e-10
a O 0 2.703038015638981e-09
splicing O 0 3.472165701623453e-07
mutation O 0 6.639453431489528e-07
( O 0 3.315170431505976e-07
IVS1 O 0 0.001451574033126235
- O 0 0.0001584549609106034
15c O 0 0.002640960505232215
- O 0 0.000272960722213611
- O 0 0.0005136259132996202
> O 0 0.00019039989274460822
g O 0 6.029899850545917e-06
) O 0 1.9567732323366727e-08
which O 0 2.6917605921994436e-09
creates O 0 1.8878974117342295e-07
a O 0 4.4802177967540047e-08
new O 0 4.593624680637731e-07
acceptor O 0 0.00011364348756615072
splice O 0 0.0001708788040559739
site O 0 8.863566108630039e-06
. O 0 7.49961327528581e-06

The O 0 4.739641099149594e-06
pathological O 0 0.0002600594889372587
significance O 0 3.2247990588984976e-07
of O 0 1.6960255422304726e-08
the O 0 2.8222123304999513e-08
point O 0 2.6922350571112474e-07
mutations O 0 1.789783527783584e-05
G197W O 0 0.0007360166637226939
, O 0 3.1102007369554485e-07
W427R O 0 0.0002623311011120677
, O 0 1.8660978540196993e-08
and O 0 3.331890985336372e-09
the O 0 3.537415693699586e-09
in O 0 2.296517642719209e-08
- O 0 6.30035501671955e-05
frame O 0 5.1695624279091135e-05
deletion O 0 0.00014228728832677007
390delGly O 0 0.00017284112982451916
were O 0 7.107579858001145e-09
assessed O 0 1.5302373412851011e-07
by O 0 1.5290629873376815e-09
their O 0 9.178906523743535e-10
respective O 0 1.5316411250410056e-08
expression O 0 2.8958366371512057e-08
in O 0 4.043124057773184e-09
a O 0 3.1642084508121116e-08
prokaryotic O 0 1.0780567208712455e-05
system O 0 4.775183697347529e-07
using O 0 3.59031488983419e-08
site O 0 5.619521061817068e-07
- O 0 6.547406519530341e-05
directed O 0 3.527705985106877e-06
mutagenesis O 0 0.0006896939594298601
. O 0 8.552549843443558e-06

These O 0 2.3778300146659603e-06
mutations O 0 6.087024667067453e-05
resulted O 0 7.45386478229193e-06
in O 0 1.473122779316327e-07
the O 0 1.4766082756523247e-07
absence O 0 3.828915396297816e-06
or O 0 1.6643312505948415e-07
a O 0 1.836753966699689e-07
dramatic O 0 2.0758625396410935e-05
decrease O 0 1.5478632121812552e-05
of O 0 2.6011349518739735e-07
CPO O 0 0.000581858679652214
activity O 0 2.772635298242676e-06
. O 0 4.051385076309089e-06

The O 0 1.1665252941384097e-06
two O 0 1.999962790932841e-07
polymorphisms O 0 7.851792361179832e-06
were O 0 2.7565310034560753e-08
localized O 0 1.7937309166882187e-05
in O 0 9.690946711771176e-08
noncoding O 0 3.837990152533166e-05
part O 0 1.2293616791225759e-08
of O 0 2.381940200635313e-09
the O 0 8.308920662614128e-09
gene O 0 2.980452791234711e-07
1 O 0 6.011097042346591e-08
) O 0 3.2517309733748334e-08
a O 0 6.593530343934617e-08
C O 0 0.00018186424858868122
/ O 0 0.00020953475905116647
G O 0 9.237625818059314e-06
polymorphism O 0 3.722682038187486e-07
in O 0 3.842246076857236e-09
the O 0 1.9696845043881694e-08
promotor O 0 0.0007000140030868351
region O 0 3.329091669002082e-07
, O 0 1.5157240795815596e-08
142 O 0 7.575294489470252e-07
bp O 0 1.6345933318007155e-06
upstream O 0 5.075512632402024e-08
from O 0 1.423776208042682e-09
the O 0 1.0167180430897815e-09
transcriptional O 0 1.2419782535744162e-07
initiation O 0 1.3689724198684416e-07
site O 0 8.400488837878584e-08
( O 0 1.83588170443727e-07
- O 0 2.1548596123466268e-05
142C O 0 0.0003247360000386834
/ O 0 0.00011451558384578675
G O 0 1.2864729797001928e-05
) O 0 1.58444386499923e-08
, O 0 1.9849084598178024e-09
and O 0 1.3180818658753424e-09
2 O 0 1.7651254680117745e-08
) O 0 5.536159530805662e-09
a O 0 3.814163651583158e-09
6 O 0 1.8788664135627187e-07
bp O 0 2.686459083633963e-06
deletion O 0 1.5874466043896973e-06
polymorphism O 0 9.852254123643434e-08
in O 0 1.3565079060029461e-09
the O 0 2.3747002142471274e-09
3 O 0 5.8841497008188526e-08
noncoding O 0 2.7616099487204337e-06
part O 0 2.1496391333641895e-09
of O 0 7.463551998654339e-10
the O 0 8.241996418689723e-09
CPO O 0 5.1583210733952e-06
gene O 0 1.075521325333284e-07
, O 0 1.7792748607803333e-08
574 O 0 1.623324897082057e-05
bp O 0 1.4019849459145917e-06
downstream O 0 3.780357005211954e-08
of O 0 5.885558151952353e-10
the O 0 1.039338837216519e-09
last O 0 8.761435132953466e-09
base O 0 2.3786803637904086e-09
of O 0 5.1349641205789e-10
the O 0 2.420918132628458e-09
normal O 0 1.3952288213658903e-07
termination O 0 1.1366068065399304e-05
codon O 0 1.3702593832931598e-06
( O 0 6.854048706372851e-07
+ O 0 0.00012789851462002844
574 O 0 0.0006705536507070065
delATTCTT O 0 0.00186542933806777
) O 0 1.988499661820242e-06
. O 0 2.684796982066473e-06

Five O 0 7.375566201517358e-05
intragenic O 0 0.23197831213474274
dimorphisms O 0 0.04986559599637985
are O 0 1.7657036721629993e-07
now O 0 4.210722295283631e-07
well O 0 6.467295321499478e-08
characterized O 0 8.84542714629788e-06
and O 0 1.4564042416509437e-08
the O 0 7.261116596879447e-09
high O 0 3.260267646965076e-07
degree O 0 1.0496615487909366e-07
of O 0 2.2663968479719188e-08
allelic O 0 0.0008601806475780904
heterogeneity O 0 0.00033557077404111624
in O 0 2.9419275051623117e-06
HC B-Disease 1 0.9890760183334351
is O 0 2.286049323174666e-07
demonstrated O 0 3.671022454909689e-07
with O 0 1.2408245986250677e-08
seven O 0 1.6992538931503987e-08
new O 0 1.4857270969059755e-08
different O 0 1.4433535477920145e-09
mutations O 0 5.476226405676243e-08
making O 0 2.5478272824841497e-09
a O 0 2.398663045966032e-09
total O 0 3.528843661726455e-09
of O 0 2.6409272990690624e-08
nineteen O 0 4.757182614412159e-05
CPO O 0 0.039924830198287964
gene B-Disease 0 0.002292661927640438
defects I-Disease 1 0.5769888758659363
reported O 0 7.559226560260868e-06
so O 0 1.2882425437510392e-07
far O 0 4.3143811012669175e-07
. O 0 4.747562059037591e-07
. O 0 3.818628101726063e-06

Coincidence O 0 8.578142114856746e-06
of O 0 1.868254884129783e-07
two O 0 1.9486338942442671e-07
novel O 0 9.274114745494444e-06
arylsulfatase O 0 0.0006519246380776167
A O 0 6.803817313993932e-07
alleles O 0 2.5353078854095656e-06
and O 0 1.2012230854452355e-07
mutation O 0 1.1690527571772691e-05
459 O 0 0.0007149897865019739
+ O 0 0.0005078500253148377
1G O 0 0.003982816822826862
> O 0 1.8702314264373854e-05
A O 0 4.366869532645978e-08
within O 0 1.093327206547201e-08
a O 0 9.500897135694686e-08
family O 0 4.716554940387141e-06
with O 0 1.7979917174670845e-05
metachromatic B-Disease 1 0.9975678324699402
leukodystrophy I-Disease 1 0.9989476799964905
: O 0 3.2479117635375587e-06
molecular O 0 1.031451802191441e-06
basis O 0 2.354339123655791e-08
of O 0 2.3491632816785568e-07
phenotypic O 0 0.0003128337557427585
heterogeneity O 0 0.005864448379725218
. O 0 4.958173303748481e-05

In O 0 1.8467601421434665e-06
a O 0 7.662631560378941e-07
family O 0 2.535651219659485e-06
with O 0 1.1824463541643127e-07
three O 0 1.0182132115232889e-07
siblings O 0 2.700666846067179e-05
, O 0 8.312014898592679e-08
one O 0 2.2182154779670782e-08
developed O 0 5.0172320698038675e-06
classical O 0 1.2636001883947756e-05
late O 0 0.0021219439804553986
infantile O 1 0.9980910420417786
metachromatic B-Disease 1 0.998611569404602
leukodystrophy I-Disease 1 0.9993140697479248
( O 0 0.007676669862121344
MLD B-Disease 1 0.9983502626419067
) O 0 1.1417345376685262e-05
, O 0 2.526146545278607e-06
fatal O 0 0.010593553073704243
at O 0 5.512180791811261e-07
age O 0 3.5220484733144986e-06
5 O 0 4.095173267160135e-07
years O 0 2.9515339861063694e-07
, O 0 6.521114670476891e-08
with O 0 9.697063205749146e-07
deficient O 0 0.3663599193096161
arylsulfatase O 0 0.00811705831438303
A O 0 3.2289490263792686e-06
( O 0 9.797319762583356e-06
ARSA O 0 0.4587171673774719
) O 0 1.5739743730591726e-07
activity O 0 4.187196012139793e-08
and O 0 4.207257831012612e-08
increased O 0 2.3691379738011165e-06
galactosylsulfatide O 0 0.006752533372491598
( O 0 2.1420624761958607e-05
GS O 1 0.5524121522903442
) O 0 4.056368652527453e-06
excretion O 0 9.483264875598252e-05
. O 0 5.168666575627867e-06

The O 0 8.78273624493886e-07
two O 0 1.3089311323710717e-07
other O 0 1.7019014819652512e-07
siblings O 0 3.907263089786284e-05
, O 0 4.5089493028172e-07
apparently O 0 1.2744758350891061e-06
healthy O 0 4.8177789722103626e-06
at O 0 1.0404922790030469e-07
12 O 0 1.5411717413371662e-07
( O 0 1.5164360434027913e-07
1 O 0 1.5934789132643346e-07
/ O 0 1.641369999560993e-05
2 O 0 4.979508361202534e-08
) O 0 6.5827214790203925e-09
and O 0 1.7296176713088585e-09
15 O 0 2.907614415903481e-08
years O 0 7.288774384051067e-08
, O 0 1.9085701907783914e-08
respectively O 0 8.02392463583601e-08
, O 0 8.393998385258783e-09
and O 0 3.2166973529257348e-09
their O 0 9.801212286220107e-09
father O 0 2.7959806629951345e-06
, O 0 2.1020102280999708e-07
apparently O 0 8.825229542708257e-07
healthy O 0 3.839753844658844e-06
as O 0 1.6847891970428464e-08
well O 0 2.6779302331192412e-08
, O 0 6.141077335541922e-08
presented O 0 2.792668055917602e-06
ARSA O 1 0.5758955478668213
and O 0 2.6575168021736317e-07
GS O 0 0.010617210529744625
values O 0 1.68967115854457e-08
within O 0 6.787379991379794e-09
the O 0 2.5998547314998177e-08
range O 0 2.9111270123394206e-06
of O 0 1.9296307073091157e-05
MLD B-Disease 1 0.9972617626190186
patients O 1 0.7794878482818604
. O 0 9.10831950022839e-05

Mutation O 0 0.00012659862113650888
screening O 0 5.814765700051794e-06
and O 0 6.375097427735454e-08
sequence O 0 8.568183318402589e-08
analysis O 0 2.6238569716952043e-07
disclosed O 0 1.9480576156638563e-06
the O 0 7.81757769630076e-09
involvement O 0 2.3350735034455283e-07
of O 0 4.941225650867409e-09
three O 0 2.494611095471555e-08
different O 0 1.37076483497367e-07
ARSA O 1 0.9557896256446838
mutations O 0 3.760297204280505e-06
being O 0 6.440273203622837e-09
the O 0 4.704701073166007e-09
molecular O 0 1.453671245599253e-07
basis O 0 1.4149271088115256e-08
of O 0 1.716345963131971e-07
intrafamilial O 0 0.012126331217586994
phenotypic O 0 0.0005552261136472225
heterogeneity O 0 0.005331719759851694
. O 0 3.732298864633776e-05

The O 0 4.9348658649250865e-05
late O 0 0.014919253066182137
infantile O 1 0.9968783855438232
patient O 1 0.9556180238723755
inherited O 1 0.6644548177719116
from O 0 2.5985912088799523e-06
his O 0 2.0229024357831804e-06
mother O 0 1.3031427442911081e-05
the O 0 6.376046002287694e-08
frequent O 0 3.780595307034673e-06
0 O 0 4.21626600655145e-06
- O 0 0.0001948389399331063
type O 0 1.2281016097404063e-05
mutation O 0 5.483090262714541e-06
459 O 0 0.00040320123662240803
+ O 0 0.00020654452964663506
1G O 0 0.0014273944543674588
> O 0 3.869699503411539e-05
A O 0 5.416588422235691e-08
, O 0 1.1773733099573747e-08
and O 0 2.644888086322794e-09
from O 0 9.50297796009636e-09
his O 0 5.978168360343261e-08
father O 0 5.308971253725758e-07
a O 0 5.6854322139088254e-08
novel O 0 9.041985435942479e-07
, O 0 3.176198859478063e-08
single O 0 5.545811632146069e-08
basepair O 0 0.0002358669153181836
microdeletion O 0 1.8746241039480083e-05
of O 0 3.58899887586972e-09
guanine O 0 6.011865849586684e-08
at O 0 5.212607678828363e-09
nucleotide O 0 1.05206634515298e-08
7 O 0 1.77330186090785e-08
in O 0 9.16526587957378e-09
exon O 0 9.658866474637762e-06
1 O 0 8.727046179046738e-07
( O 0 1.6451764395242208e-06
7delG O 0 0.0002587612543720752
) O 0 1.5974395637385896e-06
. O 0 1.8484090560377808e-06

The O 0 3.335852852615062e-06
two O 0 1.7842011175162042e-06
clinically O 0 0.002042982494458556
unaffected O 0 0.00025052501587197185
siblings O 0 1.261390934814699e-05
carried O 0 1.37672316213866e-07
the O 0 9.306352666271778e-08
maternal O 0 0.00012957226135767996
mutation O 0 1.5813688150956295e-05
459 O 0 0.002158890478312969
+ O 0 0.001214491669088602
1G O 0 0.0089911799877882
> O 0 5.357515692594461e-05
A O 0 6.433412380602022e-08
and O 0 5.001818070837771e-09
, O 0 2.5292923311326376e-09
on O 0 1.2080204614406398e-09
their O 0 5.253290691342727e-09
paternal O 0 5.702118869521655e-06
allele O 0 4.0892098240874475e-07
, O 0 3.6194247599041773e-09
a O 0 4.375346307483596e-09
novel O 0 4.765011851759482e-08
cytosine O 0 1.2889232436918974e-07
to O 0 4.197068914635338e-09
thymidine O 0 1.97488111552957e-06
transition O 0 7.175292893180085e-08
at O 0 1.5229835170771366e-08
nucleotide O 0 1.822672146545301e-07
2435 O 0 0.0003047753998544067
in O 0 1.3978401547376507e-08
exon O 0 5.4371575970435515e-06
8 O 0 1.0437162956122847e-07
, O 0 6.8196266411746365e-09
resulting O 0 2.2562264945236166e-08
in O 0 2.2838924085277768e-09
substitution O 0 1.851233299987598e-08
of O 0 1.2926034465010616e-08
alanine O 0 6.44965548417531e-05
464 O 0 9.317355579696596e-05
by O 0 6.504593557110638e-07
valine O 0 0.0008774293237365782
( O 0 1.0189082786382642e-05
A464V O 0 0.0010661121923476458
) O 0 4.345422894402873e-06
. O 0 4.497685495152837e-06

The O 0 9.524531378701795e-06
fathers O 0 8.261146285803989e-05
genotype O 0 0.0006675685290247202
thus O 0 4.956793418386951e-06
was O 0 1.1327729225740768e-05
7delG O 0 0.08964326977729797
/ O 0 0.08887815475463867
A464V O 0 0.02165142633020878
. O 0 3.4509565011831e-05

Mutation O 0 0.0015791383339092135
A464V O 0 0.0027844179421663284
was O 0 1.0718837302192696e-06
not O 0 6.300549415527712e-08
found O 0 8.933970718771889e-08
in O 0 2.377103811568304e-07
18 O 0 4.9068319640355185e-05
unrelated O 0 0.23358967900276184
MLD B-Disease 1 0.9992250204086304
patients O 0 0.23580606281757355
and O 0 1.04112507415266e-06
50 O 0 4.240193902660394e-06
controls O 0 6.86518833390437e-05
. O 0 1.5504308976233006e-05

A464V O 0 0.005045172292739153
, O 0 6.831333848822396e-06
although O 0 2.2389174318959704e-06
clearly O 0 5.61594424652867e-06
modifying O 0 0.001065920921973884
ARSA O 1 0.9620795249938965
and O 0 1.6934167433646508e-05
GS O 1 0.9925698637962341
levels O 0 5.4179250582819805e-05
, O 0 7.317831887121429e-07
apparently O 0 2.74847798209521e-06
bears O 0 1.2139837963331956e-05
little O 0 8.984960686575505e-07
significance O 0 7.889915991654561e-07
for O 0 4.3584159925558197e-07
clinical O 0 0.005408372264355421
manifestation O 0 0.00211613648571074
of O 0 7.204583653219743e-06
MLD B-Disease 1 0.9983025789260864
, O 0 3.1954666610545246e-06
mimicking O 0 0.00042589614167809486
the O 0 1.358262238682073e-06
frequent O 0 0.0010270321508869529
ARSA O 1 0.988272488117218
pseudodeficiency O 0 0.45267048478126526
allele O 0 0.0007097210618667305
. O 0 2.2586418708669953e-05

Our O 0 3.859693151753163e-06
results O 0 3.129605147478287e-06
demonstrate O 0 2.107434738718439e-06
that O 0 3.89713079584908e-08
in O 0 8.591290168169508e-08
certain O 0 5.317479008226655e-07
genetic O 0 0.0006656870828010142
conditions O 0 0.005675855558365583
MLD B-Disease 1 0.9980443716049194
- O 0 0.011154653504490852
like O 0 2.5336004910059273e-05
ARSA O 1 0.8836121559143066
and O 0 1.320787532677059e-06
GS O 0 0.3242236077785492
values O 0 9.214014085046074e-08
need O 0 9.067099426829373e-08
not O 0 2.6983248968548423e-09
be O 0 1.4525287639344242e-08
paralleled O 0 0.00045928728650324047
by O 0 0.00012245825200807303
clinical O 1 0.9917263984680176
disease O 1 0.9986912608146667
, O 0 5.581168238677492e-07
a O 0 4.7271277026084135e-07
finding O 0 6.24770154900034e-06
with O 0 2.647301516844891e-05
serious O 0 0.483455091714859
diagnostic O 0 0.46464604139328003
and O 0 0.00010124852997250855
prognostic O 1 0.9538139700889587
implications O 0 0.12461687624454498
. O 0 0.0002683359489310533

Moreover O 0 0.00015958822041284293
, O 0 5.943383712292416e-06
further O 0 1.556363895360846e-05
ARSA O 1 0.9234466552734375
alleles O 0 0.0001049161801347509
functionally O 0 9.585036605130881e-05
similar O 0 1.3780027074972168e-06
to O 0 9.950017556548119e-07
A464V O 0 0.02310875430703163
might O 0 1.455889901080809e-06
exist O 0 3.1559689972482374e-08
which O 0 2.3300357199218524e-09
, O 0 3.5806841935936973e-09
together O 0 6.243341399425617e-09
with O 0 4.6108642237641106e-08
0 O 0 8.54775498737581e-06
- O 0 0.009209614247083664
type O 0 0.0004021436907351017
mutations O 0 1.073429848474916e-05
, O 0 4.773326054419158e-07
may O 0 3.4700778996921144e-06
cause O 0 0.0006869242060929537
pathological O 0 0.3132264018058777
ARSA O 1 0.9958024621009827
and O 0 1.29997861222364e-05
GS O 1 0.9939153790473938
levels O 0 1.9950641217292286e-05
, O 0 1.1221943196915163e-07
but O 0 7.61570149165891e-08
not O 0 3.026839578978979e-07
clinical O 0 0.030343323945999146
outbreak O 0 0.15338459610939026
of O 0 1.039531639435154e-06
the O 0 0.0006835192325524986
disease O 1 0.9986036419868469
. O 0 1.1815229299827479e-05
. O 0 3.134527651127428e-05

Human O 1 0.7013233304023743
MLH1 O 1 0.9870232343673706
deficiency O 1 0.9974800944328308
predisposes O 1 0.9903572201728821
to O 0 0.00998254306614399
hematological B-Disease 1 0.9971206188201904
malignancy I-Disease 1 0.9980664849281311
and O 0 0.04814852401614189
neurofibromatosis B-Disease 1 0.9981259703636169
type I-Disease 0 0.028888961300253868
1 I-Disease 0 0.00016476951714139432
. O 0 5.380637594498694e-05

Heterozygous O 0 0.0035745506174862385
germ O 0 0.35459083318710327
- O 0 0.000613488897215575
line O 0 7.251013357745251e-06
mutations O 0 3.401354433663073e-06
in O 0 2.6287803933655596e-08
the O 0 6.949507280751277e-08
DNA O 0 3.247995482524857e-05
mismatch O 0 0.29601696133613586
repair O 0 0.1262432038784027
genes O 0 1.6400008462369442e-05
lead O 0 5.371250517782755e-05
to O 0 0.00013186268915887922
hereditary B-Disease 1 0.9956623911857605
nonpolyposis I-Disease 1 0.9984477758407593
colorectal I-Disease 1 0.9996337890625
cancer I-Disease 1 0.9992063641548157
. O 0 0.0055048707872629166

The O 0 0.05908991023898125
disease O 1 0.9979954957962036
susceptibility O 0 0.03773300349712372
of O 0 1.2180228168290341e-06
individuals O 0 5.409425739344442e-06
who O 0 3.4208303532068385e-06
constitutionally O 0 8.614739272161387e-06
lack O 0 4.360570983408252e-06
both O 0 2.8322702405603195e-07
wild O 0 0.00011313076538499445
- O 0 0.014157436788082123
type O 0 0.00039944570744410157
alleles O 0 4.661972707253881e-05
is O 0 9.020333209264209e-07
unknown O 0 5.402985607361188e-06
. O 0 8.635006452095695e-06

We O 0 1.8519097011449048e-06
have O 0 1.0072800904481483e-07
identified O 0 1.3702289436423598e-07
three O 0 2.3557944928143115e-08
offspring O 0 6.522211606352357e-06
in O 0 1.1768230478992336e-06
a O 0 0.000430192390922457
hereditary B-Disease 1 0.9987861514091492
nonpolyposis I-Disease 1 0.9995138645172119
colorectal I-Disease 1 0.9999198913574219
cancer I-Disease 1 0.999824583530426
family O 0 0.2329908311367035
who O 0 0.006706438027322292
developed O 1 0.8627951741218567
hematological B-Disease 1 0.9995211362838745
malignancy I-Disease 1 0.9989442229270935
at O 0 3.0571311526728095e-06
a O 0 4.574747265451151e-07
very O 0 2.4394142883465975e-07
early O 0 9.570343308951124e-07
age O 0 5.0758499128278345e-06
, O 0 7.093173337580083e-08
and O 0 1.046714181995867e-08
at O 0 1.1136201294448256e-08
least O 0 2.013334166051095e-09
two O 0 4.722887081420879e-10
of O 0 1.5574584955047044e-09
them O 0 1.224258117105137e-08
displayed O 0 1.7260121012441232e-06
signs O 0 0.0001326634082943201
of O 0 1.0765372280729935e-05
neurofibromatosis B-Disease 1 0.9992530941963196
type I-Disease 0 0.0012331234756857157
1 I-Disease 0 3.3720240026013926e-05
( O 0 6.489139923360199e-05
NF1 B-Disease 1 0.5074412226676941
) O 0 3.701731202454539e-06
. O 0 5.173109457246028e-06

DNA O 0 4.0366139728575945e-06
sequence O 0 5.523220352188218e-07
analysis O 0 4.42132090938685e-07
and O 0 1.2063487986324617e-07
allele O 0 4.379366600915091e-06
- O 0 1.4550275409419555e-05
specific O 0 3.1653069498815967e-08
amplification O 0 1.6794573411971214e-06
in O 0 8.601861445356462e-09
two O 0 1.032502972009297e-08
siblings O 0 1.8721335436566733e-05
revealed O 0 3.019463974851533e-06
a O 0 7.241009711833613e-07
homozygous O 0 0.00016755860997363925
MLH1 O 1 0.8231658935546875
mutation O 0 0.00012680860527325422
( O 0 8.73999215400545e-06
C676T O 0 0.005731311626732349
- O 0 0.013238074257969856
- O 0 0.032349832355976105
> O 0 0.009835421107709408
Arg226Stop O 0 0.010189250111579895
) O 0 2.8888086944789393e-06
. O 0 2.6243701540806796e-06

Thus O 0 6.2237058955361135e-06
, O 0 1.5761449958517915e-06
a O 0 1.4462996205111267e-06
homozygous O 0 0.00021712064335588366
germ O 0 0.49467453360557556
- O 0 0.002813134342432022
line O 0 7.633389759575948e-05
MLH1 O 1 0.6088309288024902
mutation O 0 0.00015618895122315735
and O 0 2.2264030121732503e-05
consequent O 1 0.9403813481330872
mismatch O 1 0.9967256784439087
repair O 1 0.9984472393989563
deficiency O 1 0.9990102052688599
results O 0 6.5229519350396e-06
in O 0 7.168288789216604e-07
a O 0 2.4608518288005143e-05
mutator O 1 0.9907377362251282
phenotype O 1 0.8071557283401489
characterized O 1 0.545281171798706
by O 0 0.002202495699748397
leukemia B-Disease 1 0.9996371269226074
and O 0 0.0035422001965343952
/ O 1 0.9982831478118896
or O 0 0.18991442024707794
lymphoma B-Disease 1 0.9998119473457336
associated O 0 0.01679103821516037
with O 0 0.006127426400780678
neurofibromatosis B-Disease 1 0.9996734857559204
type I-Disease 0 0.008025702089071274
1 I-Disease 0 1.0939364074147306e-05
. O 0 1.5814975995454006e-06
. O 0 5.7563138398109e-06

Missense O 0 0.00854696985334158
mutations O 0 0.00010062319779535756
in O 0 1.372236226870882e-07
the O 0 3.502880119299334e-08
most O 0 1.4925779723284904e-08
ancient O 0 1.315486173325553e-07
residues O 0 1.4897685218784318e-07
of O 0 1.5871114200649572e-08
the O 0 3.362819995800237e-07
PAX6 O 0 0.18824434280395508
paired O 0 4.429766704561189e-05
domain O 0 2.323527724001906e-06
underlie O 0 0.00020405775285325944
a O 0 1.1977219855907606e-06
spectrum O 0 0.00013559886428993195
of O 0 5.925316145294346e-05
human O 1 0.9106676578521729
congenital B-Disease 1 0.99947589635849
eye I-Disease 1 0.9975958466529846
malformations I-Disease 1 0.9975230097770691
. O 0 0.0021744591649621725

Mutations O 0 2.361716906307265e-05
of O 0 2.422670490886958e-07
the O 0 1.203329702548217e-06
human O 0 0.00011567069304874167
PAX6 O 1 0.9872826337814331
gene O 0 0.026865771040320396
underlie O 1 0.9875885844230652
aniridia B-Disease 1 0.9990528225898743
( O 0 0.2279668003320694
congenital B-Disease 1 0.999339759349823
absence I-Disease 0 5.494384095072746e-05
of I-Disease 0 2.024244167841971e-07
the I-Disease 0 5.22144955539261e-06
iris I-Disease 0 0.2517070770263672
) O 0 1.188632495541242e-06
, O 0 1.6874238895070448e-07
a O 0 1.174012822957593e-06
rare O 0 0.0006404038867913187
dominant O 0 0.004865015856921673
malformation B-Disease 1 0.9910812973976135
of I-Disease 0 2.3502236672356958e-06
the I-Disease 0 4.248850018484518e-05
eye I-Disease 1 0.7241775393486023
. O 0 7.746338087599725e-05

The O 0 1.5200746474874904e-06
spectrum O 0 1.0521934200369287e-05
of O 0 2.755248942776234e-06
PAX6 O 1 0.9763075113296509
mutations O 0 0.003718241583555937
in O 0 0.00025508232647553086
aniridia B-Disease 1 0.9992628693580627
patients O 1 0.5631616115570068
is O 0 3.04198607636863e-07
highly O 0 5.811117489429307e-07
biased O 0 8.738672363506339e-07
, O 0 1.7769483662277707e-08
with O 0 1.7528362761254357e-08
92 O 0 1.790511532817618e-06
% O 0 6.979977928978087e-09
of O 0 9.295522684915625e-10
all O 0 4.4598555959396435e-09
reported O 0 2.528055347283953e-06
mutations O 0 1.7369034139846917e-06
leading O 0 2.970878369978891e-07
to O 0 3.938777126677451e-08
premature O 0 0.0002297332976013422
truncation O 0 4.697737040260108e-06
of O 0 4.128108077594561e-09
the O 0 1.2169943275353035e-08
protein O 0 3.3440664992667735e-07
( O 0 1.7499374393992184e-07
nonsense O 0 8.293991413665935e-07
, O 0 6.219214032654463e-09
splicing O 0 8.443426224857831e-08
, O 0 7.691724590586091e-09
insertions O 0 3.879613927892933e-07
and O 0 1.3910313789722295e-08
deletions O 0 1.0116679050042876e-06
) O 0 1.3154228817313651e-08
and O 0 1.1192839988183323e-09
just O 0 2.0981452131252354e-09
2 O 0 1.336425814457698e-08
% O 0 2.8094819803925475e-09
leading O 0 4.649951534929642e-09
to O 0 2.833211998343188e-10
substitution O 0 3.1136473399584474e-09
of O 0 3.971338813357761e-10
one O 0 1.2917178437987786e-09
amino O 0 1.878378519393209e-08
acid O 0 4.693052062521019e-07
by O 0 1.0736824762602737e-08
another O 0 2.382403039291603e-07
( O 0 2.715400341912755e-06
missense O 0 0.0001639126567170024
) O 0 2.337016894671251e-06
. O 0 3.2984955851134146e-06

The O 0 2.030560153798433e-06
extraordinary O 0 6.520967417600332e-06
conservation O 0 1.5619773421349237e-06
of O 0 2.8868916146507217e-08
the O 0 1.4423970640109474e-07
PAX6 O 0 0.009488553740084171
protein O 0 1.530829933926725e-07
at O 0 1.903397262026374e-08
the O 0 2.4051685088011254e-09
amino O 0 2.6976572087278328e-08
acid O 0 1.3147515574019053e-06
level O 0 3.2054578014140134e-07
amongst O 0 6.10007873547147e-07
vertebrates O 0 3.360617847647518e-05
predicts O 0 0.0014258899027481675
that O 0 2.8811331276301644e-07
pathological O 0 0.019770681858062744
missense O 0 0.005330915562808514
mutations O 0 5.749956835643388e-05
should O 0 1.400381108851434e-07
in O 0 1.0870665079210085e-07
fact O 0 5.427979772321123e-07
be O 0 1.69938019212168e-08
common O 0 6.380693662322301e-07
even O 0 2.581070077667391e-07
though O 0 7.264181078880938e-08
they O 0 2.681455724129478e-09
are O 0 4.809329823274311e-09
hardly O 0 3.9777678466634825e-06
ever O 0 2.194886747020064e-06
seen O 0 1.8680369976209477e-05
in O 0 2.6091100153280422e-05
aniridia B-Disease 1 0.9967233538627625
patients O 1 0.8484238386154175
. O 0 0.00013794846017844975

This O 0 3.308188752271235e-06
indicates O 0 7.398652996926103e-06
that O 0 2.8806873331177485e-08
there O 0 1.5082720850045916e-08
is O 0 1.2187643783079238e-08
a O 0 1.3712146085254062e-07
heavy O 0 0.00016822890029288828
ascertainment O 0 0.019321957603096962
bias O 0 1.0367188224336132e-05
in O 0 1.1436659619334932e-08
the O 0 1.0654203741466972e-08
selection O 0 7.341738239574624e-08
of O 0 2.0845966730576038e-07
patients O 0 0.014032624661922455
for O 0 2.2350177459884435e-06
PAX6 O 1 0.8986064195632935
mutation O 0 1.182413507194724e-05
analysis O 0 8.633622172737887e-08
and O 0 1.2560402495864764e-08
that O 0 5.762813781728937e-09
the O 0 9.24210539210435e-08
missing O 0 4.617492595571093e-05
PAX6 O 1 0.876345694065094
missense O 0 0.026078609749674797
mutations O 0 0.0004374840937089175
frequently O 0 2.3641754523850977e-05
may O 0 4.420592449605465e-05
underlie O 0 0.021835001185536385
phenotypes O 0 0.0014624001923948526
distinct O 0 3.7812408208992565e-06
from O 0 1.550816887174733e-05
textbook O 0 0.2572839558124542
aniridia B-Disease 1 0.9851794838905334
. O 0 0.00013954288442619145

Here O 0 3.500971388348262e-06
we O 0 9.618704410740975e-08
present O 0 1.4501542011657875e-07
four O 0 1.4404670878320758e-07
novel O 0 4.820063622901216e-05
PAX6 O 1 0.8719044923782349
missense O 0 0.003129557939246297
mutations O 0 1.3796154235024005e-05
, O 0 7.100184262753828e-08
two O 0 1.5931409080849335e-08
in O 0 3.4501198342695716e-07
association O 0 5.875273564015515e-05
with O 0 7.3770934250205755e-06
atypical O 1 0.8626097440719604
phenotypes O 1 0.6660704016685486
ectopia B-Disease 1 0.9746878147125244
pupillae I-Disease 1 0.9003377556800842
( O 0 5.515923839993775e-05
displaced B-Disease 0 0.0003863703168462962
pupils I-Disease 0 8.427677676081657e-05
) O 0 2.411914465483278e-05
and O 0 0.00010793410910991952
congenital B-Disease 1 0.9994353652000427
nystagmus I-Disease 1 0.9727551937103271
( O 0 8.510202860634308e-06
searching B-Disease 0 7.319504220504314e-06
gaze I-Disease 0 0.0009774394566193223
) O 0 3.4954658190144983e-07
, O 0 1.3520734754024488e-08
and O 0 4.038438028430846e-09
two O 0 5.934007951680087e-09
in O 0 1.3999083137150592e-07
association O 0 5.2250161388656124e-06
with O 0 2.2848264791264228e-07
more O 0 1.4172601368045434e-06
recognizable O 0 0.012641103006899357
aniridia B-Disease 1 0.9796778559684753
phenotypes O 0 0.11430671066045761
. O 0 7.216992526082322e-05

Strikingly O 0 0.00039945979369804263
, O 0 8.61120383888192e-07
all O 0 4.489884375402653e-08
four O 0 1.136330141093822e-07
mutations O 0 1.719443730507919e-06
are O 0 2.662623899141181e-09
located O 0 1.31565123240307e-08
within O 0 6.5709424568183294e-09
the O 0 4.556929056320769e-08
PAX6 O 0 0.02270088903605938
paired O 0 5.616265298158396e-06
domain O 0 2.254772937249072e-07
and O 0 1.4892536981392368e-08
affect O 0 1.1501920482714922e-07
amino O 0 1.536342963959214e-08
acids O 0 1.6526627177881892e-08
which O 0 1.2247900471606954e-09
are O 0 3.6195887953560657e-10
highly O 0 8.779301730044153e-09
conserved O 0 1.1102459396283848e-08
in O 0 2.5341502229991875e-09
all O 0 3.5672276244014256e-09
known O 0 1.3648295293933188e-07
paired O 0 7.908969564596191e-06
domain O 0 1.4438493280977127e-06
proteins O 0 1.4761874354007887e-06
. O 0 4.230217655276647e-06

Our O 0 1.8296399275641306e-06
results O 0 9.797485063245404e-07
support O 0 1.8200458384853846e-07
the O 0 2.5190148633669196e-08
hypothesis O 0 6.100194696045946e-07
that O 0 3.7486191928337576e-09
the O 0 3.840011419953271e-09
under O 0 3.375079771217315e-08
- O 0 3.830971763818525e-06
representation O 0 1.1465381533071195e-08
of O 0 4.326073721472312e-08
missense O 0 0.0009833702351897955
mutations O 0 2.867851799237542e-05
is O 0 3.324922488445736e-07
caused O 0 0.00010549322178121656
by O 0 4.061770084717864e-07
ascertainment O 0 0.09254980832338333
bias O 0 4.366627399576828e-05
and O 0 8.773815096674298e-08
suggest O 0 5.613789539893332e-07
that O 0 6.720278555860659e-09
a O 0 1.7492617132575106e-07
substantial O 0 2.298970866831951e-05
burden O 0 0.010396282188594341
of O 0 3.608765473472886e-05
PAX6 B-Disease 1 0.999139666557312
- I-Disease 1 0.9988139867782593
related I-Disease 1 0.9914924502372742
disease I-Disease 1 0.9995287656784058
remains O 0 7.765257760183886e-05
to O 0 4.5446515173352964e-07
be O 0 2.037006083810411e-07
uncovered O 0 0.0002907021844293922
. O 0 1.6024579281292972e-06
. O 0 9.734824743645731e-06

The O 0 2.6145673928112956e-06
chromosomal O 0 6.765369471395388e-05
order O 0 1.5103944406291703e-07
of O 0 4.370060935343645e-08
genes O 0 1.5001419342297595e-06
controlling O 0 2.0382865841384046e-05
the O 0 4.5947419380354404e-07
major O 0 3.1814292015042156e-05
histocompatibility O 1 0.9763374328613281
complex O 0 1.2701896594080608e-05
, O 0 1.2897609167339397e-06
properdin O 0 0.024830210953950882
factor O 0 3.6711167922476307e-05
B O 0 0.0004169463354628533
, O 0 5.062315722170752e-07
and O 0 1.0296768095940934e-06
deficiency B-Disease 1 0.8116390705108643
of I-Disease 0 2.7587701012521393e-09
the I-Disease 0 5.532106328587361e-09
second I-Disease 0 2.62131525374798e-08
component I-Disease 0 2.939943044566462e-07
of I-Disease 0 4.959479937838296e-08
complement I-Disease 0 7.833580639271531e-06
. O 0 7.284852017619414e-06

The O 0 2.2385331703844713e-06
relationship O 0 2.291091959705227e-06
of O 0 2.7328423968242532e-08
the O 0 4.882888759993875e-08
genes O 0 4.932961132908531e-07
coding O 0 8.717566743143834e-06
for O 0 1.0627093871562465e-07
HLA O 0 0.014023544266819954
to O 0 1.2229885548720176e-08
those O 0 1.4745813459171586e-08
coding O 0 2.8084766654501436e-06
for O 0 6.703970711896545e-08
properdin O 0 0.004475676454603672
Factor O 0 2.077734279737342e-05
B O 0 0.0002343694504816085
allotypes O 0 0.0020814239978790283
and O 0 2.008974178124845e-07
for O 0 9.744082944962429e-07
deficiency B-Disease 1 0.7769632339477539
of I-Disease 0 3.138738380314976e-09
the I-Disease 0 2.8845730248860946e-09
second I-Disease 0 7.334037821493666e-09
component I-Disease 0 2.993984082877432e-08
of I-Disease 0 6.298852994746085e-09
complement I-Disease 0 1.1978293059655698e-06
( O 0 2.96322605208843e-06
C2 O 0 0.0338972769677639
) O 0 6.453433343267534e-08
was O 0 1.0510674997021852e-08
studied O 0 4.155570110242479e-08
in O 0 3.8116205303140305e-08
families O 0 1.5803940414116369e-06
of O 0 6.342457709251903e-06
patients O 1 0.9496867656707764
with O 0 0.040550533682107925
connective O 1 0.9993517994880676
tissue O 1 0.9993265867233276
disorders O 1 0.999125063419342
. O 0 0.005437085404992104

Patients O 0 0.029070669785141945
were O 0 2.4360525685551693e-07
selected O 0 2.3785709402091015e-07
because O 0 1.4643489976151614e-07
they O 0 8.158709263739183e-09
were O 0 2.330401116523717e-08
heterozygous O 0 9.044253602041863e-06
or O 0 2.9389827886916464e-06
homozygous O 0 0.000851263350341469
for O 0 0.0010815482819452882
C2 B-Disease 1 0.9982017278671265
deficiency I-Disease 1 0.9984959363937378
. O 0 0.0002930678310804069

12 O 0 7.748056304990314e-06
families O 0 2.2625324618275044e-06
with O 0 3.258555238971894e-07
15 O 0 1.931839733515517e-06
matings O 0 0.0010788243962451816
informative O 0 0.0002007314469665289
for O 0 0.001277232775464654
C2 B-Disease 1 0.9991939663887024
deficiency I-Disease 1 0.9992631077766418
were O 0 1.0033691069111228e-06
found O 0 6.93461106493487e-06
. O 0 1.2116473953938112e-05

Of O 0 9.958570217349916e-07
57 O 0 1.025888468575431e-05
informative O 0 1.126815641327994e-05
meioses O 0 0.0005452246405184269
, O 0 3.856285601955278e-08
two O 0 4.0842182968958696e-09
crossovers O 0 2.65644757746486e-07
were O 0 3.3966478518721033e-09
noted O 0 1.1080716433298221e-07
between O 0 4.42603777628392e-07
the O 0 6.098855010350235e-05
C2 B-Disease 1 0.9995242357254028
deficiency I-Disease 1 0.9995651841163635
gene O 0 2.737679096753709e-06
and O 0 7.051369976807109e-08
the O 0 6.901714186824393e-07
HLA O 1 0.9246857762336731
- O 0 0.009591588750481606
B O 0 0.00011535872909007594
gene O 0 2.803023733122245e-07
, O 0 3.059766884305759e-09
with O 0 2.9351556740664364e-09
a O 0 2.592179804139505e-08
recombinant O 0 4.195313067612005e-06
fraction O 0 3.6598959241018747e-07
of O 0 8.606772183838984e-08
0 O 0 1.1437418834248092e-05
. O 0 6.031889824953396e-06

035 O 1 0.7701385617256165
. O 0 0.001842946163378656

A O 0 9.511315511190332e-06
lod O 0 0.000146232865517959
score O 0 1.4968949813010113e-07
of O 0 2.7896517096337448e-08
13 O 0 1.3347704452826292e-07
was O 0 1.9925224137296027e-08
calculated O 0 2.709145441315286e-08
for O 0 4.744235226894489e-08
linkage O 0 0.00015943079779390246
between O 0 0.00020005181431770325
C2 B-Disease 1 0.9992443323135376
deficiency I-Disease 1 0.999414324760437
and O 0 5.147008778294548e-06
HLA O 1 0.9481396675109863
- O 0 0.002141518285498023
B O 0 9.93482899502851e-06
at O 0 7.861583384283222e-09
a O 0 3.354336142180614e-09
maximum O 0 9.879196127826617e-09
likelihood O 0 3.754252020371496e-08
value O 0 5.54756185433547e-10
of O 0 5.954322035428561e-10
the O 0 5.363537614044844e-09
recombinant O 0 9.124556186179689e-07
fraction O 0 1.3223714745436155e-07
of O 0 5.028374516768963e-08
0 O 0 8.254369276983198e-06
. O 0 3.3592473300814163e-06

04 O 0 0.0484401136636734
. O 0 0.00039736874168738723

18 O 0 1.1929959327972028e-05
families O 0 1.5389495047202217e-06
with O 0 9.115599652886885e-08
21 O 0 2.993253929162165e-07
informative O 0 8.544956813238969e-07
matings O 0 3.878521965816617e-05
for O 0 3.337088827493062e-08
both O 0 8.716168764522081e-08
properdin O 0 0.004109867382794619
Factor O 0 1.9944667656091042e-05
B O 0 0.0001599939860170707
allotype O 0 0.0018993500852957368
and O 0 1.616536110304878e-06
HLA O 1 0.862150251865387
- O 0 0.009076704271137714
B O 0 7.606047438457608e-05
were O 0 2.661142950444173e-08
found O 0 5.323262826095743e-07
. O 0 3.9024675970722456e-06

Of O 0 1.2762358210238745e-06
72 O 0 3.181966167176142e-05
informative O 0 2.5683175408630632e-05
meioses O 0 0.003063166281208396
, O 0 2.049250156233029e-07
three O 0 6.171288902123706e-08
recombinants O 0 0.0009810671908780932
were O 0 4.566332201250134e-09
found O 0 8.69356853172576e-09
, O 0 6.52245635279769e-09
giving O 0 1.979204711233251e-08
a O 0 1.7928709183934188e-08
recombinant O 0 2.6111761144420598e-06
fraction O 0 2.4055970015979256e-07
of O 0 6.37463557495721e-08
0 O 0 1.3327799933904316e-05
. O 0 4.120670837437501e-06

042 O 0 0.09167888760566711
. O 0 0.0008736281306482852

A O 0 1.0550368642725516e-05
lod O 0 0.00010066511458717287
score O 0 8.614262014816632e-08
of O 0 2.0515845022828216e-08
16 O 0 1.6810231784347707e-07
between O 0 6.289083103183657e-07
HLA O 0 0.44803425669670105
- O 0 0.000803416536655277
B O 0 3.991534686065279e-05
and O 0 5.0122398675966906e-08
Factor O 0 2.260677774756914e-06
B O 0 1.861814052972477e-05
allotypes O 0 3.1607658456778154e-05
was O 0 5.356126209221657e-09
calculated O 0 7.739316743027302e-09
at O 0 5.964942317859823e-09
a O 0 4.633130767928151e-09
maximum O 0 1.7916196526357453e-08
likelihood O 0 1.4389321734142868e-07
value O 0 1.1842531399963718e-09
of O 0 6.688090081752307e-10
the O 0 5.433918648378722e-09
recombinant O 0 1.4855168046779e-06
fraction O 0 1.4421962646338216e-07
of O 0 6.281111097905523e-08
0 O 0 8.105122105916962e-06
. O 0 4.737119525088929e-06

04 O 0 0.0926198959350586
. O 0 0.0009151549893431365

A O 0 5.591068202193128e-06
crossover O 0 6.509261766041163e-06
was O 0 3.771139347463759e-07
shown O 0 1.4408820447897597e-07
to O 0 9.938673883880256e-09
have O 0 4.123197783201249e-09
occurred O 0 2.2005670174962688e-08
between O 0 5.5711790736268085e-09
genes O 0 3.4765221812449454e-08
for O 0 1.3373385954196237e-08
Factor O 0 1.5067515732880565e-06
B O 0 1.6446727386210114e-05
and O 0 2.963422218726919e-07
HLA O 1 0.5184997916221619
- O 0 0.0009566583321429789
D O 0 0.0010240464471280575
, O 0 1.244004810274646e-08
in O 0 9.469612649581904e-09
which O 0 8.445648802535288e-08
HLA O 0 0.22316087782382965
- O 0 0.0042450870387256145
D O 0 0.03057333640754223
segregared O 0 0.0007497371989302337
with O 0 1.3505703009286663e-06
HLA O 1 0.586193323135376
- O 0 0.00017407811537850648
A O 0 1.140826952905627e-06
and O 0 6.395339369191788e-07
B O 0 0.0004819087916985154
. O 0 5.487379894475453e-06

These O 0 2.608381009849836e-06
studies O 0 4.177666141913505e-06
suggest O 0 1.7079219105653465e-06
that O 0 1.0960122587277965e-08
the O 0 1.1181451320396718e-08
genes O 0 1.9468524214971694e-07
for O 0 1.2900078161237616e-07
Factor O 0 4.528216231847182e-05
B O 0 0.021323060616850853
and O 0 0.00032848186674527824
C2 B-Disease 1 0.9996451139450073
deficiency I-Disease 1 0.9996310472488403
are O 0 9.300936021361395e-09
located O 0 3.40736256987384e-08
outside O 0 1.1884218942270763e-08
those O 0 8.007561724809875e-09
for O 0 2.14338470527764e-07
HLA O 0 0.2755622863769531
, O 0 3.506657364482635e-08
that O 0 1.478715150327048e-09
the O 0 1.248632419681428e-09
order O 0 3.4340850163516734e-09
of O 0 8.494061454200619e-09
genese O 0 0.00029643718153238297
is O 0 1.850693678306925e-07
HLA O 0 0.05189252644777298
- O 0 2.6742336558527313e-05
A O 0 1.2653644887450355e-07
, O 0 7.469710538998697e-08
- O 0 2.448968189128209e-05
B O 0 8.361917025467847e-06
, O 0 5.209410502970968e-08
- O 0 6.14662712905556e-05
D O 0 0.0005477269878610969
, O 0 8.99622989436466e-08
Factor O 0 3.973888851760421e-06
B O 0 0.0005184729234315455
allotype O 0 0.2906930446624756
, O 0 0.0008503986755385995
C2 B-Disease 1 0.9996020197868347
deficiency I-Disease 1 0.9995800852775574
, O 0 4.7909026079651085e-08
that O 0 2.36825004051866e-09
the O 0 9.034382131289931e-09
genes O 0 5.899511847928807e-07
coding O 0 0.00017073744675144553
for O 0 5.602269447990693e-05
C2 B-Disease 1 0.999510645866394
deficiency I-Disease 1 0.999555766582489
and O 0 4.452879807104182e-07
Factor O 0 6.247487362998072e-06
B O 0 1.790507485566195e-05
allotypes O 0 2.4617364033474587e-05
are O 0 7.813906188758324e-10
approximately O 0 5.797100133264621e-09
3 O 0 4.237717377009176e-08
- O 0 5.076900379208382e-06
- O 0 2.382669435974094e-06
5 O 0 5.979604367212232e-08
centimorgans O 0 5.825816970173037e-06
from O 0 6.911855976454717e-09
the O 0 1.88812006030048e-08
HLA O 0 0.0030886612366884947
- O 0 7.076455858623376e-06
A O 0 1.1278152101112937e-07
and O 0 2.1407456074484799e-07
HLA O 0 0.40061458945274353
- O 0 0.0008899269159883261
B O 0 0.00010356325947213918
loci O 0 8.292773259199748e-07
, O 0 8.042491117521422e-09
and O 0 3.780527890739904e-09
that O 0 1.6387314838439693e-09
the O 0 1.2503323709722736e-08
apparent O 0 3.663122470243252e-06
lack O 0 3.579307019663247e-07
of O 0 9.383508192684076e-09
recombinants O 0 0.00026964081916958094
between O 0 6.908300065333606e-08
the O 0 1.2942543037297582e-07
Factor O 0 3.88300686609e-05
B O 0 0.0014941641129553318
gene O 0 0.00017498043598607183
and O 0 0.0004947010311298072
C2 B-Disease 1 0.9995835423469543
deficiency I-Disease 1 0.9997501969337463
gene O 0 5.969879202893935e-05
suggests O 0 3.408855945963296e-06
that O 0 3.2798592730642895e-09
these O 0 8.876585577688445e-10
two O 0 2.8486675240912973e-09
genes O 0 2.1591431220713275e-07
lie O 0 4.1730046973498247e-07
in O 0 6.696415866258576e-09
close O 0 2.6632806182647073e-08
proximity O 0 1.3472934767833067e-07
to O 0 6.6931207243214885e-09
one O 0 2.9674513513100464e-08
another O 0 1.307635216107883e-06
. O 0 5.487944690685254e-06

Distribution O 0 5.286198756948579e-06
of O 0 1.4615128520745202e-06
emerin O 0 0.008890287950634956
and O 0 4.307344624976395e-06
lamins O 0 0.07154904305934906
in O 0 7.222333238132705e-07
the O 0 9.620573564461665e-07
heart O 0 0.012225868180394173
and O 0 2.4597761694167275e-06
implications O 0 0.0016215043142437935
for O 0 2.8693402782664634e-05
Emery B-Disease 1 0.7315204739570618
- I-Disease 1 0.9934875965118408
Dreifuss I-Disease 1 0.9969967603683472
muscular I-Disease 1 0.9981945157051086
dystrophy I-Disease 1 0.9973648190498352
. O 0 0.0027930322103202343

Emerin O 0 0.0028915763832628727
is O 0 1.1006943623215193e-06
a O 0 9.229383977071848e-07
nuclear O 0 1.0945990652544424e-05
membrane O 0 2.416167035335093e-06
protein O 0 2.643084826559061e-07
which O 0 1.2810309257815788e-08
is O 0 1.4474399456787523e-08
missing O 0 6.916770871612243e-07
or O 0 4.426493376286089e-07
defective O 0 0.0017566400347277522
in O 0 1.1825420187960844e-05
Emery B-Disease 1 0.5429045557975769
- I-Disease 1 0.9925762414932251
Dreifuss I-Disease 1 0.9978038668632507
muscular I-Disease 1 0.9987967014312744
dystrophy I-Disease 1 0.9990668892860413
( O 0 0.006098293233662844
EDMD B-Disease 1 0.9945726990699768
) O 0 4.1113515180768445e-05
. O 0 1.4223855032469146e-05

It O 0 7.778521080581413e-07
is O 0 7.801672552432137e-08
one O 0 8.828602737764868e-09
member O 0 1.467367916063722e-08
of O 0 3.63274565984284e-09
a O 0 5.1907143472362804e-08
family O 0 7.546366873611987e-07
of O 0 2.5208419174305163e-07
lamina O 1 0.8009402751922607
- O 0 0.001440470921806991
associated O 0 6.923930868651951e-07
proteins O 0 2.31444570175654e-08
which O 0 6.112980344141761e-09
includes O 0 2.633654219152959e-07
LAP1 O 0 0.003733182791620493
, O 0 3.4766355838655727e-07
LAP2 O 0 0.0020685831550508738
and O 0 1.1845653489217511e-06
lamin O 1 0.5085142850875854
B O 0 0.02417011745274067
receptor O 0 0.0029401916544884443
( O 0 8.380865619983524e-05
LBR O 1 0.9885098338127136
) O 0 5.9764975048892666e-06
. O 0 5.7339434533787426e-06

A O 0 2.8445588213799056e-06
panel O 0 4.991250989405671e-06
of O 0 1.6787627998837706e-07
16 O 0 5.876876002730569e-06
monoclonal O 0 0.002084349049255252
antibodies O 0 0.000536206120159477
( O 0 8.940854968386702e-06
mAbs O 0 0.014740187674760818
) O 0 1.4445227236592473e-07
has O 0 5.529426694295125e-09
been O 0 8.849115884501657e-10
mapped O 0 2.078065364230497e-08
to O 0 6.222817816592396e-10
six O 0 1.5949187526231867e-09
specific O 0 1.9886525759460483e-09
sites O 0 2.544825683514773e-09
throughout O 0 3.0872842060603034e-09
the O 0 5.570647498842618e-09
emerin O 0 4.213544525555335e-05
molecule O 0 1.5048661339278624e-07
using O 0 6.64618156065444e-08
phage O 0 0.0001681116846157238
- O 0 9.61582554737106e-06
displayed O 0 3.2122545690072e-07
peptide O 0 1.0048198646472883e-06
libraries O 0 4.6254957197788826e-08
and O 0 3.7238621075630363e-09
has O 0 4.320060753570942e-09
been O 0 9.312132731587042e-10
used O 0 2.909415597329712e-09
to O 0 1.907223712294126e-08
localize O 0 0.00037866333150304854
emerin O 0 0.017460579052567482
in O 0 7.317021868402662e-07
human O 0 1.526341657154262e-05
and O 0 3.895692134392448e-05
rabbit O 1 0.9406232833862305
heart O 1 0.8751007318496704
. O 0 0.00013369560474529862

Several O 0 1.0542835298110731e-05
mAbs O 0 0.004481244366616011
against O 0 4.130487468501087e-06
different O 0 8.263059498858638e-07
emerin O 0 0.08095632493495941
epitopes O 0 0.005675291642546654
did O 0 5.716225359719829e-07
not O 0 3.3221329687194157e-08
recognize O 0 3.3368617096130038e-06
intercalated O 0 0.00038995969225652516
discs O 0 5.020156822865829e-05
in O 0 3.421664871439134e-07
the O 0 1.0490605291124666e-06
heart O 0 0.06346513330936432
, O 0 2.7047315143136075e-07
though O 0 6.122609619296782e-08
they O 0 6.1855462973881e-09
recognized O 0 2.1203460676133545e-07
cardiomyocyte O 0 0.00041403083014301956
nuclei O 0 2.1124028535268735e-06
strongly O 0 3.433812594266783e-07
, O 0 1.1176227054932042e-08
both O 0 2.7501119159722975e-09
at O 0 2.3112077585096813e-08
the O 0 2.7188981732706452e-08
rim O 0 7.707889017183334e-05
and O 0 7.904950649617604e-08
in O 0 2.38789397144501e-07
intranuclear O 0 0.004477625247091055
spots O 0 9.316284376836848e-06
or O 0 8.365948360733455e-07
channels O 0 2.554876118665561e-06
. O 0 4.614384579326725e-06

A O 0 0.00021276275219861418
polyclonal O 0 0.1624220460653305
rabbit O 0 0.26146095991134644
antiserum O 0 0.13933737576007843
against O 0 0.00016789668006822467
emerin O 0 0.15296271443367004
did O 0 2.285729578943574e-06
recognize O 0 2.2974347757553915e-06
both O 0 6.477961989048708e-08
nuclear O 0 1.0580697562545538e-05
membrane O 0 2.1194980490690796e-06
and O 0 5.016514847966391e-08
intercalated O 0 0.00013337956625036895
discs O 0 5.804554348287638e-06
but O 0 8.9598373165245e-09
, O 0 4.558221800010642e-09
after O 0 2.1111688397468242e-08
affinity O 0 2.0556194613163825e-07
purification O 0 3.80720706516513e-07
against O 0 2.453000291779972e-08
a O 0 1.4214218246877408e-08
pure O 0 2.8358459758237586e-07
- O 0 7.332577661145478e-05
emerin O 0 0.00014881632523611188
band O 0 1.0016895402031878e-07
on O 0 3.440450813130269e-09
a O 0 3.552468186285296e-08
western O 0 8.645731668366352e-07
blot O 0 0.0003519322781357914
, O 0 2.875236404520365e-08
it O 0 1.3612984517408222e-08
stained O 0 0.0001295324764214456
only O 0 8.961563047193977e-09
the O 0 9.647992982309006e-08
nuclear O 0 4.7430901759071276e-05
membrane O 0 5.9641322877723724e-05
. O 0 4.02546947952942e-06

These O 0 2.229133997388999e-06
results O 0 2.307434215254034e-06
would O 0 9.248347510038002e-08
not O 0 7.557931169799303e-09
be O 0 3.488862532208259e-09
expected O 0 1.099016557759569e-07
if O 0 7.787355826849307e-08
immunostaining O 0 0.00020763032080139965
at O 0 3.914698538665107e-07
intercalated O 0 0.0006157047464512289
discs O 0 1.5762512703076936e-05
were O 0 2.9843871818258094e-09
due O 0 6.213608116922842e-08
to O 0 1.8368749854502653e-09
a O 0 5.22540943848071e-09
product O 0 2.2559209611472397e-08
of O 0 3.1413436296645614e-09
the O 0 1.225877923616281e-07
emerin O 0 0.010172605514526367
gene O 0 1.7026219438776025e-06
and O 0 3.497152079035004e-08
, O 0 2.9018909941669335e-08
therefore O 0 1.697407370215842e-08
, O 0 8.252063921077024e-09
cast O 0 1.88655064903287e-08
some O 0 6.945555242054979e-09
doubt O 0 3.865027053961967e-07
upon O 0 2.0565522618198884e-08
the O 0 9.032110881435074e-08
hypothesis O 0 0.0001088238277588971
that O 0 2.357877565373201e-05
cardiac B-Disease 1 0.9990798234939575
defects I-Disease 1 0.9981194138526917
in O 0 4.6495941205648705e-05
EDMD B-Disease 1 0.9975681900978088
are O 0 3.020207657300489e-07
caused O 0 8.565052121412009e-05
by O 0 5.772982447638242e-08
absence O 0 2.014700612562592e-06
of O 0 2.070017757205278e-07
emerin O 0 0.028938839212059975
from O 0 4.779275514010806e-06
intercalated O 0 0.03194417804479599
discs O 0 0.0015396359376609325
. O 0 2.972250513266772e-05

Although O 0 2.6800726118381135e-05
emerin O 0 0.0010142674436792731
was O 0 3.1596039207215654e-07
abundant O 0 2.3111995517410833e-07
in O 0 1.982809294531762e-08
the O 0 1.956381368017901e-08
membranes O 0 1.0991482213285053e-06
of O 0 2.956621081295907e-08
cardiomyocyte O 0 0.006924901623278856
nuclei O 0 5.148324362380663e-06
, O 0 5.16533198435809e-08
it O 0 4.839243672449811e-09
was O 0 2.0539845380085353e-08
absent O 0 4.6561220301555295e-07
from O 0 3.0394801342481514e-08
many O 0 1.0119807569708428e-07
non O 0 2.930516711785458e-05
- O 0 0.09022422879934311
myocyte O 1 0.8660404682159424
cells O 0 3.053529508179054e-05
in O 0 3.7493074955818884e-07
the O 0 2.4631706310174195e-06
heart O 0 0.0835111066699028
. O 0 1.605827310413588e-05

This O 0 3.9835120446696237e-07
distribution O 0 5.205016009313113e-07
of O 0 1.684854282757442e-07
emerin O 0 0.0025857461150735617
was O 0 6.569879218432106e-08
similar O 0 3.018917027475254e-08
to O 0 3.4363587531061057e-09
that O 0 2.0128387845375073e-09
of O 0 1.3641132667885358e-08
lamin O 0 0.005728018935769796
A O 0 3.5954138866145513e-07
, O 0 3.8561754678312354e-08
a O 0 5.460112717514676e-08
candidate O 0 4.176818890755385e-07
gene O 0 9.665617426435347e-07
for O 0 4.3914347713780444e-08
an O 0 5.636745186166081e-07
autosomal O 0 0.024205245077610016
form O 0 7.855657713662367e-06
of O 0 2.314285302418284e-05
EDMD B-Disease 1 0.9932142496109009
. O 0 0.0002004426351049915

In O 0 8.997772056318354e-06
contrast O 0 0.00010353897232562304
, O 0 3.3878892281791195e-05
lamin O 1 0.9457849860191345
B1 O 1 0.97879558801651
was O 0 6.685850166832097e-07
absent O 0 4.121492565900553e-06
from O 0 2.955094089429622e-07
cardiomyocyte O 0 0.0013766728807240725
nuclei O 0 4.960226306138793e-06
, O 0 1.65469302260135e-07
showing O 0 3.6744552289746935e-06
that O 0 9.564504352965741e-07
lamin O 1 0.9662517309188843
B1 O 1 0.9898993372917175
is O 0 2.028978762780298e-08
not O 0 1.5961176824674794e-09
essential O 0 8.499231540781693e-09
for O 0 4.545823717450048e-09
localization O 0 1.0213365158051602e-06
of O 0 2.3802154913710183e-08
emerin O 0 0.0002470040926709771
to O 0 5.143447978639415e-08
the O 0 3.94687361904289e-07
nuclear O 0 0.0005136136314831674
lamina O 1 0.5985949635505676
. O 0 2.4621214834041893e-05

Lamin O 1 0.964949369430542
B1 O 1 0.9791063070297241
is O 0 1.9705878457898507e-06
also O 0 3.4861909625760745e-07
almost O 0 6.834720807091799e-07
completely O 0 7.0596720433968585e-06
absent O 0 8.023277769098058e-05
from O 0 2.6968709789798595e-05
skeletal O 1 0.9637817740440369
muscle O 1 0.6958377361297607
nuclei O 0 0.002151619642972946
. O 0 0.00010548186401138082

In O 0 3.774643482756801e-05
EDMD B-Disease 0 0.17281027138233185
, O 0 3.0509809789691644e-07
the O 0 3.813373083971783e-08
additional O 0 1.1421078482953817e-07
absence O 0 2.154349886041018e-06
of O 0 1.921733428389416e-06
lamin O 1 0.993902325630188
B1 O 1 0.9979661703109741
from O 0 3.4257514926139265e-05
heart O 1 0.5645981431007385
and O 0 1.7902102626976557e-05
skeletal O 1 0.9850835204124451
muscle O 0 0.285103440284729
nuclei O 0 8.329316915478557e-05
which O 0 5.952419996901881e-07
already O 0 9.408507139596622e-06
lack O 0 3.477766222204082e-05
emerin O 0 0.03731318190693855
may O 0 6.197842594701797e-07
offer O 0 6.763513482610506e-08
an O 0 8.398641782036975e-09
alternative O 0 2.3806384774616163e-07
explanation O 0 2.230239033451653e-07
of O 0 4.424543220693522e-08
why O 0 2.927237574112951e-06
these O 0 1.8417810565551918e-07
tissues O 0 0.00041119803790934384
are O 0 1.4675377713047055e-07
particularly O 0 1.629802500247024e-05
affected O 0 0.00010038617620011792
. O 0 1.7937040865945164e-06
. O 0 6.759174084436381e-06

Genetic O 0 3.583870056900196e-05
mapping O 0 3.5273696994408965e-06
of O 0 1.5317074542053888e-07
the O 0 6.673542998214543e-07
copper B-Disease 0 0.0008789954008534551
toxicosis I-Disease 1 0.6410678029060364
locus O 0 4.7067955165402964e-05
in O 0 1.5356420135503868e-06
Bedlington O 0 0.05712612718343735
terriers O 0 0.0003975667932536453
to O 0 2.421271005914605e-07
dog O 0 8.193284156732261e-05
chromosome O 0 5.060074727225583e-06
10 O 0 5.033652428210189e-08
, O 0 1.2531065962662069e-08
in O 0 1.0857875487602087e-08
a O 0 1.6835853955399216e-07
region O 0 8.651094503875356e-06
syntenic O 0 0.004445610102266073
to O 0 1.289884892230475e-07
human O 0 6.471524102380499e-06
chromosome O 0 0.0002782091614790261
region O 0 5.5734355555614457e-05
2p13 O 0 0.04234999418258667
- O 0 0.029056254774332047
p16 O 0 0.010737010277807713
. O 0 1.671439349593129e-05

Abnormal O 1 0.9654671549797058
hepatic B-Disease 1 0.9901221394538879
copper I-Disease 0 0.1617179811000824
accumulation I-Disease 0 0.04454914480447769
is O 0 3.0845308174320962e-06
recognized O 0 6.091455816203961e-06
as O 0 7.1673712227493525e-06
an O 0 0.0016057508764788508
inherited B-Disease 1 0.9996167421340942
disorder I-Disease 1 0.999691367149353
in O 0 1.0139656296814792e-05
man O 0 0.00034418710856698453
, O 0 7.36171614335035e-06
mouse O 0 0.014462715946137905
, O 0 9.71209829003783e-06
rat O 0 0.056922487914562225
and O 0 3.3144481221825117e-06
dog O 0 0.0014902664115652442
. O 0 1.8494196410756558e-05

The O 0 1.2411071111273486e-05
major O 0 0.00012487656204029918
cause O 0 0.0004297062405385077
of O 0 6.0674988162645604e-06
hepatic B-Disease 1 0.9964935183525085
copper I-Disease 0 0.02297305501997471
accumulation I-Disease 0 0.0035130854230374098
in O 0 5.021560127715929e-07
man O 0 3.514020363581949e-06
is O 0 1.1626851659229942e-07
a O 0 1.5575506040477194e-06
dysfunctional O 0 0.24723485112190247
ATP7B O 1 0.929745078086853
gene O 0 0.0008207333739846945
, O 0 0.00010982199455611408
causing O 1 0.8686853647232056
Wilson B-Disease 1 0.9646915197372437
disease I-Disease 1 0.9989509582519531
( O 0 0.009144957177340984
WD B-Disease 1 0.9970893263816833
) O 0 3.321938856970519e-05
. O 0 1.7570962882018648e-05

Mutations O 0 0.00013496573956217617
in O 0 1.0440293181090965e-06
the O 0 1.8616985926200869e-06
ATP7B O 0 0.08508768677711487
genes O 0 2.6094585336977616e-06
have O 0 2.315779212835878e-08
also O 0 2.550770261677826e-08
been O 0 2.0895440044910174e-08
demonstrated O 0 1.0892796353800804e-06
in O 0 4.808938456335454e-07
mouse O 0 0.0010466669918969274
and O 0 6.878821295686066e-06
rat O 0 0.04675113037228584
. O 0 2.261603185615968e-05

The O 0 2.2125836039776914e-05
ATP7B O 0 0.25201475620269775
gene O 0 4.802673720405437e-05
has O 0 3.7504807437471754e-07
been O 0 3.713855178943959e-08
excluded O 0 6.221185913091176e-07
in O 0 2.5221012833753775e-08
the O 0 4.1588684496218775e-08
much O 0 1.9785534277616534e-06
rarer O 0 0.03732260316610336
human O 0 0.0008160917204804718
copper B-Disease 1 0.9893068671226501
overload I-Disease 1 0.999244213104248
disease O 1 0.9991888403892517
non B-Disease 0 0.012678993865847588
- I-Disease 1 0.8588148355484009
Indian I-Disease 0 0.022218303754925728
childhood I-Disease 1 0.9963715076446533
cirrhosis I-Disease 1 0.9993529915809631
, O 0 4.088860805495642e-05
indicating O 0 0.0011527021415531635
genetic O 0 0.016685955226421356
heterogeneity O 0 0.09113964438438416
. O 0 9.047568164533004e-05

By O 0 1.0489252417755779e-05
investigating O 0 7.291737711057067e-05
the O 0 5.981207323202398e-06
common O 0 0.0006317375809885561
autosomal O 1 0.9622419476509094
recessive O 1 0.9868897199630737
copper B-Disease 1 0.8555766344070435
toxicosis I-Disease 1 0.996467113494873
( O 0 0.0003488881920929998
CT B-Disease 0 0.4525456726551056
) O 0 7.203911991382483e-07
in O 0 4.3587317577475915e-07
Bedlington O 0 0.17870141565799713
terriers O 0 0.001503580599091947
, O 0 9.837570047466215e-08
we O 0 6.028409327285544e-09
have O 0 2.5255226798748254e-09
identified O 0 1.5113359452811892e-08
a O 0 2.721590952603492e-08
new O 0 8.697832640791603e-07
locus O 0 0.0004444505029823631
involved O 0 2.5770123102120124e-05
in O 0 0.0011719658505171537
progressive O 1 0.9971908926963806
liver B-Disease 1 0.9995642304420471
disease I-Disease 1 0.9990156888961792
. O 0 0.003302023746073246

We O 0 3.4341931041126372e-06
examined O 0 1.5774407074786723e-05
whether O 0 5.319614047039067e-07
the O 0 1.147909870269359e-06
WD B-Disease 1 0.9895768165588379
gene O 0 4.7426874516531825e-05
ATP7B O 0 0.008308589458465576
was O 0 1.2373874369586702e-07
also O 0 4.047076274105166e-08
causative O 0 1.8091855963575654e-05
for O 0 2.7514576572684746e-07
CT B-Disease 0 0.0783562883734703
by O 0 2.7911898570209814e-08
investigating O 0 6.184145036058908e-07
the O 0 4.954365095954927e-08
chromosomal O 0 0.0002789310528896749
co O 0 4.808342782780528e-05
- O 0 4.231244747643359e-05
localization O 0 2.463687451381702e-06
of O 0 2.6749644277401785e-08
ATP7B O 0 0.003623000578954816
and O 0 4.951663257202199e-08
C04107 O 0 1.5165276636253111e-05
, O 0 3.6417713289438325e-09
using O 0 4.280094056952066e-09
fluorescence O 0 1.9360545877589175e-07
in O 0 1.540398031352197e-08
situ O 0 4.258975604898296e-05
hybridization O 0 6.809673323004972e-06
( O 0 1.5097751884241006e-06
FISH O 0 7.391543931589695e-06
) O 0 1.087134592125949e-06
. O 0 2.0873446828773012e-06

C04107 O 0 0.002808616729453206
is O 0 1.1443836456237477e-06
an O 0 6.943213293197914e-07
anonymous O 0 2.8714286600006744e-05
microsatellite O 0 0.024343106895685196
marker O 0 0.00034996651811525226
closely O 0 2.07701505132718e-05
linked O 0 0.00037124950904399157
to O 0 1.5366340448963456e-05
CT B-Disease 1 0.9505558609962463
. O 0 5.350101855583489e-05

However O 0 1.2727116882160772e-05
, O 0 5.9387316468928475e-06
BAC O 0 0.0008750936831347644
clones O 0 0.00020566863531712443
containing O 0 4.245664513291558e-06
ATP7B O 0 0.005059237126260996
and O 0 2.2829621570963354e-07
C04107 O 0 5.797262565465644e-05
mapped O 0 8.378484039894829e-07
to O 0 1.8602378304422018e-08
the O 0 8.708342136287683e-08
canine O 0 0.0010206549195572734
chromosome O 0 1.784490086720325e-05
regions O 0 1.4070720908421208e-06
CFA22q11 O 0 0.002476851223036647
and O 0 2.909973204623384e-07
CFA10q26 O 0 0.003814446972683072
, O 0 1.2357470779988944e-07
respectively O 0 2.1712972397835983e-07
, O 0 4.3990969089691134e-08
demonstrating O 0 5.792631441181584e-07
that O 0 2.5976098072533205e-07
WD B-Disease 1 0.9594902992248535
cannot O 0 1.9017501529106084e-07
be O 0 1.0760133228870927e-08
homologous O 0 3.163178689646884e-06
to O 0 1.7678008816801594e-06
CT B-Disease 0 0.45825281739234924
. O 0 2.6764990252559073e-05

The O 0 7.123445357137825e-06
copper O 0 0.00017814247985370457
transport O 0 2.739148294494953e-05
genes O 0 1.0808576917042956e-05
CTR1 O 0 0.022639859467744827
and O 0 7.90318495091924e-07
CTR2 O 0 0.008750970475375652
were O 0 1.4351408950119549e-08
also O 0 2.25417888799484e-08
excluded O 0 2.656690867297584e-07
as O 0 1.2244426805807507e-08
candidate O 0 9.790398536324574e-08
genes O 0 1.8741526730536862e-07
for O 0 2.260206883875071e-07
CT B-Disease 0 0.2113313376903534
since O 0 1.979216648351212e-07
they O 0 2.3620472244800794e-09
both O 0 7.041945249142145e-09
mapped O 0 2.243318249384174e-06
to O 0 4.776363198288891e-07
canine O 0 0.08012056350708008
chromosome O 0 0.001173245022073388
region O 0 0.00012790350592695177
CFA11q22 O 0 0.13023006916046143
. O 0 3.174116864101961e-05

2 O 0 0.00016511535795871168
- O 0 0.00265903165563941
22 O 0 0.00012807825987692922
. O 0 5.0815877330023795e-05

5 O 0 0.0007219575345516205
. O 0 0.00031943980138748884

A O 0 2.5414376523258397e-06
transcribed O 0 2.5337610622955253e-06
sequence O 0 2.4836873535605264e-07
identified O 0 1.286710187287099e-07
from O 0 3.151445326921021e-08
the O 0 6.434983390590787e-08
C04107 O 0 0.0004562850226648152
- O 0 7.558600918855518e-05
containing O 0 1.6598011143287295e-06
BAC O 0 0.0002837334468495101
was O 0 4.2778516728958493e-08
found O 0 1.0199252109543977e-08
to O 0 1.9447836674402197e-09
be O 0 6.974837374329468e-10
homologous O 0 1.2768211377078842e-07
to O 0 2.9956563896149646e-09
a O 0 2.0608441175795633e-08
gene O 0 5.466364427775261e-07
expressed O 0 9.439321502213716e-08
from O 0 6.323085699477815e-08
human O 0 2.151801709260326e-06
chromosome O 0 0.00017154421948362142
2p13 O 0 0.015227527357637882
- O 0 0.0027634138241410255
p16 O 0 0.0006626184331253171
, O 0 5.439033046172881e-08
a O 0 9.321220773017558e-08
region O 0 4.341274859598343e-07
devoid O 0 6.608197509194724e-07
of O 0 9.718875482178646e-09
any O 0 6.078324332747798e-08
positional O 0 3.154429577989504e-05
candidate O 0 9.311701433034614e-06
genes O 0 3.2802905479911715e-05
. O 0 2.3114705982152373e-05

Molecular O 0 1.3487217074725777e-05
analysis O 0 5.741981112805661e-07
of O 0 7.754613307042746e-08
the O 0 2.614425511637819e-07
APC B-Disease 0 0.00016744488675612956
gene O 0 1.261694364984578e-06
in O 0 8.883284152716442e-08
205 O 0 1.4383806956175249e-05
families O 0 5.902421662540291e-07
: O 0 8.265242286142893e-07
extended O 0 2.3334159777732566e-06
genotype O 0 0.0002870814350899309
- O 0 0.000421287608332932
phenotype O 0 0.00019408896332606673
correlations O 0 9.879237040877342e-06
in O 0 6.479561989181093e-07
FAP B-Disease 0 0.18710283935070038
and O 0 4.909157524934926e-08
evidence O 0 3.530441006205365e-08
for O 0 4.205482628805157e-09
the O 0 4.3037107211318926e-09
role O 0 2.4782210061857768e-08
of O 0 3.767206280258506e-08
APC B-Disease 0 0.0006594471633434296
amino O 0 1.9098995380772976e-06
acid O 0 0.00017785753880161792
changes O 0 0.00013343260798137635
in O 0 0.012820380739867687
colorectal B-Disease 1 0.9996342658996582
cancer I-Disease 1 0.9994243383407593
predisposition O 1 0.9952098727226257
. O 0 0.0007966153207235038

BACKGROUND O 0 0.0004945776890963316
/ O 0 0.002538231434300542
AIMS O 0 4.639464896172285e-05
The O 0 2.17852038986166e-06
development O 0 0.00017283156921621412
of O 0 0.003610253566876054
colorectal B-Disease 1 0.9998661279678345
cancer I-Disease 1 0.9994896650314331
and O 0 4.75898076501835e-07
a O 0 1.843457368977397e-07
variable O 0 6.714182632094889e-07
range O 0 4.0256668398797046e-07
of O 0 1.5829672861400468e-07
extracolonic O 0 0.33954495191574097
manifestations O 0 0.04365963116288185
in O 0 0.0005060082767158747
familial B-Disease 1 0.9992602467536926
adenomatous I-Disease 1 0.9995087385177612
polyposis I-Disease 1 0.9996519088745117
( O 0 0.14398907124996185
FAP B-Disease 1 0.9974121451377869
) O 0 2.6766647351905704e-06
is O 0 2.237088914114338e-08
the O 0 4.6105634865512e-09
result O 0 2.653874275893031e-08
of O 0 5.891671150948241e-09
the O 0 9.513173182540413e-08
dominant O 0 4.836150401388295e-05
inheritance O 0 0.006814795546233654
of O 0 0.003903445089235902
adenomatous B-Disease 1 0.9995904564857483
polyposis I-Disease 1 0.9995442032814026
coli I-Disease 1 0.9986966252326965
( O 0 0.0010921339271590114
APC B-Disease 0 0.15779739618301392
) O 0 1.7550662960275076e-05
gene O 0 7.668556645512581e-05
mutations O 0 0.00013940698408987373
. O 0 1.1959405128436629e-05

In O 0 2.5511606054351432e-06
this O 0 1.5977030898284283e-07
study O 0 6.03737589699449e-07
, O 0 3.4923196778891e-08
direct O 0 3.819378235903059e-08
mutation O 0 3.405024244784727e-07
analysis O 0 1.4608973586405227e-08
of O 0 2.882208249843643e-09
the O 0 5.2456233134989816e-08
APC B-Disease 0 0.0002629939990583807
gene O 0 8.813882459435263e-07
was O 0 9.232288711302772e-09
performed O 0 8.80596662256039e-09
to O 0 5.198270702777563e-09
determine O 0 2.720797454003332e-07
genotype O 0 0.00025548168923705816
- O 0 0.00036761214141733944
phenotype O 0 8.926502778194845e-05
correlations O 0 9.383311976307596e-07
for O 0 2.668787679738216e-08
nine O 0 1.7492544657216058e-06
extracolonic O 0 0.11141858994960785
manifestations O 0 6.373874930432066e-05
and O 0 2.8065914037256334e-08
to O 0 1.4712268736616352e-08
investigate O 0 6.128931318016839e-07
the O 0 1.0954880735880579e-07
incidence O 0 0.0012862484436482191
of O 0 3.1412679390996345e-07
APC B-Disease 0 0.037761155515909195
mutations O 0 0.00013340245641302317
in O 0 1.0133913747267798e-05
non O 0 0.024304712191224098
- O 1 0.9961397051811218
FAP O 1 0.9978153705596924
colorectal B-Disease 1 0.9995469450950623
cancer I-Disease 1 0.9989426732063293
. O 0 0.0012940098531544209

METHODS O 0 9.015207069751341e-06
The O 0 1.9048081867367728e-06
APC B-Disease 0 0.0003829427878372371
gene O 0 3.649499149105395e-06
was O 0 1.2128492699048365e-07
analysed O 0 7.734700488981616e-07
in O 0 4.504689599116318e-08
190 O 0 5.0048834054905456e-06
unrelated O 0 4.6085271605988964e-05
FAP B-Disease 0 0.0833357721567154
and O 0 7.151913905545371e-07
15 O 0 2.4110313461278565e-05
non O 0 0.03595210611820221
- O 1 0.9980267882347107
FAP O 1 0.9992756247520447
colorectal B-Disease 1 0.9998676776885986
cancer I-Disease 1 0.9997712969779968
patients O 0 0.21813435852527618
using O 0 3.5847563140123384e-06
denaturing O 0 0.1717303991317749
gradient O 0 0.00038368385867215693
gel O 0 0.004781730473041534
electrophoresis O 0 2.9503666155505925e-05
, O 0 2.025587519938199e-08
the O 0 7.315177352751334e-09
protein O 0 1.7800223872654897e-07
truncation O 0 3.6014578199683456e-06
test O 0 1.0564482977315492e-07
, O 0 5.886257259390959e-09
and O 0 6.355766579702049e-09
direct O 0 1.0950910933615887e-07
sequencing O 0 4.195245310256723e-06
. O 0 2.1779158032586565e-06

RESULTS O 0 0.00011389624705770984
Chain O 0 9.420912101631984e-05
terminating O 0 4.418207026901655e-05
signals O 0 5.845740815857425e-07
were O 0 1.1745427741516323e-08
only O 0 1.6657835999467352e-08
identified O 0 5.217325451667421e-07
in O 0 5.51465177522914e-07
patients O 0 0.0009098995360545814
belonging O 0 4.3707197505682416e-07
to O 0 4.4264762522061574e-08
the O 0 4.737354117878567e-07
FAP B-Disease 1 0.6682013273239136
group O 0 1.3017825949646067e-05
( O 0 4.173202614765614e-05
105 O 0 0.0006017470150254667
patients O 0 0.05563021078705788
) O 0 5.791471721749986e-06
. O 0 5.4682750487700105e-06

Amino O 0 9.909374966809992e-06
acid O 0 2.6413856176077388e-05
changes O 0 1.016880332826986e-06
were O 0 2.9538421486563493e-08
identified O 0 2.6681368581193965e-07
in O 0 1.3215192495863448e-07
four O 0 8.664368920108245e-07
patients O 0 0.0018747877329587936
, O 0 3.696343853221151e-08
three O 0 3.6338956288517466e-09
of O 0 2.2353786377493634e-08
whom O 0 8.511627243024122e-07
belonged O 0 3.840592626147554e-07
to O 0 1.725453557810397e-08
the O 0 1.2234509938480187e-07
non O 0 5.435831917566247e-05
- O 0 0.20469126105308533
FAP O 1 0.9819168448448181
group O 0 0.000996107468381524
of O 0 0.05176140367984772
colorectal B-Disease 1 0.9997735619544983
cancer I-Disease 1 0.9996621608734131
patients O 1 0.9956827163696289
. O 0 0.0010807017097249627

Genotype O 0 0.09870090335607529
- O 0 0.1995898336172104
phenotype O 0 0.022013653069734573
correlations O 0 0.0001843089412432164
identified O 0 4.274709226592677e-06
significant O 0 8.402616913372185e-07
differences O 0 1.8059629383060383e-06
in O 0 3.446771401627302e-08
the O 0 1.5482362059060506e-08
nature O 0 1.8940866652883415e-07
of O 0 2.5436040829163176e-08
certain O 0 2.258914719277527e-06
extracolonic O 1 0.6847098469734192
manifestations O 0 0.15354879200458527
in O 0 0.00014606369950342923
FAP B-Disease 1 0.998883068561554
patients O 0 0.07287375628948212
belonging O 0 1.3122224800099502e-06
to O 0 8.590716760181749e-08
three O 0 3.0186873800630565e-07
mutation O 0 6.653411401202902e-05
subgroups O 0 7.335124246310443e-05
. O 0 1.655189953453373e-05

CONCLUSIONS O 0 8.607884228695184e-05
Extended O 0 8.084627916105092e-05
genotype O 0 0.00919860228896141
- O 0 0.01216995157301426
phenotype O 0 0.0006776484078727663
correlations O 0 9.0258054115111e-06
made O 0 6.305129574002422e-08
in O 0 4.2024460356060445e-08
this O 0 4.889505689220641e-08
study O 0 1.905167891891324e-06
may O 0 4.247136473622959e-07
have O 0 1.9034216425239947e-09
the O 0 4.577755952084317e-09
potential O 0 1.179909574489102e-07
to O 0 2.798785203594889e-09
determine O 0 7.46668771256509e-09
the O 0 2.5487214561081828e-09
most O 0 7.0494441395396734e-09
appropriate O 0 7.269767365869484e-08
surveillance O 0 7.353576620516833e-06
and O 0 3.3330197766190395e-06
prophylactic O 1 0.7563462853431702
treatment O 0 0.3205152451992035
regimens O 0 0.13397429883480072
for O 0 1.7294489680352854e-06
those O 0 1.5998368326108903e-05
patients O 0 0.2051086127758026
with O 0 1.5386356608360074e-05
mutations O 0 0.0026270721573382616
associated O 0 0.00012530070671346039
with O 0 1.5719293514848687e-05
life O 0 0.004747078754007816
threatening O 1 0.9434862732887268
conditions O 0 0.06305338442325592
. O 0 0.00020526860316749662

This O 0 1.211053472616186e-06
study O 0 2.857664867406129e-06
also O 0 1.4435944706292503e-07
provided O 0 2.6082591375597985e-07
evidence O 0 2.1422609108867618e-07
for O 0 4.134808051503569e-08
the O 0 8.295496201071728e-08
pathological O 0 0.000147730388562195
nature O 0 1.0386383308969016e-07
of O 0 8.271225482303635e-09
amino O 0 9.89653230476506e-08
acid O 0 3.0967657949076965e-06
changes O 0 1.2201138588352478e-07
in O 0 7.964595738485514e-08
APC O 0 0.00016249530017375946
associated O 0 1.5697442279360985e-07
with O 0 5.360359622841315e-08
both O 0 4.835694085159048e-07
FAP B-Disease 1 0.7158292531967163
and O 0 1.732364580675494e-05
non O 0 0.24376463890075684
- O 1 0.9983086585998535
FAP O 1 0.99920254945755
colorectal B-Disease 1 0.9998512268066406
cancer I-Disease 1 0.9997612833976746
patients O 1 0.9958871006965637
. O 0 9.94832516880706e-05
. O 0 0.00016714913363102823

Inherited B-Disease 1 0.99299156665802
colorectal I-Disease 1 0.9983684420585632
polyposis I-Disease 1 0.9981887936592102
and O 1 0.7179328203201294
cancer B-Disease 1 0.999129593372345
risk O 0 0.013468364253640175
of O 0 1.0809521882038098e-06
the O 0 1.0775233022286557e-05
APC O 0 0.1328401267528534
I1307K O 0 0.10847613960504532
polymorphism O 0 0.0011707608355209231
. O 0 3.439985084696673e-05

Germ O 0 0.3001459240913391
- O 0 0.0003130682453047484
line O 0 3.2309819744114066e-06
and O 0 2.791259987589001e-07
somatic O 0 3.571082925191149e-05
truncating O 0 0.0003651563310995698
mutations O 0 1.9825993149424903e-06
of O 0 1.6899805999059936e-08
the O 0 1.3986753799599683e-07
APC B-Disease 0 0.00035004745586775243
gene O 0 5.816945076730917e-07
are O 0 4.882914073078837e-09
thought O 0 1.3746108606937923e-07
to O 0 5.158244107406063e-07
initiate O 0 0.0688772052526474
colorectal B-Disease 1 0.9995142221450806
tumor I-Disease 1 0.9982545971870422
formation O 0 0.2070632427930832
in O 0 0.0604979433119297
familial B-Disease 1 0.9994915723800659
adenomatous I-Disease 1 0.9996955394744873
polyposis I-Disease 1 0.9998601675033569
syndrome I-Disease 1 0.9997581839561462
and O 0 0.01689446158707142
sporadic O 1 0.993854284286499
colorectal O 1 0.9993343949317932
carcinogenesis O 1 0.9977987408638
, O 0 0.00014477496733888984
respectively O 0 0.00016240325930994004
. O 0 5.925717778154649e-05

Recently O 0 3.950711106881499e-05
, O 0 1.058647512763855e-06
an O 0 9.866994332696777e-07
isoleucine O 0 0.0015274769393727183
- O 0 0.0006291658501140773
- O 0 0.00024418230168521404
> O 0 0.00011753448779927567
lysine O 0 7.4559980021149386e-06
polymorphism O 0 5.222990466791089e-07
at O 0 6.881406733327822e-08
codon O 0 1.3281287465360947e-06
1307 O 0 0.0001189499453175813
( O 0 4.3054865273006726e-07
I1307K O 0 7.2971306508407e-06
) O 0 1.0459658028594276e-08
of O 0 1.8172311433417576e-09
the O 0 3.1570888125997953e-08
APC B-Disease 0 0.00014633050886914134
gene O 0 6.055118433323514e-07
has O 0 1.0194273869501558e-08
been O 0 2.2709738534132384e-09
identified O 0 1.1308163294643236e-08
in O 0 3.7141580921939976e-09
6 O 0 7.964793269366055e-08
% O 0 3.877815402120177e-08
- O 0 4.1742728171811905e-06
7 O 0 6.804155106010512e-08
% O 0 5.080701193094228e-09
of O 0 3.098610923402134e-09
the O 0 1.271760794452348e-07
Ashkenazi O 0 0.00023758431780152023
Jewish O 0 4.987387001165189e-06
population O 0 4.961484592058696e-06
. O 0 7.632257620571181e-06

To O 0 9.017941920319572e-06
assess O 0 0.00015421860734932125
the O 0 6.267456456043874e-07
risk O 0 1.6920930647756904e-05
of O 0 1.3557817979403808e-08
this O 0 4.30354063496452e-08
common O 0 6.13855809206143e-06
APC B-Disease 0 0.04154302179813385
allelic O 0 0.19963262975215912
variant O 0 0.4373874366283417
in O 0 0.0010256314417347312
colorectal O 1 0.9996829032897949
carcinogenesis O 1 0.9955005049705505
, O 0 9.312528277405363e-07
we O 0 8.244072091656562e-09
have O 0 1.7400473284467921e-09
analyzed O 0 2.126968112747818e-08
a O 0 9.635061637425224e-09
large O 0 8.807868567828336e-08
cohort O 0 1.3442197996482719e-05
of O 0 1.1796733190294617e-07
unselected O 0 0.10915616899728775
Ashkenazi O 0 0.0008525706944055855
Jewish O 0 3.580782959033968e-06
subjects O 0 2.1803580239065923e-05
with O 0 0.0004774283734150231
adenomatous B-Disease 1 0.9993016719818115
polyps I-Disease 1 0.9979377388954163
and O 0 5.378057176130824e-05
. O 0 0.0004053086740896106
or O 0 0.4827253520488739
colorectal B-Disease 1 0.9999011754989624
cancer I-Disease 1 0.9996349811553955
, I-Disease 0 7.859140396249131e-07
for O 0 3.552997895894805e-07
the O 0 2.0795816908503184e-06
APC O 0 0.028158504515886307
I1307K O 0 0.01103257667273283
polymorphism O 0 0.00026207586051896214
. O 0 9.810764822759666e-06

The O 0 9.86790928436676e-06
APC O 0 0.0026381611824035645
I1307K O 0 0.0013460904592648149
allele O 0 1.322307525697397e-05
was O 0 1.448827191552482e-07
identified O 0 7.895518194800388e-08
in O 0 2.257616849021815e-08
48 O 0 3.9977228993848257e-07
( O 0 5.691258664342058e-08
10 O 0 7.370442034471125e-09
. O 0 3.2856262155434024e-09
1 O 0 2.8657975548185277e-08
% O 0 3.3956130351953107e-08
) O 0 4.8977657485238524e-08
of O 0 2.721493217450188e-07
476 O 0 0.16561006009578705
patients O 0 0.12467280775308609
. O 0 3.661844311864115e-05

Compared O 0 7.062809800117975e-06
with O 0 1.2400349191921123e-07
the O 0 2.79560676830215e-08
frequency O 0 2.6021913512863648e-08
in O 0 4.455434243766376e-09
two O 0 2.1363875113422637e-09
separate O 0 4.094430394729898e-08
population O 0 5.601014763101375e-08
control O 0 4.606899750569937e-08
groups O 0 8.08784061945289e-09
, O 0 1.1938357857843584e-08
the O 0 3.860311181824727e-08
APC O 0 0.0016071078134700656
I1307K O 0 0.00208135973662138
allele O 0 7.993120561877731e-06
is O 0 3.2104470193417e-08
associated O 0 1.4255138580665516e-07
with O 0 2.1750167888967553e-08
an O 0 5.612746178940142e-08
estimated O 0 9.183734619000461e-06
relative O 0 1.0106830814038403e-05
risk O 0 0.00010115453187609091
of O 0 1.2353771694506577e-07
1 O 0 9.980952199839521e-06
. O 0 9.445690920983907e-06

5 O 0 0.00022681010887026787
- O 0 0.0020780907943844795
1 O 0 5.685171709046699e-05
. O 0 3.6779358197236434e-05

7 O 0 0.00041129367309622467
for O 0 0.000594936718698591
colorectal B-Disease 1 0.9974741339683533
neoplasia I-Disease 1 0.9930132031440735
( O 0 2.0204410247970372e-05
both O 0 1.2356533716229023e-06
P O 0 0.006595945917069912
= O 0 0.0005378538626246154
. O 0 3.1481436053582e-06
01 O 0 0.010650299489498138
) O 0 3.2768464279797627e-06
. O 0 3.3883138712553773e-06

Furthermore O 0 4.2820418457267806e-05
, O 0 1.4994224102338194e-06
compared O 0 3.754965291591361e-06
with O 0 1.0910376886386075e-06
noncarriers O 0 0.011414970271289349
, O 0 2.945610958704492e-06
APC O 0 0.005254911724478006
I1307K O 0 0.004111356567591429
carriers O 0 2.6406853066873737e-05
had O 0 7.045414207595968e-08
increased O 0 2.2193164284090017e-07
numbers O 0 8.479367608060784e-08
of O 0 8.8840272383095e-07
adenomas B-Disease 1 0.9964106678962708
and O 0 0.0044418442994356155
colorectal B-Disease 1 0.9997155070304871
cancers I-Disease 1 0.9972303509712219
per O 0 4.5270689952303655e-06
patient O 0 0.0034467948134988546
( O 0 7.11999518898665e-06
P O 0 0.0017180639551952481
= O 0 6.528042285935953e-05
. O 0 7.52387521174569e-08
03 O 0 0.00010256964014843106
) O 0 2.9627006625787544e-08
, O 0 5.2294373276140504e-09
as O 0 1.3784559049767608e-09
well O 0 2.0339878670228018e-09
as O 0 7.618632835715289e-09
a O 0 1.9741871426504076e-07
younger O 0 7.167390867834911e-05
age O 0 0.00013801146997138858
at O 0 0.00012188669643364847
diagnosis O 1 0.9483829140663147
. O 0 8.292313577840105e-05

We O 0 1.883855702544679e-06
conclude O 0 3.974366336478852e-06
that O 0 7.373538579713568e-08
the O 0 4.953519692207919e-07
APC O 0 0.0020588377956300974
I1307K O 0 0.005051583983004093
variant O 0 0.00029984465800225735
leads O 0 5.463974048325326e-06
to O 0 5.075885951555392e-07
increased O 0 0.00017037850921042264
adenoma B-Disease 1 0.9984233379364014
formation O 0 6.319381554931169e-06
and O 0 1.5256146568276563e-08
directly O 0 1.740493082991179e-08
contributes O 0 5.477228910422127e-07
to O 0 3.992530750451806e-09
3 O 0 4.461219305085251e-08
% O 0 2.4830518086105258e-08
- O 0 2.6054176487377845e-06
4 O 0 6.905481342300845e-08
% O 0 1.5028676969564003e-08
of O 0 1.3903124873593242e-08
all O 0 9.390877266923781e-07
Ashkenazi O 0 0.22223271429538727
Jewish O 0 0.2847139537334442
colorectal B-Disease 1 0.9995006322860718
cancer I-Disease 1 0.9988242983818054
. O 0 0.0005330092972144485

The O 0 8.210372470784932e-06
estimated O 0 6.124767969595268e-05
relative O 0 0.0001605572906555608
risk O 0 0.002259741770103574
for O 0 2.666607997525716e-06
carriers O 0 0.005520129110664129
may O 0 1.1946592167078052e-05
justify O 0 0.0001076353364624083
specific O 0 4.895216534350766e-07
clinical O 0 9.702755778562278e-05
screening O 0 3.0003984647919424e-06
for O 0 1.8086117492543963e-08
the O 0 2.4617087035494478e-08
360 O 0 1.4034710602572886e-06
, O 0 1.1596067395203136e-07
000 O 0 2.2468468614533776e-06
Americans O 0 1.5965028410391824e-07
expected O 0 5.555848048288681e-08
to O 0 1.0115075887995317e-08
harbor O 0 1.0411397852294613e-05
this O 0 1.254572534747922e-08
allele O 0 3.209589067409979e-06
, O 0 4.9881016650488164e-08
and O 0 4.975558809405811e-08
genetic O 0 1.5651775129299494e-06
testing O 0 1.5126575192425662e-07
in O 0 2.77884870669709e-09
the O 0 1.6791068535582099e-09
setting O 0 2.8468493340483292e-08
of O 0 2.1063542021693138e-08
long O 0 2.2807544155512005e-05
- O 0 0.0006895365659147501
term O 0 1.594677632965613e-05
- O 0 0.00033300978248007596
outcome O 0 5.747690920543391e-06
studies O 0 6.6040670390066225e-06
may O 0 1.0474756891198922e-05
impact O 0 0.00022691351477988064
significantly O 0 0.06510321795940399
on O 0 0.04559691995382309
colorectal B-Disease 1 0.999893069267273
cancer I-Disease 1 0.9998445510864258
prevention O 1 0.9191800355911255
in O 0 2.213200559708639e-06
this O 0 1.4061853335078922e-06
population O 0 7.2579314291942865e-06
. O 0 1.079801677406067e-05

Localization O 0 8.029569289647043e-05
of O 0 1.3067799500277033e-06
human O 0 1.8775010175886564e-05
BRCA1 O 0 0.0016598079819232225
and O 0 2.343126510595539e-07
its O 0 2.1995730037360772e-07
loss O 0 3.960548929171637e-05
in O 0 1.8702603199471923e-07
high O 0 1.2295535270823166e-05
- O 0 0.003039164235815406
grade O 0 0.00034615257754921913
, O 0 5.435560524347238e-06
non B-Disease 0 0.0030271296855062246
- I-Disease 1 0.9832947254180908
inherited I-Disease 1 0.9963719844818115
breast I-Disease 1 0.9982263445854187
carcinomas I-Disease 1 0.9978253841400146
. O 0 0.0003713128389790654

Although O 0 3.4410479656799e-06
the O 0 3.3689511269585637e-07
link O 0 2.5513818400213495e-06
between O 0 6.367029072862351e-07
the O 0 9.863844752544537e-06
BRCA1 O 1 0.8409819006919861
tumour B-Disease 1 0.9981805086135864
- O 0 0.05331146717071533
suppressor O 0 0.03383409604430199
gene O 0 9.36453725444153e-05
and O 0 5.925107325310819e-05
hereditary B-Disease 1 0.998306393623352
breast I-Disease 1 0.999698281288147
and I-Disease 1 0.9910969734191895
ovarian I-Disease 1 0.9999444484710693
cancer I-Disease 1 0.9998154044151306
is O 0 2.722598765103612e-06
established O 0 1.0113919870491372e-06
, O 0 8.895576542045092e-08
the O 0 2.9168962356607153e-08
role O 0 4.3266763327665103e-07
, O 0 5.520409374071278e-08
if O 0 7.277671354444237e-09
any O 0 2.184199043853141e-09
, O 0 1.1293957768998553e-08
of O 0 4.286394883479261e-08
BRCA1 O 0 0.008560633286833763
in O 0 3.566179657354951e-06
non B-Disease 0 0.014267132617533207
- I-Disease 1 0.9942843317985535
familial I-Disease 1 0.9985652565956116
cancers I-Disease 1 0.9984647035598755
is O 0 9.982094525184948e-06
unclear O 0 7.128578727133572e-05
. O 0 3.663039024104364e-05

BRCA1 O 0 0.2591061592102051
mutations O 0 0.00018647112301550806
are O 0 2.6029738364741206e-07
rare O 0 2.8644819394685328e-05
in O 0 4.904336947220145e-06
sporadic B-Disease 0 0.03528523072600365
cancers I-Disease 1 0.9967103004455566
, O 0 1.439749098608445e-06
but O 0 4.210059785236808e-07
loss O 0 0.00014217621355783194
of O 0 3.935038250801881e-07
BRCA1 O 0 0.04404250532388687
resulting O 0 6.062646207283251e-06
from O 0 3.6520404478324053e-07
reduced O 0 2.7304020022711484e-06
expression O 0 9.826936775425565e-08
or O 0 4.536194708748553e-08
incorrect O 0 2.7005614811059786e-07
subcellular O 0 4.978624019713607e-06
localization O 0 3.414868615436717e-06
is O 0 1.2260715998024807e-08
postulated O 0 2.174743514160582e-07
to O 0 1.910244629144131e-09
be O 0 1.3229455309016203e-09
important O 0 1.6662664137356842e-08
in O 0 7.251070996971976e-07
non B-Disease 0 0.0013591923052445054
- I-Disease 1 0.9947513937950134
familial I-Disease 1 0.9984570741653442
breast I-Disease 1 0.9992471933364868
and I-Disease 1 0.8725258111953735
ovarian I-Disease 1 0.9996302127838135
cancers I-Disease 1 0.9988916516304016
. O 0 0.001433736295439303

Epigenetic O 0 0.033556848764419556
loss O 0 0.02256111241877079
, O 0 5.941348717897199e-06
however O 0 1.0189178283326328e-06
, O 0 2.8967713205929613e-07
has O 0 9.904557174422735e-08
not O 0 9.443369641815025e-09
received O 0 2.3321983633195487e-07
general O 0 5.869678716408089e-07
acceptance O 0 2.9745413485215977e-05
due O 0 1.3981901929582818e-06
to O 0 2.8001428731272426e-08
controversy O 0 7.300112656594138e-07
regarding O 0 3.114795177339147e-08
the O 0 1.5065987568618766e-08
subcellular O 0 1.3668397969013313e-06
localization O 0 1.4251728543968056e-06
of O 0 3.47169830661187e-08
BRCA1 O 0 0.0006622945656999946
proteins O 0 8.927258932089899e-08
, O 0 1.2082332467855394e-08
reports O 0 1.1460024929021984e-08
of O 0 1.3257595021798352e-09
which O 0 4.810568388080583e-09
have O 0 2.1976591657590916e-09
ranged O 0 7.013202321104473e-07
from O 0 1.4841126549924866e-08
exclusively O 0 5.285162529844456e-08
nuclear O 0 1.7510938050691038e-06
, O 0 9.276292622928395e-09
to O 0 6.8626468952004416e-09
conditionally O 0 5.009954747947631e-06
nuclear O 0 1.018519583340094e-06
, O 0 6.521398976389037e-09
to O 0 7.613142116724703e-09
the O 0 2.206830487239131e-07
ER O 0 0.15325388312339783
/ O 0 0.0017328242538496852
golgi O 0 0.0003236480988562107
, O 0 9.16586007093656e-09
to O 0 4.773769823884777e-09
cytoplasmic O 0 2.50975040216872e-06
invaginations O 0 1.897363290481735e-05
into O 0 3.244321788997695e-08
the O 0 1.0511400461155063e-07
nucleus O 0 1.323364722338738e-05
. O 0 6.0859629229526035e-06

In O 0 1.6682291743563837e-06
an O 0 3.3758593076527177e-07
attempt O 0 2.218551117039169e-06
to O 0 1.8721233630003553e-07
resolve O 0 2.1104027837282047e-05
this O 0 3.571430085003158e-08
issue O 0 8.69840562245372e-07
, O 0 5.1373394427400854e-08
we O 0 9.363002817508459e-09
have O 0 3.301029849467341e-08
comprehensively O 0 0.0002615329867694527
characterized O 0 0.0003383085422683507
19 O 0 3.304044366814196e-05
anti O 0 0.043110191822052
- O 1 0.6248378157615662
BRCA1 O 1 0.578333854675293
antibodies O 0 0.0020597411785274744
. O 0 1.630614133318886e-05

These O 0 2.209906142525142e-06
reagents O 0 6.277529610088095e-05
detect O 0 9.281954589823727e-06
a O 0 1.8663529033347004e-07
220 O 0 3.0556911951862276e-06
- O 0 0.00023572977806907147
kD O 0 0.001887527178041637
protein O 0 3.9024945408527856e-07
localized O 0 1.6831244238346699e-06
in O 0 7.514149302778605e-09
discrete O 0 1.845751427254072e-07
nuclear O 0 6.488444341812283e-06
foci O 0 2.0374605810502544e-05
in O 0 3.171682649849572e-08
all O 0 2.3093171819255076e-08
epithelial O 0 0.008984358981251717
cell O 0 3.878192728734575e-05
lines O 0 1.2924944030601182e-06
, O 0 3.436242579368809e-08
including O 0 2.990839576000326e-08
those O 0 6.490378723356116e-08
derived O 0 3.0301025617518462e-06
from O 0 0.00017875622143037617
breast B-Disease 1 0.9976390600204468
malignancies I-Disease 1 0.9894816875457764
. O 0 0.00019658486417029053

Immunohistochemical O 0 0.353836327791214
staining O 0 0.0031327337492257357
of O 0 8.367995178559795e-06
human O 0 0.002844609087333083
breast O 1 0.997453510761261
specimens O 0 0.0003932369581889361
also O 0 1.3145171351425233e-06
revealed O 0 9.80702243396081e-05
BRCA1 O 0 0.08399205654859543
nuclear O 0 0.0005576958646997809
foci O 0 0.053315669298172
in O 0 0.0006441723089665174
benign O 1 0.9987106323242188
breast O 1 0.9992851614952087
, O 0 0.026555048301815987
invasive B-Disease 1 0.9987169504165649
lobular I-Disease 1 0.9993917942047119
cancers I-Disease 1 0.9976978898048401
and O 0 4.258670742274262e-05
low B-Disease 0 0.09311851114034653
- I-Disease 1 0.9462761878967285
grade I-Disease 1 0.9116471409797668
ductal I-Disease 1 0.9969898462295532
carcinomas I-Disease 1 0.9962581396102905
. O 0 0.00039773277239874005

Conversely O 0 0.0033232723362743855
, O 0 1.626785524422303e-05
BRCA1 O 0 0.0022937178146094084
expression O 0 4.316580543672899e-06
was O 0 6.681631248284248e-07
reduced O 0 7.831600669305772e-06
or O 0 7.881973829171329e-07
undetectable O 0 0.0001839611359173432
in O 0 7.671856927515819e-09
the O 0 2.641721952301168e-09
majority O 0 1.7721388800850946e-08
of O 0 1.6310020001242265e-08
high O 0 1.2228215382492635e-05
- O 0 0.007349624298512936
grade O 0 0.006371200084686279
, O 0 8.725602674530819e-05
ductal B-Disease 1 0.9993504881858826
carcinomas I-Disease 1 0.998934805393219
, O 0 9.102453759624041e-07
suggesting O 0 4.330740011937451e-06
that O 0 1.6840342453861012e-08
absence O 0 1.6941072544796043e-06
of O 0 7.781102908666071e-07
BRCA1 O 0 0.4625333249568939
may O 0 3.26778058479249e-06
contribute O 0 8.80717777818063e-07
to O 0 1.385769454742558e-08
the O 0 5.642812439532463e-08
pathogenesis O 0 0.0002555182436481118
of O 0 7.370386079230684e-09
a O 0 5.5567170420545153e-08
significant O 0 2.91294981025203e-07
percentage O 0 1.8392479432804976e-06
of O 0 3.453830686339643e-06
sporadic B-Disease 1 0.8992133140563965
breast I-Disease 1 0.999618411064148
cancers I-Disease 1 0.9986300468444824
. O 0 3.9522783481515944e-05
. O 0 5.549829438677989e-05

